<SEC-DOCUMENT>0001576280-21-000105.txt : 20211104
<SEC-HEADER>0001576280-21-000105.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104170848
ACCESSION NUMBER:		0001576280-21-000105
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Guardant Health, Inc.
		CENTRAL INDEX KEY:			0001576280
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				454139254
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38683
		FILM NUMBER:		211381067

	BUSINESS ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		855-698-8887

	MAIL ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gh-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1,d:e165b3dd2cd64109ae663021d54143ae--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:gh="http://guardanthealth.com/20210930" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gh-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8xLTEtMS0xLTA_1ebc3fef-3191-490a-9b7e-da87793ceb5d">false</ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8yLTEtMS0xLTA_f335cb2a-7f98-4f73-bdf2-0335c1009288">2021</ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8zLTEtMS0xLTA_04253823-d364-40cd-be6b-3e10bb295267">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV80LTEtMS0xLTA_cc6c33e3-7bf5-4b65-bef8-3aa2c4483ab9">0001576280</ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV81LTEtMS0xLTA_91634e41-c25d-45e3-95cf-39fc8f4c1846">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0wLTEtMS0w_9d07a004-36a9-48d1-b674-4d4b1c3ba821">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i62c26cb48e8240adb2b3260459d61952_D20201101-20201130" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83My9mcmFnOjJiNzg4MWMyMGE4NDQ0YTQ5OGRmOGU5NmU4ZGMwZjQzL3RleHRyZWdpb246MmI3ODgxYzIwYTg0NDRhNDk4ZGY4ZTk2ZThkYzBmNDNfMTA5_e5a2080c-fda6-46ce-b3d4-db3949b22b3c">0.0071523</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNTI5L2ZyYWc6MDRmNGNhODQzZGQ2NGEwM2FjYTQyNGNjZmU1NGU0NTAvdGV4dHJlZ2lvbjowNGY0Y2E4NDNkZDY0YTAzYWNhNDI0Y2NmZTU0ZTQ1MF82NTk3MDY5NzY2OTA1_25b69c68-6c8b-4d22-b043-d460ddb8e898">0</ix:nonFraction><ix:nonNumeric contextRef="i5f2aaefc2c4e43a4a37ff326738a3f25_D20200526-20200526" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYwOA_1a96adcc-20aa-4c2d-b632-070a36d742ec">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gh-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i257839cad923440aa7e18dfdf53c45f1_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87072388cc314ce488bc187e99179f36_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13d009641754c8c975c6fe1fe537d29_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb188ab333be4dc08b9c5f417ad86fe8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb78fae6878478e8cd70530ed7da501_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d56b88a0c04c4c8b36e3c969d626f2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93be9beff734563914f49b1f9d826c1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cde6611fe144c878e5f147907f65625_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a0784b897b4b27a75ddbda8d07eaf8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b5b40f197c4b2b865e8b6c841941a6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2724b9af04a45ff87503e333da07ebd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bee42491de4f5c82ed9ebfd0441c85_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906ccbde79194f08bb0f80f06e646f90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db331e94f874da2baee789ff575651f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d4e7bb16784bd9821eebce7010e751_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661bf286fe924b48b215bb888a02d853_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ac4fdfdbf1465f928c369ad560835b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b663835ceaf4a199e40a3acf8f4be0b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa05344a7c40424eb0df008620fe83e9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8d6e638e7348069924511ee4d47851_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55be54d3da949a5a9de5778b8b05dec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fce8977c7741018238eb1946bda5f1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bad68bc160b4bb083ffeadb14d426c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a25d82718384a71a7a9e81dc3b6f434_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9963cbea62ef4985b9e091e63f42672e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00f5560ad1c408eb348e0b4b24055ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3cecf4e8114f768c9e12d1be9f15ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11487705f65f4d059cb0b6be76a69cd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e83cfa49ff4496aa510e2385e131bc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4f1518b17d478bac803e4fdfda2df2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8678c58ece47b29c05d97165d5d969_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8137948ad1cf4ec2ae5768ff46f1e611_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae691b8ed7640cbba3e0cfbe95f8ce8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea4d482e7e042e7a7764275e7e2b782_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d815861a524636a58d12c0365da761_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b1ceded2d84e4d989b48de6331e0bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1c87214cd44be4b4ddea1be858f87b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e0e7a381cb4c54b6fa6ca304bcfb9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea269815d434d1da3aa9ef5ae46f173_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ee9c09290c467d9d3e214ca77c3592_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539db53b7f21487595b91dc1d07cc09b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6724a88cebfe46be8cd1c0db1eb07e71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bba3a03f7745a29d33398d6eff80ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d6010708ee46bfb896d95969e67179_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1fba2cc4574405a14c237af96ff0aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6905570ee74c4bbab460aeff1b55a0cb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iaacefe81c0f14186af54df7f09699324_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09d1ad0faad479daa3acc238b4cd800_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9601fedfcd4106983c11355226e3ab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956c76338cf9472792fc8fb1eb5c02f1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98fa25d42954af2baa244b886e1c86d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1b80c40c794c5483e2a614b550e4df_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1b5cb3bc064b06ab1c3b5a280c72e7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99f62e950344ebd9a1b6da0b6c5ce54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be6ab2fcffb478c974ac3fefc049dbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad452344b214db5813fddb4470c5555_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ebea8c7fe84cd99c89b4a20e1252ee_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17fe7f4e508446f9ee412617b8ed455_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e32f7150de24707acc5c5ece9051c90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gh:Guardant360CDxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b5b98c81024b9fa1cc9ef6f43bb435_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64931530ecf46b0b986e9644237b683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82f3289e43a450fb918eac02af264ac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb65abbec30b4f71a61b44720b765997_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4823a55ced453d9a74182e29b5dab5_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2a1b5721c14e62ae22216f233394a8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ddcd6f8bc5427ea47298e84035d15d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d59f69aa9304c82926efc78bf2688b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10beec7190eb42289690ddc970be2e86_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b22c3fce9b49408a166a3ade4c8098_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i696cb7034a6f4fb389687d5640e8bc6f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9afa11a3f342b681841d1bdf79f0eb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:GuardantHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b82c98a5b04b45b4ba1de5d14ba5cd_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c382b53abce461ab4ceb209bd8a2229_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c715ccc41be43d897292cbe1d39f9f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43dd801a43d47509034a8a6ad46dfe4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3a1976e448f44da9ad1282432ecaeac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e2ff3854534beeaf5dc50347518efe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacafa40cbdf74f16a6b76e5fdc92f851_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b0c64f26ce4de4af37ae79bd0d1434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7b2e27a68941b58e1e1594d4e640e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f4b951f099240f586e94280a7a195c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731507644762422f81775c71bb607b97_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64406783e2224dfaa1cac0323c19c1f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17983378a2a4dfcb8807f9d3349a6ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b3d8119d074276b8c7bb266b246df3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia094abf062614978a5479b8fdfa6ba48_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ddcdc04122487cb058c12bdc3fea32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef80966c25e4f1aa85af95075561dd8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9d64efcd8c4a0f82752998dc008845_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6490275f39504f90b9b21f3da8745ba7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6c732b2f1046c48b1d0d53909608fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9aa35947e840c4b0b33827767997bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76479fc684134352b6d1f8659b4db3ef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7711072385f46159fba26d2b137c91c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc2ce09c97a54496b5adf47fc9df36f8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia644451d18b64b7891f97794ae28ed16_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609248da19584e879becf882254ecfb7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda5c7f43186404280efac8c9a712d5b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873b7ae2fa894be79e1fc9fe51be3fdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5652f79c7265447095ac9b9f6f19cae7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede67ca17f9c40bbbeff9eb83a33fa3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d94d00f18354bbfbb8b4c63e3b1c4fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb4a56587574e1d832fec1efcbaec69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83bff0162ba402f8a5a944a54a92646_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009e431b909f4623af5c2eedf68ec9ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e521bd99f3f4da5a1d7079867423b9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if515c37e228643f3898be215740476d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d51626bd954ba3a9951e2ea7a902f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06071e62b6544aba8290bd086369fa36_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ca599f32394a52802faedc82b745af_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b460bf00d240ccaa69bfe375444037_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c53847548a49db87515a3ddbad4e6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00d793f144d4af4a1ce283df7b0e5b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f752295bdb0485d837d6f29e1adac2e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4544e28f7504c5c8262ad98b729df14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8439291e86774964951a992f2d6ab802_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5288cacba948db9667020c833d81ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911375a84b704c0ab9bb33fe21b322dd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e3f9841c1a4adea92f051369b7a09e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9a75142a80484ebfaba480ea0f7c83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271b6a1089814cb6944c8c41c026a282_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2672bc23d34d2783b636a52ec86105_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10b7a8bcf704572915d199375bb6896_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d01bf14b454648b34a008c20d39400_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c794762acd24ec4b36b7bc0040e7a7b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbef017000f243ac8d113e85196f3c88_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1066cfd83fc4ddb923b546c7803df9f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddd38c4b0ed4cddb1ce69265363289b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1d770a04da46f0b432b0284fb196c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f931c2c6fc4c78a009b5427bf45c7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c3f12b90c242a3ae68a02bd72acb55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4550cb15256748d2a89b9750438c5b41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if196b52749ca4701a0fa9abedbed7ded_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib821d04236034791b8d3fa9b120448ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad5e0b1db685472892b3b4d4be7ab044_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ce7dd079ac4bfd882a6e3d866ee98c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bb0381128745be8004975327b5b957_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9648256b9c411694a641721c1541a0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32f5d1807074b2793d40078426095aa_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96636707b48c4179884f86ea7ec8a02f_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c26cb48e8240adb2b3260459d61952_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993c2da446a34875acb1c40b068b3089_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55c4a05385cc4fc18d198385dd93c921_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e71a02ecacf4adcb391e6c7f12702d1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb77ccae9a74814b7e00acb580b3aab_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gh:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia25c787a137a4bec9fd1a061e1adf313_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gh:PaloAltoCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f9ba8b79324beb88e8b7488d9694c8_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gh:patent</xbrli:measure></xbrli:unit><xbrli:context id="i32f365a013324f7ab9a257ec6616bfe4_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="petition"><xbrli:measure>gh:petition</xbrli:measure></xbrli:unit><xbrli:context id="i660c0774906b43d8862cee0a47049547_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705721d0e67244739b045350d485c93f_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9963f628118f43db994c73aa2c0b5931_D20201210-20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18022bf9450402f8ce4975ec504ea61_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b665c40a8f47ea8cd85e635363d20c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8d9afb89dd4632a8f43a7e0dfca6af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85be72137c66452fa6b52b9f18871115_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619cc50dcce348cc8689f3c9699ad658_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib95921a37c5e43f49a9c3c37215251e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2b5342dde3448c8891ca3d99b1978a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e477370d1a64fd2a0fa21ffcda04720_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51f14efceef46e083455712a43bf986_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63475ab401474e89bee5f05a4a47acd0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc5ee952cf84418b7016f83429f0aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic958cc4df2714adb8e2a85c3302cae4e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940221e6cce645cfb6a90604dac8cbe8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e73ee9eef8e49aab2ec36819934f632_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9815d0d7cb41b09b77791966e52c75_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i565831a0298547cd9661d27b9d9d2944_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b69d916f624dad9b518cabc4589b73_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2aaefc2c4e43a4a37ff326738a3f25_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie634a7fb83674c7d92b925a5d6a99ec1_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e7591cbb12410598b75394c40acba8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c7f0c0ebc94b6bbbcfabf0a1fae5db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51021850ccb4f1fadfb3bdbae1f91d3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17cb1196a064f4088f3fc6c035e9d72_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia097fb6e0e4d41ed842060e7bc5260e5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7a51301dcf41c98545f06434fe3b72_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:EquityIncentivePlanTrancheAxis">gh:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gh:EquityIncentivePlanTrancheAxis">gh:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia601d039561f4097b3df49643250b3bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3300f2c9ff4ec6a29cf3cc30f0a698_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8537a86f1af94a2daf05f30b67b193e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f17ed5a12ca4a6abb0cea17b1730fef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f46661f1f446eeb205375c1af434fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d04197610e4189a303bead82651edb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc36477bea5640ec874839095e170908_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f4b78122abd4e8eb313c8e1a7719f92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7fba181b054fabb73999b47d483dbf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f6cfe7e6404cae9e7b6b09a000b0cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4023c5dcd0439fb73518c68885f959_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007fd51f89bf4055aa793319535aa53c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22b70d2f2e34c20a09a9012c59cd21a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66ec163b0d848a3a230072df877cf55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23565c372dc4ccbb89ffb28f7af1b0e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77295fc586c94e54a8fba5426ea17938_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if994b46b023d4d5fa18a833907f95a23_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c5b239ffb4440f80781154268288d9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ba431512174cc5bfce850e0b0b12a2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2e85ec40be47df923a27894e32515d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477964bc10504bb0938d30103ef7edac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1104e86268b4788bd3ab46af5668636_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58da51c726c84bb7a102eab630e19383_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3851733963a44f5b6ab5baa83678583_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36d7e888e844c6ab365df40d7c9fb62_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439505c15efb47c09a20226584e2c489_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e2eb5867bd4abdad9efdb23c03648e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd8dd76287347a8994cc91cb0f37e54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1590c4a013498998b04d6183682906_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563548405428432e9be4583d990c20a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1764a9cb4164255b21e4e0410cbdd27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i467c75e1f7b948f5a7efd31013b1df18_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f3361b30354d25bc950de5b659ed29_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61bba0a88cc44568eb34939ff6408d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051dbab8706f4e6c98fecf9f6683eeac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0255fd6f42d4f048e85959bd465c936_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dae2902d6664783b4358b0e7fc11e28_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebaae8e37d2b469097bb427b4661df0f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c69dc8a627e4728912a6ed479ffc345_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e9f1511fdf4cfcb8763f4f23670aa0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9347e34e544e4e239b40143f08c828bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a11b9af24a42609ff2239dde8e7b4f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68413562a6147688552dc1e0f887f19_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8824d00a82d749e4ae56c26f8bf3f10d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181b6be341c14cacb65432c7b26b5d1a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754a60ee0b734d8c8d484dab169687c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa67442147d24fb6a1c2a53972720ac1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac62ba63e55f4ede8b1e77117a996888_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4779950a41b74addaabf2b2059d74b21_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237f233fbe394afd8d627b2eb131fc5b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323c4b627b0a459fba3b36b35483f280_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d16e8391a8340adbde54906d31ca966_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca0eb25cb4e48be9a03dadf144d511d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d2bc7082434cad8d5831042bf6a66e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b784372c3354db186e4207099919653_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibade6416d9d94221aaa09a5c56f76ec5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idac36981cc6c40c8b223afae0434d59f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1277ed3fdf429fb8b2ce51e59b628c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1476a97484154965919c2e362fd4d837_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd900800a93495eafddef1dfbea5516_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d20b34408944d6f96387d39fb1726ed_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23bce519e74e4d918ca90a92c7c39f65_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if34f8da1addc4820a1cb6767365cb8a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818a62562a3c4a978a87e6b139e9bdc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3edbb27baf14454882593f853aa8325b_D20211101-20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ie165b3dd2cd64109ae663021d54143ae_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI3_a56e1fec-3131-4b45-97ff-65f4bc0f90da">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM2_7ddd3b42-9dfe-41d9-87bf-28fa6cfca110">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yNjQ_1af382ad-a4a1-46c0-ba7c-2376a5a93312">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI4_fe9f4122-5468-40c3-871d-55497f7daea0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM3_c822194f-4e05-446f-a639-3915ae263f64">001-38683</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMx_1dcf2aa8-0b28-45ec-a4ed-c99123456331">GUARDANT HEALTH, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDNlZGUwMmQ2ZDRkNDAzNDgxMjIyYzA1YmZkYzFiMzkvdGFibGVyYW5nZTowM2VkZTAyZDZkNGQ0MDM0ODEyMjJjMDViZmRjMWIzOV8wLTAtMS0xLTA_590dcc66-468a-4d23-879f-ed25a57dd147">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDNlZGUwMmQ2ZDRkNDAzNDgxMjIyYzA1YmZkYzFiMzkvdGFibGVyYW5nZTowM2VkZTAyZDZkNGQ0MDM0ODEyMjJjMDViZmRjMWIzOV8wLTItMS0xLTA_e5bb52cc-0bed-49a8-aed6-85b23958fc88">45-4139254</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI1_6d97a27f-b489-49a8-b24e-796ddf537fdd">505 Penobscot Dr.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI2_4587ddbd-4c76-48b9-b677-02cd48cc99db">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI5_75e3f54a-c69a-4891-ac26-c2ded90c3d5c">California</ix:nonNumeric>, <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMy_80d2ded5-e388-4e25-b012-f93405b4e63c">94063</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMz_d35e8417-e5a4-45d5-9607-93d130fa1735">855</ix:nonNumeric>) <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM0_53a00bd6-924e-4ef2-b1d6-dd7ebfa30f4e">698-8887</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTAtMS0xLTE0OTg3_eb81e164-9ce9-4187-a33f-0bcf78e2b5b7">Common Stock, $0.00001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTEtMS0xLTE1MDU3_401a7043-3e2e-4292-ac68-7c0a4aa76c0a">GH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTItMS0xLTE1MDU3_7255250f-b9a5-47b6-b78f-fac692deef8a">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM1_3b091813-d4ed-4091-8111-d199f9c51bf2">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM4_85858d7b-6803-4022-ae99-28f0e0d11687">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.887%"><tr><td style="width:1.0%"></td><td style="width:28.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N18wLTAtMS0xLTA_d15b0d6b-5a7a-4641-ab0e-dc549afde48f">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N18yLTMtMS0xLTA_e1137a89-4659-4a39-931c-5189bfa7bf5a">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N180LTEtMS0xLTA_9ab329bd-a3bf-4495-9914-25d3bf11e500">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMw_2725c5e9-d43a-4910-8d31-89f55b6bb32f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;29, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i257839cad923440aa7e18dfdf53c45f1_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMjYx_37a44129-68b2-4734-884c-ff3a4644bb8e">101,656,348</ix:nonFraction> shares of common stock, $0.00001 par value per share, outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GUARDANT HEALTH, INC.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_13">Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_22">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_28">Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_37">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_37">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_109">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_109">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_109">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_169">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_169">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_169">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_175">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_175">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_175">55</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_178">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_181">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_181">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_181">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_184">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_184">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_184">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_187">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_187">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_187">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_190">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_190">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_190">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_193">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_193">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_193">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_196">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_196">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_196">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_199">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_199">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_199">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie165b3dd2cd64109ae663021d54143ae_202">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_202">58</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, including the section  titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business, our financial condition, our results of operations, our cash flows, and the industry and environment in which we operate. Statements that include words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;intend&#8221; and &#8220;expect,&#8221; variations of these words, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and elsewhere in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, in Part II, Item 1A, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and elsewhere in this Quarterly Report on Form 10-Q, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated.&#160; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_10"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_13"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Item 1. Unaudited Condensed Consolidated Financial Statements</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_16"></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMy0xLTEtMS0w_06621355-4dd0-4a84-8a4e-fb0141571e28">832,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMy0zLTEtMS0w_c6f1c789-7726-4e48-8cba-3b9e6bb22c88">832,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Short-term marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNC0xLTEtMS0w_4304e9f6-3041-4d0a-9bcc-65da590771d4">653,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNC0zLTEtMS0w_0c746a16-5c93-4036-828e-96f7eb51eeab">961,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNS0xLTEtMS0w_42451ebe-27bf-42c6-991b-840620fdcebf">60,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNS0zLTEtMS0w_df0846c9-491e-46f7-aee7-01ff8704d4d2">53,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNi0xLTEtMS0w_b9dc1304-83ff-4aaa-982b-fbec8efcfe79">24,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNi0zLTEtMS0w_9f095775-b2f5-40e4-b762-a6d05adabd98">22,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNy0xLTEtMS0w_df88cbbc-1a29-4a12-9ac5-69b26803c2ad">21,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNy0zLTEtMS0w_40d4cfe9-a4f7-4d9c-8ae3-9bc83f94e100">17,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOC0xLTEtMS0w_defd9942-b2b5-4c0e-a175-79dbdb83b0a2">1,593,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOC0zLTEtMS0w_c8b1e79c-f1ec-4da4-bcff-10bb6298e1f3">1,888,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Long-term marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOS0xLTEtMS0w_6377a85a-d6db-4a22-b062-2cea03db05a5">250,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOS0zLTEtMS0w_719898c1-50c5-46a6-b8af-b435f1a7b0d5">246,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTAtMS0xLTEtMA_8c8b2d85-7ec0-4725-917d-052419eb7764">106,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTAtMy0xLTEtMA_7d5f97d6-3438-406c-af15-522f97e1a028">62,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTEtMS0xLTEtMA_2b4cb95c-2ee4-49dd-8207-cbdf0d1ed2db">196,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTEtMy0xLTEtMA_6bdb7429-ae9b-4d65-bc9f-db4c3eb56b44">37,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intangible assets, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTItMS0xLTEtMA_ea3513dc-500e-4c44-ace2-8c01c71dc01e">14,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTItMy0xLTEtMA_46d4ba4e-9b54-4111-a415-439000c127da">16,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTMtMS0xLTEtMA_f6864097-dd02-4328-9dc3-d24246396fdc">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTMtMy0xLTEtMA_6e832056-35be-4e58-89d7-4347ed9729fb">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other assets, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTUtMS0xLTEtMA_e193948d-d04c-46f1-8c7d-9b3ed6310c2c">61,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTUtMy0xLTEtMA_a188304b-f34d-476d-b59c-7d2ebeb70465">17,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa">2,225,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b">2,271,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTktMS0xLTEtMA_c12fc3bb-8144-4e2f-a8fe-68f95c7705eb">15,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTktMy0xLTEtMA_d9469699-3c4b-480f-bb63-9bae0423f6b7">7,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjAtMS0xLTEtMA_4c757bd4-b5b5-40fc-bce0-d83b8fdbd1af">38,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjAtMy0xLTEtMA_f04a75f5-569c-464c-831e-0ab98660fd03">28,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjEtMS0xLTEtMA_c69ba13a-4c00-4e2d-9330-63551aa91c1d">40,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjEtMy0xLTEtMA_6a2826e9-a72b-4735-a8cc-d05cb86b5bd6">22,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjItMS0xLTEtMA_f5441a6e-b084-4e44-b16a-e96ba46b2aed">7,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjItMy0xLTEtMA_9654345c-d0f2-4b54-a03a-defc1dd2d729">8,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjQtMS0xLTEtMA_9c707816-6b57-41b2-82a6-c285a930d6ce">102,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjQtMy0xLTEtMA_746db415-9a5a-4b77-96b5-4dd5601e060d">66,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjUtMS0xLTEtMA_d266e7d0-f166-47a2-8527-27db01ab2a52">1,134,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjUtMy0xLTEtMA_a113d7cc-f76c-4d9e-b481-04f76a6dd8f8">806,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjYtMS0xLTEtMA_957c58f0-bd46-4ecb-a974-125c706703e2">216,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjYtMy0xLTEtMA_de428892-ced6-470a-9e11-476dc5b8d05e">41,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjgtMS0xLTEtMA_cf1b7e90-acb3-4f36-969d-1d563ea7bb05">3,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjgtMy0xLTEtMA_3cfc0e12-5a50-4fe0-80e0-03753d7daa60">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba">1,456,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014">916,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzEtMS0xLTEtMA_e1d21720-5ac5-4e24-a84e-9f6a1d5558f9">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzEtMy0xLTEtMA_9d7f9405-efa1-4863-bc66-9eca932acaea">57,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzMy_5486e4b0-56d7-4d1d-bd0e-3daf0d228292"><ix:nonFraction unitRef="usdPerShare" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzMy_81ce9684-08d9-43b2-95a4-f1ea3e36ab4c">0.00001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzQ2_67bc6b00-e2c9-4bcd-8494-128005b70bf1"><ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzQ2_b8f3322a-1bbb-4c93-bdbb-909501c78743">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2021, and December&#160;31, 2020; <ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzg0_1f46c38d-cc7a-43b5-9c72-128ea4d93cc4"><ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzg0_9867a4f9-1a9f-4e3b-896a-62117c016c8f">101,623,257</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzkx_41e77e7c-4dea-4787-a5c0-51c255e4bb7a"><ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzkx_aea314a5-1577-43bd-9895-26418e8afa71">100,213,985</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2021, and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMS0xLTEtMA_d1f6580d-30f6-4b52-b4d4-20cf63b31c3c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMy0xLTEtMA_90f34f71-24ca-472b-8eec-16c064659285">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzQtMS0xLTEtMA_2e820141-3029-4359-8ab8-0fd0633f07df">1,626,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzQtMy0xLTEtMA_0d2e9a3d-f5de-4909-a208-0113781050de">1,902,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accumulated other comprehensive income </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzUtMS0xLTEtMA_212b561d-7ea6-4cf3-8059-f28efbc31af4">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzUtMy0xLTEtMA_d030ae9b-e067-45ae-99fd-a976830b37f5">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzYtMS0xLTEtMA_72599b93-cbfc-4f2c-b492-35b4b39f011b">916,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzYtMy0xLTEtMA_ea337442-6bf9-478a-8ccf-83c0017b2f17">606,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Stockholders&#8217; Equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzctMS0xLTEtMA_dd6f8206-9e4b-428f-bd9b-19215bc6abbc">709,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzctMy0xLTEtMA_e56f7039-1d48-40a5-b496-67106dce071b">1,298,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzgtMS0xLTEtMA_2b302aaa-88f9-4f87-9361-68f0ae913dd9">2,225,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzgtMy0xLTEtMA_0bc9b131-af64-4701-8168-8268a6a05c69">2,271,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b" continuedAt="i1d67f940a04d42febffc53c32cc32930" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of September&#160;30, 2021, and&#160;December&#160;31, 2020, this balance includes $<ix:nonFraction unitRef="usd" contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMTcw_9cce2791-d380-4915-9a21-a4afc7a5c203">24.8</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMTc3_98024a33-36ea-459d-9997-632dd6f1ce11">35.0</ix:nonFraction> million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$<ix:nonFraction unitRef="usd" contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMzMw_27c7ef38-d0b6-4910-8c39-e98f06b0218c">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMzM3_6faf0b88-7102-4200-9809-5a33746a05fb">4.9</ix:nonFraction> million, respectively,&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, </ix:footnote></span><ix:continuation id="i1d67f940a04d42febffc53c32cc32930"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC0yLTEtMS0w_b83a3486-e888-486c-a84d-f3fb240cc697">79,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC00LTEtMS0w_53018183-84c7-49ec-b7f7-6578c9f2998e">60,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC02LTEtMS0w_fcef5b7f-a432-4ea8-a81a-f0b97e1a40ca">215,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC04LTEtMS0w_742163d8-c70c-4faf-89c0-8e07f24c8051">171,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS0yLTEtMS0w_fd995c82-fe9d-492e-af8a-20c5b3d9853a">15,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS00LTEtMS0w_fc82e93f-d70e-47c6-b0df-633c32f52671">14,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS02LTEtMS0w_957e9a85-02ce-428f-869d-21fca000af0c">49,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS04LTEtMS0w_2bc14ac4-3ab0-43d2-a251-d5f08d24e0ba">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi0yLTEtMS0w_670114de-9831-4dd2-9f0a-2bc3bcb7e481">94,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi00LTEtMS0w_078f1c85-cea3-4633-b193-4f83eb932e1e">74,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi02LTEtMS0w_b5b0f52a-8bf5-4fcb-b147-ff098c21ea9e">265,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi04LTEtMS0w_17f0abda-0142-4a0b-acb9-307c0fc1d359">208,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC0yLTEtMS0w_33e7bd0c-f862-4691-92da-c0f6b69fb501">29,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC00LTEtMS0w_83218ee7-e304-4d23-8ff9-f6b90705c83e">16,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC02LTEtMS0w_4c2dc5a9-2b8c-402e-abbc-54ccd9d4ae98">78,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC04LTEtMS0w_7fe8aa60-1765-49d6-8754-3ac20e105b38">52,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS0yLTEtMS0w_05d8bac4-240d-45b6-b246-8b72ba0866c0">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS00LTEtMS0w_9d3f3e0d-9b7a-4c59-a40f-1b51af4f1959">4,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS02LTEtMS0w_f268b065-3380-452c-9271-a2444f6e2bb1">11,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS04LTEtMS0w_5cce8f62-70d3-4903-b71f-f0bf13880972">11,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtMi0xLTEtMA_96e1dfaa-9c8c-4dc5-9633-7535fddfa3d4">70,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtNC0xLTEtMA_b8c458ef-2aa2-4d22-bebc-aa0e35d87c85">36,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtNi0xLTEtMA_c936ce0f-15c9-42b5-9405-d2de1b6c0113">190,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtOC0xLTEtMA_a63bc231-77ab-4ff2-956f-f39207d13f13">109,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtMi0xLTEtMA_4572cf7d-ec5e-4d82-8602-85d74cfb6801">50,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtNC0xLTEtMA_a5777e50-20da-422d-861f-0546facd48b4">25,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtNi0xLTEtMA_b56d2da1-778c-45d4-8280-3ec6350716c1">132,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtOC0xLTEtMA_97067742-0432-4030-a7dc-3af62d639c4a">75,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItMi0xLTEtMA_51cfe6d3-1c53-4a7d-a45e-37a032c2e105">50,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItNC0xLTEtMA_9cc0ece4-2a79-4a7e-aac7-f57b7aeccef0">66,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItNi0xLTEtMA_d74c2f85-1d43-45f3-ac49-4e3d161c7359">166,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItOC0xLTEtMA_faadc261-c868-40cf-bb73-c3d1e03c1e41">123,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total costs and operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtMi0xLTEtMA_e87257ae-23cc-4937-8fa2-095cd9c1d6c6">202,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtNC0xLTEtMA_5d9f6851-ed4b-4a01-ba54-b4c427e4ecb1">148,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtNi0xLTEtMA_1be0e7a9-26e0-4e87-ab40-ed9411ec60ea">578,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtOC0xLTEtMA_5f88204a-6198-41ee-8179-89227075a913">372,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtMi0xLTEtMA_efc06eab-0717-47ec-8234-7a8505b34ad1">107,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtNC0xLTEtMA_8444b5f4-821e-444f-82f1-a7b7fbe9bae9">74,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtNi0xLTEtMA_7f76d54b-a455-4b1a-aa3a-d2b4a3c5d62e">312,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtOC0xLTEtMA_95276797-0b5c-45b7-b5c0-fe995ab3f6b9">163,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtMi0xLTEtMA_cb32dceb-4bae-435e-a466-f0d73e08ca6b">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtNC0xLTEtMA_dfdc1d4b-b31c-4a82-bbef-bc82a011f3e6">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtNi0xLTEtMA_625728c7-63aa-40a0-a9fa-eff0a3754c04">3,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtOC0xLTEtMA_dd069029-4e52-46e2-bd84-c2ee48a3b610">8,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtMi0xLTEtMA_a2a58ef3-28b7-4d65-907d-d564627d5cc5">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtNC0xLTEtMA_86d5f7c3-12b7-434e-8dbf-d04c19af1f28">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtNi0xLTEtMA_1057dda5-c7b0-4786-a6ae-6ae465657102">1,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtOC0xLTEtMA_d9da2904-9819-4781-aa42-633c7f3b498b">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctMi0xLTEtMA_d015a16a-66ea-4282-be38-363a51c216dd">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctNC0xLTEtMA_454666e2-1d08-4378-b931-95eacc6086b3">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctNi0xLTEtMA_7322cf65-6c9e-4e77-ae83-0a6c12a8ae4a">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctOC0xLTEtMA_c5f8545d-f0d9-4897-80eb-c5d42a0d9c6a">2,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtMi0xLTEtMA_131a382a-11a5-4198-bf7f-711f8c8bb1df">107,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtNC0xLTEtMA_56daff61-34d4-46f2-8ac5-3f6a4d8feef4">71,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtNi0xLTEtMA_3d2a8f84-3f55-4473-ac68-1a9dc362d4af">312,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtOC0xLTEtMA_d1806d68-94c5-445d-9c8d-a1b2547b4098">153,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktMi0xLTEtMA_7167e935-bd39-4674-b999-85c10edcd50c">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktNC0xLTEtMA_aa8608c7-5b48-421a-b58a-be3f48502f5b">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktNi0xLTEtMA_f53f78e1-ff80-4087-9b73-53491d5784fe">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktOC0xLTEtMA_1ecf9643-2d94-4ae3-94e7-1500e18166e0">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtMi0xLTEtMA_59db747f-076e-4505-9eb7-1d22cbfc1b0d">107,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtNC0xLTEtMA_a0121778-5a45-46b2-9f6a-7836e37a0777">71,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtNi0xLTEtMA_ad364a64-db59-488b-9385-7093fb39c5fd">312,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtOC0xLTEtMA_8cd55105-bc67-4660-8f5a-4e79dc7c7479">153,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtMi0xLTEtMA_f3e119d4-f9f5-4feb-bfd5-3afdbd85b20f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtNC0xLTEtMA_749f4ff8-6a22-4cf2-b99a-881220d0b919">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtNi0xLTEtMA_47a648a4-d589-4149-b2f5-5365477bdd8d">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtOC0xLTEtMA_b4834c52-aa07-4182-8f9b-57e006c71cb7">6,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItMi0xLTEtMA_366a6785-efd6-47e7-b843-571410c64cf6"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItMi0xLTEtMA_5447ec3a-3a9e-44e4-98a6-3feb085ad11a">107,526</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNC0xLTEtMA_410ffa11-4a5a-49bc-b8d7-7fed493daba2"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNC0xLTEtMA_c548aac7-7661-484b-9b6f-b4f6c35316e8">77,670</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNi0xLTEtMA_042a4ad0-eecf-496c-86af-a6963d056692"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNi0xLTEtMA_5b7296af-6c8c-42a3-ab5d-61f9f3040771">314,759</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItOC0xLTEtMA_4d2f0a82-606b-4aa5-a6d1-23bb36549fa5"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItOC0xLTEtMA_c7ecd8fd-6dbd-409a-8476-c91a3efb1e8e">160,038</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtMi0xLTEtMA_8d523389-6bb3-4a2b-a73a-1573fa2cbe6a"><ix:nonFraction unitRef="usdPerShare" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtMi0xLTEtMA_d945464a-6ab8-49b2-aafd-f94dca4f4947">1.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNC0xLTEtMA_a937a2b6-dccf-491e-9fad-0ab1220a4630"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNC0xLTEtMA_c3dcaf05-f431-449d-9632-3bc7c368dece">0.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNi0xLTEtMA_e312dd27-7785-4b85-a892-ccdde8c3ae69"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNi0xLTEtMA_e939f6dc-867e-4158-ba4c-e54ab28117bf">3.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtOC0xLTEtMA_4c390a83-7e9c-4e03-96d3-fac429e1419c"><ix:nonFraction unitRef="usdPerShare" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtOC0xLTEtMA_7ae52ad2-a258-48d7-abbf-8cb7e6947465">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtMi0xLTEtMA_3547942d-001f-4f89-9522-43b8ed67973f"><ix:nonFraction unitRef="shares" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtMi0xLTEtMA_5036dc6e-bb14-4fef-850b-f10c73d98915">101,420</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNC0xLTEtMA_08983a6c-b99c-4ced-840d-737f5a71a651"><ix:nonFraction unitRef="shares" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNC0xLTEtMA_cf6de157-4e44-4669-9ab7-a2e06d25892c">99,554</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNi0xLTEtMA_2a1dc424-e264-474e-ad8e-ac2aac3ddd5f"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNi0xLTEtMA_5c25cd97-5ffd-4e1c-a043-bb3a1fd5fb96">101,184</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtOC0xLTEtMA_74fc4605-5672-419d-831c-43e6ab0cf64a"><ix:nonFraction unitRef="shares" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtOC0xLTEtMA_772ea594-c73c-4bfb-a0b9-e5a0b2538257">96,659</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy0yLTEtMS0w_bd079a2a-3529-4fc8-b1ab-5af8054a8542">107,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy00LTEtMS0w_afe3d011-0c0c-4d4d-b6f7-78ad906ec9c9">71,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy02LTEtMS0w_d821f2b5-d24e-45a5-82a3-ad24e1af1b08">312,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy04LTEtMS0w_3419fcd5-e91b-49ef-beb5-31f276075917">153,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax impact:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS0yLTEtMS0w_6da303e4-ce51-44e0-8892-1b7554bb20c0">513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS00LTEtMS0w_2f3bac1c-c742-4529-b07c-e135280fd99e">1,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS02LTEtMS0w_9c427ec2-9b06-46af-9d98-abe7872e7d82">2,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS04LTEtMS0w_927a9e61-1a0a-41c4-8ffd-7dada6bde1d9">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Foreign currency translation adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi0yLTEtMS0w_83e4d5a6-78bf-4d84-ad3f-4e6a7d8c803c">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi00LTEtMS0w_0c46dc78-4cfb-409b-b1b8-3cb84faa331d">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi02LTEtMS0w_6f252e36-6503-42a9-b071-f49278322c6d">1,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi04LTEtMS0w_48e48474-4645-4392-b5fd-6494d52e290a">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy0yLTEtMS0w_7ded6ce1-0a5d-4876-b1a4-3f417af88a39">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy00LTEtMS0w_dd430b23-ed79-4d4c-9a06-859c141e50eb">1,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy02LTEtMS0w_6692368d-db3f-4546-97bf-1e6c0b126156">3,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy04LTEtMS0w_7ecfc6b6-d5e8-47c5-a125-d552df85ac16">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC0yLTEtMS0w_49c5cb53-41ba-4a6b-a87c-7e5de924349c">108,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC00LTEtMS0w_f26f38df-786c-4726-8ac1-519ab4d61e01">73,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC02LTEtMS0w_05f0ff98-a682-46ae-9db0-d5fb4604ae33">315,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC04LTEtMS0w_daa57f63-e63d-48e6-97da-64b95756a17a">150,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS0yLTEtMS0w_e47ad6dd-3add-4eea-8f0c-104479179eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS00LTEtMS0w_19dfe005-6718-464b-9ae6-2062cb999009">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS02LTEtMS0w_fe003414-d2d5-4d12-a1b4-19405f124dd7">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS04LTEtMS0w_14ca654a-304b-484c-954e-4df60a97f179">6,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Guardant Health, Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtMi0xLTEtMA_276c9a93-7a5b-4034-9dd4-8a0a438b63e0">108,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtNC0xLTEtMA_bada12ec-9c65-446e-8a58-2fd489c13af4">79,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtNi0xLTEtMA_7e4d5ce7-bcfd-47da-a3d3-1669d830f1d9">318,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtOC0xLTEtMA_0118bd5c-38c4-4cfd-b385-abb2e899a504">157,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13d009641754c8c975c6fe1fe537d29_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xLTEtMS0w_0b20eb0c-ff84-40ae-b3a6-423b1bc8c955">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb188ab333be4dc08b9c5f417ad86fe8_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0zLTEtMS0w_ffa0007a-e22b-4bf4-ac7d-fddd55f967e5">101,265,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb188ab333be4dc08b9c5f417ad86fe8_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy01LTEtMS0w_b9c38def-ffe7-44e1-93c2-b1fa493c8fa3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb78fae6878478e8cd70530ed7da501_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy03LTEtMS0w_11805495-1df5-4cc2-94f0-ff2540e5e26d">1,597,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d56b88a0c04c4c8b36e3c969d626f2_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy05LTEtMS0w_b3dc244a-524c-498c-95af-207c5641b03b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93be9beff734563914f49b1f9d826c1_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xMS0xLTEtMA_17d1be39-d438-49b3-9dd5-663c7010a40e">809,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xMy0xLTEtMA_48a284fa-6e8a-40c8-996d-06ef2c02fc52">788,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cde6611fe144c878e5f147907f65625_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS0zLTEtMS0w_ab29cb40-6225-4f99-b775-5f2bb1743f1d">257,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS03LTEtMS0w_338fe924-ef42-4eff-9df3-22461d91d86c">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS0xMy0xLTEtMA_938854cf-bc13-4381-a35d-6240e88848aa">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cde6611fe144c878e5f147907f65625_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNi0zLTEtMS0w_97e1303e-9b3f-4c0b-9305-b5d024f75afa">100,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock exercised early</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNy03LTEtMS0w_5d983468-c76c-4043-abef-b103c331a608">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNy0xMy0xLTEtMA_3574ca90-bd1f-4981-905a-36b97a764dc3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfOS03LTEtMS0w_2f17a900-675f-46b7-9fbf-e08b291e7928">7,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfOS0xMy0xLTEtMA_69e01742-8672-4b11-be73-c8ff59e95e2c">7,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTAtNy0xLTEtMA_4f7b0022-68fa-458c-867d-f7df23341777">35,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTAtMTMtMS0xLTA_9bc7b9a6-1558-456d-845a-48c73201c258">35,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5a0784b897b4b27a75ddbda8d07eaf8_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTItOS0xLTEtMA_cdb69281-481d-417e-9a62-f0a34ed48704">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTItMTMtMS0xLTA_36142a70-c353-48cf-a054-d950995c6c53">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74b5b40f197c4b2b865e8b6c841941a6_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTMtMTEtMS0xLTA_9e674bb5-6070-47ca-8fa3-a741df528012">107,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTMtMTMtMS0xLTA_b9eff289-2e19-4519-9599-b98fcedd2084">107,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMS0xLTEtMA_935f6e45-ccec-45dd-b9a2-31a20babbb7b">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMy0xLTEtMA_1083dc46-43a7-42e5-9f22-d8b14055c19c">101,623,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtNS0xLTEtMA_06b78a72-a9b8-4e94-a79c-8dec2c6d409d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bee42491de4f5c82ed9ebfd0441c85_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtNy0xLTEtMA_98eb6bfd-bf04-43b2-bb56-3ac75f1945cb">1,626,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtOS0xLTEtMA_9c9a84c1-f4b2-404b-9bc0-7e92891d62cd">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i906ccbde79194f08bb0f80f06e646f90_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMTEtMS0xLTA_1fe24627-72f1-4a47-959a-595eaa52546e">916,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMTMtMS0xLTA_b370948c-c442-4204-9999-79442a8a56ba">709,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June&#160;30, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db331e94f874da2baee789ff575651f_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xLTEtMS0w_3ca451e6-7612-4646-97ee-2ae3ffca6059">50,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6d4e7bb16784bd9821eebce7010e751_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0zLTEtMS0w_8771296e-d964-418f-806e-eff139ce69cc">99,312,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d4e7bb16784bd9821eebce7010e751_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy01LTEtMS0w_ca0a3455-375f-4aaa-8a2f-ea436b63e48c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661bf286fe924b48b215bb888a02d853_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy03LTEtMS0w_71528abc-f71b-458a-a10e-35a1da87de08">1,544,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ac4fdfdbf1465f928c369ad560835b_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy05LTEtMS0w_1d2d7c77-5006-43b6-83dc-7c4fd31c4b35">5,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b663835ceaf4a199e40a3acf8f4be0b_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xMS0xLTEtMA_e1aa2b26-b145-4040-9e58-c4401b960799">435,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa05344a7c40424eb0df008620fe83e9_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xMy0xLTEtMA_6310d344-22b2-4645-9dbf-52f8cc9ad786">1,114,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS0zLTEtMS0w_16450200-3673-4d64-87d9-b5f568e8f045">533,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS03LTEtMS0w_6d217bb3-8688-4fd3-ae34-da401c618bc8">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS0xMy0xLTEtMA_d93473a1-74d9-4a2b-b958-b778bab18443">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNi0zLTEtMS0w_4d5e0248-82ac-4984-a238-53e43b4fe23b">50,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock exercised early</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNy03LTEtMS0w_f4fb1880-43ba-42f6-9599-8e3d4cb62d50">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNy0xMy0xLTEtMA_17a4febc-ce88-484a-bf17-15e8d751ee16">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOC03LTEtMS0w_b578a940-5da5-4953-9283-71320a72486a">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOC0xMy0xLTEtMA_036fd14c-1fb0-400a-9588-2df3e93c661e">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOS03LTEtMS0w_034b1e54-cc10-473e-9149-c279f81f4dcd">55,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOS0xMy0xLTEtMA_6bbaf747-2c1e-44bc-9f34-d5dcfe82f249">55,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8d6e638e7348069924511ee4d47851_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMS0xLTEtMA_2f831246-7204-4abc-aacf-6f5a9a9fa520">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMTEtMS0xLTA_d37edb77-d75f-4faf-8a67-01829797fe99">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMTMtMS0xLTA_4dd3cd7c-b104-4850-bbca-a2a5b2350a29">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55be54d3da949a5a9de5778b8b05dec_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTEtOS0xLTEtMA_a6c56227-29b0-4053-9516-a7157ec16e8e">1,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTEtMTMtMS0xLTA_b519796a-6054-4f47-854b-3b20e98285ba">1,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTItMTEtMS0xLTA_980feaf3-ca9c-4cc4-84e2-5ebd63cd22e4">71,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTItMTMtMS0xLTA_0f2e1652-da04-4bb1-ab15-1a5ee1be853f">71,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2020</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fce8977c7741018238eb1946bda5f1_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMS0xLTEtMA_8f72da3c-e5ac-4700-86bf-3ce5b17fa47c">56,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMy0xLTEtMA_04d3adc4-95bd-4659-a18e-be2d79acce85">99,897,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtNS0xLTEtMA_1be25b82-418b-4e0c-a255-95ec8fdeeeee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a25d82718384a71a7a9e81dc3b6f434_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtNy0xLTEtMA_5140dd94-0b27-42a8-b9d9-f7e8a0dab161">1,601,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963cbea62ef4985b9e091e63f42672e_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtOS0xLTEtMA_8514285a-d043-4e0f-bf3a-029678d819b9">3,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00f5560ad1c408eb348e0b4b24055ee_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMTEtMS0xLTA_f13bd795-812b-4d78-b1a8-958f1e8de70d">512,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMTMtMS0xLTA_43e105e3-6522-4d54-90ec-f85d58bd35a4">1,092,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3cecf4e8114f768c9e12d1be9f15ea_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xLTEtMS0w_fc6f3e16-f9d1-42de-8d84-7728bf86ac2e">57,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11487705f65f4d059cb0b6be76a69cd9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0zLTEtMS0w_66a39f67-6630-4de8-a805-9c3a758c3585">100,213,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11487705f65f4d059cb0b6be76a69cd9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy01LTEtMS0w_63c91e57-64bf-493d-a417-4756a6d62970">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e83cfa49ff4496aa510e2385e131bc3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy03LTEtMS0w_c78da577-73e6-4011-b089-62960e569a21">1,902,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4f1518b17d478bac803e4fdfda2df2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy05LTEtMS0w_4284a0c8-a987-43ae-aa3a-bc353715eee7">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d8678c58ece47b29c05d97165d5d969_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xMS0xLTEtMA_482860b6-0381-4431-a748-7b6566559b7e">606,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xMy0xLTEtMA_a6ffec3d-736c-4b79-884d-01d638a29560">1,298,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0wLTEtMS0w_9d07a004-36a9-48d1-b674-4d4b1c3ba821">Cumulative effect adjustment for ASU 2020-06 adoption</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8137948ad1cf4ec2ae5768ff46f1e611_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS03LTEtMS0w_cfd27988-0ffa-4126-8301-90bae6cc710d">330,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae691b8ed7640cbba3e0cfbe95f8ce8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0xMS0xLTEtMA_bfe4a634-4cb5-4e68-a318-c23674b734e5">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ea4d482e7e042e7a7764275e7e2b782_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0xMy0xLTEtMA_2d7ffb5a-7a73-4f4f-8d6c-fde2669721e9">325,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi0zLTEtMS0w_cd60d698-4f75-4001-a4ca-6f61cac90e6f">629,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi03LTEtMS0w_5b25ceca-b3fa-49bd-b58d-f48f864fbd7b">7,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi0xMy0xLTEtMA_43abde13-0422-4ef4-b0ad-75b1a62aa70d">7,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNy0zLTEtMS0w_901283e7-0933-4562-8a84-e67905542c8b">719,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock exercised early</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOC03LTEtMS0w_7db49632-2387-4a1f-a68e-eceeae391353">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOC0xMy0xLTEtMA_b216ba57-5ecc-410a-a346-841b436e4771">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS0zLTEtMS0w_18bfe04a-84e4-48ac-80ea-c676e3ba0cc5">60,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS03LTEtMS0w_60d27bde-6d05-4f22-a37d-09003b80f19b">5,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS0xMy0xLTEtMA_3380f8e0-2d96-4d8e-abf4-83e160d55822">5,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTAtNy0xLTEtMA_7d93fe16-8e0c-4765-ad9d-1aecef41466e">82,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTAtMTMtMS0xLTA_8dea9d34-f81f-4195-b46a-e713131c952d">82,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTEtNy0xLTEtMA_33aa7909-43a8-4944-bbfb-2c4d8610c07d">124,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTEtMTMtMS0xLTA_037426ac-8282-4dac-a57a-b8f3fda651a3">124,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17b1ceded2d84e4d989b48de6331e0bb_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMS0xLTEtMA_ffcd5aa1-9fe8-4522-974f-aa472e0227f6">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMTEtMS0xLTA_af2cbc72-a36d-408f-bf56-b9e14b500511">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMTMtMS0xLTA_9947f491-3f58-415e-a316-eb4bc300994e">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb1c87214cd44be4b4ddea1be858f87b_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTMtOS0xLTEtMA_4d169002-1158-4026-a624-32120b7ef2c3">3,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTMtMTMtMS0xLTA_72b48c53-9c70-4f02-a659-ed76e4e18fbd">3,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTQtMTEtMS0xLTA_888d76a9-70ba-45ac-84b7-17d597505155">312,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTQtMTMtMS0xLTA_452a4222-82d7-4300-a365-add3e8740514">312,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMS0xLTEtMA_23bd9f84-0cd5-4105-b784-4e002c9f09bc">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMy0xLTEtMA_d7268e2c-6cdc-4ac0-9f5a-5355a9716c55">101,623,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtNS0xLTEtMA_2d022738-876d-4a7c-8acf-5343d6b4d211">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bee42491de4f5c82ed9ebfd0441c85_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtNy0xLTEtMA_3319d528-2011-427d-8175-6cc3c03cb433">1,626,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtOS0xLTEtMA_2dc5ede6-a2ae-4617-9aab-60eba7681b5f">593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i906ccbde79194f08bb0f80f06e646f90_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMTEtMS0xLTA_8f9a9255-901e-4d3a-9df2-5297ef24ef6e">916,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMTMtMS0xLTA_16847d75-2647-46fa-a231-07149e6a725d">709,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e0e7a381cb4c54b6fa6ca304bcfb9e_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xLTEtMS0w_eb400862-f49a-4149-933c-f090d6a17dd9">49,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ea269815d434d1da3aa9ef5ae46f173_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0zLTEtMS0w_483915b3-eaca-44f7-a816-2c82645bd858">94,261,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea269815d434d1da3aa9ef5ae46f173_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy01LTEtMS0w_20915152-e809-4687-8ad5-869c4482092e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ee9c09290c467d9d3e214ca77c3592_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy03LTEtMS0w_c72442b8-4117-4441-a513-256fc02b0ace">1,150,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539db53b7f21487595b91dc1d07cc09b_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy05LTEtMS0w_f441c1fa-b47a-4e59-a2f8-176e1344013b">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6724a88cebfe46be8cd1c0db1eb07e71_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xMS0xLTEtMA_695f7501-824c-450f-a976-b449b5cf21eb">352,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bba3a03f7745a29d33398d6eff80ab_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xMy0xLTEtMA_defe43bc-0f61-4cfa-9186-b3a98db6c6c0">798,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0wLTEtMS0wL3RleHRyZWdpb246MzI2MjgzNTQzZmJlNDQzODlkOWFjMjI4NmQ0ZTMwMGNfNzU_cbc2c8b7-5cfc-4c94-b705-e6aeecda812c">1,130</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0zLTEtMS0w_b0b1a74a-9d15-49cf-8fb8-9801c63c96b6">4,312,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC03LTEtMS0w_9b561957-df9d-4a42-9b1c-28bff2d6b5e1">354,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0xMy0xLTEtMA_2eeed08b-7580-4627-91e2-5f0967aec114">354,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy0zLTEtMS0w_1f2330c4-9527-4b15-bba5-52e23b3cf6e8">1,188,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy03LTEtMS0w_423f1443-3bbe-4bdd-9ed5-823bd8ca1a92">7,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy0xMy0xLTEtMA_a5851b4e-00d1-4aeb-94e1-2914c9b1a48d">7,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOC0zLTEtMS0w_36f2bb5e-8422-432a-a874-c616b99c76c8">76,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock exercised early</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOS03LTEtMS0w_5c48fe21-d655-4cf2-9e0d-c39c5d5a3bd1">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOS0xMy0xLTEtMA_b387270c-cbbf-4d7f-ba21-08dd8b0a62db">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtMy0xLTEtMA_b8ad8744-bf3d-41e8-b826-16c117cdec37">58,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtNy0xLTEtMA_02d8afb7-43a6-4502-a253-3e09e331b651">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtMTMtMS0xLTA_da9aad17-467d-41cc-ad9c-4a3d5659707e">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTEtNy0xLTEtMA_426f44a7-df70-42a5-a2e1-3cfca3d48d0f">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTEtMTMtMS0xLTEyNDE2_07c839c8-80b3-4ebc-b0b6-80bc71749fd4">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTItNy0xLTEtMA_14af7db6-cf63-40fa-9b3f-bc06d1be5396">87,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTItMTMtMS0xLTA_13bb65a0-e61d-4bb0-8bf0-373ed2165502">87,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1fba2cc4574405a14c237af96ff0aa_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMS0xLTEtMA_84c23637-7637-459c-b500-3b7db180d6dc">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMTEtMS0xLTA_e29469a3-f9fd-46aa-8ef5-50d6495cb2bc">6,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMTMtMS0xLTA_2cbc9f15-6e58-435c-969b-f92cce70cbd2">6,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss,  net of tax impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6905570ee74c4bbab460aeff1b55a0cb_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTQtOS0xLTEtMA_7dd58df0-b3e4-4210-bc22-75f245c3aab8">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTQtMTMtMS0xLTA_fefc3041-e799-4040-93cc-4287d3605171">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTUtMTEtMS0xLTA_fcfd98d3-d81a-4637-bb9d-5da1f4db44aa">153,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTUtMTMtMS0xLTA_f19e266d-dff5-42b9-8951-3624e187d9c2">153,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2020</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fce8977c7741018238eb1946bda5f1_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMS0xLTEtMA_e749f706-ee09-4647-ace9-0c257203abbb">56,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMy0xLTEtMA_fe38ee37-0c6e-4f12-ac72-d72e3b4ad430">99,897,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtNS0xLTEtMA_a4612355-685d-4c67-80ba-c404d52b3875">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a25d82718384a71a7a9e81dc3b6f434_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtNy0xLTEtMA_28c5538c-cff0-41ca-92b6-b2b0ac9c8b0c">1,601,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963cbea62ef4985b9e091e63f42672e_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtOS0xLTEtMA_6c27a84f-cf47-4c30-bdad-ec8d82c23147">3,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00f5560ad1c408eb348e0b4b24055ee_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMTEtMS0xLTA_9a38ae06-86bc-4de7-b81a-7d9a04a7de77">512,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMTMtMS0xLTA_83069195-d152-4fad-83d4-f190fb8df4c3">1,092,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES:</span></div></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net loss   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNC0xLTEtMS0w_0ec7906a-b4e6-4f5b-a1f4-c9bf48690d47">312,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNC0zLTEtMS0w_a7c1cdf7-7b22-4f0d-93fd-dad28d174cec">153,238</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNi0xLTEtMS0w_609d9de2-891f-4075-80d2-752c0f823cfb">16,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNi0zLTEtMS0w_3fbf5393-0e29-4a90-ac11-dcd67d6435ea">11,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-cash operating lease costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:NonCashOperatingLeaseCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNy0xLTEtMS0w_9908d6c1-9ad1-418f-927e-7959ede4ea7c">17,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:NonCashOperatingLeaseCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNy0zLTEtMS0w_6a30eb55-6146-47fe-94f4-9ecd647a21e8">3,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Charge of in-process research and development costs with no alternative future use</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfOC0xLTEtMS0w_538a55dd-3446-4809-bf94-027ee8308dce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfOC0zLTEtMS0w_1c1f77fd-8adb-42ea-b970-0780d77d4414">8,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Re-valuation of contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTAtMS0xLTEtMA_11dfd5d4-3fe4-4a9f-b374-534f4e1cb9c6">1,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTAtMy0xLTEtMA_7f6f078a-38b8-4797-bea0-8eb0c266164d">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-cash stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTEtMS0xLTEtMA_c890506c-f53a-489a-b007-b3c6f3ae60ce">124,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTEtMy0xLTEtMA_1e8aa657-3a94-4f46-9597-c804489d3ac4">87,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTItMS0xLTEtMA_0de30a19-d9be-46c7-9a2c-15efc6bef2e0">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTItMy0xLTEtMA_529e86d5-bf33-4392-94bc-9d15947295b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Amortization of premium (discount) on marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTMtMS0xLTEtMA_1fb27ddb-4cdb-4aaa-99ea-91179dd581ef">9,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTMtMy0xLTEtMA_e559d943-1d01-466d-ab49-99e6206639eb">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Credit loss adjustment and others</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTUtMS0xLTEtMA_b9dc5f99-ff22-4305-9895-b5beec2c1000">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTUtMy0xLTEtMA_fad02ed2-694b-4057-96ca-055081fa6907">8,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTctMS0xLTEtMA_1692bfdb-a7b8-4c02-9775-98a1ba2eeb62">7,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTctMy0xLTEtMA_e2c0fee7-40e7-4978-81e3-0c846f128093">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventory   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTgtMS0xLTEtMA_c9d2fa5d-3f76-4651-81df-9bbda0d95368">2,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTgtMy0xLTEtMA_9bc8da7c-67d8-44ae-928a-ceb34005c39d">12,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTktMS0xLTEtMA_80e502ed-c247-4f83-b80a-c17ea6d65806">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTktMy0xLTEtMA_df19ad1b-4485-4012-8fd1-7aed95ea3253">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other assets   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjAtMS0xLTEtMA_423b905a-4395-4f51-8897-7c54cc49ce46">3,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjAtMy0xLTEtMA_57534bd8-d5ec-4fc5-aa7a-4b147ea33940">7,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accounts payable   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjEtMS0xLTEtMA_71560655-3fc4-4058-a832-090296d7f8bd">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjEtMy0xLTEtMA_03b43ded-038d-4767-8d9c-f999b8e8112c">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued compensation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjItMS0xLTEtMA_c6a4a336-8ac1-4025-aa5c-3a9a22e553cb">10,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjItMy0xLTEtMA_452e5e17-b18e-4e5b-bcbd-abc3f7886160">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjMtMS0xLTEtMA_74707f10-9965-43ee-aeeb-68b6f1bf41c3">10,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjMtMy0xLTEtMA_11d0d7d8-2d68-4961-8975-e51efb2e6dea">1,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjQtMS0xLTEtMA_815ca379-5f7e-49ff-9857-d49fea74126c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjQtMy0xLTEtMA_4096dd2f-49df-4aba-accd-7c85e58e94a6">3,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred revenue   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjUtMS0xLTEtMA_945545a7-214a-4efb-8523-b22846204813">1,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjUtMy0xLTEtMA_9661a8ab-c81c-4e2d-8849-dd186272db58">4,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjYtMS0xLTEtMA_f137baab-65be-4d8f-905b-7fdbd0a2b115">132,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjYtMy0xLTEtMA_7021926b-9744-40a5-9d55-b886b660485c">44,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjgtMS0xLTEtMA_b1753776-4f85-4990-aba7-9883f955339d">334,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjgtMy0xLTEtMA_31ff3d9e-6b86-4f2c-80bd-c9d1daec3eba">580,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Maturity of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjktMS0xLTEtMA_482c6efd-a236-4e74-a313-622b2f97e141">627,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjktMy0xLTEtMA_b0fa3fc0-4074-404e-8f44-0d8a39f377c9">307,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-marketable equity and other related investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzAtMS0xLTEtMA_1ac1fac0-5f39-4b05-9d77-ceb25fdf212b">39,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzAtMy0xLTEtMA_9995facb-cad3-4ebb-88a7-6c31aae900c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzItMS0xLTEtMA_f4f49416-8b74-4837-927a-0c222ea9e876">50,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzItMy0xLTEtMA_27ca7fde-f4ce-46e9-b11e-6c28753ade3f">28,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchase of intangible assets and capitalized license obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzMtMS0xLTEtMA_58531ac7-23b7-44d7-86bd-c0f1aa4ba8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzMtMy0xLTEtMA_f972e67d-bce5-495a-8dae-f86b60dafb18">17,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzUtMS0xLTEtMA_5ce45d18-f040-4e3c-a0f4-5cc036e3996a">203,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzUtMy0xLTEtMA_1a9f9053-b9d8-4529-8548-57fd5a2c01a3">319,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Payments made on finance lease obligations   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzgtMS0xLTEtMA_bf0b3745-8ec9-4ce8-a9a5-8a2a04d992ae">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzgtMy0xLTEtMA_7e08ffd0-b9f6-46fb-a16b-8206d54e97cc">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Proceeds from issuance of common stock upon exercise of stock options   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzktMS0xLTEtMA_07ee67ac-0db5-48c0-b407-f3dbe79bd57e">7,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzktMy0xLTEtMA_8d174a1e-c651-4da4-8432-9d751a4faf25">7,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Proceeds from issuances of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDAtMS0xLTEtMA_5dd767d9-fbfa-4155-8d84-866717a5e8ba">5,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDAtMy0xLTEtMA_50137bd2-c149-4af1-8b95-937e5e8a1430">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDEtMS0xLTEtMA_ed5e0741-c5d2-4850-b738-e2d5f90fc97e">82,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDEtMy0xLTEtMA_ea4f06b4-ca25-4215-be9b-f141a10ce2ea">2,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Proceeds from public offering, net of underwriting discounts and commissions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDItMS0xLTEtMA_4d2041ac-a1c0-4b65-b598-0c686e83b8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDItMy0xLTEtMA_728b2fde-251e-4e3b-b7be-14bb74f47b6d">355,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of offering costs related to public offering </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDMtMS0xLTEtMA_faf52011-fb56-4d9b-9f59-a7baac4a613b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDMtMy0xLTEtMA_92026a29-de4b-44e4-8ab2-dca62a53300d">1,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of offering costs related to borrowings on convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDQtMS0xLTEtMA_91b72a46-2edd-45fe-8b8d-fae101caf04c">784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDQtMy0xLTEtMA_e48877e3-8bf7-4658-828a-928b010c6cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDYtMS0xLTEtMA_7b78fb62-bc9b-4b22-baf5-136b69e9ec02">70,604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDYtMy0xLTEtMA_292d40e7-272d-4ba0-80c6-b0c01fa429f8">363,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDctMS0xLTEtMA_9023e808-2e1c-4034-9630-7e97d6e16540">1,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDctMy0xLTEtMA_35e3fced-bc37-4d8c-8e69-cc1999ab598b">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDgtMS0xLTEtMA_1274a69f-e475-449e-898b-c3ac044b69c3">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDgtMy0xLTEtMA_a99d8bab-60fe-4fd8-85dd-822941438776">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents&#8212;Beginning of period   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDktMS0xLTEtMA_842be821-89e6-44a1-a3a8-ddc3efdeab72">832,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bba3a03f7745a29d33398d6eff80ab_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDktMy0xLTEtMA_a8ea6572-a805-46ed-a279-a71ce3529c76">143,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash, cash equivalents and restricted cash&#8212;End of period   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTAtMS0xLTEtMA_66f4200c-5c03-48bb-9e8a-0cca4b3b2645">832,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTAtMy0xLTEtMA_7c294035-ab78-4871-8de7-bc37abb3e2bc">142,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTItMS0xLTEtMA_db466b64-a398-4da8-9963-27e28af96699">171,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTItMy0xLTEtMA_5085cde6-c670-426e-a2eb-0a0b76dc3f5b">10,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Noncash Investing and Financing Activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTYtMS0xLTEtMA_de576ea0-ff5a-4a3e-bd47-63a2a9068032">9,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTYtMy0xLTEtMA_fb2411eb-cd68-48ad-954e-593c2bc58dfe">4,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="gh:EquitySecuritiesFVNIIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTctMS0xLTEtMA_ee8088c3-00bc-4796-8807-720dc33930a4">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="gh:EquitySecuritiesFVNIIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTctMy0xLTEtMA_9c5a2832-b30b-4053-b94b-6f6c7f15a498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment acquired under finance leases</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" name="gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjAtMS0xLTEtMA_87b4af49-45d5-46bc-bde9-3adc307e644e">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" name="gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjAtMy0xLTEtMA_af6ae759-52d5-4dba-bec9-e36b722d0748">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjMtMS0xLTEtMA_a1e9dae8-87cb-443c-9cb0-3c3048704a37">832,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjMtMy0xLTEtMA_9b55a652-736c-4946-8d29-14fc8c519a06">142,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Restricted cash &#8211; included in other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjUtMS0xLTEtMA_996ff4fc-7f8b-4c1a-a08b-b75b4aaa9460">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjUtMy0xLTEtMA_c05244e8-4e71-4987-8297-6ab05da5b691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjYtMS0xLTEtMA_cf701a90-9405-48eb-8a15-f79d7e671368">832,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjYtMy0xLTEtMA_93e9221f-1663-4282-9b67-c8d12455dc8c">142,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guardant Health, Inc.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_40"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80MC9mcmFnOjI4MmZiMjI3OGY3MTQ4MjY4ZDdhNTBmNWYxNDBiZjNjL3RleHRyZWdpb246MjgyZmIyMjc4ZjcxNDgyNjhkN2E1MGY1ZjE0MGJmM2NfMjc0OQ_f9a350d1-52d8-4223-b8c7-0b9cedc39c6a" continuedAt="i2fae1163e1e9437ea210a9a04208b8a2" escape="true">Description of Business</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2fae1163e1e9437ea210a9a04208b8a2" continuedAt="ibe11e0eb1c564072a58da024fdef71fc">Guardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a liquid or tissue biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company provides its Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. In February 2021, the Company launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, the Company launched Guardant360 TissueNext, the Company's first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. The Company is also developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's tests, the Company has also developed the GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="ibe11e0eb1c564072a58da024fdef71fc" continuedAt="ic814bfa4f970424eb896ed249f195263"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#8220;SoftBank&#8221;). Under the terms of the joint venture agreement, the Company holds a <ix:nonFraction unitRef="number" contextRef="iaacefe81c0f14186af54df7f09699324_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80MC9mcmFnOjI4MmZiMjI3OGY3MTQ4MjY4ZDdhNTBmNWYxNDBiZjNjL3RleHRyZWdpb246MjgyZmIyMjc4ZjcxNDgyNjhkN2E1MGY1ZjE0MGJmM2NfMjUzOQ_7d58d4d5-4a41-4b1a-be76-6ec732dca86b">50</ix:nonFraction>% ownership interest in the Joint Venture. As of September&#160;30, 2021, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic814bfa4f970424eb896ed249f195263">) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.</ix:continuation> </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_43"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1ODE_30c861d9-3a67-4bb7-9aae-aaf3ce4a4a79" continuedAt="ic1eef2b417f44728b6b9eac356873ba0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic1eef2b417f44728b6b9eac356873ba0" continuedAt="i9e4579ec77d446f0868d515956fc27cc"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MTM_0c4b380d-d489-4cb2-b5b3-bfc99e0870d7" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable securities as of September&#160;30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzA_e2539ea8-0782-494e-a7ac-75b4fbee7df7" continuedAt="i98a331aee2a441b69aa4a21c3f10c141" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i9e4579ec77d446f0868d515956fc27cc" continuedAt="if258d3da7c494ff0a90010373fd8af15"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98a331aee2a441b69aa4a21c3f10c141" continuedAt="i7419d748c3624a33830237ece56b6ca5">marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. </ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7419d748c3624a33830237ece56b6ca5">The extent to which the coronavirus 2019, or COVID-19 pandemic, will ultimately impact the Company&#8217;s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzQ_90e45fa8-6879-41aa-914d-a6d90a1dfa4e" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of September&#160;30, 2021, the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2021, and 2020, and cash flows for the nine months ended September&#160;30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MTY_3f390fa7-2d76-4dd6-bf19-0b7053e562a4" continuedAt="i7c971a1b8db44360bf6aaae8bb966224" escape="true">Foreign Currency </ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c971a1b8db44360bf6aaae8bb966224">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021, and 2020, foreign currency transaction gains and losses were immaterial.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of payroll withholding related to the Company's enrollment in certain voluntary disability insurance plan. Restricted cash balance as of September&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjE1MQ_495feb50-f6e2-4736-aa66-48ded28d6753">0.3</ix:nonFraction> million, which was included in other assets in the accompanying consolidated balance sheets. The Company did <ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjI1NQ_2085745b-4723-4a90-b599-89e4b8b83f1f">no</ix:nonFraction>t&#160;have any restricted cash as of December&#160;31, 2020. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investee. The Company's non-marketable equity and other related investments totaled $<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjY3MQ_1f2266e7-3773-4524-8ff0-964f738236c7">39.4</ix:nonFraction>&#160;million as of September&#160;30, 2021, and are included in other assets, net on the accompanying condensed consolidated balance sheets. The Company did <ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjc5Nw_447ec9f0-a59e-442e-abd3-3f80e52f37e1">no</ix:nonFraction>t&#160;have such non-marketable equity and other related investments as of December&#160;31, 2020. Non-marketable securities are subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="if258d3da7c494ff0a90010373fd8af15" continuedAt="id35eeb1704f04482872b95ebe167a347"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. Pursuant to one of the investments in non-marketable securities purchased by the Company, and subject to the Company purchasing additional non-marketable securities from the same investee, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022.  As of September&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt-sec:numwordsen" name="gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNzc4MA_30664576-aaa6-407b-bc72-f9474bc84434">no</ix:nonFraction> impairment or adjustments to carrying value of non-marketable securities have been recorded. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions. </span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjE_8c8b3037-079c-4928-9c2f-0f1715885989" continuedAt="ieae638f331cb4f2d8c16d39eda490028" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjI_5117d3fc-cbcc-48ba-acd3-280010872e11" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNS04LTEtMS0w_0e3aa0d9-afb1-4bb4-9ad2-bad9ac0590e1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id09d1ad0faad479daa3acc238b4cd800_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNS0xMi0xLTEtMA_136e82b1-52c6-40ae-9366-5ad1659681dd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f9601fedfcd4106983c11355226e3ab_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0yLTEtMS0w_675ad97d-f5c6-4045-8d9f-adab461dec95">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i956c76338cf9472792fc8fb1eb5c02f1_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi00LTEtMS0w_12a617ae-74c6-4431-984d-f543a9527047">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id98fa25d42954af2baa244b886e1c86d_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi02LTEtMS0w_4fc961c7-fe76-4a8c-bb86-d602175abe5c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b1b80c40c794c5483e2a614b550e4df_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi04LTEtMS0w_0512b19b-820c-4f41-9b4a-449d26e0a768">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd1b5cb3bc064b06ab1c3b5a280c72e7_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0xMC0xLTEtMA_24beb290-e56d-4e68-9cfe-0ba58b10b287">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id99f62e950344ebd9a1b6da0b6c5ce54_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0xMi0xLTEtMA_87cb2d48-00e1-45dd-bd7d-5a10db48c954">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3be6ab2fcffb478c974ac3fefc049dbb_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfOC0xMi0xLTEtMA_6e1ccbcd-0f3e-4fe1-8e0d-66626adfed2f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icad452344b214db5813fddb4470c5555_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfOS0xMi0xLTEtMA_5bf5e24e-23d4-4c17-991f-8b0f19447820">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="id35eeb1704f04482872b95ebe167a347" continuedAt="iaf4582585a0740e7a0fcaebf421c7b0f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieae638f331cb4f2d8c16d39eda490028">The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $<ix:nonFraction unitRef="usd" contextRef="i26ebea8c7fe84cd99c89b4a20e1252ee_I20200831" decimals="-5" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesBeforeAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTA4OTc_c1755caf-f0fb-499d-9d5d-0cda8950f6d8">8.0</ix:nonFraction>&#160;million payable over a period of <ix:nonNumeric contextRef="ib17fe7f4e508446f9ee412617b8ed455_D20200801-20200831" format="ixt-sec:duryear" name="gh:ContractualReceivablesTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTA5MjU_e3351e46-f11d-4f61-8cd5-3c1ab307bd99">6</ix:nonNumeric> years. In December 2020, the Company received the first installment payment of $<ix:nonFraction unitRef="usd" contextRef="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="gh:ProceedsFromContractualReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTEwMDE_0c295483-fca7-4f6e-9279-8969d85806e6">1.0</ix:nonFraction>&#160;million. The Company has evaluated and recorded a credit loss for the remaining $<ix:nonFraction unitRef="usd" contextRef="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTEwNzY_444b54fc-6b36-4307-9460-e70af265f511">7.0</ix:nonFraction>&#160;million considering the third-party's credit worthiness and lack of financial history.</ix:continuation> <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NTg_71200bc4-dada-4a33-a34d-a2cbfc7e7d9f" continuedAt="ibbcf5f641340421292754cf7289cc26d" escape="true">The following table presents the receivable and the related credit loss amounts: </ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:justify"><ix:continuation id="ibbcf5f641340421292754cf7289cc26d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to (Reversed from) Other Income (Expense), Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassi<br/>fication</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousand)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0yLTEtMS0w_2fb0e785-5ddb-4426-bc11-5f186ace238b">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi00LTEtMS0w_83cd1fed-23d0-487f-aed8-4a6248a2a913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi02LTEtMS0w_23af7ccd-579e-496e-a1d7-60955661c040"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi02LTEtMS0w_4f9bbdae-d86b-4975-b408-41d881fb6a12">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesCreditLossExpenseReversalCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi04LTEtMS0w_5f0d3d7b-cfe2-4076-9946-137031adef01"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesCreditLossExpenseReversalCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi04LTEtMS0w_866af9c5-0ac0-415c-891c-ce838ade17dc">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesCreditLossReclassificationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMC0xLTEtMA_48a6f414-e6d0-4054-b264-220a5adfabb4"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesCreditLossReclassificationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMC0xLTEtMA_ad0c6e5b-b800-4dfd-8286-1de1f59f955f">1,100</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMi0xLTEtMA_040f367a-1de2-445b-9c9a-24741b43ec41"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMi0xLTEtMA_823648d8-f496-49d7-913e-cb8f75a1a2ff">1,100</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xNC0xLTEtMA_cd82553d-fbd4-4c13-972b-c346d583289d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xNi0xLTEtMA_37e07972-c586-4f2c-b20d-4028297f479c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0yLTEtMS0w_f84465d7-959a-4daa-a794-4e2062d1ce26">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy00LTEtMS0w_04f26103-7f97-4a11-98bc-375accd42fb2">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy02LTEtMS0w_2927f5e1-050f-47e7-80dc-0593b1e1d7e2"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy02LTEtMS0w_fbae9863-f1c7-4cb8-9397-c60854831cc5">7,000</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy04LTEtMS0w_c449c60d-ab80-462d-b95b-86821ebca492"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy04LTEtMS0w_c89b6b00-7018-4814-8327-1642f49c1190">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesCreditLossReclassificationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMC0xLTEtMA_13019451-10d6-41c6-9f25-cdad66ee8833"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesCreditLossReclassificationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMC0xLTEtMA_372eae03-88d8-4370-86d0-9742385051c3">1,100</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMi0xLTEtMA_86f6bda5-1801-47b5-9268-ba310f90fe30"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:ContractualReceivablesAllowanceForCreditLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMi0xLTEtMA_ab553b4e-2524-4369-8458-53232c01a6ea">5,900</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xNC0xLTEtMA_ced6de35-451f-4aa8-9ae8-eb7662b081d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:fixed-zero" name="gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xNi0xLTEtMA_f4b153df-2f64-4e42-b37a-612784775e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTI_9a0dc935-67a5-4563-acac-87a270a44003" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of September&#160;30, 2021, and December&#160;31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are presented under accounts receivable, net and other assets, net on the Company&#8217;s condensed consolidated balance sheets and include balances due from commercial and governmental payers, and biopharmaceutical customers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of&#160;September&#160;30, 2021, the Company had contract assets of&#160;$<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI2OTM_ba2d2c68-1434-479b-9815-f51547121086">30.9</ix:nonFraction> million which was recorded in accounts receivable, net. As of December&#160;31, 2020, the Company had contract assets of $<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI3ODk_029177a4-7a50-4136-b164-9e3a11cc53ca">15.6</ix:nonFraction> million which was recorded in accounts receivable, net, which included $<ix:nonFraction unitRef="usd" contextRef="i7e32f7150de24707acc5c5ece9051c90_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI4NTU_f12cb5a4-3f66-4ffa-ad14-7158d25d702a">8.4</ix:nonFraction> million of unbilled receivable relating to Guardant360 CDx.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:AssetAcquisitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzY_f5e32478-7b6f-49d7-af3c-782e9c73118a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Nzc_f70804e2-dd23-41b7-affc-a7c4f1b1cb39" continuedAt="ie2825af3199243df8f70e52c5238db6b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="iaf4582585a0740e7a0fcaebf421c7b0f" continuedAt="ie45da208b37a4089ac4529eced04ab1d"><ix:continuation id="ie2825af3199243df8f70e52c5238db6b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;<ix:nonFraction unitRef="segment" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTQ5NjE_bdde96b4-87f3-4ef9-b7ef-fe05b6aba832">one</ix:nonFraction>&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;September&#160;30, 2021, there has been&#160;<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTUxMjQ_ee8cb5e8-6fd9-40ea-89b5-f2cdc0a25050"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTUxMjQ_f6f3f747-ccaf-4fc1-abd2-b48c757cb769">no</ix:nonFraction></ix:nonFraction>&#160;impairment of goodwill or IPR&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately <ix:nonNumeric contextRef="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTU0NjM_a376c67a-b4b6-45bb-a7f7-344736d93d1e">6</ix:nonNumeric>&#8212;<ix:nonNumeric contextRef="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTU0NjY_c4660f4f-fc13-46da-846a-5445efda280a">12</ix:nonNumeric> years.</span></div></ix:continuation><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MDI_9219e0ac-8eb0-409a-87e4-7e0f6e4e49c3" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTM_c0a2bc3f-138a-4114-9e3b-bca7b7b84533" continuedAt="i0bbf0e927fe947748b1ff7825cad3181" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1ODg_b3896ebf-ea1a-4ebd-a6f4-0a019e3bf771" continuedAt="i82ce44c012f94b7c9bb19241af530d2c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ie45da208b37a4089ac4529eced04ab1d" continuedAt="i47d2fd746b9941d4a527aeafe71bfdc7"><ix:continuation id="i82ce44c012f94b7c9bb19241af530d2c" continuedAt="iffab883dbdd74d2abf6b0da7fecfaa2b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended September 30, 2021, and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjE4ODg_6ea9c8d5-2c13-4374-881f-bfe5737e27c9">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjE4OTU_69012c17-4084-485b-9a08-3f1b7a8c6bf0">11.4</ix:nonFraction>&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the nine months ended September 30, 2021, and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjIyMzA_dda9043a-1ecc-439e-8c95-e9b88aac484e">17.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjIyMzc_f77ac5a6-55a3-4aa4-9b7c-a84dc1964e7b">21.9</ix:nonFraction>&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i47d2fd746b9941d4a527aeafe71bfdc7" continuedAt="i52bc8a0425dd4bf3a5406f4626fe8115"><ix:continuation id="iffab883dbdd74d2abf6b0da7fecfaa2b" continuedAt="i88856eab9f134af58092d83a3ad04d60"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Kits fulfillment related revenues are recognized when such products are delivered.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of September&#160;30, 2021, and December&#160;31, 2020, the deferred revenue balance was $<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzMTc_18bb29e7-be07-4456-84ba-b303104afbbf">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzMjQ_8f05f607-7f46-435d-a9de-6c0f54b588d7">8.6</ix:nonFraction> million, respectively, which included $<ix:nonFraction unitRef="usd" contextRef="i45b5b98c81024b9fa1cc9ef6f43bb435_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzNTc_47971e80-8fa0-4a20-8e10-314f728ddfd3">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic64931530ecf46b0b986e9644237b683_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzNjQ_3c9eb14f-68d9-4d7b-b250-5f3a3b9162f6">3.0</ix:nonFraction> million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the nine months ended September 30, 2021, that was included in the deferred revenue balance as of December&#160;31, 2020, was $<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA2NDk_6b0e8a2c-e1fc-4f80-997c-c381bac544ed">8.0</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="id82f3289e43a450fb918eac02af264ac_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA2NjI_b80e44c7-78c0-4896-83bc-be78a0fec205">3.0</ix:nonFraction> million represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;Revenue recognized in the nine months ended September 30, 2020, that was included in the deferred revenue balance as of December&#160;31, 2019, was $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA4ODc_d8842100-3462-4443-b69b-0f2232465794">8.8</ix:nonFraction> million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i52bc8a0425dd4bf3a5406f4626fe8115" continuedAt="ie80193c86c4546ff9074e2c995ff143f"><ix:continuation id="i88856eab9f134af58092d83a3ad04d60"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:CostsofPrecisionOncologyTestingPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjA_e8741694-5ca8-4cd4-aa1e-b6bb4d20c5dc" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Precision Oncology Testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:CostofDevelopmentServicesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Njc_4acda242-c6e8-4d37-8037-88d891679bd7" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzI_64b07252-5e24-411a-82b3-de1e3d2f637f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTY_ebe6d8f3-99bd-413b-885d-919abddc5d9b" continuedAt="i1c7a3bd198fe40a9b6c3866ac0c2132c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ie80193c86c4546ff9074e2c995ff143f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1c7a3bd198fe40a9b6c3866ac0c2132c">The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTc_334f26d1-875d-4112-867d-4fb24ae537c8" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Njk_176db5bc-7755-4989-a1af-eed4545fd8c6" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the Company&#8217;s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020, from additional paid-in capital to convertible senior notes, net.</span></div></ix:nonNumeric></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_49"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfODU0Nw_ae3cb713-f0a2-4feb-834a-98fed1ebf70a" continuedAt="ia650b7dc06b14f8884d4620214d2066a" escape="true">Investment in Joint Venture</ix:nonNumeric></span></div><ix:continuation id="ia650b7dc06b14f8884d4620214d2066a" continuedAt="i6b188101cd9841b3af20ff4fdcb6626b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the joint venture agreement, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjM2_7b2680ba-6a1e-4e66-b368-dcad2c783a66">9.0</ix:nonFraction> million for <ix:nonFraction unitRef="shares" contextRef="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531" decimals="INF" format="ixt:num-dot-decimal" name="gh:EquityMethodInvestmentSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjQz_603cceff-c425-4320-b712-714b67875612">40,000</ix:nonFraction> shares of common stock, or <ix:nonFraction unitRef="number" contextRef="iaacefe81c0f14186af54df7f09699324_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjcz_41ae4a6c-542b-4813-979f-7aacdd17fdb4">50</ix:nonFraction>% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $<ix:nonFraction unitRef="usd" contextRef="ieb65abbec30b4f71a61b44720b765997_I20180531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNzYw_1c5ac419-bb5a-4d19-8c81-839aaf57d76e">41.0</ix:nonFraction> million for <ix:nonFraction unitRef="shares" contextRef="ief4823a55ced453d9a74182e29b5dab5_D20180501-20180531" decimals="INF" format="ixt:num-dot-decimal" name="gh:EquityMethodInvestmentSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNzY3_1823b01c-6ce8-44b4-a71f-e25e87d30a40">40,000</ix:nonFraction> shares of common stock, or the other <ix:nonFraction unitRef="number" contextRef="ieb65abbec30b4f71a61b44720b765997_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfODA3_524fe210-d3df-420f-be8d-dbe8c75d8816">50</ix:nonFraction>% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to <ix:nonFraction unitRef="shares" contextRef="ibd2a1b5721c14e62ae22216f233394a8_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTIwMQ_8d01e02b-e1d9-4dc0-8324-d51477b87b67">89,000,000</ix:nonFraction> shares consisting of <ix:nonFraction unitRef="shares" contextRef="i45ddcd6f8bc5427ea47298e84035d15d_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTIyNQ_14999843-b5e0-4cdf-8c94-44d5abb723e8">80,000,000</ix:nonFraction> shares of Class A common stock and <ix:nonFraction unitRef="shares" contextRef="i4d59f69aa9304c82926efc78bf2688b7_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTI2Mw_df93af18-7399-4229-9d18-d494fe7efa34">9,000,000</ix:nonFraction> shares of Class B (non-voting) common stock; and authorized <ix:nonFraction unitRef="shares" contextRef="i10beec7190eb42289690ddc970be2e86_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTMyNg_6a210836-08a5-4068-9da6-8e45c43f2d2f">80,000,000</ix:nonFraction> shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for <ix:nonFraction unitRef="shares" contextRef="i63b22c3fce9b49408a166a3ade4c8098_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="gh:PreferredStockSharesIssuedUponConversionOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTU0NA_206bfac8-d8b8-4420-9f3d-13506999c65d">1,000</ix:nonFraction> shares of Series A preferred stock. As a result, each of the Company and the affiliate of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i6b188101cd9841b3af20ff4fdcb6626b" continuedAt="ied2532225feb49cea3a9b6a693e02b70"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SoftBank held <ix:nonFraction unitRef="shares" contextRef="i696cb7034a6f4fb389687d5640e8bc6f_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTY1MQ_1aa0ae32-c546-430f-8efc-dcae327276b6"><ix:nonFraction unitRef="shares" contextRef="i8f9afa11a3f342b681841d1bdf79f0eb_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTY1MQ_6a050987-f5f9-46df-91f9-828173b3f801">40,000,000</ix:nonFraction></ix:nonFraction> shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $<ix:nonFraction unitRef="usdPerShare" contextRef="i28b82c98a5b04b45b4ba1de5d14ba5cd_D20200601-20200630" decimals="INF" name="us-gaap:PreferredStockDividendRatePerDollarAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTc3OQ_c97406b0-dace-4566-af4a-143d344f4583">0.05</ix:nonFraction> per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#8217;s 2020 Equity Incentive Plan pursuant to which <ix:nonFraction unitRef="shares" contextRef="i7c382b53abce461ab4ceb209bd8a2229_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjAxMQ_ba230c2b-f63b-415b-8660-d002865a9815">4,595,555</ix:nonFraction> shares of Class B common stock have been reserved for issuance. As of September&#160;30, 2021, and December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i9c715ccc41be43d897292cbe1d39f9f0_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjA5Ng_510772ce-da33-454e-8133-32a1987f1606"><ix:nonFraction unitRef="shares" contextRef="i9c715ccc41be43d897292cbe1d39f9f0_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjA5Ng_5a087e6c-8c2f-49a0-a32c-dc10bd535760">313,331</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjEwMw_3400e461-2f78-40e6-8309-cfc5cdad80f9"><ix:nonFraction unitRef="shares" contextRef="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjEwMw_6a06f09b-4366-4637-b1fa-75dad79665ef">no</ix:nonFraction></ix:nonFraction> shares of Class B common stock have been issued and outstanding, respectively, and <ix:nonFraction unitRef="shares" contextRef="if43dd801a43d47509034a8a6ad46dfe4_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_2e2de2e6-60b4-4a23-a9bb-f432967b2a45"><ix:nonFraction unitRef="shares" contextRef="if43dd801a43d47509034a8a6ad46dfe4_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_619c3c5f-b458-4a4a-bb92-6842d505781f"><ix:nonFraction unitRef="shares" contextRef="ia3a1976e448f44da9ad1282432ecaeac_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_8c1af167-9e7d-46eb-b07c-84c9691fcd0e"><ix:nonFraction unitRef="shares" contextRef="ia3a1976e448f44da9ad1282432ecaeac_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_ad1152e9-7750-4dbf-84f2-896cedb35237">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Class A common stock have been issued and outstanding. As of September&#160;30, 2021, and December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_1ca7777c-4c8c-46e0-a81b-b64717b79117"><ix:nonFraction unitRef="shares" contextRef="if9e2ff3854534beeaf5dc50347518efe_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_31101f83-7085-42be-a94b-72a51332685c"><ix:nonFraction unitRef="shares" contextRef="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_c1190f83-7838-4f57-a367-a8afbeaea1c0"><ix:nonFraction unitRef="shares" contextRef="if9e2ff3854534beeaf5dc50347518efe_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_f9afd8c4-8a9d-48de-8b83-5879fd49334e">80,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series A preferred stock have been issued and outstanding.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#8220;VIE&#8221;) and the Company has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, and December&#160;31, 2020, the Joint Venture had total assets of approximately $<ix:nonFraction unitRef="usd" contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjkzOQ_9cce2791-d380-4915-9a21-a4afc7a5c203">24.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjk0Ng_98024a33-36ea-459d-9997-632dd6f1ce11">35.0</ix:nonFraction> million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of September&#160;30, 2021, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put-call arrangements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;<ix:nonFraction unitRef="number" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" name="gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNTc5Mg_2eb6ed8a-8b21-44bf-b356-7838fac9df3d">20</ix:nonFraction>%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;<ix:nonFraction unitRef="number" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" name="gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjE0NQ_999b760f-6d78-484f-a4ac-385210f323fd">40</ix:nonFraction>%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;<ix:nonFraction unitRef="number" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" name="gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjM1Ng_0fbe4b64-759a-4803-8a07-2cba9f45f6ad">40</ix:nonFraction>%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ied2532225feb49cea3a9b6a693e02b70"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right, the Company will choose the form of consideration. On November 1, 2021, the Company elected to exercise the call right and provided its intent to purchase all shares held by SoftBank pursuant to a time-based trigger, see Note 17.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_52"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzUy_4982a2b8-c2e8-4e06-beee-89e00b564872" continuedAt="i96babee3565e41108e65600a3fbf834c" escape="true">Condensed Consolidated Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i96babee3565e41108e65600a3fbf834c" continuedAt="i4222764a49274d57aecfa24cd495c87f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzU0_746e96b1-06a1-4e64-b977-8197c6806cc8" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacafa40cbdf74f16a6b76e5fdc92f851_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMy0xLTEtMS0w_03cd4e8a-d334-4b65-87c8-a1fc2d135d37">56,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b0c64f26ce4de4af37ae79bd0d1434_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMy0zLTEtMS0w_5e336178-1186-4b09-9320-3eb6bd5653ec">40,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7b2e27a68941b58e1e1594d4e640e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNC0xLTEtMS0w_228174a7-a382-4917-bc6a-8044963b3d72">35,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4b951f099240f586e94280a7a195c6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNC0zLTEtMS0w_b584fc1d-4502-45a1-9006-6a9d0e57b3b6">34,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i731507644762422f81775c71bb607b97_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNS0xLTEtMS0w_84d396eb-3a71-4331-97c7-a0b811f68773">16,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64406783e2224dfaa1cac0323c19c1f1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNS0zLTEtMS0w_f463adcb-e60f-474f-8456-4326662e2c8f">10,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17983378a2a4dfcb8807f9d3349a6ee_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNi0xLTEtMS0w_ce8f8656-f0e3-456f-adc4-2e66fd958ece">42,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b3d8119d074276b8c7bb266b246df3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNi0zLTEtMS0w_2926220e-d282-4efa-a292-75db33e70cb0">7,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia094abf062614978a5479b8fdfa6ba48_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNy0xLTEtMS0w_9dfc7878-d4a8-4d93-9bb8-2a8607d562dd">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ddcdc04122487cb058c12bdc3fea32_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNy0zLTEtMS0w_5ad6803f-3ef8-462f-8ef1-f54982042f09">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef80966c25e4f1aa85af95075561dd8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOC0xLTEtMS0w_ce80f6bc-aefc-4e61-a090-65ab9d5092bd">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9d64efcd8c4a0f82752998dc008845_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOC0zLTEtMS0w_c5e663cb-bdee-45a0-9e7f-cf9c3f8d5911">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOS0xLTEtMS0w_7bb85959-d92c-46fd-b258-1bc521f2ee76">155,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOS0zLTEtMS0w_02988271-da94-422f-a812-936ecb4694c4">97,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTAtMS0xLTEtMA_69182f24-0dfd-45bf-a796-d14eabe3a991">49,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTAtMy0xLTEtMA_a7fd494a-3c89-4dbd-bd8f-38af23401cf7">34,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTEtMS0xLTEtMA_f879a610-2c85-488b-b724-0bca152d9055">106,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTEtMy0xLTEtMA_26595568-8d26-40c8-9182-8edecc7c7ec2">62,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjAw_cc17f784-72cf-4c2a-a679-cf2925a0e33d">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjA3_93e38e33-e4a7-4b8d-b93f-2ca1845bbf9c">3.8</ix:nonFraction> million for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjQ4_dbbfa71d-e150-4021-b22a-dcae2b43985a">14.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjU1_7ed22917-18a2-4a94-ac51-cd8950a9b9b6">10.0</ix:nonFraction> million for the nine months ended September 30, 2021, and 2020, respectively.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i4222764a49274d57aecfa24cd495c87f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzU5_bb3d3885-56e7-46b3-91fd-643ccb034fb8" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMy0xLTEtMS0w_bde564e9-9efa-4d91-863f-a2ec11f0d7ad">8,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMy0zLTEtMS0w_7ab094a6-59d7-4af9-9453-911354881fce">6,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued tax liabilities   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNC0xLTEtMS0w_7cefbe15-1d4d-4513-9802-d52ae82e271b">4,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNC0zLTEtMS0w_506d0a6d-a3ed-446e-8eb4-e33a96599f7c">4,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued professional services   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNS0xLTEtMS0w_8e7d8153-6861-40aa-a6bf-2f0902edca19">6,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNS0zLTEtMS0w_bbb003a0-5cb5-4f79-902d-959b55e24ab1">3,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials and studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:AccruedClinicalTrialsandStudies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNi0xLTEtMS0w_d1f3d726-d9ae-4573-b4e9-2e4ab5291c40">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:AccruedClinicalTrialsandStudies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNi0zLTEtMS0w_9cd9c762-f4e7-44dd-8a77-faa1fde0cdf8">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued legal expenses   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNy0xLTEtMS0w_b478e0b1-87ca-4b74-a322-f3abc016e2ca">5,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNy0zLTEtMS0w_3f9f4524-725d-4ee0-b082-353665e524e2">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:AccruedExpensesPropertyandEquipmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfOS0xLTEtMS0w_8b9131a4-5cb3-4de3-9d96-8887bbfa09f3">7,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:AccruedExpensesPropertyandEquipmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfOS0zLTEtMS0w_fc4a932b-d012-4864-b406-45f462d5e6d4">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued royalty obligations   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTAtMS0xLTEtMA_b0b3370b-5dda-47d2-baaf-a5d4eb651d02">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTAtMy0xLTEtMA_0a4c7f27-b7f1-452b-819e-fe618810b5c4">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTEtMS0xLTEtMA_809f0f70-772a-4cb6-9571-b808588aa8d2">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTEtMy0xLTEtMA_a87c9052-7e23-4c36-8065-5d3aff12db27">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accrued expenses   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTItMS0xLTEtMA_49b59118-7e8e-4af4-8129-33466e95de54">40,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTItMy0xLTEtMA_f63960fb-bbbd-4f6e-ad7f-a20f72e9fd45">22,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_58"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEyNg_1afd7b0f-53e2-405a-a34c-2c78aefa6f5e" continuedAt="i131ad16f7f4b4ecc977aa16018d96642" escape="true">Fair Value Measurements, Cash Equivalents and Marketable Securities  </ix:nonNumeric></span></div><ix:continuation id="i131ad16f7f4b4ecc977aa16018d96642" continuedAt="i591da1f178ba40758fd9685809468784"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEyMQ_34699fa7-8669-4f33-9911-b18bf75db62a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTExNQ_bd2880d4-5cf3-4c8d-b465-d31e436fd53c" continuedAt="i6ef3f73f58254e419a05edc99eeeb054" escape="true">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i591da1f178ba40758fd9685809468784" continuedAt="i982596324d304771966b19af9db59f90"><ix:continuation id="i6ef3f73f58254e419a05edc99eeeb054"><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6490275f39504f90b9b21f3da8745ba7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi0xLTEtMS0w_c56f6681-820d-43fd-9d75-a1c70f731fc7">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6c732b2f1046c48b1d0d53909608fe_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi0zLTEtMS0w_8527889c-75ca-4569-bd66-c5fa8b3a71b1">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9aa35947e840c4b0b33827767997bb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi01LTEtMS0w_ec5935c3-28b5-4c7e-9379-d1352bc6606d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76479fc684134352b6d1f8659b4db3ef_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi03LTEtMS0w_5b2748cf-c875-49e5-bdb7-0a9d80b9bf2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy0xLTEtMS0w_ed26e8b6-7e3c-41ca-aab2-ff29d8cf9503">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy0zLTEtMS0w_ee97c5d9-6d22-4303-94d9-d6898b8cf4d0">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy01LTEtMS0w_791490c0-1a7b-403a-81ba-dab3e343fc6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy03LTEtMS0w_1727f9cd-3152-4012-989e-145eacea17f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2ce09c97a54496b5adf47fc9df36f8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtMS0xLTEtMA_ddfdfd9d-9459-445a-838f-2a76a6c7924d">653,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia644451d18b64b7891f97794ae28ed16_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtMy0xLTEtMA_7801fd9e-e37c-4581-9bca-1da078a5ffff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609248da19584e879becf882254ecfb7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtNS0xLTEtMA_f6dec186-4690-4cee-a443-c7429a6e0d54">653,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda5c7f43186404280efac8c9a712d5b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtNy0xLTEtMA_ffd32575-2ecb-434a-8a49-46bded637d1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtMS0xLTEtMA_f928d958-ffef-4624-9a9a-4ba40237e4d7">653,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtMy0xLTEtMA_98b79714-842e-42df-9215-3c4bb9a4de56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtNS0xLTEtMA_661b22e1-80cc-4308-af9d-968fe9b0af05">653,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtNy0xLTEtMA_7681caf5-9d9b-4683-b6c4-d772c2547f5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2ce09c97a54496b5adf47fc9df36f8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtMS0xLTEtMA_99f1cd44-6c2e-4479-83db-2ab5f9e74311">250,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia644451d18b64b7891f97794ae28ed16_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtMy0xLTEtMA_09b78d66-bf4b-42fa-8f2b-0d08c1577ce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609248da19584e879becf882254ecfb7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtNS0xLTEtMA_cc301e9d-5ffc-4bf1-a544-654eec1d17fe">250,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda5c7f43186404280efac8c9a712d5b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtNy0xLTEtMA_fa3470df-6945-4c2e-b615-8b40924f4616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtMS0xLTEtMA_c51c753e-a271-4f26-b83d-d5fedc347646">250,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtMy0xLTEtMA_cc366fb1-f6fe-4756-bcdc-27bcb53c0ac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtNS0xLTEtMA_d95e7aa1-5c4b-4b72-861e-5577a7d5ff07">250,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtNy0xLTEtMA_123d826d-786e-4a21-9fa8-afad561bc5af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtMS0xLTEtMA_39245a6a-067e-4d68-a5cc-5868f656d582">1,639,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtMy0xLTEtMA_5aa2e542-7480-49d3-987c-a68b0d5360be">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtNS0xLTEtMA_ec9aba6b-b3ba-4fe4-ae23-9e7e00db787c">903,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtNy0xLTEtMA_25d57d45-5114-4061-a6ae-7d2778965e19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtMS0xLTEtMA_4760e5ad-d642-4256-9940-2784fdfcfc73">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtMy0xLTEtMA_65343b5c-a28e-4055-b4ab-7cd645313bc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtNS0xLTEtMA_3fb32291-ff6a-43d2-b745-b43e9a6347cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtNy0xLTEtMA_725918b0-b231-4c26-bb4b-bba382bf10fc">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktMS0xLTEtMA_676ee558-85e6-4ce1-bea4-074553c538b7">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktMy0xLTEtMA_05f01c3e-a289-4e3a-b21f-9b86d742f716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7711072385f46159fba26d2b137c91c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktNS0xLTEtMA_8d168fb1-7d76-4f3e-ab22-9d759c7a0469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktNy0xLTEtMA_c0cc67a0-f580-4b81-a87c-2010b420dfe5">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873b7ae2fa894be79e1fc9fe51be3fdb_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS0xLTEtMS0w_7d74e6df-b7ca-4f29-869e-2973d13d28f4">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5652f79c7265447095ac9b9f6f19cae7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS0zLTEtMS0w_d1db0f75-a6f1-4707-b7bf-80014f82c9a3">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede67ca17f9c40bbbeff9eb83a33fa3f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS01LTEtMS0w_a4c46c3a-917d-430c-a1b8-068caead496c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94d00f18354bbfbb8b4c63e3b1c4fc_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS03LTEtMS0w_c72b277b-a59e-485d-8e91-05a4e3430640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi0xLTEtMS0w_53496c75-fc51-40db-a16f-69d2a7ba10b4">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi0zLTEtMS0w_3b7a2190-4228-42a0-9d17-f55ac5cb2ee2">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi01LTEtMS0w_ba48f1e7-0704-418c-b5b2-9a0d9a769740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi03LTEtMS0w_5c3b87a5-c49c-4697-bcfb-e5f1abf2f33a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e521bd99f3f4da5a1d7079867423b9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS0xLTEtMS0w_3272e55e-d5a1-4218-aded-70931e1fc615">961,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if515c37e228643f3898be215740476d1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS0zLTEtMS0w_91fb617e-f3bf-4564-a7da-3c9df586e73d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d51626bd954ba3a9951e2ea7a902f5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS01LTEtMS0w_a17dac20-7255-4550-8d72-2a7865c5554b">961,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS03LTEtMS0w_6a2077ed-a323-4261-a3bb-e12a18829fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtMS0xLTEtMA_5f029713-b4fa-446c-9611-af97f9398dab">961,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtMy0xLTEtMA_8df6a536-f673-43f7-a565-1fa48a021caa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtNS0xLTEtMA_64aaa371-ea64-4028-b024-7630ff981a95">961,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtNy0xLTEtMA_fb4c38d8-dcb0-4163-8562-2d03000c53d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e521bd99f3f4da5a1d7079867423b9c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItMS0xLTEtMA_03011851-fa5d-409d-897a-47c33d1f2804">246,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if515c37e228643f3898be215740476d1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItMy0xLTEtMA_0696c767-72e0-44fc-8f01-388637ab2451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d51626bd954ba3a9951e2ea7a902f5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItNS0xLTEtMA_c4bb1070-ba9d-4975-b7af-8b8f9a7b6db2">246,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItNy0xLTEtMA_b48e9f90-1e64-490d-b2c6-61f6b20ea51b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtMS0xLTEtMA_1de9c488-bd01-46d6-8a97-154ef43b008d">246,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtMy0xLTEtMA_deff9131-ca85-4c58-8983-7e55b407f693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtNS0xLTEtMA_b6fa010e-8f9a-4972-9090-efb023843e70">246,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtNy0xLTEtMA_5ceb6c89-f8bd-4045-af2a-f54a0727e4d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtMS0xLTEtMA_935db3f3-2f6e-4634-a476-591c2ffd0dc3">1,829,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtMy0xLTEtMA_f05d854d-7bd0-45c3-81f5-d36c7ff6820a">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtNS0xLTEtMA_a13a0031-fd49-4643-8f0f-bf0b3b9c7235">1,208,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtNy0xLTEtMA_f093d1cc-70bd-4c6e-afd3-07a570ab7902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctMS0xLTEtMA_657510fb-d913-45a4-973f-340cce057ba5">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctMy0xLTEtMA_40913565-35f5-4143-9f3b-ebfc6c34d625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctNS0xLTEtMA_56ada1c7-dd25-431c-a2e1-2d8bf4e37f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctNy0xLTEtMA_f3f53890-24c5-42d0-8f3c-6e331551195c">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtMS0xLTEtMA_9d203523-0488-47ea-aa9c-1c7fbbc89a44">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtMy0xLTEtMA_5b836e4d-119b-4789-a799-271b50b3a60c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtNS0xLTEtMA_12e47ce6-9b01-46d6-8cc5-7646a60b407b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtNy0xLTEtMA_664dd12a-16bc-497e-82ca-8414fccd6cce">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. As of September&#160;30, 2021, and December&#160;31, 2020, contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfMzEyMA_f79c3e34-dac8-4972-9ed9-f086a4d61b33">3.1</ix:nonFraction> million and </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i982596324d304771966b19af9db59f90" continuedAt="i15e91b29b6e64a879fffd0f0e0d1634b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfMzEyNw_9a3bf6e8-8f7d-479c-b338-7a47c9e8f33b">1.2</ix:nonFraction> million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the redeemable noncontrolling interest as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 3 measurement. The fair value of the redeemable noncontrolling interest was determined using a of the income approach and the market approach, and estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted-average costs of capital and future market conditions, among others.</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTExMg_4dd9eb73-d62a-4164-8efb-535411640ee9" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments for the three and nine months ended September&#160;30, 2021, and 2020:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06071e62b6544aba8290bd086369fa36_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0yLTEtMS0w_a7db3ca4-3d37-4e2f-9dbe-23d55e4358ec">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ca599f32394a52802faedc82b745af_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi00LTEtMS0w_b105af10-aebf-449a-863a-6efdc42a8c9e">50,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b460bf00d240ccaa69bfe375444037_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi02LTEtMS0w_65ffa79c-1d0d-420f-9da4-1ae5a94c3f15">57,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c53847548a49db87515a3ddbad4e6b_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi04LTEtMS0w_a47749fe-d267-4281-a3b9-d89af77e1d76">49,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00d793f144d4af4a1ce283df7b0e5b8_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xMC0xLTEtMA_6aa391eb-2b7f-4e96-a6c2-885ccfd20020">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f752295bdb0485d837d6f29e1adac2e_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xMi0xLTEtMA_fb278127-ea32-4cd5-858d-5f0a20b16563">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4544e28f7504c5c8262ad98b729df14_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xNC0xLTEtMA_0a495ef2-6595-41be-a478-a90d4891f4f9">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8439291e86774964951a992f2d6ab802_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xNi0xLTEtMA_96597df3-87b8-41e5-bb99-f4aeb52a997e">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0yLTEtMS0w_3585d83b-3a3c-43cd-b327-a7cd083dc2ae">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC00LTEtMS0w_1bbe1963-111e-4a22-8de5-0c5ff618a319">7,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC02LTEtMS0w_a118f0c1-1230-4104-8544-1755267d14db">7,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC04LTEtMS0w_6f7d8ab0-a5e2-4426-acbf-a58eb5221a05">10,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xMC0xLTEtMA_772f976b-7c2c-4c70-b340-977050012a5c">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xMi0xLTEtMA_df64d670-b070-4dec-ac70-3145d18e684a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xNC0xLTEtMA_e804fb09-a8b5-4b67-8d8b-033f7d540f1f">1,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xNi0xLTEtMA_8a1d808e-feed-43c8-9445-6c379d5be0c0">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0yLTEtMS0w_3535b43f-abf7-4a62-84b8-2ef1cf8408e6">1,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS00LTEtMS0w_6eeb41f1-f05e-4abf-b684-de69151a180e">1,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS02LTEtMS0w_2d059ee0-6012-44c4-a2b6-e8e7168f63de">5,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS04LTEtMS0w_635cd595-e8e3-48a6-aa4e-e0a51c5664a3">3,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xMC0xLTEtMA_74dda088-7317-489f-a912-9e04ba86c44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xMi0xLTEtMA_effff7f4-4ae2-4c29-85bf-6df1de67d3a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xNC0xLTEtMA_3d1efef2-0715-46f6-a519-0c1c25d5851a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xNi0xLTEtMA_0fe66b03-60b7-48b0-a11f-994d7f54192c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMi0xLTEtMA_fbe7abf1-034d-4e5d-ae03-3953c7e21151">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtNC0xLTEtMA_6806c808-0cf6-4a1a-be89-2880c2d92195">56,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtNi0xLTEtMA_61d2a64a-ece6-403d-b839-3f81eac72faf">59,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtOC0xLTEtMA_a150a367-763c-4b85-b26f-4844402ead04">56,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTAtMS0xLTA_510571ce-121e-4fe4-89f8-eef67f966254">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5288cacba948db9667020c833d81ef_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTItMS0xLTA_b2d52a61-f527-42fc-ad0b-599d23dc6e51">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTQtMS0xLTA_fc2b1d52-4c99-4fec-b600-aee870a8cf9f">3,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5288cacba948db9667020c833d81ef_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTYtMS0xLTA_df1b2dbb-df34-48bc-9f19-6ead6c3d0bc9">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the Convertible Notes as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to the fair value of the Convertible Notes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="gh:DebtSecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEzMA_7f10f62a-add7-4047-a68f-4fbf688c0250" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS0xLTEtMS0w_74d285ac-bc85-4deb-9878-8ea4dddb1722">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS0zLTEtMS0w_1a497d72-dd0e-42cf-a2e1-ac61658f9811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS01LTEtMS0w_a5a8fb04-4173-4aa0-902a-dad6fa1c0176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS03LTEtMS0w_ba89f9d1-23dd-483c-b58b-72e738a43870">735,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy0xLTEtMS0w_72aef112-95e4-442b-ab80-6c8f7e9875b5">903,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy0zLTEtMS0w_4a813dd5-ab36-42cb-9b97-ca12096f440c">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy01LTEtMS0w_d62b1b6a-2133-4be6-aaf0-a8c5d2ffa808">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy03LTEtMS0w_1e7e93c1-5bbd-4049-8f9c-048f8fa71c4f">903,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC0xLTEtMS0w_69eefd2d-4038-4edd-b8c2-d80f2a99b3d8">1,639,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC0zLTEtMS0w_35d5f023-0ccc-4077-a684-141cb02f28ef">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC01LTEtMS0w_aeb068dc-59f8-4abf-a3be-c5b54a3ea19e">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC03LTEtMS0w_68754a48-4ac8-48b6-9680-81bae2976276">1,639,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC0xLTEtMS0w_2ca4fdb1-6fc9-4a7d-b3ed-31a22dcb0155">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC0zLTEtMS0w_223e9851-25e1-4017-a15d-11bbf449e692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC01LTEtMS0w_94c9a62f-bc70-44e7-be61-79137768ce39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC03LTEtMS0w_54a3d6d1-8b00-4912-8ff0-febfa0c5cc0f">620,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi0xLTEtMS0w_cba74df1-7cb7-4f8d-ba99-6ada7846fbd1">1,206,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi0zLTEtMS0w_1ea7e876-d9fe-4948-abf8-9e00122bea55">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi01LTEtMS0w_10744056-58ee-449b-b350-3fe5c6522939">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi03LTEtMS0w_6b0b5117-e140-4970-a556-e1234fd8ef71">1,208,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy0xLTEtMS0w_04fca653-00a1-40d9-9f8b-c4d0051c0b5b">1,826,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy0zLTEtMS0w_9d9be5bc-04ac-44de-932d-4f2a96745eb3">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy01LTEtMS0w_a20a23a2-e6d8-4aff-b16d-2937fa893810">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy03LTEtMS0w_0ee7a3b9-0dd3-402e-9329-84812e360b34">1,829,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15e91b29b6e64a879fffd0f0e0d1634b">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and nine months ended September&#160;30, 2021, and 2020, respectively. The maturities of the Company&#8217;s long-term marketable securities range from <ix:nonNumeric contextRef="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930" format="ixt-sec:duryear" name="gh:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTA5Mw_9baf6dfa-1643-42e2-9348-2ee72bc6b22d">1.3</ix:nonNumeric> to <ix:nonNumeric contextRef="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930" format="ixt-sec:duryear" name="gh:LongTermMarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTA5OQ_fc8e8ff4-1b3b-4928-9d7a-430888951fa1">2.0</ix:nonNumeric> years as of September&#160;30, 2021.</ix:continuation> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTMzMg_4bf4f5ea-ff53-4523-8b4d-f9bf65d15849" continuedAt="i17fa5a3b4b214a1f8a13eb95b32cbb3a" escape="true">Patent License Acquisition</ix:nonNumeric></span></div><ix:continuation id="i17fa5a3b4b214a1f8a13eb95b32cbb3a"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#8220;KeyGene&#8221;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#8220;SPLA&#8221;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#8217;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="gh:PaymentInConnectionWithaLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfNTkz_277af3bc-63bd-4ab3-bb57-1a558822a367">18.5</ix:nonFraction> million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $<ix:nonFraction unitRef="usd" contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="gh:AssetAcquisitionTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfODAw_c05a1722-a790-4584-9763-7430a9630329">0.6</ix:nonFraction> million of certain capitalizable transaction costs, was allocated to various components of the SPLA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated $<ix:nonFraction unitRef="usd" contextRef="i271b6a1089814cb6944c8c41c026a282_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfOTE4_1a53c513-7829-4f06-9c8e-3ae40f29af8e">9.4</ix:nonFraction> million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of <ix:nonNumeric contextRef="i2d2672bc23d34d2783b636a52ec86105_D20200301-20200331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTAxOQ_23b55838-1545-4cec-99c7-a54f1e8a95ee">6</ix:nonNumeric>-<ix:nonNumeric contextRef="ia10b7a8bcf704572915d199375bb6896_D20200301-20200331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTAyMg_838209fc-3c41-4983-a0c2-fd2e584faa72">12</ix:nonNumeric> years. The Company allocated $<ix:nonFraction unitRef="usd" contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTA0OA_9ae96913-a04f-4788-bf1e-2a4c9a94db78">8.5</ix:nonFraction> million to IPR&amp;D technology, which have no alternative future use and was included in research and development expenses for the nine months ended September 30, 2020. The remaining $<ix:nonFraction unitRef="usd" contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTE4OQ_01064467-56f9-4518-900c-65dbcb00d767">1.2</ix:nonFraction> million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the nine months ended September 30, 2020.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_67"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzg5_68bcbf86-54e1-4a71-afbe-64596cd1459f" continuedAt="i3dbd0a28532c41e993ee69d05e54c0f0" escape="true">Intangible Assets, Net and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i3dbd0a28532c41e993ee69d05e54c0f0" continuedAt="ida44d2ffb6d743e7b29c786c1e1dcb7a"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzkx_ce2baa1c-1e63-4b9a-a39e-df4112f153c8" escape="true"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzk1_0c584096-ee60-472b-801f-7a5087585bb9" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d01bf14b454648b34a008c20d39400_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi0yLTEtMS0w_6b4842ba-1906-4a67-875a-b4813dfdf117">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d01bf14b454648b34a008c20d39400_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi00LTEtMS0w_05504d66-8d95-41b9-a58e-d4212a1473a9">2,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d01bf14b454648b34a008c20d39400_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi02LTEtMS0w_246d9209-b701-49b0-839c-ab50ba77beb8">9,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c794762acd24ec4b36b7bc0040e7a7b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi04LTEtMS0w_80d95229-46e8-40c3-b288-536af9b9aedb">9.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbef017000f243ac8d113e85196f3c88_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy0yLTEtMS0w_8fe9d3c6-dc24-4ba7-ab8d-56b63fe50144">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbef017000f243ac8d113e85196f3c88_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy00LTEtMS0w_79dd260d-effe-4528-be0c-4b46ff7d9f49">1,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbef017000f243ac8d113e85196f3c88_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy02LTEtMS0w_cc364949-957f-4cf4-a2a8-1265d20a07ff">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1066cfd83fc4ddb923b546c7803df9f_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy04LTEtMS0w_e767320d-b5e8-4dde-beb9-d7810d194b70">4.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC0yLTEtMS0w_622d942a-5fb9-41a2-9406-a2e638b8468f">16,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC00LTEtMS0w_19870b4b-4d20-4197-acc6-3aabb96068be">3,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC02LTEtMS0w_1c2df040-c8a5-4f4e-816e-323caf7c4f28">13,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddd38c4b0ed4cddb1ce69265363289b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTAtMi0xLTEtMA_de26858f-c0ed-44f7-a911-18b6cd3fc44c">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddd38c4b0ed4cddb1ce69265363289b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTAtNi0xLTEtMA_9e36b696-f58d-4c67-8a4c-9a158fa8ed01">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTEtMi0xLTEtMA_b9a33209-ca90-44a3-ad2c-381650e7c750">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTEtNi0xLTEtMA_a4793931-c8a3-41df-81ab-87d49dd0fbe1">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:IntangibleAssetsGrossIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItMi0xLTEtMA_8ad1b081-2825-48a2-9389-59de469934c3">21,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItNC0xLTEtMA_9ba80860-36aa-431d-a700-98ddef824e45">3,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItNi0xLTEtMA_e703a015-b88a-4084-81c8-938aca67597a">17,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS0yLTEtMS0w_001588be-b27b-451c-bd76-794bc6d5208d">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS00LTEtMS0w_cf71f10d-147a-4c18-a176-13d5f9ed3b3e">1,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS02LTEtMS0w_d69a8e81-0d64-4700-884e-9f9f4e78947c">10,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22f931c2c6fc4c78a009b5427bf45c7c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS04LTEtMS0w_cec361b2-c8ea-47d3-87be-da615f09bc4b">9.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi0yLTEtMS0w_0eb436a8-b9fc-489f-8516-d5c327170980">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi00LTEtMS0w_c49c108c-4632-4cd1-948f-7cf2fa980159">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi02LTEtMS0w_e75589d6-5bef-4f50-a055-eda3105982e7">4,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54c3f12b90c242a3ae68a02bd72acb55_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi04LTEtMS0w_b4d62483-2889-4504-9cde-0bd85d5bb531">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy0yLTEtMS0w_949db51c-6a10-41f7-8311-cb8a0246f311">16,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy00LTEtMS0w_a71b8914-02f3-42c4-a91f-ab778e01d8f6">2,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy02LTEtMS0w_ab2db01d-e07d-4251-b9d6-98679488b4a0">14,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4550cb15256748d2a89b9750438c5b41_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfOS0yLTEtMS0w_e28778f0-658b-4682-8c25-1f5a2770755a">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4550cb15256748d2a89b9750438c5b41_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfOS02LTEtMS0w_c609d1af-dcba-415d-aad9-a40894dbef43">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTAtMi0xLTEtMA_1fc3015f-e79e-4b28-b83e-e4f053610230">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTAtNi0xLTEtMA_710cb8b3-d452-483b-b44d-7fc69732d045">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:IntangibleAssetsGrossIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtMi0xLTEtMA_d7a7da66-0bf1-4ef8-96ab-8b3dbfc27e76">21,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtNC0xLTEtMA_8c321440-0814-494e-aa10-5bb3a4947cb8">2,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtNi0xLTEtMA_aecf971c-aa8f-475d-b3fa-43a387a01424">19,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ida44d2ffb6d743e7b29c786c1e1dcb7a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMTg2_bcf339e9-bd3a-49cb-9d9d-b89c04b3edf7">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMTkz_c2794460-96cf-4071-b1e0-0e0befee2a61">0.5</ix:nonFraction> million for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMjMz_07316d43-dfac-4be7-87d5-2ffe787e2e13">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMjQw_5712f109-5e66-408e-825e-6fb83fc514ad">1.3</ix:nonFraction> million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzg3_0b558a82-99b7-42a9-bd16-782d9d87d179" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfMy0yLTEtMS0w_282b2c4e-16e0-4926-a43d-b98ca564294b">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNC0yLTEtMS0w_cc809e69-4c5e-485d-a342-a13955005022">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNS0yLTEtMS0w_d91d7655-cbe5-4292-9c63-92473d5c7eb6">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNi0yLTEtMS0w_d1267957-d0d3-456a-af5b-43dc72e280ca">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNy0yLTEtMS0w_498835f2-d55b-4dac-bc8e-e3b6c01c1f68">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfOC0yLTEtMS0w_b04728c5-30de-4168-978a-657991c2f72d">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfOS0yLTEtMS0w_23cd2fd2-5cc1-40b7-9484-f673fd514317">13,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_70"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzUxOA_52cf20ec-1950-4a28-8f5f-a88d650540b2" continuedAt="i752f189a95d3474982a3c0a0c532583f" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i752f189a95d3474982a3c0a0c532583f" continuedAt="i3f23cd717328442c8e4c97295b2bfa98"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzY_ee821ba5-a3b8-4a94-90b5-3297375e6cb0">1.15</ix:nonFraction>&#160;billion principal amount of its <ix:nonFraction unitRef="number" contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTAz_18c82480-88f3-49d1-8b0d-997e8ad4b8bf">0</ix:nonFraction>% Convertible Senior Notes due 2027 (the &#8220;2027 Notes&#8221;). The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding <ix:nonFraction unitRef="number" contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130" decimals="3" name="gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzY2_fd9cb0fb-06c2-4542-aa5e-b13dffbf0914">0.50</ix:nonFraction>% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTAxOQ_b89b2434-2bc1-43b9-81a0-1b1e683b877c">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="d" contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTA2Nw_9f444d07-aec4-46c1-90e5-13f09a0a8627">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="d" contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTEyMw_9d0b8ead-c10b-46b7-bacd-0356664b7b48">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter (the &#8220;sale price condition&#8221;);</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the <ix:nonFraction unitRef="d" contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTI2OQ_adbf9f87-b393-4161-8dd7-61ac5bb66df0">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="d" contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTMyMA_ae674e24-ad98-4532-9886-94234fa13b7c">ten</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than <ix:nonFraction unitRef="number" contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130" decimals="2" name="gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTQ5OQ_07317533-e19a-4f4a-80f7-b8dc3b2245a7">98</ix:nonFraction>% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon the occurrence of specified corporate events</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#8217;s election. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMjI3Nw_78a5b9ad-fc81-4569-a992-bf0eabdc6853">139.82</ix:nonFraction> per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#8220;Make-Whole Fundamental Change&#8221; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i3f23cd717328442c8e4c97295b2bfa98" continuedAt="i4976e6dd4d1344929eb7942739032373"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company&#8217;s common stock exceeds <ix:nonFraction unitRef="number" contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzIzOA_6c3445ef-ee0d-4ecb-af59-b8c64b0c208a">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="d" contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzI4OQ_fcdcd00e-6711-4af5-aded-25ab1eca78da">20</ix:nonFraction> trading days, whether or not consecutive, during the <ix:nonFraction unitRef="d" contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzM0NQ_a71fe676-9562-4809-ab40-a7b7cd601e97">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain corporate events that constitute a &#8220;Fundamental Change&#8221; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#8217;s common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bbf0e927fe947748b1ff7825cad3181">In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the 2027 Notes were not convertible as of September&#160;30, 2021, the net carrying amount of the 2027 Notes was classified as a long-term liability. </span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzUyMQ_027818f7-5052-43f1-a062-92b6c960d1de" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the 2027 Notes as of September&#160;30, 2021, and December&#160;31, 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNC0yLTEtMS0w_0e9bba29-6ba9-4d54-aa54-7360632ea9d8">1,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNC00LTEtMS0w_0a7f5077-a5ca-4521-b842-7ddd11440499">1,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNS0yLTEtMS0w_34910eaf-505e-4e5e-94cb-554d190d6912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNS00LTEtMS0w_571d5066-6737-43c5-8337-8071f25f0c50">331,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNi0yLTEtMS0w_a1e71469-c8c9-4f7a-9335-62bba696bc9a">15,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNi00LTEtMS0w_24e898fd-3592-46d9-890e-4e6bf7efde29">12,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNy0yLTEtMS0w_3c11471e-c6d3-4339-8dda-b0e7cbd1a952">1,134,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNy00LTEtMS0w_c9718e6b-9829-4d70-b8fd-754389e123c6">806,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component recorded at issuance:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:fixed-zero" name="gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTAtMi0xLTEtMA_48a47d4f-00cd-41fe-81c5-948c41b0a570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTAtNC0xLTEtMA_0d0938ac-6df3-4ab8-a2dc-f3cbc2025da8">335,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:fixed-zero" name="gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTEtMi0xLTEtMA_0703ed2a-e7f4-468a-b370-98de9d76e0bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTEtNC0xLTEtMA_6dc99527-1243-4a26-9351-f5753cbad520">5,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recorded in equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTItMi0xLTEtMA_fee4e7ac-2f46-4335-9f69-4e5b2aba3b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTItNC0xLTEtMA_c37ca35a-22d9-4be3-bdc5-61280da0ee72">330,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of the 2027 Notes was $<ix:nonFraction unitRef="usd" contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTY5OQ_a6f94cec-edc0-48b3-8483-41a6193f19ac">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTcwNg_58890d5a-56aa-47f8-aa52-9efb89a3db90">1.3</ix:nonFraction> billion as of September&#160;30, 2021, and December&#160;31, 2020, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized in relation to amortization of debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i82ce7dd079ac4bfd882a6e3d866ee98c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTk2NA_fc979885-a64f-405d-81b1-7a8c5bbcd450">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26bb0381128745be8004975327b5b957_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTk3MQ_119c4079-2983-4806-a2ea-7f8662b12fa7">1.9</ix:nonFraction> million for the three and nine months ended September 30, 2021, which represented an effective interest rate of <ix:nonFraction unitRef="number" contextRef="icd9648256b9c411694a641721c1541a0_I20210930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjA1NQ_d8b1a760-a313-409c-aae7-635d2b04455c">0.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icd9648256b9c411694a641721c1541a0_I20210930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjA2Mg_58bd9cfe-6612-4e9b-9608-3794be82864e">0.2</ix:nonFraction>% and for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Hedges</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions (the "2027 Note Hedges") with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="id32f5d1807074b2793d40078426095aa_I20201116" decimals="2" name="gh:ConvertibleDebtHedgeStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjU2OQ_f75ed84d-139f-4542-8808-0418ccac50df">182.60</ix:nonFraction> per share, which represents a premium of <ix:nonFraction unitRef="number" contextRef="id32f5d1807074b2793d40078426095aa_I20201116" decimals="2" name="gh:ConvertibleDebtHedgeSharePricePremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjYxMw_be4e3459-0816-406f-9eaf-71095f90ad8d">75</ix:nonFraction>% over the last reported sale price of the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i4976e6dd4d1344929eb7942739032373" continuedAt="ie4e01151520b4bf3b9ad02bc5beca886"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="id32f5d1807074b2793d40078426095aa_I20201116" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjY4Mw_7a788924-f8f8-4a65-b05f-f8e04992c175">104.34</ix:nonFraction> per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4e01151520b4bf3b9ad02bc5beca886">As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#8217; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i96636707b48c4179884f86ea7ec8a02f_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzM4OQ_9344ccbb-2467-44dc-8653-15b795e0a204">90.0</ix:nonFraction> million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.</ix:continuation> </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_76"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5OA_f3a52f43-0457-43d9-8cb5-86b95a55338c" continuedAt="i2d629ee52c464e1ebdc5bd0755470d4d" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i2d629ee52c464e1ebdc5bd0755470d4d" continuedAt="ie07bbd4c1d2a4428b007fbe928ebf78c"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has&#160;entered into various operating lease agreements for office space,&#160;data center, lab and warehouse use, with remaining terms ranging from <ix:nonNumeric contextRef="i993c2da446a34875acb1c40b068b3089_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTY3_41863c3c-be73-42d1-8dad-bfff5d220c66">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="i55c4a05385cc4fc18d198385dd93c921_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTcz_d2027ecc-966b-4004-a338-55827039900d">12</ix:nonNumeric> years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  In July 2020, the Company entered into <ix:nonFraction unitRef="segment" contextRef="i8e71a02ecacf4adcb391e6c7f12702d1_I20200731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberOfOperatingLeasesLeaseNotYetCommenced" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfNzU3_968b04d5-498b-42ff-95e7-4010a764b3fe">two</ix:nonFraction> lease agreements for additional office space in Palo Alto, California ("Palo Alto Lease") and in San Diego, California ("San Diego Lease"). The San Diego Lease has a term of <ix:nonNumeric contextRef="i2cb77ccae9a74814b7e00acb580b3aab_I20200731" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfOTM0_662dac67-e255-4342-8b65-e4a65f8d9a04">8</ix:nonNumeric> years with rent payments commencing in May 2022.  The Palo Alto Lease has a term of <ix:nonNumeric contextRef="ia25c787a137a4bec9fd1a061e1adf313_I20200731" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTAxNQ_67767046-5b6e-46eb-af84-4408397745b9">12</ix:nonNumeric> years with an option to renew the lease term for an additional <ix:nonNumeric contextRef="i86f9ba8b79324beb88e8b7488d9694c8_D20200701-20200731" format="ixt-sec:durwordsen" name="gh:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTA3NQ_37ff9c23-1ec7-413e-bb1c-b937d26651bc">ten years</ix:nonNumeric> which has not been considered in the determination of ROU or the lease liability as the Company does not consider it reasonably certain of exercising the renewal option. Rent payments for the Palo Alto Lease will commence in October 2021. Both leases consist of fixed and variable payments and are being accounting for as operating leases. The Company took possession of these facilities in March 2021.  The Company estimated the incremental borrowing rate to determine the present value of lease payments for the San Diego and Palo Alto leases using trading data of the Company's convertible debt adjusted for credit rating and market yield curves.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTc1OA_b3d80fe0-99b9-4f5e-b485-1442cd824c1b">6.9</ix:nonFraction> million and immaterial for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTgwNg_31fa2b62-9df8-4703-9e9e-63343b27f421">17.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTgxMw_90ce8044-f1d3-4ac5-93ef-5014f0a5a165">3.3</ix:nonFraction> million for the nine months ended September 30, 2021, and 2020, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). </span></div><div style="margin-bottom:3pt;text-align:center"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5MA_fe5dfa65-c30d-4825-a566-25536335e2a4" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMi0yLTEtMS0w_eda8ee7a-c249-45aa-b076-480c4b63702a">10.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMi00LTEtMS0w_ae1126a1-39c1-4fc6-aee1-b48edf47b912">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMy0yLTEtMS0w_818aad37-d45d-40fc-b8e3-642ed982a40b">4.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMy00LTEtMS0w_3768da79-35c4-4e68-8d32-fa4176d52b72">8.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ie07bbd4c1d2a4428b007fbe928ebf78c"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5Ng_89c05493-0988-4547-8a25-067ad97b0882" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of September&#160;30, 2021:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:81.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMy0xLTEtMS0w_23ad892f-5c58-491a-9cbd-4f6b2f99a52f">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNC0xLTEtMS0w_d2c0cf46-1278-4941-b56c-73b294287851">21,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNS0xLTEtMS0w_46dd5f4c-8c83-4e03-88b0-96afbe1c49ba">28,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNi0xLTEtMS0w_0b5ae216-bcd1-400d-9f21-42f0cbd3c707">31,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNy0xLTEtMS0w_f7b1e6c2-04de-46cb-b163-b02438017819">32,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfOC0xLTEtMS0w_4c100dc6-ab1b-4c2e-8a35-aeea767838cd">177,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfOS0xLTEtMS0w_5d0ae08e-4abd-40e6-a01f-3d109f7e7234">294,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTAtMS0xLTEtMA_9c15df33-696e-4a14-98e9-f7cf2bae1851">52,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="gh:LesseeOperatingLeaseLiabilityLeaseIncentive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTEtMS0xLTEtMA_1d69f968-a166-4aa5-b0cd-7a05e04faffb">16,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTItMS0xLTEtMA_6e68fb6c-5044-4fef-ac25-2ea6b893a2ec">225,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_79"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNjQ4MA_666bfde0-422d-4cc1-b37d-4f096d0f4b26" continuedAt="i0720f4454c3a486a88fcca0734bac452" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i0720f4454c3a486a88fcca0734bac452" continuedAt="i93220d0b73ce46b58192ae2769c70438"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i93220d0b73ce46b58192ae2769c70438" continuedAt="ia7a490fded0f40fb8ed1d8a19e0e53b3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, the Company filed a lawsuit against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) in the United States District Court for the District of Delaware. The Company has alleged that Foundation Medicine has infringed <ix:nonFraction unitRef="patent" contextRef="i32f365a013324f7ab9a257ec6616bfe4_D20171101-20171130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzIwMQ_9042d187-0c0c-42bf-987e-01a224468045">four</ix:nonFraction> of the Company&#8217;s digital sequencing technology patents. Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license and non-infringement. The parties are seeking damages, injunctive relief and attorneys&#8217; fees. Discovery in the lawsuit has closed, and a number of pre-trial motions were filed in September and October 2020. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foundation Medicine also filed <ix:nonFraction unitRef="petition" contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzYzNg_d45bd9e8-42ea-4981-a292-3fc53d72eccc">six</ix:nonFraction> petitions for inter partes review with the PTAB, challenging the patentability of all <ix:nonFraction unitRef="segment" contextRef="i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzcyNQ_a4e49dfe-677e-4ed1-9caf-8b8e0c7575c6">four</ix:nonFraction> of the patents asserted by the Company. The PTAB denied institution of inter partes review for <ix:nonFraction unitRef="segment" contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsDenied" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzgyMw_91df4695-1fa4-4df9-8712-68b1f91c50c8">four</ix:nonFraction> of the <ix:nonFraction unitRef="petition" contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzgzMw_4e1e6ff7-f035-422b-9352-630d73cd9fd8">six</ix:nonFraction> petitions filed by Foundation Medicine and instituted inter partes review for the remaining <ix:nonFraction unitRef="petition" contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberOfPetitionsFiledRemaining" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzkyOA_b3490dc7-12ac-41a4-a23c-2d8c856216a2">two</ix:nonFraction> petitions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, the Company filed a lawsuit against Foundation Medicine in the United States District Court for the District of Delaware, wherein the Company alleged that Foundation Medicine infringes <ix:nonFraction unitRef="patent" contextRef="i705721d0e67244739b045350d485c93f_D20201101-20201130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDE0OA_3ebd72cd-d3aa-4232-84fa-337b7a538c6e">seven</ix:nonFraction> of the Company&#8217;s patents.  Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license, non-infringement, and that the Company has violated Section 2 of Sherman Act. In December 2020, the Company filed a Motion for a Preliminary Injunction to prohibit Foundation Medicine from practicing <ix:nonFraction unitRef="patent" contextRef="i9963f628118f43db994c73aa2c0b5931_D20201210-20201210" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDUxNw_c98ef83c-5dae-46ea-88e3-45960279f0d2">two</ix:nonFraction> of the asserted patents.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company filed <ix:nonFraction unitRef="patent" contextRef="ib18022bf9450402f8ce4975ec504ea61_D20210301-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDU4Mg_ecb2eb5c-e3fd-43a9-8597-46e8c3e857e0">two</ix:nonFraction> lawsuits against Foundation Medicine GmbH in the District Court of Munich I in Germany, wherein the Company alleged that Foundation Medicine GmbH infringes two of the Company&#8217;s patents.  Final hearings on this matter are scheduled for December 2021.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a binding term sheet with Foundation Medicine, which upon execution of a definitive settlement agreement, will result in the dismissal of all pending patent litigation worldwide between the parties. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and Personal Genome Diagnostics, Inc. settled the patent infringement lawsuit brought by the Company. Under the terms of the confidential settlement, the lawsuit and counterclaims, as well as other challenges to the Company&#8217;s patents, have been dismissed.   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, TwinStrand Biosciences, Inc. (&#8220;TwinStrand Biosciences&#8221;) and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#8217; allegations. The court has not yet entered a case scheduling order.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">False Advertising Dispute</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia7a490fded0f40fb8ed1d8a19e0e53b3">In May 2021, the Company also filed a lawsuit against Natera, Inc. (&#8220;Natera&#8221;) in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#8217;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#8217;s Signatera assay. The Company is seeking a Preliminary Injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. Discovery is ongoing and the court has scheduled a hearing for November 2021 to hear argument on the Company&#8217;s motion to dismiss Natera&#8217;s counterclaims and for a case management conference.</ix:continuation> </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_82"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNjg4_bd377b7a-2d83-4a9c-bb59-9782dba1df9c" continuedAt="i4dfabc0f56874c66b254da36a31e1f54" escape="true">Common Stock</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4dfabc0f56874c66b254da36a31e1f54" continuedAt="id5ac7a40c13d46a7a1e8242aad3031bf">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of September&#160;30, 2021, and December&#160;31, 2020, <ix:nonFraction unitRef="usd" contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:DividendsCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfMTg0_38a38f3f-9f14-4b59-91ae-aa647069361e"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:DividendsCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfMTg0_5c1e2a8e-ce8f-43dc-822b-c4bade9e254f">no</ix:nonFraction></ix:nonFraction> dividends on the Company's common stock had been declared by the Board of Directors.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="id5ac7a40c13d46a7a1e8242aad3031bf"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNjky_70b7732c-3484-43f0-916d-368d56386854" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01b665c40a8f47ea8cd85e635363d20c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMi0xLTEtMS0w_49078e12-6974-4fde-972f-1815df4b5970">2,516,868</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e8d9afb89dd4632a8f43a7e0dfca6af_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMi0zLTEtMS0w_eecb6cf8-87c7-4e02-afe5-f8ee6f928cfb">3,101,181</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85be72137c66452fa6b52b9f18871115_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMy0xLTEtMS0w_006c3aab-fb07-4d21-b82b-0db4a72a37f6">1,128,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMy0zLTEtMS0w_ccfeddc4-3981-46e6-9dee-35d8143ea09b">1,118,655</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNC0xLTEtMS0w_a6f1eb21-c18d-45ba-98b1-32b2539bc1db">2,260,764</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNC0zLTEtMS0w_4beac3f7-48bc-4a0b-bf41-bca8fedf65d3">3,391,148</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNS0xLTEtMS0w_8b278a11-28cd-481c-b4c9-86c56e7a73e5">383,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib51f14efceef46e083455712a43bf986_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNS0zLTEtMS0w_a4b450b8-3d6b-4626-b48f-cf4be218244e">377,922</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63475ab401474e89bee5f05a4a47acd0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNi0xLTEtMS0w_380aee71-c832-4f66-8b23-7798613555b9">5,803,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc5ee952cf84418b7016f83429f0aba_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNi0zLTEtMS0w_6316fac2-d0e1-40ef-a19e-fd658e209a52">1,819,223</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNy0xLTEtMS0w_df78bcec-3506-413f-95cb-d776e6981f7c">1,475,593</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940221e6cce645cfb6a90604dac8cbe8_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNy0zLTEtMS0w_80d4765f-3e32-47fa-b63d-1c8864115908">1,536,491</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfOC0xLTEtMS0w_b9ab4d53-a9a8-4a0a-b799-47fa05f98a40">13,568,420</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfOC0zLTEtMS0w_45b0b1e1-b89e-421d-8fc6-2cd7eab8cabd">11,344,620</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offering</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company completed an underwritten public offering, in which it issued and sold <ix:nonFraction unitRef="shares" contextRef="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNDg4_878c655f-0be4-4f0f-9ed8-e30becd814f0">4,312,500</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa05344a7c40424eb0df008620fe83e9_I20200630" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNTMy_bc307a55-6ee6-494e-81cf-790887185039">84.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNTgz_e4b729aa-5c57-476e-b404-c90d65fe7ce5">354.6</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_85"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNTE_6ba53f55-2d0a-48e8-85f6-7e676af914b2" continuedAt="i7770e7bb4a104fdb848c3aaf400a2c87" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i7770e7bb4a104fdb848c3aaf400a2c87" continuedAt="i74ddff25db2d4248aba818187615ec30"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDM_a9c34162-ca06-41ac-be5c-bf1d2dfe9f26" continuedAt="id62cfa0b8736440b87b12d21732429fc" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:30.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS0xLTEtMS0w_b416812e-5ddb-4d5b-adb4-e2dadb7f0f94">1,819,223</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS0zLTEtMS0w_d1f3155a-077c-4121-97a8-64cd8743c0fc">3,101,181</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS01LTEtMS0w_6f7df88c-aa0e-4f5b-81c6-7f41b31ad7e2">15.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS03LTEtMS0w_ae34104f-468f-40c3-aa74-5cb4c429107b">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS05LTEtMS0w_9d1f5124-0f53-4058-82ba-3d70d8f4a32f">350,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNi0xLTEtMS0w_25471479-8827-42eb-a350-6ac51b5ca47d">3,689,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy0xLTEtMS0w_5a1ee355-e3ec-4215-ade1-8b87402cb4bb">164,147</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy0zLTEtMS0w_38befbce-7ae6-4b08-b241-cd69c11ec58e">164,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy01LTEtMS0w_d63a13f4-a7cd-4e52-b9b2-7baa08d8a325">122.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOC0zLTEtMS0w_52d0907f-b395-486f-8370-f6d01d1298ba">629,246</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOC01LTEtMS0w_f0832aec-484a-422f-a46e-2612e6fd3db2">10.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS0xLTEtMS0w_b7be0468-391b-44eb-b95a-46f21d9fc618">63,286</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS0zLTEtMS0w_b3dac8ac-d583-4d3e-83fa-806032ada546">119,214</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS01LTEtMS0w_f0bf4557-1a6e-417b-a575-68d8839b0a26">49.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTAtMS0xLTEtMA_4a68a15c-9591-4dfd-988d-682968a5f45c">398,117</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTEtMS0xLTEtMA_095b6e6d-8c10-42ee-99c0-7bc217e99d7b">241,627</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTMtMS0xLTEtMA_31435547-eb3b-4a8c-9c56-a53184459f2e">558,254</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTQtMS0xLTEtMA_7b9a8170-8b0c-4ac9-942d-d92f8cb54315">52,917</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTUtMS0xLTEtMA_5b687fe4-c3df-4527-98b1-b253bfe92ba1">47,498</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtMS0xLTEtMA_8026375d-56f1-4ca1-8147-951870ce19d2">5,803,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtMy0xLTEtMA_e7ee1f08-3da5-4cfa-8afb-68de29f3311b">2,516,868</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtNS0xLTEtMA_59933617-213e-47cf-b1f1-9a17171a66b0">22.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtNy0xLTEtMA_b981e2e3-dbc2-4b29-8afe-eefbb9a62094">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtOS0xLTEtMA_403dabe9-124a-41df-8e56-10b4a63b6945">259,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctMy0xLTEtMA_4ff670ea-2ce4-4933-be1e-7f9d3743f2f6">1,943,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctNS0xLTEtMA_aa439630-b8f1-4c27-a964-183a595fe50d">10.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctNy0xLTEtMA_ce1d0154-c86b-42ee-836f-750648221909">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctOS0xLTEtMA_616eb1e6-e540-439b-8578-91195578e93d">222,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2021, an additional <ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzEz_25471479-8827-42eb-a350-6ac51b5ca47d">3,689,000</ix:nonFraction>&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $<ix:nonFraction unitRef="usd" contextRef="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzAy_7c283342-e210-4788-9ef3-4008f0e7dfb4">28.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzA5_11ceb661-53b6-4bef-b5e6-1069fa9e5db9">46.8</ix:nonFraction> million for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzQ5_7978c4ff-c0f4-46f7-b887-70fcead20684">77.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzU2_7a465b34-8ee7-4a5b-8139-4a980ed4dea9">97.1</ix:nonFraction> million for the nine months ended September 30, 2021, and 2020, respectively.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i74ddff25db2d4248aba818187615ec30" continuedAt="i30f61e4ab8394d888de7292ea6996a63"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODU4_2fd031a7-347c-4a4c-b0b0-64a116ce90ba">65.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODY1_8db0e89e-a817-4fed-9cd0-33235f1637d9">49.73</ix:nonFraction> per share for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfOTE1_370c92d2-7ef1-42a9-afa3-43e23e9f0d14">72.14</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfOTIy_e841f933-88bf-494f-b8f7-6acf7f568c57">46.85</ix:nonFraction> per share for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested options as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTAzNA_665cd398-2665-46f0-9634-91febfce04f8">22.7</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTEwNw_75653c38-2ce6-44d6-ab48-de50bb93922a">2.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDU_e3419835-4b4e-48b8-ab5f-7d6cced113fa" continuedAt="i84b4cdea3a79447c95e98a58532565a8" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfMy0yLTEtMS0w_0e709b57-68f6-44de-9deb-e4e88a01acf6">1,118,655</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfMy00LTEtMS0w_4f1a26c6-8e8d-4231-9cab-cfbb060f1bfa">92.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNC0yLTEtMS0w_d33ab799-8b87-4eac-829c-06e6c1d84d65">398,117</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNC00LTEtMS0w_9ade2a05-de40-4ad0-9973-fd7fa48e3fe5">130.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNS0yLTEtMS0w_01e79ae6-d2a5-4330-a69e-3be563fa6618">146,998</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNS00LTEtMS0w_c773666b-7fd7-40eb-8b48-6a98280cfac3">89.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNi0yLTEtMS0w_d0306c9c-d59e-48f2-bcfd-a8abdedce667">241,627</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNi00LTEtMS0w_1a2411f2-7654-40b5-a39d-b9f59b4933a9">94.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85be72137c66452fa6b52b9f18871115_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNy0yLTEtMS0w_bc52a205-389a-40e2-b7c3-6e8591468062">1,128,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i85be72137c66452fa6b52b9f18871115_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNy00LTEtMS0w_98fe4874-8caa-4d12-8861-607a518d80d8">106.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested restricted stock units as of September&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i85be72137c66452fa6b52b9f18871115_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQyNQ_30bd69f5-8039-4c99-a17a-d1a554493c50">105.2</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ5OA_88aac20f-814c-4fd5-b40c-7f645afb427b">3.0</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant performance-based restricted stock units (&#8220;PSUs&#8221;) under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of <ix:nonNumeric contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTg1NQ_30611ca7-e187-42b7-8f6c-5bc450156f06">4</ix:nonNumeric> years and an additional service period requirement of <ix:nonNumeric contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130" format="ixt-sec:durwordsen" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTkwNg_ef782f27-a7da-43cd-99d1-ec39fa0bd2c9">six months</ix:nonNumeric> after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of <ix:nonNumeric contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjA1NA_550220f4-532a-4536-a27f-a8eda72e098c">4</ix:nonNumeric> years. The PSUs are expected to be expensed over a period of approximately <ix:nonNumeric contextRef="i5e73ee9eef8e49aab2ec36819934f632_D20201101-20201130" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjEyNg_14007bef-ca03-4868-8226-5c48fe6b06de">4</ix:nonNumeric> years to <ix:nonNumeric contextRef="i5e9815d0d7cb41b09b77791966e52c75_D20201101-20201130" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjEzMg_bb49fa28-43f9-414e-bf73-7d03e3c891e1">4.5</ix:nonNumeric> years subject to meeting the respective performance metrics and service requirements. As of September&#160;30, 2021, a significant portion of these PSUs are not expected to achieve the related performance metrics, and therefore, no stock-based compensation expense was recorded for the PSUs that were not probable to vest.</span></div><ix:continuation id="i84b4cdea3a79447c95e98a58532565a8" continuedAt="ifa0c3920379d4309b3b7b3a93c295831"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib51f14efceef46e083455712a43bf986_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfMy0yLTEtMS0w_66456bb0-6664-4f1f-bb94-cb7074de3d18">377,922</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib51f14efceef46e083455712a43bf986_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfMy00LTEtMS0w_830a8b77-19ee-459c-a108-9e6bcb3a9e54">113.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNC0yLTEtMS0w_00323579-ba86-4e2b-b5c8-3bf048649a8c">52,917</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNC00LTEtMS0w_fea382e5-31d3-4904-9bad-99217e1dcce0">135.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNi0yLTEtMS0w_12983697-8771-4498-8b48-d3e020f046df">47,498</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNi00LTEtMS0w_8d207a6e-60fd-4ad2-be55-9b92cbf35964">113.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNy0yLTEtMS0w_5fb30d3a-9540-4869-90ed-b87771cf9429">383,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNy00LTEtMS0w_201051ce-1047-4806-9c34-e6c9fba4269d">116.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation recorded for the PSUs for the three and nine months ended September&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i565831a0298547cd9661d27b9d9d2944_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjY0Ng_129d6966-af77-4187-b8d3-b8475e39fd06">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjY1Mw_667521ae-f6ed-4dab-863c-e44d67de4c77">1.0</ix:nonFraction> million, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjc2MA_4d976869-d869-4ba0-b4f8-83ca0c58a4a9">4.4</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjgzMw_1435693b-d5ab-4005-86f3-91360194a6ca">3.4</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Board of Directors approved and granted <ix:nonFraction unitRef="shares" contextRef="i11b69d916f624dad9b518cabc4589b73_D20200526-20200526" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjkzMQ_79a2107d-03b1-47f0-ac50-7e3f546564d6">1,695,574</ix:nonFraction> market-based restricted stock units (&#8220;MSUs&#8221;) under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i30f61e4ab8394d888de7292ea6996a63" continuedAt="i547158e7adf4483898808b7cf65e9e71"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of <ix:nonNumeric contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526" format="ixt-sec:durday" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzQyMw_7d049e99-8ad5-4ec9-90a7-7cce8b0bbf20">30</ix:nonNumeric> consecutive calendar days. The share price goal can be met any time during the <ix:nonNumeric contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMjI_ddf025ff-d5d1-4539-ad7a-2c62a69cf9e2">seven-year</ix:nonNumeric> performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYwOA_1a96adcc-20aa-4c2d-b632-070a36d742ec">six</span> to <ix:nonNumeric contextRef="ie634a7fb83674c7d92b925a5d6a99ec1_D20200526-20200526" format="ixt-sec:durwordsen" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYxNA_37ec67ed-72b9-4924-9e4a-79b62b4d416d">twelve months</ix:nonNumeric> depending on the time of vesting within the <ix:nonNumeric contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzY_b1ee1bb3-c808-4cda-baf9-2aadff518538">seven-year</ix:nonNumeric> performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDY_1a1b937d-326a-476b-b5f9-c9b9db607688" continuedAt="i944ea752dfca4583965115c601d1b9af" escape="true">The following table presents additional information relating to each MSU award:</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><ix:continuation id="i944ea752dfca4583965115c601d1b9af"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"></td><td style="width:33.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1e7591cbb12410598b75394c40acba8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMS00LTEtMS0w_9346542f-d0e4-4e17-abec-5e021766c651">565,192</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5c7f0c0ebc94b6bbbcfabf0a1fae5db_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMi00LTEtMS0w_bcfbfa1f-babc-4b3f-823e-111e0a57d3da">565,191</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic51021850ccb4f1fadfb3bdbae1f91d3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMy00LTEtMS0w_62868087-8475-4941-a35b-110716705403">565,191</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted-average grant date fair value of the MSUs was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNDkyOA_f40c8f8e-0fbb-411c-9917-c8d7727963bd">67.00</ix:nonFraction> and the weighted-average derived service period was estimated to be in the range of <ix:nonNumeric contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTAxNQ_3b85c181-c757-4863-9b64-963374243db4">0.83</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTAyMA_d6c123cd-0988-4b19-9b82-3e2cd1699506">2.07</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, Tranche 1 of the MSUs became vested because it has met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of <ix:nonNumeric contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526" format="ixt-sec:durday" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTI0Nw_7d049e99-8ad5-4ec9-90a7-7cce8b0bbf20">30</ix:nonNumeric> consecutive calendar days. <ix:continuation id="ifa0c3920379d4309b3b7b3a93c295831" continuedAt="i49312f4bbded494584cf840daf383135">A summary of the Company&#8217;s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:</ix:continuation></span></div><ix:continuation id="i49312f4bbded494584cf840daf383135"><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Market-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfMy0yLTEtMS0w_36a133ff-dcbc-41a4-9841-3b9cdc0735e9">3,391,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfMy00LTEtMS0w_7db91cee-8028-4321-88ad-0ce969237f0f">67.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNS0yLTEtMS0w_a16f8411-bb7e-495e-a115-9604849b4927">572,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNS00LTEtMS0w_9c68287e-f9c7-4fc9-9727-0c082ecce539">70.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNi0yLTEtMS0w_94d6e005-d1e2-4208-ab84-262570449c8e">558,254</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNi00LTEtMS0w_0c710991-029e-49f6-b9bd-a5b1ed58e82f">70.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNy0yLTEtMS0w_ac7ceab4-c106-4004-b5a6-5c87303832fe">2,260,764</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNy00LTEtMS0w_b53b7493-7da8-4875-bc6c-318e07707a45">65.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for the MSUs was $<ix:nonFraction unitRef="usd" contextRef="ib17cb1196a064f4088f3fc6c035e9d72_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTU4NA_6cd2b749-792e-4d10-9ef5-7a2418996acc">22.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia097fb6e0e4d41ed842060e7bc5260e5_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjkwMw_9fc7696f-fdc6-4aec-8e06-f92e3047b308">46.8</ix:nonFraction> million, for the three months ended September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjk3NA_f63a3b89-5180-410b-b65a-d4013a0a1163">88.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9b7a51301dcf41c98545f06434fe3b72_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjk4Mg_cd6b4d88-21d4-4c32-9f5b-c9e735383ecc">65.1</ix:nonFraction> million, for the nine months ended September 30, 2021, and 2020, respectively, which was recorded in general and administrative expenses on the condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTc4NQ_951af714-d1ff-4929-9335-94708abba68e">26.4</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTg1OA_68553626-9610-4119-87a8-22b8d17fbe4a">0.7</ix:nonNumeric> years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the <ix:nonNumeric contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzA_7c8fbb10-8c70-4ccf-a5e4-b439b38f6f20">seven-year</ix:nonNumeric> performance period will automatically be forfeited and terminated without further consideration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMEA 2020 Equity Incentive Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan (the &#8220;AMEA 2020 Plan&#8221;), under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to employees of the Joint Venture or its affiliates. Nonstatutory stock options may be granted to </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i547158e7adf4483898808b7cf65e9e71" continuedAt="i798eff065df2422fa3ce558d634bdca2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees, directors and non-employee consultants. Stock options may be granted at an exercise price of not less than the fair market value of the Joint Venture's common stock on the date of grant, determined by the board of directors of the Joint Venture. Options generally vest over <ix:nonNumeric contextRef="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzE0Mg_7533f655-faa9-481a-8717-3a5a755f82fe">4</ix:nonNumeric> years and expire as determined by the board of directors of the Joint Venture, provided that the term of options may not exceed <ix:nonNumeric contextRef="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzI2Nw_855bd80a-5046-4067-8aca-a4da1cb3d698">10</ix:nonNumeric> years from the date of grant. For individuals holding more than <ix:nonFraction unitRef="number" contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930" decimals="2" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzMyOA_faadef54-ea5c-4f18-9a49-84569253c8a1">10</ix:nonFraction>% of the total combined voting power of all classes of stock of the Joint Venture, the exercise price of an option will not be less than <ix:nonFraction unitRef="number" contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzQ2Ng_46424901-55c8-4082-8f80-c1d9c53acc61">110</ix:nonFraction>% of the fair market value of the Joint Venture's common stock on the date of grant, and the term of the option will not exceed <ix:nonNumeric contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzU5NQ_0834f348-7a09-4e16-9e2e-672466b5710a">5</ix:nonNumeric> years. A total of <ix:nonFraction unitRef="shares" contextRef="i7c382b53abce461ab4ceb209bd8a2229_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzYxMA_ba230c2b-f63b-415b-8660-d002865a9815">4,595,555</ix:nonFraction> shares of the Joint Venture's Class B common stock are initially reserved for issuance under the AMEA 2020 Plan, and the number of shares may be increased in accordance with the terms of the AMEA 2020 Plan. </span></div><ix:continuation id="id62cfa0b8736440b87b12d21732429fc"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:30.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia601d039561f4097b3df49643250b3bf_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS0xLTEtMS0w_d7459af0-08cf-4c5d-b034-e440174394fd">542,220</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia601d039561f4097b3df49643250b3bf_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS0zLTEtMS0w_ae011c27-0480-4550-bf50-7b8d45a995f8">4,053,335</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia601d039561f4097b3df49643250b3bf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS01LTEtMS0w_40db6d1b-fe37-49a1-a2b9-2ff53f0ffaa8">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a3300f2c9ff4ec6a29cf3cc30f0a698_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS03LTEtMS0w_ada1c4f9-e7c8-4a08-b883-31c069a12278">9.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia601d039561f4097b3df49643250b3bf_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS05LTEtMS0w_2d0c8c3a-a38a-4121-9d50-b81bdbd14961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy0xLTEtMS0w_d8b4c39f-72d9-4c52-905a-ebb892d89915">826,667</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy0zLTEtMS0w_affd7d92-0fe2-4915-a012-1e77a9807f98">826,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy01LTEtMS0w_ad096325-851a-44dd-a9c9-0c31a9789d2a">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOC0zLTEtMS0w_e71d00a2-0aa9-450a-9eee-49dd11e10fcb">313,331</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOC01LTEtMS0w_4436f0f2-4b81-4091-99bf-9c820bd0b80c">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS0xLTEtMS0w_73200141-97e0-408a-b85d-5b354a99178d">382,780</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS0zLTEtMS0w_ce2508b1-1b31-480e-a7d4-d1194a34a41b">382,780</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS01LTEtMS0w_845177c0-238d-4d86-ac2e-d00f8cf07dfb">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtMS0xLTEtMA_8f158f00-5805-413c-876a-545aa2159053">98,333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtMy0xLTEtMA_ebe7cae7-66ad-4cb2-ba7e-8d5de6823e8c">4,183,891</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtNS0xLTEtMA_009923cf-10b9-43d7-a00a-f223ba51e8ae">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtNy0xLTEtMA_037c6b56-96c3-4bd5-b0d2-26f098510c02">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtOS0xLTEtMA_61fcdfc0-9fde-4a10-a64b-8fe7ec5eaff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtMy0xLTEtMA_1dd05d2e-7154-4e50-8eae-8953d8ed4aa0">2,341,259</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtNS0xLTEtMA_ee69048c-c923-443a-abae-b85a5553fd42">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtNy0xLTEtMA_b2fd0939-cfc0-44cf-96c4-64b0e0d7d9f0">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtOS0xLTEtMA_7188fb65-4add-4b47-8730-13a0d86ab32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODAwOQ_3d774657-1ca4-4c29-af94-f386ca76e6f4"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f17ed5a12ca4a6abb0cea17b1730fef_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODAwOQ_91821abc-a9af-449d-8bb3-899eddadd143">0.33</ix:nonFraction></ix:nonFraction> per share for the three and nine months ended September&#160;30, 2021. Future stock-based compensation for unvested options as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODExNg_02344129-de3b-440f-9dd2-1677713d2d10">0.6</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODE4OQ_fb717be5-6362-4f24-8a0e-dd4ef44a7162">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDA_70f793fa-621a-4c31-a389-a4351e3de4f6" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f46661f1f446eeb205375c1af434fe_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS0yLTEtMS0w_56876c57-22ce-4904-a607-08991b4c5f51">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d04197610e4189a303bead82651edb_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS00LTEtMS0w_1286242a-45e4-4d41-bf59-dc22c0b7b106">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc36477bea5640ec874839095e170908_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS02LTEtMS0w_bd20bcbe-0023-4992-90f5-ba97545d556a">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f4b78122abd4e8eb313c8e1a7719f92_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS04LTEtMS0w_07fc54e2-9ad3-457e-bec2-e463febe5422">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense   </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fba181b054fabb73999b47d483dbf_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi0yLTEtMS0w_a92137d9-0d8d-4d59-b0ef-fd9a1bc36639">4,416</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f6cfe7e6404cae9e7b6b09a000b0cd_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi00LTEtMS0w_10f7a5c9-4efc-4884-b5b9-2a1a836c3524">2,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4023c5dcd0439fb73518c68885f959_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi02LTEtMS0w_ef8cb0f6-c882-4d84-8076-a6980ba98fff">13,280</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007fd51f89bf4055aa793319535aa53c_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi04LTEtMS0w_d6eae337-e56a-472a-888b-fde213d7d152">7,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22b70d2f2e34c20a09a9012c59cd21a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy0yLTEtMS0w_e3226267-e6db-4cfb-95b7-328c3da9cbf2">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66ec163b0d848a3a230072df877cf55_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy00LTEtMS0w_c8556d26-b202-4ee2-864f-4f8d61750c9b">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23565c372dc4ccbb89ffb28f7af1b0e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy02LTEtMS0w_ca9d0b94-58f3-4b2f-af55-ded28bbca1c4">10,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77295fc586c94e54a8fba5426ea17938_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy04LTEtMS0w_564d38ae-cf10-4fcf-8349-daf104339be4">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense   </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if994b46b023d4d5fa18a833907f95a23_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC0yLTEtMS0w_a9f54e4c-4cf5-4c27-8540-61db626ec4f8">25,933</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c5b239ffb4440f80781154268288d9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC00LTEtMS0w_1cf856e3-10dc-4d85-97c2-68b91f71eff7">50,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ba431512174cc5bfce850e0b0b12a2_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC02LTEtMS0w_4ef2e752-91ae-486a-9af2-7ba3873570a2">98,687</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2e85ec40be47df923a27894e32515d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC04LTEtMS0w_b39629e1-3501-441b-99a4-638e7832abe2">72,573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS0yLTEtMS0w_99361a42-5422-417f-840e-a5c04690369f">35,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS00LTEtMS0w_bcb848d6-560f-41cd-9674-06638ba3175b">55,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS02LTEtMS0w_7701832f-4d7a-448c-952f-9d79f2b69a04">124,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS04LTEtMS0w_6519dad4-191c-46b8-9ac0-4be00c957415">87,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i798eff065df2422fa3ce558d634bdca2" continuedAt="ibd1fea5653d84950954a13f675e867cc"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options</span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzQ_c780dc8f-8aa5-40fc-ac8f-801118a6d6dd" continuedAt="i29ac257ae16d4d668563aef342c0e7c2" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC0yLTEtMS0wL3RleHRyZWdpb246OTRhMjgzYmNhN2M3NDMzZGIxNzIzNjlkODc0NTRlMjZfNA_6e118c77-e1ed-4870-acbc-b3ea36287aa6">5.94</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC0yLTEtMS0wL3RleHRyZWdpb246OTRhMjgzYmNhN2M3NDMzZGIxNzIzNjlkODc0NTRlMjZfMzg0ODI5MDY5NzI0MA_eb68ae23-2bee-4a63-b412-182c9c4d206e">6.04</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC00LTEtMS0wL3RleHRyZWdpb246OTZlNmZiNzI5M2Q2NDJjNWFkYmFlY2U1MjQ1YzUzMjdfNA_2f14ce3d-224a-48f6-9869-8a0aa3fe353d">5.95</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC00LTEtMS0wL3RleHRyZWdpb246OTZlNmZiNzI5M2Q2NDJjNWFkYmFlY2U1MjQ1YzUzMjdfOQ_79eeb905-6cb6-4bf5-aba7-588e9e06f82e">6.04</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC02LTEtMS0wL3RleHRyZWdpb246MGNmYTE4NTZhYWQ1NDc0N2JkYmY5NmYwMWY1ZGZlNWVfNA_36921610-3487-4ff5-8159-dfded6740632">5.49</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC02LTEtMS0wL3RleHRyZWdpb246MGNmYTE4NTZhYWQ1NDc0N2JkYmY5NmYwMWY1ZGZlNWVfOQ_0f45860c-9668-48ed-a1ab-1d13438c13ce">6.04</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC04LTEtMS0wL3RleHRyZWdpb246MGFhNzA3NTBhMzc0NGNmOGI3ZmE5ZDEzYjJkMDQ2YTRfNA_a260ebf9-50c2-4265-9f92-1af09050c80a">5.50</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC04LTEtMS0wL3RleHRyZWdpb246MGFhNzA3NTBhMzc0NGNmOGI3ZmE5ZDEzYjJkMDQ2YTRfOQ_ecaf8ea2-93a3-49be-8b60-5c5d11461bf0">6.10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS0yLTEtMS0wL3RleHRyZWdpb246NzAzYjdjMWVlOTI4NGM3YjlhZDY5OTllNWY4ZjAzNzdfNA_16628cfa-1517-4f8b-bee9-8b32fae71c70">63.6</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS0yLTEtMS0wL3RleHRyZWdpb246NzAzYjdjMWVlOTI4NGM3YjlhZDY5OTllNWY4ZjAzNzdfMzg0ODI5MDY5NzI0MA_cb512461-48a0-4cae-9727-4fd539111c99">66.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS00LTEtMS0wL3RleHRyZWdpb246YWFlZjE0MTQ2Y2UxNDM5YmE5YmFiYTMzNGY3N2E1ZGVfNA_20e1165e-25cf-4075-a1dc-2259e8df946c">63.6</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS00LTEtMS0wL3RleHRyZWdpb246YWFlZjE0MTQ2Y2UxNDM5YmE5YmFiYTMzNGY3N2E1ZGVfOQ_5aaecb16-6a68-4841-81a5-e45de404acfc">68.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS02LTEtMS0wL3RleHRyZWdpb246MTAzNWFiNjE3MDM1NGZlMGIzNDc2NGExZGRmZDAwNTlfNA_fa610f93-5385-4848-8f99-cf98f0af1da6">63.6</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS02LTEtMS0wL3RleHRyZWdpb246MTAzNWFiNjE3MDM1NGZlMGIzNDc2NGExZGRmZDAwNTlfOQ_c0de5afe-4072-4ac6-9d07-a6f6d60dc5f8">66.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS04LTEtMS0wL3RleHRyZWdpb246NGQzY2NiNzFjMDBmNDEzMzlhN2I0MzNiMjUyZTUyYzRfNA_0b6ebdf9-e947-4279-8df4-c1f48a674ebb">63.6</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS04LTEtMS0wL3RleHRyZWdpb246NGQzY2NiNzFjMDBmNDEzMzlhN2I0MzNiMjUyZTUyYzRfOQ_66d2ec70-bdeb-45ee-a6d1-781b4f8385c0">73.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi0yLTEtMS0wL3RleHRyZWdpb246ZjQ3YmZkNGFhOWU5NDhlZGJmNzIzNzRiN2FjMGFkNzNfNA_71046898-60af-431d-8c7c-ed9f5ce10e4a">0.3</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi0yLTEtMS0wL3RleHRyZWdpb246ZjQ3YmZkNGFhOWU5NDhlZGJmNzIzNzRiN2FjMGFkNzNfMzg0ODI5MDY5NzIzMA_38f5fa04-6233-44bf-a4c0-da1f2d77062a">0.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi00LTEtMS0wL3RleHRyZWdpb246YTY3N2Q0ZTg2NzFhNDMzOTk3NTcxZWJhNzRiM2I1MzhfNA_0ace16ed-e7b5-4ddd-935d-e03bca322122">0.3</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi00LTEtMS0wL3RleHRyZWdpb246YTY3N2Q0ZTg2NzFhNDMzOTk3NTcxZWJhNzRiM2I1MzhfOQ_2c4d335c-cfa7-4fd4-911a-b387165f71a4">0.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi02LTEtMS0wL3RleHRyZWdpb246ZjA0YjE4YmVkMzgwNGMzYzg1YjVlOTgyZTRjOTgwZWRfNA_78a3c1f4-481f-42f9-9e5a-463d19143e67">0.3</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi02LTEtMS0wL3RleHRyZWdpb246ZjA0YjE4YmVkMzgwNGMzYzg1YjVlOTgyZTRjOTgwZWRfOQ_ba20112d-fc36-43ec-9306-59a332a38be4">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi04LTEtMS0wL3RleHRyZWdpb246MjIyMzE3MTk3MzE5NGMyMGI5YTlhMTlhNWViMGZjMDJfNA_50ea9350-d318-4e2f-96b6-5d5354c23359">0.3</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi04LTEtMS0wL3RleHRyZWdpb246MjIyMzE3MTk3MzE5NGMyMGI5YTlhMTlhNWViMGZjMDJfOQ_8ed836c2-b94c-450f-87d7-11ef80b42ef3">1.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy0yLTEtMS0wL3RleHRyZWdpb246ZDAxN2RhNDk4NTE0NGE3NmI2MGM4ZmI3YmJjMTE5ODNfNA_4d688716-c839-4ba6-9aaf-e9919c9ea5aa">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy00LTEtMS0wL3RleHRyZWdpb246MGZjMmJlNmIxNzNhNDllZmFlOTUwMmQ1YTc1YjFjMzRfNA_7cd5a465-b716-4976-87d2-a40e24ba178b">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy02LTEtMS0wL3RleHRyZWdpb246YTg3OTliY2I1NjYyNDhkNzg0NGE3MGEwNWQwODcwYmZfNA_695ec1a2-d33e-4b55-a435-adfda566e0b4">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy04LTEtMS0wL3RleHRyZWdpb246OGZjMTYyYTQzOWVjNDhjMDk3MTY0ZDgxODBlMGJkYWRfNA_a9a813d5-9dfc-4f55-a7dc-28c06e2d4e5c">&#8212;</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company and the Joint Venture, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. The grant date fair value of the Joint Venture's common stock has been determined by the board of directors of the Joint Venture. The grant date fair value of the Joint Venture&#8217;s common stock was determined using valuation methodologies which utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the Joint Venture&#8217;s common stock, the methodologies used to estimate the enterprise value of the Joint Venture were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Joint Venture derived the expected volatility from the average historical volatility over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Joint Venture does not have any trading history for its common stock. The Joint Venture will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and the Joint Venture does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTE4NzI_072dc7d3-cb70-49c9-9408-a62c8542b4e1">zero</ix:nonFraction>.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="ibd1fea5653d84950954a13f675e867cc" continuedAt="i90e320aa802b44e9abcecc9a20ee10b3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of MSUs</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risky Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risky rate represents the Company's cost of equity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discount for Lack of Marketability </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of <ix:nonNumeric contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxNDg_89af3b10-21cd-4272-a468-6890eef3af3b">0.83</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxNTM_af8250f9-80ed-4896-9c46-703963f407c0">2.07</ix:nonNumeric> years; expected volatility of <ix:nonFraction unitRef="number" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxODA_6ae1c5f2-81e5-4033-a416-724107404827">65.5</ix:nonFraction>%; a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyMTM_fe7ee76f-41b3-4bb1-8516-84ad40b2e283">0.53</ix:nonFraction>%; a <ix:nonFraction unitRef="number" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyMTk_20b2819f-7afb-4f36-91f3-2314f0209efc">zero</ix:nonFraction> dividend yield; a risky rate (cost of equity) of <ix:nonFraction unitRef="number" contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930" decimals="2" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyNzE_40e31eed-18e3-4776-8b48-5de1ecc3a924">16</ix:nonFraction>%; and a discount for post-vesting restrictions of <ix:nonFraction unitRef="number" contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMzMjM_3772d537-9987-444b-9a59-9b76586a9b4a">10.4</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMzMjg_e5e4974e-ce17-4750-9146-103a1559de47">14.5</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="ic36d7e888e844c6ab365df40d7c9fb62_I20180930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM1MTk_7e95da1b-5ce6-4c0b-a6bd-177975ad7ca5">922,250</ix:nonFraction> shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional <ix:nonFraction unitRef="shares" contextRef="i439505c15efb47c09a20226584e2c489_D20200101-20200101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM2NDU_60006fc1-39cb-4fb5-b383-5e744897de87">942,614</ix:nonFraction>&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;<ix:nonFraction unitRef="number" contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM5MjM_2d0b50d9-ed69-41ab-bbf0-d7e3bf2c7cc6">10</ix:nonFraction>%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;<ix:nonFraction unitRef="number" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQwOTY_7f299e09-f476-443c-bcf7-6d56be56bbe2">85</ix:nonFraction>%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;<ix:nonNumeric contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" format="ixt-sec:durwordsen" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNTA_c538abca-714d-4de1-9871-15033d3636a5">six-month</ix:nonNumeric> offering periods beginning on May 15 and November 15 of each year. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock purchased under the ESPP were <ix:nonFraction unitRef="shares" contextRef="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQzODU_1d6467e8-bb09-4e38-8f16-7b441780a947"><ix:nonFraction unitRef="shares" contextRef="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQzODU_38fd94fd-f3ce-46b9-a1ce-f4bd47c74472">nil</ix:nonFraction></ix:nonFraction> for the three months ended September 30, 2021, and 2020, respectively, and <ix:nonFraction unitRef="shares" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjYzNw_a07b1abf-3550-41c5-8122-16d425a76e03">60,898</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjY0MQ_9f7d01f3-a501-4732-b7d8-317fe24182af">58,164</ix:nonFraction> for the nine months ended September 30, 2021, and 2020, respectively. The total compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ0OTk_8c623721-400a-4d9e-96a6-864d602fc8b2">0.9</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1MDY_f01452c0-09a3-42b0-bab0-47ca1da94932">0.7</ix:nonFraction> million for the three months ended </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><ix:continuation id="i90e320aa802b44e9abcecc9a20ee10b3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021, and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1NDY_8df388e1-9482-4b4e-845f-fb8ba2a9b976">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1NTM_d15fc64e-a0c1-41bd-818e-87f2114d5aac">2.3</ix:nonFraction> million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No ESPP shares were issued for the three months ended September 30, 2021, and 2020. <ix:continuation id="i29ac257ae16d4d668563aef342c0e7c2" continuedAt="i6046c6237cf14c95b882cc4b7d969f15">The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><ix:continuation id="i6046c6237cf14c95b882cc4b7d969f15"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:73.378%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.940%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)   </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNC0yLTEtMS0wL3RleHRyZWdpb246YjEyYTJmMGZmODc0NGYyOTg1NDUwNzdiODBkYjQ5ODBfMjE5OTAyMzI1NTU1OQ_5c5e68e6-06be-46bc-ba5c-4c228396f36f">0.50</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNC00LTEtMS0wL3RleHRyZWdpb246MTc3MjU4YTU0NGJmNGE0ZGFhNzhlMDllNThmZmIwOWRfMjE5OTAyMzI1NTU1OQ_3778eebb-70ca-429e-98f3-d48cd075b446">0.50</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility   </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNS0yLTEtMS0wL3RleHRyZWdpb246NTgzMWRlNWI4NjU1NGJkNzk1YzU5OWY0ODI0ZmM3NmFfMzg0ODI5MDY5NzIyMA_63737d03-97cd-400d-aba9-a6d5159cfc82">50.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNS00LTEtMS0wL3RleHRyZWdpb246ZjQwZWJiY2FlNzNhNDYwMTk5NmFlNjI0N2ZlOWU0ZjZfMzg0ODI5MDY5NzIyMA_336a0222-c8ad-4e64-bd9e-8a05fac6d870">73.2</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate   </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNi0yLTEtMS0wL3RleHRyZWdpb246ZjFiYjFhYjZjYTQ1NGVjZGJhNmQ4NzZhZmJkM2JlOWZfMzg0ODI5MDY5NzIyMA_19de8809-b274-4e7a-ad2a-7d97ce3b814b">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNi00LTEtMS0wL3RleHRyZWdpb246N2M2NTJjYmI4NDM2NDgxYzlkMThhMmJiNDY1NTRjNTdfMzg0ODI5MDY5NzIyMA_6cc664f3-efb7-4ab0-9eb3-fafb81e26902">0.2</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield   </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNy0yLTEtMS0wL3RleHRyZWdpb246M2MwMDY3M2RiMmUwNGVjNmI3YWYzMmE4MmNlNTEyZjZfMzg0ODI5MDY5NzIyMA_bff8a38c-a972-4fc3-9bd6-6cf27415031c">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNy00LTEtMS0wL3RleHRyZWdpb246YjU4MzJlYmUwZDk4NDc2YTk5ZDFjZDI2MWE4MTJhY2FfMzg0ODI5MDY5NzIyMA_bc15e89b-163d-46bb-a0ad-aa39091247f5">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the unrecognized stock-based compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUyMjg_05cfa7d3-5536-4b81-a40d-fb77cf7e64c5">0.4</ix:nonFraction> million, which is expected to be recognized over the remaining term of the offering period of <ix:nonNumeric contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMTc_db9bd134-c0c2-4f12-95c0-a11675922c19">0.1</ix:nonNumeric> years.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_91"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTIx_e5648c8c-ded9-45c3-addd-041d1bfeb634" continuedAt="i0acfbd0af4db457695ff483b40528e60" escape="true">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i0acfbd0af4db457695ff483b40528e60" continuedAt="ic3bd833f886b438fa01de3ec872a1514"><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTMw_8bf660a5-ded4-4a83-9083-8b191aa56c88" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS0yLTEtMS0w_871af2b6-a833-4041-96a1-4818e4986676">107,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS00LTEtMS0w_d503e420-597b-401c-9c6e-db68d1af4b22">71,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS02LTEtMS0w_2113e4af-267f-459f-b464-b968d1f9626c">312,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS04LTEtMS0w_87fe84f7-7ce4-4d19-8efd-dbf1fc1810e3">153,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi0yLTEtMS0w_f3e119d4-f9f5-4feb-bfd5-3afdbd85b20f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi00LTEtMS0w_749f4ff8-6a22-4cf2-b99a-881220d0b919">6,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi02LTEtMS0w_47a648a4-d589-4149-b2f5-5365477bdd8d">2,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi04LTEtMS0w_b4834c52-aa07-4182-8f9b-57e006c71cb7">6,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy0yLTEtMS0w_5fb15a6f-99ce-48c3-9458-8326d07d546e"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy0yLTEtMS0w_874ad18e-18fc-40c0-8475-233b2cc75eae">107,526</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy00LTEtMS0w_7cf8edec-5b3a-4ed9-bc33-fd74fbd6afb0"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy00LTEtMS0w_8dc8426e-3495-49b2-abd9-940fb6ad33ae">77,670</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy02LTEtMS0w_3be0f175-2ef8-4054-be41-1f693fdc6a60"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy02LTEtMS0w_da0bdad3-4ec1-4239-b438-526e1d366870">314,759</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy04LTEtMS0w_3bfae457-11d1-47f2-a894-526199e6ba38"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy04LTEtMS0w_6a771443-e1a8-44c8-980b-3f6ac4a0489b">160,038</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC0yLTEtMS0w_5e8f5e54-daf5-40fe-8053-de9221edde10"><ix:nonFraction unitRef="usdPerShare" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC0yLTEtMS0w_e34d2365-82d7-4a0a-87aa-636ae63fcf99">1.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC00LTEtMS0w_3591fe49-89e0-47fe-a4c5-f6869b685ed2"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC00LTEtMS0w_83e47ca5-1995-4378-b87c-f29fe85827c9">0.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC02LTEtMS0w_3143a1bd-0fa1-4325-a914-b9e2191d59f0"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC02LTEtMS0w_85e3b458-8f5c-4861-b22e-18dc4a83b75d">3.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC04LTEtMS0w_7621e41c-04a9-4d82-9e2d-310264887c94"><ix:nonFraction unitRef="usdPerShare" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC04LTEtMS0w_9d92cafd-0d32-4843-b8ba-9eba258af409">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS0yLTEtMS0w_3547942d-001f-4f89-9522-43b8ed67973f"><ix:nonFraction unitRef="shares" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS0yLTEtMS0w_5036dc6e-bb14-4fef-850b-f10c73d98915">101,420</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS00LTEtMS0w_08983a6c-b99c-4ced-840d-737f5a71a651"><ix:nonFraction unitRef="shares" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS00LTEtMS0w_cf6de157-4e44-4669-9ab7-a2e06d25892c">99,554</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS02LTEtMS0w_2a1dc424-e264-474e-ad8e-ac2aac3ddd5f"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS02LTEtMS0w_5c25cd97-5ffd-4e1c-a043-bb3a1fd5fb96">101,184</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS04LTEtMS0w_74fc4605-5672-419d-831c-43e6ab0cf64a"><ix:nonFraction unitRef="shares" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS04LTEtMS0w_772ea594-c73c-4bfb-a0b9-e5a0b2538257">96,659</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. <ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTI1_02b4e333-b4f1-4ac3-b46c-58652c53ccaf" continuedAt="i0ae744feb44b470da68293d5d938cf1f" escape="true">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt"><ix:continuation id="ic3bd833f886b438fa01de3ec872a1514" continuedAt="i47206590f9a74dffba21fb842a0ae63c"><ix:continuation id="i0ae744feb44b470da68293d5d938cf1f" continuedAt="id8df6f7141574cb2aab93258004b822f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:39.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5e2eb5867bd4abdad9efdb23c03648e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS0yLTEtMS0w_62efed84-e1e2-40e6-954f-8b9758e9e3f8">2,628</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cd8dd76287347a8994cc91cb0f37e54_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS00LTEtMS0w_9b5bc1fc-c864-4a44-8041-44db36f93184">3,662</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f1590c4a013498998b04d6183682906_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS02LTEtMS0w_ee33895e-b06c-42ee-b04c-7bdfd930a064">2,753</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i563548405428432e9be4583d990c20a5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS04LTEtMS0w_c22de784-81ce-4479-8e67-0de8380d8807">4,021</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1764a9cb4164255b21e4e0410cbdd27_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi0yLTEtMS0w_2de635c5-2112-4623-81a0-fc9be61f71fe">1,185</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i467c75e1f7b948f5a7efd31013b1df18_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi00LTEtMS0w_467eb1f8-f055-49a5-bff1-4955dbf06d61">650</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59f3361b30354d25bc950de5b659ed29_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi02LTEtMS0w_f87fbf75-662d-441c-8382-54fa9c014923">1,151</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61bba0a88cc44568eb34939ff6408d3_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi04LTEtMS0w_2135ef09-9ad5-4bfe-a2fa-389593c7428d">563</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i051dbab8706f4e6c98fecf9f6683eeac_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy0yLTEtMS0w_04fbb347-b3ae-4615-a769-7837ea086df2">2,261</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0255fd6f42d4f048e85959bd465c936_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy00LTEtMS0w_baad7cc8-671b-4923-869f-033dab293a30">3,391</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dae2902d6664783b4358b0e7fc11e28_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy02LTEtMS0w_04fe90d0-1e50-4874-9056-3c1bf511aaeb">2,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebaae8e37d2b469097bb427b4661df0f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy04LTEtMS0w_a5cb9038-fb44-4175-b39f-8dbcb2b3d619">1,577</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c69dc8a627e4728912a6ed479ffc345_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC0yLTEtMS0w_d74a9d26-ed59-439b-b392-63ad0e76aef0">395</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48e9f1511fdf4cfcb8763f4f23670aa0_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC00LTEtMS0w_ded898d0-cc09-4c40-954a-57ac50b9d193">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9347e34e544e4e239b40143f08c828bd_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC02LTEtMS0w_a370ddda-b6e7-426e-9d59-2c43f579a931">404</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a11b9af24a42609ff2239dde8e7b4f_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC04LTEtMS0w_daa5dd98-9a61-4bdd-92a5-b363bd5a6a13">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68413562a6147688552dc1e0f887f19_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS0yLTEtMS0w_1fadedbb-aa75-42d4-9cad-0d1790036f53">51</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8824d00a82d749e4ae56c26f8bf3f10d_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS00LTEtMS0w_ac606696-b6f6-4f93-ac9c-5f6b3a3c7f87">38</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i181b6be341c14cacb65432c7b26b5d1a_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS02LTEtMS0w_dcb3adbe-158e-4321-ba3c-5e2c2285e643">47</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i754a60ee0b734d8c8d484dab169687c5_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS04LTEtMS0w_00a75b04-8fd2-4fa4-803b-eb318961a003">39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa67442147d24fb6a1c2a53972720ac1_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtMi0xLTEtMA_d64f52fa-a845-4c83-996a-1155da6e4d72">6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac62ba63e55f4ede8b1e77117a996888_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtNC0xLTEtMA_85b5def6-832d-454a-9eac-7839230f5786">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4779950a41b74addaabf2b2059d74b21_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtNi0xLTEtMA_d145173a-24a3-4b13-a671-c967dd38ba95">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i237f233fbe394afd8d627b2eb131fc5b_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtOC0xLTEtMA_f432a02d-6430-4789-a52d-45c3ae12b410">20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i323c4b627b0a459fba3b36b35483f280_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtMi0xLTEtMA_3d095cf1-2090-4b5b-b0de-1c88c8d5711e">8,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d16e8391a8340adbde54906d31ca966_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtNC0xLTEtMA_781b2d3b-e009-4334-8ad5-9211d314adc0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ca0eb25cb4e48be9a03dadf144d511d_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtNi0xLTEtMA_e392967d-7a58-4524-b855-e521283c571c">8,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54d2bc7082434cad8d5831042bf6a66e_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtOC0xLTEtMA_c78e0491-2695-4ef5-9cf6-d87f70bd7e02">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItMi0xLTEtMA_4b7e821e-d185-4bc8-80ba-e7d222011d7e">14,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItNC0xLTEtMA_15527ff0-67fa-4b7c-a7ac-0acba1b3cf14">7,758</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItNi0xLTEtMA_74f6544c-ab4d-4f4f-bb0c-4981ca617568">14,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItOC0xLTEtMA_c5cdd3b7-bdf5-452f-8297-b0aa48140cd9">6,220</ix:nonFraction></span></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:continuation id="i47206590f9a74dffba21fb842a0ae63c"><ix:continuation id="id8df6f7141574cb2aab93258004b822f">(1)&#160;&#160;&#160;&#160;Excludes stock options of <ix:nonFraction unitRef="shares" contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfODY0_89dd03fe-ba09-4bcc-9ffe-20599db2cb3d">4,183,891</ix:nonFraction> shares outstanding under the AMEA 2020 Plan as of September&#160;30, 2021.</ix:continuation></ix:continuation>  </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_94"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85NC9mcmFnOjc2NzI0YmM1YWRkZDRkNmViNTM3OGVhYTNhY2Y4M2M2L3RleHRyZWdpb246NzY3MjRiYzVhZGRkNGQ2ZWI1Mzc4ZWFhM2FjZjgzYzZfNjI3_8f3c0024-4031-4738-9430-23320d1fe239" continuedAt="i64462dc0eebb4d8d88622633f63c4ca4" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i64462dc0eebb4d8d88622633f63c4ca4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three and nine months ended September&#160;30, 2021 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three and nine months ended September&#160;30, 2021, and 2020, relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_97"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfNDM3_388a06db-fbaf-4e9d-abc4-c5a996d0c181" continuedAt="i312dea6441824379a7fe85ebe0939881" escape="true">Segment and Geographic Information</ix:nonNumeric></span></div><ix:continuation id="i312dea6441824379a7fe85ebe0939881"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates as one operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfNDM5_e793a97f-e81e-4959-b994-f79855d92492" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b784372c3354db186e4207099919653_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS0yLTEtMS0w_5bcb4e5d-8309-4422-94e6-3e061accfd82">90,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibade6416d9d94221aaa09a5c56f76ec5_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS00LTEtMS0w_c59f0e97-4ec0-416e-b869-003894b411ce">65,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac36981cc6c40c8b223afae0434d59f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS02LTEtMS0w_51db8b26-72d2-47d2-9a3f-f533905fd3e0">250,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1277ed3fdf429fb8b2ce51e59b628c_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS04LTEtMS0w_cd57ff8c-4108-4d42-91aa-3a7b821dec8f">191,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1476a97484154965919c2e362fd4d837_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi0yLTEtMS0w_478603a8-6ae6-40e5-a7ff-3c62d89f6d6e">4,358</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd900800a93495eafddef1dfbea5516_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi00LTEtMS0w_f26a8c04-86f4-4737-80e3-9eca6356ae44">8,956</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d20b34408944d6f96387d39fb1726ed_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi02LTEtMS0w_0243a2d4-cc5c-447a-a7d7-56f45ce4f42b">14,956</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bce519e74e4d918ca90a92c7c39f65_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi04LTEtMS0w_7e533262-3bc2-4cc8-ba02-17ed15edaf52">16,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy0yLTEtMS0w_b6906b6e-b247-49e5-966f-77b72ab9a64b">94,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy00LTEtMS0w_a02d1179-bcbd-43bd-b46c-83f693701ff5">74,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy02LTEtMS0w_2992733a-102b-480b-aedf-9e8b39497741">265,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy04LTEtMS0w_4093fdc6-961c-4fc9-89af-5a6166c33883">208,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and nine months ended September&#160;30, 2021,&#160;and&#160;2020, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, and December&#160;31, 2020, <ix:nonFraction unitRef="number" contextRef="if34f8da1addc4820a1cb6767365cb8a3_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfMzE5_0991db3f-9d26-49e0-93ae-5c39f07a8459">98</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i818a62562a3c4a978a87e6b139e9bdc9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfMzI2_f6dfc713-ba1e-405e-9c15-6dca403ad0ff">94</ix:nonFraction>%, respectively, of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div></ix:continuation><div id="ie165b3dd2cd64109ae663021d54143ae_100"></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDAvZnJhZzoxNTEwYzY0ZmQ4Mjc0ZGI5YjExOWQ5OTFjMmIyOTkzOC90ZXh0cmVnaW9uOjE1MTBjNjRmZDgyNzRkYjliMTE5ZDk5MWMyYjI5OTM4XzEwMDE_48c2cabe-77a8-4c8e-a2a0-35bd5eefdf48" continuedAt="ia8ac04379d5a4d86aa77ad09216f031c" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="ia8ac04379d5a4d86aa77ad09216f031c" continuedAt="i26d5b88904ec4b6a8a9845ffdb296abe"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i26d5b88904ec4b6a8a9845ffdb296abe">The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#8217;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved.</ix:continuation></span></div><div id="ie165b3dd2cd64109ae663021d54143ae_106"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDYvZnJhZzo2ZTI2MTliMjEyNjU0YjYwYWJmY2Q2YThlY2Y2NmRmNy90ZXh0cmVnaW9uOjZlMjYxOWIyMTI2NTRiNjBhYmZjZDZhOGVjZjY2ZGY3XzE2Nw_7d37c028-1ea4-4b27-a7b9-870ea0a4ede8" continuedAt="ia423baf40235448ebc656a9849af6c58" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ia423baf40235448ebc656a9849af6c58">On November 1, 2021, the Company exercised its call right contained in its joint venture agreement with SoftBank. As a result of the exercise of these rights, the Company will purchase all Joint Venture shares held by SoftBank at a price to be negotiated between the parties or established by a third-party valuation firm utilizing the financial and operating assumptions outlined in the joint venture agreement. Pursuant to the joint venture agreement, the fair value of the Joint Venture will be no less than an amount that yields a <ix:nonFraction unitRef="number" contextRef="i3edbb27baf14454882593f853aa8325b_D20211101-20211101" decimals="2" name="gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDYvZnJhZzo2ZTI2MTliMjEyNjU0YjYwYWJmY2Q2YThlY2Y2NmRmNy90ZXh0cmVnaW9uOjZlMjYxOWIyMTI2NTRiNjBhYmZjZDZhOGVjZjY2ZGY3XzM4NDgyOTA3MTE4NTQ_362e0c12-5f26-4dd6-8122-197aba49e5cd">20</ix:nonFraction>% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture. Settlement of the aggregate purchase price will be in cash, shares, or a combination of cash and shares, at SoftBank&#8217;s discretion. The Company expects to purchase all shares held by SoftBank in the Joint Venture on or before the end of the second quarter of 2022. No changes to the fair value of the redeemable noncontrolling interest have been reflected as of end of September 30, 2021.</ix:continuation>   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_109"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_112"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, beliefs, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and in Part II, Item 1A, &#8220;Risk Factors&#8221;  of this Quarterly Report on Form 10-Q.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_115"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a liquid and tissue biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we provide our Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. Our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, patients who may benefit from treatment with osimertinib (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EGFR exon 19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> deletions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">exon 20 T790M or exon 21 L858R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations), amivantamab-vmjw (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EGFR exon 20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> insertion mutations), and sotorasib (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations), which have been developed by our biopharmaceutical customers AstraZeneca, Janssen Biotech and Amgen, respectively. In February 2021, we launched our Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, we launched Guardant360 TissueNext, our first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. We are developing tests under our LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening, and individuals at a higher risk for developing cancer with early detection. We have also developed our GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated total revenue of $94.8 million and $74.6 million for the three months ended September 30, 2021, and 2020, respectively, and $265.5 million and $208.4 million for the nine months ended September 30, 2021, and 2020, respectively. We also incurred net losses of $107.5 million and $71.7 million for the three months ended September 30, 2021, and 2020, respectively, and $312.5 million and $153.2 million for the nine months ended September 30, 2021, and 2020, respectively. We have funded our operations to date principally from the sale of our stock, convertible senior notes, and revenue from our precision oncology testing and development services and other. As of September&#160;30, 2021, we had cash, cash equivalents and marketable securities of $1.7 billion.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_118"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors affecting our performance</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Testing volume, pricing and customer mix. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average reimbursement for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients&#8217; insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Revenue from clinical tests for patients covered by Medicare represented approximately 48% and 44% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precision oncology revenue from clinical customers</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended September 30, 2021, and 2020, respectively, and approximately 44% and 39% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precision oncology revenue from clinical customers</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September 30, 2021, and 2020, respectively. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Payer coverage and reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Precision oncology revenue from tests for clinical customers is calculated based on our expected cash collections, using the estimated variable consideration. The variable consideration is estimated based on historical collection patterns as well as the potential for changes in future reimbursement behavior by one or more payers. Estimation of the impact of the potential for changes in reimbursement requires significant judgment and considers payers' past patterns of changes in reimbursement as well as any stated plans to implement changes. Any cash collections over the expected reimbursement period exceeding the estimated variable consideration is recorded in future periods based on actual cash received. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider&#8221;. Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. Because we are not contracted with these payers, they determine the amount that they are willing to reimburse us for any of our tests and they can prospectively and retrospectively adjust the amount of reimbursement, adding to the complexity in estimating the variable consideration. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our tests and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our tests are reimbursed both from commercial and governmental payers. In addition, Z-Code Identifiers are used by certain payers, including under Medicare's Molecular Diagnostic Services Program, or MolDx, to supplement CPT codes for our molecular diagnostics tests. Changes to the codes used to report to payers may result in significant changes in its reimbursement. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In March 2020, we began to receive reimbursement from Medicare for claims submitted, with respect to Guardant360 clinical tests performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin other than NSCLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in March 2018. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the FDA approval of our Guardant360 CDx test, a new Z-Code Identifier was issued in August 2020.  In January 2021, a proprietary laboratory analyses, or PLA code was issued for our Guardant360 CDx with an effective date in April 2021. Additionally, based on this new PLA code, we applied to the Centers for Medicare and Medicaid Services or CMS for our Guardant360 CDx test to become an advanced diagnostic laboratory test, or ADLT. In March 2021, CMS approved ADLT status to the Guardant360 CDx test, which would allow us to bill Medicare at the lowest available commercial rate for the first three quarters from April 1, 2021. After the initial three quarters, we can bill Medicare for Guardant360 CDx services at the median rate of claims paid by commercial payers. We are in the process of negotiating reimbursement for our Guardant Reveal, Guardant Response and Guardant360 TissueNext tests from commercial and governmental payers. Due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our tests, previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. Additionally, if coding changes were to occur, payments for certain uses of our tests could be reduced, put on hold, or eliminated. This variability and unpredictability could increase the risk of future revenue reversal and result in our failing to meet any previously publicly stated guidance we may provide. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Biopharmaceutical customers. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue also depends on our ability to attract, maintain and expand relationships with biopharmaceutical customers. As we continue to develop these relationships, we expect to support a growing number of clinical trials globally and continue to have opportunities to offer our platform to such customers for development services, including companion diagnostic development, novel target discovery and validation, as well as clinical trial enrollment. For example, our tests are being developed as companion diagnostics under collaborations with biopharmaceutical companies, including AstraZeneca, Amgen, Daiichi Sankyo, Janssen Biotech, and Radius Health.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Research and development. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant aspect of our business is our investment in research and development, including the development of new products. In particular, we have invested heavily in clinical studies as we believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers. With respect to our LUNAR program, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, aiming to recruit approximately 13,000 patients and evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults. We have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">International expansion. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals or partnerships with research organizations. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the&#160;Americas&#160;and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Sales and marketing expense.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our sales and marketing expense, increase in headcount, and in particular, our various marketing programs around existing and new product introductions.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our general and administrative expense, and in particular, our stock-based compensation expense. Our equity awards, including market-based and performance-based restricted stock units, are intended to retain and incentivize employees to lead us to sustained, long-term superior financial and operational performance.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">COVID-19 Global Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The glob</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">al outbreak of coronavirus 2019, or COVID-19, has disrupted, and we expect will continue to disrupt, our operations. To protect the health and well-being of our workforce, partners, vendors and customers, we have provided free COVID-19 testing for all of our employees, contractors and their dependents, implemented social distance and building entry policies at work, and followed California&#8217;s public health orders and the guidance from the Centers for Disease Control and Prevention. The COVID-19 global pandemic has negatively affected, and we expect will continue to negatively affect, our revenue and our clinical studies. For example, our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. In addition, disruptions caused by the pandemic have adversely affected the quantity and quality of certain sequencers, reagents, blood tubes and other similar materials that are critical to our commercial and research and development programs. We currently have a limited amount of stock of these components. Failure in the future to secure sufficient supply of critical components could materially and adversely affect our ability to manufacture or supply marketed products and product candidates or complete our ongoing research and development programs on the timelines previously established, which could materially and adversely affect our business and future prospects. The severity of the impact on our business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including the duration and severity of the pandemic and the impact of any variants of the virus on us, our customers, and our suppliers. In August 2020, we launched our Guardant-19 test and received the FDA&#8217;s emergency use authorization for use in the detection of the novel coronavirus. The test was being offered to our employees and to select partner organizations via our CLIA-certified clinical laboratory. Effective August 2021, we have discontinued offering the test to third parties. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A,&#160;&#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2020, and Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q, for more information.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_127"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of results of operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenue from two sources: (i) precision oncology testing and (ii) development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Precision oncology testing revenue is generated from sales of our tests to clinical and biopharmaceutical customers. In the United States, through September&#160;30, 2021, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. We submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin and for Guardant360 CDx clinical testing performed for qualifying patients diagnosed with solid tumor cancers who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established since March 2018. Revenue from clinical tests for patients covered by Medicare represented approximately 48% and 44% of our precision oncology revenue from clinical customers during the three months ended September 30, 2021, and 2020, respectively, and 44% and 39% of our precision oncology revenue from clinical customers during the nine months ended September 30, 2021, and 2020, respectively. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Development services and other revenue primarily represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, as well as GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services and other revenue can vary over time as different projects start and complete.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of precision oncology testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Cost of precision oncology testing generally consists of cost of materials, inventory write-downs, direct labor, including employee benefits, bonus, and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples such as sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, depreciation of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents.&#160;While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but we expect the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of development services and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Cost of development services and other primarily includes costs incurred for the performance of development services requested by our customers comprising of direct labor and material costs including any inventory write-downs. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services and other will vary depending on the nature, timing and scope of customer projects.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits including stock-based compensation, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses and stock-based compensation, as well as marketing, sales incentives, and educational activities and allocated overhead expenses. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our tests.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our general and administrative expenses include costs for our executive, accounting and finance, information technology, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased stock-based compensation expense, including resulting from the market-based restricted stock units granted to our Co-Chief Executive Officers in May 2020. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses being incurred.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of charges relating to amortization of debt issuance costs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists of foreign currency exchange gains and losses, payments due and received in relation to the settlement of a patent dispute, net of credit losses, and the relief fund grant from the Department of Health and Human Services, or HHS, under the U.S. Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_133"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table set forth the significant components of our results of operations for the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision oncology testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development services and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of development services and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,288)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,252)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,793)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,784)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,430)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,602)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,122)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,670)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,459)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts include stock-based compensation expense as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of precision oncology testing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_136"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2021 and 2020</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $94.8 million for the three months ended September 30, 2021, compared to $74.6 million for the three months ended September 30, 2020, an increase of $20.2 million, or 27%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing revenue increased to $79.3 million for the three months ended September 30, 2021, from $60.4 million for the three months ended September 30, 2020, an increase of $18.9 million, or 31%. This increase in precision oncology testing revenue was primarily due to an increase in sample volume. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for clinical customers increased to $61.3 million in the three months ended September 30, 2021, from $48.3 million in the three months ended September 30, 2020, primarily due to an  increase in the number of Guardant360 tests and an overall increase in average selling price per test, offset by a decrease of $8.2 million in cash collections exceeding the estimated variable consideration related to samples processed in previous periods. Tests for clinical customers increased to 22,806 for the three months ended September 30, 2021, from 16,950 for the three months ended September 30, 2020. </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for biopharmaceutical customers was $17.9 million in the three months ended September 30, 2021, and $12.0 million in the three months ended September 30, 2020, respectively. Tests for biopharmaceutical customers increased to 4,839 for the three months ended September 30, 2021, from 3,071 for the three months ended September 30, 2020, primarily due to an increase in the number of biopharmaceutical customers and their contracted projects.  </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other revenue increased to $15.5 million for the three months ended September 30, 2021 from $14.2 million for the three months ended September 30, 2020, an increase of $1.3 million, or 9%. This increase in development services and other revenue was primarily due to progression of collaboration projects from biopharmaceutical customers for companion diagnostic development services during the three months ended September 30, 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue may be adversely impacted by the COVID-19 pandemic in future periods depending on the duration and severity of the pandemic and the impact of any variants of the virus.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue and Gross Margin</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue was $30.8 million for the three months ended September 30, 2021, compared to $21.2 million for the three months ended September 30, 2020, an increase of $9.6 million, or 45%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing revenue was $29.7 million for the three months ended September 30, 2021, compared to $16.7 million for the three months ended September 30, 2020, an increase of $13.0 million, or 78%. This increase in cost of precision oncology testing was primarily due to a $7.0&#160;million increase in material costs, $4.8 million increase in labor and manufacturing overhead costs, and a $1.3 million increase in other costs including costs related to freight and curation of test results for physicians.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other was $1.2 million for the three months ended September 30, 2021, compared to $4.5 million for the three months ended September 30, 2020, a decrease of $3.3 million, or 74%. This decrease in cost of development services and other was primarily due to timing of work performed on our companion diagnostic development service contracts.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin for the three months ended September 30, 2021, was 67% compared to 72% for the three months ended September 30, 2020. The decrease in gross margin is primarily due to higher average cost per test resulting from the varied product mix of precision oncology testing, partially offset by gross margin improvement of development services and other. Our gross margin may be adversely impacted by the COVID-19 pandemic for the affected periods.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $71.0 million for the three months ended September 30, 2021, compared to $36.2 million for the three months ended September 30, 2020, an increase of $34.7 million, or 96%. This increase in research and development expense was primarily due to an increase of $13.2 million in personnel-related costs for employees in our research and development group, including a $2.0 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology and clinical studies. The increase is also attributable to an increase of $9.9 million in material costs, an increase of $6.3 million in outside service costs, and an increase of $3.5 million related to allocated facilities and information technology infrastructure costs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing expense</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $50.2 million for the three months ended September 30, 2021, compared to $25.1 million for the three months ended September 30, 2020, an increase of $25.1 million, or 100%. This increase was primarily due to an increase of $18.6 million in personnel-related costs, including a $1.7 million increase in stock-based compensation, associated with the expansion of our commercial organization. The increase is also attributable to an increase of $3.2 million related to allocated facilities and information technology infrastructure costs, and an increase of $2.4 million related to marketing activities. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $50.1 million for the three months ended September 30, 2021, compared to $66.3 million for the three months ended September 30, 2020, a decrease of $16.2 million, or 24%. This decrease was primarily due to the vesting of Tranche 1 shares of market-based restricted stock units on January 1, 2021, granted to our Co-Chief Executive Officers, which resulted in a reduction of stock-based compensation expense in the amount of $24.1 million, offset by an increase of $3.7 million in professional service expenses related to outside legal, accounting, consulting and IT services, and an increase of $1.8 million related to allocated facilities and information technology infrastructure costs. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $0.7 million for the three months ended September 30, 2021, compared to $2.3 million for the three months ended September 30, 2020, a decrease of $1.6 million, or 70%. This decrease was primarily due to a significant decrease in interest rate as the U.S. Federal Reserve lowered the risk-free interest rate to nearly zero, partially offset by an increase in cash, cash equivalents and marketable securities related to the receipt of cash proceeds from borrowings on our convertible senior notes issued in November 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $0.6 million for the three months ended September 30, 2021, primarily due to the amortization of debt issuance costs. Interest expense was immaterial for the three months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net included foreign currency exchange losses of $0.1 million for the three months ended September 30, 2021. For the three months ended September 30, 2020, other income (expense), net included foreign currency exchange gains of $0.3 million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was immaterial for the three months ended September 30, 2021, and 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2021 and 2020</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $265.5 million for the nine months ended September 30, 2021, compared to $208.4 million for the nine months ended September 30, 2020, an increase of $57.1 million, or 27%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology testing revenue increased to $215.6 million for the nine months ended September 30, 2021 from $171.6 million for the nine months ended September 30, 2020, an increase of $44.0 million, or 26%. This increase in precision oncology testing revenue was primarily due to an increase in sample volume. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for clinical customers increased to $172.2 million for the nine months ended September 30, 2021, from $125.9 million for the nine months ended September 30, 2020, mainly due to an increase in the number of physicians ordering Guardant360 tests and an overall increase in average selling price per test, offset by a decrease of $4.1 million in excess cash collections exceeding the estimated variable consideration related to samples processed in previous periods. Tests for clinical customers increased to 62,026 for the nine months ended September 30, 2021, from 45,901 for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision oncology revenue from tests for biopharmaceutical customers was $43.4 million in the nine months ended September 30, 2021, and $45.7 million in the nine months ended September 30, 2020, respectively. The decrease in revenue was primarily due to a decrease in average selling price per test, partially offset by an increase in tests. Tests for biopharmaceutical customers increased to 12,014 for the nine months ended September 30, 2021, from 11,142 for the nine months ended September 30, 2020, primarily due to an increase in the number of biopharmaceutical customers and their contracted projects. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development services and other revenue increased to $49.9 million for the nine months ended September 30, 2021, from $36.8 million for the nine months ended September 30, 2020, an increase of $13.1 million, or 36%. This increase in development services and other revenue was primarily due to progression of collaboration projects from biopharmaceutical customers for companion diagnostic development services and receipt of regulatory approval of two of our companion diagnostic programs during the nine months ended September 30, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue may be adversely impacted by the COVID-19 pandemic in future periods depending on the duration and severity of the pandemic and the impact of any variants of the virus.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue and Gross Margin</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue was $89.5 million for the nine months ended September 30, 2021, compared to $64.1 million for the nine months ended September 30, 2020, an increase of $25.4 million, or 40%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing revenue was $78.1 million for the nine months ended September 30, 2021, compared to $52.7 million for the nine months ended September 30, 2020, an increase of $25.4 million, or 48%. This increase in cost of precision oncology testing was attributable to an increase in sample volumes and was primarily due to a $15.1 million increase in material costs, an $8.0 million increase in production labor and overhead </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs, and a $3.0 million increase in other costs including costs related to freight and curation of test results for physicians, offset by a $0.6 million decrease in royalties.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development services and other was $11.3 million for the nine months ended September 30, 2021, compared to $11.4 million for the nine months ended September 30, 2020, a decrease of $0.1 million, or 1%.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin for the nine months ended September 30, 2021 was 66% compared to 69% for the nine months ended September 30, 2020. The decrease in gross margin is primarily due to higher average cost per test resulting from the varied product mix of precision oncology testing, partially offset by gross margin improvement of development services and other. Our gross margin may be adversely impacted by the COVID-19 pandemic depending on how long the pandemic lasts and the severity of the situation in coming quarters.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $190.2 million for the nine months ended September 30, 2021, compared to $109.6 million for the nine months ended September 30, 2020, an increase of $80.6 million, or 74%. This increase in research and development expense was primarily due to an increase of $37.0 million in personnel-related costs for employees in our research and development group, including a $5.9 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology and clinical studies, an increase of $23.6 million in material costs related to various programs, an increase of $14.2 million in outside service costs, and an increase of $10.0 million related to allocated facility and information technology infrastructure costs, offset by a decrease of $8.5 million relating to in-process research and development (IPR&amp;D) technology expensed in connection with a patent license acquisition that occurred in March 2020. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and marketing expense</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $132.3 million for the nine months ended September 30, 2021, compared to $75.2 million for the nine months ended September 30, 2020, an increase of $57.1 million, or 76%. This increase was primarily due to an increase of $38.7 million in personnel-related costs, including a $4.0 million increase in stock-based compensation, associated with the expansion of our commercial organization, an increase of $8.8 million related to allocated facility and information technology infrastructure costs and an increase of $7.5 million related to marketing activities. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $166.4 million for the nine months ended September 30, 2021, compared to $123.3 million for the nine months ended September 30, 2020, an increase of $43.1 million, or 35%. This increase was primarily due to an increase of $33.6 million in personnel-related costs, including a $26.1 million increase in stock-based compensation primarily in connection with the issuance of market-based restricted stock units to our Co-Chief Executive Officers as well as an increase in our headcount, an increase of $6.0 million in professional </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service expenses related to outside legal, accounting, consulting and IT services, and an increase of $4.0 million related to allocated facilities and information technology infrastructure costs, offset by a decrease of $1.2 million related to settlement costs in connection with a patent license acquisition that occurred in March 2020. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $3.3 million for the nine months ended September 30, 2021, compared to $8.3 million for the nine months ended September 30, 2020, a decrease of $5.0 million, or 60%. This decrease was primarily due to a significant decrease in interest rate as the U.S. Federal Reserve lowered the risk-free interest rate to nearly zero, partially offset by a significant increase in cash, cash equivalents and marketable securities related to the receipt of cash proceeds from our follow-on public offering completed in June 2020 and borrowings on our convertible senior notes issued in November 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1.9 million for the nine months ended September 30, 2021, primarily due to the amortization of debt issuance costs. Interest expense was immaterial for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Not meaningful</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net included asset management fees of $0.5 million for the nine months ended September 30, 2021. For the nine months ended September 30, 2020, other income (expense), net included receipt of $1.8&#160;million received from HHS&#8217;s relief fund under the CARES Act.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was immaterial for the nine months ended September 30, 2021, and 2020.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_148"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses and negative cash flows from operations since our inception, and as of September&#160;30, 2021, we had an accumulated deficit of $916.9 million. We expect to incur additional operating losses in the near future </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our operating expenses will increase as we continue to invest in clinical trials and develop new products, expand our sales organization, and increase our marketing efforts to drive market adoption of our tests. As demand for our tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements could also increase if we require additional laboratory capacity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date principally from the sale of stock, convertible debt and through revenue from precision oncology testing and development services and other. As of September&#160;30, 2021, we had cash and cash equivalents of $832.4 million and marketable securities of $903.8 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to provide liquidity while ensuring capital preservation. Currently, our investments are held in marketable securities consisting of United States treasury securities and non-marketable securities in the form of private equity investments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flows from operations, will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this report. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development services and other is expected to grow long-term, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our available cash, cash equivalents and marketable securities and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in our Form 10-K for the year ended December&#160;31, 2020, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods presented:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the nine months ended September 30, 2021, was $132.0 million, which resulted from a net loss of $312.5 million, partially offset by non-cash charges of $171.9 million and net change in our operating assets and liabilities of $8.6 million. Non-cash charges primarily consisted of $124.6 million of stock-based compensation, $17.8 million&#160;of non-cash operating lease costs, $16.2 million of depreciation and amortization, $9.5 million&#160;of amortization of premium on marketable investments, and $1.9 million of amortization of debt issuance costs. The net change in our operating assets and liabilities was primarily the result of a $10.6 million increase in accrued compensation due to increased personnel, a $10.5 million increase in accrued expenses and other liabilities and a $6.9 million increase in accounts payable, partially offset by a $7.4 million increase in accounts receivable, net, a $5.8 million increase in prepaid expenses and other current assets, a $3.2 million increase in other assets, net, and a $2.0 million increase in inventory due to higher testing volumes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the nine months ended September 30, 2020 was $44.7 million, which resulted from a net loss of $153.2 million and net change in our operating assets and liabilities of $11.7 million, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by non-cash charges of $120.2 million. Non-cash charges primarily consisted of $87.4 million of stock-based compensation, $11.5 million of depreciation and amortization, $8.5 million of charge of in-process research and development costs with no alternative future use, $8.1 million of credit loss adjustment and others, $3.3 million&#160;of non-cash operating lease costs, and $1.6 million&#160;of amortization of premium on investment. The net change in our operating assets and liabilities was primarily the result of a $12.6 million increase in inventory due to higher testing volumes, a $7.6 million increase in other assets for long-term portions of payments due from a third-party in relation to the settlement of a patent dispute reached in the three months ended September 30, 2020, a $4.9 million decrease in deferred revenue, and a $3.5 million payment of operating lease liabilities net of receipt of tenant improvement allowance, partially offset by a $11.6 million decrease in accounts receivables, and a $5.5 million increase in accrued compensation due to increased personnel.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the nine months ended September 30, 2021, was $203.5 million, which resulted primarily from maturities of marketable securities of $627.1 million, partially offset by purchases of marketable securities of $334.1 million, purchases of property and equipment of $50.4 million and purchase of non-marketable equity and other related investments of $39.1 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the nine months ended September 30, 2020, was $319.4 million, which resulted primarily from purchases of marketable securities of $580.2 million, purchases of property and equipment of $28.9 million and purchases of intangible assets and capitalized license obligations of $17.9 million, partially offset by maturities of marketable securities of $307.5 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the nine months ended September 30, 2021, was $70.6 million, which was primarily due to taxes paid related to net share settlement of restricted stock units of $82.2 million, partially offset by proceeds from exercise of stock options of $7.1 million and proceeds from issuances of common stock under employee stock purchase plan of $5.4 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the nine months ended September 30, 2020, was $363.6 million, which was primarily due to proceeds from a follow-on offering of our common stock, net of underwriting discounts and commissions and offering expenses payable by us, of $354.6&#160;million, proceeds from exercise of stock options of $7.4 million, and proceeds from issuances of common stock under employee stock purchase plan of $4.0 million, partially offset by taxes paid related to net share settlement of restricted stock units of $2.2 million.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_154"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_157"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance sheet arrangements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_160"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and in Item 7, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020. During the three and nine months ended September&#160;30, 2021, there were no material changes to our critical accounting policies from those discussed previously. </span></div><div id="ie165b3dd2cd64109ae663021d54143ae_166"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_169"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness. As of September&#160;30, 2021, we had cash and cash equivalents of $832.4 million held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities. As of September&#160;30, 2021, we had short-term marketable securities of $653.6 million and long-term marketable securities of $250.2 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of&#160;September&#160;30, 2021, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate&#160;$6.1 million&#160;decline of the fair value of our available-for-sale securities and a hypothetical 100 basis point decrease in interest rates would have resulted in an approximate&#160;$1.1 million&#160;increase of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue is generated in the United States. Through September&#160;30, 2021, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of September&#160;30, 2021, the effect of a hypothetical 10% change in foreign currency exchange rates would not be material to our financial condition or results of operations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">54</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_175"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Co-Chief Executive Officers, or Co-CEOs, and our Chief Financial Officer, or CFO with the participation of other members of our management, have evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our Co-CEOs and our CFO have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that a number of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on effectiveness of controls and procedures</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Co-CEOs and our CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_181"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies &#8211; Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Note 10 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_184"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as&#160;risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended&#160;December&#160;31, 2020, filed with the SEC on February 25, 2021. The risks and uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. During the first quarter of fiscal 2021, there were no material changes to our previously disclosed risk factors. Besides risk factors disclosed in the Annual Report and this Quarterly Report, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and Part I, Item 2, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_187"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_190"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_193"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie165b3dd2cd64109ae663021d54143ae_196"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_199"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:7.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit318-k.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-38683</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/9/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit328-k.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-38683</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/9/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex311.htm">Certification of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex311.htm">Co-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex311.htm">Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex312.htm">Certification of the Co-Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex313.htm">Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex321.htm">Certification of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex321.htm">Co-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex321.htm">Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex322.htm">Certification of the Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="gh-0930x2021x10qxex323.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">57</span></div></div></div><div id="ie165b3dd2cd64109ae663021d54143ae_202"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie165b3dd2cd64109ae663021d54143ae_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GUARDANT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Helmy Eltoukhy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ AmirAli Talasaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Bell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>gh-0930x2021x10qxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib763b28ab61f46ff99f939cd57727089_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helmy Eltoukhy, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>gh-0930x2021x10qxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if92dede14c7f4495abf9f506f75891cb_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, AmirAli Talasaz, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>gh-0930x2021x10qxex313.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i86b29b606071489e901cdec0d9ab1d0f_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Bell, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>gh-0930x2021x10qxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7fb1276614384867a48ee4ec1a83a77d_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmy Eltoukhy</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>gh-0930x2021x10qxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i252b67b33f0f4ccfa35186e6f0e2e301_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmirAli Talasaz</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.3
<SEQUENCE>7
<FILENAME>gh-0930x2021x10qxex323.htm
<DESCRIPTION>EX-32.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0457a848eb484b7cb22c3c628c4c116f_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bell</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer and Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>gh-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gh="http://guardanthealth.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://guardanthealth.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://guardanthealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://guardanthealth.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinJointVenture" roleURI="http://guardanthealth.com/role/InvestmentinJointVenture">
        <link:definition>2109103 - Disclosure - Investment in Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinJointVentureDetails" roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails">
        <link:definition>2410405 - Disclosure - Investment in Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponents" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents">
        <link:definition>2111104 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsTables" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables">
        <link:definition>2312302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
        <link:definition>2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails">
        <link:definition>2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails">
        <link:definition>2415408 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecurities" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities">
        <link:definition>2116105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2317303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
        <link:definition>2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2421412 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PatentLicenseAcquisition" roleURI="http://guardanthealth.com/role/PatentLicenseAcquisition">
        <link:definition>2122106 - Disclosure - Patent License Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PatentLicenseAcquisitionDetails" roleURI="http://guardanthealth.com/role/PatentLicenseAcquisitionDetails">
        <link:definition>2423413 - Disclosure - Patent License Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwill" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill">
        <link:definition>2124107 - Disclosure - Intangible Assets, Net and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillTables" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables">
        <link:definition>2325304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
        <link:definition>2426414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillNarrativeDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails">
        <link:definition>2427415 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails">
        <link:definition>2428416 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://guardanthealth.com/role/Debt">
        <link:definition>2129108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://guardanthealth.com/role/DebtTables">
        <link:definition>2330305 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://guardanthealth.com/role/DebtNarrativeDetails">
        <link:definition>2431417 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofConvertibleSeniorNotesDetails" roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails">
        <link:definition>2432418 - Disclosure - Debt - Components of Convertible Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://guardanthealth.com/role/Leases">
        <link:definition>2133109 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://guardanthealth.com/role/LeasesTables">
        <link:definition>2334306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2435419 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseInformationDetails" roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails">
        <link:definition>2436420 - Disclosure - Leases - Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails">
        <link:definition>2437421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1">
        <link:definition>2437421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://guardanthealth.com/role/CommitmentsandContingencies">
        <link:definition>2138110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2439422 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://guardanthealth.com/role/CommonStock">
        <link:definition>2140111 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://guardanthealth.com/role/CommonStockTables">
        <link:definition>2341307 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://guardanthealth.com/role/CommonStockDetails">
        <link:definition>2442423 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://guardanthealth.com/role/StockBasedCompensation">
        <link:definition>2143112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://guardanthealth.com/role/StockBasedCompensationTables">
        <link:definition>2344308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails">
        <link:definition>2447426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
        <link:definition>2448427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAMEA2020EquityIncentivePlanDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails">
        <link:definition>2449428 - Disclosure - Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2450429 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationofStockOptionsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails">
        <link:definition>2451430 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2452431 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders">
        <link:definition>2153113 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables">
        <link:definition>2354309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails">
        <link:definition>2455432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>2456433 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://guardanthealth.com/role/IncomeTaxes">
        <link:definition>2157114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation">
        <link:definition>2158115 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables">
        <link:definition>2359310 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationDetails" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails">
        <link:definition>2460434 - Disclosure - Segment and Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://guardanthealth.com/role/RelatedPartyTransactions">
        <link:definition>2161116 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://guardanthealth.com/role/SubsequentEvents">
        <link:definition>2162117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://guardanthealth.com/role/SubsequentEventsDetails">
        <link:definition>2463435 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gh_NumberOfPetitionsFiledRemaining" abstract="false" name="NumberOfPetitionsFiledRemaining" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" abstract="false" name="DebtInstrumentConvertibleIssuanceCostsEquityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_Guardant360CDxMember" abstract="true" name="Guardant360CDxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLiabilityLeaseIncentive" abstract="false" name="LesseeOperatingLeaseLiabilityLeaseIncentive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PrecisionOncologyTestingMember" abstract="true" name="PrecisionOncologyTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLoss" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossReclassificationNoncurrent" abstract="false" name="ContractualReceivablesCreditLossReclassificationNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_LongTermMarketableSecuritiesMaturityPeriod" abstract="false" name="LongTermMarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" abstract="false" name="EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_NumberofPetitionsDenied" abstract="false" name="NumberofPetitionsDenied" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossReclassificationCurrent" abstract="false" name="ContractualReceivablesCreditLossReclassificationCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ChargeOfInProcessResearchAndDevelopment" abstract="false" name="ChargeOfInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CashCashEquivalentsandDebtSecuritiesFairValue" abstract="false" name="CashCashEquivalentsandDebtSecuritiesFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_AccruedClinicalTrialsandStudies" abstract="false" name="AccruedClinicalTrialsandStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PatentandCovenantRightsMember" abstract="true" name="PatentandCovenantRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_EquityMethodInvestmentSharesPurchased" abstract="false" name="EquityMethodInvestmentSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_KeyGenePatentLicenseAcquisitionMember" abstract="true" name="KeyGenePatentLicenseAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_NonCashOperatingLeaseCosts" abstract="false" name="NonCashOperatingLeaseCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" abstract="false" name="ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CostofDevelopmentServices" abstract="false" name="CostofDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossExpenseReversalCurrent" abstract="false" name="ContractualReceivablesCreditLossExpenseReversalCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_GuardantHealthIncMember" abstract="true" name="GuardantHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_EquityIncentivePlanTrancheDomain" abstract="true" name="EquityIncentivePlanTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_GuardantHealthAMEAIncMember" abstract="true" name="GuardantHealthAMEAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_A2018IncentiveAwardPlanMember" abstract="true" name="A2018IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" abstract="false" name="DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_ConversionPeriodThreeMember" abstract="true" name="ConversionPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EquitySecuritiesFVNIIncurredButNotYetPaid" abstract="false" name="EquitySecuritiesFVNIIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gh_CostofDevelopmentServicesPolicyTextBlock" abstract="false" name="CostofDevelopmentServicesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_ContractualReceivablesTerm" abstract="false" name="ContractualReceivablesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_CostsofPrecisionOncologyTesting" abstract="false" name="CostsofPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" abstract="false" name="ContractualReceivablesAllowanceForCreditLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedEarly" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" abstract="false" name="ContractualReceivablesCreditLossExpenseReversalNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_RevenuefromPrecisionOncologyTesting" abstract="false" name="RevenuefromPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CostsofPrecisionOncologyTestingPolicyTextBlock" abstract="false" name="CostsofPrecisionOncologyTestingPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ConvertibleDebtHedgeSharePricePremiumPercentage" abstract="false" name="ConvertibleDebtHedgeSharePricePremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_AMEA2020PlanMember" abstract="true" name="AMEA2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" abstract="false" name="VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" abstract="false" name="VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" abstract="false" name="ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PreferredStockSharesIssuedUponConversionOfCommonStock" abstract="false" name="PreferredStockSharesIssuedUponConversionOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_RevenuefromDevelopmentServices" abstract="false" name="RevenuefromDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EstimatedLitigationLiabilityLegalFeesCurrent" abstract="false" name="EstimatedLitigationLiabilityLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AccruedExpensesPropertyandEquipmentCurrent" abstract="false" name="AccruedExpensesPropertyandEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EquityIncentivePlanTrancheAxis" abstract="true" name="EquityIncentivePlanTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossCurrent" abstract="false" name="ContractualReceivablesAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" abstract="false" name="PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" abstract="false" name="ContractualReceivablesAllowanceForCreditLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_SoftBankMember" abstract="true" name="SoftBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_PaymentInConnectionWithaLicenseAgreement" abstract="false" name="PaymentInConnectionWithaLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" abstract="false" name="DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" abstract="false" name="ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_NumberOfOperatingLeasesLeaseNotYetCommenced" abstract="false" name="NumberOfOperatingLeasesLeaseNotYetCommenced" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" abstract="true" name="FoundationMedicineInc.vs.GuardantHealthInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_AssetAcquisitionPolicyTextBlock" abstract="false" name="AssetAcquisitionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ConvertibleSeniorNotesDue2027Member" abstract="true" name="ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_PaloAltoCaliforniaMember" abstract="true" name="PaloAltoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ProceedsFromContractualReceivable" abstract="false" name="ProceedsFromContractualReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_NumberofPetitionsFiled" abstract="false" name="NumberofPetitionsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" abstract="false" name="UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_DebtSecuritiesTableTextBlock" abstract="false" name="DebtSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" abstract="false" name="DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gh_AssetAcquisitionTransactionCosts" abstract="false" name="AssetAcquisitionTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ConvertibleDebtHedgeStrikePrice" abstract="false" name="ConvertibleDebtHedgeStrikePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="gh_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" abstract="false" name="DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>gh-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_33f42701-cb19-4185-beee-07d8aca16396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_AssetsCurrent_33f42701-cb19-4185-beee-07d8aca16396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_fdb4126d-d9fb-4211-9ddd-b22de8305234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_fdb4126d-d9fb-4211-9ddd-b22de8305234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_336b5045-3d0e-404b-8cde-2c72649987b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_336b5045-3d0e-404b-8cde-2c72649987b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c73944aa-8691-494a-b7bc-fd1c45d317fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c73944aa-8691-494a-b7bc-fd1c45d317fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_00c4c9ab-2e17-49ee-bf4a-d1d1b26834c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_00c4c9ab-2e17-49ee-bf4a-d1d1b26834c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5e5a8f7e-3dbb-4af1-be35-fe3d7e753ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_Goodwill_5e5a8f7e-3dbb-4af1-be35-fe3d7e753ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_63220347-fabd-4266-a398-cc07d5f11883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2efb67e6-e1a7-47d2-86e8-99106417039b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_63220347-fabd-4266-a398-cc07d5f11883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8be5390e-f582-4db4-9f33-3660e24d3abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_3c522c8d-a9dc-492c-a340-726c8fc3e5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8be5390e-f582-4db4-9f33-3660e24d3abd" xlink:to="loc_us-gaap_CommonStockValueOutstanding_3c522c8d-a9dc-492c-a340-726c8fc3e5e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b08cdb0b-6fb5-4986-8a4f-e637d57a44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8be5390e-f582-4db4-9f33-3660e24d3abd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b08cdb0b-6fb5-4986-8a4f-e637d57a44d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e701ae20-a4ec-4e78-bbde-a5012c5953c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8be5390e-f582-4db4-9f33-3660e24d3abd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e701ae20-a4ec-4e78-bbde-a5012c5953c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_335c0686-a20a-4ea0-b2bc-62ed1715e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8be5390e-f582-4db4-9f33-3660e24d3abd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_335c0686-a20a-4ea0-b2bc-62ed1715e049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2d89191-e48f-48b3-9044-0f16646b4733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c0b7b271-935b-4d05-b7f4-e44969540804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2d89191-e48f-48b3-9044-0f16646b4733" xlink:to="loc_us-gaap_Liabilities_c0b7b271-935b-4d05-b7f4-e44969540804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_52a47728-8e5f-4c2a-a069-af8fda38af31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2d89191-e48f-48b3-9044-0f16646b4733" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_52a47728-8e5f-4c2a-a069-af8fda38af31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75788e4c-7f70-43eb-a953-26e4141e6869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2d89191-e48f-48b3-9044-0f16646b4733" xlink:to="loc_us-gaap_StockholdersEquity_75788e4c-7f70-43eb-a953-26e4141e6869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_44551c95-ab25-49c9-95c9-1642491c5cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_40a286a4-179b-415b-b25e-4819f8bd69ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44551c95-ab25-49c9-95c9-1642491c5cd6" xlink:to="loc_us-gaap_LiabilitiesCurrent_40a286a4-179b-415b-b25e-4819f8bd69ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_b42486e0-c5dd-4595-a1da-a6f9e397f378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44551c95-ab25-49c9-95c9-1642491c5cd6" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_b42486e0-c5dd-4595-a1da-a6f9e397f378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db6a155c-acfd-4d26-8265-baaca16f02ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44551c95-ab25-49c9-95c9-1642491c5cd6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db6a155c-acfd-4d26-8265-baaca16f02ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9a6277da-47e9-451c-982d-7e41e098a809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44551c95-ab25-49c9-95c9-1642491c5cd6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9a6277da-47e9-451c-982d-7e41e098a809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ac07332-6773-44be-8a0a-27b7a5c7054c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ac07332-6773-44be-8a0a-27b7a5c7054c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_5d273a12-d2c2-47e7-a329-61d63019255a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_5d273a12-d2c2-47e7-a329-61d63019255a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e5760ec2-eaea-4183-8cda-edb995f22d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e5760ec2-eaea-4183-8cda-edb995f22d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7cfcf0ff-8fea-4660-aa6b-751ef82f9b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:to="loc_us-gaap_InventoryNet_7cfcf0ff-8fea-4660-aa6b-751ef82f9b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe1c064a-5610-4e56-9298-ec0c751f9ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ded0f1c2-9454-47b0-afe2-40ff49d7945c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe1c064a-5610-4e56-9298-ec0c751f9ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3d11d0ad-5d7a-4b3c-bc40-c0caf0ce8198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ae3e3ece-6667-49b3-b6c8-6fbcea6869a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d11d0ad-5d7a-4b3c-bc40-c0caf0ce8198" xlink:to="loc_us-gaap_AccountsPayableCurrent_ae3e3ece-6667-49b3-b6c8-6fbcea6869a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_2e2a467d-ba52-4b8b-9913-094861587090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d11d0ad-5d7a-4b3c-bc40-c0caf0ce8198" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_2e2a467d-ba52-4b8b-9913-094861587090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28f582df-cdab-479f-ae6b-9cd15c2f6a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d11d0ad-5d7a-4b3c-bc40-c0caf0ce8198" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28f582df-cdab-479f-ae6b-9cd15c2f6a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ce921a7f-b020-4623-875a-0fa8f0c78f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d11d0ad-5d7a-4b3c-bc40-c0caf0ce8198" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ce921a7f-b020-4623-875a-0fa8f0c78f52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff73bd49-3084-403d-90aa-062b2d489d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_60b4453a-c6d6-41e4-ab72-8fd80694d867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff73bd49-3084-403d-90aa-062b2d489d34" xlink:to="loc_us-gaap_ProfitLoss_60b4453a-c6d6-41e4-ab72-8fd80694d867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_9df9d996-a513-4ab3-9594-8fa883e9302f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff73bd49-3084-403d-90aa-062b2d489d34" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_9df9d996-a513-4ab3-9594-8fa883e9302f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9640712d-1c46-46c9-ac13-aa94a00d66fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0bd560f0-aa50-48a2-ab1f-be6a4ef1a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9640712d-1c46-46c9-ac13-aa94a00d66fe" xlink:to="loc_us-gaap_Revenues_0bd560f0-aa50-48a2-ab1f-be6a4ef1a0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dbfd0826-2edb-49ff-b190-009f5314ca72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9640712d-1c46-46c9-ac13-aa94a00d66fe" xlink:to="loc_us-gaap_CostsAndExpenses_dbfd0826-2edb-49ff-b190-009f5314ca72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9f42eae4-f1f5-4e80-ad23-7fc070c60ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27f032d0-2895-4ba5-b571-f2ff04380de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9f42eae4-f1f5-4e80-ad23-7fc070c60ca6" xlink:to="loc_us-gaap_ProfitLoss_27f032d0-2895-4ba5-b571-f2ff04380de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_8abc971a-7fc9-4381-8c9d-0530ac50bd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9f42eae4-f1f5-4e80-ad23-7fc070c60ca6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_8abc971a-7fc9-4381-8c9d-0530ac50bd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_443f1008-5009-4a15-994c-159d48b1fb14" xlink:href="gh-20210930.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_443f1008-5009-4a15-994c-159d48b1fb14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices_e6030c53-d2fa-449a-908b-aaf61690e106" xlink:href="gh-20210930.xsd#gh_CostofDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:to="loc_gh_CostofDevelopmentServices_e6030c53-d2fa-449a-908b-aaf61690e106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_71069508-2a14-46de-ab3a-4b8e37285e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_71069508-2a14-46de-ab3a-4b8e37285e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_dc4e99be-777c-4269-9bb1-99a3757eb2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_dc4e99be-777c-4269-9bb1-99a3757eb2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a2a6ebd4-7e48-4379-b3d2-2bc5ac6b819c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_406545e5-5b58-4929-9304-ea7219eb84a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a2a6ebd4-7e48-4379-b3d2-2bc5ac6b819c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_90ac4d05-040e-429a-8977-af01dbeef64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b95623e1-1425-4786-bea5-190160e57a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_90ac4d05-040e-429a-8977-af01dbeef64b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b95623e1-1425-4786-bea5-190160e57a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_affbf786-60ac-41db-a51a-da983ab9fbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_90ac4d05-040e-429a-8977-af01dbeef64b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_affbf786-60ac-41db-a51a-da983ab9fbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4b7d74ad-a535-4b61-ab4f-666389dced04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_02b034ca-363e-4e06-8739-8724d4e9fe49" xlink:href="gh-20210930.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4b7d74ad-a535-4b61-ab4f-666389dced04" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_02b034ca-363e-4e06-8739-8724d4e9fe49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices_0c3d4a37-92fa-4249-aa55-0821351da12c" xlink:href="gh-20210930.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4b7d74ad-a535-4b61-ab4f-666389dced04" xlink:to="loc_gh_RevenuefromDevelopmentServices_0c3d4a37-92fa-4249-aa55-0821351da12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7d9f27-27a9-493a-87f9-d4d12a8787fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4f6ecdb5-b7f2-45d0-9d27-14fa5a4a24a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7d9f27-27a9-493a-87f9-d4d12a8787fa" xlink:to="loc_us-gaap_OperatingIncomeLoss_4f6ecdb5-b7f2-45d0-9d27-14fa5a4a24a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_53766c27-61d4-40e5-86ea-abe2b4001aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7d9f27-27a9-493a-87f9-d4d12a8787fa" xlink:to="loc_us-gaap_InvestmentIncomeInterest_53766c27-61d4-40e5-86ea-abe2b4001aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5b00e45e-bb2a-42da-9d8f-32ebb62d5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7d9f27-27a9-493a-87f9-d4d12a8787fa" xlink:to="loc_us-gaap_InterestExpense_5b00e45e-bb2a-42da-9d8f-32ebb62d5d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e108378b-2985-4b74-8b59-b9dd7ddbe81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7d9f27-27a9-493a-87f9-d4d12a8787fa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e108378b-2985-4b74-8b59-b9dd7ddbe81e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_215ac1e3-0b28-4c4e-8ec7-d8a27f06ebdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5c69cb10-6602-435a-9104-8c73486522fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_215ac1e3-0b28-4c4e-8ec7-d8a27f06ebdf" xlink:to="loc_us-gaap_ProfitLoss_5c69cb10-6602-435a-9104-8c73486522fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_69941c8b-57df-4612-ba5d-c83ecff82f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_215ac1e3-0b28-4c4e-8ec7-d8a27f06ebdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_69941c8b-57df-4612-ba5d-c83ecff82f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d1386b1-4261-400d-b80a-ca227fbd500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_35c600ac-2a3c-4ef5-abbd-daae894cf784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d1386b1-4261-400d-b80a-ca227fbd500e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_35c600ac-2a3c-4ef5-abbd-daae894cf784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f3b5505-1cb8-48bb-9e79-4085913ec946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d1386b1-4261-400d-b80a-ca227fbd500e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4f3b5505-1cb8-48bb-9e79-4085913ec946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cb9afd79-e706-433e-8679-b065d9c88c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d7c38c78-1ed5-4f04-990c-4b10140158ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cb9afd79-e706-433e-8679-b065d9c88c64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d7c38c78-1ed5-4f04-990c-4b10140158ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_af7d4959-472c-4a3d-ac9a-29b0494d51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cb9afd79-e706-433e-8679-b065d9c88c64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_af7d4959-472c-4a3d-ac9a-29b0494d51f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_46328b8e-3645-4cd5-9c86-72e06ece4537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_46328b8e-3645-4cd5-9c86-72e06ece4537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e468fe9-2cd6-4913-a323-6733f86e49fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e468fe9-2cd6-4913-a323-6733f86e49fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_e9306266-4420-4d07-977f-bb06dcd745bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_e9306266-4420-4d07-977f-bb06dcd745bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78d95f08-0097-4af2-8a95-19cb59440956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78d95f08-0097-4af2-8a95-19cb59440956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_89a2f1ab-d3a6-4063-8457-a32a54323d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69415f0d-86f1-47c1-9bdc-6248c27fd121" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_89a2f1ab-d3a6-4063-8457-a32a54323d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5354af1f-859c-41d8-bb1a-3cac73c404b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_ProfitLoss_5354af1f-859c-41d8-bb1a-3cac73c404b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1603b73d-8469-4914-a90e-e84536d602d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1603b73d-8469-4914-a90e-e84536d602d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts_954869ea-8b45-4fbd-9e34-33b6a7834220" xlink:href="gh-20210930.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_gh_NonCashOperatingLeaseCosts_954869ea-8b45-4fbd-9e34-33b6a7834220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_d016e6ac-1b38-4778-b0fa-472b77d0325f" xlink:href="gh-20210930.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_d016e6ac-1b38-4778-b0fa-472b77d0325f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a5432a2a-1cbe-4149-bdaf-2b9bd012fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a5432a2a-1cbe-4149-bdaf-2b9bd012fc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e1acc55-23f2-4f17-ac3f-5c0f6ded8ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_ShareBasedCompensation_7e1acc55-23f2-4f17-ac3f-5c0f6ded8ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_dec252ba-5974-459c-8edc-45602a40909f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_dec252ba-5974-459c-8edc-45602a40909f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2be0f96f-b4e4-46ab-b2e6-0020c6171d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2be0f96f-b4e4-46ab-b2e6-0020c6171d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e4a672d7-39da-4fec-a7f3-f2adda99560b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e4a672d7-39da-4fec-a7f3-f2adda99560b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbd530c-f26f-499a-b37a-844935aa7efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbd530c-f26f-499a-b37a-844935aa7efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3742bbeb-2b03-4cb9-93ea-6b4d0114e245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3742bbeb-2b03-4cb9-93ea-6b4d0114e245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f66fadbd-9abe-4c02-b131-f54112d6a73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f66fadbd-9abe-4c02-b131-f54112d6a73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a0a3eceb-02ab-4278-8b57-0cce6e817e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a0a3eceb-02ab-4278-8b57-0cce6e817e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c0e920c2-8307-4a22-975f-e523d86b3e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c0e920c2-8307-4a22-975f-e523d86b3e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b2f23c80-ee51-4fc4-83f4-6d566047355f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b2f23c80-ee51-4fc4-83f4-6d566047355f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7b502f0a-cb6f-4887-aa0e-bbc8fc94806a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7b502f0a-cb6f-4887-aa0e-bbc8fc94806a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_5a33b341-3209-48c3-b68a-f0cc5cc343be" xlink:href="gh-20210930.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_5a33b341-3209-48c3-b68a-f0cc5cc343be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d5f0437c-a6a4-496e-b59f-a1511ba44b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b732e90e-e08f-4dbc-8397-c379cc56cb29" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d5f0437c-a6a4-496e-b59f-a1511ba44b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a7b9d9e9-c1cb-40f5-8d87-21a467af48b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a7b9d9e9-c1cb-40f5-8d87-21a467af48b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_15fc6d87-f7fc-4396-abdc-a82a84b095e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_15fc6d87-f7fc-4396-abdc-a82a84b095e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f877064e-cb89-4ed4-8b83-f68ac2b4b4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f877064e-cb89-4ed4-8b83-f68ac2b4b4f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_173a191b-a612-492c-841d-cae6c4fd9954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_173a191b-a612-492c-841d-cae6c4fd9954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3040afa3-9d1a-4ccc-8542-e5e989076aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3040afa3-9d1a-4ccc-8542-e5e989076aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4dfc4aa9-f310-4a8f-99a9-05bd548b8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4dfc4aa9-f310-4a8f-99a9-05bd548b8ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_239c4c73-bf2f-401d-a3ae-07bf9c5022fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aaf35caf-ac6c-42ee-a3be-b824dd76fd3a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_239c4c73-bf2f-401d-a3ae-07bf9c5022fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_975ace5c-c2d6-4f4e-b4fc-b60d94c6907a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea2513b1-e02c-4259-a0a5-2aed385fcf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_975ace5c-c2d6-4f4e-b4fc-b60d94c6907a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea2513b1-e02c-4259-a0a5-2aed385fcf76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88fb3ba3-b689-49d2-b04a-cb1bd903495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_975ace5c-c2d6-4f4e-b4fc-b60d94c6907a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88fb3ba3-b689-49d2-b04a-cb1bd903495c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da897fe2-3677-40aa-a6f9-3f0beedb3b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_975ace5c-c2d6-4f4e-b4fc-b60d94c6907a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da897fe2-3677-40aa-a6f9-3f0beedb3b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9f7eaa7-f40d-4b48-acf3-80d1e1832f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_975ace5c-c2d6-4f4e-b4fc-b60d94c6907a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9f7eaa7-f40d-4b48-acf3-80d1e1832f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e37ff7ea-b057-404a-8bb0-5ac1768881c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81f2fae0-e0d9-46d2-a8ca-fb23e7f92879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e37ff7ea-b057-404a-8bb0-5ac1768881c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81f2fae0-e0d9-46d2-a8ca-fb23e7f92879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a8ba6ae9-2cc5-4bd5-8578-5973fd6038b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e37ff7ea-b057-404a-8bb0-5ac1768881c2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a8ba6ae9-2cc5-4bd5-8578-5973fd6038b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_2e30c848-5f5d-440d-9639-62a2b922704a" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_22e2b60d-104a-4062-8bfa-9487e6bc9d9b" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_2e30c848-5f5d-440d-9639-62a2b922704a" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_22e2b60d-104a-4062-8bfa-9487e6bc9d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_688cd61b-5716-4333-9ce8-843cc907552c" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_2e30c848-5f5d-440d-9639-62a2b922704a" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_688cd61b-5716-4333-9ce8-843cc907552c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_9031eba8-6da9-459a-9d0c-651e7d90ead8" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_f8f0f95c-fd4a-4d9c-947b-70d082df3c47" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_9031eba8-6da9-459a-9d0c-651e7d90ead8" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_f8f0f95c-fd4a-4d9c-947b-70d082df3c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_f2368973-ec64-4055-805b-d7737746614e" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_9031eba8-6da9-459a-9d0c-651e7d90ead8" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_f2368973-ec64-4055-805b-d7737746614e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_760dce8c-d6b4-46dd-9e84-6b29d9e8cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_46bd4e73-3bd9-4be7-80dc-7101e71cefe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_760dce8c-d6b4-46dd-9e84-6b29d9e8cb88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_46bd4e73-3bd9-4be7-80dc-7101e71cefe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddcaf183-d0bf-4922-a171-cf9e3494d631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_760dce8c-d6b4-46dd-9e84-6b29d9e8cb88" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddcaf183-d0bf-4922-a171-cf9e3494d631" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_258fb82c-dcee-4a98-b1ca-43cf623d2e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_258fb82c-dcee-4a98-b1ca-43cf623d2e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1ffeefd5-e5aa-4e4e-8393-fc2a653a319e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1ffeefd5-e5aa-4e4e-8393-fc2a653a319e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e6719703-b371-4fbd-ba50-5ff9810aa5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e6719703-b371-4fbd-ba50-5ff9810aa5ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_c5234de2-1efa-4303-9186-dbe94bb9a87c" xlink:href="gh-20210930.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_c5234de2-1efa-4303-9186-dbe94bb9a87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_a1242710-264f-4f1a-a158-b5f8876b9ae1" xlink:href="gh-20210930.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_a1242710-264f-4f1a-a158-b5f8876b9ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_bce0bab6-effe-4b62-bbb4-34ec763ca0e6" xlink:href="gh-20210930.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_bce0bab6-effe-4b62-bbb4-34ec763ca0e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_0bd7c2bd-cd1a-4b86-91c5-3aba73ca3f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_0bd7c2bd-cd1a-4b86-91c5-3aba73ca3f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_13560d94-bfc9-4d56-88cf-a7d5aecaa8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e24aea45-a583-4bac-b966-f80fe91d1962" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_13560d94-bfc9-4d56-88cf-a7d5aecaa8ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c0b7fca6-dfaf-4b10-9a56-1a50fa53b957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_36532305-1afe-4418-a726-641d7465b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c0b7fca6-dfaf-4b10-9a56-1a50fa53b957" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_36532305-1afe-4418-a726-641d7465b8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_35a6f48e-0d94-434a-b0d3-169016cf00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ad8af301-db61-4312-be92-311284819212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_35a6f48e-0d94-434a-b0d3-169016cf00a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ad8af301-db61-4312-be92-311284819212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_18d44c69-3ee0-4016-8993-bf2a0d3822d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_35a6f48e-0d94-434a-b0d3-169016cf00a1" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_18d44c69-3ee0-4016-8993-bf2a0d3822d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_1f1531ef-213b-4299-925d-7ce980bac059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_35a6f48e-0d94-434a-b0d3-169016cf00a1" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_1f1531ef-213b-4299-925d-7ce980bac059" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bebe625d-090c-4d45-91ea-6281b27f4df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c600da75-4e3b-49bf-93b1-913f28f758eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bebe625d-090c-4d45-91ea-6281b27f4df0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c600da75-4e3b-49bf-93b1-913f28f758eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9f57f5f6-6d4d-4d2c-ae53-fb7a6776bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bebe625d-090c-4d45-91ea-6281b27f4df0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9f57f5f6-6d4d-4d2c-ae53-fb7a6776bba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d520819e-492c-4fcd-9397-abfd36953f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bebe625d-090c-4d45-91ea-6281b27f4df0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d520819e-492c-4fcd-9397-abfd36953f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_20d4c68a-c196-4d9d-a402-5df14d2506d9" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73289282-d4d2-4f7c-8eba-85db6844902e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_20d4c68a-c196-4d9d-a402-5df14d2506d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73289282-d4d2-4f7c-8eba-85db6844902e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fbdf516-915b-4af8-a2c7-68b8ffaa6370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_20d4c68a-c196-4d9d-a402-5df14d2506d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fbdf516-915b-4af8-a2c7-68b8ffaa6370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_f41c13d6-a58b-4b94-b1b6-75e2b2a192bb" xlink:href="gh-20210930.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_20d4c68a-c196-4d9d-a402-5df14d2506d9" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_f41c13d6-a58b-4b94-b1b6-75e2b2a192bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_406ebf58-b67e-4030-9c08-2e4abc1020c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b3ad7d22-42ac-4c5a-8c1d-b9df3600e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_406ebf58-b67e-4030-9c08-2e4abc1020c3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b3ad7d22-42ac-4c5a-8c1d-b9df3600e3b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_f6cf164e-74d5-4bce-a3b0-17117fb3d448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b793d886-2f77-4195-bad2-c0ccfcca2a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_f6cf164e-74d5-4bce-a3b0-17117fb3d448" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b793d886-2f77-4195-bad2-c0ccfcca2a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_1244822f-30ec-4a78-b990-3fe827175eda" xlink:href="gh-20210930.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62c99dd0-f6e7-4f1a-ae2b-55edcc14a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill_1244822f-30ec-4a78-b990-3fe827175eda" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62c99dd0-f6e7-4f1a-ae2b-55edcc14a8a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_151918cb-5ef9-4927-a831-6197b3b7e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c317aead-c296-4f91-859c-962f7b8dffff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_151918cb-5ef9-4927-a831-6197b3b7e5da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c317aead-c296-4f91-859c-962f7b8dffff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bbd5d03a-59fc-442f-9b31-ea199599dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_151918cb-5ef9-4927-a831-6197b3b7e5da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bbd5d03a-59fc-442f-9b31-ea199599dd3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_91174e5c-2a4d-4b8e-a092-5c8346fb055d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_91174e5c-2a4d-4b8e-a092-5c8346fb055d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_450b09eb-874b-4f78-acdd-3fb517974183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_450b09eb-874b-4f78-acdd-3fb517974183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ddda74a1-f89d-4178-aac7-c2e9fbf30125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ddda74a1-f89d-4178-aac7-c2e9fbf30125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b11ca21e-c4b0-4cb0-85b6-2210706b7c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b11ca21e-c4b0-4cb0-85b6-2210706b7c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16397204-7c00-45bf-ae2b-e9d74502eb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16397204-7c00-45bf-ae2b-e9d74502eb2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_3ab7dec5-3603-4bba-8ca5-6c97cf3d093f" xlink:href="gh-20210930.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_18c7b09c-c998-41dd-a5fb-c21594362c1c" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_3ab7dec5-3603-4bba-8ca5-6c97cf3d093f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8a61b366-5450-46c6-9777-13dea74ebe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_351cb6e5-51b9-44b0-87e0-1eef3a3e8e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a61b366-5450-46c6-9777-13dea74ebe5c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_351cb6e5-51b9-44b0-87e0-1eef3a3e8e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_53772d24-91aa-4866-871f-55e7c1272664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a61b366-5450-46c6-9777-13dea74ebe5c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_53772d24-91aa-4866-871f-55e7c1272664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_91a7ecff-92ce-4f06-bae9-3b97f03cf1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a61b366-5450-46c6-9777-13dea74ebe5c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_91a7ecff-92ce-4f06-bae9-3b97f03cf1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_33a8242a-f699-4b0d-9b06-26c39efe2b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_6a8a1f95-58ae-4b01-ade9-5d81b3c550c2" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_33a8242a-f699-4b0d-9b06-26c39efe2b1b" xlink:to="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_6a8a1f95-58ae-4b01-ade9-5d81b3c550c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_dc92cf09-9ca4-42e0-9912-8948f984c9ab" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_33a8242a-f699-4b0d-9b06-26c39efe2b1b" xlink:to="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_dc92cf09-9ca4-42e0-9912-8948f984c9ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9649f49e-d6c4-4ec5-853a-9262238a0465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_52eb0cb9-574a-4f45-83aa-b556184d9f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9649f49e-d6c4-4ec5-853a-9262238a0465" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_52eb0cb9-574a-4f45-83aa-b556184d9f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_3b2db6dc-0005-4073-b266-5f7ef3fe1095" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityLeaseIncentive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9649f49e-d6c4-4ec5-853a-9262238a0465" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_3b2db6dc-0005-4073-b266-5f7ef3fe1095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_516d32ce-4d14-4213-8ab4-da66ba5370f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9649f49e-d6c4-4ec5-853a-9262238a0465" xlink:to="loc_us-gaap_OperatingLeaseLiability_516d32ce-4d14-4213-8ab4-da66ba5370f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b707032-f0bc-41f0-ac32-ff79e47a9277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b707032-f0bc-41f0-ac32-ff79e47a9277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b9565ac6-3c63-4a91-84e2-75bffb317172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b9565ac6-3c63-4a91-84e2-75bffb317172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0643af4d-6924-4d9f-b847-cf84e85bb56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0643af4d-6924-4d9f-b847-cf84e85bb56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f9c000e-fae4-4493-994e-c09b9dd9eb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f9c000e-fae4-4493-994e-c09b9dd9eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_830ca63f-3a4b-4649-a578-e85ab223d210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_830ca63f-3a4b-4649-a578-e85ab223d210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_bd259906-f329-4a17-97e3-4ffa84c50cd7" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70dcfd57-3826-4ffb-b14b-b77dee99e235" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_bd259906-f329-4a17-97e3-4ffa84c50cd7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gh-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended" id="ibd984ef9edbb47e295dbc40c0d1e2ffe_CondensedConsolidatedBalanceSheetsunauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1b498ce-f392-452a-9121-df398908e091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1b498ce-f392-452a-9121-df398908e091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99cc3b9a-972c-4d6a-92c1-c7b52e86479e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99cc3b9a-972c-4d6a-92c1-c7b52e86479e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0cd48137-0400-42b6-9c9e-43e8ad873df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0cd48137-0400-42b6-9c9e-43e8ad873df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23b91801-7459-40b0-803f-ac4c0dead79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesIssued_23b91801-7459-40b0-803f-ac4c0dead79c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8196ffb9-be08-427b-8c9f-86cc9f7a90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_Assets_8196ffb9-be08-427b-8c9f-86cc9f7a90c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ee012a2-d329-4d28-93f8-7d27cad532a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_Liabilities_5ee012a2-d329-4d28-93f8-7d27cad532a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:to="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_362afdeb-d14e-49b6-b37c-9b80a07c62d6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_362afdeb-d14e-49b6-b37c-9b80a07c62d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d4ba9600-f1e9-4d74-90ba-e0cd4662a26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d4ba9600-f1e9-4d74-90ba-e0cd4662a26d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="extended" id="i89351f4542974f329a4cc073b70bcef4_CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_cb98ed40-4cca-4929-a0cf-9470b5a90277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_cb98ed40-4cca-4929-a0cf-9470b5a90277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_2b92205d-992f-45ec-8041-d36b888063fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_2b92205d-992f-45ec-8041-d36b888063fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_996eef9a-7957-4311-bc97-46039d9d79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bed95d32-ceb0-46e4-9da9-b5d8e3c03131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_SharesOutstanding_bed95d32-ceb0-46e4-9da9-b5d8e3c03131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c827b3f-ab60-4288-b684-fa7f9fe66d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockholdersEquity_1c827b3f-ab60-4288-b684-fa7f9fe66d8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_e12060f7-b8ba-43d0-89c0-a9d03ec9ba59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_e12060f7-b8ba-43d0-89c0-a9d03ec9ba59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1eededc3-3ca5-4766-b13b-7b6adcc631e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1eededc3-3ca5-4766-b13b-7b6adcc631e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2dcce290-db85-4d11-b538-cc9b77ad8acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2dcce290-db85-4d11-b538-cc9b77ad8acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_148829e7-b596-43a4-ba74-28de1bde8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_148829e7-b596-43a4-ba74-28de1bde8a78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_137bd4aa-690a-4504-9dba-0d79b24326bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_137bd4aa-690a-4504-9dba-0d79b24326bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e64568a-cdf9-4b80-8ad9-6fc12e0030a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e64568a-cdf9-4b80-8ad9-6fc12e0030a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_286b290a-7a19-4878-9524-92c98f2ef143" xlink:href="gh-20210930.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_286b290a-7a19-4878-9524-92c98f2ef143" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5f84c9cb-ddca-45a5-b8af-8baa4c1467a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5f84c9cb-ddca-45a5-b8af-8baa4c1467a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea0436e3-2288-4b01-8501-db028d6de362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea0436e3-2288-4b01-8501-db028d6de362" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d8b8fe34-db4c-48aa-a635-02d91cd7cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d8b8fe34-db4c-48aa-a635-02d91cd7cc21" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_892f7257-1757-48d9-bf45-2cf6b81f23d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_892f7257-1757-48d9-bf45-2cf6b81f23d6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34cd8f20-84df-4517-84b5-f249af667338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34cd8f20-84df-4517-84b5-f249af667338" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_21b03bb9-d62a-4c70-a690-8968413cdcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_ProfitLoss_21b03bb9-d62a-4c70-a690-8968413cdcca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_da0d2bb0-d789-47f9-8eb7-0db7f6512a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ce52f63f-d38a-4dd6-a5c2-643bea48a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:to="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a69d4fe3-9d3c-4845-a77e-73c98290ae52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:to="loc_us-gaap_EquityComponentDomain_a69d4fe3-9d3c-4845-a77e-73c98290ae52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:to="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_4999a43e-e9d6-4871-bcf9-c5684aab69c2" xlink:href="gh-20210930.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_4999a43e-e9d6-4871-bcf9-c5684aab69c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_027c4d30-63d6-4cf4-9718-a7f4f39b1037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_CommonStockMember_027c4d30-63d6-4cf4-9718-a7f4f39b1037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fdad09a7-d75a-4399-8078-d272d5fc8a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fdad09a7-d75a-4399-8078-d272d5fc8a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88bd9afe-8005-4349-ab31-4f241edf9061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88bd9afe-8005-4349-ab31-4f241edf9061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1714810b-4c88-45cd-a809-c9af4abba2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_RetainedEarningsMember_1714810b-4c88-45cd-a809-c9af4abba2b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3866bfa7-607f-433d-8ea7-0a4cb28f036a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3866bfa7-607f-433d-8ea7-0a4cb28f036a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_663a071c-9b42-4b60-92fd-e639584c428a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_663a071c-9b42-4b60-92fd-e639584c428a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="ica40edcbd57b4f97b37ee21b511f6be2_DescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b212f782-25e4-4d73-923f-d321cfd9c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b212f782-25e4-4d73-923f-d321cfd9c51a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3e49f251-a1a5-4717-8b5f-afd00bebf80f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3e49f251-a1a5-4717-8b5f-afd00bebf80f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_ca744c32-fd1f-469f-bb21-0887156a7e59" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:to="loc_gh_GuardantHealthAMEAIncMember_ca744c32-fd1f-469f-bb21-0887156a7e59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="icf19f7823d7445d59f21fd2891bc071e_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a3439384-b37c-4031-a785-fa4e3b124998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a3439384-b37c-4031-a785-fa4e3b124998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d728e251-6a0f-4a6b-91a6-e8e2821e5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_RestrictedCash_d728e251-6a0f-4a6b-91a6-e8e2821e5ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d1e7c748-865c-451d-a394-ccfc4049d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d1e7c748-865c-451d-a394-ccfc4049d6b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_d6dae44e-b4fd-4e2f-8c8d-bdc361620313" xlink:href="gh-20210930.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_d6dae44e-b4fd-4e2f-8c8d-bdc361620313" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_ebac60c3-e04a-4d45-b5bb-edacc88b397c" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_ebac60c3-e04a-4d45-b5bb-edacc88b397c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm_6162f415-afce-4c44-803a-6a18edf47a24" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesTerm_6162f415-afce-4c44-803a-6a18edf47a24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable_d98d2f5e-2d45-434d-b416-a51696e0836a" xlink:href="gh-20210930.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ProceedsFromContractualReceivable_d98d2f5e-2d45-434d-b416-a51696e0836a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_c91d6def-1042-48d4-ab9e-61d9e2a2a6f4" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_c91d6def-1042-48d4-ab9e-61d9e2a2a6f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dafb7be6-dbee-483f-9432-4bf50a06c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dafb7be6-dbee-483f-9432-4bf50a06c44f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1177d49f-5062-422e-8654-974572b8448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1177d49f-5062-422e-8654-974572b8448f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_56a8f8c4-e0ea-4b5f-b2d6-e041698b0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_56a8f8c4-e0ea-4b5f-b2d6-e041698b0f8d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6e71367e-9089-4b3c-9517-f6edd23a7e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6e71367e-9089-4b3c-9517-f6edd23a7e1f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc75b5ed-60ac-43a2-8412-e6863e9da3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc75b5ed-60ac-43a2-8412-e6863e9da3d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_de404f0c-05b9-41e7-b7e7-3b2fcb843c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_de404f0c-05b9-41e7-b7e7-3b2fcb843c82" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3b9f2239-6a53-4591-b516-0c5e5648a106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3b9f2239-6a53-4591-b516-0c5e5648a106" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a1f89c0b-0b85-420c-bd71-6360c28a8a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a1f89c0b-0b85-420c-bd71-6360c28a8a3e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_503b9ed7-d140-4036-9dd1-a508b760f133_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:to="loc_srt_RangeMember_503b9ed7-d140-4036-9dd1-a508b760f133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:to="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_863d242e-a76b-4045-97e8-49559fba9ad5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:to="loc_srt_MinimumMember_863d242e-a76b-4045-97e8-49559fba9ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f6c3b2e-3e99-4fbd-b161-c94f7c039b27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:to="loc_srt_MaximumMember_8f6c3b2e-3e99-4fbd-b161-c94f7c039b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b428a3b0-635e-485c-aa0c-f6ef99720e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b428a3b0-635e-485c-aa0c-f6ef99720e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28636aab-cde1-46e8-be1b-25e40078b8a7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:to="loc_srt_ProductsAndServicesDomain_28636aab-cde1-46e8-be1b-25e40078b8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:to="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_Guardant360CDxMember_6e11a7d0-4780-4869-9561-55693cbd6a8c" xlink:href="gh-20210930.xsd#gh_Guardant360CDxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:to="loc_gh_Guardant360CDxMember_6e11a7d0-4780-4869-9561-55693cbd6a8c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended" id="ia3b0e2e4ef404056bdc3a481b0b7c572_SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_825f3224-3d31-45e1-aa6f-fbcc64775037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_825f3224-3d31-45e1-aa6f-fbcc64775037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:to="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3ec82d8a-23b8-45bf-8543-3cc151047f33_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:to="loc_srt_NameOfMajorCustomerDomain_3ec82d8a-23b8-45bf-8543-3cc151047f33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:to="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_69d38c19-3963-4b02-845b-fef7e53e5539" xlink:href="gh-20210930.xsd#gh_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerAMember_69d38c19-3963-4b02-845b-fef7e53e5539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_fa6559a5-7cc9-428f-bfc9-7531842229f7" xlink:href="gh-20210930.xsd#gh_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerBMember_fa6559a5-7cc9-428f-bfc9-7531842229f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_bb66fa55-28cb-4e70-b47d-1def64666bd7" xlink:href="gh-20210930.xsd#gh_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerCMember_bb66fa55-28cb-4e70-b47d-1def64666bd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_5ff7faf9-5b7a-45da-a289-f32eaab44eeb" xlink:href="gh-20210930.xsd#gh_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerDMember_5ff7faf9-5b7a-45da-a289-f32eaab44eeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d44bfa37-3072-48b2-9a80-21034a062155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d44bfa37-3072-48b2-9a80-21034a062155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ca81b2b6-718e-4a34-b125-b2718ea0cd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ca81b2b6-718e-4a34-b125-b2718ea0cd62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_207a930b-2f75-4175-a3d2-021b8ca3ea11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_207a930b-2f75-4175-a3d2-021b8ca3ea11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d472fa65-a49d-483c-a63a-7896983c1a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:to="loc_us-gaap_SalesRevenueNetMember_d472fa65-a49d-483c-a63a-7896983c1a92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4d7ce231-d747-4d3f-b7d5-d027bac01c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:to="loc_us-gaap_AccountsReceivableMember_4d7ce231-d747-4d3f-b7d5-d027bac01c1b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#InvestmentinJointVentureDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="extended" id="i28f33ce40c8a49bc85b75edeb64a5d18_InvestmentinJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_fcd81869-15aa-4047-941a-44dd15f59f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_fcd81869-15aa-4047-941a-44dd15f59f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_26f47cc4-db29-44c3-a681-cdaf7d6c140d" xlink:href="gh-20210930.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_26f47cc4-db29-44c3-a681-cdaf7d6c140d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_edc81a60-a352-4edc-9c8e-3db53d7a110c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_edc81a60-a352-4edc-9c8e-3db53d7a110c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_92c598b1-8dd6-46f3-91df-386872067810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_92c598b1-8dd6-46f3-91df-386872067810" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a7929045-eca7-4b6b-a07b-61c696d8fc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a7929045-eca7-4b6b-a07b-61c696d8fc75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0dc9026a-94f9-4da6-8c02-583055f4745a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0dc9026a-94f9-4da6-8c02-583055f4745a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_26e66ed0-0e6e-49f0-bfac-e43dd69dfec2" xlink:href="gh-20210930.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_26e66ed0-0e6e-49f0-bfac-e43dd69dfec2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a8fa5873-6389-4435-b93e-4af7d3e3e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a8fa5873-6389-4435-b93e-4af7d3e3e0a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_e1ac307b-1c89-435a-9428-cc5744251ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_e1ac307b-1c89-435a-9428-cc5744251ce8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_757a0fe2-bfd1-40cf-bf84-c9f23674312f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_757a0fe2-bfd1-40cf-bf84-c9f23674312f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2330f763-c3c6-474f-a56d-51a2449547cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesIssued_2330f763-c3c6-474f-a56d-51a2449547cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f4bc1dae-b1c2-4894-9b66-58142d48ac07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f4bc1dae-b1c2-4894-9b66-58142d48ac07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3ec25306-592b-4199-869b-1979812a1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3ec25306-592b-4199-869b-1979812a1fa8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_922bfe77-c721-4b00-8dac-577b1c9582e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_Assets_922bfe77-c721-4b00-8dac-577b1c9582e7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_ac0d73c6-f683-4212-86c8-305006b30127" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_ac0d73c6-f683-4212-86c8-305006b30127" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_bfc160c2-1296-403c-8f14-fefd12e7a9e0" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_bfc160c2-1296-403c-8f14-fefd12e7a9e0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_02b602ae-654d-439a-be12-3d099db58055_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_02b602ae-654d-439a-be12-3d099db58055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_86212c15-a1e8-4118-be36-f3c2b1c131ab" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:to="loc_gh_GuardantHealthAMEAIncMember_86212c15-a1e8-4118-be36-f3c2b1c131ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d8c670d6-6fdc-4484-962d-ca19894e4ab0_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:to="loc_dei_EntityDomain_d8c670d6-6fdc-4484-962d-ca19894e4ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:to="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_8393dbae-7357-49a9-9b30-9bfeaefde1a1" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:to="loc_gh_SoftBankMember_8393dbae-7357-49a9-9b30-9bfeaefde1a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ad900927-61a2-4e53-8609-42943aae6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ad900927-61a2-4e53-8609-42943aae6ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f3b6a2d-54f3-4add-904d-cd324efcb64f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:to="loc_us-gaap_ClassOfStockDomain_4f3b6a2d-54f3-4add-904d-cd324efcb64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:to="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_916806bb-8ba6-4f07-a2fa-5ad37f6377ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_CommonClassAMember_916806bb-8ba6-4f07-a2fa-5ad37f6377ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c92f2be0-24f9-4608-bae9-59e8b7e6bcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_CommonClassBMember_c92f2be0-24f9-4608-bae9-59e8b7e6bcaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ea4506f7-f952-408c-9940-97824cb8f806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ea4506f7-f952-408c-9940-97824cb8f806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f211b862-d2ae-4e65-a287-8cf4f2da3bc5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f211b862-d2ae-4e65-a287-8cf4f2da3bc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_3e4b681e-8041-435c-a621-5bd67dff7b28" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:to="loc_gh_SoftBankMember_3e4b681e-8041-435c-a621-5bd67dff7b28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember_f0cf6998-ccb7-4b99-87c6-0fbaff527c6d" xlink:href="gh-20210930.xsd#gh_GuardantHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:to="loc_gh_GuardantHealthIncMember_f0cf6998-ccb7-4b99-87c6-0fbaff527c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5bed5c2c-19cb-4993-aecc-5d9ab674b218_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:to="loc_us-gaap_PlanNameDomain_5bed5c2c-19cb-4993-aecc-5d9ab674b218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:to="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_a476b4a0-7aed-4f69-8014-aa8184cf242b" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:to="loc_gh_AMEA2020PlanMember_a476b4a0-7aed-4f69-8014-aa8184cf242b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended" id="iedeb6b6920aa44a29cce167b39138b99_CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c6dac3f9-1d3d-4bf7-ad1f-2721db4c6ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c6dac3f9-1d3d-4bf7-ad1f-2721db4c6ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_471533cd-e85b-481f-9916-98ae1b7b30c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_471533cd-e85b-481f-9916-98ae1b7b30c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d50ee66-263b-40bc-bba2-e576d8d7721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d50ee66-263b-40bc-bba2-e576d8d7721f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40db2e91-7517-4c57-b081-a3aa6b059603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40db2e91-7517-4c57-b081-a3aa6b059603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_11bd38d9-8b9a-41e7-a519-54b9561ae8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_11bd38d9-8b9a-41e7-a519-54b9561ae8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_da0f64e5-cad8-41c0-b1a1-5fe08756ae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_da0f64e5-cad8-41c0-b1a1-5fe08756ae8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_be2c19fc-ec8d-4a73-a412-9541c445a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_ComputerEquipmentMember_be2c19fc-ec8d-4a73-a412-9541c445a5e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_69475237-c11f-4a62-aa01-c5e8737f161f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_ConstructionInProgressMember_69475237-c11f-4a62-aa01-c5e8737f161f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_04066d80-96ed-491f-a7ee-dc67850eb177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_04066d80-96ed-491f-a7ee-dc67850eb177" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9ac8157-4caa-43ec-ba81-c4dbb0b28675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9ac8157-4caa-43ec-ba81-c4dbb0b28675" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="iffc56862c0ad49c7a8edf892d7ba438d_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d72843d-3470-4e24-8b06-20ab3ce9efab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d72843d-3470-4e24-8b06-20ab3ce9efab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_19f45925-417e-4d56-9481-a53e76a5d1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_19f45925-417e-4d56-9481-a53e76a5d1f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_d3787376-22b8-40a3-be8c-00969c94d395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_d3787376-22b8-40a3-be8c-00969c94d395" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_afdc612e-dced-491e-9df7-710ffddac377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_afdc612e-dced-491e-9df7-710ffddac377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_969cb158-6a46-40bd-9a10-88c1ae4c6c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_969cb158-6a46-40bd-9a10-88c1ae4c6c15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_02b36968-7e45-4e19-84fd-511cca0838d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_02b36968-7e45-4e19-84fd-511cca0838d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_26b5fe85-5718-40f7-8b53-30068dc2af2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_26b5fe85-5718-40f7-8b53-30068dc2af2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48838eb5-63db-4507-bfde-dcf36b945c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48838eb5-63db-4507-bfde-dcf36b945c0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1afcf9cd-1418-4c0c-983d-aab1572389b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1afcf9cd-1418-4c0c-983d-aab1572389b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f92cbf6f-4627-484c-9dec-c3341b98bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f92cbf6f-4627-484c-9dec-c3341b98bf6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565ddc56-bce3-4126-9335-cb96b1ad3796_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565ddc56-bce3-4126-9335-cb96b1ad3796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_a84b971b-f113-4dbb-9ece-fd006b76f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_a84b971b-f113-4dbb-9ece-fd006b76f724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de2dc48f-06e3-4c04-91c9-e5436f84ac42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de2dc48f-06e3-4c04-91c9-e5436f84ac42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_68ceaf7f-317b-4e28-a98c-3ef42e714a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_68ceaf7f-317b-4e28-a98c-3ef42e714a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97d9ec25-1eac-49a7-943e-c87bf4888b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97d9ec25-1eac-49a7-943e-c87bf4888b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6e305a95-07a2-4994-88c2-194dcee13f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6e305a95-07a2-4994-88c2-194dcee13f98" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i520468d549924529b9f6d735239d10ab_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3360b5-dd75-4bb3-999c-a760a2e34dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3360b5-dd75-4bb3-999c-a760a2e34dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LongTermMarketableSecuritiesMaturityPeriod_f27c7a85-a785-41bb-9a66-6a5ea26e274d" xlink:href="gh-20210930.xsd#gh_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:to="loc_gh_LongTermMarketableSecuritiesMaturityPeriod_f27c7a85-a785-41bb-9a66-6a5ea26e274d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1f7fcc79-2c1a-4ab7-b570-8fc596df9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1f7fcc79-2c1a-4ab7-b570-8fc596df9b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4962630a-3b21-4b91-82b3-9b8c7492d73b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4962630a-3b21-4b91-82b3-9b8c7492d73b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1ea4e0af-3d5d-4c29-8683-0904f3fa1a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1ea4e0af-3d5d-4c29-8683-0904f3fa1a83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6788a402-a4fe-4b99-b0f5-da7937882a7a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:to="loc_srt_RangeMember_6788a402-a4fe-4b99-b0f5-da7937882a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:to="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d75510ad-27f5-4609-b039-debc5000557c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:to="loc_srt_MinimumMember_d75510ad-27f5-4609-b039-debc5000557c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45d792c1-69b7-42c5-88f0-b1e5ebbf098e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:to="loc_srt_MaximumMember_45d792c1-69b7-42c5-88f0-b1e5ebbf098e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended" id="i50f3db3726804f94b5ae5ce0f5084ddf_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9b6bb7d0-0fe3-4512-bcbe-ce6943635238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9b6bb7d0-0fe3-4512-bcbe-ce6943635238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_ccf5517a-d58a-4e71-a617-563deb810d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_ccf5517a-d58a-4e71-a617-563deb810d75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_d1f6cd3f-da05-489e-8469-9fd8db41710e" xlink:href="gh-20210930.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_d1f6cd3f-da05-489e-8469-9fd8db41710e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0accebc1-176e-4008-998b-d64ef6cf921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f87f7ba8-35ad-4616-a461-09a8b4d04b4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f87f7ba8-35ad-4616-a461-09a8b4d04b4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_893fd932-e737-4282-bb34-472fd1ae2d57" xlink:href="gh-20210930.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_893fd932-e737-4282-bb34-472fd1ae2d57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_7ec6579e-27cf-4069-a252-8f5a1626eb6c" xlink:href="gh-20210930.xsd#gh_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:to="loc_gh_ContingentConsiderationMember_7ec6579e-27cf-4069-a252-8f5a1626eb6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dea62d64-a5af-4eaa-9576-5e14f01e109b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dea62d64-a5af-4eaa-9576-5e14f01e109b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7a1a0de6-0943-4832-83ba-d9d1d4f60b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7a1a0de6-0943-4832-83ba-d9d1d4f60b89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0098b595-53aa-4fc9-9291-2ef273ea2ae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0098b595-53aa-4fc9-9291-2ef273ea2ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_467def99-7f03-4d43-a65b-0b013a426893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_467def99-7f03-4d43-a65b-0b013a426893" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i6f31efb73d0f41e993b2f1d3212d0715_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3f0aeea-9839-451a-a771-56f75b48a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3f0aeea-9839-451a-a771-56f75b48a3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9fea062-2b09-4248-ac56-2b7987842d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9fea062-2b09-4248-ac56-2b7987842d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_050b6101-db2c-48a4-a3a9-ee5f895eded2" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_050b6101-db2c-48a4-a3a9-ee5f895eded2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_80cf8ea0-7134-4af1-b177-1e823fa9373f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_80cf8ea0-7134-4af1-b177-1e823fa9373f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9527a8a-7fc5-485f-9d7f-2f7d4cd04621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9527a8a-7fc5-485f-9d7f-2f7d4cd04621" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63512582-4b3d-44fc-b9a3-c4b8eda6423a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63512582-4b3d-44fc-b9a3-c4b8eda6423a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4639ade5-a3bd-40e2-bb68-92b5586f9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4639ade5-a3bd-40e2-bb68-92b5586f9fec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_8f3a8563-8b9c-4bb6-967c-126658b91228" xlink:href="gh-20210930.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_8f3a8563-8b9c-4bb6-967c-126658b91228" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8424254f-708b-4317-be8f-967cf93cd7c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8424254f-708b-4317-be8f-967cf93cd7c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9a6629ce-92ba-40dd-8a44-7d8e63efc8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9a6629ce-92ba-40dd-8a44-7d8e63efc8cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e0457e4f-24f7-4ed6-9691-8c15ca9d65f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e0457e4f-24f7-4ed6-9691-8c15ca9d65f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#PatentLicenseAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" xlink:type="extended" id="ib3b8aa74ea674e42a15fcf5af54d3ef3_PatentLicenseAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement_610bd847-d410-41e5-b765-bbfcae340e3d" xlink:href="gh-20210930.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_PaymentInConnectionWithaLicenseAgreement_610bd847-d410-41e5-b765-bbfcae340e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts_b111d08a-2b75-4e1c-8e4f-70aa213d54f9" xlink:href="gh-20210930.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_AssetAcquisitionTransactionCosts_b111d08a-2b75-4e1c-8e4f-70aa213d54f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d113dbb3-3365-46a5-b7ed-61499bbe48ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d113dbb3-3365-46a5-b7ed-61499bbe48ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fa738bf-c4b3-4ded-a7a8-180e2c4a36ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fa738bf-c4b3-4ded-a7a8-180e2c4a36ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_64104535-618a-4675-b729-d0addb4d101c" xlink:href="gh-20210930.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_64104535-618a-4675-b729-d0addb4d101c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_f4845d3b-ff9c-41be-880c-d783190285c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_LitigationSettlementExpense_f4845d3b-ff9c-41be-880c-d783190285c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember_2397eb5c-7b2c-4135-bad5-a8f2a9cbb666" xlink:href="gh-20210930.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:to="loc_gh_KeyGenePatentLicenseAcquisitionMember_2397eb5c-7b2c-4135-bad5-a8f2a9cbb666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf841f22-3a39-444a-98bc-5019d5abceb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf841f22-3a39-444a-98bc-5019d5abceb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember_72bd1add-4cc6-44a0-b59d-753f64992586" xlink:href="gh-20210930.xsd#gh_PatentandCovenantRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:to="loc_gh_PatentandCovenantRightsMember_72bd1add-4cc6-44a0-b59d-753f64992586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:to="loc_srt_RangeMember_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:to="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b912f8bd-0655-4eec-9f85-265383e2f45f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:to="loc_srt_MinimumMember_b912f8bd-0655-4eec-9f85-265383e2f45f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5cafae7-a9a7-46d4-9d17-fb9572f2ce6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:to="loc_srt_MaximumMember_a5cafae7-a9a7-46d4-9d17-fb9572f2ce6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended" id="i392c86e2af514aa791e0056a8d514ba9_IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38ab0468-e706-405d-931a-4a9246e36bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38ab0468-e706-405d-931a-4a9246e36bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7710c7d-4e0d-4c67-97db-8bf3d0cba29c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7710c7d-4e0d-4c67-97db-8bf3d0cba29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_708bcd1d-cd8b-4c9b-b1a9-0a2521fb5bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_708bcd1d-cd8b-4c9b-b1a9-0a2521fb5bc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6a7319cb-932a-454d-b7fc-9588dd72fb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6a7319cb-932a-454d-b7fc-9588dd72fb43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c9e8e4f2-25dc-44c8-82c4-dab4a55c79b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c9e8e4f2-25dc-44c8-82c4-dab4a55c79b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8e55b18a-a347-4bc9-a07c-875bc8da4f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_Goodwill_8e55b18a-a347-4bc9-a07c-875bc8da4f4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_f709e097-556c-4939-a1ea-19269bfc309c" xlink:href="gh-20210930.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_f709e097-556c-4939-a1ea-19269bfc309c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b601b221-ec03-4361-8819-1d3ff81200c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b601b221-ec03-4361-8819-1d3ff81200c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9c637b4-6b93-494e-9bf3-5e9ca90b5569_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9c637b4-6b93-494e-9bf3-5e9ca90b5569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2aeb77e8-12dd-4323-ac6d-a0017b68813c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:to="loc_us-gaap_LicensingAgreementsMember_2aeb77e8-12dd-4323-ac6d-a0017b68813c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_782ea84d-ce0b-47fa-880d-45ce85bae919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_782ea84d-ce0b-47fa-880d-45ce85bae919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a2eb2d28-b097-42f1-8f0c-9d344469b434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a2eb2d28-b097-42f1-8f0c-9d344469b434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c68891bd-b42d-4b08-921d-054c2b1d802e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c68891bd-b42d-4b08-921d-054c2b1d802e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="extended" id="ic1f1078b9058408bbc3f6cbade63dc25_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_abc9a38e-053d-45b6-a4a5-d6028323cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_abc9a38e-053d-45b6-a4a5-d6028323cb27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8b68eb2a-ee0c-47d4-9711-f71e6ee73d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8b68eb2a-ee0c-47d4-9711-f71e6ee73d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_ad1544f3-cff4-4320-bfd7-d5f7f76db0a6" xlink:href="gh-20210930.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_ad1544f3-cff4-4320-bfd7-d5f7f76db0a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f2406ef9-2bab-41b3-a023-83c205d7d033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f2406ef9-2bab-41b3-a023-83c205d7d033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_dd4014d7-954f-4aa2-9efc-d1ebf4043fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_dd4014d7-954f-4aa2-9efc-d1ebf4043fa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2e93802e-a5c7-4cce-a83a-49ab8a6b3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2e93802e-a5c7-4cce-a83a-49ab8a6b3a18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_ef5947dd-d604-4aa4-9838-58554a2be772" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_ef5947dd-d604-4aa4-9838-58554a2be772" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1e74d01a-5d85-4d1f-a593-a8809c739c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1e74d01a-5d85-4d1f-a593-a8809c739c89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d6181ad2-e996-452e-b928-330f72957a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d6181ad2-e996-452e-b928-330f72957a80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5067a59f-2303-4a76-b2ef-2ec946e1662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5067a59f-2303-4a76-b2ef-2ec946e1662a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31e8a642-3d0f-459e-9d88-8765a7778ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31e8a642-3d0f-459e-9d88-8765a7778ed1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d64fe734-2441-44dc-9ca4-53ccc8fb9fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d64fe734-2441-44dc-9ca4-53ccc8fb9fce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice_0f1febc3-9a11-4805-9e03-122e81b10698" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_ConvertibleDebtHedgeStrikePrice_0f1febc3-9a11-4805-9e03-122e81b10698" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_fc3798bc-bcdd-4cee-aa45-b4498c0ca20e" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_fc3798bc-bcdd-4cee-aa45-b4498c0ca20e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_91bda23c-3b2b-408b-9856-436783023391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_SharePrice_91bda23c-3b2b-408b-9856-436783023391" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_bfc07c32-3aaa-4849-80d7-bf314deaf618" xlink:href="gh-20210930.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_bfc07c32-3aaa-4849-80d7-bf314deaf618" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_e1551bcd-76b8-4d8b-8fa7-9792ce0b35d7" xlink:href="gh-20210930.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_e1551bcd-76b8-4d8b-8fa7-9792ce0b35d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4838201d-799a-4310-8633-17b2250005e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4838201d-799a-4310-8633-17b2250005e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_440f3d05-4169-4c18-a115-ec81dba957fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:to="loc_us-gaap_ConvertibleDebtMember_440f3d05-4169-4c18-a115-ec81dba957fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_27af1c62-fa62-4ef6-9be5-56445b282329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:to="loc_us-gaap_SeniorNotesMember_27af1c62-fa62-4ef6-9be5-56445b282329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_e2365016-4b89-48d8-92d8-9865c111a1c5_default" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:to="loc_gh_DebtInstrumentConversionDomain_e2365016-4b89-48d8-92d8-9865c111a1c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:to="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember_ac9fe74a-4fec-4ec1-8c83-7478d01d604f" xlink:href="gh-20210930.xsd#gh_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodOneMember_ac9fe74a-4fec-4ec1-8c83-7478d01d604f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember_fc3f88d8-5633-46cd-bd99-aa4eaacf53d2" xlink:href="gh-20210930.xsd#gh_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodTwoMember_fc3f88d8-5633-46cd-bd99-aa4eaacf53d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember_f0807dff-08c1-4216-ba56-25bf418637e7" xlink:href="gh-20210930.xsd#gh_ConversionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodThreeMember_f0807dff-08c1-4216-ba56-25bf418637e7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended" id="ic11c5493f32a494fa6d2fbeccf83db57_DebtComponentsofConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fa6feda1-b392-4986-a35c-bd72f2cb19c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fa6feda1-b392-4986-a35c-bd72f2cb19c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4def47f0-810e-4c36-b26d-2893b37f90b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4def47f0-810e-4c36-b26d-2893b37f90b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5e9ee181-3319-4faf-8ad3-0b2b35bf7058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5e9ee181-3319-4faf-8ad3-0b2b35bf7058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_746a0f7c-f2c6-4ed3-92ae-e7043cef597d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_LongTermDebt_746a0f7c-f2c6-4ed3-92ae-e7043cef597d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_62bfd090-abe0-4a6c-85ef-3fb0b92eb60a" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_62bfd090-abe0-4a6c-85ef-3fb0b92eb60a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_01bc1192-275c-4652-935c-ce9bb3467a52" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_01bc1192-275c-4652-935c-ce9bb3467a52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_ddb3f229-c096-4058-b32a-fb53b5a63e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_ddb3f229-c096-4058-b32a-fb53b5a63e41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89c7cca9-82bd-4549-96b6-451c92471d40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89c7cca9-82bd-4549-96b6-451c92471d40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fe357502-041c-4e2f-98aa-f8207ececbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:to="loc_us-gaap_ConvertibleDebtMember_fe357502-041c-4e2f-98aa-f8207ececbab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:to="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7290a881-e065-4eb6-af11-3c2b33a041cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7290a881-e065-4eb6-af11-3c2b33a041cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_a6ce4626-e19f-494c-a617-5d7409204d46" xlink:href="gh-20210930.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_a6ce4626-e19f-494c-a617-5d7409204d46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie8b3480b0946423a886d85a73e5883a8_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e25b45bb-172b-4b9a-b079-82a24a807254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e25b45bb-172b-4b9a-b079-82a24a807254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_9f10e17c-3670-445d-a43c-599b2eca70fb" xlink:href="gh-20210930.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_9f10e17c-3670-445d-a43c-599b2eca70fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_521dcbed-00c8-4e62-b93e-c2cde29708d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_521dcbed-00c8-4e62-b93e-c2cde29708d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_76b08a24-d30b-4ecb-8a62-4a00aeceef21" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_76b08a24-d30b-4ecb-8a62-4a00aeceef21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8c2dfda7-a3dc-4491-97c1-8f76a649e1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_OperatingLeaseExpense_8c2dfda7-a3dc-4491-97c1-8f76a649e1b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_654db38d-7907-4cb0-a9c3-306cbac1b2f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:to="loc_srt_RangeMember_654db38d-7907-4cb0-a9c3-306cbac1b2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:to="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_455a52bc-d50a-4f1a-82ef-d683ecc399e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:to="loc_srt_MinimumMember_455a52bc-d50a-4f1a-82ef-d683ecc399e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d992d45f-265c-4af3-a59e-c2fd2a14b724" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:to="loc_srt_MaximumMember_d992d45f-265c-4af3-a59e-c2fd2a14b724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c98f6c71-fd84-40cf-89ff-a8bc348d85b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c98f6c71-fd84-40cf-89ff-a8bc348d85b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f867c58d-60a7-459b-88f2-eac7c0f6a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:to="loc_us-gaap_BuildingMember_f867c58d-60a7-459b-88f2-eac7c0f6a297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:to="loc_srt_SegmentGeographicalDomain_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:to="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SanDiegoCaliforniaMember_ed36f81c-4f49-4129-9dad-ee8d219d3761" xlink:href="gh-20210930.xsd#gh_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:to="loc_gh_SanDiegoCaliforniaMember_ed36f81c-4f49-4129-9dad-ee8d219d3761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaloAltoCaliforniaMember_69e05c91-e3da-46dc-9250-e830492fa694" xlink:href="gh-20210930.xsd#gh_PaloAltoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:to="loc_gh_PaloAltoCaliforniaMember_69e05c91-e3da-46dc-9250-e830492fa694" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ibb1118d945aa488fbedefb2456a315a8_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_deed75eb-3a86-4bc7-9244-345920e6eb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_deed75eb-3a86-4bc7-9244-345920e6eb86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled_1f002e4c-2b39-45ed-bde0-241be2c2a166" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberofPetitionsFiled_1f002e4c-2b39-45ed-bde0-241be2c2a166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied_40527d6c-2ff3-46c3-b5ad-2ad808a4c3e4" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsDenied"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberofPetitionsDenied_40527d6c-2ff3-46c3-b5ad-2ad808a4c3e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfPetitionsFiledRemaining_108b46be-7a8c-4a40-9b10-74232e1a7c21" xlink:href="gh-20210930.xsd#gh_NumberOfPetitionsFiledRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberOfPetitionsFiledRemaining_108b46be-7a8c-4a40-9b10-74232e1a7c21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:to="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_69c2f8ec-b6bc-4bae-80fd-308ea4d35669_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:to="loc_srt_LitigationCaseTypeDomain_69c2f8ec-b6bc-4bae-80fd-308ea4d35669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:to="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_6d5ce881-e5c4-425e-8ad1-24109df4567c" xlink:href="gh-20210930.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:to="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_6d5ce881-e5c4-425e-8ad1-24109df4567c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended" id="idaa1afc83ebc456d9d0bdc4ce6d3c365_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_5a94d00a-d52b-4d4c-b9a1-e140a0e4fc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_DividendsCommonStock_5a94d00a-d52b-4d4c-b9a1-e140a0e4fc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56535570-28e5-4b09-a345-e7fd91efa340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56535570-28e5-4b09-a345-e7fd91efa340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6332614-1bd9-4d5f-91e1-84d0239f64ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6332614-1bd9-4d5f-91e1-84d0239f64ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a87c14a0-12d2-42c1-ada0-74db0d27c580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a87c14a0-12d2-42c1-ada0-74db0d27c580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0088c626-5d20-4517-89ec-fda4381d3228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0088c626-5d20-4517-89ec-fda4381d3228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:to="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18541ab1-4b58-4b06-ad87-90949a706bb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18541ab1-4b58-4b06-ad87-90949a706bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b586c7ba-90bb-403b-9352-90e44acd7819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b586c7ba-90bb-403b-9352-90e44acd7819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb57bb2e-b7e9-46da-bcf3-becbae67fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb57bb2e-b7e9-46da-bcf3-becbae67fa5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_aa10e44e-cb2a-46f5-b9ef-9948e35c58d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_PerformanceSharesMember_aa10e44e-cb2a-46f5-b9ef-9948e35c58d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_f1289b11-ae1f-4da6-a171-fbef577e0a67" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_f1289b11-ae1f-4da6-a171-fbef577e0a67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_15e3befc-76aa-46a4-b482-6222bf19a5c9" xlink:href="gh-20210930.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_15e3befc-76aa-46a4-b482-6222bf19a5c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dc1ed33a-c472-4df9-9494-7688126773fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_EmployeeStockMember_dc1ed33a-c472-4df9-9494-7688126773fd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i6838aa97e6434a3bbce20c99dcca5758_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_661f6b01-386b-494c-ac3f-2cd5a6ae0c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_661f6b01-386b-494c-ac3f-2cd5a6ae0c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_65741888-ae4a-4dba-aa0f-fdc9d7a40643" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_65741888-ae4a-4dba-aa0f-fdc9d7a40643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_02943116-ce7a-4aad-8737-0f65450d7cd6" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_02943116-ce7a-4aad-8737-0f65450d7cd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_3b1f628c-a6eb-4f21-97c3-b1c86f38b7cd" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_3b1f628c-a6eb-4f21-97c3-b1c86f38b7cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acaf6adc-5ce5-455b-a682-79d6e7ba63fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7517ec0e-205a-42e5-aa55-3a598c0f7624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7517ec0e-205a-42e5-aa55-3a598c0f7624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7772b1c-aeb2-4d00-beb1-33ba8d93aef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7772b1c-aeb2-4d00-beb1-33ba8d93aef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1a9fb0d-e996-4573-9554-22e6266250fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1a9fb0d-e996-4573-9554-22e6266250fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_08309f15-b0fb-4544-9fba-9c1255724be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_08309f15-b0fb-4544-9fba-9c1255724be8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d097146-355a-4a16-8183-217a03005f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e981eda8-abd3-4f45-8c4b-9adbd7bf371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e981eda8-abd3-4f45-8c4b-9adbd7bf371d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c2ba357-bbd1-465d-95a3-52b0f411cf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c2ba357-bbd1-465d-95a3-52b0f411cf9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c5ad634-ecec-4444-b11b-58e929881e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c5ad634-ecec-4444-b11b-58e929881e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27cc2ee5-ba63-4d4a-9379-8b1028ffad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27cc2ee5-ba63-4d4a-9379-8b1028ffad6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1c9ed38-ca43-4a11-911e-36c419f66fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1c9ed38-ca43-4a11-911e-36c419f66fe0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c481014a-49f6-4c90-b49a-f70da279152f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14201d62-407f-45d8-aeb0-90dfc59f930b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14201d62-407f-45d8-aeb0-90dfc59f930b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bce64e4b-b458-4e2f-b37e-65d7cccdd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bce64e4b-b458-4e2f-b37e-65d7cccdd3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc41a270-028a-4863-bb87-cc0c32bde51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc41a270-028a-4863-bb87-cc0c32bde51e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_49e82322-e318-4e33-a612-19e3635074db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_49e82322-e318-4e33-a612-19e3635074db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4070ce00-0efe-4b61-9bd2-66fae2d5b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4070ce00-0efe-4b61-9bd2-66fae2d5b60b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_46b82259-cffb-4c5d-851b-babe3d29f91f" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_46b82259-cffb-4c5d-851b-babe3d29f91f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:to="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c802639-1127-43aa-8ade-0b76c6491fcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c802639-1127-43aa-8ade-0b76c6491fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_f80c53d6-ec9a-4370-ab59-e3d72d49f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_StockOptionMember_f80c53d6-ec9a-4370-ab59-e3d72d49f58d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c96f13bb-7f6c-4b92-8c9d-227e6c5f2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_RestrictedStockMember_c96f13bb-7f6c-4b92-8c9d-227e6c5f2c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7d903b59-d328-432b-828f-ed5db0942df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_PerformanceSharesMember_7d903b59-d328-432b-828f-ed5db0942df9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_0f4f1082-726e-4b6f-b1ce-b715c099246d" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_0f4f1082-726e-4b6f-b1ce-b715c099246d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i0b0af0da267f4b82a49c6ea28ddfef22_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5d22b351-ebbc-43b0-a40d-da75f5e4ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5d22b351-ebbc-43b0-a40d-da75f5e4ea76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d0c53cd-d731-4877-aa8a-0432914bfedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d0c53cd-d731-4877-aa8a-0432914bfedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_dd63204e-6a50-45f1-b89a-9937c43f1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_dd63204e-6a50-45f1-b89a-9937c43f1bd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2e9cc93-bac7-4ef4-8fcc-14cfeeebccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2e9cc93-bac7-4ef4-8fcc-14cfeeebccc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f3c73fea-f306-4c80-a521-501a59a4c233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f3c73fea-f306-4c80-a521-501a59a4c233" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_a1b3b119-79a5-4028-ab6f-20affad1287e" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_a1b3b119-79a5-4028-ab6f-20affad1287e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0631b867-35ba-4c93-8b76-0917b98f25d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0631b867-35ba-4c93-8b76-0917b98f25d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6fbfbcc-ba9b-45b3-8380-88bbb9b7dc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6fbfbcc-ba9b-45b3-8380-88bbb9b7dc6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f01a3557-df65-426a-91be-269ca529acd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f01a3557-df65-426a-91be-269ca529acd1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_16de2c49-f75b-4106-8e1f-a79c18824bdc" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_16de2c49-f75b-4106-8e1f-a79c18824bdc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_a8aa72b6-e507-41da-baa3-19ef5eccf298" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_a8aa72b6-e507-41da-baa3-19ef5eccf298" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_5ceb717e-eeb1-4fcf-9969-9c703bb7d104" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_5ceb717e-eeb1-4fcf-9969-9c703bb7d104" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a61286c5-3477-4b6c-820d-8fb7728ddcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a61286c5-3477-4b6c-820d-8fb7728ddcd8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bac8d698-53b1-4471-b534-52c69c58784b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bac8d698-53b1-4471-b534-52c69c58784b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_92b529d9-ad73-4fe5-aa57-09b4f0d22e9d" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_92b529d9-ad73-4fe5-aa57-09b4f0d22e9d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ec4675b6-9a73-4a5b-94e0-545ac42c377c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ec4675b6-9a73-4a5b-94e0-545ac42c377c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3d4f6aa-3827-42aa-b457-218a7092d686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3d4f6aa-3827-42aa-b457-218a7092d686" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fd47eae-e480-4a49-8e45-e804f13f0705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fd47eae-e480-4a49-8e45-e804f13f0705" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5953c99e-aeca-451e-aa0d-509306a0b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5953c99e-aeca-451e-aa0d-509306a0b2ce" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5d5bc8a-849a-49b7-a1cd-204f1a1a0c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5d5bc8a-849a-49b7-a1cd-204f1a1a0c28" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_2bed0328-40ce-4f25-9b6b-5b9b363b8bba" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_2bed0328-40ce-4f25-9b6b-5b9b363b8bba" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_9e2c7136-1577-4ab4-b988-d89389c59e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_9e2c7136-1577-4ab4-b988-d89389c59e02" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cdd4ba36-b336-43a6-a8a1-1ce423d5a712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cdd4ba36-b336-43a6-a8a1-1ce423d5a712" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_571178d9-e3eb-47d0-82f8-70ea1f552fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_571178d9-e3eb-47d0-82f8-70ea1f552fc3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4d006172-139b-469d-ade1-a98b58f8b680" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4d006172-139b-469d-ade1-a98b58f8b680" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4cf9ac91-4629-4865-a56d-f010cb800ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4cf9ac91-4629-4865-a56d-f010cb800ce9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d738b438-c602-4bd3-a414-2bfa39cc330b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d738b438-c602-4bd3-a414-2bfa39cc330b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6d72a463-d073-48d5-a77e-dfd9e2537c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6d72a463-d073-48d5-a77e-dfd9e2537c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cbda719c-ccdd-40f7-929f-07c6894f88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cbda719c-ccdd-40f7-929f-07c6894f88ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_a317fda3-0a71-4983-8dfe-6ab8c7dc8a71" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_a317fda3-0a71-4983-8dfe-6ab8c7dc8a71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff63abc5-665a-41dd-800d-3b8ae565b729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_PerformanceSharesMember_ff63abc5-665a-41dd-800d-3b8ae565b729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d803c4cf-c29a-40c7-a207-d9a78bc45eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_EmployeeStockMember_d803c4cf-c29a-40c7-a207-d9a78bc45eb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ef840f4-f563-4059-9da9-484c89e2eae6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:to="loc_srt_RangeMember_6ef840f4-f563-4059-9da9-484c89e2eae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:to="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a9fe12d2-a46d-43f2-90e4-3329a4873a60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:to="loc_srt_MinimumMember_a9fe12d2-a46d-43f2-90e4-3329a4873a60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6803c258-0e2f-4403-9493-5e833a8b3c7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:to="loc_srt_MaximumMember_6803c258-0e2f-4403-9493-5e833a8b3c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ddc19682-3741-42de-a84c-c845b73ef64f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ddc19682-3741-42de-a84c-c845b73ef64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_55d1d7ba-b7f4-4557-82c5-ae8e78dfbbb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:to="loc_srt_ChiefExecutiveOfficerMember_55d1d7ba-b7f4-4557-82c5-ae8e78dfbbb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a4d413db-c3d8-4521-b838-70ded9e3825e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a4d413db-c3d8-4521-b838-70ded9e3825e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_b477945d-a5bc-424b-932d-d1901e1768bc" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:to="loc_gh_GuardantHealthAMEAIncMember_b477945d-a5bc-424b-932d-d1901e1768bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c07da464-14d0-4fc6-b12f-e53fb2c07864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:to="loc_us-gaap_ClassOfStockDomain_c07da464-14d0-4fc6-b12f-e53fb2c07864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:to="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_54b853c9-b2f6-45b3-9345-22e30bb7d7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:to="loc_us-gaap_CommonClassBMember_54b853c9-b2f6-45b3-9345-22e30bb7d7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_876ffb43-e47b-4bf5-b116-fca017c4c591_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:to="loc_us-gaap_PlanNameDomain_876ffb43-e47b-4bf5-b116-fca017c4c591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:to="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_896068c2-4d00-4435-851f-8754f3b3a818" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:to="loc_gh_AMEA2020PlanMember_896068c2-4d00-4435-851f-8754f3b3a818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheDomain_378602c0-b8e2-4ff2-97d5-38a3e0df33e8_default" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:to="loc_gh_EquityIncentivePlanTrancheDomain_378602c0-b8e2-4ff2-97d5-38a3e0df33e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:to="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheOneMember_4f6569f5-8176-40ca-ae2a-b0df33be958e" xlink:href="gh-20210930.xsd#gh_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:to="loc_gh_TrancheOneMember_4f6569f5-8176-40ca-ae2a-b0df33be958e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheTwoMember_4d0681f6-8629-46ee-859c-b7fa94735ce5" xlink:href="gh-20210930.xsd#gh_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:to="loc_gh_TrancheTwoMember_4d0681f6-8629-46ee-859c-b7fa94735ce5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" id="iae393e689cc443b8ad95e2d0c817a4ad_StockBasedCompensationRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8d1dbe46-26b7-431b-bf52-817e0375b391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8d1dbe46-26b7-431b-bf52-817e0375b391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa5b1cfb-19bd-494d-a14b-5432ea7ef699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa5b1cfb-19bd-494d-a14b-5432ea7ef699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_058292ad-a9cc-4deb-9b79-15852aa54abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_058292ad-a9cc-4deb-9b79-15852aa54abb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ad7814fa-0c6b-47e6-9363-e4b96c1eb3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ad7814fa-0c6b-47e6-9363-e4b96c1eb3ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_812b83bb-361f-4877-9e3c-c387d2fc0909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8123c8d5-6049-4175-88c5-4667d65df459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8123c8d5-6049-4175-88c5-4667d65df459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2aba7df-889e-4fcc-a878-0217350e0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2aba7df-889e-4fcc-a878-0217350e0ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e606687b-f087-4da4-ab61-d90ccbffb5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e606687b-f087-4da4-ab61-d90ccbffb5c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62ea854d-4bc0-45ed-9ac4-7d6db3479692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62ea854d-4bc0-45ed-9ac4-7d6db3479692" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4060211-4536-4e1e-9286-b05442205d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:to="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cfe6377-c3c4-4d5f-980f-401652653469_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cfe6377-c3c4-4d5f-980f-401652653469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b2757cd-05c1-41df-ab68-419f61cd9536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b2757cd-05c1-41df-ab68-419f61cd9536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_2e60d2e8-7600-4c8b-9dce-ba5baeb4a27e" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_2e60d2e8-7600-4c8b-9dce-ba5baeb4a27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_15d453d8-8a08-48ae-a3e3-388467bc384a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_us-gaap_PerformanceSharesMember_15d453d8-8a08-48ae-a3e3-388467bc384a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended" id="i78755788e75e4fa38b413c743eb283e5_StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_30b247d0-d41b-4144-a022-bd5f254b5819" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_30b247d0-d41b-4144-a022-bd5f254b5819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:to="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a88f2e81-0619-47b1-9919-5a34d514b11d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a88f2e81-0619-47b1-9919-5a34d514b11d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8537fb4e-2c9c-453c-bc51-ee611aef130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:to="loc_us-gaap_PerformanceSharesMember_8537fb4e-2c9c-453c-bc51-ee611aef130c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:to="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cf4a758e-d728-46f5-bbf9-611a51ad70b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:to="loc_us-gaap_VestingDomain_cf4a758e-d728-46f5-bbf9-611a51ad70b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:to="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8c2b2b85-4193-412a-a179-6be56506e7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8c2b2b85-4193-412a-a179-6be56506e7ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_018856e6-9f82-4299-b918-be0c0b202840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_018856e6-9f82-4299-b918-be0c0b202840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a5f57195-0d60-4207-b271-88c34044b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a5f57195-0d60-4207-b271-88c34044b3af" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationAMEA2020EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails" xlink:type="extended" id="if7f2c04bb9b647f88815d20239fbc471_StockBasedCompensationAMEA2020EquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf23d7ff-0dee-46f9-991f-b4453b312c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf23d7ff-0dee-46f9-991f-b4453b312c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_893ca2ef-2f60-43f5-aa29-cdf3d2aa94d9" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_893ca2ef-2f60-43f5-aa29-cdf3d2aa94d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_7086ddab-dc99-4d52-aef4-775889563b9f" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_7086ddab-dc99-4d52-aef4-775889563b9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50667ff0-46a2-4ce7-9b74-7258c55596e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28a7868d-0671-4ad3-8ba6-05ec9378fab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28a7868d-0671-4ad3-8ba6-05ec9378fab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95c9aa61-9282-48b2-8e67-e1d9d450b170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95c9aa61-9282-48b2-8e67-e1d9d450b170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_01b666da-043c-4db4-b112-ad5a7709d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_01b666da-043c-4db4-b112-ad5a7709d9e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69f7a889-f63c-44f8-aa2f-77588ebbccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69f7a889-f63c-44f8-aa2f-77588ebbccb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67fbf892-a2fe-4b91-ba04-66f75921b728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_415fe152-635a-4e03-a7ca-a5da59c80b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_415fe152-635a-4e03-a7ca-a5da59c80b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee685f9d-0b75-4178-a673-083c9ca92ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee685f9d-0b75-4178-a673-083c9ca92ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4921e6b-abcc-4faa-9a54-21a377487445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4921e6b-abcc-4faa-9a54-21a377487445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfbd4128-d851-4705-b600-0c8cd59de53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfbd4128-d851-4705-b600-0c8cd59de53b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_116bf156-af7f-4230-b84c-cae143a826e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_116bf156-af7f-4230-b84c-cae143a826e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_debc17b8-9c5d-4470-b34d-bf357fbe30a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61d0c435-4557-4080-955b-553d820edcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61d0c435-4557-4080-955b-553d820edcdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2d0faa32-0553-4386-b844-8e937aa46765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2d0faa32-0553-4386-b844-8e937aa46765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3bcd3b9-3112-4c03-8274-e305fc715219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3bcd3b9-3112-4c03-8274-e305fc715219" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_453b4db8-1f40-4566-a850-dcf26135bd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_453b4db8-1f40-4566-a850-dcf26135bd78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_834946d9-0c98-481e-bebd-141ab18bcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_834946d9-0c98-481e-bebd-141ab18bcbe4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:to="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:to="loc_us-gaap_PlanNameDomain_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:to="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_563ef5c4-7e20-49a0-910b-508ed3ab62ad" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:to="loc_gh_AMEA2020PlanMember_563ef5c4-7e20-49a0-910b-508ed3ab62ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_654253f6-32fa-4c16-8cdb-0f724ac8cedc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:to="loc_us-gaap_ClassOfStockDomain_654253f6-32fa-4c16-8cdb-0f724ac8cedc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:to="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_635d85e2-2aeb-4586-82cc-d33ee77fdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:to="loc_us-gaap_CommonClassBMember_635d85e2-2aeb-4586-82cc-d33ee77fdc8f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i7f7a25961e0a4e3d9e0191d18f536794_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dd19689-d862-464c-96d5-a8c7161ef2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dd19689-d862-464c-96d5-a8c7161ef2de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_416d58e8-1e42-41e0-a23e-d9dd5090a6ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_416d58e8-1e42-41e0-a23e-d9dd5090a6ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_278f3993-628d-4cc1-b275-0875201b5790" xlink:href="gh-20210930.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_gh_PrecisionOncologyTestingMember_278f3993-628d-4cc1-b275-0875201b5790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_94156ce3-57c0-46b5-826d-6948633dccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_94156ce3-57c0-46b5-826d-6948633dccb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_57a1e144-50f6-4ba5-8e70-1fee4d9b7ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_57a1e144-50f6-4ba5-8e70-1fee4d9b7ac2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7cd74e88-886b-4f59-a905-d7a6f39ad8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7cd74e88-886b-4f59-a905-d7a6f39ad8f6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended" id="ibaba5a4c6ec741cca8f36830e705fd7e_StockBasedCompensationValuationofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3eb770d2-b2ab-4f2f-8def-d01c64a747ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3eb770d2-b2ab-4f2f-8def-d01c64a747ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6607c0a4-c3b8-4271-a7fb-cbbd5dad7fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6607c0a4-c3b8-4271-a7fb-cbbd5dad7fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fd26d93b-36a0-4108-87b0-1f181435b3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fd26d93b-36a0-4108-87b0-1f181435b3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dde290c-96ce-4c5c-8270-c65f4c9bf56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dde290c-96ce-4c5c-8270-c65f4c9bf56c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:to="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74b62b65-cc08-474e-8f6e-f75b70e814ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_74b62b65-cc08-474e-8f6e-f75b70e814ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cc9c0cc2-29ae-42ca-9c4c-08b03814c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cc9c0cc2-29ae-42ca-9c4c-08b03814c9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:to="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_102f96e0-90d8-4d80-87d6-6ac20eb33a3b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:to="loc_srt_RangeMember_102f96e0-90d8-4d80-87d6-6ac20eb33a3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:to="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_549aba10-0142-4117-8222-cc76902daa1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:to="loc_srt_MinimumMember_549aba10-0142-4117-8222-cc76902daa1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3826dee-ff24-4a99-825b-32d2a441126b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:to="loc_srt_MaximumMember_f3826dee-ff24-4a99-825b-32d2a441126b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i1568d646e9d34e18bf907d7ab7cb3d5b_StockBasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e288a27a-c1e2-4800-bff4-4d63c72ed3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e288a27a-c1e2-4800-bff4-4d63c72ed3bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba270629-53b3-4ab2-9a05-a23d676b7dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba270629-53b3-4ab2-9a05-a23d676b7dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_83eb76ed-3d39-4ee2-aed3-4a59fabdabbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_83eb76ed-3d39-4ee2-aed3-4a59fabdabbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24900fb5-234c-475c-91f0-413f533b57c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24900fb5-234c-475c-91f0-413f533b57c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:to="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5e69698-5b53-49ec-a1ae-25b157acc2c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5e69698-5b53-49ec-a1ae-25b157acc2c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_606ad38b-414d-4139-adc5-559d9db7be4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:to="loc_us-gaap_EmployeeStockMember_606ad38b-414d-4139-adc5-559d9db7be4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="i8100af3278c04135bb97456bc4aa6025_NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0470b13e-9a6b-495e-98d1-09ba310a5521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0470b13e-9a6b-495e-98d1-09ba310a5521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad695483-e540-4eda-a889-8b94d027a550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad695483-e540-4eda-a889-8b94d027a550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_282352af-adc3-4654-98f6-8df0e813b116_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_282352af-adc3-4654-98f6-8df0e813b116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_333613e9-d4b4-4aa0-b781-5718b64aa018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_333613e9-d4b4-4aa0-b781-5718b64aa018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56eaa90a-7814-44ee-96ce-15ca30410465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56eaa90a-7814-44ee-96ce-15ca30410465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e4e88918-beeb-45ad-8f55-09501e491077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_PerformanceSharesMember_e4e88918-beeb-45ad-8f55-09501e491077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_86f887db-a884-4212-b4fe-b7cd046484ff" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_86f887db-a884-4212-b4fe-b7cd046484ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_da31cef3-e1e7-425f-823c-10fa711e8b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_EmployeeStockMember_da31cef3-e1e7-425f-823c-10fa711e8b8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d7e304df-e119-4b32-8fdf-9b5a9b9df95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d7e304df-e119-4b32-8fdf-9b5a9b9df95b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f1834ef5-9733-41d0-8370-080dd5744af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_SeniorNotesMember_f1834ef5-9733-41d0-8370-080dd5744af8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d99e485a-5cb3-4275-a761-394d04c9c28c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:to="loc_us-gaap_PlanNameDomain_d99e485a-5cb3-4275-a761-394d04c9c28c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:to="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_8b9a2005-9a0f-49d2-ab39-f82978b6787c" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:to="loc_gh_AMEA2020PlanMember_8b9a2005-9a0f-49d2-ab39-f82978b6787c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7055eece-1ffc-4b32-af47-bae14563910c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:to="loc_us-gaap_ClassOfStockDomain_7055eece-1ffc-4b32-af47-bae14563910c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:to="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7cf357a3-d24d-45a5-8571-49dd355f60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:to="loc_us-gaap_CommonClassBMember_7cf357a3-d24d-45a5-8571-49dd355f60c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SegmentandGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended" id="ib50a8f3fd889449ca83a856953902465_SegmentandGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a3fe3f7b-8f3b-4eae-ab9d-80cd56d68fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:to="loc_us-gaap_Revenues_a3fe3f7b-8f3b-4eae-ab9d-80cd56d68fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3ca0f4ee-e4a6-4c14-9b8b-d4352faca7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3ca0f4ee-e4a6-4c14-9b8b-d4352faca7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f4117da5-a3fa-4435-9775-9aa55b663342_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:to="loc_srt_SegmentGeographicalDomain_f4117da5-a3fa-4435-9775-9aa55b663342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:to="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_414ce1e7-ae7e-4040-acea-dafc4d2c0358" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:to="loc_country_US_414ce1e7-ae7e-4040-acea-dafc4d2c0358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_323f1763-3916-413b-b627-3d070a259966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:to="loc_us-gaap_NonUsMember_323f1763-3916-413b-b627-3d070a259966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5317153b-df64-4761-8e20-661027283539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5317153b-df64-4761-8e20-661027283539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_b62582f4-4552-439e-9237-0a3b4675deba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:to="loc_us-gaap_AssetsMember_b62582f4-4552-439e-9237-0a3b4675deba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_af6f3808-50a7-4142-949e-04f08c64d4ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_af6f3808-50a7-4142-949e-04f08c64d4ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b71fd8b0-2938-4b9e-929a-e1b78af2f179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b71fd8b0-2938-4b9e-929a-e1b78af2f179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_494cda56-7d0d-4240-bbd4-53e9a7f697f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_494cda56-7d0d-4240-bbd4-53e9a7f697f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_7946030c-4bad-4221-858a-a74d72893458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_7946030c-4bad-4221-858a-a74d72893458" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SubsequentEventsDetails" xlink:type="extended" id="id3a1caaad86144cb8be24c153ff0c3f9_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_d9ab904b-aaec-42c6-9a8c-3efc0f8fd440" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_d9ab904b-aaec-42c6-9a8c-3efc0f8fd440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:to="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_de0bb532-417c-439a-8f3f-342726b065ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_de0bb532-417c-439a-8f3f-342726b065ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_678dff75-761f-44cf-88c5-df777324c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:to="loc_us-gaap_SubsequentEventMember_678dff75-761f-44cf-88c5-df777324c7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:to="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_704d4c95-ceb9-46b4-87b3-694ab272492c_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:to="loc_dei_EntityDomain_704d4c95-ceb9-46b4-87b3-694ab272492c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:to="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_478fe68b-39eb-49db-882a-ccf490129dbe" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:to="loc_gh_SoftBankMember_478fe68b-39eb-49db-882a-ccf490129dbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gh-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gh_SoftBankMember_b90df26a-87b2-4719-8989-9e0bd6412792_terseLabel_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank</link:label>
    <link:label id="lab_gh_SoftBankMember_label_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:label id="lab_gh_SoftBankMember_documentation_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SoftBankMember" xlink:to="lab_gh_SoftBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3c42215d-bc4d-437f-8a56-69c7be1cd276_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_341fddfb-03db-4818-8fb7-064a51c91bda_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7224a90d-7f6d-4eaa-a28f-a63c841a506d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_7e84b250-21cb-41a9-9b5d-703c691fbe6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c59a76ac-0feb-4a2a-992c-3f0da213d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_2ca5253c-d252-4fff-941b-d7a3344f7fcf_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_0b4f6a00-3707-405b-8e4d-d135c39df18f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7c7fdda9-c604-4e22-8b71-e5327d56d33e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82fb9b42-4e00-462e-add7-e5b0af89603c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_43bbc087-6168-4a7c-a0b2-8f07bc17d98e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_4a628406-6fe6-4457-a37c-2f1333b4e797_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_f2717cc4-73db-4f4c-b51d-d65f4ecc62c1_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_da712f40-a183-4815-a717-fb0968a5e148_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_929ba19c-20ac-4e9b-88d9-69f20e473218_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_03cf025b-a670-438a-9938-4381e7529cc5_totalLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:to="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_87eb2e54-01e3-4f66-84da-f2699e1163ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fd8911f6-e221-4d4b-88c7-67b7c0dee498_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f952da4-c3e1-4561-9b93-239cfbbd3706_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ad7f5d77-b770-4af4-8d38-f12f8d7c4bb1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_17a458ac-6820-4b09-82e2-6f12a3b88793_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7ba9f31b-fab6-4b14-9db5-6038c5f821a8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-marketable equity and other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_db5be9c8-9cf0-4245-964b-05b1ae54b1ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2a9ec51e-8f31-49de-b04c-0fdd758a6f7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberOfPetitionsFiledRemaining_23d9e90a-0ddf-43b1-9621-98ac11a415d6_terseLabel_en-US" xlink:label="lab_gh_NumberOfPetitionsFiledRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions remaining</link:label>
    <link:label id="lab_gh_NumberOfPetitionsFiledRemaining_label_en-US" xlink:label="lab_gh_NumberOfPetitionsFiledRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Petitions Filed, Remaining</link:label>
    <link:label id="lab_gh_NumberOfPetitionsFiledRemaining_documentation_en-US" xlink:label="lab_gh_NumberOfPetitionsFiledRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Petitions Filed, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfPetitionsFiledRemaining" xlink:href="gh-20210930.xsd#gh_NumberOfPetitionsFiledRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberOfPetitionsFiledRemaining" xlink:to="lab_gh_NumberOfPetitionsFiledRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dd25813b-4925-44c1-b1c2-384312609b5e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73236192-1a2d-4626-9678-a718eaaaa4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9775e93e-b8a3-4caf-add2-1db13a6131b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_84e7f00e-1d01-45ea-9dcd-d24ee4d0d29f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fd71139c-f0a0-4bca-82d0-2a1a0dcb900f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_671db1e8-ff81-4301-ac47-db0939d4c7b3_terseLabel_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and debt securities, fair value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_label_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_documentation_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:href="gh-20210930.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:to="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_74fe6907-ed97-4301-bbfa-5ce19c3148d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4bf4b04-04ea-4ee9-8894-7c982b6f4947_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0eeea23a-f15e-4bcc-9571-65aa0071e688_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54c523a3-834c-4a46-ab15-fbb09fa62df0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dd42bca4-5836-45be-a760-ab5c4f48b026_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1942ae61-83bb-4664-b33a-d3c9cfe832c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_43084746-2e2e-415d-a7af-f4b4c2618dce_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_label_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_documentation_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthAMEAIncMember" xlink:to="lab_gh_GuardantHealthAMEAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_82b7f0a2-166b-4a05-80ff-385285b60315_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6a19d873-8536-41c2-987a-f9e8977d0572_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb59de73-ee6b-4b6d-9531-9ab180c50037_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_391d1cab-c527-4c2b-b66f-863b45a10fbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e34e4eea-de74-42cc-baae-a6ffa2e2ea0f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_eaefa0f7-cf13-4e9e-b143-548e47dfc04d_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual receivables, credit loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_b6ad096a-0c5d-46b7-ab59-897e9082453b_negatedTerseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions: charged to other income (expense), net, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_cb5ca15f-d000-4947-8436-2f8d131fe581_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_197bd969-0b9c-4cb5-b5de-423dc3c623b6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend rate (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_c4aac86e-2e99-4a3f-a55d-dfcfc03a46fb_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Receivables and Related Credit Loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss [Table Text Block]</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerBMember_32893f6f-ddb2-450c-b68c-94937c36095c_terseLabel_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_gh_CustomerBMember_label_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gh_CustomerBMember_documentation_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember" xlink:href="gh-20210930.xsd#gh_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerBMember" xlink:to="lab_gh_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_33fb272d-4fd6-478c-bb50-3f564e97f8bb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d718c8ef-3584-48f9-9c90-2f60fae343ba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_67a59328-a953-46ce-af5b-580df15a5625_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_48149d92-f2bb-443e-8b1c-435b014658fa_terseLabel_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible senior note hedges</link:label>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_label_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</link:label>
    <link:label id="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_documentation_en-US" xlink:label="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:href="gh-20210930.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:to="lab_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_a8f7ea6b-38c8-4897-a58e-f3a0988ab176_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of prior dispute between parties</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_939aa497-f7fe-4529-b8e6-a79794d957a9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_TrancheOneMember_0dfb6a1f-f0e3-428f-9597-0fdc376ebda5_terseLabel_en-US" xlink:label="lab_gh_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_gh_TrancheOneMember_label_en-US" xlink:label="lab_gh_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_gh_TrancheOneMember_documentation_en-US" xlink:label="lab_gh_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheOneMember" xlink:href="gh-20210930.xsd#gh_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_TrancheOneMember" xlink:to="lab_gh_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_81241d9a-b12d-4e5c-8c24-257b155a5dcd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b65548b1-e2bf-45be-abf6-eaac06962aa3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_631dede4-0b9e-4db8-a98b-657104109c5e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f33fd7a-dee3-449f-bbd3-7bc4bc73fe8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ac74495-88d7-4f93-a64d-87a8a9e46089_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36f50c72-4b4d-4b5e-aeca-860410f39eed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_f6523554-23e0-4eda-b87d-1c1646870b01_negatedPeriodStartLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, financing receivable, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_e28d961a-81f6-4ecc-ab1b-ac4cb8d065f4_negatedPeriodEndLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, financing receivable, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_8edeaa98-866c-4f44-bcfd-416449a99fee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_0ff68438-5c93-409d-ba98-61b357b9e660_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_614a42d8-c48d-414f-bc86-1b54d1fb3e2f_terseLabel_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="gh-20210930.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e17ddfe-bb0d-4f9a-b1e7-29339116bed3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of MSU (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4aca4c35-86d6-4714-9732-aef86ef093f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_784de837-a2ae-44e8-a98f-ac1fbb8fa67e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0aa7bac9-cadf-4739-94ce-7d23a4bb5c82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_c93c318e-3ac9-49df-8ff4-98044e21de5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e4f868a-0601-4376-bfab-1a6afe4702d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e7b35fd2-aee0-4036-a085-e395b411ef58_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a6e1e019-1af9-48d3-a39b-c2dd74cb3469_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_c45609f9-db7c-4c5d-9ccb-d8f4d835a21b_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional service period requirement</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_cf95600e-26b9-4cd4-bcfe-dec31fe6a515_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_73b7880f-f1f2-4cb5-8ed7-d19dfcf191e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1197126c-96d6-4ce7-ad9b-64d708e8a34d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_1d3467d1-c029-4d24-ba95-4215c2eeefb1_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConversionDomain" xlink:to="lab_gh_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_c59a5d26-5447-45ca-9a42-9d114bb8f4df_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db098753-88ff-436a-9629-fd5060ba0193_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d5b456b5-99fb-4795-8de7-d99b70b0b0ae_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_77c7a3a1-c72f-4e97-81d0-ce38f5be25ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e07994d-4a94-4f8b-85d8-8a92e8eb604c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00c90e52-243e-476b-9067-a65cd475470d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_413c5709-481f-4e20-9278-4f29f7e22735_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_43410359-9c75-4cf1-99e1-d7c55c3b2641_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-based Restricted Stock Units Vesting Conditions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1729d101-eb8a-4c06-bb6a-6183c5fdf849_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_4d8d73cc-580b-43ff-9ebb-a14891ee7b61_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price of stock issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_cb5532c3-dce0-4eb7-aac7-3e2ccf37d108_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ccbf7af6-f398-4335-bdce-c0b9d10e13dc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PatentandCovenantRightsMember_d3a7f8f7-adcc-4169-ab73-1e0f528b8555_terseLabel_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights</link:label>
    <link:label id="lab_gh_PatentandCovenantRightsMember_label_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights [Member]</link:label>
    <link:label id="lab_gh_PatentandCovenantRightsMember_documentation_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember" xlink:href="gh-20210930.xsd#gh_PatentandCovenantRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PatentandCovenantRightsMember" xlink:to="lab_gh_PatentandCovenantRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a49c2829-9598-4666-9158-2b801b1f9125_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f5d46221-b699-4bf8-b227-f8e2b2565ed9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_7a5762f1-2ba0-444b-bd2c-1360151adc21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_50691af3-9977-4d29-99ab-90fddd9df83b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_58cf83e2-1b7b-40a4-933d-781057bbe55b_terseLabel_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number lease agreements, not yet commenced</link:label>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_label_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases, Lease Not yet Commenced</link:label>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_documentation_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases, Lease Not yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:href="gh-20210930.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:to="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_58b2ba12-b72c-4031-b30f-0756da2ef6e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_923bc045-b7ec-4df3-a33e-dc8df8034484_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_85f50fe0-f0f1-4f51-acc3-5682776e69fa_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risky rate, cost of equity</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_19a4f9df-9cca-4e4b-a37b-0a4ca43cc80b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_000bc47d-478f-4e43-ae3a-b97e5bfad70d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22cdf6ac-13c3-460b-bf47-8a23cb08ea70_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_547382b0-701e-4fb3-8800-404abb76e842_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate, ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8d2a136a-572d-4223-a19f-f5cfb217a6b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbeb567d-e6b7-49c2-99b2-fddebd162a5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a8e35aba-4190-49e7-bf74-52bdd849b88d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_02e81675-aed1-4c36-b19c-d77b81cbb7fe_terseLabel_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2027</link:label>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_gh_ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member" xlink:href="gh-20210930.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleSeniorNotesDue2027Member" xlink:to="lab_gh_ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_16ec9d58-ef89-4f73-8ccb-335cfd857b96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ec77354b-fc8e-4f59-a224-8f15fa9d757b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_308dd44f-610f-4f37-aa90-0004e0b9d408_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent_77d5b7cf-a2cb-4c7f-b971-da3da8d6bc2b_negatedTerseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions: charged to other income (expense), net, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Expense (Reversal), Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossExpenseReversalCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dbd51024-3c51-4fac-92de-6c1579938d79_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContingentConsiderationMember_f09ba099-1c16-4472-b315-81e61cf45574_terseLabel_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_label_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember" xlink:href="gh-20210930.xsd#gh_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContingentConsiderationMember" xlink:to="lab_gh_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_114ab365-449f-4436-bba8-a4db29627464_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_a764acdc-ff7f-44f8-a72d-c86953849092_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0118306c-40fc-4811-b5d7-35d22ae5d9c1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9bece5bd-e5c7-4006-af8a-acdc3e305bb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesTerm_e1767baf-752a-4bda-a0a5-2d621eb52a74_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and other assets, term</link:label>
    <link:label id="lab_gh_ContractualReceivablesTerm_label_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Term</link:label>
    <link:label id="lab_gh_ContractualReceivablesTerm_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesTerm" xlink:to="lab_gh_ContractualReceivablesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74e56d9f-a1d0-4c87-8ab8-cd5dd4138284_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_11388914-5cc4-4e9f-a89e-c1a654cb1e2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ecf9c078-8be5-4655-890c-c4218df460b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_da7a0efb-f674-4cde-b825-1cdd7995efd0_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_588f4f06-122b-4153-9a19-c08ed227bd77_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_573623d8-80b1-4568-befe-f2031d203f3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-marketable equity and other related investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_d5192ae6-d35e-406f-8032-078e02b1e1ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for post-vesting restrictions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_fdfb074f-6331-4814-8cf6-0de9ef8c7fcf_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5e705428-f235-45aa-9f0b-9e471f74b3c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_12eed89d-ded5-4890-9fc5-d2c3e61f6d3f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_b13ece4e-adf1-4c14-a81f-d2c9222a1595_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_gh_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConversionAxis" xlink:to="lab_gh_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_260ce98d-ab35-4fe5-b043-61916f8015b7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment for ASU 2020-06 adoption</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_18214077-cce2-40bc-8895-e764ac5404a4_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_2bc33890-a13e-46ad-a62e-7f21bf890425_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, gross amount, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d02b29d0-b039-4e72-bc3f-8808884de0c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ce9bf907-ad1c-45e9-9e0b-9c08001d1200_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit loss adjustment and others</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c7ef185d-ea3b-40f9-b1d3-917acc1335d6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from cash collections exceeding estimated variable consideration</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_ba49e78f-9d5b-4380-919e-94c307d408c3_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant&#160;</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_649043e7-483a-4081-8009-f900be020d02_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_272bb757-5c74-4070-bef7-1a839672d3cb_terseLabel_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trials and studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_label_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_documentation_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies" xlink:href="gh-20210930.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedClinicalTrialsandStudies" xlink:to="lab_gh_AccruedClinicalTrialsandStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LongTermMarketableSecuritiesMaturityPeriod_c2df6c53-b11e-4c4b-a41e-8919dcdaa476_terseLabel_en-US" xlink:label="lab_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term maturity period (years)</link:label>
    <link:label id="lab_gh_LongTermMarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities, Maturity Period</link:label>
    <link:label id="lab_gh_LongTermMarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:href="gh-20210930.xsd#gh_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:to="lab_gh_LongTermMarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_327ad91b-34b1-4194-9c45-132d5ccaf4c3_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_label_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Policy Text Block]</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:href="gh-20210930.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:to="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fa9153fd-1c11-47c8-b9cb-a6b832ad3abe_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_b0c74cb5-ff58-4489-9668-8597973cfa76_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2af2309d-88bd-4b8f-bce1-d3558dd4a251_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2b0346ea-dfc8-448d-9ec8-b146dc9e5545_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e2d2c2e-d0df-4bd4-a2ea-94ad72f83c06_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_206a6301-a212-44a8-befe-ad115e198c09_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_15e16f46-34a4-47dd-bbdd-c8c0167d67d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_71ee938d-2367-4f44-84b6-e7c259c267de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_461e482f-25d9-4348-9b90-2edb88932f99_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_fa1a9534-0251-4a29-a66b-b862dda50c64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_8acecc34-f220-4467-b9fc-2480d8afaf94_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2798d3bd-98c0-4ca4-8d3b-564c8aae0207_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 1 - $120 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b9a2ed1e-46e5-43de-bed8-47f930db49bc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1e3af910-7e64-4979-ac88-f9b46185388d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_081af9c4-a6c0-40f1-b8d0-9980c6ce0786_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreements and other covenant rights</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_097c733c-0265-4cca-b778-51ce2938ce5c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d4f7ec93-ab2d-4ca2-a842-fd6018b5a66c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bda4b4dc-1ab2-4113-98d7-84771e6cb277_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_fd3ace1b-d00b-491d-b50c-6781b9c2d3da_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0a2c358-9e71-4e5c-98ed-fc2a4e120154_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_41896ed4-f8bb-4e56-8824-c0f645ad0f91_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cee52d09-8f56-477a-8ade-cd0f052c455e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_854103f0-ec4e-4b52-934d-50346f46df6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in joint venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_2497f628-1416-4164-8ddb-12a8cd1bfdc4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_67ae3ca9-8946-4976-a6c4-5a7daf5a1768_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_97f88cd3-56c6-4de2-a38a-dbc420d18979_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_118ba556-26da-4c40-8f37-30f4d1b368db_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f58bf366-e0a4-4b9a-975c-7931057e20ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019d3479-1eb6-440a-825b-29678c7a046c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_07682b3d-5100-433e-b251-4a217f42555d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount recorded in equity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9ef2d25c-a1c2-4f1e-ac47-8559e0142d4d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_da5cf949-4ba8-40be-b034-04b9d05855a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re-valuation of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_a54e2cef-1b4a-43ba-90c2-8f382d6df340_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_34958ff3-e15a-446a-af39-f10d70c9e01f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b41b157-9420-40ca-9bff-7c496b48f184_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d70d10b0-8b2e-4575-b669-8cacff2bb3dc_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_f33c2669-a526-433b-ab0f-3f4524493ab1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_a0ce5850-1a8c-4de2-9899-16165869a9c2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and nonfinancial liabilities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_b7efea08-3a3f-4b70-93a1-356c726cf64b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_0ec210fc-ed40-4125-927c-05ec9c2eabf3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt issuance costs, net of amortization</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_254627d8-2393-4061-b20d-d9db0360d596_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_31cc5852-0ed6-4bb5-a9af-589e5853e8a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax impact:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ed0e70e1-c48c-404d-a9d6-2a8ea768b275_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_86534b9a-44be-42a0-a734-9365948e56fe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_19a2519b-6078-435a-acef-491680ce8365_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_84ae3039-9715-47f9-a221-f7615c365aeb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8b2f9bec-6199-475f-a52c-8d51202c2b55_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid_8cdbfeeb-c46c-43cf-ab58-9fedbb283e91_terseLabel_en-US" xlink:label="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid_label_en-US" xlink:label="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI Incurred But Not Yet Paid</link:label>
    <link:label id="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:href="gh-20210930.xsd#gh_EquitySecuritiesFVNIIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:to="lab_gh_EquitySecuritiesFVNIIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a5decc31-50f8-4131-83db-1e175fc2323c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6bd38cb1-36f4-4e6a-b172-87fb25622f6e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6f08bbe1-31fe-4b4f-b812-dcf2d2668350_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_4db9fb1d-1cb3-4080-8d70-9d4e7394a30c_terseLabel_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual receivables, installment payment</link:label>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_label_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Receivable</link:label>
    <link:label id="lab_gh_ProceedsFromContractualReceivable_documentation_en-US" xlink:label="lab_gh_ProceedsFromContractualReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable" xlink:href="gh-20210930.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ProceedsFromContractualReceivable" xlink:to="lab_gh_ProceedsFromContractualReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_82ba4bda-8c96-42e9-98d5-74b3e355fa9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_1e4a8ca5-e0f5-466a-9c42-1973bb5243f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostofDevelopmentServices_7df25249-423d-410f-bf3c-142c3292122c_terseLabel_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of development services and other</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_label_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_documentation_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices" xlink:href="gh-20210930.xsd#gh_CostofDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostofDevelopmentServices" xlink:to="lab_gh_CostofDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_78e89bd0-2879-4148-a063-c532e9f20a37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average exercise price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PaloAltoCaliforniaMember_a1117ae0-212f-427f-8708-cd637746e8bb_terseLabel_en-US" xlink:label="lab_gh_PaloAltoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palo Alto, California</link:label>
    <link:label id="lab_gh_PaloAltoCaliforniaMember_label_en-US" xlink:label="lab_gh_PaloAltoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palo Alto, California [Member]</link:label>
    <link:label id="lab_gh_PaloAltoCaliforniaMember_documentation_en-US" xlink:label="lab_gh_PaloAltoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palo Alto, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaloAltoCaliforniaMember" xlink:href="gh-20210930.xsd#gh_PaloAltoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaloAltoCaliforniaMember" xlink:to="lab_gh_PaloAltoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a64e86c-abb4-47a7-a824-77ad6426ea00_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_39420178-a5d6-4a78-926c-c7041cf48f82_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_88bf85f9-4608-4323-a415-09526406c383_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_0b144c2e-1138-4ef7-a384-7d7b4f6dbaa2_terseLabel_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition</link:label>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_label_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition [Member]</link:label>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_documentation_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember" xlink:href="gh-20210930.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_KeyGenePatentLicenseAcquisitionMember" xlink:to="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_71cf2f01-1c47-478c-b7b2-2a3e4625909b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9df431a4-550c-4f5f-a4b1-f5856a16be13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7472ad64-3d86-426d-8a81-7365214c8520_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e67bf994-720c-4830-9cba-bc8b23e61177_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aea83d8a-b2a4-444c-bfbc-9893eed29050_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerDMember_88ff10de-8bb2-44e2-ab50-65b1c59bf1df_terseLabel_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_gh_CustomerDMember_label_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gh_CustomerDMember_documentation_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember" xlink:href="gh-20210930.xsd#gh_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerDMember" xlink:to="lab_gh_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3128d352-79f7-4abe-a45c-cc7eeb7f982c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f40eb487-b4e5-47de-afcd-4f0d9e6575dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_31d172bc-56f2-4584-ada8-dba7f46c4829_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_Guardant360CDxMember_ee9e2fb0-ab26-4781-aa9d-857843557aff_terseLabel_en-US" xlink:label="lab_gh_Guardant360CDxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant360CDx</link:label>
    <link:label id="lab_gh_Guardant360CDxMember_label_en-US" xlink:label="lab_gh_Guardant360CDxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant360CDx [Member]</link:label>
    <link:label id="lab_gh_Guardant360CDxMember_documentation_en-US" xlink:label="lab_gh_Guardant360CDxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant360CDx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_Guardant360CDxMember" xlink:href="gh-20210930.xsd#gh_Guardant360CDxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_Guardant360CDxMember" xlink:to="lab_gh_Guardant360CDxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_4d085a8a-6ff1-46f5-9317-80c9542603d3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock subject to repurchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ac9a9cd2-e8a0-45f3-a0e7-c4ad6455bdb3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d5ea064-0882-401f-bbc2-5e61648503a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c261f063-6626-4324-9a51-7be736609c29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_78929290-7925-4b99-933e-cde9ff16cbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96944a2f-bcb2-43e5-9d61-5e396b03af15_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_eab88773-83f1-4fc1-8766-024f667afe4f_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e0f60d0c-d3c3-49aa-86d1-d4111652dc2f_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_83a78694-0d29-42ae-8661-48faa7db25e4_terseLabel_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reclassified and converted into preferred stock (in shares)</link:label>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_label_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued Upon Conversion Of Common Stock</link:label>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_documentation_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued Upon Conversion Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:href="gh-20210930.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:to="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_843a74b1-f0f6-42ed-a28a-bb96f29e6bb0_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting" xlink:href="gh-20210930.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTesting" xlink:to="lab_gh_CostsofPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5347994d-994c-43f6-969a-220886e6c926_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0251bf4e-2d41-40f3-a725-58ea853dea5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d9030efd-941f-4a2c-9b18-efb3dab97cda_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a314e912-9663-4ce9-8f01-23badd5470a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5ea0b979-99db-4b35-82ad-46367a379624_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent License Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1b1ce821-6966-4642-ba97-1aec933c0244_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_08a7f658-1f14-4368-97fd-078e692cfefe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs related to borrowings on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_53c49bfc-ef7e-4507-8094-c02a6086710e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_fea061d0-d3e8-4f93-b879-6049b033e75d_terseLabel_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision oncology testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting" xlink:href="gh-20210930.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromPrecisionOncologyTesting" xlink:to="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_59217491-c104-41e1-94cd-7afc89e777f2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d11cf23f-96d2-42ed-a080-7366f534b74f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_e0ced600-ca53-441d-974f-afe0c95523e5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9c111ff5-c88b-4492-a8c4-3cae5859387d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4b0194ff-d9c8-43ca-b3ee-0f332e979451_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_bf739786-2698-4ba2-930b-b99e2968dfd4_terseLabel_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_label_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:href="gh-20210930.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:to="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5baeef09-82c9-4283-8b49-d1d1175fc9c9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_97065694-9337-401a-9581-0960e8458269_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8017b7f6-8f79-4c71-b6b4-6f5495cfd7e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_030c67e8-a4dd-48a8-b86e-23e106ce8413_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_6fb3b04e-d9ce-4bb6-9714-27d4f77b018c_negatedPeriodStartLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, financing receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_fa5ffe58-d2ff-4ada-9bcd-f39e3bd64796_negatedPeriodEndLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, financing receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:to="lab_gh_ContractualReceivablesAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5570506a-1e66-4729-9e87-d62affa0a25d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, net</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a416f6ca-4933-468f-87a2-7dd71c2f8f1f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9bfb74b4-8cac-42fd-90b4-4ff1e9fc173e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e9bf46db-1a10-4987-a947-871ba4542d42_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f718295e-314f-4811-8341-af39c2bb09c9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ab697e9a-8025-46b0-b133-e3ae2ea504f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_728652a5-3dd0-4471-922f-200de5793193_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_3ff61de1-1db7-4f83-8843-70f019dd1ce3_negatedTerseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, allowance for credit loss, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossReclassificationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossReclassificationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_77212b05-29f2-4334-bb21-3c05301d82df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital, stock issued, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a5ab6bc3-1417-473e-9dd0-f3570a63da2f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f09a05ef-2c21-4262-889f-a11a52638a00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d3ecd16c-ae11-45e5-90b0-ac54ba94560f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8ce0d508-a1e0-44a1-8ef3-fb06d3231b3e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_64a979db-032b-4f97-aff9-0bcb6f11c882_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_32b848d9-ca16-4d3e-ba90-4ec5d2d0d96a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f46fe48b-c301-4814-9514-6b86b5b4929b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0c7e47ff-6d0e-4a63-a10c-51d87e91e4cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dd462c78-0d2f-48e8-bee3-0f02bd9bf00c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_75b87ee9-54d3-4457-b913-b2dc2d3891a4_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f240660-8675-430a-a058-c87ae80cf1ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_668d3878-db3f-4c66-a3c2-61b461132e63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1906c1db-7c47-4d85-bed1-38e88293e8cf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76cd1cb-37ae-4c60-975d-a88459e18027_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e971dd62-b2ed-4dd4-9578-440744c492ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_23dc2b9c-545a-44ea-92ad-e9026f9abc20_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_23830b9c-1eeb-4d59-9d80-384014817bf5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6eeeddb9-2d33-453b-8122-e8ec96f4c39c_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_c4b54bce-a2cb-42e3-8032-680a8c24545b_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5ba55c27-45f5-41f6-bc6c-a0ff4d38b183_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_cbee5a06-a6d6-438b-a43c-3745cd2d1532_terseLabel_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_label_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_documentation_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember" xlink:href="gh-20210930.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PrecisionOncologyTestingMember" xlink:to="lab_gh_PrecisionOncologyTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_5703d46b-df7f-433c-b46f-fe18f47757a3_terseLabel_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_label_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesTableTextBlock" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesTableTextBlock" xlink:to="lab_gh_DebtSecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5344d7a9-401f-4cad-a055-975ace9ad54e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5773c43a-1edd-4415-b162-e174fc92c4c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a3bfe6b-a252-467f-bfd3-dd877e815b62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases_09e714bc-4dbc-498a-ac15-5fd839e988f8_terseLabel_en-US" xlink:label="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment acquired under finance leases</link:label>
    <link:label id="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases_label_en-US" xlink:label="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Acquired Under Finance Leases</link:label>
    <link:label id="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases_documentation_en-US" xlink:label="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Acquired Under Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:href="gh-20210930.xsd#gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:to="lab_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dcb94c68-dab4-4e7b-9878-2a1d7bd901a7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94d9ab65-6c52-462d-b5b4-da27abe56908_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_c099c0c1-a609-4357-ab07-932c4204edd2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4274ce24-5be9-4fe7-8563-3eebf7270297_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_e169ae46-37b8-4f21-a9a1-5ed5ce728fb8_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6cc5476c-771d-4d53-b5b0-a4429ff603c1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_94473b77-cdd2-44f5-890e-5e853085809b_terseLabel_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge of in-process research and development costs with no alternative future use</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_4838fe89-2e09-4abb-96e5-87c1413c0b87_verboseLabel_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development expensed</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge Of In Process Research And Development</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge Of In Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment" xlink:href="gh-20210930.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ChargeOfInProcessResearchAndDevelopment" xlink:to="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_9b9e12bc-1b0d-4d17-8dbc-ba1fa5789bc7_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of MSUs (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_642493d2-e620-4399-b6dd-684cf8740774_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d33bc47d-148b-414f-a1ce-4612127e7a73_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f6d84477-f4d0-4c1e-b8b5-c30ff0f248cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0b565fae-52b0-4905-8189-ee205ebe53df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8025a050-4e5e-4500-a360-1e901597816b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81266c06-aad0-4fba-a715-4dfeed274c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_0d10821c-a72f-46ad-8948-703009a63557_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_41b85342-eca9-4162-8830-e53ffe7b4038_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_afc6f36b-c3b8-4955-adae-d81ebc6d6738_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_27589577-a89e-4a89-a7d6-4239c145f15c_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, transaction costs</link:label>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_label_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts" xlink:href="gh-20210930.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionTransactionCosts" xlink:to="lab_gh_AssetAcquisitionTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e271ed1c-d7be-45ab-8338-b2f5413ffbaf_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_45b19cf1-2be8-4344-8529-ac46327b684c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f8c6bade-c054-4098-bd2d-8a1dc21fb0a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_428745a1-3233-4e13-b310-501fbcb46182_terseLabel_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in connection with a license agreement</link:label>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_label_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Connection With a License Agreement</link:label>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_documentation_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Connection With a License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement" xlink:href="gh-20210930.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentInConnectionWithaLicenseAgreement" xlink:to="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c36737ec-0685-4ea1-98e6-8c807e1abbee_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a89be19c-e495-4ae9-9f9c-4f4519aa301e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_137ce4a9-6879-4754-b6c6-9595e5ab9f82_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_f424ec56-b240-429e-a766-1781b040d980_negatedTerseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_9dce2e04-a06b-4cd3-b00c-9f19d883e390_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total market-based restricted stock units approved and granted (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_43c664cb-b17e-457b-ad92-72ab5d991a30_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_d32cff6d-a965-40fb-89e9-a812e0c4aa43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Joint Venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75a6787f-4351-49f3-a4f5-69b30508b788_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_078af2c3-9e96-401b-83fc-8cca622970be_totalLabel_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:href="gh-20210930.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_6b5679ac-576c-45fe-bb36-609c100c1688_negatedTerseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: lease incentives</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Lease Incentive</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Lease Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityLeaseIncentive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:to="lab_gh_LesseeOperatingLeaseLiabilityLeaseIncentive" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_3eea1c9d-de46-4a6f-9f85-28df9019567e_terseLabel_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_label_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostofDevelopmentServicesPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:href="gh-20210930.xsd#gh_CostofDevelopmentServicesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:to="lab_gh_CostofDevelopmentServicesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_72c51512-32b1-4c5b-9162-440793fe50a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_46c8fa53-3776-4e63-a6b3-c8c26e580d1f_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_46163f2e-ef06-4667-a048-263e607a95e9_terseLabel_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_label_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</link:label>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_documentation_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:href="gh-20210930.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:to="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ec75cd5f-3f34-4776-8806-5a87cf8a3eec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1d9e733a-fa35-48d9-aa0e-31b39b1da764_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AMEA2020PlanMember_3199b32d-5d41-425f-be23-d4f681e36b74_terseLabel_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan</link:label>
    <link:label id="lab_gh_AMEA2020PlanMember_label_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan [Member]</link:label>
    <link:label id="lab_gh_AMEA2020PlanMember_documentation_en-US" xlink:label="lab_gh_AMEA2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMEA 2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AMEA2020PlanMember" xlink:to="lab_gh_AMEA2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_db4209ea-97a2-42c0-bc75-e141dd38c9a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_81cf1ab0-16a0-4d5d-ae49-d58ca49ecf2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1045fd9b-632e-4adf-b670-919db85d6299_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_aebf5a1e-1c00-4887-9af7-4917f14d6318_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c6206d1f-bfbb-4e88-a555-6bb1b95bcd01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_22129158-2bee-4008-9909-62695d4be9a5_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_251b6872-3fb9-4809-b765-b5f4a13f81f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_82c34e1a-9bc0-4f0b-99e0-11f92a8ca99a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_9be4cbdb-2d53-452e-a68a-1c3553238e19_terseLabel_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_label_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_documentation_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:href="gh-20210930.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:to="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_605e742a-023c-4bfd-addd-639f2d0569ff_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_3721ffb4-a146-476c-9628-8d3e7346ac40_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ee09b7e1-c7ed-4ab6-af16-9044eb789d62_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8d3c7523-9ed7-4c79-82fc-6d7ce514c8c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e38e1ea4-c8c5-445a-b922-8e7337558ce5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option term, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_4c6ff141-e6c2-4723-90af-ef027118f4b6_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock units holding period during vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_12e6039f-7aca-4b3d-9108-a866b13da3fe_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8bf42703-6b8f-465c-b189-6eb050430774_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f6dc699d-bfad-48a8-a9c5-0284adffe4bb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2859007b-c0f7-4eeb-a4c1-6eccfb7286ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_5fc9f675-586e-43f2-8ca7-d0c2b21657c9_terseLabel_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development services and other</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_label_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_documentation_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices" xlink:href="gh-20210930.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromDevelopmentServices" xlink:to="lab_gh_RevenuefromDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c79064b-0bcf-4546-a953-d46ffd18ff79_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7bce2222-77c4-4229-96ed-fa4f8d1bf0b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_5f600729-b025-45be-b71b-3c0a9bc5a6ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area</link:label>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_label_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:to="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_60c2b226-c3f4-4d66-a156-f4c96abd700d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 - $150 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4d06576f-7a7e-42bb-b9bf-cd85b72f7464_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58669f1c-88e1-4f93-a5af-547e7c102a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0e749edb-7ded-4135-9a18-21a5870e4270_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_45184498-8797-485e-819e-c7eba3cbeec3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_751cb24f-a78a-4377-b6d9-f558f429e450_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_53a7a155-53df-4512-ab72-891886e30006_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_TrancheTwoMember_78263964-338c-435c-87f1-62bda4c3b90f_terseLabel_en-US" xlink:label="lab_gh_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_gh_TrancheTwoMember_label_en-US" xlink:label="lab_gh_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_gh_TrancheTwoMember_documentation_en-US" xlink:label="lab_gh_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheTwoMember" xlink:href="gh-20210930.xsd#gh_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_TrancheTwoMember" xlink:to="lab_gh_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_28daca40-4589-46bf-a878-cddff2744240_negatedTerseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: issuance costs</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_label_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Issuance Costs, Equity Component</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Issuance Costs, Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:to="lab_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a400ef9a-f680-46fb-80bc-47b434bb3b92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Level 3 Activity</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_21c5950a-62df-4d5b-9ad8-43aabc959e56_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2ba2d569-7d79-43d1-9ccc-f92c10aaaa6a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_7a949ad5-4d21-4ef3-a903-c9f54634553c_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d4b5614c-6d5a-4377-8f52-017dafeed488_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f2d153a-ebb6-4043-8a03-dd6bcceea10b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e386ec81-55f0-452d-aab7-b07acc46f9a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_2e9ed899-e2b4-454f-b0bb-e637702c8982_terseLabel_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price, premium</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_label_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Share Price, Premium Percentage</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_documentation_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Share Price, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:to="lab_gh_ConvertibleDebtHedgeSharePricePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b979e1bb-6c13-4466-b22d-c253941dec3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7764d889-7031-47f6-908d-7f59cd095188_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_cd98cc54-c5a1-4f83-9f5c-b1cf31241805_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum special interest rate percentage</link:label>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_label_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</link:label>
    <link:label id="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_documentation_en-US" xlink:label="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:href="gh-20210930.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:to="lab_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ebac1e06-62a8-4c48-af03-7386868f2c88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_34e3152d-404d-457d-956f-215fec81d1f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1110a3c5-2da8-4197-abc9-cbc2d0bebc75_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_bb6a80ad-73ba-4ce5-aa3b-08526698e85a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f8250be-4ba6-4fe4-b7d9-460ffddc762c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_49589899-a60e-46eb-ad76-a7ce575d0df1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9f33943b-5093-4869-8935-fc65e0f00bf1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8dadf0eb-8f87-4762-8c52-95458c980041_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2881e8c8-9ea3-47e4-837a-04a4ca48f6f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_137d1885-da39-4a9d-acf2-c8a69d621d69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_07a65b86-0ef3-4ea9-aef0-0f951d51edf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_e9e0b131-5990-4471-abe5-54ca34893ced_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal lease term, lease not yet commenced</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:to="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bd957828-8faf-4e9e-8fdf-d972012033e6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_59edb7a2-7a9f-41af-9a69-995e4a9a105e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ead05f-3a26-4715-99de-f4e516e5d6d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ebbc92bb-2b07-4a78-b8f2-9b41e4ede4a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_89e8a0ca-5973-4c31-b126-34a5d7fdbe46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_87c1a2fb-320a-4515-9cc8-35b6cfeaad1f_terseLabel_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Hedges, strike price (in dollars per share)</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_label_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Strike Price</link:label>
    <link:label id="lab_gh_ConvertibleDebtHedgeStrikePrice_documentation_en-US" xlink:label="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Hedge, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConvertibleDebtHedgeStrikePrice" xlink:to="lab_gh_ConvertibleDebtHedgeStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_23ac76bc-6d04-4dd9-807b-be298113a977_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_29648e48-3bc4-439c-9ce3-2ffef6ec97b3_terseLabel_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, shares purchased (in shares)</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_label_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_documentation_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased" xlink:href="gh-20210930.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityMethodInvestmentSharesPurchased" xlink:to="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b21d4523-5799-426e-8f11-d446ec804439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c7fba0cb-0279-4cfb-86d6-69efe765561b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0c80462b-9229-434a-85c5-0c6034d9de2d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d74b59bc-a532-4076-8c6a-b9b8e67a8473_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_145c3cfe-5532-4c44-afb8-d2b1078ba39f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_2ed17b9d-36b8-4d9f-947a-b19528d31b9e_terseLabel_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_label_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_documentation_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:href="gh-20210930.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_2a3bb8e8-0dee-43d2-87db-0a80a19d7a0d_terseLabel_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or adjustments of non-marketable securities</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_label_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</link:label>
    <link:label id="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_documentation_en-US" xlink:label="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:href="gh-20210930.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:to="lab_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e2feb3f4-933a-46bd-bb4e-c1dacad1cb27_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5e1d24b8-9b93-4b7f-9525-2be0ba93bb56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_c6820740-db33-4b44-af9b-1e26522e479c_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5aa70b59-aa99-42fd-a58e-60058b4ba539_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398c519c-4d83-478a-af7e-d57d04f0a7cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, grants in period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_757240c5-3359-4c90-96ce-42c9ec8b5a2e_terseLabel_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease costs</link:label>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_label_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Operating Lease Costs</link:label>
    <link:label id="lab_gh_NonCashOperatingLeaseCosts_documentation_en-US" xlink:label="lab_gh_NonCashOperatingLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Operating Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts" xlink:href="gh-20210930.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NonCashOperatingLeaseCosts" xlink:to="lab_gh_NonCashOperatingLeaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e50cf124-1baa-4d4b-bf2a-b96990bb89ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_c5208c1d-361b-4bd5-af7b-ba313a3a1eec_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Notes</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_label_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Equity Component Before Issuance Costs</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Equity Component, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:to="lab_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_9a9d34ca-e4b8-4687-bdaf-287dfa654622_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ef57c8d-44a7-402c-ae29-707c910ea4eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodThreeMember_acd65835-9d78-4763-88f3-8a08df350905_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three</link:label>
    <link:label id="lab_gh_ConversionPeriodThreeMember_label_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodThreeMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember" xlink:href="gh-20210930.xsd#gh_ConversionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodThreeMember" xlink:to="lab_gh_ConversionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0b37b3c8-a353-4e89-81e2-e1fe828253ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_80aa7c46-2b57-4bc9-b507-69f80f6106ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_7466e6bc-6534-4737-bc2e-c78d87b3826a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_0c50942d-8e33-4dda-ba2d-8d39648367fe_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_39d8d635-303d-4f86-92dc-5257bd3301c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_50ea583f-106e-44f9-ad3e-67a8e012dead_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e2b074f8-88b6-4874-8a80-3c8c156389ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_25494d26-43d7-4e60-ae66-ddd097da97bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; included in other assets, net</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_001969be-249f-498a-b362-7bb611423c68_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock share price goal</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsMember_d08d49be-e5a9-4ead-8cc9-c5f1ae973bc4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsMember_label_en-US" xlink:label="lab_us-gaap_AssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsMember" xlink:to="lab_us-gaap_AssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ba6a82ee-b0ab-4ca7-b85f-0bedd17734da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price&#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6f7e51af-b802-4a6c-a1fc-40105a832bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5261367-0e70-4667-90f8-da16cfb8c982_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9059cb25-977c-4443-a091-c9310337f4cf_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SanDiegoCaliforniaMember_d85cec64-0d6d-40ad-8b3a-b6d0f32e2d38_terseLabel_en-US" xlink:label="lab_gh_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_gh_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_gh_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_gh_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_gh_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SanDiegoCaliforniaMember" xlink:href="gh-20210930.xsd#gh_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SanDiegoCaliforniaMember" xlink:to="lab_gh_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a8732a6f-83e6-45e9-a4c4-c818b677cd2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39d5b25d-f9ee-4540-a0f0-692eb36fde45_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_b4079655-a604-430d-8ce0-d221ea8b0575_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7cbedde1-50be-487f-a56e-8977c193aae0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (as a percent of the fair value of common stock)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3448f7d2-422e-454e-bc69-c313500e038e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_79237c13-d949-4b52-99ad-f2320d30ec3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a10bfe19-26a0-454f-bd75-3f1b077f719e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_bffde7a8-c782-4166-b552-1968e443facc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_50a9db19-88d6-47b1-9c82-655a4ccdd6ba_negatedTerseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, allowance for credit loss, noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Noncurrent</link:label>
    <link:label id="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Credit Loss, Reclassification, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossReclassificationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:to="lab_gh_ContractualReceivablesCreditLossReclassificationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_2e103bf2-3c43-4e92-9de8-1d185faffe32_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_e7dfc3e9-ebd7-45bc-aa92-a9768565ced1_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 plan annual increase (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_97c75b2b-bd4b-4a7b-8ad3-4f8052721778_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3c124dfa-89f6-4c21-ad55-ed5a307beeb4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cad71683-53ab-4d3f-8cbc-1d36f990e2f9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fb9a2368-4fcf-4023-93f7-13226b3dd530_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5e5fb82b-161d-4e2d-9078-eb39105b3fd0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f3c242f9-a26a-453e-a3eb-373e98028081_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca4dcd89-59d7-4f98-be8d-642aa26a7412_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerCMember_4339e2e9-0543-4235-9740-1a0c0db46a23_terseLabel_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_gh_CustomerCMember_label_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gh_CustomerCMember_documentation_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember" xlink:href="gh-20210930.xsd#gh_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerCMember" xlink:to="lab_gh_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b816652b-022a-42e0-9447-ec40cfb2bc1b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4e3d7b99-56ca-4e37-82f7-72b514011013_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_421c9f78-d541-4093-9172-688e05488d83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0ac7cbd0-266a-4eb7-a9ca-da97b01be66b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_60d9badc-9bce-4fb0-babd-fd48fc1ed894_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7b1c0ddb-0fef-4061-8b01-e1d781c58254_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net of underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2b7ae4ff-cded-4753-a0fe-1ce780d37e7f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_9c97c4c6-a0f1-418e-89be-d4116eee0379_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_b2796526-c7a1-4d73-b81f-43a4c1fb6f5f_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1c5ba367-bcac-4bea-a256-3d4751e4a33e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_75e88d81-0012-4c6d-803e-81f2ef4851c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_50303cdf-a879-41ba-8b1f-02c1d5a7a33b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b31629e3-1972-411d-bc87-a2405747f306_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d16436ec-1e3f-4403-b829-4884d7bc1782_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_e8660a42-1e04-4800-bb9b-136fb43e07ad_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0def6237-f457-4457-b90c-a9e4f1bb5594_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1eef78f1-cb34-4a57-86e8-fc30016900f7_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a3aa999b-4ee3-4e69-8232-2dabd5c16f32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_83ade32c-b334-41aa-a7be-e43f1d9417d8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6bc01257-a542-43f4-b86c-2ffe9843d6f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_36178049-3c12-4377-b05c-d20a3f4ad4ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_03f1013d-917d-41ec-92f9-efeed927e45d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fair value of contingent consideration at acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5e0f091f-5a3c-4be5-8ef6-00de353945da_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability from business acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_6d50f4ff-aa11-4cac-ab29-8844bee6c792_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, long-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bd4cf67-2719-44ee-981b-19b097ecec4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_GuardantHealthIncMember_47f007b3-66d0-439e-ae26-7d3230222318_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc.</link:label>
    <link:label id="lab_gh_GuardantHealthIncMember_label_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthIncMember_documentation_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember" xlink:href="gh-20210930.xsd#gh_GuardantHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthIncMember" xlink:to="lab_gh_GuardantHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0572f8a0-0aed-4d33-a8d0-80cc25b7aa3a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_481c4786-1b79-4d6a-b2b4-4eba31995894_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0659eb82-1f4e-4729-9c7a-2df91a5d0adf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b414de-c003-4837-8c8b-63ac5939c946_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_ae043e45-683e-45ee-ae76-3bff9c44e5dd_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, patents allegedly infringed upon, number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_497834af-f070-469e-aee7-5bbf685d416b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_df78f3e9-7d22-466b-b6a7-579634b7a0af_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e2353e45-7b0d-408c-ba99-8b2d00133547_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fb4ae1a6-f95d-4ee8-83be-f2ca74b94639_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_70131d73-c243-438a-8ddc-a43446eebcf8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_702cd972-58b6-41e5-a212-7814131327d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_43671e2c-1001-4ddb-a9ca-c49ec8e7456b_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of fair value that is no less than internal rate of return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:to="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerAMember_5a970ce6-be3f-4497-8a82-e820293c612c_terseLabel_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_gh_CustomerAMember_label_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gh_CustomerAMember_documentation_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember" xlink:href="gh-20210930.xsd#gh_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerAMember" xlink:to="lab_gh_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b720f269-bdce-42b0-8fbe-3a5c09c2361e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f0a91e84-6af9-461b-b8b4-efc55845dad7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_604d20cf-1174-4acf-b35f-b3aa7dfd2a5b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_3ea85669-7ea7-4cf5-9cd7-4451cf73c5bf_totalLabel_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, cash and cash equivalents and debt securities available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:to="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_30c96022-cf00-43af-84a1-0b7bd8d63db4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4427af81-6c41-4a41-996b-e4ca1527d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodOneMember_c7bb0bd2-2c04-4251-a52d-c7ef138f2dd1_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_gh_ConversionPeriodOneMember_label_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember" xlink:href="gh-20210930.xsd#gh_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodOneMember" xlink:to="lab_gh_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6895a791-e0b2-4d65-89b4-5185e5ce4797_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_8e72bafa-4ad4-481e-aea1-f513802902fc_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_df362bea-e84e-46f2-9e78-9ba152bd827d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_7c65c0aa-8bd5-414e-bb94-733a17ae3ae3_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ada763c1-af1e-4641-b387-302ae6ea7be4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ff278706-277f-45e0-98c4-f647eb953eaf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Guardant Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ae7c4102-608f-4a3c-9f2c-46183a414325_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d12b69b1-12b0-4c1e-a590-b87a7b68f786_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_5480432b-a6ff-4668-9da7-96d0412208ee_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, redemption value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e8edbcfb-1c35-4fb9-9477-cd1b97d85d54_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_2064abdb-3dbf-473f-98b7-e430945421bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b1088f92-c3e8-459b-b24b-42bd5435048b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock unit vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_b240ac92-ed89-455a-8ba4-351d86a3056c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, short-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fe2ba385-fa50-4fc5-a65a-b05dd48f582e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_03b05737-ab95-4525-a30a-65cc53984e1e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_80ba2384-a79c-4437-bb92-be1c2e1f5da7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a86fb672-6367-4338-927c-f57f6f1e1f30_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberofPetitionsDenied_1b9de223-93ed-44b3-9041-d889811afe22_terseLabel_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions denied</link:label>
    <link:label id="lab_gh_NumberofPetitionsDenied_label_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Denied</link:label>
    <link:label id="lab_gh_NumberofPetitionsDenied_documentation_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Denied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsDenied"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPetitionsDenied" xlink:to="lab_gh_NumberofPetitionsDenied" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e49f4b0b-b484-4d13-b046-176a2d6fe85b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_5e408c8e-dfce-4399-b4fc-cac97b9185d1_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_adf35548-2d03-480e-a67e-c2a2ce4cb4ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4396503a-0ae6-40af-8e71-52907c96ee0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1ce2863a-9099-4e57-a5d6-4b1bb406f8cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bb56517f-d12f-4bc7-8cee-5a9843cd0b37_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_500b0d8c-94c5-495c-ade0-c0b1387a521e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_5348420e-88b2-439f-97ac-7a8b3c791402_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty obligations</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_86134498-a7c5-4616-b743-cf5194cb7e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3959f5f0-764c-4744-b6b1-353ddce7b5ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcb6df94-4902-408f-82bd-1f94902a8532_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8761b92d-3070-4f29-a042-3af8a4d7f6b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_245a9307-d114-49e9-b684-11ceb9ed0dce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_c5dd0ec7-aacc-49d4-a19d-be86c87b2b9e_terseLabel_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_1251fb10-2c92-4bf2-84c0-e449cd897cfd_verboseLabel_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_gh_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_gh_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_1dd955fc-d47b-4e75-bc7a-21e61ac6933f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_010e1050-bf4c-4fe2-ad16-a4784394cac8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_8a01a5ea-f420-410c-86aa-47e906a23fa3_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of joint venture threshold</link:label>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_label_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</link:label>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:to="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_e92c0e34-4b72-4b04-9377-dfc222f201ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets and capitalized license obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_56df9242-87a1-4ba8-9e76-df4993313893_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8481ddfc-fe8f-466f-86cc-a96c31197e6f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2aa630d-d614-4751-9613-a8a5a9562225_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_1e98945f-1e7a-47a3-8595-ae6c1ab9117a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a43649d4-9ab0-470f-8826-5d3a5289257a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9f15e638-73b2-44fa-8316-62effb682b40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a82f81a9-3cde-4cd9-8baa-0ac90fa58bee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2db0eb79-294a-41b8-8213-7d047812deaa_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_840d7c4f-296b-47c2-8a61-c9a9b4a78c56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_497f40ec-b321-4e26-b923-f3f7aaea3dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ec7f9f95-d30f-4f50-aa7c-9565481ff4cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_95679607-0e70-4769-9674-a21a90278030_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_ab8a34b5-0a1e-477d-9f82-ee65d6fb70b8_terseLabel_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and other assets due from a third-party</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss</link:label>
    <link:label id="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, Before Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:to="lab_gh_ContractualReceivablesBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_90a7e611-1fe3-4c85-b3db-cf6a4379ce23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_08002b25-7e8b-47e4-be87-367639d0215e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instrument Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6728ad08-e538-4401-88d5-f7db3e85a6ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_247220ee-500a-438f-b711-7e64825d415b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_85c15dcd-ccaf-4471-907c-59443d609426_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_22044db4-1b49-4e1b-b858-c3f608647afa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ConversionPeriodTwoMember_0e96b6af-ae44-45d8-9427-58dcfa19f10b_terseLabel_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_gh_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_gh_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_gh_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember" xlink:href="gh-20210930.xsd#gh_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ConversionPeriodTwoMember" xlink:to="lab_gh_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6245f616-95f8-4f32-bcbc-406b70e83f82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5100749e-c3a8-489c-a060-d0c599b0727f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_39726932-be7f-4ef8-9cd7-6d32f11bc506_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f086bd4a-8a2f-4bfe-9c05-4f0a50c047f1_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_391718ab-73ea-4a8b-8386-61e1817ad72b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_f4d06bc7-5a7c-434a-bfaa-748c6cba5c10_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_331eaa6a-7762-4b9d-b074-3dce7feeb7c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 3 - $200 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_192ab3ef-28f5-40c5-b39c-cef4b220ffdd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78cb833d-11ce-48ac-9d75-abffc1467666_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_c0552131-9814-46f4-bb70-137b91012cc4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3fc53c9c-cbd0-4595-9c50-28a7a34730bd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6435f562-bfb7-4648-940f-9ace8879427a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_4be8eae8-b6d6-4b9b-adb7-36be08e15528_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0eba913d-26b9-4a0c-9b41-65fb59422f3c_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_735e9a50-b220-4af6-af13-438ec41cef95_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_1c98f1a3-fe21-456f-85f5-a555778cc5fe_terseLabel_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accrued expenses</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_label_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_documentation_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:href="gh-20210930.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:to="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_ee47995d-a42e-41bc-b12c-fd1cfe09f3ee_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:href="gh-20210930.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:to="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1437eb67-ab13-4a35-8f52-8b56b32699f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_45ba2561-2a35-42b9-9aa4-08ce8352311a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bdbefe97-c0c0-43cb-9c02-6d89139fc99e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_b27912cf-1595-48aa-aa5f-0c90629c8a72_terseLabel_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_label_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</link:label>
    <link:label id="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_documentation_en-US" xlink:label="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:to="lab_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5d7df730-9cec-4013-a4e9-85a1ff8e45a4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_cd0a19b1-6c76-4250-a295-f3df27193687_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f0a3abf8-c6b3-46e2-89ef-b63fc18cdb6b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a64c9b02-2c8a-4289-8a60-28f7e58a33fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e9feb44-0e8a-46fd-b593-ad04079c4a4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium (discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_70f87f79-e427-48ad-9f1e-826e20c050d7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ce8bfd95-b1cd-4ad2-a07a-8ec6385ed931_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4ee11d23-8ae0-4752-9d23-96505e509017_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityIncentivePlanTrancheAxis_3722845a-6671-4120-8e7e-8868bb8e2517_terseLabel_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche [Axis]</link:label>
    <link:label id="lab_gh_EquityIncentivePlanTrancheAxis_label_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche [Axis]</link:label>
    <link:label id="lab_gh_EquityIncentivePlanTrancheAxis_documentation_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheAxis" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityIncentivePlanTrancheAxis" xlink:to="lab_gh_EquityIncentivePlanTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e7cddde3-6306-4012-90a0-babe034fdd6a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_b88fed2c-6938-45aa-88a9-7acb69282b44_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_811cdb6e-5afb-4d5e-9de6-2c730c3990f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5e982d2-ed59-494f-9fa4-ec95c77d9e30_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3acdd655-14d6-4e1e-8f1a-f226a64204f7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0047899c-59fe-4567-93c6-58ce05b0ecff_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7aab1f4f-714f-4434-ae9f-8937af7fecbc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberofPetitionsFiled_29cf469a-2951-487f-b5be-2b3753d642db_terseLabel_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_label_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_documentation_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPetitionsFiled" xlink:to="lab_gh_NumberofPetitionsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6e06ea60-5daf-4eb4-ae36-2caea99b5673_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_767aeb7d-2840-4c28-b089-7decb9dfd590_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f1f60dc7-9280-4006-a667-3f17e7e77edb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b890c0c8-8716-4511-8dcc-9d012477a8cb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_514a2635-0f22-498b-a65f-62f563d4fecb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2fdf3487-eace-4bc8-9ee4-e8c1c9c87dde_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_28bf51e9-6fb3-435c-b975-313f0d9bc43a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_9e754e54-4628-40de-9c07-8b789dc71118_terseLabel_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember" xlink:href="gh-20210930.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RedeemableNoncontrollingInterestMember" xlink:to="lab_gh_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b81a8cb7-05ed-4c45-96ef-cac9442aba2c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ce98bb6c-d269-4bbf-b40e-3d8dcffcb7ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_972b5625-9d2d-4a7e-91ce-16226514d447_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_38a79e5b-012d-44af-8d84-ee47110d14c4_terseLabel_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc.</link:label>
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_label_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_documentation_en-US" xlink:label="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:href="gh-20210930.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:to="lab_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b84aa3ac-bdf2-4211-84cf-d9bb7023227e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b8dd4b55-31bb-4300-8dfc-0f5a951b46e8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_600e3250-704a-49c5-9ad3-5a25218eef88_totalLabel_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing receivable, net amount, current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_label_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss Net, Current</link:label>
    <link:label id="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_documentation_en-US" xlink:label="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Receivables, After Allowance For Credit Loss Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:to="lab_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_153d341a-eb93-46a0-a7dc-64b7cb87dba3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_580c7b88-ace2-476f-8be2-fd2feefb835a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4013cce4-eba7-4b1c-8343-1758876dc27e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46ab3464-2acd-4145-8e6c-3bd7ef238ac8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ec188ce-3899-41ea-be7b-2ebc8bad4166_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_12799de7-cd52-47ed-9254-6f5a14531cc8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_804298fe-e968-417b-86ef-d2eca446cc80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss), net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a36c2683-e075-42e2-9f44-88da1763ebdd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0dd0b555-9c77-44a4-936d-567cce49dca8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1585e76b-f2c6-4bfe-9f92-7db759ed2a05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average derivative service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_dccc563d-0653-406c-935c-45e10717154b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a3eeccb9-e462-4746-bf82-2e082989245e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a23a2480-dd7c-49a9-b531-aeab5889ec97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_688c4dc9-20a1-4453-afb0-0f982fea3ad6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_322dc4bd-54de-49df-9697-92a40e12d76d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7c9bdc35-48f2-4006-bc32-0357fb4764e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_30176a3f-adf9-4368-99d5-cb8138deb202_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityIncentivePlanTrancheDomain_a46f27c8-c4a3-4a6c-941a-70981605da09_terseLabel_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche [Domain]</link:label>
    <link:label id="lab_gh_EquityIncentivePlanTrancheDomain_label_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche [Domain]</link:label>
    <link:label id="lab_gh_EquityIncentivePlanTrancheDomain_documentation_en-US" xlink:label="lab_gh_EquityIncentivePlanTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheDomain" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityIncentivePlanTrancheDomain" xlink:to="lab_gh_EquityIncentivePlanTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_85d25512-54a7-4c47-a03b-81ddeee309b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c321decc-a81e-45d4-ae52-15e1072303ee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f41f9cdf-49d5-435a-8df5-442cc81c7607_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6817929-315f-4838-ae3b-1afb89af9dd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_247595cb-b840-4534-9aef-9929b07d35cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ee674e1a-c0ef-4148-8495-591bfcf8d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3942ce0-a664-4fb3-8bda-1ec4e698155c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1968eb4a-5d3b-456f-9f95-77dbce96d7f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_881a4967-4ada-4607-a864-d84431a337ce_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9dfac16c-a43f-4fb0-af37-241731aec4c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d855bb03-fe0f-432a-9bd1-4da0971752c2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_680e9a6a-a998-42a3-a1dd-547b8adaf45f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_068a2ad9-7df8-4ab9-ad88-1a8953901814_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP obligation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c6e73a0d-156d-4629-aa88-bd059dc88045_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_54c2e451-ea0f-480d-95bb-7a34861c03dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a4e8c0e6-0b3a-417a-8baf-515be20f56e0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_e6839575-6fbb-454d-a2cc-e0db6bdcf47f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3d57ee8c-1ff3-4a56-b7c7-d9138bf0f8a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1a980902-d792-493c-a4eb-6686585ea90a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7c0e48b3-bf2f-42f7-a3e5-431cfd2a0f96_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_872df9ca-d7f5-4b6d-bf76-ecf484cdafb7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_25f95caf-7035-42b8-bd23-050b5069ec5e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_831f6b62-8733-428f-a73c-a9e8bbdb26a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a349596b-2ce6-4c1f-a2b3-fb7205207ddd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ec7dd232-7d5a-430c-acac-230bdbeb7d8b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_11b75898-d296-4f31-9faf-6d8aea13bb1e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_37935905-4379-45e7-96b5-01c99bb0ec41_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_74cd3e8c-e017-4f0a-b4dd-deb5e14d1ded_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5019c1ec-c507-45d5-91b4-cfad23a6b0d9_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_23e830c3-ff78-4da2-a7a9-a86759f16384_verboseLabel_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Incentive Award Plan</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_label_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember" xlink:href="gh-20210930.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_A2018IncentiveAwardPlanMember" xlink:to="lab_gh_A2018IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_105a103e-3509-4bf9-be17-d6439e95ee0f_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_b62f63f9-105d-4216-b210-f7153df4ec8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_2df7ebb4-02f7-44b8-9cfe-27497592fdfa_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage for individual's combined voting power triggering five year option term</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b1342841-eb47-478c-b516-f6370be5e915_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_782b0a14-05e8-468d-acd5-bc285e7834a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a5665dbd-7e80-454d-a49f-5f0c24759027_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5bf0a84a-7464-44e5-8130-9d82a74ee878_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September&#160;30, 2021, and December&#160;31, 2020; 101,623,257 and 100,213,985 shares issued and outstanding as of September&#160;30, 2021, and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_588688ad-f7c7-4ebf-89b3-fae74daa1741_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock exercised early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:href="gh-20210930.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:to="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2fadc79b-bb8b-4a92-abf1-59020d8a1517_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_cd9a2b66-2e82-4d09-ae6c-8fbf2d0f268a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_495e10c6-5faa-412d-a073-6812fa82cbe6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e86f59f3-a133-4e75-9751-7ebcff0f3a34_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_36b8910c-a59d-41c2-9ff1-8215e2833994_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount, net of amortization</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_57c3c3c7-7b73-4d8a-b24f-620f45616e90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_616ea3d2-43f3-4195-bfda-aa643b59ca92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a94400c-955b-456b-9a6d-a6e2e415583f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gh-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c05b010-6a26-4dc5-b4f3-1c40100e4cb7,g:5f279c63-27a5-4218-aacc-107e627597d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:type="simple" xlink:href="gh-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2d01740d-0822-4176-9b36-c39b261f114c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentType_2d01740d-0822-4176-9b36-c39b261f114c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b0e79d16-f719-4f71-a13a-807709ac4cab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentQuarterlyReport_b0e79d16-f719-4f71-a13a-807709ac4cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6c5d9e7d-17a6-448d-90c6-31abafaf8ccc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentPeriodEndDate_6c5d9e7d-17a6-448d-90c6-31abafaf8ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_717fef55-5a98-4899-a1ee-0d52194cf1b6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentTransitionReport_717fef55-5a98-4899-a1ee-0d52194cf1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_96fc1ee3-6b12-4d44-87a9-a669a726d160" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityFileNumber_96fc1ee3-6b12-4d44-87a9-a669a726d160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_19db2f1e-82fc-4717-9ac2-0cdaa23caf38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityRegistrantName_19db2f1e-82fc-4717-9ac2-0cdaa23caf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fa695cca-59b3-435e-aa30-6e1d9e0a1335" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fa695cca-59b3-435e-aa30-6e1d9e0a1335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_06d4866b-fa95-42b0-a785-7d818960c895" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityTaxIdentificationNumber_06d4866b-fa95-42b0-a785-7d818960c895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_66c7a055-d196-4747-a356-e7ad1fe2b24a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityAddressAddressLine1_66c7a055-d196-4747-a356-e7ad1fe2b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7ef5ad8f-f8ee-454c-b28d-45767da6b937" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityAddressCityOrTown_7ef5ad8f-f8ee-454c-b28d-45767da6b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cbc5731c-fc3c-433b-8dcb-0a3a20609e7e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityAddressStateOrProvince_cbc5731c-fc3c-433b-8dcb-0a3a20609e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_626cfaab-1d32-4da7-9905-efbb75c40b3b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityAddressPostalZipCode_626cfaab-1d32-4da7-9905-efbb75c40b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_01dc776e-3397-4899-9f66-b527317addce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_CityAreaCode_01dc776e-3397-4899-9f66-b527317addce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aa485ce5-4e05-4d98-ac8c-d26cf3cea596" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_LocalPhoneNumber_aa485ce5-4e05-4d98-ac8c-d26cf3cea596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_98ebd830-1a35-4044-8dc1-81418a356ac0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_Security12bTitle_98ebd830-1a35-4044-8dc1-81418a356ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7b656c50-a026-4a43-93bc-8ce327ecf09c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_TradingSymbol_7b656c50-a026-4a43-93bc-8ce327ecf09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cc0675df-e9ee-4e78-8a5c-6673229b457c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_SecurityExchangeName_cc0675df-e9ee-4e78-8a5c-6673229b457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bdff01ab-92b1-48e7-92ed-ac93f407fe9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityCurrentReportingStatus_bdff01ab-92b1-48e7-92ed-ac93f407fe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2e58f12d-2da4-4e75-bd6b-e605c89b8981" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityInteractiveDataCurrent_2e58f12d-2da4-4e75-bd6b-e605c89b8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7050fddf-fdc2-4601-abe2-745577b6e802" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityFilerCategory_7050fddf-fdc2-4601-abe2-745577b6e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ef9ace50-7b1b-4999-a02f-7c5a5e7bb182" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntitySmallBusiness_ef9ace50-7b1b-4999-a02f-7c5a5e7bb182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_056c8c60-f661-45a3-a28a-9f687e20b125" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityEmergingGrowthCompany_056c8c60-f661-45a3-a28a-9f687e20b125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9b01087b-93a2-4e62-bf04-4db4ecb9e765" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityShellCompany_9b01087b-93a2-4e62-bf04-4db4ecb9e765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e91fa4d2-f3ec-42ca-9842-da58579cc37e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e91fa4d2-f3ec-42ca-9842-da58579cc37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6b804d20-e9fa-4e2e-b750-3175fb3eb9cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_AmendmentFlag_6b804d20-e9fa-4e2e-b750-3175fb3eb9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ceb10947-bf5c-40f0-b55d-2b56757877cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentFiscalYearFocus_ceb10947-bf5c-40f0-b55d-2b56757877cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e5dad16-cc8f-4171-ad75-f65b02618b1e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e5dad16-cc8f-4171-ad75-f65b02618b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a81d3794-6d25-445b-8749-17ad62980fa0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_EntityCentralIndexKey_a81d3794-6d25-445b-8749-17ad62980fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_58d05d85-1717-4a8c-99fd-cc69a6b4d235" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_562149be-733a-4db5-94ad-538dd89defed" xlink:to="loc_dei_CurrentFiscalYearEndDate_58d05d85-1717-4a8c-99fd-cc69a6b4d235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0bb69255-de0b-485b-9469-e223d5e22d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bb69255-de0b-485b-9469-e223d5e22d02" xlink:to="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83e27d69-93a1-4a9b-84d9-5b141cbf1b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83e27d69-93a1-4a9b-84d9-5b141cbf1b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c910e718-6ab1-4993-af8e-fc39ed0f0429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c910e718-6ab1-4993-af8e-fc39ed0f0429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1c45ed22-2e1c-462b-88e0-cd3edc95051f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1c45ed22-2e1c-462b-88e0-cd3edc95051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_589a6400-19c6-43ef-800f-9601b516ed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_InventoryNet_589a6400-19c6-43ef-800f-9601b516ed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7bfb088-be82-4314-9b39-d8605376b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7bfb088-be82-4314-9b39-d8605376b08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9d0d0815-d380-4ec2-aa2a-91290201b990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6f5cf796-887e-4de9-b9ad-d79b67085b81" xlink:to="loc_us-gaap_AssetsCurrent_9d0d0815-d380-4ec2-aa2a-91290201b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5613cdc7-2616-427b-9b6e-24f1d59798b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5613cdc7-2616-427b-9b6e-24f1d59798b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7675a3ad-40ef-452d-9343-d39ab6fd7bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7675a3ad-40ef-452d-9343-d39ab6fd7bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95b14ab7-0f00-446b-a675-944fe005f617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95b14ab7-0f00-446b-a675-944fe005f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d34a2169-bcdc-485b-8a1b-10c34d148b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d34a2169-bcdc-485b-8a1b-10c34d148b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1727babf-b4e6-429c-ab1e-91ab8612e239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_Goodwill_1727babf-b4e6-429c-ab1e-91ab8612e239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ef836c6e-1765-4c71-9830-49a028194212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ef836c6e-1765-4c71-9830-49a028194212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9fd7328c-b0eb-463a-9c2e-8bdb1098b946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85478d9d-f148-4ca2-ae5e-72ae676b6013" xlink:to="loc_us-gaap_Assets_9fd7328c-b0eb-463a-9c2e-8bdb1098b946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bb69255-de0b-485b-9469-e223d5e22d02" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_21240197-54aa-491d-8971-dc42405ecd02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:to="loc_us-gaap_AccountsPayableCurrent_21240197-54aa-491d-8971-dc42405ecd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_c0a2a8ae-922e-452c-9f91-3496ab5616ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_c0a2a8ae-922e-452c-9f91-3496ab5616ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44a7c6b3-73ef-430e-9c42-6224941040e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44a7c6b3-73ef-430e-9c42-6224941040e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_332a277d-c513-4b3a-89dd-2243e009c07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_332a277d-c513-4b3a-89dd-2243e009c07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bee26214-c9a6-4ebe-a46f-ab05dba5fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16779e60-6b5d-4e23-bb07-62d90ccfb429" xlink:to="loc_us-gaap_LiabilitiesCurrent_bee26214-c9a6-4ebe-a46f-ab05dba5fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_47d146c6-7c83-4dd3-8c2d-2fbc3f01356c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_47d146c6-7c83-4dd3-8c2d-2fbc3f01356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a74ad32d-5be8-4475-aa22-2afd2787c658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a74ad32d-5be8-4475-aa22-2afd2787c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_71ac5ee5-9c51-4b36-8d57-cd4f7a22f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_71ac5ee5-9c51-4b36-8d57-cd4f7a22f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ec91ff42-d144-4611-9596-a5161398e157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_Liabilities_ec91ff42-d144-4611-9596-a5161398e157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7d41b1b2-ccf8-4ddb-b534-40ed83428597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7d41b1b2-ccf8-4ddb-b534-40ed83428597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_7b48598e-ccfb-426a-b3d5-e9e5ce039c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:to="loc_us-gaap_CommonStockValueOutstanding_7b48598e-ccfb-426a-b3d5-e9e5ce039c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6f4765ea-7002-4485-bbc2-ec584a701762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6f4765ea-7002-4485-bbc2-ec584a701762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d780239-fe04-4cee-8a63-864456314a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d780239-fe04-4cee-8a63-864456314a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8aab2591-cc81-4eb9-867d-255c32915013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8aab2591-cc81-4eb9-867d-255c32915013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de19e7d5-3062-4e1e-9231-12f9fcb7545b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a369a159-10e9-4138-b996-b61e5620f729" xlink:to="loc_us-gaap_StockholdersEquity_de19e7d5-3062-4e1e-9231-12f9fcb7545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a71ea44a-3c3f-4699-bbe8-01195b77e7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fa227f7-f173-4769-8d50-b0828490f776" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a71ea44a-3c3f-4699-bbe8-01195b77e7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0658e52-7fae-4db8-80e3-b95e2b4487c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0658e52-7fae-4db8-80e3-b95e2b4487c4" xlink:to="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:to="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_362afdeb-d14e-49b6-b37c-9b80a07c62d6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d4ba9600-f1e9-4d74-90ba-e0cd4662a26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_93c2de67-f852-44e1-8cbc-af7fd429c23c" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d4ba9600-f1e9-4d74-90ba-e0cd4662a26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0fb93e29-a360-4081-9bf0-5c00aabde153" xlink:to="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1b498ce-f392-452a-9121-df398908e091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1b498ce-f392-452a-9121-df398908e091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99cc3b9a-972c-4d6a-92c1-c7b52e86479e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99cc3b9a-972c-4d6a-92c1-c7b52e86479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0cd48137-0400-42b6-9c9e-43e8ad873df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0cd48137-0400-42b6-9c9e-43e8ad873df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23b91801-7459-40b0-803f-ac4c0dead79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_CommonStockSharesIssued_23b91801-7459-40b0-803f-ac4c0dead79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8196ffb9-be08-427b-8c9f-86cc9f7a90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_Assets_8196ffb9-be08-427b-8c9f-86cc9f7a90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ee012a2-d329-4d28-93f8-7d27cad532a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37ae4f1e-7d25-4581-89e9-e88f9f3e9b0a" xlink:to="loc_us-gaap_Liabilities_5ee012a2-d329-4d28-93f8-7d27cad532a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_505fde24-919b-4af8-8662-edf9cbff4d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_RevenuesAbstract_505fde24-919b-4af8-8662-edf9cbff4d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_fe64336b-5d00-4a98-ae2d-7f4e06e8a6a9" xlink:href="gh-20210930.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_505fde24-919b-4af8-8662-edf9cbff4d75" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_fe64336b-5d00-4a98-ae2d-7f4e06e8a6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices_30f90eca-3783-477a-9c46-d9ba861c57e9" xlink:href="gh-20210930.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_505fde24-919b-4af8-8662-edf9cbff4d75" xlink:to="loc_gh_RevenuefromDevelopmentServices_30f90eca-3783-477a-9c46-d9ba861c57e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ed5e4b44-085c-45e5-931c-8d3c35dad4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_505fde24-919b-4af8-8662-edf9cbff4d75" xlink:to="loc_us-gaap_Revenues_ed5e4b44-085c-45e5-931c-8d3c35dad4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_d2c5fce5-1d22-445e-88d7-13f49d95c9e1" xlink:href="gh-20210930.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_d2c5fce5-1d22-445e-88d7-13f49d95c9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices_7090dc21-2c9c-45ca-8a80-044da5fb35e5" xlink:href="gh-20210930.xsd#gh_CostofDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_gh_CostofDevelopmentServices_7090dc21-2c9c-45ca-8a80-044da5fb35e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_711d5f55-d451-4ed0-a634-73194b41d4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_711d5f55-d451-4ed0-a634-73194b41d4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_ca540550-2913-4423-99bb-283e97dff8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_us-gaap_SellingAndMarketingExpense_ca540550-2913-4423-99bb-283e97dff8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_22362044-087f-4fed-9bd4-debd393d7201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_22362044-087f-4fed-9bd4-debd393d7201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b67d89cf-36ab-4a53-885a-4a1f5e888b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_8baff2c0-d39f-49f7-b9b2-4deffc4e15f8" xlink:to="loc_us-gaap_CostsAndExpenses_b67d89cf-36ab-4a53-885a-4a1f5e888b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58746ff9-7e2e-422d-b75b-8769dfca0a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_OperatingIncomeLoss_58746ff9-7e2e-422d-b75b-8769dfca0a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7303e9ad-9e30-4d72-8252-ca1e5a94af6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7303e9ad-9e30-4d72-8252-ca1e5a94af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4446b335-40b4-43c4-8920-29519d975ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_InterestExpense_4446b335-40b4-43c4-8920-29519d975ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c4af7d25-5f16-4c19-ac6c-87e084a34dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c4af7d25-5f16-4c19-ac6c-87e084a34dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b916fb0-d4b8-4ae3-94ab-ad156f6b84e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b916fb0-d4b8-4ae3-94ab-ad156f6b84e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c4b396d3-2afb-4f42-8c74-7849f64cfc63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c4b396d3-2afb-4f42-8c74-7849f64cfc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7d766f90-5121-4e71-a936-6121d899738e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_ProfitLoss_7d766f90-5121-4e71-a936-6121d899738e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_260ced00-efb5-4563-8760-b61eeb80f7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_260ced00-efb5-4563-8760-b61eeb80f7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7c8538d9-319b-4412-a91f-68d3aaf85f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7c8538d9-319b-4412-a91f-68d3aaf85f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_78b3c3a2-8b48-4387-b63f-42b5ff036289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_78b3c3a2-8b48-4387-b63f-42b5ff036289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_299d14a0-21c3-42d8-8587-858419fe7371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_EarningsPerShareBasic_299d14a0-21c3-42d8-8587-858419fe7371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e681f74c-71bd-4b4f-977c-5fd746019543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e681f74c-71bd-4b4f-977c-5fd746019543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82196865-b1e8-48ba-9594-70c1ef50c90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82196865-b1e8-48ba-9594-70c1ef50c90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b91a0a0-8625-456e-b60f-305c821342c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ad6d6456-0f0b-4fa2-9f13-06ab8f92eac9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b91a0a0-8625-456e-b60f-305c821342c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_64932401-2414-4511-b221-47f8af885d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:to="loc_us-gaap_ProfitLoss_64932401-2414-4511-b221-47f8af885d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff4b6188-2cdd-4121-8e97-1a22c5697919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff4b6188-2cdd-4121-8e97-1a22c5697919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_85766b7f-7d59-4084-9502-5748951c8993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff4b6188-2cdd-4121-8e97-1a22c5697919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_85766b7f-7d59-4084-9502-5748951c8993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_402dc09a-9582-466f-a1e5-7e34b9bb1aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff4b6188-2cdd-4121-8e97-1a22c5697919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_402dc09a-9582-466f-a1e5-7e34b9bb1aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ddce9bc-907d-49d1-8825-f2eb32dbcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff4b6188-2cdd-4121-8e97-1a22c5697919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ddce9bc-907d-49d1-8825-f2eb32dbcd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94d24458-a9b0-4975-8a66-f31280fee5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94d24458-a9b0-4975-8a66-f31280fee5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_abf3c697-6399-4314-8ad8-83a35f097bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_abf3c697-6399-4314-8ad8-83a35f097bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_262d59cb-73cb-4d20-aebc-081569b5dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_379180f7-8394-4cf1-b7a1-ee936ebaf154" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_262d59cb-73cb-4d20-aebc-081569b5dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7bfe963f-38ee-4dce-9e76-c2821743c188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7bfe963f-38ee-4dce-9e76-c2821743c188" xlink:to="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a69d4fe3-9d3c-4845-a77e-73c98290ae52" xlink:to="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_4999a43e-e9d6-4871-bcf9-c5684aab69c2" xlink:href="gh-20210930.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_4999a43e-e9d6-4871-bcf9-c5684aab69c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_027c4d30-63d6-4cf4-9718-a7f4f39b1037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_CommonStockMember_027c4d30-63d6-4cf4-9718-a7f4f39b1037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fdad09a7-d75a-4399-8078-d272d5fc8a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fdad09a7-d75a-4399-8078-d272d5fc8a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88bd9afe-8005-4349-ab31-4f241edf9061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88bd9afe-8005-4349-ab31-4f241edf9061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1714810b-4c88-45cd-a809-c9af4abba2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08d29898-bf8a-4123-97e6-eb46a0dc7984" xlink:to="loc_us-gaap_RetainedEarningsMember_1714810b-4c88-45cd-a809-c9af4abba2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3866bfa7-607f-433d-8ea7-0a4cb28f036a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_663a071c-9b42-4b60-92fd-e639584c428a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_720a263b-57b6-4eff-9e0a-dc9cb8ad77fc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_663a071c-9b42-4b60-92fd-e639584c428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_de969989-74c1-4371-89f8-e6530af008a2" xlink:to="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_cb98ed40-4cca-4929-a0cf-9470b5a90277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_cb98ed40-4cca-4929-a0cf-9470b5a90277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_2b92205d-992f-45ec-8041-d36b888063fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_2b92205d-992f-45ec-8041-d36b888063fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_996eef9a-7957-4311-bc97-46039d9d79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9e4f4ddd-764e-423c-818e-e809c4118c27" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_996eef9a-7957-4311-bc97-46039d9d79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eed7f472-4b73-4562-bf38-1ef894cfa625" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bed95d32-ceb0-46e4-9da9-b5d8e3c03131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_SharesOutstanding_bed95d32-ceb0-46e4-9da9-b5d8e3c03131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c827b3f-ab60-4288-b684-fa7f9fe66d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockholdersEquity_1c827b3f-ab60-4288-b684-fa7f9fe66d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_e12060f7-b8ba-43d0-89c0-a9d03ec9ba59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_e12060f7-b8ba-43d0-89c0-a9d03ec9ba59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1eededc3-3ca5-4766-b13b-7b6adcc631e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1eededc3-3ca5-4766-b13b-7b6adcc631e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2dcce290-db85-4d11-b538-cc9b77ad8acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2dcce290-db85-4d11-b538-cc9b77ad8acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_148829e7-b596-43a4-ba74-28de1bde8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_148829e7-b596-43a4-ba74-28de1bde8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_137bd4aa-690a-4504-9dba-0d79b24326bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_137bd4aa-690a-4504-9dba-0d79b24326bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e64568a-cdf9-4b80-8ad9-6fc12e0030a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e64568a-cdf9-4b80-8ad9-6fc12e0030a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_286b290a-7a19-4878-9524-92c98f2ef143" xlink:href="gh-20210930.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_286b290a-7a19-4878-9524-92c98f2ef143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5f84c9cb-ddca-45a5-b8af-8baa4c1467a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5f84c9cb-ddca-45a5-b8af-8baa4c1467a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea0436e3-2288-4b01-8501-db028d6de362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea0436e3-2288-4b01-8501-db028d6de362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d8b8fe34-db4c-48aa-a635-02d91cd7cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d8b8fe34-db4c-48aa-a635-02d91cd7cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_892f7257-1757-48d9-bf45-2cf6b81f23d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_892f7257-1757-48d9-bf45-2cf6b81f23d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34cd8f20-84df-4517-84b5-f249af667338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34cd8f20-84df-4517-84b5-f249af667338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_21b03bb9-d62a-4c70-a690-8968413cdcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_ProfitLoss_21b03bb9-d62a-4c70-a690-8968413cdcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_da0d2bb0-d789-47f9-8eb7-0db7f6512a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_SharesOutstanding_da0d2bb0-d789-47f9-8eb7-0db7f6512a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ce52f63f-d38a-4dd6-a5c2-643bea48a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85e7943a-632c-4158-8a7f-adc76d3b29fc" xlink:to="loc_us-gaap_StockholdersEquity_ce52f63f-d38a-4dd6-a5c2-643bea48a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c9b611a-3bea-4d48-88b0-8d988de3db59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_449f5195-8cea-4286-a82c-3a49c2eadf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c9b611a-3bea-4d48-88b0-8d988de3db59" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_449f5195-8cea-4286-a82c-3a49c2eadf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4802a524-fefd-49a1-b3ea-0356982e82bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4802a524-fefd-49a1-b3ea-0356982e82bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_46c99287-687d-478b-bc31-c7c49ac6f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4802a524-fefd-49a1-b3ea-0356982e82bb" xlink:to="loc_us-gaap_ProfitLoss_46c99287-687d-478b-bc31-c7c49ac6f8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4802a524-fefd-49a1-b3ea-0356982e82bb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2a461a07-a96a-4385-9ef6-cd01ddbdf6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2a461a07-a96a-4385-9ef6-cd01ddbdf6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonCashOperatingLeaseCosts_f3719bf7-e319-4716-8aeb-5c3b2b3df06b" xlink:href="gh-20210930.xsd#gh_NonCashOperatingLeaseCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_gh_NonCashOperatingLeaseCosts_f3719bf7-e319-4716-8aeb-5c3b2b3df06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_c6a5b620-3d71-4940-a515-682e7217c5f4" xlink:href="gh-20210930.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_c6a5b620-3d71-4940-a515-682e7217c5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4cb9a74-330f-4f06-b31e-53980b675d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4cb9a74-330f-4f06-b31e-53980b675d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_09ab0fd2-698d-4f05-b8b2-a662c5d3f1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_ShareBasedCompensation_09ab0fd2-698d-4f05-b8b2-a662c5d3f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_192166e9-a675-4095-b6fc-bb7b62d4424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_192166e9-a675-4095-b6fc-bb7b62d4424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5f7c32f5-5b7c-4e39-b1a2-ccb41e41ed25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5f7c32f5-5b7c-4e39-b1a2-ccb41e41ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_50991bee-ae5f-4f8f-a8ec-bbcf59b351d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_50991bee-ae5f-4f8f-a8ec-bbcf59b351d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb0dc02e-616f-4536-be72-efa6b77c181a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_47acdf51-a9b6-4d65-b858-038b8c80e78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_47acdf51-a9b6-4d65-b858-038b8c80e78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c2612485-b134-409d-81b0-02b6d34362ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c2612485-b134-409d-81b0-02b6d34362ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22fac0ee-c2e6-4288-8771-68aa5bf9998f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22fac0ee-c2e6-4288-8771-68aa5bf9998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_462d7462-7246-4b04-b33a-683b9659e4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_462d7462-7246-4b04-b33a-683b9659e4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5555088-f66f-40f1-9490-07a47609510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5555088-f66f-40f1-9490-07a47609510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_4bf0e72f-d8fb-4228-9ab4-13fcf5146d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_4bf0e72f-d8fb-4228-9ab4-13fcf5146d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4aa3bdda-8ad7-4518-ac99-43f5278388b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4aa3bdda-8ad7-4518-ac99-43f5278388b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_f5dddcfb-ce3b-4d58-b97d-5fd63d8660a4" xlink:href="gh-20210930.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_f5dddcfb-ce3b-4d58-b97d-5fd63d8660a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bd03a55d-057b-4cd8-8c56-d607c3e5c861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_56ac0e4e-124c-4a11-9daa-d07996184137" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bd03a55d-057b-4cd8-8c56-d607c3e5c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fcf81df-7da8-48ee-9ed0-d02d27630d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4802a524-fefd-49a1-b3ea-0356982e82bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fcf81df-7da8-48ee-9ed0-d02d27630d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_57559f93-9fc3-4b09-aaf5-0d26d6bdce02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_57559f93-9fc3-4b09-aaf5-0d26d6bdce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cbd4b1eb-1405-46f7-9512-1c910c7c3923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cbd4b1eb-1405-46f7-9512-1c910c7c3923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_11e5f3eb-7ef1-409b-81e1-3244a5046f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_11e5f3eb-7ef1-409b-81e1-3244a5046f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8127892-28e4-44c7-8e30-c440b41c06ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8127892-28e4-44c7-8e30-c440b41c06ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f72714e1-73a3-457f-88ba-723f783bc050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f72714e1-73a3-457f-88ba-723f783bc050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a5bece4-ad58-40c6-8fe2-26856927abe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c6a34fba-1420-4c8e-8764-a4ceec9db973" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a5bece4-ad58-40c6-8fe2-26856927abe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5f126d3a-b000-4a80-a555-0baa5f920af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5f126d3a-b000-4a80-a555-0baa5f920af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4975cecf-abae-429b-bb1d-be4117b32b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4975cecf-abae-429b-bb1d-be4117b32b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_bebb211a-8ae9-421c-9459-dc9d66fb843b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_ProceedsFromStockPlans_bebb211a-8ae9-421c-9459-dc9d66fb843b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ce0cb2b-1b64-42cd-b578-45a177babe62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ce0cb2b-1b64-42cd-b578-45a177babe62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_704cab94-b09e-4f73-90c9-7ad85515f7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_704cab94-b09e-4f73-90c9-7ad85515f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e546150d-cdb8-4cf3-8bfc-4f0ade4353b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e546150d-cdb8-4cf3-8bfc-4f0ade4353b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2cb73d91-d509-49e8-84e4-733b43fb42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2cb73d91-d509-49e8-84e4-733b43fb42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a345204-1454-4adc-973b-7294e043a8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8df621b1-d6af-484b-b174-39d926b3c717" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a345204-1454-4adc-973b-7294e043a8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b17cf46-64a0-4a12-a101-090a00baf0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b17cf46-64a0-4a12-a101-090a00baf0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_37774eb5-d79c-4782-a65e-a5c2ee6beae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_37774eb5-d79c-4782-a65e-a5c2ee6beae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0c398e-35d4-413b-92dd-03d3c4f8c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0c398e-35d4-413b-92dd-03d3c4f8c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fda69879-8ea5-480c-bbc9-e8b27de55e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fda69879-8ea5-480c-bbc9-e8b27de55e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_bffaa547-c53b-4cdf-b8d9-ac4dc8b0007e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_bffaa547-c53b-4cdf-b8d9-ac4dc8b0007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f731b896-7fb3-471d-b049-f0342ea8047e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_bffaa547-c53b-4cdf-b8d9-ac4dc8b0007e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f731b896-7fb3-471d-b049-f0342ea8047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fcb70580-daa1-4a20-9ba6-84cd70c491d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fcb70580-daa1-4a20-9ba6-84cd70c491d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_da26e961-a52e-4a10-a1e9-bfd496f085eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fcb70580-daa1-4a20-9ba6-84cd70c491d3" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_da26e961-a52e-4a10-a1e9-bfd496f085eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecuritiesFVNIIncurredButNotYetPaid_f20ca67c-93b9-4db4-b43a-e4a9dce90e80" xlink:href="gh-20210930.xsd#gh_EquitySecuritiesFVNIIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fcb70580-daa1-4a20-9ba6-84cd70c491d3" xlink:to="loc_gh_EquitySecuritiesFVNIIncurredButNotYetPaid_f20ca67c-93b9-4db4-b43a-e4a9dce90e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases_3831c3ee-ef88-4b8e-8ada-66e19de1a99f" xlink:href="gh-20210930.xsd#gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fcb70580-daa1-4a20-9ba6-84cd70c491d3" xlink:to="loc_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases_3831c3ee-ef88-4b8e-8ada-66e19de1a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_551ef1a3-7ee8-43bc-950d-71ed36e17a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_455e5891-4c93-4bde-ac37-0fc59e9240ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_551ef1a3-7ee8-43bc-950d-71ed36e17a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e363a845-1aa1-4786-bc3f-b852f6bc4f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_551ef1a3-7ee8-43bc-950d-71ed36e17a3e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e363a845-1aa1-4786-bc3f-b852f6bc4f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_50b97280-0737-4001-8673-abb04e3c16ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_551ef1a3-7ee8-43bc-950d-71ed36e17a3e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_50b97280-0737-4001-8673-abb04e3c16ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c15fec88-9fea-4aae-b52e-d31b47a491ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_551ef1a3-7ee8-43bc-950d-71ed36e17a3e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c15fec88-9fea-4aae-b52e-d31b47a491ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gh-20210930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c45766ab-d82c-4faa-80a6-f245c0763ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_03f9bf6c-8c7f-412c-a1f3-02ea1af272fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c45766ab-d82c-4faa-80a6-f245c0763ac7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_03f9bf6c-8c7f-412c-a1f3-02ea1af272fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11693b32-d2f6-4f11-a6cb-696851e59129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11693b32-d2f6-4f11-a6cb-696851e59129" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e49f251-a1a5-4717-8b5f-afd00bebf80f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_ca744c32-fd1f-469f-bb21-0887156a7e59" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_72e9919e-4c00-4b66-9d49-bdcf2ad603b8" xlink:to="loc_gh_GuardantHealthAMEAIncMember_ca744c32-fd1f-469f-bb21-0887156a7e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_2616d1ef-9bda-4b2c-af26-0245d64ad6fa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b212f782-25e4-4d73-923f-d321cfd9c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e6b6743-9361-4058-8509-5174af38bfed" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b212f782-25e4-4d73-923f-d321cfd9c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f5f4602c-5e7f-48bb-8161-7668df28aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_079437d4-14ba-429d-abda-788c8dfbfe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f5f4602c-5e7f-48bb-8161-7668df28aa9c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_079437d4-14ba-429d-abda-788c8dfbfe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a20a873-46ec-497d-81ec-a8b139f550fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a20a873-46ec-497d-81ec-a8b139f550fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8ee4a0a6-7ecf-425e-a131-8b06aab5ee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_UseOfEstimates_8ee4a0a6-7ecf-425e-a131-8b06aab5ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_8294cec6-ddee-4845-9328-d468dbf0be28" xlink:href="gh-20210930.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_8294cec6-ddee-4845-9328-d468dbf0be28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fcbafa36-2bd2-41d9-a241-0f1b8f791645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fcbafa36-2bd2-41d9-a241-0f1b8f791645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_23a7d08e-a185-4c3c-ae80-97eea29b1a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_23a7d08e-a185-4c3c-ae80-97eea29b1a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_4559eb96-dbde-4e52-ae01-1f3a879bd328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_4559eb96-dbde-4e52-ae01-1f3a879bd328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock_6b73e9a4-f83d-4574-b3b6-a90be0a639f1" xlink:href="gh-20210930.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_gh_AssetAcquisitionPolicyTextBlock_6b73e9a4-f83d-4574-b3b6-a90be0a639f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e8af8772-94ae-48c5-a141-9431ac5e6bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e8af8772-94ae-48c5-a141-9431ac5e6bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1cb7befc-9b86-485c-8467-6704f151176f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1cb7befc-9b86-485c-8467-6704f151176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_fd2abb0d-2dcc-4049-af23-a16d0a4b209b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_DebtPolicyTextBlock_fd2abb0d-2dcc-4049-af23-a16d0a4b209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c0d5bada-dc99-4ede-b797-e311426ad623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c0d5bada-dc99-4ede-b797-e311426ad623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_d82e4a2d-2136-4ff5-b2d8-c2457a075ac3" xlink:href="gh-20210930.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_d82e4a2d-2136-4ff5-b2d8-c2457a075ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServicesPolicyTextBlock_5107908d-7f29-4185-8973-84ec35585b32" xlink:href="gh-20210930.xsd#gh_CostofDevelopmentServicesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_gh_CostofDevelopmentServicesPolicyTextBlock_5107908d-7f29-4185-8973-84ec35585b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_edd69215-f0a2-4740-ba6a-0275d6f671bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_edd69215-f0a2-4740-ba6a-0275d6f671bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14765161-e7b9-428f-8ebe-69266c631628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14765161-e7b9-428f-8ebe-69266c631628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e587bda5-6d1c-4992-a90d-ad0a50c7fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e587bda5-6d1c-4992-a90d-ad0a50c7fd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c366274f-bd06-4e74-b307-4e1671a3d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c366274f-bd06-4e74-b307-4e1671a3d3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_deb6c7a6-fc31-482d-bc0a-0bfca09a5bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e496e9c-e481-45a4-bce9-2559adc17e70" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_deb6c7a6-fc31-482d-bc0a-0bfca09a5bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6284703c-ecb4-4e8d-8002-fc35c58366d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e1e05a09-34bd-4b2e-b8c3-f22c9dd123d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6284703c-ecb4-4e8d-8002-fc35c58366d2" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e1e05a09-34bd-4b2e-b8c3-f22c9dd123d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_0ab68657-5c0c-40f4-9cda-6c2838a32ac3" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6284703c-ecb4-4e8d-8002-fc35c58366d2" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock_0ab68657-5c0c-40f4-9cda-6c2838a32ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c83c2be-60b1-4202-878c-d326cb13cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c83c2be-60b1-4202-878c-d326cb13cf2a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_503b9ed7-d140-4036-9dd1-a508b760f133" xlink:to="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_863d242e-a76b-4045-97e8-49559fba9ad5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:to="loc_srt_MinimumMember_863d242e-a76b-4045-97e8-49559fba9ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f6c3b2e-3e99-4fbd-b161-c94f7c039b27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ff75fc7-3a18-4a32-9cad-23d5eb20918a" xlink:to="loc_srt_MaximumMember_8f6c3b2e-3e99-4fbd-b161-c94f7c039b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66375da2-c9de-4e5c-9b71-b6e5ff6d5bca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b428a3b0-635e-485c-aa0c-f6ef99720e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79feef85-1f1f-4cd8-a68f-5b1be9ce76ab" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b428a3b0-635e-485c-aa0c-f6ef99720e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28636aab-cde1-46e8-be1b-25e40078b8a7" xlink:to="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_Guardant360CDxMember_6e11a7d0-4780-4869-9561-55693cbd6a8c" xlink:href="gh-20210930.xsd#gh_Guardant360CDxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bdd038db-1feb-4e5a-b463-2c7e7317e623" xlink:to="loc_gh_Guardant360CDxMember_6e11a7d0-4780-4869-9561-55693cbd6a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2822a43e-4ed9-4ab9-a9b3-1540d7151b3b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a3439384-b37c-4031-a785-fa4e3b124998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a3439384-b37c-4031-a785-fa4e3b124998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d728e251-6a0f-4a6b-91a6-e8e2821e5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_RestrictedCash_d728e251-6a0f-4a6b-91a6-e8e2821e5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d1e7c748-865c-451d-a394-ccfc4049d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d1e7c748-865c-451d-a394-ccfc4049d6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_d6dae44e-b4fd-4e2f-8c8d-bdc361620313" xlink:href="gh-20210930.xsd#gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue_d6dae44e-b4fd-4e2f-8c8d-bdc361620313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_ebac60c3-e04a-4d45-b5bb-edacc88b397c" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLoss_ebac60c3-e04a-4d45-b5bb-edacc88b397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesTerm_6162f415-afce-4c44-803a-6a18edf47a24" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesTerm_6162f415-afce-4c44-803a-6a18edf47a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ProceedsFromContractualReceivable_d98d2f5e-2d45-434d-b416-a51696e0836a" xlink:href="gh-20210930.xsd#gh_ProceedsFromContractualReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ProceedsFromContractualReceivable_d98d2f5e-2d45-434d-b416-a51696e0836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_c91d6def-1042-48d4-ab9e-61d9e2a2a6f4" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_c91d6def-1042-48d4-ab9e-61d9e2a2a6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_dafb7be6-dbee-483f-9432-4bf50a06c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_dafb7be6-dbee-483f-9432-4bf50a06c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1177d49f-5062-422e-8654-974572b8448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1177d49f-5062-422e-8654-974572b8448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_56a8f8c4-e0ea-4b5f-b2d6-e041698b0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_56a8f8c4-e0ea-4b5f-b2d6-e041698b0f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6e71367e-9089-4b3c-9517-f6edd23a7e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6e71367e-9089-4b3c-9517-f6edd23a7e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc75b5ed-60ac-43a2-8412-e6863e9da3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc75b5ed-60ac-43a2-8412-e6863e9da3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_de404f0c-05b9-41e7-b7e7-3b2fcb843c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_de404f0c-05b9-41e7-b7e7-3b2fcb843c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3b9f2239-6a53-4591-b516-0c5e5648a106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3b9f2239-6a53-4591-b516-0c5e5648a106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a1f89c0b-0b85-420c-bd71-6360c28a8a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5874e966-d2e2-4387-9442-238c664e524c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a1f89c0b-0b85-420c-bd71-6360c28a8a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d11d946-5ae9-46e4-becb-a91c18b81a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d11d946-5ae9-46e4-becb-a91c18b81a29" xlink:to="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3ec82d8a-23b8-45bf-8543-3cc151047f33" xlink:to="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_69d38c19-3963-4b02-845b-fef7e53e5539" xlink:href="gh-20210930.xsd#gh_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerAMember_69d38c19-3963-4b02-845b-fef7e53e5539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_fa6559a5-7cc9-428f-bfc9-7531842229f7" xlink:href="gh-20210930.xsd#gh_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerBMember_fa6559a5-7cc9-428f-bfc9-7531842229f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_bb66fa55-28cb-4e70-b47d-1def64666bd7" xlink:href="gh-20210930.xsd#gh_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerCMember_bb66fa55-28cb-4e70-b47d-1def64666bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_5ff7faf9-5b7a-45da-a289-f32eaab44eeb" xlink:href="gh-20210930.xsd#gh_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1d3ae4ad-6975-4a8f-bc47-47abd2c5bcce" xlink:to="loc_gh_CustomerDMember_5ff7faf9-5b7a-45da-a289-f32eaab44eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d44bfa37-3072-48b2-9a80-21034a062155" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ca81b2b6-718e-4a34-b125-b2718ea0cd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_43b2a773-39ce-411f-a28e-c4c136a01b7c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ca81b2b6-718e-4a34-b125-b2718ea0cd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_207a930b-2f75-4175-a3d2-021b8ca3ea11" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d472fa65-a49d-483c-a63a-7896983c1a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:to="loc_us-gaap_SalesRevenueNetMember_d472fa65-a49d-483c-a63a-7896983c1a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4d7ce231-d747-4d3f-b7d5-d027bac01c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f11d2ac7-1df0-4f5a-bfaf-4baee0c8da64" xlink:to="loc_us-gaap_AccountsReceivableMember_4d7ce231-d747-4d3f-b7d5-d027bac01c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f8c83838-ec02-4aba-9a2f-3aa53e660cff" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_825f3224-3d31-45e1-aa6f-fbcc64775037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_4117c531-93ff-441b-b3a5-103edf0cd0b6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_825f3224-3d31-45e1-aa6f-fbcc64775037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_2ce46b91-0195-4ebf-87be-e38a93d52b73" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent_2ce46b91-0195-4ebf-87be-e38a93d52b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_b7aceed2-b7b7-48f1-988d-6e5a3feb8e8a" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:to="loc_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent_b7aceed2-b7b7-48f1-988d-6e5a3feb8e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_f7547969-bdc6-49b4-bc0c-f48a7bb3be61" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_f7547969-bdc6-49b4-bc0c-f48a7bb3be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalCurrent_f9a0e421-8780-43a4-b796-f0273190ba5a" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalCurrent_f9a0e421-8780-43a4-b796-f0273190ba5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent_b30e6a2c-f9f1-4bad-a078-ecf0cc9a7e99" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossReclassificationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesCreditLossReclassificationCurrent_b30e6a2c-f9f1-4bad-a078-ecf0cc9a7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_4c798ff4-85b5-4a25-94b1-fdc4ab870bba" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossCurrent_4c798ff4-85b5-4a25-94b1-fdc4ab870bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_81df6d69-a7bd-4bb3-ad61-6f9874bb3e1e" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_81df6d69-a7bd-4bb3-ad61-6f9874bb3e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_31f6b87c-e5f9-4e0d-89e0-f2d5a718081b" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent_31f6b87c-e5f9-4e0d-89e0-f2d5a718081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_36694a6d-26d9-4ab8-9737-ed3ea72bf447" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesCreditLossReclassificationNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesCreditLossReclassificationNoncurrent_36694a6d-26d9-4ab8-9737-ed3ea72bf447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_22d7b14f-7298-4e3a-b816-b78348febc15" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAllowanceForCreditLossNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_4aea405c-d4fc-4912-b367-ce9285ddabe0" xlink:to="loc_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent_22d7b14f-7298-4e3a-b816-b78348febc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_4b483d2f-6db5-4c8c-b97a-754f69753bbd" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:to="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent_4b483d2f-6db5-4c8c-b97a-754f69753bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_360e5f1e-ac74-4d2f-bd30-f1c05d66e412" xlink:href="gh-20210930.xsd#gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f072281-92b6-49fa-aa0f-21ddcdf985f1" xlink:to="loc_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent_360e5f1e-ac74-4d2f-bd30-f1c05d66e412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="simple" xlink:href="gh-20210930.xsd#InvestmentinJointVenture"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0747b6b3-29f6-4a49-b1bb-bd2a5a6fa9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_07a60260-54a1-44c9-b281-d46fd8df05be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0747b6b3-29f6-4a49-b1bb-bd2a5a6fa9ce" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_07a60260-54a1-44c9-b281-d46fd8df05be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#InvestmentinJointVentureDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7e065bf5-aaf7-4204-bf82-e54214c9ad87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7e065bf5-aaf7-4204-bf82-e54214c9ad87" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02b602ae-654d-439a-be12-3d099db58055" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_86212c15-a1e8-4118-be36-f3c2b1c131ab" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_916abb99-f2d5-4048-8021-0db6d038fef3" xlink:to="loc_gh_GuardantHealthAMEAIncMember_86212c15-a1e8-4118-be36-f3c2b1c131ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d8c670d6-6fdc-4484-962d-ca19894e4ab0" xlink:to="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_8393dbae-7357-49a9-9b30-9bfeaefde1a1" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1132d5b4-6c7f-49be-a53f-142c47f707fa" xlink:to="loc_gh_SoftBankMember_8393dbae-7357-49a9-9b30-9bfeaefde1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b0d2ddee-fdd5-42ee-88b7-56ee2c90bb86" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ad900927-61a2-4e53-8609-42943aae6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1b21720e-cbd0-43e2-9c4d-a67f753b6a79" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ad900927-61a2-4e53-8609-42943aae6ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f3b6a2d-54f3-4add-904d-cd324efcb64f" xlink:to="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_916806bb-8ba6-4f07-a2fa-5ad37f6377ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_CommonClassAMember_916806bb-8ba6-4f07-a2fa-5ad37f6377ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c92f2be0-24f9-4608-bae9-59e8b7e6bcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_CommonClassBMember_c92f2be0-24f9-4608-bae9-59e8b7e6bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ea4506f7-f952-408c-9940-97824cb8f806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20b00b3e-b0cf-4fac-bb8b-1314f6a4df82" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ea4506f7-f952-408c-9940-97824cb8f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f211b862-d2ae-4e65-a287-8cf4f2da3bc5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_3e4b681e-8041-435c-a621-5bd67dff7b28" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:to="loc_gh_SoftBankMember_3e4b681e-8041-435c-a621-5bd67dff7b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember_f0cf6998-ccb7-4b99-87c6-0fbaff527c6d" xlink:href="gh-20210930.xsd#gh_GuardantHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fb71a6d-8570-4f55-be7e-06dc5d709241" xlink:to="loc_gh_GuardantHealthIncMember_f0cf6998-ccb7-4b99-87c6-0fbaff527c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5bed5c2c-19cb-4993-aecc-5d9ab674b218" xlink:to="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_a476b4a0-7aed-4f69-8014-aa8184cf242b" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cbd3e370-0a6f-40ed-857a-219d4e2dc960" xlink:to="loc_gh_AMEA2020PlanMember_a476b4a0-7aed-4f69-8014-aa8184cf242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c68e5ef8-a1a5-4c14-869b-51d1cedee418" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_fcd81869-15aa-4047-941a-44dd15f59f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_fcd81869-15aa-4047-941a-44dd15f59f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_26f47cc4-db29-44c3-a681-cdaf7d6c140d" xlink:href="gh-20210930.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_26f47cc4-db29-44c3-a681-cdaf7d6c140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_edc81a60-a352-4edc-9c8e-3db53d7a110c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_edc81a60-a352-4edc-9c8e-3db53d7a110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_92c598b1-8dd6-46f3-91df-386872067810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_92c598b1-8dd6-46f3-91df-386872067810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a7929045-eca7-4b6b-a07b-61c696d8fc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a7929045-eca7-4b6b-a07b-61c696d8fc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0dc9026a-94f9-4da6-8c02-583055f4745a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0dc9026a-94f9-4da6-8c02-583055f4745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_26e66ed0-0e6e-49f0-bfac-e43dd69dfec2" xlink:href="gh-20210930.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_26e66ed0-0e6e-49f0-bfac-e43dd69dfec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a8fa5873-6389-4435-b93e-4af7d3e3e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a8fa5873-6389-4435-b93e-4af7d3e3e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_e1ac307b-1c89-435a-9428-cc5744251ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_e1ac307b-1c89-435a-9428-cc5744251ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_757a0fe2-bfd1-40cf-bf84-c9f23674312f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_757a0fe2-bfd1-40cf-bf84-c9f23674312f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2330f763-c3c6-474f-a56d-51a2449547cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesIssued_2330f763-c3c6-474f-a56d-51a2449547cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f4bc1dae-b1c2-4894-9b66-58142d48ac07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f4bc1dae-b1c2-4894-9b66-58142d48ac07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3ec25306-592b-4199-869b-1979812a1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3ec25306-592b-4199-869b-1979812a1fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_922bfe77-c721-4b00-8dac-577b1c9582e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_us-gaap_Assets_922bfe77-c721-4b00-8dac-577b1c9582e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_ac0d73c6-f683-4212-86c8-305006b30127" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_ac0d73c6-f683-4212-86c8-305006b30127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_bfc160c2-1296-403c-8f14-fefd12e7a9e0" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0e54d301-7835-4fc2-b87f-080668c8bf16" xlink:to="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_bfc160c2-1296-403c-8f14-fefd12e7a9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d34b77a1-8144-4240-981e-50ec25bd8c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f310f6ae-cecf-4f2d-a8fa-77140eab8df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d34b77a1-8144-4240-981e-50ec25bd8c37" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f310f6ae-cecf-4f2d-a8fa-77140eab8df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f7bc04f-6bb4-4e0d-b8f3-aa0ba3adf6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d5f05c5-92a1-4a9c-8fe0-9870eb24fdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f7bc04f-6bb4-4e0d-b8f3-aa0ba3adf6d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d5f05c5-92a1-4a9c-8fe0-9870eb24fdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_91017d54-9fd2-4171-a4c2-907d3403c848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f7bc04f-6bb4-4e0d-b8f3-aa0ba3adf6d5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_91017d54-9fd2-4171-a4c2-907d3403c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_46668f46-937a-41c6-8fa5-c34884e5f2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_46668f46-937a-41c6-8fa5-c34884e5f2f5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40db2e91-7517-4c57-b081-a3aa6b059603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_11bd38d9-8b9a-41e7-a519-54b9561ae8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_11bd38d9-8b9a-41e7-a519-54b9561ae8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_da0f64e5-cad8-41c0-b1a1-5fe08756ae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_da0f64e5-cad8-41c0-b1a1-5fe08756ae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_be2c19fc-ec8d-4a73-a412-9541c445a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_ComputerEquipmentMember_be2c19fc-ec8d-4a73-a412-9541c445a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_69475237-c11f-4a62-aa01-c5e8737f161f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_ConstructionInProgressMember_69475237-c11f-4a62-aa01-c5e8737f161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_04066d80-96ed-491f-a7ee-dc67850eb177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_04066d80-96ed-491f-a7ee-dc67850eb177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9ac8157-4caa-43ec-ba81-c4dbb0b28675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_62d67b37-4ad5-48eb-b18e-ae478591de5e" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9ac8157-4caa-43ec-ba81-c4dbb0b28675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990fa44e-f707-4eb1-b597-bfb042185c86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c6dac3f9-1d3d-4bf7-ad1f-2721db4c6ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c6dac3f9-1d3d-4bf7-ad1f-2721db4c6ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_471533cd-e85b-481f-9916-98ae1b7b30c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_471533cd-e85b-481f-9916-98ae1b7b30c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d50ee66-263b-40bc-bba2-e576d8d7721f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a6950064-b0eb-4747-83fc-958bf221703e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d50ee66-263b-40bc-bba2-e576d8d7721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20adc8d1-5864-43dc-ade5-34c1325d9ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d903bc61-6e24-44a5-9797-b632a3d4d919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_20adc8d1-5864-43dc-ade5-34c1325d9ecd" xlink:to="loc_us-gaap_Depreciation_d903bc61-6e24-44a5-9797-b632a3d4d919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c0769b8-fc8c-4c2b-b6a6-27db3b885a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c0769b8-fc8c-4c2b-b6a6-27db3b885a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_16552618-0a64-4ad2-84ee-5c86ecc028a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_16552618-0a64-4ad2-84ee-5c86ecc028a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f22d2075-0bed-417c-8623-d022588e7dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f22d2075-0bed-417c-8623-d022588e7dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_9eed0a0c-59a6-401b-b915-9a55780a4247" xlink:href="gh-20210930.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_9eed0a0c-59a6-401b-b915-9a55780a4247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_70d8dfcd-1462-48da-b40d-8b44a0d95839" xlink:href="gh-20210930.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_70d8dfcd-1462-48da-b40d-8b44a0d95839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_8c1cb748-0a76-4dfa-947f-1cc866ea01c1" xlink:href="gh-20210930.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_8c1cb748-0a76-4dfa-947f-1cc866ea01c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cb387541-1569-49b4-96c6-9629df28ab48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cb387541-1569-49b4-96c6-9629df28ab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0d650982-6daa-4fc0-be98-e4cfe23632aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0d650982-6daa-4fc0-be98-e4cfe23632aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2268ce6e-8534-4689-87e1-9a9f8a22afbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a5b9adb3-ba6c-4ad0-88e0-025d0ad38f4d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2268ce6e-8534-4689-87e1-9a9f8a22afbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d78b5408-da21-4433-9e6d-9080115ddba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b45dabe7-6c9b-46b4-a0ba-b551575f7728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d78b5408-da21-4433-9e6d-9080115ddba4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b45dabe7-6c9b-46b4-a0ba-b551575f7728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dd8229d5-4b6a-4e58-9745-497c43ff09a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_589ff6ad-23ee-4933-a482-19a72edde19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd8229d5-4b6a-4e58-9745-497c43ff09a1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_589ff6ad-23ee-4933-a482-19a72edde19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_43def0c2-55e5-4d5b-8840-7602d99c7b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd8229d5-4b6a-4e58-9745-497c43ff09a1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_43def0c2-55e5-4d5b-8840-7602d99c7b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesTableTextBlock_8f7f2441-8baf-46f2-928f-3d6a4011a09d" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd8229d5-4b6a-4e58-9745-497c43ff09a1" xlink:to="loc_gh_DebtSecuritiesTableTextBlock_8f7f2441-8baf-46f2-928f-3d6a4011a09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fefc251e-0f61-4940-94e7-bebad7b765b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fefc251e-0f61-4940-94e7-bebad7b765b2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_26b5fe85-5718-40f7-8b53-30068dc2af2b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48838eb5-63db-4507-bfde-dcf36b945c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1da35890-9e33-4d81-80b5-afa6086c50ec" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48838eb5-63db-4507-bfde-dcf36b945c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1afcf9cd-1418-4c0c-983d-aab1572389b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f92cbf6f-4627-484c-9dec-c3341b98bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea26f9ec-7676-443a-9c6f-e62e53d5af05" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f92cbf6f-4627-484c-9dec-c3341b98bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_565ddc56-bce3-4126-9335-cb96b1ad3796" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_a84b971b-f113-4dbb-9ece-fd006b76f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae424ae7-fe48-40c4-ac20-53e8e7517dbc" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_a84b971b-f113-4dbb-9ece-fd006b76f724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de2dc48f-06e3-4c04-91c9-e5436f84ac42" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_68ceaf7f-317b-4e28-a98c-3ef42e714a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_68ceaf7f-317b-4e28-a98c-3ef42e714a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97d9ec25-1eac-49a7-943e-c87bf4888b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97d9ec25-1eac-49a7-943e-c87bf4888b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6e305a95-07a2-4994-88c2-194dcee13f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90bc1185-56b7-4b62-ac2a-a5fd7c25f969" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6e305a95-07a2-4994-88c2-194dcee13f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dceb0a73-ca93-4810-963e-40e391c37f3f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d72843d-3470-4e24-8b06-20ab3ce9efab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d72843d-3470-4e24-8b06-20ab3ce9efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_19f45925-417e-4d56-9481-a53e76a5d1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_19f45925-417e-4d56-9481-a53e76a5d1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_d3787376-22b8-40a3-be8c-00969c94d395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_d3787376-22b8-40a3-be8c-00969c94d395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_afdc612e-dced-491e-9df7-710ffddac377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_afdc612e-dced-491e-9df7-710ffddac377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_969cb158-6a46-40bd-9a10-88c1ae4c6c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_969cb158-6a46-40bd-9a10-88c1ae4c6c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_02b36968-7e45-4e19-84fd-511cca0838d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea7af87d-d9d5-458d-8bb8-099e28ffef62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_02b36968-7e45-4e19-84fd-511cca0838d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b39d0adb-13ad-4903-841f-6a4f254bb2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b39d0adb-13ad-4903-841f-6a4f254bb2d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c5ee9ec-2aeb-4f28-bd86-9e332c73d75d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1f7fcc79-2c1a-4ab7-b570-8fc596df9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9eb8c87a-99be-4ed0-add0-efc653fcb5f7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1f7fcc79-2c1a-4ab7-b570-8fc596df9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4962630a-3b21-4b91-82b3-9b8c7492d73b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1ea4e0af-3d5d-4c29-8683-0904f3fa1a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c408aa6b-e749-4184-80a3-d09b84bc3dd6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1ea4e0af-3d5d-4c29-8683-0904f3fa1a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6788a402-a4fe-4b99-b0f5-da7937882a7a" xlink:to="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d75510ad-27f5-4609-b039-debc5000557c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:to="loc_srt_MinimumMember_d75510ad-27f5-4609-b039-debc5000557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45d792c1-69b7-42c5-88f0-b1e5ebbf098e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a796c675-8e36-4d06-9cc9-2703438a823d" xlink:to="loc_srt_MaximumMember_45d792c1-69b7-42c5-88f0-b1e5ebbf098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95e3dd81-ce77-4efe-809a-602a6e253c75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3360b5-dd75-4bb3-999c-a760a2e34dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7f3360b5-dd75-4bb3-999c-a760a2e34dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LongTermMarketableSecuritiesMaturityPeriod_f27c7a85-a785-41bb-9a66-6a5ea26e274d" xlink:href="gh-20210930.xsd#gh_LongTermMarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c17ad9de-5af4-4405-92ad-d0bcae2621e1" xlink:to="loc_gh_LongTermMarketableSecuritiesMaturityPeriod_f27c7a85-a785-41bb-9a66-6a5ea26e274d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9842c36b-fa95-45cd-8367-c803f201edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9842c36b-fa95-45cd-8367-c803f201edbb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f87f7ba8-35ad-4616-a461-09a8b4d04b4b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_893fd932-e737-4282-bb34-472fd1ae2d57" xlink:href="gh-20210930.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_893fd932-e737-4282-bb34-472fd1ae2d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_7ec6579e-27cf-4069-a252-8f5a1626eb6c" xlink:href="gh-20210930.xsd#gh_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413c661f-d20c-4030-b22e-ac21e7dd378d" xlink:to="loc_gh_ContingentConsiderationMember_7ec6579e-27cf-4069-a252-8f5a1626eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dea62d64-a5af-4eaa-9576-5e14f01e109b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7a1a0de6-0943-4832-83ba-d9d1d4f60b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6097aee9-86c1-4dbc-ac36-9d10caa745f7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7a1a0de6-0943-4832-83ba-d9d1d4f60b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0098b595-53aa-4fc9-9291-2ef273ea2ae2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_467def99-7f03-4d43-a65b-0b013a426893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1f297a9e-0c3a-4045-9a5f-beecd1308624" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_467def99-7f03-4d43-a65b-0b013a426893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c822330a-e456-4a98-9643-44d1eaef4e97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f06776-838c-4e84-a9b9-4ed0cbf76fbd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9b6bb7d0-0fe3-4512-bcbe-ce6943635238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9b6bb7d0-0fe3-4512-bcbe-ce6943635238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_ccf5517a-d58a-4e71-a617-563deb810d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_ccf5517a-d58a-4e71-a617-563deb810d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_d1f6cd3f-da05-489e-8469-9fd8db41710e" xlink:href="gh-20210930.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_d1f6cd3f-da05-489e-8469-9fd8db41710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0accebc1-176e-4008-998b-d64ef6cf921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4f1fb547-6312-4cae-86e1-1f7d9b9505a2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0accebc1-176e-4008-998b-d64ef6cf921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b6e3f72e-a1bb-4e4d-bf8e-47be5eb920c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b6e3f72e-a1bb-4e4d-bf8e-47be5eb920c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8424254f-708b-4317-be8f-967cf93cd7c0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9a6629ce-92ba-40dd-8a44-7d8e63efc8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9a6629ce-92ba-40dd-8a44-7d8e63efc8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e0457e4f-24f7-4ed6-9691-8c15ca9d65f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b99b5ebf-045a-4b1f-a362-3280d7cbdffe" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e0457e4f-24f7-4ed6-9691-8c15ca9d65f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ea1f1699-bbe0-467c-b6d9-8d55434656fa" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3f0aeea-9839-451a-a771-56f75b48a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3f0aeea-9839-451a-a771-56f75b48a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9fea062-2b09-4248-ac56-2b7987842d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9fea062-2b09-4248-ac56-2b7987842d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_050b6101-db2c-48a4-a3a9-ee5f895eded2" xlink:href="gh-20210930.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_050b6101-db2c-48a4-a3a9-ee5f895eded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_80cf8ea0-7134-4af1-b177-1e823fa9373f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_80cf8ea0-7134-4af1-b177-1e823fa9373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9527a8a-7fc5-485f-9d7f-2f7d4cd04621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9527a8a-7fc5-485f-9d7f-2f7d4cd04621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63512582-4b3d-44fc-b9a3-c4b8eda6423a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63512582-4b3d-44fc-b9a3-c4b8eda6423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4639ade5-a3bd-40e2-bb68-92b5586f9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4639ade5-a3bd-40e2-bb68-92b5586f9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_8f3a8563-8b9c-4bb6-967c-126658b91228" xlink:href="gh-20210930.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb8596be-8d52-4ffc-8b53-b9281f9e713d" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_8f3a8563-8b9c-4bb6-967c-126658b91228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAcquisition" xlink:type="simple" xlink:href="gh-20210930.xsd#PatentLicenseAcquisition"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_289c47e3-8bf7-4972-8ff7-825d067c051d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88fd8dda-6451-4fef-863d-79c80d575463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_289c47e3-8bf7-4972-8ff7-825d067c051d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88fd8dda-6451-4fef-863d-79c80d575463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#PatentLicenseAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33d33a6f-2a37-49a9-9922-24ad8a934626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33d33a6f-2a37-49a9-9922-24ad8a934626" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2b95fee-1c36-4b20-b0c3-5d0d347a8fa5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember_2397eb5c-7b2c-4135-bad5-a8f2a9cbb666" xlink:href="gh-20210930.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_28505d73-0496-45a0-b0ae-59cc589f5043" xlink:to="loc_gh_KeyGenePatentLicenseAcquisitionMember_2397eb5c-7b2c-4135-bad5-a8f2a9cbb666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cf841f22-3a39-444a-98bc-5019d5abceb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember_72bd1add-4cc6-44a0-b59d-753f64992586" xlink:href="gh-20210930.xsd#gh_PatentandCovenantRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0df6cee1-a3ac-411a-a428-e20914a2dae5" xlink:to="loc_gh_PatentandCovenantRightsMember_72bd1add-4cc6-44a0-b59d-753f64992586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ef80e271-7f2c-4f7c-a58d-ee84ad38de7e" xlink:to="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b912f8bd-0655-4eec-9f85-265383e2f45f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:to="loc_srt_MinimumMember_b912f8bd-0655-4eec-9f85-265383e2f45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5cafae7-a9a7-46d4-9d17-fb9572f2ce6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f03b96d-edb2-4faf-badc-1b49e2bd9708" xlink:to="loc_srt_MaximumMember_a5cafae7-a9a7-46d4-9d17-fb9572f2ce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82b21a77-fb37-4138-b621-41ae05756c23" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement_610bd847-d410-41e5-b765-bbfcae340e3d" xlink:href="gh-20210930.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_PaymentInConnectionWithaLicenseAgreement_610bd847-d410-41e5-b765-bbfcae340e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts_b111d08a-2b75-4e1c-8e4f-70aa213d54f9" xlink:href="gh-20210930.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_AssetAcquisitionTransactionCosts_b111d08a-2b75-4e1c-8e4f-70aa213d54f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d113dbb3-3365-46a5-b7ed-61499bbe48ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d113dbb3-3365-46a5-b7ed-61499bbe48ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fa738bf-c4b3-4ded-a7a8-180e2c4a36ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fa738bf-c4b3-4ded-a7a8-180e2c4a36ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_64104535-618a-4675-b729-d0addb4d101c" xlink:href="gh-20210930.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_64104535-618a-4675-b729-d0addb4d101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_f4845d3b-ff9c-41be-880c-d783190285c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_be792cc2-e4f4-48fe-8e40-f101bc77c1eb" xlink:to="loc_us-gaap_LitigationSettlementExpense_f4845d3b-ff9c-41be-880c-d783190285c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwill"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79a5af38-b522-4c28-b8fb-cba87ca77082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_775e7b62-990d-4bcb-b786-8f4c285fd895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79a5af38-b522-4c28-b8fb-cba87ca77082" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_775e7b62-990d-4bcb-b786-8f4c285fd895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b8ccf23-4c54-4dae-8acd-ad4e8588747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bd764fdf-c10a-4c0a-af62-8c8855d05c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b8ccf23-4c54-4dae-8acd-ad4e8588747a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bd764fdf-c10a-4c0a-af62-8c8855d05c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_04ebb9ee-6ee3-4c2a-9bf6-31d8b5145612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b8ccf23-4c54-4dae-8acd-ad4e8588747a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_04ebb9ee-6ee3-4c2a-9bf6-31d8b5145612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_28cfabb9-f7ab-44cb-aef5-23b053608947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b8ccf23-4c54-4dae-8acd-ad4e8588747a" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_28cfabb9-f7ab-44cb-aef5-23b053608947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ec868138-e2eb-4322-bbf8-48d9a3bb2f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ec868138-e2eb-4322-bbf8-48d9a3bb2f45" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c637b4-6b93-494e-9bf3-5e9ca90b5569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2aeb77e8-12dd-4323-ac6d-a0017b68813c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:to="loc_us-gaap_LicensingAgreementsMember_2aeb77e8-12dd-4323-ac6d-a0017b68813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_782ea84d-ce0b-47fa-880d-45ce85bae919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f474dc7e-1724-4d7e-ae12-b304011485c7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_782ea84d-ce0b-47fa-880d-45ce85bae919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a2eb2d28-b097-42f1-8f0c-9d344469b434" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c68891bd-b42d-4b08-921d-054c2b1d802e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c29e4450-4516-40bb-a88c-916b44b21042" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c68891bd-b42d-4b08-921d-054c2b1d802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_01060091-b96c-4b0b-a7ab-fa587cf6f8a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38ab0468-e706-405d-931a-4a9246e36bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38ab0468-e706-405d-931a-4a9246e36bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7710c7d-4e0d-4c67-97db-8bf3d0cba29c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f7710c7d-4e0d-4c67-97db-8bf3d0cba29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_708bcd1d-cd8b-4c9b-b1a9-0a2521fb5bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_708bcd1d-cd8b-4c9b-b1a9-0a2521fb5bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6a7319cb-932a-454d-b7fc-9588dd72fb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6a7319cb-932a-454d-b7fc-9588dd72fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c9e8e4f2-25dc-44c8-82c4-dab4a55c79b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c9e8e4f2-25dc-44c8-82c4-dab4a55c79b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8e55b18a-a347-4bc9-a07c-875bc8da4f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_Goodwill_8e55b18a-a347-4bc9-a07c-875bc8da4f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_f709e097-556c-4939-a1ea-19269bfc309c" xlink:href="gh-20210930.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_f709e097-556c-4939-a1ea-19269bfc309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b601b221-ec03-4361-8819-1d3ff81200c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8b46337-b646-499d-8764-89ebab119382" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b601b221-ec03-4361-8819-1d3ff81200c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5cf992e6-141c-47ee-81f2-613de577d922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_20ee42f6-ef0b-4e5b-bf20-30d2ac751a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5cf992e6-141c-47ee-81f2-613de577d922" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_20ee42f6-ef0b-4e5b-bf20-30d2ac751a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3ce07bc3-d81f-4348-a94f-543d4aeae16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3ce07bc3-d81f-4348-a94f-543d4aeae16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6e08d6ad-6692-451b-a15c-af5ea539e20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6e08d6ad-6692-451b-a15c-af5ea539e20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fec45a5-00cc-4281-b957-ae984caf4448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fec45a5-00cc-4281-b957-ae984caf4448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e9f93015-3957-4cb5-b51f-eca880eabea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e9f93015-3957-4cb5-b51f-eca880eabea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_328db6d4-5252-4388-87bd-7df1a7a8906b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_328db6d4-5252-4388-87bd-7df1a7a8906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_4fb29c76-269b-4cdb-a2a9-a2ee7f2da786" xlink:href="gh-20210930.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_4fb29c76-269b-4cdb-a2a9-a2ee7f2da786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f42b3bc-e94a-4b51-9c3d-4b64a3876ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf18cd8-f65a-46f0-b596-5cbd42c70aee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f42b3bc-e94a-4b51-9c3d-4b64a3876ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Debt" xlink:type="simple" xlink:href="gh-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9d259f80-9984-4d18-97b1-c6a9e315f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_83896481-b400-48ff-a39a-88f6310bc9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9d259f80-9984-4d18-97b1-c6a9e315f0e4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_83896481-b400-48ff-a39a-88f6310bc9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtTables" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_567c01c3-d171-486f-97b5-1abd7272cc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_027d2ed7-b298-4c04-9e62-777e04471b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_567c01c3-d171-486f-97b5-1abd7272cc69" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_027d2ed7-b298-4c04-9e62-777e04471b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_186ab23f-851c-4660-8210-641a2e6583b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_186ab23f-851c-4660-8210-641a2e6583b4" xlink:to="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba8435c8-e6d9-47d5-9288-243c7a7f3cf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_e1551bcd-76b8-4d8b-8fa7-9792ce0b35d7" xlink:href="gh-20210930.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_faf0007d-d17d-4853-a463-8f0e6a8b3853" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_e1551bcd-76b8-4d8b-8fa7-9792ce0b35d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4838201d-799a-4310-8633-17b2250005e1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_440f3d05-4169-4c18-a115-ec81dba957fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:to="loc_us-gaap_ConvertibleDebtMember_440f3d05-4169-4c18-a115-ec81dba957fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_27af1c62-fa62-4ef6-9be5-56445b282329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_810b33cd-901d-4e4c-a021-e4c6c3b71e24" xlink:to="loc_us-gaap_SeniorNotesMember_27af1c62-fa62-4ef6-9be5-56445b282329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionAxis_e2365016-4b89-48d8-92d8-9865c111a1c5" xlink:to="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodOneMember_ac9fe74a-4fec-4ec1-8c83-7478d01d604f" xlink:href="gh-20210930.xsd#gh_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodOneMember_ac9fe74a-4fec-4ec1-8c83-7478d01d604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodTwoMember_fc3f88d8-5633-46cd-bd99-aa4eaacf53d2" xlink:href="gh-20210930.xsd#gh_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodTwoMember_fc3f88d8-5633-46cd-bd99-aa4eaacf53d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConversionPeriodThreeMember_f0807dff-08c1-4216-ba56-25bf418637e7" xlink:href="gh-20210930.xsd#gh_ConversionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_DebtInstrumentConversionDomain_f1f0c260-8428-4f9d-81e0-23f1097b7212" xlink:to="loc_gh_ConversionPeriodThreeMember_f0807dff-08c1-4216-ba56-25bf418637e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a70bd3-1ded-4dcd-ba94-218297838c28" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_abc9a38e-053d-45b6-a4a5-d6028323cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_abc9a38e-053d-45b6-a4a5-d6028323cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8b68eb2a-ee0c-47d4-9711-f71e6ee73d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8b68eb2a-ee0c-47d4-9711-f71e6ee73d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_ad1544f3-cff4-4320-bfd7-d5f7f76db0a6" xlink:href="gh-20210930.xsd#gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage_ad1544f3-cff4-4320-bfd7-d5f7f76db0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f2406ef9-2bab-41b3-a023-83c205d7d033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f2406ef9-2bab-41b3-a023-83c205d7d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_dd4014d7-954f-4aa2-9efc-d1ebf4043fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_dd4014d7-954f-4aa2-9efc-d1ebf4043fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2e93802e-a5c7-4cce-a83a-49ab8a6b3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2e93802e-a5c7-4cce-a83a-49ab8a6b3a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_ef5947dd-d604-4aa4-9838-58554a2be772" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate_ef5947dd-d604-4aa4-9838-58554a2be772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1e74d01a-5d85-4d1f-a593-a8809c739c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1e74d01a-5d85-4d1f-a593-a8809c739c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d6181ad2-e996-452e-b928-330f72957a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d6181ad2-e996-452e-b928-330f72957a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5067a59f-2303-4a76-b2ef-2ec946e1662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5067a59f-2303-4a76-b2ef-2ec946e1662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31e8a642-3d0f-459e-9d88-8765a7778ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31e8a642-3d0f-459e-9d88-8765a7778ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d64fe734-2441-44dc-9ca4-53ccc8fb9fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d64fe734-2441-44dc-9ca4-53ccc8fb9fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeStrikePrice_0f1febc3-9a11-4805-9e03-122e81b10698" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeStrikePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_ConvertibleDebtHedgeStrikePrice_0f1febc3-9a11-4805-9e03-122e81b10698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_fc3798bc-bcdd-4cee-aa45-b4498c0ca20e" xlink:href="gh-20210930.xsd#gh_ConvertibleDebtHedgeSharePricePremiumPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_ConvertibleDebtHedgeSharePricePremiumPercentage_fc3798bc-bcdd-4cee-aa45-b4498c0ca20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_91bda23c-3b2b-408b-9856-436783023391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_us-gaap_SharePrice_91bda23c-3b2b-408b-9856-436783023391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_bfc07c32-3aaa-4849-80d7-bf314deaf618" xlink:href="gh-20210930.xsd#gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b9f7de6-a263-4e14-b1d4-7c5786705779" xlink:to="loc_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges_bfc07c32-3aaa-4849-80d7-bf314deaf618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#DebtComponentsofConvertibleSeniorNotesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a1792617-a8cd-429c-8e3d-4d49896777c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a1792617-a8cd-429c-8e3d-4d49896777c1" xlink:to="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89c7cca9-82bd-4549-96b6-451c92471d40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fe357502-041c-4e2f-98aa-f8207ececbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0c4f46-f6cb-4ce5-853b-54bfaa9b4b70" xlink:to="loc_us-gaap_ConvertibleDebtMember_fe357502-041c-4e2f-98aa-f8207ececbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:to="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7290a881-e065-4eb6-af11-3c2b33a041cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ConvertibleSeniorNotesDue2027Member_a6ce4626-e19f-494c-a617-5d7409204d46" xlink:href="gh-20210930.xsd#gh_ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2ff3aaf-1c2f-43cb-a8c4-7871d007d6b0" xlink:to="loc_gh_ConvertibleSeniorNotesDue2027Member_a6ce4626-e19f-494c-a617-5d7409204d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e0ea6906-59e0-4d81-b125-33b3ccd68bad" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fa6feda1-b392-4986-a35c-bd72f2cb19c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fa6feda1-b392-4986-a35c-bd72f2cb19c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4def47f0-810e-4c36-b26d-2893b37f90b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4def47f0-810e-4c36-b26d-2893b37f90b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5e9ee181-3319-4faf-8ad3-0b2b35bf7058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5e9ee181-3319-4faf-8ad3-0b2b35bf7058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_746a0f7c-f2c6-4ed3-92ae-e7043cef597d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_LongTermDebt_746a0f7c-f2c6-4ed3-92ae-e7043cef597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_62bfd090-abe0-4a6c-85ef-3fb0b92eb60a" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts_62bfd090-abe0-4a6c-85ef-3fb0b92eb60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_01bc1192-275c-4652-935c-ce9bb3467a52" xlink:href="gh-20210930.xsd#gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent_01bc1192-275c-4652-935c-ce9bb3467a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_ddb3f229-c096-4058-b32a-fb53b5a63e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3d86a83-d928-468b-a9b7-c7527d04fcc2" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_ddb3f229-c096-4058-b32a-fb53b5a63e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:type="simple" xlink:href="gh-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_befbd3f8-a1f3-4017-9227-878f14b720b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a6387179-e099-4cc7-84af-6374dc09369e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_befbd3f8-a1f3-4017-9227-878f14b720b8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a6387179-e099-4cc7-84af-6374dc09369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e6a4ebf2-d724-41f7-9939-2c857ca1c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_69cb2442-cb06-4cef-a667-6782d1a8590a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6a4ebf2-d724-41f7-9939-2c857ca1c1ef" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_69cb2442-cb06-4cef-a667-6782d1a8590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba6d4aa2-d634-46f1-a2cf-612de247e302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6a4ebf2-d724-41f7-9939-2c857ca1c1ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba6d4aa2-d634-46f1-a2cf-612de247e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fe7e9c67-5b3b-4ab2-af46-a9857fdbd58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe7e9c67-5b3b-4ab2-af46-a9857fdbd58d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_654db38d-7907-4cb0-a9c3-306cbac1b2f3" xlink:to="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_455a52bc-d50a-4f1a-82ef-d683ecc399e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:to="loc_srt_MinimumMember_455a52bc-d50a-4f1a-82ef-d683ecc399e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d992d45f-265c-4af3-a59e-c2fd2a14b724" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_573832b2-c094-4d1e-8e8f-7fd25ce26776" xlink:to="loc_srt_MaximumMember_d992d45f-265c-4af3-a59e-c2fd2a14b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c98f6c71-fd84-40cf-89ff-a8bc348d85b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f867c58d-60a7-459b-88f2-eac7c0f6a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c187bdf-4aa1-4907-91b8-1d637467ba2a" xlink:to="loc_us-gaap_BuildingMember_f867c58d-60a7-459b-88f2-eac7c0f6a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8ea30524-a15b-4de8-a6c4-dfe23f7e4c20" xlink:to="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SanDiegoCaliforniaMember_ed36f81c-4f49-4129-9dad-ee8d219d3761" xlink:href="gh-20210930.xsd#gh_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:to="loc_gh_SanDiegoCaliforniaMember_ed36f81c-4f49-4129-9dad-ee8d219d3761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaloAltoCaliforniaMember_69e05c91-e3da-46dc-9250-e830492fa694" xlink:href="gh-20210930.xsd#gh_PaloAltoCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7f198ce-5b5e-486a-b077-3dfc5d791870" xlink:to="loc_gh_PaloAltoCaliforniaMember_69e05c91-e3da-46dc-9250-e830492fa694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f96012dc-de90-4bc0-b442-783aaf1b69e6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e25b45bb-172b-4b9a-b079-82a24a807254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e25b45bb-172b-4b9a-b079-82a24a807254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_9f10e17c-3670-445d-a43c-599b2eca70fb" xlink:href="gh-20210930.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_9f10e17c-3670-445d-a43c-599b2eca70fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_521dcbed-00c8-4e62-b93e-c2cde29708d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_521dcbed-00c8-4e62-b93e-c2cde29708d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_76b08a24-d30b-4ecb-8a62-4a00aeceef21" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract_76b08a24-d30b-4ecb-8a62-4a00aeceef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8c2dfda7-a3dc-4491-97c1-8f76a649e1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dffc0f57-3c0a-459c-9072-0917385f6dae" xlink:to="loc_us-gaap_OperatingLeaseExpense_8c2dfda7-a3dc-4491-97c1-8f76a649e1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3845e461-fa22-4b37-b655-3e195bb60fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c6573eca-57b9-4a5a-893d-3b6638a50135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3845e461-fa22-4b37-b655-3e195bb60fc1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c6573eca-57b9-4a5a-893d-3b6638a50135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79e76847-b38d-4efc-aeb5-b6d18c072f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3845e461-fa22-4b37-b655-3e195bb60fc1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79e76847-b38d-4efc-aeb5-b6d18c072f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4d308471-1731-4234-8351-f6a8da8dedd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4d308471-1731-4234-8351-f6a8da8dedd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cfc1f8b5-4e91-4b37-94c0-79db6dbbe8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cfc1f8b5-4e91-4b37-94c0-79db6dbbe8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12d9741b-7cb4-4654-9458-c2517ecedb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12d9741b-7cb4-4654-9458-c2517ecedb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_29fa6a33-5f6d-488b-b131-61e61b644e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_29fa6a33-5f6d-488b-b131-61e61b644e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4827cb26-85ff-4464-9e03-dc0bfbf73925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4827cb26-85ff-4464-9e03-dc0bfbf73925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_433bae40-e197-4ed3-8f1d-66fc120367c9" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_433bae40-e197-4ed3-8f1d-66fc120367c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_797de60e-8287-45b1-bfdd-7f41cf4e8e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_797de60e-8287-45b1-bfdd-7f41cf4e8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6c592473-e110-4c54-a66a-383673096099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6c592473-e110-4c54-a66a-383673096099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_ed3b7dad-de7a-4543-b2f1-606012d7eb90" xlink:href="gh-20210930.xsd#gh_LesseeOperatingLeaseLiabilityLeaseIncentive"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityLeaseIncentive_ed3b7dad-de7a-4543-b2f1-606012d7eb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dcc2a91b-dc11-4ceb-89ed-699f3d1ddd50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b23ff15-20da-46ca-b464-94791071087d" xlink:to="loc_us-gaap_OperatingLeaseLiability_dcc2a91b-dc11-4ceb-89ed-699f3d1ddd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20210930.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gh-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ccdb66b-48ab-44b3-b19f-cbea13ff8434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6e00438a-fc90-4408-9ecd-8391461a69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ccdb66b-48ab-44b3-b19f-cbea13ff8434" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6e00438a-fc90-4408-9ecd-8391461a69ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49b2a549-c95a-471b-81b5-179b9a774882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_49b2a549-c95a-471b-81b5-179b9a774882" xlink:to="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:to="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_69c2f8ec-b6bc-4bae-80fd-308ea4d35669" xlink:to="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_6d5ce881-e5c4-425e-8ad1-24109df4567c" xlink:href="gh-20210930.xsd#gh_FoundationMedicineInc.vs.GuardantHealthInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9a3809ac-a863-4b60-807d-b146ea4d61c3" xlink:to="loc_gh_FoundationMedicineInc.vs.GuardantHealthInc.Member_6d5ce881-e5c4-425e-8ad1-24109df4567c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2d5536ed-1a1d-4950-ac85-7c4c0e7ebd8e" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_deed75eb-3a86-4bc7-9244-345920e6eb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_deed75eb-3a86-4bc7-9244-345920e6eb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled_1f002e4c-2b39-45ed-bde0-241be2c2a166" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsFiled"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberofPetitionsFiled_1f002e4c-2b39-45ed-bde0-241be2c2a166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied_40527d6c-2ff3-46c3-b5ad-2ad808a4c3e4" xlink:href="gh-20210930.xsd#gh_NumberofPetitionsDenied"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberofPetitionsDenied_40527d6c-2ff3-46c3-b5ad-2ad808a4c3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfPetitionsFiledRemaining_108b46be-7a8c-4a40-9b10-74232e1a7c21" xlink:href="gh-20210930.xsd#gh_NumberOfPetitionsFiledRemaining"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6810f42a-8ffa-4e8a-8ac7-f449d6826255" xlink:to="loc_gh_NumberOfPetitionsFiledRemaining_108b46be-7a8c-4a40-9b10-74232e1a7c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:type="simple" xlink:href="gh-20210930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_496d487a-6260-44ba-a5d1-c9d64cee1c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3ee9c22-06c5-4d19-8258-7fadf8068d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_496d487a-6260-44ba-a5d1-c9d64cee1c03" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3ee9c22-06c5-4d19-8258-7fadf8068d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockTables" xlink:type="simple" xlink:href="gh-20210930.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dec110b5-366e-434d-b142-5b8dad571bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_2ed579f3-5170-4937-8bc0-8e7eedd1f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dec110b5-366e-434d-b142-5b8dad571bed" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_2ed579f3-5170-4937-8bc0-8e7eedd1f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e0af872f-dcd6-4eac-ac09-6e913ea10f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0af872f-dcd6-4eac-ac09-6e913ea10f08" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:to="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_18541ab1-4b58-4b06-ad87-90949a706bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b586c7ba-90bb-403b-9352-90e44acd7819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b586c7ba-90bb-403b-9352-90e44acd7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb57bb2e-b7e9-46da-bcf3-becbae67fa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb57bb2e-b7e9-46da-bcf3-becbae67fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_aa10e44e-cb2a-46f5-b9ef-9948e35c58d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_PerformanceSharesMember_aa10e44e-cb2a-46f5-b9ef-9948e35c58d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_f1289b11-ae1f-4da6-a171-fbef577e0a67" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_f1289b11-ae1f-4da6-a171-fbef577e0a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_15e3befc-76aa-46a4-b482-6222bf19a5c9" xlink:href="gh-20210930.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_15e3befc-76aa-46a4-b482-6222bf19a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dc1ed33a-c472-4df9-9494-7688126773fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e75b262b-0346-4931-b052-63a836d0c3ec" xlink:to="loc_us-gaap_EmployeeStockMember_dc1ed33a-c472-4df9-9494-7688126773fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b758f50-baa2-4b68-9633-6d99117743b7" xlink:to="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_5a94d00a-d52b-4d4c-b9a1-e140a0e4fc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_DividendsCommonStock_5a94d00a-d52b-4d4c-b9a1-e140a0e4fc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56535570-28e5-4b09-a345-e7fd91efa340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56535570-28e5-4b09-a345-e7fd91efa340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6332614-1bd9-4d5f-91e1-84d0239f64ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6332614-1bd9-4d5f-91e1-84d0239f64ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a87c14a0-12d2-42c1-ada0-74db0d27c580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a87c14a0-12d2-42c1-ada0-74db0d27c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0088c626-5d20-4517-89ec-fda4381d3228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d936df2-1083-48f2-9e85-3aa0047276b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0088c626-5d20-4517-89ec-fda4381d3228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75f99091-cf90-49c0-96b3-3b13f3979d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d8877d0c-7d04-4fd4-bc36-6047900d1233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75f99091-cf90-49c0-96b3-3b13f3979d19" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d8877d0c-7d04-4fd4-bc36-6047900d1233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a63de02d-dce1-4c23-ad15-b1f647274841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a63de02d-dce1-4c23-ad15-b1f647274841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7bb24d90-91da-465e-b118-89847dd7f92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7bb24d90-91da-465e-b118-89847dd7f92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_b4b70f30-f3c8-4b2c-8e71-a2889fdf3c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_b4b70f30-f3c8-4b2c-8e71-a2889fdf3c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_99fd7f21-b97f-4a26-8371-97ce28c4b04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_99fd7f21-b97f-4a26-8371-97ce28c4b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_deac3f43-568d-4fd4-9cd6-719a8038cd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45905ab8-9e6d-45d6-9b7c-834b8389f127" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_deac3f43-568d-4fd4-9cd6-719a8038cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e778735f-6a0f-420d-acc5-0caa4f3c7bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e778735f-6a0f-420d-acc5-0caa4f3c7bd7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:to="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3c802639-1127-43aa-8ade-0b76c6491fcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_f80c53d6-ec9a-4370-ab59-e3d72d49f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_StockOptionMember_f80c53d6-ec9a-4370-ab59-e3d72d49f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c96f13bb-7f6c-4b92-8c9d-227e6c5f2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_RestrictedStockMember_c96f13bb-7f6c-4b92-8c9d-227e6c5f2c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7d903b59-d328-432b-828f-ed5db0942df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_us-gaap_PerformanceSharesMember_7d903b59-d328-432b-828f-ed5db0942df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_0f4f1082-726e-4b6f-b1ce-b715c099246d" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ea1bc9b-da93-4ae8-8574-86b61b77137b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_0f4f1082-726e-4b6f-b1ce-b715c099246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f697a9c-9236-4077-9f65-ae1f3154c8df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_661f6b01-386b-494c-ac3f-2cd5a6ae0c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_661f6b01-386b-494c-ac3f-2cd5a6ae0c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_65741888-ae4a-4dba-aa0f-fdc9d7a40643" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_65741888-ae4a-4dba-aa0f-fdc9d7a40643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_02943116-ce7a-4aad-8737-0f65450d7cd6" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_02943116-ce7a-4aad-8737-0f65450d7cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_3b1f628c-a6eb-4f21-97c3-b1c86f38b7cd" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_3b1f628c-a6eb-4f21-97c3-b1c86f38b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acaf6adc-5ce5-455b-a682-79d6e7ba63fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_78b77924-71d7-4a50-808b-e10f07e2a7e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acaf6adc-5ce5-455b-a682-79d6e7ba63fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7517ec0e-205a-42e5-aa55-3a598c0f7624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7517ec0e-205a-42e5-aa55-3a598c0f7624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7772b1c-aeb2-4d00-beb1-33ba8d93aef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7772b1c-aeb2-4d00-beb1-33ba8d93aef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1a9fb0d-e996-4573-9554-22e6266250fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1a9fb0d-e996-4573-9554-22e6266250fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_08309f15-b0fb-4544-9fba-9c1255724be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_08309f15-b0fb-4544-9fba-9c1255724be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d097146-355a-4a16-8183-217a03005f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0091f9a8-c912-462a-be74-de5ec6279408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d097146-355a-4a16-8183-217a03005f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e981eda8-abd3-4f45-8c4b-9adbd7bf371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e981eda8-abd3-4f45-8c4b-9adbd7bf371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c2ba357-bbd1-465d-95a3-52b0f411cf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c2ba357-bbd1-465d-95a3-52b0f411cf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c5ad634-ecec-4444-b11b-58e929881e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c5ad634-ecec-4444-b11b-58e929881e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27cc2ee5-ba63-4d4a-9379-8b1028ffad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_27cc2ee5-ba63-4d4a-9379-8b1028ffad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1c9ed38-ca43-4a11-911e-36c419f66fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1c9ed38-ca43-4a11-911e-36c419f66fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c481014a-49f6-4c90-b49a-f70da279152f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_52f9cbb9-048e-45a8-b800-ea4926dd3166" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c481014a-49f6-4c90-b49a-f70da279152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14201d62-407f-45d8-aeb0-90dfc59f930b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14201d62-407f-45d8-aeb0-90dfc59f930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bce64e4b-b458-4e2f-b37e-65d7cccdd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bce64e4b-b458-4e2f-b37e-65d7cccdd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc41a270-028a-4863-bb87-cc0c32bde51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc41a270-028a-4863-bb87-cc0c32bde51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_49e82322-e318-4e33-a612-19e3635074db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_49e82322-e318-4e33-a612-19e3635074db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4070ce00-0efe-4b61-9bd2-66fae2d5b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_daef568f-9820-41e6-9477-506cdba4f806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4070ce00-0efe-4b61-9bd2-66fae2d5b60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_46b82259-cffb-4c5d-851b-babe3d29f91f" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ca5bec-a880-4e1d-9c24-21a57e26a43a" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_46b82259-cffb-4c5d-851b-babe3d29f91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b232c30e-b6c3-42d7-879c-7f84706e7f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b232c30e-b6c3-42d7-879c-7f84706e7f3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d738b438-c602-4bd3-a414-2bfa39cc330b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6d72a463-d073-48d5-a77e-dfd9e2537c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6d72a463-d073-48d5-a77e-dfd9e2537c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cbda719c-ccdd-40f7-929f-07c6894f88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cbda719c-ccdd-40f7-929f-07c6894f88ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_a317fda3-0a71-4983-8dfe-6ab8c7dc8a71" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_a317fda3-0a71-4983-8dfe-6ab8c7dc8a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff63abc5-665a-41dd-800d-3b8ae565b729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_PerformanceSharesMember_ff63abc5-665a-41dd-800d-3b8ae565b729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d803c4cf-c29a-40c7-a207-d9a78bc45eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f5683-5b1d-4e33-9092-274a0a227dca" xlink:to="loc_us-gaap_EmployeeStockMember_d803c4cf-c29a-40c7-a207-d9a78bc45eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ef840f4-f563-4059-9da9-484c89e2eae6" xlink:to="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a9fe12d2-a46d-43f2-90e4-3329a4873a60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:to="loc_srt_MinimumMember_a9fe12d2-a46d-43f2-90e4-3329a4873a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6803c258-0e2f-4403-9493-5e833a8b3c7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75c0860c-bbd8-4aaa-848e-ca5525b3de28" xlink:to="loc_srt_MaximumMember_6803c258-0e2f-4403-9493-5e833a8b3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ddc19682-3741-42de-a84c-c845b73ef64f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_55d1d7ba-b7f4-4557-82c5-ae8e78dfbbb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9e0c0565-2978-449c-9cbb-7d90bcb9c266" xlink:to="loc_srt_ChiefExecutiveOfficerMember_55d1d7ba-b7f4-4557-82c5-ae8e78dfbbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4d413db-c3d8-4521-b838-70ded9e3825e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_b477945d-a5bc-424b-932d-d1901e1768bc" xlink:href="gh-20210930.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f710599e-d7aa-4396-8857-9f43f0822926" xlink:to="loc_gh_GuardantHealthAMEAIncMember_b477945d-a5bc-424b-932d-d1901e1768bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c07da464-14d0-4fc6-b12f-e53fb2c07864" xlink:to="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_54b853c9-b2f6-45b3-9345-22e30bb7d7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dd8f232e-3a5e-4d6f-aa35-f70a025096d6" xlink:to="loc_us-gaap_CommonClassBMember_54b853c9-b2f6-45b3-9345-22e30bb7d7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_876ffb43-e47b-4bf5-b116-fca017c4c591" xlink:to="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_896068c2-4d00-4435-851f-8754f3b3a818" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ea6fb7c2-c9e9-4d44-81d0-326859499311" xlink:to="loc_gh_AMEA2020PlanMember_896068c2-4d00-4435-851f-8754f3b3a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:href="gh-20210930.xsd#gh_EquityIncentivePlanTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_EquityIncentivePlanTrancheAxis_378602c0-b8e2-4ff2-97d5-38a3e0df33e8" xlink:to="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheOneMember_4f6569f5-8176-40ca-ae2a-b0df33be958e" xlink:href="gh-20210930.xsd#gh_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:to="loc_gh_TrancheOneMember_4f6569f5-8176-40ca-ae2a-b0df33be958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_TrancheTwoMember_4d0681f6-8629-46ee-859c-b7fa94735ce5" xlink:href="gh-20210930.xsd#gh_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_EquityIncentivePlanTrancheDomain_29b114a3-abb2-4117-abd7-aefb61eaf1ef" xlink:to="loc_gh_TrancheTwoMember_4d0681f6-8629-46ee-859c-b7fa94735ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b6be70c-f84e-46b8-b8d5-6ef58e483541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5d22b351-ebbc-43b0-a40d-da75f5e4ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5d22b351-ebbc-43b0-a40d-da75f5e4ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d0c53cd-d731-4877-aa8a-0432914bfedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d0c53cd-d731-4877-aa8a-0432914bfedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_dd63204e-6a50-45f1-b89a-9937c43f1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_dd63204e-6a50-45f1-b89a-9937c43f1bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2e9cc93-bac7-4ef4-8fcc-14cfeeebccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2e9cc93-bac7-4ef4-8fcc-14cfeeebccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f3c73fea-f306-4c80-a521-501a59a4c233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f3c73fea-f306-4c80-a521-501a59a4c233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_a1b3b119-79a5-4028-ab6f-20affad1287e" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod_a1b3b119-79a5-4028-ab6f-20affad1287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0631b867-35ba-4c93-8b76-0917b98f25d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0631b867-35ba-4c93-8b76-0917b98f25d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6fbfbcc-ba9b-45b3-8380-88bbb9b7dc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6fbfbcc-ba9b-45b3-8380-88bbb9b7dc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f01a3557-df65-426a-91be-269ca529acd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f01a3557-df65-426a-91be-269ca529acd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_16de2c49-f75b-4106-8e1f-a79c18824bdc" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_16de2c49-f75b-4106-8e1f-a79c18824bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_a8aa72b6-e507-41da-baa3-19ef5eccf298" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_a8aa72b6-e507-41da-baa3-19ef5eccf298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_5ceb717e-eeb1-4fcf-9969-9c703bb7d104" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_5ceb717e-eeb1-4fcf-9969-9c703bb7d104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a61286c5-3477-4b6c-820d-8fb7728ddcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a61286c5-3477-4b6c-820d-8fb7728ddcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bac8d698-53b1-4471-b534-52c69c58784b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bac8d698-53b1-4471-b534-52c69c58784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_92b529d9-ad73-4fe5-aa57-09b4f0d22e9d" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm_92b529d9-ad73-4fe5-aa57-09b4f0d22e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ec4675b6-9a73-4a5b-94e0-545ac42c377c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ec4675b6-9a73-4a5b-94e0-545ac42c377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3d4f6aa-3827-42aa-b457-218a7092d686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3d4f6aa-3827-42aa-b457-218a7092d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fd47eae-e480-4a49-8e45-e804f13f0705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fd47eae-e480-4a49-8e45-e804f13f0705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5953c99e-aeca-451e-aa0d-509306a0b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5953c99e-aeca-451e-aa0d-509306a0b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5d5bc8a-849a-49b7-a1cd-204f1a1a0c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5d5bc8a-849a-49b7-a1cd-204f1a1a0c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_2bed0328-40ce-4f25-9b6b-5b9b363b8bba" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_2bed0328-40ce-4f25-9b6b-5b9b363b8bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_9e2c7136-1577-4ab4-b988-d89389c59e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_9e2c7136-1577-4ab4-b988-d89389c59e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cdd4ba36-b336-43a6-a8a1-1ce423d5a712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cdd4ba36-b336-43a6-a8a1-1ce423d5a712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_571178d9-e3eb-47d0-82f8-70ea1f552fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_571178d9-e3eb-47d0-82f8-70ea1f552fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4d006172-139b-469d-ade1-a98b58f8b680" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4d006172-139b-469d-ade1-a98b58f8b680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4cf9ac91-4629-4865-a56d-f010cb800ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f695ceb8-8fb5-47ea-a8ee-e475170efe2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4cf9ac91-4629-4865-a56d-f010cb800ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bf3f83-1fe2-48ee-8c42-100e2c38354b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bf3f83-1fe2-48ee-8c42-100e2c38354b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:to="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7cfe6377-c3c4-4d5f-980f-401652653469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b2757cd-05c1-41df-ab68-419f61cd9536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b2757cd-05c1-41df-ab68-419f61cd9536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_2e60d2e8-7600-4c8b-9dce-ba5baeb4a27e" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_2e60d2e8-7600-4c8b-9dce-ba5baeb4a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_15d453d8-8a08-48ae-a3e3-388467bc384a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf50afba-38c3-4431-ab8d-f8103a3a5ac0" xlink:to="loc_us-gaap_PerformanceSharesMember_15d453d8-8a08-48ae-a3e3-388467bc384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43c1ec11-1c38-4aad-a35d-24a70f017694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8d1dbe46-26b7-431b-bf52-817e0375b391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8d1dbe46-26b7-431b-bf52-817e0375b391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa5b1cfb-19bd-494d-a14b-5432ea7ef699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa5b1cfb-19bd-494d-a14b-5432ea7ef699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_058292ad-a9cc-4deb-9b79-15852aa54abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_058292ad-a9cc-4deb-9b79-15852aa54abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ad7814fa-0c6b-47e6-9363-e4b96c1eb3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ad7814fa-0c6b-47e6-9363-e4b96c1eb3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_812b83bb-361f-4877-9e3c-c387d2fc0909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9cb65c2-c874-4018-8d25-cc627f625fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_812b83bb-361f-4877-9e3c-c387d2fc0909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_040a7036-12b7-4832-8cc4-db7bddfec923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8123c8d5-6049-4175-88c5-4667d65df459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8123c8d5-6049-4175-88c5-4667d65df459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2aba7df-889e-4fcc-a878-0217350e0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2aba7df-889e-4fcc-a878-0217350e0ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e606687b-f087-4da4-ab61-d90ccbffb5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e606687b-f087-4da4-ab61-d90ccbffb5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62ea854d-4bc0-45ed-9ac4-7d6db3479692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62ea854d-4bc0-45ed-9ac4-7d6db3479692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4060211-4536-4e1e-9286-b05442205d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_16f87055-c6d0-4961-a4b3-8c5caa2716da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d4060211-4536-4e1e-9286-b05442205d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b140bc6-23ba-4349-b1e9-949af92f5c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b140bc6-23ba-4349-b1e9-949af92f5c69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:to="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a88f2e81-0619-47b1-9919-5a34d514b11d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8537fb4e-2c9c-453c-bc51-ee611aef130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05d284a7-aa3a-414a-b787-df499143c9b1" xlink:to="loc_us-gaap_PerformanceSharesMember_8537fb4e-2c9c-453c-bc51-ee611aef130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:to="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_cf4a758e-d728-46f5-bbf9-611a51ad70b5" xlink:to="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8c2b2b85-4193-412a-a179-6be56506e7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8c2b2b85-4193-412a-a179-6be56506e7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_018856e6-9f82-4299-b918-be0c0b202840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_018856e6-9f82-4299-b918-be0c0b202840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a5f57195-0d60-4207-b271-88c34044b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5fc4bcbd-fac0-4af2-9495-97f94d3c6003" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a5f57195-0d60-4207-b271-88c34044b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff739c20-c4b1-4811-a00a-a731b3ebac32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_30b247d0-d41b-4144-a022-bd5f254b5819" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6649e55-c8fe-475b-a67d-7c54be66eaae" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_30b247d0-d41b-4144-a022-bd5f254b5819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationAMEA2020EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38a48e3-8141-412c-86a4-11e2b2a0a765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38a48e3-8141-412c-86a4-11e2b2a0a765" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:to="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_dbe3def3-4b27-4cd1-9aa9-26dd37517a2a" xlink:to="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_563ef5c4-7e20-49a0-910b-508ed3ab62ad" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_84e8da0c-5bf9-41f7-a78a-036188ab611a" xlink:to="loc_gh_AMEA2020PlanMember_563ef5c4-7e20-49a0-910b-508ed3ab62ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654253f6-32fa-4c16-8cdb-0f724ac8cedc" xlink:to="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_635d85e2-2aeb-4586-82cc-d33ee77fdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d5654-8d5a-43d1-8738-a9cd2a3b4f53" xlink:to="loc_us-gaap_CommonClassBMember_635d85e2-2aeb-4586-82cc-d33ee77fdc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_baabe152-b00f-49f9-bb1e-9c6f34dd626f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:href="gh-20210930.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf23d7ff-0dee-46f9-991f-b4453b312c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf23d7ff-0dee-46f9-991f-b4453b312c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_893ca2ef-2f60-43f5-aa29-cdf3d2aa94d9" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross_893ca2ef-2f60-43f5-aa29-cdf3d2aa94d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_7086ddab-dc99-4d52-aef4-775889563b9f" xlink:href="gh-20210930.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross_7086ddab-dc99-4d52-aef4-775889563b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50667ff0-46a2-4ce7-9b74-7258c55596e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_00b53929-479a-4d23-a1a6-68821371ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50667ff0-46a2-4ce7-9b74-7258c55596e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28a7868d-0671-4ad3-8ba6-05ec9378fab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28a7868d-0671-4ad3-8ba6-05ec9378fab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95c9aa61-9282-48b2-8e67-e1d9d450b170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95c9aa61-9282-48b2-8e67-e1d9d450b170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_01b666da-043c-4db4-b112-ad5a7709d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_01b666da-043c-4db4-b112-ad5a7709d9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69f7a889-f63c-44f8-aa2f-77588ebbccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_69f7a889-f63c-44f8-aa2f-77588ebbccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67fbf892-a2fe-4b91-ba04-66f75921b728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d10d2ef5-048e-4cf3-93f7-0c54d198e36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67fbf892-a2fe-4b91-ba04-66f75921b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_415fe152-635a-4e03-a7ca-a5da59c80b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_415fe152-635a-4e03-a7ca-a5da59c80b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee685f9d-0b75-4178-a673-083c9ca92ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee685f9d-0b75-4178-a673-083c9ca92ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4921e6b-abcc-4faa-9a54-21a377487445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4921e6b-abcc-4faa-9a54-21a377487445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfbd4128-d851-4705-b600-0c8cd59de53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfbd4128-d851-4705-b600-0c8cd59de53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_116bf156-af7f-4230-b84c-cae143a826e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_116bf156-af7f-4230-b84c-cae143a826e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_debc17b8-9c5d-4470-b34d-bf357fbe30a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0a2b6f3-e435-449b-bb8b-16d315a4a22a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_debc17b8-9c5d-4470-b34d-bf357fbe30a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61d0c435-4557-4080-955b-553d820edcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61d0c435-4557-4080-955b-553d820edcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2d0faa32-0553-4386-b844-8e937aa46765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2d0faa32-0553-4386-b844-8e937aa46765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3bcd3b9-3112-4c03-8274-e305fc715219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4479bc03-6fe3-4960-b102-f97b623ce30d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b3bcd3b9-3112-4c03-8274-e305fc715219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_453b4db8-1f40-4566-a850-dcf26135bd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_453b4db8-1f40-4566-a850-dcf26135bd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_834946d9-0c98-481e-bebd-141ab18bcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f979eb6-260e-4eaa-9db9-619552fb79f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_834946d9-0c98-481e-bebd-141ab18bcbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f81b81b0-73f2-47b3-9021-d630edfbfbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f81b81b0-73f2-47b3-9021-d630edfbfbfb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_416d58e8-1e42-41e0-a23e-d9dd5090a6ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_278f3993-628d-4cc1-b275-0875201b5790" xlink:href="gh-20210930.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_gh_PrecisionOncologyTestingMember_278f3993-628d-4cc1-b275-0875201b5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_94156ce3-57c0-46b5-826d-6948633dccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_94156ce3-57c0-46b5-826d-6948633dccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_57a1e144-50f6-4ba5-8e70-1fee4d9b7ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_57a1e144-50f6-4ba5-8e70-1fee4d9b7ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7cd74e88-886b-4f59-a905-d7a6f39ad8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff753338-2635-4f2d-b516-52a403df8945" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7cd74e88-886b-4f59-a905-d7a6f39ad8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df27996b-6f68-4796-9466-2501eb77829c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dd19689-d862-464c-96d5-a8c7161ef2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20e37f4-9b98-4d5b-b644-f6fd26c5f06a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dd19689-d862-464c-96d5-a8c7161ef2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_157db373-e029-4f6d-a32d-6031b14a1673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_157db373-e029-4f6d-a32d-6031b14a1673" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:to="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_74b62b65-cc08-474e-8f6e-f75b70e814ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cc9c0cc2-29ae-42ca-9c4c-08b03814c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdd9623e-99f7-46a8-bf3e-4a20f2b81224" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cc9c0cc2-29ae-42ca-9c4c-08b03814c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:to="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_102f96e0-90d8-4d80-87d6-6ac20eb33a3b" xlink:to="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_549aba10-0142-4117-8222-cc76902daa1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:to="loc_srt_MinimumMember_549aba10-0142-4117-8222-cc76902daa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3826dee-ff24-4a99-825b-32d2a441126b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a070e7bd-278c-44e1-ae98-7df95a639a5e" xlink:to="loc_srt_MaximumMember_f3826dee-ff24-4a99-825b-32d2a441126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf4e125-3497-4860-bafc-ea5705913714" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3eb770d2-b2ab-4f2f-8def-d01c64a747ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3eb770d2-b2ab-4f2f-8def-d01c64a747ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6607c0a4-c3b8-4271-a7fb-cbbd5dad7fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6607c0a4-c3b8-4271-a7fb-cbbd5dad7fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fd26d93b-36a0-4108-87b0-1f181435b3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fd26d93b-36a0-4108-87b0-1f181435b3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dde290c-96ce-4c5c-8270-c65f4c9bf56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9063ec9-c11f-4c32-b9d9-8d3baf802ddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dde290c-96ce-4c5c-8270-c65f4c9bf56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40b76681-5a16-4a0e-9cdd-f5cc8a1f9177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40b76681-5a16-4a0e-9cdd-f5cc8a1f9177" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:to="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b5e69698-5b53-49ec-a1ae-25b157acc2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_606ad38b-414d-4139-adc5-559d9db7be4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1afc847a-163e-47b1-9e30-6a9043980ee9" xlink:to="loc_us-gaap_EmployeeStockMember_606ad38b-414d-4139-adc5-559d9db7be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd766786-7084-4fa1-8f0b-4bdb9f38758c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e288a27a-c1e2-4800-bff4-4d63c72ed3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e288a27a-c1e2-4800-bff4-4d63c72ed3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba270629-53b3-4ab2-9a05-a23d676b7dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba270629-53b3-4ab2-9a05-a23d676b7dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_83eb76ed-3d39-4ee2-aed3-4a59fabdabbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_83eb76ed-3d39-4ee2-aed3-4a59fabdabbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24900fb5-234c-475c-91f0-413f533b57c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805e91a-b662-48d7-9cb3-340b16f6cd6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24900fb5-234c-475c-91f0-413f533b57c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="simple" xlink:href="gh-20210930.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e4aec6fa-6533-4dcc-a9a5-a5b7e350c2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_904a5353-4526-4d4b-9fd7-462ed4c440d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e4aec6fa-6533-4dcc-a9a5-a5b7e350c2be" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_904a5353-4526-4d4b-9fd7-462ed4c440d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="simple" xlink:href="gh-20210930.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a52b0af8-b56a-48e6-ab6e-0365c49cb70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b6d6a80d-1aff-40c1-97e3-928f7a6ac862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52b0af8-b56a-48e6-ab6e-0365c49cb70d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b6d6a80d-1aff-40c1-97e3-928f7a6ac862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b632e1e3-80dc-4820-9a02-1dec5c46a1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a52b0af8-b56a-48e6-ab6e-0365c49cb70d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b632e1e3-80dc-4820-9a02-1dec5c46a1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_03992b10-dbd5-4fa8-93c1-e4e2897a2b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_ProfitLoss_03992b10-dbd5-4fa8-93c1-e4e2897a2b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_45be69b4-c4bb-4b31-8748-1d079da0d006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_45be69b4-c4bb-4b31-8748-1d079da0d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9cff54ed-f62b-4059-87ba-b879deccd775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9cff54ed-f62b-4059-87ba-b879deccd775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca7d67f3-e40b-4752-b6c1-956dd448fae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ca7d67f3-e40b-4752-b6c1-956dd448fae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4ad5e933-5a76-434b-83be-7a951bf61486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_EarningsPerShareBasic_4ad5e933-5a76-434b-83be-7a951bf61486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02e75f9a-5f59-4c2b-a0ec-ca2a232e8573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02e75f9a-5f59-4c2b-a0ec-ca2a232e8573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1335db4-a809-48cb-bf2a-93cc82fc276c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a1335db4-a809-48cb-bf2a-93cc82fc276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2139a724-e8e4-4f21-9111-a311ec747fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e474875-8f93-406f-9c5a-3daa7c4dd553" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2139a724-e8e4-4f21-9111-a311ec747fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_753b8bb6-83d2-458a-bbe9-ee32d63fc127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_753b8bb6-83d2-458a-bbe9-ee32d63fc127" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_282352af-adc3-4654-98f6-8df0e813b116" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_333613e9-d4b4-4aa0-b781-5718b64aa018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_333613e9-d4b4-4aa0-b781-5718b64aa018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56eaa90a-7814-44ee-96ce-15ca30410465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56eaa90a-7814-44ee-96ce-15ca30410465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e4e88918-beeb-45ad-8f55-09501e491077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_PerformanceSharesMember_e4e88918-beeb-45ad-8f55-09501e491077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PerformanceBasedRestrictedStockUnitsMember_86f887db-a884-4212-b4fe-b7cd046484ff" xlink:href="gh-20210930.xsd#gh_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_gh_PerformanceBasedRestrictedStockUnitsMember_86f887db-a884-4212-b4fe-b7cd046484ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_da31cef3-e1e7-425f-823c-10fa711e8b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_EmployeeStockMember_da31cef3-e1e7-425f-823c-10fa711e8b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d7e304df-e119-4b32-8fdf-9b5a9b9df95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d7e304df-e119-4b32-8fdf-9b5a9b9df95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f1834ef5-9733-41d0-8370-080dd5744af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c33e83a1-8050-489c-a8f8-b4a16183a28b" xlink:to="loc_us-gaap_SeniorNotesMember_f1834ef5-9733-41d0-8370-080dd5744af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d99e485a-5cb3-4275-a761-394d04c9c28c" xlink:to="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AMEA2020PlanMember_8b9a2005-9a0f-49d2-ab39-f82978b6787c" xlink:href="gh-20210930.xsd#gh_AMEA2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_02b37bd9-2561-4188-b13d-becba11d6c39" xlink:to="loc_gh_AMEA2020PlanMember_8b9a2005-9a0f-49d2-ab39-f82978b6787c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7055eece-1ffc-4b32-af47-bae14563910c" xlink:to="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7cf357a3-d24d-45a5-8571-49dd355f60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_842aa933-2f8e-476b-a787-1a5db33fe5d1" xlink:to="loc_us-gaap_CommonClassBMember_7cf357a3-d24d-45a5-8571-49dd355f60c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35abc0aa-d969-44b5-baed-09ecd4ed46ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0470b13e-9a6b-495e-98d1-09ba310a5521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0470b13e-9a6b-495e-98d1-09ba310a5521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad695483-e540-4eda-a889-8b94d027a550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a468f441-0eb3-4a6e-a7c8-f1a982950bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad695483-e540-4eda-a889-8b94d027a550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gh-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_28ede55b-c718-4aec-aaa9-ae7d9674daba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_163bbddd-4574-40ca-aea7-b99602642bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28ede55b-c718-4aec-aaa9-ae7d9674daba" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_163bbddd-4574-40ca-aea7-b99602642bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="gh-20210930.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f30c3f55-41b3-45a9-8614-a2ec90b63d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_be3e2d07-83b3-4456-af53-0fef7ec6da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f30c3f55-41b3-45a9-8614-a2ec90b63d74" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_be3e2d07-83b3-4456-af53-0fef7ec6da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="gh-20210930.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c3dd67c6-a22f-4a71-9ff4-ca5ce2d20cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_23542d38-58d3-48a0-9955-25c0828acbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c3dd67c6-a22f-4a71-9ff4-ca5ce2d20cea" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_23542d38-58d3-48a0-9955-25c0828acbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SegmentandGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3906f148-8052-47b6-b572-86cd8493dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3906f148-8052-47b6-b572-86cd8493dc7b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f4117da5-a3fa-4435-9775-9aa55b663342" xlink:to="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_414ce1e7-ae7e-4040-acea-dafc4d2c0358" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:to="loc_country_US_414ce1e7-ae7e-4040-acea-dafc4d2c0358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_323f1763-3916-413b-b627-3d070a259966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c772df6d-6423-4b1f-9bfb-f2461f50b9d7" xlink:to="loc_us-gaap_NonUsMember_323f1763-3916-413b-b627-3d070a259966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5317153b-df64-4761-8e20-661027283539" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsMember_b62582f4-4552-439e-9237-0a3b4675deba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6e81567d-e1d0-4dc7-a159-c1fdc81e2383" xlink:to="loc_us-gaap_AssetsMember_b62582f4-4552-439e-9237-0a3b4675deba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af6f3808-50a7-4142-949e-04f08c64d4ce" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b71fd8b0-2938-4b9e-929a-e1b78af2f179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_454d6871-3b95-4f44-bcac-f83a559ad2c3" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b71fd8b0-2938-4b9e-929a-e1b78af2f179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_494cda56-7d0d-4240-bbd4-53e9a7f697f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_7946030c-4bad-4221-858a-a74d72893458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4134a0ff-e234-4abc-8efd-d261828fe794" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_7946030c-4bad-4221-858a-a74d72893458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ee24b502-69e6-406f-8eb0-695902bbef0f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a3fe3f7b-8f3b-4eae-ab9d-80cd56d68fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:to="loc_us-gaap_Revenues_a3fe3f7b-8f3b-4eae-ab9d-80cd56d68fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3ca0f4ee-e4a6-4c14-9b8b-d4352faca7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c449a1f9-9c1d-4496-be70-0f49ac5335d7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3ca0f4ee-e4a6-4c14-9b8b-d4352faca7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="gh-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_33a35f40-387a-422d-8787-e2b58e48886d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e3c8ca18-9554-4eda-9cb0-7132b2ec3654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_33a35f40-387a-422d-8787-e2b58e48886d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e3c8ca18-9554-4eda-9cb0-7132b2ec3654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gh-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_38aedede-ef19-4e07-b19a-fdf1ac7c5ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_41d828ae-4ffb-4865-a80f-e8ccf6357ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_38aedede-ef19-4e07-b19a-fdf1ac7c5ada" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_41d828ae-4ffb-4865-a80f-e8ccf6357ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="gh-20210930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_52767d76-7b54-4adb-999e-3e142273018c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_52767d76-7b54-4adb-999e-3e142273018c" xlink:to="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_de0bb532-417c-439a-8f3f-342726b065ce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_678dff75-761f-44cf-88c5-df777324c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feaa6b1c-b70b-43b5-b028-e88485a98749" xlink:to="loc_us-gaap_SubsequentEventMember_678dff75-761f-44cf-88c5-df777324c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:to="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_704d4c95-ceb9-46b4-87b3-694ab272492c" xlink:to="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_478fe68b-39eb-49db-882a-ccf490129dbe" xlink:href="gh-20210930.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_07270f09-b0b4-4627-b70c-80b755509d73" xlink:to="loc_gh_SoftBankMember_478fe68b-39eb-49db-882a-ccf490129dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0e77e3ca-a6a3-4df6-9382-49c21c84c8b6" xlink:to="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_d9ab904b-aaec-42c6-9a8c-3efc0f8fd440" xlink:href="gh-20210930.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_403b946c-d773-4672-981f-3b243ad70f67" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_d9ab904b-aaec-42c6-9a8c-3efc0f8fd440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>gh-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:gh="http://guardanthealth.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gh-20210930.xsd" xlink:type="simple"/>
    <context id="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i257839cad923440aa7e18dfdf53c45f1_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i95165abecdd04d43a21f2a1198ebe3f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i78e4ce20d6fa44b99855dfa0287375ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87072388cc314ce488bc187e99179f36_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id99d1f03db58476b865112b51f6b69de_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id13d009641754c8c975c6fe1fe537d29_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icb188ab333be4dc08b9c5f417ad86fe8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibdb78fae6878478e8cd70530ed7da501_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6d56b88a0c04c4c8b36e3c969d626f2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic93be9beff734563914f49b1f9d826c1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8cde6611fe144c878e5f147907f65625_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5a0784b897b4b27a75ddbda8d07eaf8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74b5b40f197c4b2b865e8b6c841941a6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie2724b9af04a45ff87503e333da07ebd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i45bee42491de4f5c82ed9ebfd0441c85_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i906ccbde79194f08bb0f80f06e646f90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5db331e94f874da2baee789ff575651f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if6d4e7bb16784bd9821eebce7010e751_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i661bf286fe924b48b215bb888a02d853_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i29ac4fdfdbf1465f928c369ad560835b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8b663835ceaf4a199e40a3acf8f4be0b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifa05344a7c40424eb0df008620fe83e9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d8d6e638e7348069924511ee4d47851_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id55be54d3da949a5a9de5778b8b05dec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58fce8977c7741018238eb1946bda5f1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1bad68bc160b4bb083ffeadb14d426c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3a25d82718384a71a7a9e81dc3b6f434_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9963cbea62ef4985b9e091e63f42672e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if00f5560ad1c408eb348e0b4b24055ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifd3cecf4e8114f768c9e12d1be9f15ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11487705f65f4d059cb0b6be76a69cd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e83cfa49ff4496aa510e2385e131bc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice4f1518b17d478bac803e4fdfda2df2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d8678c58ece47b29c05d97165d5d969_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8137948ad1cf4ec2ae5768ff46f1e611_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ae691b8ed7640cbba3e0cfbe95f8ce8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ea4d482e7e042e7a7764275e7e2b782_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11d815861a524636a58d12c0365da761_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17b1ceded2d84e4d989b48de6331e0bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb1c87214cd44be4b4ddea1be858f87b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i32e0e7a381cb4c54b6fa6ca304bcfb9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ea269815d434d1da3aa9ef5ae46f173_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5ee9c09290c467d9d3e214ca77c3592_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i539db53b7f21487595b91dc1d07cc09b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6724a88cebfe46be8cd1c0db1eb07e71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5bba3a03f7745a29d33398d6eff80ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06d6010708ee46bfb896d95969e67179_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e1fba2cc4574405a14c237af96ff0aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6905570ee74c4bbab460aeff1b55a0cb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaacefe81c0f14186af54df7f09699324_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id09d1ad0faad479daa3acc238b4cd800_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f9601fedfcd4106983c11355226e3ab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i956c76338cf9472792fc8fb1eb5c02f1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id98fa25d42954af2baa244b886e1c86d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b1b80c40c794c5483e2a614b550e4df_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd1b5cb3bc064b06ab1c3b5a280c72e7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id99f62e950344ebd9a1b6da0b6c5ce54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3be6ab2fcffb478c974ac3fefc049dbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icad452344b214db5813fddb4470c5555_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26ebea8c7fe84cd99c89b4a20e1252ee_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ib17fe7f4e508446f9ee412617b8ed455_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e32f7150de24707acc5c5ece9051c90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gh:Guardant360CDxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45b5b98c81024b9fa1cc9ef6f43bb435_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic64931530ecf46b0b986e9644237b683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id82f3289e43a450fb918eac02af264ac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ieb65abbec30b4f71a61b44720b765997_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ief4823a55ced453d9a74182e29b5dab5_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ibd2a1b5721c14e62ae22216f233394a8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i45ddcd6f8bc5427ea47298e84035d15d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4d59f69aa9304c82926efc78bf2688b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i10beec7190eb42289690ddc970be2e86_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i63b22c3fce9b49408a166a3ade4c8098_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i696cb7034a6f4fb389687d5640e8bc6f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8f9afa11a3f342b681841d1bdf79f0eb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:GuardantHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i28b82c98a5b04b45b4ba1de5d14ba5cd_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c382b53abce461ab4ceb209bd8a2229_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c715ccc41be43d897292cbe1d39f9f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if43dd801a43d47509034a8a6ad46dfe4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia3a1976e448f44da9ad1282432ecaeac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if9e2ff3854534beeaf5dc50347518efe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacafa40cbdf74f16a6b76e5fdc92f851_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i47b0c64f26ce4de4af37ae79bd0d1434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf7b2e27a68941b58e1e1594d4e640e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0f4b951f099240f586e94280a7a195c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i731507644762422f81775c71bb607b97_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64406783e2224dfaa1cac0323c19c1f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if17983378a2a4dfcb8807f9d3349a6ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia9b3d8119d074276b8c7bb266b246df3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia094abf062614978a5479b8fdfa6ba48_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0ddcdc04122487cb058c12bdc3fea32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifef80966c25e4f1aa85af95075561dd8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ieb9d64efcd8c4a0f82752998dc008845_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6490275f39504f90b9b21f3da8745ba7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a6c732b2f1046c48b1d0d53909608fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f9aa35947e840c4b0b33827767997bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i76479fc684134352b6d1f8659b4db3ef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3e5705acfb0548e7b94cd94788d1ba48_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib7711072385f46159fba26d2b137c91c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idc2ce09c97a54496b5adf47fc9df36f8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia644451d18b64b7891f97794ae28ed16_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i609248da19584e879becf882254ecfb7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifda5c7f43186404280efac8c9a712d5b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i873b7ae2fa894be79e1fc9fe51be3fdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5652f79c7265447095ac9b9f6f19cae7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iede67ca17f9c40bbbeff9eb83a33fa3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d94d00f18354bbfbb8b4c63e3b1c4fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cb4a56587574e1d832fec1efcbaec69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia83bff0162ba402f8a5a944a54a92646_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaed8b5de01f446c6891f88b6fba84cd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i009e431b909f4623af5c2eedf68ec9ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e521bd99f3f4da5a1d7079867423b9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if515c37e228643f3898be215740476d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04d51626bd954ba3a9951e2ea7a902f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06071e62b6544aba8290bd086369fa36_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i43ca599f32394a52802faedc82b745af_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i63b460bf00d240ccaa69bfe375444037_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57c53847548a49db87515a3ddbad4e6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia00d793f144d4af4a1ce283df7b0e5b8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f752295bdb0485d837d6f29e1adac2e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia4544e28f7504c5c8262ad98b729df14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8439291e86774964951a992f2d6ab802_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c5288cacba948db9667020c833d81ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i911375a84b704c0ab9bb33fe21b322dd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i99e3f9841c1a4adea92f051369b7a09e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f9a75142a80484ebfaba480ea0f7c83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i271b6a1089814cb6944c8c41c026a282_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2d2672bc23d34d2783b636a52ec86105_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia10b7a8bcf704572915d199375bb6896_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50d01bf14b454648b34a008c20d39400_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c794762acd24ec4b36b7bc0040e7a7b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idbef017000f243ac8d113e85196f3c88_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1066cfd83fc4ddb923b546c7803df9f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaddd38c4b0ed4cddb1ce69265363289b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0e1d770a04da46f0b432b0284fb196c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22f931c2c6fc4c78a009b5427bf45c7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54c3f12b90c242a3ae68a02bd72acb55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4550cb15256748d2a89b9750438c5b41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if196b52749ca4701a0fa9abedbed7ded_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:DebtInstrumentConversionAxis">gh:ConversionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ib821d04236034791b8d3fa9b120448ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iad5e0b1db685472892b3b4d4be7ab044_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82ce7dd079ac4bfd882a6e3d866ee98c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26bb0381128745be8004975327b5b957_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd9648256b9c411694a641721c1541a0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id32f5d1807074b2793d40078426095aa_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i96636707b48c4179884f86ea7ec8a02f_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i62c26cb48e8240adb2b3260459d61952_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gh:ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i993c2da446a34875acb1c40b068b3089_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i55c4a05385cc4fc18d198385dd93c921_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8e71a02ecacf4adcb391e6c7f12702d1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i2cb77ccae9a74814b7e00acb580b3aab_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gh:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia25c787a137a4bec9fd1a061e1adf313_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gh:PaloAltoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i86f9ba8b79324beb88e8b7488d9694c8_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i32f365a013324f7ab9a257ec6616bfe4_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i660c0774906b43d8862cee0a47049547_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i705721d0e67244739b045350d485c93f_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i9963f628118f43db994c73aa2c0b5931_D20201210-20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="ib18022bf9450402f8ce4975ec504ea61_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:FoundationMedicineInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01b665c40a8f47ea8cd85e635363d20c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e8d9afb89dd4632a8f43a7e0dfca6af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85be72137c66452fa6b52b9f18871115_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i619cc50dcce348cc8689f3c9699ad658_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib95921a37c5e43f49a9c3c37215251e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd2b5342dde3448c8891ca3d99b1978a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e477370d1a64fd2a0fa21ffcda04720_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib51f14efceef46e083455712a43bf986_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63475ab401474e89bee5f05a4a47acd0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3fc5ee952cf84418b7016f83429f0aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic958cc4df2714adb8e2a85c3302cae4e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i940221e6cce645cfb6a90604dac8cbe8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i5e73ee9eef8e49aab2ec36819934f632_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i5e9815d0d7cb41b09b77791966e52c75_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i565831a0298547cd9661d27b9d9d2944_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11b69d916f624dad9b518cabc4589b73_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i5f2aaefc2c4e43a4a37ff326738a3f25_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="ie634a7fb83674c7d92b925a5d6a99ec1_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="id1e7591cbb12410598b75394c40acba8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5c7f0c0ebc94b6bbbcfabf0a1fae5db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic51021850ccb4f1fadfb3bdbae1f91d3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib17cb1196a064f4088f3fc6c035e9d72_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia097fb6e0e4d41ed842060e7bc5260e5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b7a51301dcf41c98545f06434fe3b72_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:EquityIncentivePlanTrancheAxis">gh:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:EquityIncentivePlanTrancheAxis">gh:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia601d039561f4097b3df49643250b3bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a3300f2c9ff4ec6a29cf3cc30f0a698_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if58ffec0307a44cfaa204337af91208a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8537a86f1af94a2daf05f30b67b193e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0f17ed5a12ca4a6abb0cea17b1730fef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gh:AMEA2020PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1f46661f1f446eeb205375c1af434fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62d04197610e4189a303bead82651edb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc36477bea5640ec874839095e170908_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f4b78122abd4e8eb313c8e1a7719f92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b7fba181b054fabb73999b47d483dbf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38f6cfe7e6404cae9e7b6b09a000b0cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd4023c5dcd0439fb73518c68885f959_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i007fd51f89bf4055aa793319535aa53c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id22b70d2f2e34c20a09a9012c59cd21a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if66ec163b0d848a3a230072df877cf55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia23565c372dc4ccbb89ffb28f7af1b0e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77295fc586c94e54a8fba5426ea17938_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if994b46b023d4d5fa18a833907f95a23_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62c5b239ffb4440f80781154268288d9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9ba431512174cc5bfce850e0b0b12a2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b2e85ec40be47df923a27894e32515d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i477964bc10504bb0938d30103ef7edac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1104e86268b4788bd3ab46af5668636_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58da51c726c84bb7a102eab630e19383_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3851733963a44f5b6ab5baa83678583_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic36d7e888e844c6ab365df40d7c9fb62_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i439505c15efb47c09a20226584e2c489_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5e2eb5867bd4abdad9efdb23c03648e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cd8dd76287347a8994cc91cb0f37e54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f1590c4a013498998b04d6183682906_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i563548405428432e9be4583d990c20a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1764a9cb4164255b21e4e0410cbdd27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i467c75e1f7b948f5a7efd31013b1df18_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59f3361b30354d25bc950de5b659ed29_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib61bba0a88cc44568eb34939ff6408d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i051dbab8706f4e6c98fecf9f6683eeac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0255fd6f42d4f048e85959bd465c936_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8dae2902d6664783b4358b0e7fc11e28_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebaae8e37d2b469097bb427b4661df0f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c69dc8a627e4728912a6ed479ffc345_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48e9f1511fdf4cfcb8763f4f23670aa0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9347e34e544e4e239b40143f08c828bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68a11b9af24a42609ff2239dde8e7b4f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gh:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib68413562a6147688552dc1e0f887f19_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8824d00a82d749e4ae56c26f8bf3f10d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i181b6be341c14cacb65432c7b26b5d1a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i754a60ee0b734d8c8d484dab169687c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifa67442147d24fb6a1c2a53972720ac1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac62ba63e55f4ede8b1e77117a996888_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4779950a41b74addaabf2b2059d74b21_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i237f233fbe394afd8d627b2eb131fc5b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i323c4b627b0a459fba3b36b35483f280_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d16e8391a8340adbde54906d31ca966_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ca0eb25cb4e48be9a03dadf144d511d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54d2bc7082434cad8d5831042bf6a66e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b784372c3354db186e4207099919653_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibade6416d9d94221aaa09a5c56f76ec5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idac36981cc6c40c8b223afae0434d59f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide1277ed3fdf429fb8b2ce51e59b628c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1476a97484154965919c2e362fd4d837_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cd900800a93495eafddef1dfbea5516_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d20b34408944d6f96387d39fb1726ed_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23bce519e74e4d918ca90a92c7c39f65_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if34f8da1addc4820a1cb6767365cb8a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i818a62562a3c4a978a87e6b139e9bdc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3edbb27baf14454882593f853aa8325b_D20211101-20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>gh:segment</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="patent">
        <measure>gh:patent</measure>
    </unit>
    <unit id="petition">
        <measure>gh:petition</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8xLTEtMS0xLTA_1ebc3fef-3191-490a-9b7e-da87793ceb5d">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8yLTEtMS0xLTA_f335cb2a-7f98-4f73-bdf2-0335c1009288">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV8zLTEtMS0xLTA_04253823-d364-40cd-be6b-3e10bb295267">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV80LTEtMS0xLTA_cc6c33e3-7bf5-4b65-bef8-3aa2c4483ab9">0001576280</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80L2ZyYWc6MGFhZjMzZjI1YWY2NDQwNTgwMjU4Yzc0OTk1ZmFmNjQvdGFibGU6ODI4MzViMTFmNDJiNDhjNjliNDA1MjhhYWFiNzQwNDkvdGFibGVyYW5nZTo4MjgzNWIxMWY0MmI0OGM2OWI0MDUyOGFhYWI3NDA0OV81LTEtMS0xLTA_91634e41-c25d-45e3-95cf-39fc8f4c1846">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0wLTEtMS0w_9d07a004-36a9-48d1-b674-4d4b1c3ba821">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i62c26cb48e8240adb2b3260459d61952_D20201101-20201130"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83My9mcmFnOjJiNzg4MWMyMGE4NDQ0YTQ5OGRmOGU5NmU4ZGMwZjQzL3RleHRyZWdpb246MmI3ODgxYzIwYTg0NDRhNDk4ZGY4ZTk2ZThkYzBmNDNfMTA5_e5a2080c-fda6-46ce-b3d4-db3949b22b3c"
      unitRef="number">0.0071523</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNTI5L2ZyYWc6MDRmNGNhODQzZGQ2NGEwM2FjYTQyNGNjZmU1NGU0NTAvdGV4dHJlZ2lvbjowNGY0Y2E4NDNkZDY0YTAzYWNhNDI0Y2NmZTU0ZTQ1MF82NTk3MDY5NzY2OTA1_25b69c68-6c8b-4d22-b043-d460ddb8e898"
      unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="i5f2aaefc2c4e43a4a37ff326738a3f25_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYwOA_1a96adcc-20aa-4c2d-b632-070a36d742ec">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <dei:DocumentType
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI3_a56e1fec-3131-4b45-97ff-65f4bc0f90da">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM2_7ddd3b42-9dfe-41d9-87bf-28fa6cfca110">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yNjQ_1af382ad-a4a1-46c0-ba7c-2376a5a93312">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI4_fe9f4122-5468-40c3-871d-55497f7daea0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM3_c822194f-4e05-446f-a639-3915ae263f64">001-38683</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMx_1dcf2aa8-0b28-45ec-a4ed-c99123456331">GUARDANT HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDNlZGUwMmQ2ZDRkNDAzNDgxMjIyYzA1YmZkYzFiMzkvdGFibGVyYW5nZTowM2VkZTAyZDZkNGQ0MDM0ODEyMjJjMDViZmRjMWIzOV8wLTAtMS0xLTA_590dcc66-468a-4d23-879f-ed25a57dd147">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDNlZGUwMmQ2ZDRkNDAzNDgxMjIyYzA1YmZkYzFiMzkvdGFibGVyYW5nZTowM2VkZTAyZDZkNGQ0MDM0ODEyMjJjMDViZmRjMWIzOV8wLTItMS0xLTA_e5bb52cc-0bed-49a8-aed6-85b23958fc88">45-4139254</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI1_6d97a27f-b489-49a8-b24e-796ddf537fdd">505 Penobscot Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI2_4587ddbd-4c76-48b9-b677-02cd48cc99db">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzI5_75e3f54a-c69a-4891-ac26-c2ded90c3d5c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMy_80d2ded5-e388-4e25-b012-f93405b4e63c">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMz_d35e8417-e5a4-45d5-9607-93d130fa1735">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM0_53a00bd6-924e-4ef2-b1d6-dd7ebfa30f4e">698-8887</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTAtMS0xLTE0OTg3_eb81e164-9ce9-4187-a33f-0bcf78e2b5b7">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTEtMS0xLTE1MDU3_401a7043-3e2e-4292-ac68-7c0a4aa76c0a">GH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6ZDA2YTUzNzliYWRjNGFmZThjMTZhZTViZWQyZTdmNzAvdGFibGVyYW5nZTpkMDZhNTM3OWJhZGM0YWZlOGMxNmFlNWJlZDJlN2Y3MF8xLTItMS0xLTE1MDU3_7255250f-b9a5-47b6-b78f-fac692deef8a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM1_3b091813-d4ed-4091-8111-d199f9c51bf2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzM4_85858d7b-6803-4022-ae99-28f0e0d11687">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N18wLTAtMS0xLTA_d15b0d6b-5a7a-4641-ab0e-dc549afde48f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N18yLTMtMS0xLTA_e1137a89-4659-4a39-931c-5189bfa7bf5a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGFibGU6MDBiOTRlMWY5NzE1NDY5N2IxN2E4YzBhMmY3MGRjNjcvdGFibGVyYW5nZTowMGI5NGUxZjk3MTU0Njk3YjE3YThjMGEyZjcwZGM2N180LTEtMS0xLTA_9ab329bd-a3bf-4495-9914-25d3bf11e500">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMzMw_2725c5e9-d43a-4910-8d31-89f55b6bb32f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i257839cad923440aa7e18dfdf53c45f1_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xL2ZyYWc6ZmIxZDlmM2JlYTM4NGM4ODk1YTFmN2ZhZmVmNmI0MWQvdGV4dHJlZ2lvbjpmYjFkOWYzYmVhMzg0Yzg4OTVhMWY3ZmFmZWY2YjQxZF8yMjYx_37a44129-68b2-4734-884c-ff3a4644bb8e"
      unitRef="shares">101656348</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMy0xLTEtMS0w_06621355-4dd0-4a84-8a4e-fb0141571e28"
      unitRef="usd">832370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMy0zLTEtMS0w_c6f1c789-7726-4e48-8cba-3b9e6bb22c88"
      unitRef="usd">832977000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNC0xLTEtMS0w_4304e9f6-3041-4d0a-9bcc-65da590771d4"
      unitRef="usd">653601000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNC0zLTEtMS0w_0c746a16-5c93-4036-828e-96f7eb51eeab"
      unitRef="usd">961903000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNS0xLTEtMS0w_42451ebe-27bf-42c6-991b-840620fdcebf"
      unitRef="usd">60744000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNS0zLTEtMS0w_df0846c9-491e-46f7-aee7-01ff8704d4d2"
      unitRef="usd">53299000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNi0xLTEtMS0w_b9dc1304-83ff-4aaa-982b-fbec8efcfe79"
      unitRef="usd">24739000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNi0zLTEtMS0w_9f095775-b2f5-40e4-b762-a6d05adabd98"
      unitRef="usd">22716000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNy0xLTEtMS0w_df88cbbc-1a29-4a12-9ac5-69b26803c2ad"
      unitRef="usd">21958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfNy0zLTEtMS0w_40d4cfe9-a4f7-4d9c-8ae3-9bc83f94e100"
      unitRef="usd">17466000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOC0xLTEtMS0w_defd9942-b2b5-4c0e-a175-79dbdb83b0a2"
      unitRef="usd">1593412000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOC0zLTEtMS0w_c8b1e79c-f1ec-4da4-bcff-10bb6298e1f3"
      unitRef="usd">1888361000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOS0xLTEtMS0w_6377a85a-d6db-4a22-b062-2cea03db05a5"
      unitRef="usd">250226000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfOS0zLTEtMS0w_719898c1-50c5-46a6-b8af-b435f1a7b0d5"
      unitRef="usd">246597000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTAtMS0xLTEtMA_8c8b2d85-7ec0-4725-917d-052419eb7764"
      unitRef="usd">106156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTAtMy0xLTEtMA_7d5f97d6-3438-406c-af15-522f97e1a028"
      unitRef="usd">62782000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTEtMS0xLTEtMA_2b4cb95c-2ee4-49dd-8207-cbdf0d1ed2db"
      unitRef="usd">196436000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTEtMy0xLTEtMA_6bdb7429-ae9b-4d65-bc9f-db4c3eb56b44"
      unitRef="usd">37343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTItMS0xLTEtMA_ea3513dc-500e-4c44-ace2-8c01c71dc01e"
      unitRef="usd">14698000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTItMy0xLTEtMA_46d4ba4e-9b54-4111-a415-439000c127da"
      unitRef="usd">16155000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTMtMS0xLTEtMA_f6864097-dd02-4328-9dc3-d24246396fdc"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTMtMy0xLTEtMA_6e832056-35be-4e58-89d7-4347ed9729fb"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTUtMS0xLTEtMA_e193948d-d04c-46f1-8c7d-9b3ed6310c2c"
      unitRef="usd">61316000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTUtMy0xLTEtMA_a188304b-f34d-476d-b59c-7d2ebeb70465"
      unitRef="usd">17253000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa"
      unitRef="usd">2225534000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b"
      unitRef="usd">2271781000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTktMS0xLTEtMA_c12fc3bb-8144-4e2f-a8fe-68f95c7705eb"
      unitRef="usd">15674000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTktMy0xLTEtMA_d9469699-3c4b-480f-bb63-9bae0423f6b7"
      unitRef="usd">7340000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjAtMS0xLTEtMA_4c757bd4-b5b5-40fc-bce0-d83b8fdbd1af"
      unitRef="usd">38838000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjAtMy0xLTEtMA_f04a75f5-569c-464c-831e-0ab98660fd03"
      unitRef="usd">28280000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjEtMS0xLTEtMA_c69ba13a-4c00-4e2d-9330-63551aa91c1d"
      unitRef="usd">40475000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjEtMy0xLTEtMA_6a2826e9-a72b-4735-a8cc-d05cb86b5bd6"
      unitRef="usd">22639000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjItMS0xLTEtMA_f5441a6e-b084-4e44-b16a-e96ba46b2aed"
      unitRef="usd">7317000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjItMy0xLTEtMA_9654345c-d0f2-4b54-a03a-defc1dd2d729"
      unitRef="usd">8550000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjQtMS0xLTEtMA_9c707816-6b57-41b2-82a6-c285a930d6ce"
      unitRef="usd">102304000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjQtMy0xLTEtMA_746db415-9a5a-4b77-96b5-4dd5601e060d"
      unitRef="usd">66809000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjUtMS0xLTEtMA_d266e7d0-f166-47a2-8527-27db01ab2a52"
      unitRef="usd">1134180000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjUtMy0xLTEtMA_a113d7cc-f76c-4d9e-b481-04f76a6dd8f8"
      unitRef="usd">806292000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjYtMS0xLTEtMA_957c58f0-bd46-4ecb-a974-125c706703e2"
      unitRef="usd">216806000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjYtMy0xLTEtMA_de428892-ced6-470a-9e11-476dc5b8d05e"
      unitRef="usd">41565000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjgtMS0xLTEtMA_cf1b7e90-acb3-4f36-969d-1d563ea7bb05"
      unitRef="usd">3424000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjgtMy0xLTEtMA_3cfc0e12-5a50-4fe0-80e0-03753d7daa60"
      unitRef="usd">1520000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba"
      unitRef="usd">1456714000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014"
      unitRef="usd">916186000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzEtMS0xLTEtMA_e1d21720-5ac5-4e24-a84e-9f6a1d5558f9"
      unitRef="usd">59400000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzEtMy0xLTEtMA_9d7f9405-efa1-4863-bc66-9eca932acaea"
      unitRef="usd">57100000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzMy_5486e4b0-56d7-4d1d-bd0e-3daf0d228292"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzMy_81ce9684-08d9-43b2-95a4-f1ea3e36ab4c"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzQ2_67bc6b00-e2c9-4bcd-8494-128005b70bf1"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1XzQ2_b8f3322a-1bbb-4c93-bdbb-909501c78743"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzg0_1f46c38d-cc7a-43b5-9c72-128ea4d93cc4"
      unitRef="shares">101623257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzg0_9867a4f9-1a9f-4e3b-896a-62117c016c8f"
      unitRef="shares">101623257</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzkx_41e77e7c-4dea-4787-a5c0-51c255e4bb7a"
      unitRef="shares">100213985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYThkZjk5MmFmNTQ4OGM5YTJlNGJmYWJiZjkzN2I1Xzkx_aea314a5-1577-43bd-9895-26418e8afa71"
      unitRef="shares">100213985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMS0xLTEtMA_d1f6580d-30f6-4b52-b4d4-20cf63b31c3c"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzMtMy0xLTEtMA_90f34f71-24ca-472b-8eec-16c064659285"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzQtMS0xLTEtMA_2e820141-3029-4359-8ab8-0fd0633f07df"
      unitRef="usd">1626926000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzQtMy0xLTEtMA_0d2e9a3d-f5de-4909-a208-0113781050de"
      unitRef="usd">1902389000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzUtMS0xLTEtMA_212b561d-7ea6-4cf3-8059-f28efbc31af4"
      unitRef="usd">-593000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzUtMy0xLTEtMA_d030ae9b-e067-45ae-99fd-a976830b37f5"
      unitRef="usd">2697000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzYtMS0xLTEtMA_72599b93-cbfc-4f2c-b492-35b4b39f011b"
      unitRef="usd">-916914000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzYtMy0xLTEtMA_ea337442-6bf9-478a-8ccf-83c0017b2f17"
      unitRef="usd">-606592000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzctMS0xLTEtMA_dd6f8206-9e4b-428f-bd9b-19215bc6abbc"
      unitRef="usd">709420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzctMy0xLTEtMA_e56f7039-1d48-40a5-b496-67106dce071b"
      unitRef="usd">1298495000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzgtMS0xLTEtMA_2b302aaa-88f9-4f87-9361-68f0ae913dd9"
      unitRef="usd">2225534000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMzgtMy0xLTEtMA_0bc9b131-af64-4701-8168-8268a6a05c69"
      unitRef="usd">2271781000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMTcw_9cce2791-d380-4915-9a21-a4afc7a5c203"
      unitRef="usd">24800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMTc3_98024a33-36ea-459d-9997-632dd6f1ce11"
      unitRef="usd">35000000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMzMw_27c7ef38-d0b6-4910-8c39-e98f06b0218c"
      unitRef="usd">3800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfMzM3_6faf0b88-7102-4200-9809-5a33746a05fb"
      unitRef="usd">4900000</us-gaap:Liabilities>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC0yLTEtMS0w_b83a3486-e888-486c-a84d-f3fb240cc697"
      unitRef="usd">79272000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC00LTEtMS0w_53018183-84c7-49ec-b7f7-6578c9f2998e"
      unitRef="usd">60384000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC02LTEtMS0w_fcef5b7f-a432-4ea8-a81a-f0b97e1a40ca"
      unitRef="usd">215605000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNC04LTEtMS0w_742163d8-c70c-4faf-89c0-8e07f24c8051"
      unitRef="usd">171621000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromDevelopmentServices
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS0yLTEtMS0w_fd995c82-fe9d-492e-af8a-20c5b3d9853a"
      unitRef="usd">15507000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS00LTEtMS0w_fc82e93f-d70e-47c6-b0df-633c32f52671"
      unitRef="usd">14185000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS02LTEtMS0w_957e9a85-02ce-428f-869d-21fca000af0c"
      unitRef="usd">49940000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNS04LTEtMS0w_2bc14ac4-3ab0-43d2-a251-d5f08d24e0ba"
      unitRef="usd">36793000</gh:RevenuefromDevelopmentServices>
    <us-gaap:Revenues
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi0yLTEtMS0w_670114de-9831-4dd2-9f0a-2bc3bcb7e481"
      unitRef="usd">94779000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi00LTEtMS0w_078f1c85-cea3-4633-b193-4f83eb932e1e"
      unitRef="usd">74569000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi02LTEtMS0w_b5b0f52a-8bf5-4fcb-b147-ff098c21ea9e"
      unitRef="usd">265545000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfNi04LTEtMS0w_17f0abda-0142-4a0b-acb9-307c0fc1d359"
      unitRef="usd">208414000</us-gaap:Revenues>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC0yLTEtMS0w_33e7bd0c-f862-4691-92da-c0f6b69fb501"
      unitRef="usd">29665000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC00LTEtMS0w_83218ee7-e304-4d23-8ff9-f6b90705c83e"
      unitRef="usd">16699000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC02LTEtMS0w_4c2dc5a9-2b8c-402e-abbc-54ccd9d4ae98"
      unitRef="usd">78142000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOC04LTEtMS0w_7fe8aa60-1765-49d6-8754-3ac20e105b38"
      unitRef="usd">52699000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostofDevelopmentServices
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS0yLTEtMS0w_05d8bac4-240d-45b6-b246-8b72ba0866c0"
      unitRef="usd">1151000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS00LTEtMS0w_9d3f3e0d-9b7a-4c59-a40f-1b51af4f1959"
      unitRef="usd">4488000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS02LTEtMS0w_f268b065-3380-452c-9271-a2444f6e2bb1"
      unitRef="usd">11348000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfOS04LTEtMS0w_5cce8f62-70d3-4903-b71f-f0bf13880972"
      unitRef="usd">11429000</gh:CostofDevelopmentServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtMi0xLTEtMA_96e1dfaa-9c8c-4dc5-9633-7535fddfa3d4"
      unitRef="usd">70968000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtNC0xLTEtMA_b8c458ef-2aa2-4d22-bebc-aa0e35d87c85"
      unitRef="usd">36245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtNi0xLTEtMA_c936ce0f-15c9-42b5-9405-d2de1b6c0113"
      unitRef="usd">190200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTAtOC0xLTEtMA_a63bc231-77ab-4ff2-956f-f39207d13f13"
      unitRef="usd">109580000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtMi0xLTEtMA_4572cf7d-ec5e-4d82-8602-85d74cfb6801"
      unitRef="usd">50228000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtNC0xLTEtMA_a5777e50-20da-422d-861f-0546facd48b4"
      unitRef="usd">25095000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtNi0xLTEtMA_b56d2da1-778c-45d4-8280-3ec6350716c1"
      unitRef="usd">132282000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTEtOC0xLTEtMA_97067742-0432-4030-a7dc-3af62d639c4a"
      unitRef="usd">75225000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItMi0xLTEtMA_51cfe6d3-1c53-4a7d-a45e-37a032c2e105"
      unitRef="usd">50055000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItNC0xLTEtMA_9cc0ece4-2a79-4a7e-aac7-f57b7aeccef0"
      unitRef="usd">66294000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItNi0xLTEtMA_d74c2f85-1d43-45f3-ac49-4e3d161c7359"
      unitRef="usd">166366000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTItOC0xLTEtMA_faadc261-c868-40cf-bb73-c3d1e03c1e41"
      unitRef="usd">123265000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtMi0xLTEtMA_e87257ae-23cc-4937-8fa2-095cd9c1d6c6"
      unitRef="usd">202067000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtNC0xLTEtMA_5d9f6851-ed4b-4a01-ba54-b4c427e4ecb1"
      unitRef="usd">148821000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtNi0xLTEtMA_1be0e7a9-26e0-4e87-ab40-ed9411ec60ea"
      unitRef="usd">578338000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTMtOC0xLTEtMA_5f88204a-6198-41ee-8179-89227075a913"
      unitRef="usd">372198000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtMi0xLTEtMA_efc06eab-0717-47ec-8234-7a8505b34ad1"
      unitRef="usd">-107288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtNC0xLTEtMA_8444b5f4-821e-444f-82f1-a7b7fbe9bae9"
      unitRef="usd">-74252000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtNi0xLTEtMA_7f76d54b-a455-4b1a-aa3a-d2b4a3c5d62e"
      unitRef="usd">-312793000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTQtOC0xLTEtMA_95276797-0b5c-45b7-b5c0-fe995ab3f6b9"
      unitRef="usd">-163784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtMi0xLTEtMA_cb32dceb-4bae-435e-a466-f0d73e08ca6b"
      unitRef="usd">689000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtNC0xLTEtMA_dfdc1d4b-b31c-4a82-bbef-bc82a011f3e6"
      unitRef="usd">2313000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtNi0xLTEtMA_625728c7-63aa-40a0-a9fa-eff0a3754c04"
      unitRef="usd">3277000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTUtOC0xLTEtMA_dd069029-4e52-46e2-bd84-c2ee48a3b610"
      unitRef="usd">8271000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtMi0xLTEtMA_a2a58ef3-28b7-4d65-907d-d564627d5cc5"
      unitRef="usd">644000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtNC0xLTEtMA_86d5f7c3-12b7-434e-8dbf-d04c19af1f28"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtNi0xLTEtMA_1057dda5-c7b0-4786-a6ae-6ae465657102"
      unitRef="usd">1934000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTYtOC0xLTEtMA_d9da2904-9819-4781-aa42-633c7f3b498b"
      unitRef="usd">30000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctMi0xLTEtMA_d015a16a-66ea-4282-be38-363a51c216dd"
      unitRef="usd">-187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctNC0xLTEtMA_454666e2-1d08-4378-b931-95eacc6086b3"
      unitRef="usd">345000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctNi0xLTEtMA_7322cf65-6c9e-4e77-ae83-0a6c12a8ae4a"
      unitRef="usd">-720000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTctOC0xLTEtMA_c5f8545d-f0d9-4897-80eb-c5d42a0d9c6a"
      unitRef="usd">2421000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtMi0xLTEtMA_131a382a-11a5-4198-bf7f-711f8c8bb1df"
      unitRef="usd">-107430000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtNC0xLTEtMA_56daff61-34d4-46f2-8ac5-3f6a4d8feef4"
      unitRef="usd">-71602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtNi0xLTEtMA_3d2a8f84-3f55-4473-ac68-1a9dc362d4af"
      unitRef="usd">-312170000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTgtOC0xLTEtMA_d1806d68-94c5-445d-9c8d-a1b2547b4098"
      unitRef="usd">-153122000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktMi0xLTEtMA_7167e935-bd39-4674-b999-85c10edcd50c"
      unitRef="usd">96000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktNC0xLTEtMA_aa8608c7-5b48-421a-b58a-be3f48502f5b"
      unitRef="usd">68000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktNi0xLTEtMA_f53f78e1-ff80-4087-9b73-53491d5784fe"
      unitRef="usd">289000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMTktOC0xLTEtMA_1ecf9643-2d94-4ae3-94e7-1500e18166e0"
      unitRef="usd">116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtMi0xLTEtMA_59db747f-076e-4505-9eb7-1d22cbfc1b0d"
      unitRef="usd">-107526000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtNC0xLTEtMA_a0121778-5a45-46b2-9f6a-7836e37a0777"
      unitRef="usd">-71670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtNi0xLTEtMA_ad364a64-db59-488b-9385-7093fb39c5fd"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjAtOC0xLTEtMA_8cd55105-bc67-4660-8f5a-4e79dc7c7479"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtMi0xLTEtMA_f3e119d4-f9f5-4feb-bfd5-3afdbd85b20f"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtNC0xLTEtMA_749f4ff8-6a22-4cf2-b99a-881220d0b919"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtNi0xLTEtMA_47a648a4-d589-4149-b2f5-5365477bdd8d"
      unitRef="usd">2300000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjEtOC0xLTEtMA_b4834c52-aa07-4182-8f9b-57e006c71cb7"
      unitRef="usd">6800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItMi0xLTEtMA_366a6785-efd6-47e7-b843-571410c64cf6"
      unitRef="usd">-107526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItMi0xLTEtMA_5447ec3a-3a9e-44e4-98a6-3feb085ad11a"
      unitRef="usd">-107526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNC0xLTEtMA_410ffa11-4a5a-49bc-b8d7-7fed493daba2"
      unitRef="usd">-77670000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNC0xLTEtMA_c548aac7-7661-484b-9b6f-b4f6c35316e8"
      unitRef="usd">-77670000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNi0xLTEtMA_042a4ad0-eecf-496c-86af-a6963d056692"
      unitRef="usd">-314759000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItNi0xLTEtMA_5b7296af-6c8c-42a3-ab5d-61f9f3040771"
      unitRef="usd">-314759000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItOC0xLTEtMA_4d2f0a82-606b-4aa5-a6d1-23bb36549fa5"
      unitRef="usd">-160038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjItOC0xLTEtMA_c7ecd8fd-6dbd-409a-8476-c91a3efb1e8e"
      unitRef="usd">-160038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtMi0xLTEtMA_8d523389-6bb3-4a2b-a73a-1573fa2cbe6a"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtMi0xLTEtMA_d945464a-6ab8-49b2-aafd-f94dca4f4947"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNC0xLTEtMA_a937a2b6-dccf-491e-9fad-0ab1220a4630"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNC0xLTEtMA_c3dcaf05-f431-449d-9632-3bc7c368dece"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNi0xLTEtMA_e312dd27-7785-4b85-a892-ccdde8c3ae69"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtNi0xLTEtMA_e939f6dc-867e-4158-ba4c-e54ab28117bf"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtOC0xLTEtMA_4c390a83-7e9c-4e03-96d3-fac429e1419c"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjMtOC0xLTEtMA_7ae52ad2-a258-48d7-abbf-8cb7e6947465"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtMi0xLTEtMA_3547942d-001f-4f89-9522-43b8ed67973f"
      unitRef="shares">101420000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtMi0xLTEtMA_5036dc6e-bb14-4fef-850b-f10c73d98915"
      unitRef="shares">101420000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNC0xLTEtMA_08983a6c-b99c-4ced-840d-737f5a71a651"
      unitRef="shares">99554000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNC0xLTEtMA_cf6de157-4e44-4669-9ab7-a2e06d25892c"
      unitRef="shares">99554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNi0xLTEtMA_2a1dc424-e264-474e-ad8e-ac2aac3ddd5f"
      unitRef="shares">101184000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtNi0xLTEtMA_5c25cd97-5ffd-4e1c-a043-bb3a1fd5fb96"
      unitRef="shares">101184000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtOC0xLTEtMA_74fc4605-5672-419d-831c-43e6ab0cf64a"
      unitRef="shares">96659000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xOS9mcmFnOmY0OTI5MzE5ZWY2NzRlODdhYmI0ZmFlNTM1YjkzYWM4L3RhYmxlOjYyMjM1Y2FhZjMyMzRhMTRiODg2MjUzZTEzNjI1YTc5L3RhYmxlcmFuZ2U6NjIyMzVjYWFmMzIzNGExNGI4ODYyNTNlMTM2MjVhNzlfMjQtOC0xLTEtMA_772ea594-c73c-4bfb-a0b9-e5a0b2538257"
      unitRef="shares">96659000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy0yLTEtMS0w_bd079a2a-3529-4fc8-b1ab-5af8054a8542"
      unitRef="usd">-107526000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy00LTEtMS0w_afe3d011-0c0c-4d4d-b6f7-78ad906ec9c9"
      unitRef="usd">-71670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy02LTEtMS0w_d821f2b5-d24e-45a5-82a3-ad24e1af1b08"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMy04LTEtMS0w_3419fcd5-e91b-49ef-beb5-31f276075917"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS0yLTEtMS0w_6da303e4-ce51-44e0-8892-1b7554bb20c0"
      unitRef="usd">-513000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS00LTEtMS0w_2f3bac1c-c742-4529-b07c-e135280fd99e"
      unitRef="usd">-1721000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS02LTEtMS0w_9c427ec2-9b06-46af-9d98-abe7872e7d82"
      unitRef="usd">-2097000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNS04LTEtMS0w_927a9e61-1a0a-41c4-8ffd-7dada6bde1d9"
      unitRef="usd">2512000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi0yLTEtMS0w_83e4d5a6-78bf-4d84-ad3f-4e6a7d8c803c"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi00LTEtMS0w_0c46dc78-4cfb-409b-b1b8-3cb84faa331d"
      unitRef="usd">191000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi02LTEtMS0w_6f252e36-6503-42a9-b071-f49278322c6d"
      unitRef="usd">-1193000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNi04LTEtMS0w_48e48474-4645-4392-b5fd-6494d52e290a"
      unitRef="usd">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy0yLTEtMS0w_7ded6ce1-0a5d-4876-b1a4-3f417af88a39"
      unitRef="usd">-626000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy00LTEtMS0w_dd430b23-ed79-4d4c-9a06-859c141e50eb"
      unitRef="usd">-1530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy02LTEtMS0w_6692368d-db3f-4546-97bf-1e6c0b126156"
      unitRef="usd">-3290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfNy04LTEtMS0w_7ecfc6b6-d5e8-47c5-a125-d552df85ac16"
      unitRef="usd">2751000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC0yLTEtMS0w_49c5cb53-41ba-4a6b-a87c-7e5de924349c"
      unitRef="usd">-108152000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC00LTEtMS0w_f26f38df-786c-4726-8ac1-519ab4d61e01"
      unitRef="usd">-73200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC02LTEtMS0w_05f0ff98-a682-46ae-9db0-d5fb4604ae33"
      unitRef="usd">-315749000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOC04LTEtMS0w_daa57f63-e63d-48e6-97da-64b95756a17a"
      unitRef="usd">-150487000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS0yLTEtMS0w_e47ad6dd-3add-4eea-8f0c-104479179eac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS00LTEtMS0w_19dfe005-6718-464b-9ae6-2062cb999009"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS02LTEtMS0w_fe003414-d2d5-4d12-a1b4-19405f124dd7"
      unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfOS04LTEtMS0w_14ca654a-304b-484c-954e-4df60a97f179"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtMi0xLTEtMA_276c9a93-7a5b-4034-9dd4-8a0a438b63e0"
      unitRef="usd">-108152000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtNC0xLTEtMA_bada12ec-9c65-446e-8a58-2fd489c13af4"
      unitRef="usd">-79200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtNi0xLTEtMA_7e4d5ce7-bcfd-47da-a3d3-1669d830f1d9"
      unitRef="usd">-318049000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yMi9mcmFnOmZlMTk0NTZkMzlhMDQ2MmY5OWYwYWRiNmJlMjAwYzc5L3RhYmxlOjVhNmI5OWRhYWU1OTQyODY5OTgzY2RjOTYyOGZlZjg5L3RhYmxlcmFuZ2U6NWE2Yjk5ZGFhZTU5NDI4Njk5ODNjZGM5NjI4ZmVmODlfMTAtOC0xLTEtMA_0118bd5c-38c4-4cfd-b385-abb2e899a504"
      unitRef="usd">-157287000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="id13d009641754c8c975c6fe1fe537d29_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xLTEtMS0w_0b20eb0c-ff84-40ae-b3a6-423b1bc8c955"
      unitRef="usd">59400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="icb188ab333be4dc08b9c5f417ad86fe8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0zLTEtMS0w_ffa0007a-e22b-4bf4-ac7d-fddd55f967e5"
      unitRef="shares">101265100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icb188ab333be4dc08b9c5f417ad86fe8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy01LTEtMS0w_b9c38def-ffe7-44e1-93c2-b1fa493c8fa3"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdb78fae6878478e8cd70530ed7da501_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy03LTEtMS0w_11805495-1df5-4cc2-94f0-ff2540e5e26d"
      unitRef="usd">1597419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6d56b88a0c04c4c8b36e3c969d626f2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy05LTEtMS0w_b3dc244a-524c-498c-95af-207c5641b03b"
      unitRef="usd">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic93be9beff734563914f49b1f9d826c1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xMS0xLTEtMA_17d1be39-d438-49b3-9dd5-663c7010a40e"
      unitRef="usd">-809388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMy0xMy0xLTEtMA_48a284fa-6e8a-40c8-996d-06ef2c02fc52"
      unitRef="usd">788065000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8cde6611fe144c878e5f147907f65625_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS0zLTEtMS0w_ab29cb40-6225-4f99-b775-5f2bb1743f1d"
      unitRef="shares">257535</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS03LTEtMS0w_338fe924-ef42-4eff-9df3-22461d91d86c"
      unitRef="usd">1677000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNS0xMy0xLTEtMA_938854cf-bc13-4381-a35d-6240e88848aa"
      unitRef="usd">1677000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8cde6611fe144c878e5f147907f65625_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNi0zLTEtMS0w_97e1303e-9b3f-4c0b-9305-b5d024f75afa"
      unitRef="shares">100622</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNy03LTEtMS0w_5d983468-c76c-4043-abef-b103c331a608"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfNy0xMy0xLTEtMA_3574ca90-bd1f-4981-905a-36b97a764dc3"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfOS03LTEtMS0w_2f17a900-675f-46b7-9fbf-e08b291e7928"
      unitRef="usd">7199000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfOS0xMy0xLTEtMA_69e01742-8672-4b11-be73-c8ff59e95e2c"
      unitRef="usd">7199000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9d81479687bb4b0a8baae8b3e463d2e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTAtNy0xLTEtMA_4f7b0022-68fa-458c-867d-f7df23341777"
      unitRef="usd">35016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTAtMTMtMS0xLTA_9bc7b9a6-1558-456d-845a-48c73201c258"
      unitRef="usd">35016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5a0784b897b4b27a75ddbda8d07eaf8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTItOS0xLTEtMA_cdb69281-481d-417e-9a62-f0a34ed48704"
      unitRef="usd">-626000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTItMTMtMS0xLTA_36142a70-c353-48cf-a054-d950995c6c53"
      unitRef="usd">-626000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i74b5b40f197c4b2b865e8b6c841941a6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTMtMTEtMS0xLTA_9e674bb5-6070-47ca-8fa3-a741df528012"
      unitRef="usd">-107526000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTMtMTMtMS0xLTA_b9eff289-2e19-4519-9599-b98fcedd2084"
      unitRef="usd">-107526000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMS0xLTEtMA_935f6e45-ccec-45dd-b9a2-31a20babbb7b"
      unitRef="usd">59400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMy0xLTEtMA_1083dc46-43a7-42e5-9f22-d8b14055c19c"
      unitRef="shares">101623257</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtNS0xLTEtMA_06b78a72-a9b8-4e94-a79c-8dec2c6d409d"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45bee42491de4f5c82ed9ebfd0441c85_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtNy0xLTEtMA_98eb6bfd-bf04-43b2-bb56-3ac75f1945cb"
      unitRef="usd">1626926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtOS0xLTEtMA_9c9a84c1-f4b2-404b-9bc0-7e92891d62cd"
      unitRef="usd">-593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i906ccbde79194f08bb0f80f06e646f90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMTEtMS0xLTA_1fe24627-72f1-4a47-959a-595eaa52546e"
      unitRef="usd">-916914000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjYwN2E4YTkxMDU4YzQzNTJiZDVlNjg2OWYwN2UxM2U1L3RhYmxlcmFuZ2U6NjA3YThhOTEwNThjNDM1MmJkNWU2ODY5ZjA3ZTEzZTVfMTQtMTMtMS0xLTA_b370948c-c442-4204-9999-79442a8a56ba"
      unitRef="usd">709420000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i5db331e94f874da2baee789ff575651f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xLTEtMS0w_3ca451e6-7612-4646-97ee-2ae3ffca6059"
      unitRef="usd">50400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="if6d4e7bb16784bd9821eebce7010e751_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0zLTEtMS0w_8771296e-d964-418f-806e-eff139ce69cc"
      unitRef="shares">99312237</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if6d4e7bb16784bd9821eebce7010e751_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy01LTEtMS0w_ca0a3455-375f-4aaa-8a2f-ea436b63e48c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i661bf286fe924b48b215bb888a02d853_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy03LTEtMS0w_71528abc-f71b-458a-a10e-35a1da87de08"
      unitRef="usd">1544373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29ac4fdfdbf1465f928c369ad560835b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy05LTEtMS0w_1d2d7c77-5006-43b6-83dc-7c4fd31c4b35"
      unitRef="usd">5392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b663835ceaf4a199e40a3acf8f4be0b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xMS0xLTEtMA_e1aa2b26-b145-4040-9e58-c4401b960799"
      unitRef="usd">-435177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa05344a7c40424eb0df008620fe83e9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMy0xMy0xLTEtMA_6310d344-22b2-4645-9dbf-52f8cc9ad786"
      unitRef="usd">1114589000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS0zLTEtMS0w_16450200-3673-4d64-87d9-b5f568e8f045"
      unitRef="shares">533962</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS03LTEtMS0w_6d217bb3-8688-4fd3-ae34-da401c618bc8"
      unitRef="usd">3851000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNS0xMy0xLTEtMA_d93473a1-74d9-4a2b-b958-b778bab18443"
      unitRef="usd">3851000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i01bc5e7484d34f2ab2e1d34229421799_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNi0zLTEtMS0w_4d5e0248-82ac-4984-a238-53e43b4fe23b"
      unitRef="shares">50989</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNy03LTEtMS0w_f4fb1880-43ba-42f6-9599-8e3d4cb62d50"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfNy0xMy0xLTEtMA_17a4febc-ce88-484a-bf17-15e8d751ee16"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOC03LTEtMS0w_b578a940-5da5-4953-9283-71320a72486a"
      unitRef="usd">2247000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOC0xMy0xLTEtMA_036fd14c-1fb0-400a-9588-2df3e93c661e"
      unitRef="usd">2247000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia0ffc8fa3ba546088f54dd903eb48346_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOS03LTEtMS0w_034b1e54-cc10-473e-9149-c279f81f4dcd"
      unitRef="usd">55198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfOS0xMy0xLTEtMA_6bbaf747-2c1e-44bc-9f34-d5dcfe82f249"
      unitRef="usd">55198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i7d8d6e638e7348069924511ee4d47851_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMS0xLTEtMA_2f831246-7204-4abc-aacf-6f5a9a9fa520"
      unitRef="usd">6000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMTEtMS0xLTA_d37edb77-d75f-4faf-8a67-01829797fe99"
      unitRef="usd">-6000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTAtMTMtMS0xLTA_4dd3cd7c-b104-4850-bbca-a2a5b2350a29"
      unitRef="usd">-6000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id55be54d3da949a5a9de5778b8b05dec_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTEtOS0xLTEtMA_a6c56227-29b0-4053-9516-a7157ec16e8e"
      unitRef="usd">-1530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTEtMTMtMS0xLTA_b519796a-6054-4f47-854b-3b20e98285ba"
      unitRef="usd">-1530000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i82dc3c212af44baf9eaecd58f0fe9e3f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTItMTEtMS0xLTA_980feaf3-ca9c-4cc4-84e2-5ebd63cd22e4"
      unitRef="usd">-71670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTItMTMtMS0xLTA_0f2e1652-da04-4bb1-ab15-1a5ee1be853f"
      unitRef="usd">-71670000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i58fce8977c7741018238eb1946bda5f1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMS0xLTEtMA_8f72da3c-e5ac-4700-86bf-3ce5b17fa47c"
      unitRef="usd">56400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMy0xLTEtMA_04d3adc4-95bd-4659-a18e-be2d79acce85"
      unitRef="shares">99897188</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtNS0xLTEtMA_1be25b82-418b-4e0c-a255-95ec8fdeeeee"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a25d82718384a71a7a9e81dc3b6f434_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtNy0xLTEtMA_5140dd94-0b27-42a8-b9d9-f7e8a0dab161"
      unitRef="usd">1601188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9963cbea62ef4985b9e091e63f42672e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtOS0xLTEtMA_8514285a-d043-4e0f-bf3a-029678d819b9"
      unitRef="usd">3862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if00f5560ad1c408eb348e0b4b24055ee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMTEtMS0xLTA_f13bd795-812b-4d78-b1a8-958f1e8de70d"
      unitRef="usd">-512847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yNS9mcmFnOjg2YjBiNTc5YzVmZjQ3YTZiNGE0YmFhNWMzNTQzZmNlL3RhYmxlOjY2ZWRjOTgzOTE2ODQyM2RiNmE3ZWYyNzhhYWMyOTEwL3RhYmxlcmFuZ2U6NjZlZGM5ODM5MTY4NDIzZGI2YTdlZjI3OGFhYzI5MTBfMTMtMTMtMS0xLTA_43e105e3-6522-4d54-90ec-f85d58bd35a4"
      unitRef="usd">1092204000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ifd3cecf4e8114f768c9e12d1be9f15ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xLTEtMS0w_fc6f3e16-f9d1-42de-8d84-7728bf86ac2e"
      unitRef="usd">57100000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i11487705f65f4d059cb0b6be76a69cd9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0zLTEtMS0w_66a39f67-6630-4de8-a805-9c3a758c3585"
      unitRef="shares">100213985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i11487705f65f4d059cb0b6be76a69cd9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy01LTEtMS0w_63c91e57-64bf-493d-a417-4756a6d62970"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e83cfa49ff4496aa510e2385e131bc3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy03LTEtMS0w_c78da577-73e6-4011-b089-62960e569a21"
      unitRef="usd">1902389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice4f1518b17d478bac803e4fdfda2df2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy05LTEtMS0w_4284a0c8-a987-43ae-aa3a-bc353715eee7"
      unitRef="usd">2697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d8678c58ece47b29c05d97165d5d969_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xMS0xLTEtMA_482860b6-0381-4431-a748-7b6566559b7e"
      unitRef="usd">-606592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMy0xMy0xLTEtMA_a6ffec3d-736c-4b79-884d-01d638a29560"
      unitRef="usd">1298495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8137948ad1cf4ec2ae5768ff46f1e611_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS03LTEtMS0w_cfd27988-0ffa-4126-8301-90bae6cc710d"
      unitRef="usd">-330403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ae691b8ed7640cbba3e0cfbe95f8ce8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0xMS0xLTEtMA_bfe4a634-4cb5-4e68-a318-c23674b734e5"
      unitRef="usd">4437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ea4d482e7e042e7a7764275e7e2b782_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNS0xMy0xLTEtMA_2d7ffb5a-7a73-4f4f-8d6c-fde2669721e9"
      unitRef="usd">-325966000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi0zLTEtMS0w_cd60d698-4f75-4001-a4ca-6f61cac90e6f"
      unitRef="shares">629246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi03LTEtMS0w_5b25ceca-b3fa-49bd-b58d-f48f864fbd7b"
      unitRef="usd">7065000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNi0xMy0xLTEtMA_43abde13-0422-4ef4-b0ad-75b1a62aa70d"
      unitRef="usd">7065000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfNy0zLTEtMS0w_901283e7-0933-4562-8a84-e67905542c8b"
      unitRef="shares">719128</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOC03LTEtMS0w_7db49632-2387-4a1f-a68e-eceeae391353"
      unitRef="usd">39000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOC0xMy0xLTEtMA_b216ba57-5ecc-410a-a346-841b436e4771"
      unitRef="usd">39000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i11d815861a524636a58d12c0365da761_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS0zLTEtMS0w_18bfe04a-84e4-48ac-80ea-c676e3ba0cc5"
      unitRef="shares">60898</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS03LTEtMS0w_60d27bde-6d05-4f22-a37d-09003b80f19b"
      unitRef="usd">5401000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfOS0xMy0xLTEtMA_3380f8e0-2d96-4d8e-abf4-83e160d55822"
      unitRef="usd">5401000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTAtNy0xLTEtMA_7d93fe16-8e0c-4765-ad9d-1aecef41466e"
      unitRef="usd">82157000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTAtMTMtMS0xLTA_8dea9d34-f81f-4195-b46a-e713131c952d"
      unitRef="usd">82157000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6617b82e967b49c6b8d5f814500e7737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTEtNy0xLTEtMA_33aa7909-43a8-4944-bbfb-2c4d8610c07d"
      unitRef="usd">124592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTEtMTMtMS0xLTA_037426ac-8282-4dac-a57a-b8f3fda651a3"
      unitRef="usd">124592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i17b1ceded2d84e4d989b48de6331e0bb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMS0xLTEtMA_ffcd5aa1-9fe8-4522-974f-aa472e0227f6"
      unitRef="usd">2300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMTEtMS0xLTA_af2cbc72-a36d-408f-bf56-b9e14b500511"
      unitRef="usd">-2300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTItMTMtMS0xLTA_9947f491-3f58-415e-a316-eb4bc300994e"
      unitRef="usd">-2300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb1c87214cd44be4b4ddea1be858f87b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTMtOS0xLTEtMA_4d169002-1158-4026-a624-32120b7ef2c3"
      unitRef="usd">-3290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTMtMTMtMS0xLTA_72b48c53-9c70-4f02-a659-ed76e4e18fbd"
      unitRef="usd">-3290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i27b7f6ab603146a8896b60867da9a117_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTQtMTEtMS0xLTA_888d76a9-70ba-45ac-84b7-17d597505155"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTQtMTMtMS0xLTA_452a4222-82d7-4300-a365-add3e8740514"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie8487e6031c64116b02dfe2a4f88f3ac_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMS0xLTEtMA_23bd9f84-0cd5-4105-b784-4e002c9f09bc"
      unitRef="usd">59400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMy0xLTEtMA_d7268e2c-6cdc-4ac0-9f5a-5355a9716c55"
      unitRef="shares">101623257</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie2724b9af04a45ff87503e333da07ebd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtNS0xLTEtMA_2d022738-876d-4a7c-8acf-5343d6b4d211"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45bee42491de4f5c82ed9ebfd0441c85_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtNy0xLTEtMA_3319d528-2011-427d-8175-6cc3c03cb433"
      unitRef="usd">1626926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0a3edf495d84e8fa3f0befe17a0c08a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtOS0xLTEtMA_2dc5ede6-a2ae-4617-9aab-60eba7681b5f"
      unitRef="usd">-593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i906ccbde79194f08bb0f80f06e646f90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMTEtMS0xLTA_8f9a9255-901e-4d3a-9df2-5297ef24ef6e"
      unitRef="usd">-916914000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOjNiMTE2ZGVkMzFiNDQ4N2NhYTljMjQ4MTJlOTkyMGIwL3RhYmxlcmFuZ2U6M2IxMTZkZWQzMWI0NDg3Y2FhOWMyNDgxMmU5OTIwYjBfMTUtMTMtMS0xLTA_16847d75-2647-46fa-a231-07149e6a725d"
      unitRef="usd">709420000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i32e0e7a381cb4c54b6fa6ca304bcfb9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xLTEtMS0w_eb400862-f49a-4149-933c-f090d6a17dd9"
      unitRef="usd">49600000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i0ea269815d434d1da3aa9ef5ae46f173_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0zLTEtMS0w_483915b3-eaca-44f7-a816-2c82645bd858"
      unitRef="shares">94261414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0ea269815d434d1da3aa9ef5ae46f173_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy01LTEtMS0w_20915152-e809-4687-8ad5-869c4482092e"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5ee9c09290c467d9d3e214ca77c3592_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy03LTEtMS0w_c72442b8-4117-4441-a513-256fc02b0ace"
      unitRef="usd">1150090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i539db53b7f21487595b91dc1d07cc09b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy05LTEtMS0w_f441c1fa-b47a-4e59-a2f8-176e1344013b"
      unitRef="usd">1111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6724a88cebfe46be8cd1c0db1eb07e71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xMS0xLTEtMA_695f7501-824c-450f-a976-b449b5cf21eb"
      unitRef="usd">-352809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5bba3a03f7745a29d33398d6eff80ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMy0xMy0xLTEtMA_defe43bc-0f61-4cfa-9186-b3a98db6c6c0"
      unitRef="usd">798393000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0wLTEtMS0wL3RleHRyZWdpb246MzI2MjgzNTQzZmJlNDQzODlkOWFjMjI4NmQ0ZTMwMGNfNzU_cbc2c8b7-5cfc-4c94-b705-e6aeecda812c"
      unitRef="usd">1130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0zLTEtMS0w_b0b1a74a-9d15-49cf-8fb8-9801c63c96b6"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC03LTEtMS0w_9b561957-df9d-4a42-9b1c-28bff2d6b5e1"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNC0xMy0xLTEtMA_2eeed08b-7580-4627-91e2-5f0967aec114"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy0zLTEtMS0w_1f2330c4-9527-4b15-bba5-52e23b3cf6e8"
      unitRef="shares">1188519</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy03LTEtMS0w_423f1443-3bbe-4bdd-9ed5-823bd8ca1a92"
      unitRef="usd">7399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfNy0xMy0xLTEtMA_a5851b4e-00d1-4aeb-94e1-2914c9b1a48d"
      unitRef="usd">7399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOC0zLTEtMS0w_36f2bb5e-8422-432a-a874-c616b99c76c8"
      unitRef="shares">76591</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOS03LTEtMS0w_5c48fe21-d655-4cf2-9e0d-c39c5d5a3bd1"
      unitRef="usd">39000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfOS0xMy0xLTEtMA_b387270c-cbbf-4d7f-ba21-08dd8b0a62db"
      unitRef="usd">39000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i06d6010708ee46bfb896d95969e67179_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtMy0xLTEtMA_b8ad8744-bf3d-41e8-b826-16c117cdec37"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtNy0xLTEtMA_02d8afb7-43a6-4502-a253-3e09e331b651"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTAtMTMtMS0xLTA_da9aad17-467d-41cc-ad9c-4a3d5659707e"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTEtNy0xLTEtMA_426f44a7-df70-42a5-a2e1-3cfca3d48d0f"
      unitRef="usd">2247000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTEtMTMtMS0xLTEyNDE2_07c839c8-80b3-4ebc-b0b6-80bc71749fd4"
      unitRef="usd">2247000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25fbf98b755240ecb3a9542750ddac42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTItNy0xLTEtMA_14af7db6-cf63-40fa-9b3f-bc06d1be5396"
      unitRef="usd">87351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTItMTMtMS0xLTA_13bb65a0-e61d-4bb0-8bf0-373ed2165502"
      unitRef="usd">87351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i9e1fba2cc4574405a14c237af96ff0aa_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMS0xLTEtMA_84c23637-7637-459c-b500-3b7db180d6dc"
      unitRef="usd">6800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMTEtMS0xLTA_e29469a3-f9fd-46aa-8ef5-50d6495cb2bc"
      unitRef="usd">-6800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTMtMTMtMS0xLTA_2cbc9f15-6e58-435c-969b-f92cce70cbd2"
      unitRef="usd">-6800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6905570ee74c4bbab460aeff1b55a0cb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTQtOS0xLTEtMA_7dd58df0-b3e4-4210-bc22-75f245c3aab8"
      unitRef="usd">2751000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTQtMTMtMS0xLTA_fefc3041-e799-4040-93cc-4287d3605171"
      unitRef="usd">2751000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ice23b2efed4441c3a40076c0487eeb32_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTUtMTEtMS0xLTA_fcfd98d3-d81a-4637-bb9d-5da1f4db44aa"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTUtMTMtMS0xLTA_f19e266d-dff5-42b9-8951-3624e187d9c2"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i58fce8977c7741018238eb1946bda5f1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMS0xLTEtMA_e749f706-ee09-4647-ace9-0c257203abbb"
      unitRef="usd">56400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMy0xLTEtMA_fe38ee37-0c6e-4f12-ac72-d72e3b4ad430"
      unitRef="shares">99897188</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1bad68bc160b4bb083ffeadb14d426c4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtNS0xLTEtMA_a4612355-685d-4c67-80ba-c404d52b3875"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a25d82718384a71a7a9e81dc3b6f434_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtNy0xLTEtMA_28c5538c-cff0-41ca-92b6-b2b0ac9c8b0c"
      unitRef="usd">1601188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9963cbea62ef4985b9e091e63f42672e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtOS0xLTEtMA_6c27a84f-cf47-4c30-bdad-ec8d82c23147"
      unitRef="usd">3862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if00f5560ad1c408eb348e0b4b24055ee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMTEtMS0xLTA_9a38ae06-86bc-4de7-b81a-7d9a04a7de77"
      unitRef="usd">-512847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8yOC9mcmFnOjBkZTJmN2VmYjllMjQwYmI5MDMyZWQyNTE2YzNjN2U3L3RhYmxlOmU4Mjk0MTM2ODMwYTQ4MGFhNDM3N2U5NDFjZDE0MmY4L3RhYmxlcmFuZ2U6ZTgyOTQxMzY4MzBhNDgwYWE0Mzc3ZTk0MWNkMTQyZjhfMTYtMTMtMS0xLTA_83069195-d152-4fad-83d4-f190fb8df4c3"
      unitRef="usd">1092204000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNC0xLTEtMS0w_0ec7906a-b4e6-4f5b-a1f4-c9bf48690d47"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNC0zLTEtMS0w_a7c1cdf7-7b22-4f0d-93fd-dad28d174cec"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNi0xLTEtMS0w_609d9de2-891f-4075-80d2-752c0f823cfb"
      unitRef="usd">16181000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNi0zLTEtMS0w_3fbf5393-0e29-4a90-ac11-dcd67d6435ea"
      unitRef="usd">11462000</us-gaap:DepreciationDepletionAndAmortization>
    <gh:NonCashOperatingLeaseCosts
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNy0xLTEtMS0w_9908d6c1-9ad1-418f-927e-7959ede4ea7c"
      unitRef="usd">17782000</gh:NonCashOperatingLeaseCosts>
    <gh:NonCashOperatingLeaseCosts
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNy0zLTEtMS0w_6a30eb55-6146-47fe-94f4-9ecd647a21e8"
      unitRef="usd">3349000</gh:NonCashOperatingLeaseCosts>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfOC0xLTEtMS0w_538a55dd-3446-4809-bf94-027ee8308dce"
      unitRef="usd">0</gh:ChargeOfInProcessResearchAndDevelopment>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfOC0zLTEtMS0w_1c1f77fd-8adb-42ea-b970-0780d77d4414"
      unitRef="usd">8500000</gh:ChargeOfInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTAtMS0xLTEtMA_11dfd5d4-3fe4-4a9f-b374-534f4e1cb9c6"
      unitRef="usd">1845000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTAtMy0xLTEtMA_7f6f078a-38b8-4797-bea0-8eb0c266164d"
      unitRef="usd">-120000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTEtMS0xLTEtMA_c890506c-f53a-489a-b007-b3c6f3ae60ce"
      unitRef="usd">124592000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTEtMy0xLTEtMA_1e8aa657-3a94-4f46-9597-c804489d3ac4"
      unitRef="usd">87351000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTItMS0xLTEtMA_0de30a19-d9be-46c7-9a2c-15efc6bef2e0"
      unitRef="usd">1922000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTItMy0xLTEtMA_529e86d5-bf33-4392-94bc-9d15947295b8"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTMtMS0xLTEtMA_1fb27ddb-4cdb-4aaa-99ea-91179dd581ef"
      unitRef="usd">-9546000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTMtMy0xLTEtMA_e559d943-1d01-466d-ab49-99e6206639eb"
      unitRef="usd">-1636000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTUtMS0xLTEtMA_b9dc5f99-ff22-4305-9895-b5beec2c1000"
      unitRef="usd">-8000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTUtMy0xLTEtMA_fad02ed2-694b-4057-96ca-055081fa6907"
      unitRef="usd">-8056000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTctMS0xLTEtMA_1692bfdb-a7b8-4c02-9775-98a1ba2eeb62"
      unitRef="usd">7445000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTctMy0xLTEtMA_e2c0fee7-40e7-4978-81e3-0c846f128093"
      unitRef="usd">-11581000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTgtMS0xLTEtMA_c9d2fa5d-3f76-4651-81df-9bbda0d95368"
      unitRef="usd">2023000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTgtMy0xLTEtMA_9bc8da7c-67d8-44ae-928a-ceb34005c39d"
      unitRef="usd">12550000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTktMS0xLTEtMA_80e502ed-c247-4f83-b80a-c17ea6d65806"
      unitRef="usd">5758000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMTktMy0xLTEtMA_df19ad1b-4485-4012-8fd1-7aed95ea3253"
      unitRef="usd">-491000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjAtMS0xLTEtMA_423b905a-4395-4f51-8897-7c54cc49ce46"
      unitRef="usd">3226000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjAtMy0xLTEtMA_57534bd8-d5ec-4fc5-aa7a-4b147ea33940"
      unitRef="usd">7571000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjEtMS0xLTEtMA_71560655-3fc4-4058-a832-090296d7f8bd"
      unitRef="usd">6939000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjEtMy0xLTEtMA_03b43ded-038d-4767-8d9c-f999b8e8112c"
      unitRef="usd">846000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjItMS0xLTEtMA_c6a4a336-8ac1-4025-aa5c-3a9a22e553cb"
      unitRef="usd">10558000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjItMy0xLTEtMA_452e5e17-b18e-4e5b-bcbd-abc3f7886160"
      unitRef="usd">5480000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjMtMS0xLTEtMA_74707f10-9965-43ee-aeeb-68b6f1bf41c3"
      unitRef="usd">10484000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjMtMy0xLTEtMA_11d0d7d8-2d68-4961-8975-e51efb2e6dea"
      unitRef="usd">-1514000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjQtMS0xLTEtMA_815ca379-5f7e-49ff-9857-d49fea74126c"
      unitRef="usd">258000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjQtMy0xLTEtMA_4096dd2f-49df-4aba-accd-7c85e58e94a6"
      unitRef="usd">-3523000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjUtMS0xLTEtMA_945545a7-214a-4efb-8523-b22846204813"
      unitRef="usd">-1233000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjUtMy0xLTEtMA_9661a8ab-c81c-4e2d-8849-dd186272db58"
      unitRef="usd">-4940000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjYtMS0xLTEtMA_f137baab-65be-4d8f-905b-7fdbd0a2b115"
      unitRef="usd">-132029000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjYtMy0xLTEtMA_7021926b-9744-40a5-9d55-b886b660485c"
      unitRef="usd">-44704000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjgtMS0xLTEtMA_b1753776-4f85-4990-aba7-9883f955339d"
      unitRef="usd">334082000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjgtMy0xLTEtMA_31ff3d9e-6b86-4f2c-80bd-c9d1daec3eba"
      unitRef="usd">580172000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjktMS0xLTEtMA_482c6efd-a236-4e74-a313-622b2f97e141"
      unitRef="usd">627110000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMjktMy0xLTEtMA_b0fa3fc0-4074-404e-8f44-0d8a39f377c9"
      unitRef="usd">307548000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzAtMS0xLTEtMA_1ac1fac0-5f39-4b05-9d77-ceb25fdf212b"
      unitRef="usd">39076000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzAtMy0xLTEtMA_9995facb-cad3-4ebb-88a7-6c31aae900c0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzItMS0xLTEtMA_f4f49416-8b74-4837-927a-0c222ea9e876"
      unitRef="usd">50410000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzItMy0xLTEtMA_27ca7fde-f4ce-46e9-b11e-6c28753ade3f"
      unitRef="usd">28891000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzMtMS0xLTEtMA_58531ac7-23b7-44d7-86bd-c0f1aa4ba8ba"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzMtMy0xLTEtMA_f972e67d-bce5-495a-8dae-f86b60dafb18"
      unitRef="usd">17886000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzUtMS0xLTEtMA_5ce45d18-f040-4e3c-a0f4-5cc036e3996a"
      unitRef="usd">203542000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzUtMy0xLTEtMA_1a9f9053-b9d8-4529-8548-57fd5a2c01a3"
      unitRef="usd">-319401000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzgtMS0xLTEtMA_bf0b3745-8ec9-4ce8-a9a5-8a2a04d992ae"
      unitRef="usd">129000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzgtMy0xLTEtMA_7e08ffd0-b9f6-46fb-a16b-8206d54e97cc"
      unitRef="usd">125000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzktMS0xLTEtMA_07ee67ac-0db5-48c0-b407-f3dbe79bd57e"
      unitRef="usd">7065000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfMzktMy0xLTEtMA_8d174a1e-c651-4da4-8432-9d751a4faf25"
      unitRef="usd">7399000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDAtMS0xLTEtMA_5dd767d9-fbfa-4155-8d84-866717a5e8ba"
      unitRef="usd">5401000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDAtMy0xLTEtMA_50137bd2-c149-4af1-8b95-937e5e8a1430"
      unitRef="usd">3956000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDEtMS0xLTEtMA_ed5e0741-c5d2-4850-b738-e2d5f90fc97e"
      unitRef="usd">82157000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDEtMy0xLTEtMA_ea4f06b4-ca25-4215-be9b-f141a10ce2ea"
      unitRef="usd">2247000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDItMS0xLTEtMA_4d2041ac-a1c0-4b65-b598-0c686e83b8db"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDItMy0xLTEtMA_728b2fde-251e-4e3b-b7be-14bb74f47b6d"
      unitRef="usd">355730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDMtMS0xLTEtMA_faf52011-fb56-4d9b-9f59-a7baac4a613b"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDMtMy0xLTEtMA_92026a29-de4b-44e4-8ab2-dca62a53300d"
      unitRef="usd">1130000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDQtMS0xLTEtMA_91b72a46-2edd-45fe-8b8d-fae101caf04c"
      unitRef="usd">784000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDQtMy0xLTEtMA_e48877e3-8bf7-4658-828a-928b010c6cdb"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDYtMS0xLTEtMA_7b78fb62-bc9b-4b22-baf5-136b69e9ec02"
      unitRef="usd">-70604000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDYtMy0xLTEtMA_292d40e7-272d-4ba0-80c6-b0c01fa429f8"
      unitRef="usd">363583000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDctMS0xLTEtMA_9023e808-2e1c-4034-9630-7e97d6e16540"
      unitRef="usd">-1193000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDctMy0xLTEtMA_35e3fced-bc37-4d8c-8e69-cc1999ab598b"
      unitRef="usd">239000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDgtMS0xLTEtMA_1274a69f-e475-449e-898b-c3ac044b69c3"
      unitRef="usd">-284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDgtMy0xLTEtMA_a99d8bab-60fe-4fd8-85dd-822941438776"
      unitRef="usd">-283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDktMS0xLTEtMA_842be821-89e6-44a1-a3a8-ddc3efdeab72"
      unitRef="usd">832977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie5bba3a03f7745a29d33398d6eff80ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNDktMy0xLTEtMA_a8ea6572-a805-46ed-a279-a71ce3529c76"
      unitRef="usd">143228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTAtMS0xLTEtMA_66f4200c-5c03-48bb-9e8a-0cca4b3b2645"
      unitRef="usd">832693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTAtMy0xLTEtMA_7c294035-ab78-4871-8de7-bc37abb3e2bc"
      unitRef="usd">142945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTItMS0xLTEtMA_db466b64-a398-4da8-9963-27e28af96699"
      unitRef="usd">171068000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTItMy0xLTEtMA_5085cde6-c670-426e-a2eb-0a0b76dc3f5b"
      unitRef="usd">10463000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTYtMS0xLTEtMA_de576ea0-ff5a-4a3e-bd47-63a2a9068032"
      unitRef="usd">9589000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTYtMy0xLTEtMA_fb2411eb-cd68-48ad-954e-593c2bc58dfe"
      unitRef="usd">4301000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <gh:EquitySecuritiesFVNIIncurredButNotYetPaid
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTctMS0xLTEtMA_ee8088c3-00bc-4796-8807-720dc33930a4"
      unitRef="usd">346000</gh:EquitySecuritiesFVNIIncurredButNotYetPaid>
    <gh:EquitySecuritiesFVNIIncurredButNotYetPaid
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNTctMy0xLTEtMA_9c5a2832-b30b-4053-b94b-6f6c7f15a498"
      unitRef="usd">0</gh:EquitySecuritiesFVNIIncurredButNotYetPaid>
    <gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjAtMS0xLTEtMA_87b4af49-45d5-46bc-bde9-3adc307e644e"
      unitRef="usd">238000</gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases>
    <gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjAtMy0xLTEtMA_af6ae759-52d5-4dba-bec9-e36b722d0748"
      unitRef="usd">47000</gh:PropertyPlantAndEquipmentAcquiredUnderFinanceLeases>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjMtMS0xLTEtMA_a1e9dae8-87cb-443c-9cb0-3c3048704a37"
      unitRef="usd">832370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjMtMy0xLTEtMA_9b55a652-736c-4946-8d29-14fc8c519a06"
      unitRef="usd">142945000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjUtMS0xLTEtMA_996ff4fc-7f8b-4c1a-a08b-b75b4aaa9460"
      unitRef="usd">323000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjUtMy0xLTEtMA_c05244e8-4e71-4987-8297-6ab05da5b691"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjYtMS0xLTEtMA_cf701a90-9405-48eb-8a15-f79d7e671368"
      unitRef="usd">832693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47e58cd182d64c92bcf468a7c7a7a7f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8zNC9mcmFnOjhkZGNmOTU0MTE0MTRlNGQ5N2Q2YzEwNmQxNTdlZjkyL3RhYmxlOjAyNGFhMWNhNzU2NDQ2OThhM2IyMTk3ZTcxZWQ5OWI0L3RhYmxlcmFuZ2U6MDI0YWExY2E3NTY0NDY5OGEzYjIxOTdlNzFlZDk5YjRfNjYtMy0xLTEtMA_93e9221f-1663-4282-9b67-c8d12455dc8c"
      unitRef="usd">142945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80MC9mcmFnOjI4MmZiMjI3OGY3MTQ4MjY4ZDdhNTBmNWYxNDBiZjNjL3RleHRyZWdpb246MjgyZmIyMjc4ZjcxNDgyNjhkN2E1MGY1ZjE0MGJmM2NfMjc0OQ_f9a350d1-52d8-4223-b8c7-0b9cedc39c6a">Description of BusinessGuardant Health, Inc. (the &#x201c;Company&#x201d;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a liquid or tissue biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#x2019;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company provides its Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. In February 2021, the Company launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, the Company launched Guardant360 TissueNext, the Company's first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. The Company is also developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's tests, the Company has also developed the GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#x201c;Joint Venture&#x201d;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#x201c;SoftBank&#x201d;). Under the terms of the joint venture agreement, the Company holds a 50% ownership interest in the Joint Venture. As of September&#160;30, 2021, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in Joint Venture&lt;/span&gt;) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iaacefe81c0f14186af54df7f09699324_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80MC9mcmFnOjI4MmZiMjI3OGY3MTQ4MjY4ZDdhNTBmNWYxNDBiZjNjL3RleHRyZWdpb246MjgyZmIyMjc4ZjcxNDgyNjhkN2E1MGY1ZjE0MGJmM2NfMjUzOQ_7d58d4d5-4a41-4b1a-be76-6ec732dca86b"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1ODE_30c861d9-3a67-4bb7-9aae-aaf3ce4a4a79">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders&#x2019; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of September&#160;30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which the coronavirus 2019, or COVID-19 pandemic, will ultimately impact the Company&#x2019;s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated balance sheet as of September&#160;30, 2021, the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#x2019; equity for the three and nine months ended September&#160;30, 2021, and 2020, and cash flows for the nine months ended September&#160;30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021, and 2020, foreign currency transaction gains and losses were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of payroll withholding related to the Company's enrollment in certain voluntary disability insurance plan. Restricted cash balance as of September&#160;30, 2021, was $0.3 million, which was included in other assets in the accompanying consolidated balance sheets. The Company did not&#160;have any restricted cash as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investee. The Company's non-marketable equity and other related investments totaled $39.4&#160;million as of September&#160;30, 2021, and are included in other assets, net on the accompanying condensed consolidated balance sheets. The Company did not&#160;have such non-marketable equity and other related investments as of December&#160;31, 2020. Non-marketable securities are subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. Pursuant to one of the investments in non-marketable securities purchased by the Company, and subject to the Company purchasing additional non-marketable securities from the same investee, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022.  As of September&#160;30, 2021, no impairment or adjustments to carrying value of non-marketable securities have been recorded. The Company&#x2019;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0&#160;million. The Company has evaluated and recorded a credit loss for the remaining $7.0&#160;million considering the third-party's credit worthiness and lack of financial history. The following table presents the receivable and the related credit loss amounts: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Nine Months Ended September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged to (Reversed from) Other Income (Expense), Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassi&lt;br/&gt;fication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousand)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of September&#160;30, 2021, and December&#160;31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are presented under accounts receivable, net and other assets, net on the Company&#x2019;s condensed consolidated balance sheets and include balances due from commercial and governmental payers, and biopharmaceutical customers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of&#160;September&#160;30, 2021, the Company had contract assets of&#160;$30.9 million which was recorded in accounts receivable, net. As of December&#160;31, 2020, the Company had contract assets of $15.6 million which was recorded in accounts receivable, net, which included $8.4 million of unbilled receivable relating to Guardant360 CDx.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;September&#160;30, 2021, there has been&#160;no&#160;impairment of goodwill or IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6&#x2014;12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended September 30, 2021, and 2020, the Company recorded $3.2&#160;million and $11.4&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the nine months ended September 30, 2021, and 2020, the Company recorded $17.8&#160;million and $21.9&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development services and other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Kits fulfillment related revenues are recognized when such products are delivered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of September&#160;30, 2021, and December&#160;31, 2020, the deferred revenue balance was $7.3 million and $8.6 million, respectively, which included $0.6 million and $3.0 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the nine months ended September 30, 2021, that was included in the deferred revenue balance as of December&#160;31, 2020, was $8.0 million, of which $3.0 million represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;Revenue recognized in the nine months ended September 30, 2020, that was included in the deferred revenue balance as of December&#160;31, 2019, was $8.8 million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Development Services and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#x2019;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the Company&#x2019;s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020, from additional paid-in capital to convertible senior notes, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MTM_0c4b380d-d489-4cb2-b5b3-bfc99e0870d7">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders&#x2019; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of September&#160;30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzA_e2539ea8-0782-494e-a7ac-75b4fbee7df7">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-&lt;/span&gt;&lt;/div&gt;marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. The extent to which the coronavirus 2019, or COVID-19 pandemic, will ultimately impact the Company&#x2019;s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.</us-gaap:UseOfEstimates>
    <gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzQ_90e45fa8-6879-41aa-914d-a6d90a1dfa4e">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated balance sheet as of September&#160;30, 2021, the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#x2019; equity for the three and nine months ended September&#160;30, 2021, and 2020, and cash flows for the nine months ended September&#160;30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MTY_3f390fa7-2d76-4dd6-bf19-0b7053e562a4">Foreign Currency The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021, and 2020, foreign currency transaction gains and losses were immaterial.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjE1MQ_495feb50-f6e2-4736-aa66-48ded28d6753"
      unitRef="usd">300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCash
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjI1NQ_2085745b-4723-4a90-b599-89e4b8b83f1f"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjY3MQ_1f2266e7-3773-4524-8ff0-964f738236c7"
      unitRef="usd">39400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNjc5Nw_447ec9f0-a59e-442e-abd3-3f80e52f37e1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfNzc4MA_30664576-aaa6-407b-bc72-f9474bc84434"
      unitRef="usd">0</gh:EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjE_8c8b3037-079c-4928-9c2f-0f1715885989">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.&lt;/span&gt;&lt;/div&gt;The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0&#160;million. The Company has evaluated and recorded a credit loss for the remaining $7.0&#160;million considering the third-party's credit worthiness and lack of financial history.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjI_5117d3fc-cbcc-48ba-acd3-280010872e11">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Customer D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNS04LTEtMS0w_0e3aa0d9-afb1-4bb4-9ad2-bad9ac0590e1"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id09d1ad0faad479daa3acc238b4cd800_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNS0xMi0xLTEtMA_136e82b1-52c6-40ae-9366-5ad1659681dd"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3f9601fedfcd4106983c11355226e3ab_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0yLTEtMS0w_675ad97d-f5c6-4045-8d9f-adab461dec95"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i956c76338cf9472792fc8fb1eb5c02f1_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi00LTEtMS0w_12a617ae-74c6-4431-984d-f543a9527047"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id98fa25d42954af2baa244b886e1c86d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi02LTEtMS0w_4fc961c7-fe76-4a8c-bb86-d602175abe5c"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b1b80c40c794c5483e2a614b550e4df_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi04LTEtMS0w_0512b19b-820c-4f41-9b4a-449d26e0a768"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icd1b5cb3bc064b06ab1c3b5a280c72e7_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0xMC0xLTEtMA_24beb290-e56d-4e68-9cfe-0ba58b10b287"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id99f62e950344ebd9a1b6da0b6c5ce54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfNi0xMi0xLTEtMA_87cb2d48-00e1-45dd-bd7d-5a10db48c954"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3be6ab2fcffb478c974ac3fefc049dbb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfOC0xMi0xLTEtMA_6e1ccbcd-0f3e-4fe1-8e0d-66626adfed2f"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icad452344b214db5813fddb4470c5555_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOjQyNmM0Njg4NTUxZjQ1MzViNzE0YjU3NzMzYjY5YmIwL3RhYmxlcmFuZ2U6NDI2YzQ2ODg1NTFmNDUzNWI3MTRiNTc3MzNiNjliYjBfOS0xMi0xLTEtMA_5bf5e24e-23d4-4c17-991f-8b0f19447820"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLoss
      contextRef="i26ebea8c7fe84cd99c89b4a20e1252ee_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTA4OTc_c1755caf-f0fb-499d-9d5d-0cda8950f6d8"
      unitRef="usd">8000000</gh:ContractualReceivablesBeforeAllowanceForCreditLoss>
    <gh:ContractualReceivablesTerm
      contextRef="ib17fe7f4e508446f9ee412617b8ed455_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTA5MjU_e3351e46-f11d-4f61-8cd5-3c1ab307bd99">P6Y</gh:ContractualReceivablesTerm>
    <gh:ProceedsFromContractualReceivable
      contextRef="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTEwMDE_0c295483-fca7-4f6e-9279-8969d85806e6"
      unitRef="usd">1000000</gh:ProceedsFromContractualReceivable>
    <gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent
      contextRef="i4547b045c6744f4ba952c41fda49b6bf_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTEwNzY_444b54fc-6b36-4307-9460-e70af265f511"
      unitRef="usd">7000000</gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NTg_71200bc4-dada-4a33-a34d-a2cbfc7e7d9f">The following table presents the receivable and the related credit loss amounts: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Nine Months Ended September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged to (Reversed from) Other Income (Expense), Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassi&lt;br/&gt;fication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousand)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</gh:ContractualReceivablesAllowanceForCreditLossTableTextBlock>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0yLTEtMS0w_2fb0e785-5ddb-4426-bc11-5f186ace238b"
      unitRef="usd">1100000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi00LTEtMS0w_83cd1fed-23d0-487f-aed8-4a6248a2a913"
      unitRef="usd">0</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi02LTEtMS0w_23af7ccd-579e-496e-a1d7-60955661c040"
      unitRef="usd">0</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi02LTEtMS0w_4f9bbdae-d86b-4975-b408-41d881fb6a12"
      unitRef="usd">0</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesCreditLossExpenseReversalCurrent
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi04LTEtMS0w_5f0d3d7b-cfe2-4076-9946-137031adef01"
      unitRef="usd">0</gh:ContractualReceivablesCreditLossExpenseReversalCurrent>
    <gh:ContractualReceivablesCreditLossExpenseReversalCurrent
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi04LTEtMS0w_866af9c5-0ac0-415c-891c-ce838ade17dc"
      unitRef="usd">0</gh:ContractualReceivablesCreditLossExpenseReversalCurrent>
    <gh:ContractualReceivablesCreditLossReclassificationCurrent
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMC0xLTEtMA_48a6f414-e6d0-4054-b264-220a5adfabb4"
      unitRef="usd">1100000</gh:ContractualReceivablesCreditLossReclassificationCurrent>
    <gh:ContractualReceivablesCreditLossReclassificationCurrent
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMC0xLTEtMA_ad0c6e5b-b800-4dfd-8286-1de1f59f955f"
      unitRef="usd">1100000</gh:ContractualReceivablesCreditLossReclassificationCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMi0xLTEtMA_040f367a-1de2-445b-9c9a-24741b43ec41"
      unitRef="usd">1100000</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xMi0xLTEtMA_823648d8-f496-49d7-913e-cb8f75a1a2ff"
      unitRef="usd">1100000</gh:ContractualReceivablesAllowanceForCreditLossCurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xNC0xLTEtMA_cd82553d-fbd4-4c13-972b-c346d583289d"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNi0xNi0xLTEtMA_37e07972-c586-4f2c-b20d-4028297f479c"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetCurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0yLTEtMS0w_f84465d7-959a-4daa-a794-4e2062d1ce26"
      unitRef="usd">5900000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent>
    <gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy00LTEtMS0w_04f26103-7f97-4a11-98bc-375accd42fb2"
      unitRef="usd">7000000</gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i834d52dfb5ea4cbe862cfb1dcbabefeb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy02LTEtMS0w_2927f5e1-050f-47e7-80dc-0593b1e1d7e2"
      unitRef="usd">7000000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy02LTEtMS0w_fbae9863-f1c7-4cb8-9397-c60854831cc5"
      unitRef="usd">7000000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy04LTEtMS0w_c449c60d-ab80-462d-b95b-86821ebca492"
      unitRef="usd">0</gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent>
    <gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy04LTEtMS0w_c89b6b00-7018-4814-8327-1642f49c1190"
      unitRef="usd">0</gh:ContractualReceivablesCreditLossExpenseReversalNoncurrent>
    <gh:ContractualReceivablesCreditLossReclassificationNoncurrent
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMC0xLTEtMA_13019451-10d6-41c6-9f25-cdad66ee8833"
      unitRef="usd">-1100000</gh:ContractualReceivablesCreditLossReclassificationNoncurrent>
    <gh:ContractualReceivablesCreditLossReclassificationNoncurrent
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMC0xLTEtMA_372eae03-88d8-4370-86d0-9742385051c3"
      unitRef="usd">-1100000</gh:ContractualReceivablesCreditLossReclassificationNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMi0xLTEtMA_86f6bda5-1801-47b5-9268-ba310f90fe30"
      unitRef="usd">5900000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAllowanceForCreditLossNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xMi0xLTEtMA_ab553b4e-2524-4369-8458-53232c01a6ea"
      unitRef="usd">5900000</gh:ContractualReceivablesAllowanceForCreditLossNoncurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xNC0xLTEtMA_ced6de35-451f-4aa8-9ae8-eb7662b081d5"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent>
    <gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RhYmxlOmZlNzA2YWMxZWQ5ZDRiYTI5OWNlZDlhMDM0ZjQ5YmRhL3RhYmxlcmFuZ2U6ZmU3MDZhYzFlZDlkNGJhMjk5Y2VkOWEwMzRmNDliZGFfNy0xNi0xLTEtMA_f4b153df-2f64-4e42-b37a-612784775e29"
      unitRef="usd">0</gh:ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTI_9a0dc935-67a5-4563-acac-87a270a44003">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of September&#160;30, 2021, and December&#160;31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are presented under accounts receivable, net and other assets, net on the Company&#x2019;s condensed consolidated balance sheets and include balances due from commercial and governmental payers, and biopharmaceutical customers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of&#160;September&#160;30, 2021, the Company had contract assets of&#160;$30.9 million which was recorded in accounts receivable, net. As of December&#160;31, 2020, the Company had contract assets of $15.6 million which was recorded in accounts receivable, net, which included $8.4 million of unbilled receivable relating to Guardant360 CDx.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI2OTM_ba2d2c68-1434-479b-9815-f51547121086"
      unitRef="usd">30900000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI3ODk_029177a4-7a50-4136-b164-9e3a11cc53ca"
      unitRef="usd">15600000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i7e32f7150de24707acc5c5ece9051c90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTI4NTU_f12cb5a4-3f66-4ffa-ad14-7158d25d702a"
      unitRef="usd">8400000</us-gaap:ContractWithCustomerAssetNet>
    <gh:AssetAcquisitionPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzY_f5e32478-7b6f-49d7-af3c-782e9c73118a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;</gh:AssetAcquisitionPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Nzc_f70804e2-dd23-41b7-affc-a7c4f1b1cb39">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;September&#160;30, 2021, there has been&#160;no&#160;impairment of goodwill or IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6&#x2014;12 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTQ5NjE_bdde96b4-87f3-4ef9-b7ef-fe05b6aba832"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTUxMjQ_ee8cb5e8-6fd9-40ea-89b5-f2cdc0a25050"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTUxMjQ_f6f3f747-ccaf-4fc1-abd2-b48c757cb769"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTU0NjM_a376c67a-b4b6-45bb-a7f7-344736d93d1e">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMTU0NjY_c4660f4f-fc13-46da-846a-5445efda280a">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MDI_9219e0ac-8eb0-409a-87e4-7e0f6e4e49c3">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTM_c0a2bc3f-138a-4114-9e3b-bca7b7b84533">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.&lt;/span&gt;&lt;/div&gt;In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1ODg_b3896ebf-ea1a-4ebd-a6f4-0a019e3bf771">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended September 30, 2021, and 2020, the Company recorded $3.2&#160;million and $11.4&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the nine months ended September 30, 2021, and 2020, the Company recorded $17.8&#160;million and $21.9&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development services and other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Kits fulfillment related revenues are recognized when such products are delivered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of September&#160;30, 2021, and December&#160;31, 2020, the deferred revenue balance was $7.3 million and $8.6 million, respectively, which included $0.6 million and $3.0 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the nine months ended September 30, 2021, that was included in the deferred revenue balance as of December&#160;31, 2020, was $8.0 million, of which $3.0 million represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;Revenue recognized in the nine months ended September 30, 2020, that was included in the deferred revenue balance as of December&#160;31, 2019, was $8.8 million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjE4ODg_6ea9c8d5-2c13-4374-881f-bfe5737e27c9"
      unitRef="usd">3200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjE4OTU_69012c17-4084-485b-9a08-3f1b7a8c6bf0"
      unitRef="usd">11400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjIyMzA_dda9043a-1ecc-439e-8c95-e9b88aac484e"
      unitRef="usd">17800000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMjIyMzc_f77ac5a6-55a3-4aa4-9b7c-a84dc1964e7b"
      unitRef="usd">21900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzMTc_18bb29e7-be07-4456-84ba-b303104afbbf"
      unitRef="usd">7300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzMjQ_8f05f607-7f46-435d-a9de-6c0f54b588d7"
      unitRef="usd">8600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i45b5b98c81024b9fa1cc9ef6f43bb435_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzNTc_47971e80-8fa0-4a20-8e10-314f728ddfd3"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic64931530ecf46b0b986e9644237b683_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzAzNjQ_3c9eb14f-68d9-4d7b-b250-5f3a3b9162f6"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA2NDk_6b0e8a2c-e1fc-4f80-997c-c381bac544ed"
      unitRef="usd">8000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id82f3289e43a450fb918eac02af264ac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA2NjI_b80e44c7-78c0-4896-83bc-be78a0fec205"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzA4ODc_d8842100-3462-4443-b69b-0f2232465794"
      unitRef="usd">8800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <gh:CostsofPrecisionOncologyTestingPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk2MjA_e8741694-5ca8-4cd4-aa1e-b6bb4d20c5dc">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;</gh:CostsofPrecisionOncologyTestingPolicyTextBlock>
    <gh:CostofDevelopmentServicesPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Njc_4acda242-c6e8-4d37-8037-88d891679bd7">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Development Services and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.&lt;/span&gt;&lt;/div&gt;</gh:CostofDevelopmentServicesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1NzI_64b07252-5e24-411a-82b3-de1e3d2f637f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#x2019;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTY_ebe6d8f3-99bd-413b-885d-919abddc5d9b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.&lt;/span&gt;&lt;/div&gt;The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#x2019;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1OTc_334f26d1-875d-4112-867d-4fb24ae537c8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80My9mcmFnOmFiODJhYmFhNWNkYTRiMzc4MmZhZmYzMjkzZGYzZTQwL3RleHRyZWdpb246YWI4MmFiYWE1Y2RhNGIzNzgyZmFmZjMyOTNkZjNlNDBfMzk1Njk_176db5bc-7755-4989-a1af-eed4545fd8c6">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the Company&#x2019;s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020, from additional paid-in capital to convertible senior notes, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfODU0Nw_ae3cb713-f0a2-4feb-834a-98fed1ebf70a">Investment in Joint Venture&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of the Company&#x2019;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to 89,000,000 shares consisting of 80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non-voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SoftBank held 40,000,000 shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $0.05 per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#x2019;s 2020 Equity Incentive Plan pursuant to which 4,595,555 shares of Class B common stock have been reserved for issuance. As of September&#160;30, 2021, and December&#160;31, 2020, 313,331 and no shares of Class B common stock have been issued and outstanding, respectively, and no shares of Class A common stock have been issued and outstanding. As of September&#160;30, 2021, and December&#160;31, 2020, 80,000,000 shares of Series A preferred stock have been issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#x201c;VIE&#x201d;) and the Company has been identified as the VIE&#x2019;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, and December&#160;31, 2020, the Joint Venture had total assets of approximately $24.8 million and $35.0 million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#x2019;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of September&#160;30, 2021, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Put-call arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#x201c;put right&#x201d;), and the Company has a right to purchase all such shares (the &#x201c;call right&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#x2019;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#x2019;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#x2019;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#x2019;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;right, the Company will choose the form of consideration. On November 1, 2021, the Company elected to exercise the call right and provided its intent to purchase all shares held by SoftBank pursuant to a time-based trigger, see Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#x2019;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#x2019;s initial public offering (the &#x201c;IPO&#x201d;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjM2_7b2680ba-6a1e-4e66-b368-dcad2c783a66"
      unitRef="usd">9000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="i473a1b4e8c894dabb60fe3a80b41d82d_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjQz_603cceff-c425-4320-b712-714b67875612"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iaacefe81c0f14186af54df7f09699324_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjcz_41ae4a6c-542b-4813-979f-7aacdd17fdb4"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue
      contextRef="ieb65abbec30b4f71a61b44720b765997_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNzYw_1c5ac419-bb5a-4d19-8c81-839aaf57d76e"
      unitRef="usd">41000000</us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="ief4823a55ced453d9a74182e29b5dab5_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNzY3_1823b01c-6ce8-44b4-a71f-e25e87d30a40"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ieb65abbec30b4f71a61b44720b765997_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfODA3_524fe210-d3df-420f-be8d-dbe8c75d8816"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibd2a1b5721c14e62ae22216f233394a8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTIwMQ_8d01e02b-e1d9-4dc0-8324-d51477b87b67"
      unitRef="shares">89000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i45ddcd6f8bc5427ea47298e84035d15d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTIyNQ_14999843-b5e0-4cdf-8c94-44d5abb723e8"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4d59f69aa9304c82926efc78bf2688b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTI2Mw_df93af18-7399-4229-9d18-d494fe7efa34"
      unitRef="shares">9000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i10beec7190eb42289690ddc970be2e86_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTMyNg_6a210836-08a5-4068-9da6-8e45c43f2d2f"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesAuthorized>
    <gh:PreferredStockSharesIssuedUponConversionOfCommonStock
      contextRef="i63b22c3fce9b49408a166a3ade4c8098_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTU0NA_206bfac8-d8b8-4420-9f3d-13506999c65d"
      unitRef="shares">1000</gh:PreferredStockSharesIssuedUponConversionOfCommonStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i696cb7034a6f4fb389687d5640e8bc6f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTY1MQ_1aa0ae32-c546-430f-8efc-dcae327276b6"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8f9afa11a3f342b681841d1bdf79f0eb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTY1MQ_6a050987-f5f9-46df-91f9-828173b3f801"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="i28b82c98a5b04b45b4ba1de5d14ba5cd_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMTc3OQ_c97406b0-dace-4566-af4a-143d344f4583"
      unitRef="usdPerShare">0.05</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7c382b53abce461ab4ceb209bd8a2229_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjAxMQ_ba230c2b-f63b-415b-8660-d002865a9815"
      unitRef="shares">4595555</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c715ccc41be43d897292cbe1d39f9f0_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjA5Ng_510772ce-da33-454e-8133-32a1987f1606"
      unitRef="shares">313331</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c715ccc41be43d897292cbe1d39f9f0_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjA5Ng_5a087e6c-8c2f-49a0-a32c-dc10bd535760"
      unitRef="shares">313331</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjEwMw_3400e461-2f78-40e6-8309-cfc5cdad80f9"
      unitRef="shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98aa61d8a7a84cd7ab9a333a0563312a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjEwMw_6a06f09b-4366-4637-b1fa-75dad79665ef"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if43dd801a43d47509034a8a6ad46dfe4_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_2e2de2e6-60b4-4a23-a9bb-f432967b2a45"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if43dd801a43d47509034a8a6ad46dfe4_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_619c3c5f-b458-4a4a-bb92-6842d505781f"
      unitRef="shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia3a1976e448f44da9ad1282432ecaeac_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_8c1af167-9e7d-46eb-b07c-84c9691fcd0e"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia3a1976e448f44da9ad1282432ecaeac_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjE3NQ_ad1152e9-7750-4dbf-84f2-896cedb35237"
      unitRef="shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_1ca7777c-4c8c-46e0-a81b-b64717b79117"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if9e2ff3854534beeaf5dc50347518efe_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_31101f83-7085-42be-a94b-72a51332685c"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i00c1e0a61cdb46bcb6fe981301adb67a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_c1190f83-7838-4f57-a367-a8afbeaea1c0"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if9e2ff3854534beeaf5dc50347518efe_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjI2MA_f9afd8c4-8a9d-48de-8b83-5879fd49334e"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:Assets
      contextRef="id3e5b8a23e9a4553ab64d418bcd7420a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjkzOQ_9cce2791-d380-4915-9a21-a4afc7a5c203"
      unitRef="usd">24800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i70e8e7b3f13743dca3ac02d15ea764ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfMjk0Ng_98024a33-36ea-459d-9997-632dd6f1ce11"
      unitRef="usd">35000000</us-gaap:Assets>
    <gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNTc5Mg_2eb6ed8a-8b21-44bf-b356-7838fac9df3d"
      unitRef="number">0.20</gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn>
    <gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjE0NQ_999b760f-6d78-484f-a4ac-385210f323fd"
      unitRef="number">0.40</gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase>
    <gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV80OS9mcmFnOjYxNzRjNTYyNmE0ZTRlMzc5Mjg4ZTNmZTdlNGU2YjkyL3RleHRyZWdpb246NjE3NGM1NjI2YTRlNGUzNzkyODhlM2ZlN2U0ZTZiOTJfNjM1Ng_0fbe4b64-759a-4803-8a07-2cba9f45f6ad"
      unitRef="number">0.40</gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzUy_4982a2b8-c2e8-4e06-beee-89e00b564872">Condensed Consolidated Balance Sheet Components&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $5.0 million and $3.8 million for the three months ended September 30, 2021, and 2020, respectively, and $14.6 million and $10.0 million for the nine months ended September 30, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzU0_746e96b1-06a1-4e64-b977-8197c6806cc8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iacafa40cbdf74f16a6b76e5fdc92f851_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMy0xLTEtMS0w_03cd4e8a-d334-4b65-87c8-a1fc2d135d37"
      unitRef="usd">56553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i47b0c64f26ce4de4af37ae79bd0d1434_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMy0zLTEtMS0w_5e336178-1186-4b09-9320-3eb6bd5653ec"
      unitRef="usd">40216000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf7b2e27a68941b58e1e1594d4e640e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNC0xLTEtMS0w_228174a7-a382-4917-bc6a-8044963b3d72"
      unitRef="usd">35681000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f4b951f099240f586e94280a7a195c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNC0zLTEtMS0w_b584fc1d-4502-45a1-9006-6a9d0e57b3b6"
      unitRef="usd">34037000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i731507644762422f81775c71bb607b97_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNS0xLTEtMS0w_84d396eb-3a71-4331-97c7-a0b811f68773"
      unitRef="usd">16067000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i64406783e2224dfaa1cac0323c19c1f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNS0zLTEtMS0w_f463adcb-e60f-474f-8456-4326662e2c8f"
      unitRef="usd">10862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if17983378a2a4dfcb8807f9d3349a6ee_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNi0xLTEtMS0w_ce8f8656-f0e3-456f-adc4-2e66fd958ece"
      unitRef="usd">42295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia9b3d8119d074276b8c7bb266b246df3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNi0zLTEtMS0w_2926220e-d282-4efa-a292-75db33e70cb0"
      unitRef="usd">7833000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia094abf062614978a5479b8fdfa6ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNy0xLTEtMS0w_9dfc7878-d4a8-4d93-9bb8-2a8607d562dd"
      unitRef="usd">3598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie0ddcdc04122487cb058c12bdc3fea32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfNy0zLTEtMS0w_5ad6803f-3ef8-462f-8ef1-f54982042f09"
      unitRef="usd">3043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifef80966c25e4f1aa85af95075561dd8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOC0xLTEtMS0w_ce80f6bc-aefc-4e61-a090-65ab9d5092bd"
      unitRef="usd">1246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb9d64efcd8c4a0f82752998dc008845_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOC0zLTEtMS0w_c5e663cb-bdee-45a0-9e7f-cf9c3f8d5911"
      unitRef="usd">1136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOS0xLTEtMS0w_7bb85959-d92c-46fd-b258-1bc521f2ee76"
      unitRef="usd">155440000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfOS0zLTEtMS0w_02988271-da94-422f-a812-936ecb4694c4"
      unitRef="usd">97127000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTAtMS0xLTEtMA_69182f24-0dfd-45bf-a796-d14eabe3a991"
      unitRef="usd">49284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTAtMy0xLTEtMA_a7fd494a-3c89-4dbd-bd8f-38af23401cf7"
      unitRef="usd">34345000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTEtMS0xLTEtMA_f879a610-2c85-488b-b724-0bca152d9055"
      unitRef="usd">106156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmFiMjQwNjMzYjhjNzQ4ZTY5OWZhOTU2NjQwMTk1NWFmL3RhYmxlcmFuZ2U6YWIyNDA2MzNiOGM3NDhlNjk5ZmE5NTY2NDAxOTU1YWZfMTEtMy0xLTEtMA_26595568-8d26-40c8-9182-8edecc7c7ec2"
      unitRef="usd">62782000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjAw_cc17f784-72cf-4c2a-a679-cf2925a0e33d"
      unitRef="usd">5000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjA3_93e38e33-e4a7-4b8d-b93f-2ca1845bbf9c"
      unitRef="usd">3800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjQ4_dbbfa71d-e150-4021-b22a-dcae2b43985a"
      unitRef="usd">14600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMjU1_7ed22917-18a2-4a94-ac51-cd8950a9b9b6"
      unitRef="usd">10000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RleHRyZWdpb246ZjY2ZjUyNzhmYWMxNGExNzg2ODA2MzVkMDlhMDI1YWNfMzU5_bb3d3885-56e7-46b3-91fd-643ccb034fb8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMy0xLTEtMS0w_bde564e9-9efa-4d91-863f-a2ec11f0d7ad"
      unitRef="usd">8253000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMy0zLTEtMS0w_7ab094a6-59d7-4af9-9453-911354881fce"
      unitRef="usd">6632000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNC0xLTEtMS0w_7cefbe15-1d4d-4513-9802-d52ae82e271b"
      unitRef="usd">4077000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNC0zLTEtMS0w_506d0a6d-a3ed-446e-8eb4-e33a96599f7c"
      unitRef="usd">4634000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNS0xLTEtMS0w_8e7d8153-6861-40aa-a6bf-2f0902edca19"
      unitRef="usd">6815000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNS0zLTEtMS0w_bbb003a0-5cb5-4f79-902d-959b55e24ab1"
      unitRef="usd">3397000</us-gaap:AccruedProfessionalFeesCurrent>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNi0xLTEtMS0w_d1f3d726-d9ae-4573-b4e9-2e4ab5291c40"
      unitRef="usd">3351000</gh:AccruedClinicalTrialsandStudies>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNi0zLTEtMS0w_9cd9c762-f4e7-44dd-8a77-faa1fde0cdf8"
      unitRef="usd">1264000</gh:AccruedClinicalTrialsandStudies>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNy0xLTEtMS0w_b478e0b1-87ca-4b74-a322-f3abc016e2ca"
      unitRef="usd">5878000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfNy0zLTEtMS0w_3f9f4524-725d-4ee0-b082-353665e524e2"
      unitRef="usd">2875000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfOS0xLTEtMS0w_8b9131a4-5cb3-4de3-9d96-8887bbfa09f3"
      unitRef="usd">7144000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfOS0zLTEtMS0w_fc4a932b-d012-4864-b406-45f462d5e6d4"
      unitRef="usd">1156000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTAtMS0xLTEtMA_b0b3370b-5dda-47d2-baaf-a5d4eb651d02"
      unitRef="usd">195000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTAtMy0xLTEtMA_0a4c7f27-b7f1-452b-819e-fe618810b5c4"
      unitRef="usd">146000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTEtMS0xLTEtMA_809f0f70-772a-4cb6-9571-b808588aa8d2"
      unitRef="usd">4762000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTEtMy0xLTEtMA_a87c9052-7e23-4c36-8065-5d3aff12db27"
      unitRef="usd">2535000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTItMS0xLTEtMA_49b59118-7e8e-4af4-8129-33466e95de54"
      unitRef="usd">40475000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81Mi9mcmFnOmY2NmY1Mjc4ZmFjMTRhMTc4NjgwNjM1ZDA5YTAyNWFjL3RhYmxlOmYxZTRiYjdjNTY3ZTQ3NDNhOWYzMTE2MmVlMjA5ZmY1L3RhYmxlcmFuZ2U6ZjFlNGJiN2M1NjdlNDc0M2E5ZjMxMTYyZWUyMDlmZjVfMTItMy0xLTEtMA_f63960fb-bbbd-4f6e-ad7f-a20f72e9fd45"
      unitRef="usd">22639000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEyNg_1afd7b0f-53e2-405a-a34c-2c78aefa6f5e">Fair Value Measurements, Cash Equivalents and Marketable Securities  &lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. As of September&#160;30, 2021, and December&#160;31, 2020, contingent consideration liability of $3.1 million and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the fair value of the redeemable noncontrolling interest as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 3 measurement. The fair value of the redeemable noncontrolling interest was determined using a of the income approach and the market approach, and estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted-average costs of capital and future market conditions, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities for the Level 3 financial instruments for the three and nine months ended September&#160;30, 2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redeemable Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the fair value of the Convertible Notes as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information related to the fair value of the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,826,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#x2019;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and nine months ended September&#160;30, 2021, and 2020, respectively. The maturities of the Company&#x2019;s long-term marketable securities range from 1.3 to 2.0 years as of September&#160;30, 2021.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEyMQ_34699fa7-8669-4f33-9911-b18bf75db62a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTExNQ_bd2880d4-5cf3-4c8d-b465-d31e436fd53c">The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6490275f39504f90b9b21f3da8745ba7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi0xLTEtMS0w_c56f6681-820d-43fd-9d75-a1c70f731fc7"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a6c732b2f1046c48b1d0d53909608fe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi0zLTEtMS0w_8527889c-75ca-4569-bd66-c5fa8b3a71b1"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8f9aa35947e840c4b0b33827767997bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi01LTEtMS0w_ec5935c3-28b5-4c7e-9379-d1352bc6606d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76479fc684134352b6d1f8659b4db3ef_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNi03LTEtMS0w_5b2748cf-c875-49e5-bdb7-0a9d80b9bf2d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy0xLTEtMS0w_ed26e8b6-7e3c-41ca-aab2-ff29d8cf9503"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy0zLTEtMS0w_ee97c5d9-6d22-4303-94d9-d6898b8cf4d0"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy01LTEtMS0w_791490c0-1a7b-403a-81ba-dab3e343fc6b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfNy03LTEtMS0w_1727f9cd-3152-4012-989e-145eacea17f5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="idc2ce09c97a54496b5adf47fc9df36f8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtMS0xLTEtMA_ddfdfd9d-9459-445a-838f-2a76a6c7924d"
      unitRef="usd">653601000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ia644451d18b64b7891f97794ae28ed16_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtMy0xLTEtMA_7801fd9e-e37c-4581-9bca-1da078a5ffff"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i609248da19584e879becf882254ecfb7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtNS0xLTEtMA_f6dec186-4690-4cee-a443-c7429a6e0d54"
      unitRef="usd">653601000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ifda5c7f43186404280efac8c9a712d5b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTAtNy0xLTEtMA_ffd32575-2ecb-434a-8a49-46bded637d1b"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtMS0xLTEtMA_f928d958-ffef-4624-9a9a-4ba40237e4d7"
      unitRef="usd">653601000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtMy0xLTEtMA_98b79714-842e-42df-9215-3c4bb9a4de56"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtNS0xLTEtMA_661b22e1-80cc-4308-af9d-968fe9b0af05"
      unitRef="usd">653601000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTEtNy0xLTEtMA_7681caf5-9d9b-4683-b6c4-d772c2547f5a"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="idc2ce09c97a54496b5adf47fc9df36f8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtMS0xLTEtMA_99f1cd44-6c2e-4479-83db-2ab5f9e74311"
      unitRef="usd">250227000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ia644451d18b64b7891f97794ae28ed16_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtMy0xLTEtMA_09b78d66-bf4b-42fa-8f2b-0d08c1577ce5"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i609248da19584e879becf882254ecfb7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtNS0xLTEtMA_cc301e9d-5ffc-4bf1-a544-654eec1d17fe"
      unitRef="usd">250227000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ifda5c7f43186404280efac8c9a712d5b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTMtNy0xLTEtMA_fa3470df-6945-4c2e-b615-8b40924f4616"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtMS0xLTEtMA_c51c753e-a271-4f26-b83d-d5fedc347646"
      unitRef="usd">250227000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtMy0xLTEtMA_cc366fb1-f6fe-4756-bcdc-27bcb53c0ac3"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtNS0xLTEtMA_d95e7aa1-5c4b-4b72-861e-5577a7d5ff07"
      unitRef="usd">250227000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTQtNy0xLTEtMA_123d826d-786e-4a21-9fa8-afad561bc5af"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtMS0xLTEtMA_39245a6a-067e-4d68-a5cc-5868f656d582"
      unitRef="usd">1639547000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtMy0xLTEtMA_5aa2e542-7480-49d3-987c-a68b0d5360be"
      unitRef="usd">735719000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtNS0xLTEtMA_ec9aba6b-b3ba-4fe4-ae23-9e7e00db787c"
      unitRef="usd">903828000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTUtNy0xLTEtMA_25d57d45-5114-4061-a6ae-7d2778965e19"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtMS0xLTEtMA_4760e5ad-d642-4256-9940-2784fdfcfc73"
      unitRef="usd">3090000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtMy0xLTEtMA_65343b5c-a28e-4055-b4ab-7cd645313bc2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtNS0xLTEtMA_3fb32291-ff6a-43d2-b745-b43e9a6347cf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTgtNy0xLTEtMA_725918b0-b231-4c26-bb4b-bba382bf10fc"
      unitRef="usd">3090000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktMS0xLTEtMA_676ee558-85e6-4ce1-bea4-074553c538b7"
      unitRef="usd">3090000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3e5705acfb0548e7b94cd94788d1ba48_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktMy0xLTEtMA_05f01c3e-a289-4e3a-b21f-9b86d742f716"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib7711072385f46159fba26d2b137c91c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktNS0xLTEtMA_8d168fb1-7d76-4f3e-ab22-9d759c7a0469"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjkyNTM3YzAwMjVhNjRkZTlhNzNmOWVjYzcxNGZjNjVhL3RhYmxlcmFuZ2U6OTI1MzdjMDAyNWE2NGRlOWE3M2Y5ZWNjNzE0ZmM2NWFfMTktNy0xLTEtMA_c0cc67a0-f580-4b81-a87c-2010b420dfe5"
      unitRef="usd">3090000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i873b7ae2fa894be79e1fc9fe51be3fdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS0xLTEtMS0w_7d74e6df-b7ca-4f29-869e-2973d13d28f4"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5652f79c7265447095ac9b9f6f19cae7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS0zLTEtMS0w_d1db0f75-a6f1-4707-b7bf-80014f82c9a3"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iede67ca17f9c40bbbeff9eb83a33fa3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS01LTEtMS0w_a4c46c3a-917d-430c-a1b8-068caead496c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d94d00f18354bbfbb8b4c63e3b1c4fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNS03LTEtMS0w_c72b277b-a59e-485d-8e91-05a4e3430640"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi0xLTEtMS0w_53496c75-fc51-40db-a16f-69d2a7ba10b4"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi0zLTEtMS0w_3b7a2190-4228-42a0-9d17-f55ac5cb2ee2"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi01LTEtMS0w_ba48f1e7-0704-418c-b5b2-9a0d9a769740"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfNi03LTEtMS0w_5c3b87a5-c49c-4697-bcfb-e5f1abf2f33a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i7e521bd99f3f4da5a1d7079867423b9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS0xLTEtMS0w_3272e55e-d5a1-4218-aded-70931e1fc615"
      unitRef="usd">961902000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="if515c37e228643f3898be215740476d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS0zLTEtMS0w_91fb617e-f3bf-4564-a7da-3c9df586e73d"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i04d51626bd954ba3a9951e2ea7a902f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS01LTEtMS0w_a17dac20-7255-4550-8d72-2a7865c5554b"
      unitRef="usd">961902000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfOS03LTEtMS0w_6a2077ed-a323-4261-a3bb-e12a18829fe6"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtMS0xLTEtMA_5f029713-b4fa-446c-9611-af97f9398dab"
      unitRef="usd">961902000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtMy0xLTEtMA_8df6a536-f673-43f7-a565-1fa48a021caa"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtNS0xLTEtMA_64aaa371-ea64-4028-b024-7630ff981a95"
      unitRef="usd">961902000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTAtNy0xLTEtMA_fb4c38d8-dcb0-4163-8562-2d03000c53d0"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i7e521bd99f3f4da5a1d7079867423b9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItMS0xLTEtMA_03011851-fa5d-409d-897a-47c33d1f2804"
      unitRef="usd">246597000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="if515c37e228643f3898be215740476d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItMy0xLTEtMA_0696c767-72e0-44fc-8f01-388637ab2451"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i04d51626bd954ba3a9951e2ea7a902f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItNS0xLTEtMA_c4bb1070-ba9d-4975-b7af-8b8f9a7b6db2"
      unitRef="usd">246597000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ic1ee4bd0d7324d22835cfe99701a24ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTItNy0xLTEtMA_b48e9f90-1e64-490d-b2c6-61f6b20ea51b"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtMS0xLTEtMA_1de9c488-bd01-46d6-8a97-154ef43b008d"
      unitRef="usd">246597000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtMy0xLTEtMA_deff9131-ca85-4c58-8983-7e55b407f693"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtNS0xLTEtMA_b6fa010e-8f9a-4972-9090-efb023843e70"
      unitRef="usd">246597000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTMtNy0xLTEtMA_5ceb6c89-f8bd-4045-af2a-f54a0727e4d9"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtMS0xLTEtMA_935db3f3-2f6e-4634-a476-591c2ffd0dc3"
      unitRef="usd">1829129000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtMy0xLTEtMA_f05d854d-7bd0-45c3-81f5-d36c7ff6820a"
      unitRef="usd">620630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtNS0xLTEtMA_a13a0031-fd49-4643-8f0f-bf0b3b9c7235"
      unitRef="usd">1208499000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTQtNy0xLTEtMA_f093d1cc-70bd-4c6e-afd3-07a570ab7902"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctMS0xLTEtMA_657510fb-d913-45a4-973f-340cce057ba5"
      unitRef="usd">1245000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctMy0xLTEtMA_40913565-35f5-4143-9f3b-ebfc6c34d625"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctNS0xLTEtMA_56ada1c7-dd25-431c-a2e1-2d8bf4e37f99"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTctNy0xLTEtMA_f3f53890-24c5-42d0-8f3c-6e331551195c"
      unitRef="usd">1245000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0cb4a56587574e1d832fec1efcbaec69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtMS0xLTEtMA_9d203523-0488-47ea-aa9c-1c7fbbc89a44"
      unitRef="usd">1245000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia83bff0162ba402f8a5a944a54a92646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtMy0xLTEtMA_5b836e4d-119b-4789-a799-271b50b3a60c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaed8b5de01f446c6891f88b6fba84cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtNS0xLTEtMA_12e47ce6-9b01-46d6-8cc5-7646a60b407b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmNiZmMyMjUzZmI2MjQwMjVhMzM4YWRhODVmMWNhNGRjL3RhYmxlcmFuZ2U6Y2JmYzIyNTNmYjYyNDAyNWEzMzhhZGE4NWYxY2E0ZGNfMTgtNy0xLTEtMA_664dd12a-16bc-497e-82ca-8414fccd6cce"
      unitRef="usd">1245000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i96fd58fd8e514f0aa63091cd3d61ed49_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfMzEyMA_f79c3e34-dac8-4972-9ed9-f086a4d61b33"
      unitRef="usd">3100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i009e431b909f4623af5c2eedf68ec9ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfMzEyNw_9a3bf6e8-8f7d-479c-b338-7a47c9e8f33b"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTExMg_4dd9eb73-d62a-4164-8efb-535411640ee9">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities for the Level 3 financial instruments for the three and nine months ended September&#160;30, 2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redeemable Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i06071e62b6544aba8290bd086369fa36_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0yLTEtMS0w_a7db3ca4-3d37-4e2f-9dbe-23d55e4358ec"
      unitRef="usd">59400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i43ca599f32394a52802faedc82b745af_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi00LTEtMS0w_b105af10-aebf-449a-863a-6efdc42a8c9e"
      unitRef="usd">50400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i63b460bf00d240ccaa69bfe375444037_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi02LTEtMS0w_65ffa79c-1d0d-420f-9da4-1ae5a94c3f15"
      unitRef="usd">57100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i57c53847548a49db87515a3ddbad4e6b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi04LTEtMS0w_a47749fe-d267-4281-a3b9-d89af77e1d76"
      unitRef="usd">49600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia00d793f144d4af4a1ce283df7b0e5b8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xMC0xLTEtMA_6aa391eb-2b7f-4e96-a6c2-885ccfd20020"
      unitRef="usd">2120000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6f752295bdb0485d837d6f29e1adac2e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xMi0xLTEtMA_fb278127-ea32-4cd5-858d-5f0a20b16563"
      unitRef="usd">1175000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia4544e28f7504c5c8262ad98b729df14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xNC0xLTEtMA_0a495ef2-6595-41be-a478-a90d4891f4f9"
      unitRef="usd">1245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8439291e86774964951a992f2d6ab802_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfNi0xNi0xLTEtMA_96597df3-87b8-41e5-bb99-f4aeb52a997e"
      unitRef="usd">1365000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0yLTEtMS0w_3585d83b-3a3c-43cd-b327-a7cd083dc2ae"
      unitRef="usd">1920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC00LTEtMS0w_1bbe1963-111e-4a22-8de5-0c5ff618a319"
      unitRef="usd">7407000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC02LTEtMS0w_a118f0c1-1230-4104-8544-1755267d14db"
      unitRef="usd">7852000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC04LTEtMS0w_6f7d8ab0-a5e2-4426-acbf-a58eb5221a05"
      unitRef="usd">10566000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xMC0xLTEtMA_772f976b-7c2c-4c70-b340-977050012a5c"
      unitRef="usd">970000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xMi0xLTEtMA_df64d670-b070-4dec-ac70-3145d18e684a"
      unitRef="usd">70000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xNC0xLTEtMA_e804fb09-a8b5-4b67-8d8b-033f7d540f1f"
      unitRef="usd">1845000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOC0xNi0xLTEtMA_8a1d808e-feed-43c8-9445-6c379d5be0c0"
      unitRef="usd">-120000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i9247d531c5e24da08d4382aa13336ece_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0yLTEtMS0w_3535b43f-abf7-4a62-84b8-2ef1cf8408e6"
      unitRef="usd">-1920000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i4d829cf8540349efa04e8adf2606de87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS00LTEtMS0w_6eeb41f1-f05e-4abf-b684-de69151a180e"
      unitRef="usd">-1407000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i119e3fa6d44a4edd877c6a8ee5731bcf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS02LTEtMS0w_2d059ee0-6012-44c4-a2b6-e8e7168f63de"
      unitRef="usd">-5552000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i0d3b61ef18d3429c9f24b529ab074c42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS04LTEtMS0w_635cd595-e8e3-48a6-aa4e-e0a51c5664a3"
      unitRef="usd">-3766000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i49becc5f2c5d4955b1894b042f1aac2d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xMC0xLTEtMA_74dda088-7317-489f-a912-9e04ba86c44d"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="iac325a33bae940a49c21d67f76cfc27d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xMi0xLTEtMA_effff7f4-4ae2-4c29-85bf-6df1de67d3a0"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="ib651202cf2c749e9a034eec9f6b84ebc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xNC0xLTEtMA_3d1efef2-0715-46f6-a519-0c1c25d5851a"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="ie8763da8d0ec40b08e856426a7e69657_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfOS0xNi0xLTEtMA_0fe66b03-60b7-48b0-a11f-994d7f54192c"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMi0xLTEtMA_fbe7abf1-034d-4e5d-ae03-3953c7e21151"
      unitRef="usd">59400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtNC0xLTEtMA_6806c808-0cf6-4a1a-be89-2880c2d92195"
      unitRef="usd">56400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9ef0a6d78c454f4b9eb3ebacf963519d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtNi0xLTEtMA_61d2a64a-ece6-403d-b839-3f81eac72faf"
      unitRef="usd">59400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2d562e7f6f3142f5af0d265019cd3ba4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtOC0xLTEtMA_a150a367-763c-4b85-b26f-4844402ead04"
      unitRef="usd">56400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTAtMS0xLTA_510571ce-121e-4fe4-89f8-eef67f966254"
      unitRef="usd">3090000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1c5288cacba948db9667020c833d81ef_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTItMS0xLTA_b2d52a61-f527-42fc-ad0b-599d23dc6e51"
      unitRef="usd">1245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibd0c7f4768f0453d98b25d4df3a31c5c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTQtMS0xLTA_fc2b1d52-4c99-4fec-b600-aee870a8cf9f"
      unitRef="usd">3090000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1c5288cacba948db9667020c833d81ef_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOmQ4YmYxNjhjMTA4NTRlNmE4ODhjNGQ5MjMyYzBlN2E1L3RhYmxlcmFuZ2U6ZDhiZjE2OGMxMDg1NGU2YTg4OGM0ZDkyMzJjMGU3YTVfMTAtMTYtMS0xLTA_df1b2dbb-df34-48bc-9f19-6ead6c3d0bc9"
      unitRef="usd">1245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <gh:DebtSecuritiesTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTEzMA_7f10f62a-add7-4047-a68f-4fbf688c0250">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,826,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gh:DebtSecuritiesTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS0xLTEtMS0w_74d285ac-bc85-4deb-9878-8ea4dddb1722"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS0zLTEtMS0w_1a497d72-dd0e-42cf-a2e1-ac61658f9811"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS01LTEtMS0w_a5a8fb04-4173-4aa0-902a-dad6fa1c0176"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i911375a84b704c0ab9bb33fe21b322dd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNS03LTEtMS0w_ba89f9d1-23dd-483c-b58b-72e738a43870"
      unitRef="usd">735719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy0xLTEtMS0w_72aef112-95e4-442b-ab80-6c8f7e9875b5"
      unitRef="usd">903749000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy0zLTEtMS0w_4a813dd5-ab36-42cb-9b97-ca12096f440c"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy01LTEtMS0w_d62b1b6a-2133-4be6-aaf0-a8c5d2ffa808"
      unitRef="usd">108000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99e3f9841c1a4adea92f051369b7a09e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfNy03LTEtMS0w_1e7e93c1-5bbd-4049-8f9c-048f8fa71c4f"
      unitRef="usd">903828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC0xLTEtMS0w_69eefd2d-4038-4edd-b8c2-d80f2a99b3d8"
      unitRef="usd">1639468000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC0zLTEtMS0w_35d5f023-0ccc-4077-a684-141cb02f28ef"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC01LTEtMS0w_aeb068dc-59f8-4abf-a3be-c5b54a3ea19e"
      unitRef="usd">108000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjA2NzM1OTBkODVlMTRmYzk4MDRmNDM0NGVlZThlNjEzL3RhYmxlcmFuZ2U6MDY3MzU5MGQ4NWUxNGZjOTgwNGY0MzQ0ZWVlOGU2MTNfOC03LTEtMS0w_68754a48-4ac8-48b6-9680-81bae2976276"
      unitRef="usd">1639547000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC0xLTEtMS0w_2ca4fdb1-6fc9-4a7d-b3ed-31a22dcb0155"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC0zLTEtMS0w_223e9851-25e1-4017-a15d-11bbf449e692"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC01LTEtMS0w_94c9a62f-bc70-44e7-be61-79137768ce39"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5973ab7edf5a4388a5d5a0cb8e995897_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNC03LTEtMS0w_54a3d6d1-8b00-4912-8ff0-febfa0c5cc0f"
      unitRef="usd">620630000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi0xLTEtMS0w_cba74df1-7cb7-4f8d-ba99-6ada7846fbd1"
      unitRef="usd">1206195000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi0zLTEtMS0w_1ea7e876-d9fe-4948-abf8-9e00122bea55"
      unitRef="usd">2339000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi01LTEtMS0w_10744056-58ee-449b-b350-3fe5c6522939"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f9a75142a80484ebfaba480ea0f7c83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNi03LTEtMS0w_6b0b5117-e140-4970-a556-e1234fd8ef71"
      unitRef="usd">1208499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy0xLTEtMS0w_04fca653-00a1-40d9-9f8b-c4d0051c0b5b"
      unitRef="usd">1826825000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy0zLTEtMS0w_9d9be5bc-04ac-44de-932d-4f2a96745eb3"
      unitRef="usd">2339000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy01LTEtMS0w_a20a23a2-e6d8-4aff-b16d-2937fa893810"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RhYmxlOjZhOGYyZjFlNDZkYjQ4ZTg5ODgwZGVjMDM2ZGY1Mzg0L3RhYmxlcmFuZ2U6NmE4ZjJmMWU0NmRiNDhlODk4ODBkZWMwMzZkZjUzODRfNy03LTEtMS0w_0ee7a3b9-0dd3-402e-9329-84812e360b34"
      unitRef="usd">1829129000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <gh:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTA5Mw_9baf6dfa-1643-42e2-9348-2ee72bc6b22d">P1Y3M18D</gh:LongTermMarketableSecuritiesMaturityPeriod>
    <gh:LongTermMarketableSecuritiesMaturityPeriod
      contextRef="i6475b9e08fe3479eaf5cfe5d52b9be0f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV81OC9mcmFnOjg3OWI0ZTYyOGFiMTQ0ZDlhNTkyMzljMDY0NzcwN2E0L3RleHRyZWdpb246ODc5YjRlNjI4YWIxNDRkOWE1OTIzOWMwNjQ3NzA3YTRfNTA5OQ_fc8e8ff4-1b3b-4928-9d7a-430888951fa1">P2Y</gh:LongTermMarketableSecuritiesMaturityPeriod>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTMzMg_4bf4f5ea-ff53-4523-8b4d-f9bf65d15849">Patent License Acquisition&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#x201c;KeyGene&#x201d;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#x201c;SPLA&#x201d;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#x2019;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated $9.4 million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of 6-12 years. The Company allocated $8.5 million to IPR&amp;amp;D technology, which have no alternative future use and was included in research and development expenses for the nine months ended September 30, 2020. The remaining $1.2 million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <gh:PaymentInConnectionWithaLicenseAgreement
      contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfNTkz_277af3bc-63bd-4ab3-bb57-1a558822a367"
      unitRef="usd">18500000</gh:PaymentInConnectionWithaLicenseAgreement>
    <gh:AssetAcquisitionTransactionCosts
      contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfODAw_c05a1722-a790-4584-9763-7430a9630329"
      unitRef="usd">600000</gh:AssetAcquisitionTransactionCosts>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i271b6a1089814cb6944c8c41c026a282_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfOTE4_1a53c513-7829-4f06-9c8e-3ae40f29af8e"
      unitRef="usd">9400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2d2672bc23d34d2783b636a52ec86105_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTAxOQ_23b55838-1545-4cec-99c7-a54f1e8a95ee">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia10b7a8bcf704572915d199375bb6896_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTAyMg_838209fc-3c41-4983-a0c2-fd2e584faa72">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTA0OA_9ae96913-a04f-4788-bf1e-2a4c9a94db78"
      unitRef="usd">8500000</gh:ChargeOfInProcessResearchAndDevelopment>
    <us-gaap:LitigationSettlementExpense
      contextRef="i8a2cb506fd5743fe9d62d7f41f936f94_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82NC9mcmFnOjBkZTIwNGNhY2ZiZDRmMmQ4NTlkNTdhMTVlZjE1Yjk2L3RleHRyZWdpb246MGRlMjA0Y2FjZmJkNGYyZDg1OWQ1N2ExNWVmMTViOTZfMTE4OQ_01064467-56f9-4518-900c-65dbcb00d767"
      unitRef="usd">1200000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzg5_68bcbf86-54e1-4a71-afbe-64596cd1459f">Intangible Assets, Net and Goodwill&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived intangible assets was $0.5 million and $0.5 million for the three months ended September 30, 2021, and 2020, respectively, and $1.5 million and $1.3 million for the nine months ended September 30, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets&#x2014;net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzkx_ce2baa1c-1e63-4b9a-a39e-df4112f153c8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzk1_0c584096-ee60-472b-801f-7a5087585bb9">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining Weighted-Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i50d01bf14b454648b34a008c20d39400_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi0yLTEtMS0w_6b4842ba-1906-4a67-875a-b4813dfdf117"
      unitRef="usd">11886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i50d01bf14b454648b34a008c20d39400_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi00LTEtMS0w_05504d66-8d95-41b9-a58e-d4212a1473a9"
      unitRef="usd">2194000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i50d01bf14b454648b34a008c20d39400_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi02LTEtMS0w_246d9209-b701-49b0-839c-ab50ba77beb8"
      unitRef="usd">9692000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4c794762acd24ec4b36b7bc0040e7a7b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNi04LTEtMS0w_80d95229-46e8-40c3-b288-536af9b9aedb">P9Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idbef017000f243ac8d113e85196f3c88_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy0yLTEtMS0w_8fe9d3c6-dc24-4ba7-ab8d-56b63fe50144"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idbef017000f243ac8d113e85196f3c88_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy00LTEtMS0w_79dd260d-effe-4528-be0c-4b46ff7d9f49"
      unitRef="usd">1694000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idbef017000f243ac8d113e85196f3c88_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy02LTEtMS0w_cc364949-957f-4cf4-a2a8-1265d20a07ff"
      unitRef="usd">3406000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie1066cfd83fc4ddb923b546c7803df9f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfNy04LTEtMS0w_e767320d-b5e8-4dde-beb9-d7810d194b70">P4Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC0yLTEtMS0w_622d942a-5fb9-41a2-9406-a2e638b8468f"
      unitRef="usd">16986000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC00LTEtMS0w_19870b4b-4d20-4197-acc6-3aabb96068be"
      unitRef="usd">3888000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfOC02LTEtMS0w_1c2df040-c8a5-4f4e-816e-323caf7c4f28"
      unitRef="usd">13098000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaddd38c4b0ed4cddb1ce69265363289b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTAtMi0xLTEtMA_de26858f-c0ed-44f7-a911-18b6cd3fc44c"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaddd38c4b0ed4cddb1ce69265363289b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTAtNi0xLTEtMA_9e36b696-f58d-4c67-8a4c-9a158fa8ed01"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTEtMi0xLTEtMA_b9a33209-ca90-44a3-ad2c-381650e7c750"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTEtNi0xLTEtMA_a4793931-c8a3-41df-81ab-87d49dd0fbe1"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItMi0xLTEtMA_8ad1b081-2825-48a2-9389-59de469934c3"
      unitRef="usd">21876000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItNC0xLTEtMA_9ba80860-36aa-431d-a700-98ddef824e45"
      unitRef="usd">3888000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOmYxNTIyYTNhMjIwYTQ1M2M5OTEzNTI2NTU0OTQ0Y2UyL3RhYmxlcmFuZ2U6ZjE1MjJhM2EyMjBhNDUzYzk5MTM1MjY1NTQ5NDRjZTJfMTItNi0xLTEtMA_e703a015-b88a-4084-81c8-938aca67597a"
      unitRef="usd">17988000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS0yLTEtMS0w_001588be-b27b-451c-bd76-794bc6d5208d"
      unitRef="usd">11886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS00LTEtMS0w_cf71f10d-147a-4c18-a176-13d5f9ed3b3e"
      unitRef="usd">1367000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0e1d770a04da46f0b432b0284fb196c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS02LTEtMS0w_d69a8e81-0d64-4700-884e-9f9f4e78947c"
      unitRef="usd">10519000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i22f931c2c6fc4c78a009b5427bf45c7c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNS04LTEtMS0w_cec361b2-c8ea-47d3-87be-da615f09bc4b">P9Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi0yLTEtMS0w_0eb436a8-b9fc-489f-8516-d5c327170980"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi00LTEtMS0w_c49c108c-4632-4cd1-948f-7cf2fa980159"
      unitRef="usd">1064000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5885fdd8a51a4a1eb0c7bbda64e3b439_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi02LTEtMS0w_e75589d6-5bef-4f50-a055-eda3105982e7"
      unitRef="usd">4036000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i54c3f12b90c242a3ae68a02bd72acb55_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNi04LTEtMS0w_b4d62483-2889-4504-9cde-0bd85d5bb531">P4Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy0yLTEtMS0w_949db51c-6a10-41f7-8311-cb8a0246f311"
      unitRef="usd">16986000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy00LTEtMS0w_a71b8914-02f3-42c4-a91f-ab778e01d8f6"
      unitRef="usd">2431000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfNy02LTEtMS0w_ab2db01d-e07d-4251-b9d6-98679488b4a0"
      unitRef="usd">14555000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4550cb15256748d2a89b9750438c5b41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfOS0yLTEtMS0w_e28778f0-658b-4682-8c25-1f5a2770755a"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4550cb15256748d2a89b9750438c5b41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfOS02LTEtMS0w_c609d1af-dcba-415d-aad9-a40894dbef43"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTAtMi0xLTEtMA_1fc3015f-e79e-4b28-b83e-e4f053610230"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTAtNi0xLTEtMA_710cb8b3-d452-483b-b44d-7fc69732d045"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtMi0xLTEtMA_d7a7da66-0bf1-4ef8-96ab-8b3dbfc27e76"
      unitRef="usd">21876000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtNC0xLTEtMA_8c321440-0814-494e-aa10-5bb3a4947cb8"
      unitRef="usd">2431000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjI0NGE3NmRhMWRiOTQzODQ5YWQ2ZWE1YjRlODBkZTliL3RhYmxlcmFuZ2U6MjQ0YTc2ZGExZGI5NDM4NDlhZDZlYTViNGU4MGRlOWJfMTEtNi0xLTEtMA_aecf971c-aa8f-475d-b3fa-43a387a01424"
      unitRef="usd">19445000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMTg2_bcf339e9-bd3a-49cb-9d9d-b89c04b3edf7"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMTkz_c2794460-96cf-4071-b1e0-0e0befee2a61"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMjMz_07316d43-dfac-4be7-87d5-2ffe787e2e13"
      unitRef="usd">1500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMjQw_5712f109-5e66-408e-825e-6fb83fc514ad"
      unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RleHRyZWdpb246OTYyNDdiY2QwNmFhNGQwNjkwMjM0YTg0MmJhNmFiZmRfMzg3_0b558a82-99b7-42a9-bd16-782d9d87d179">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets&#x2014;net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfMy0yLTEtMS0w_282b2c4e-16e0-4926-a43d-b98ca564294b"
      unitRef="usd">491000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNC0yLTEtMS0w_cc809e69-4c5e-485d-a342-a13955005022"
      unitRef="usd">1947000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNS0yLTEtMS0w_d91d7655-cbe5-4292-9c63-92473d5c7eb6"
      unitRef="usd">1947000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNi0yLTEtMS0w_d1267957-d0d3-456a-af5b-43dc72e280ca"
      unitRef="usd">1953000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfNy0yLTEtMS0w_498835f2-d55b-4dac-bc8e-e3b6c01c1f68"
      unitRef="usd">1705000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfOC0yLTEtMS0w_b04728c5-30de-4168-978a-657991c2f72d"
      unitRef="usd">5055000</gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV82Ny9mcmFnOjk2MjQ3YmNkMDZhYTRkMDY5MDIzNGE4NDJiYTZhYmZkL3RhYmxlOjE3ODIwMGE2MzM3ZTQ3YjY4Y2RmNzY2YTJlM2Q1Y2E5L3RhYmxlcmFuZ2U6MTc4MjAwYTYzMzdlNDdiNjhjZGY3NjZhMmUzZDVjYTlfOS0yLTEtMS0w_23cd2fd2-5cc1-40b7-9484-f673fd514317"
      unitRef="usd">13098000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzUxOA_52cf20ec-1950-4a28-8f5f-a88d650540b2">Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company issued $1.15&#160;billion principal amount of its 0% Convertible Senior Notes due 2027 (the &#x201c;2027 Notes&#x201d;). The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter (the &#x201c;sale price condition&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;during the five consecutive business days immediately after any ten consecutive trading day period (the &#x201c;measurement period&#x201d;) if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;upon the occurrence of specified corporate events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#x2019;s election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $139.82 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#x201c;Make-Whole Fundamental Change&#x201d; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#x2019;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company&#x2019;s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If certain corporate events that constitute a &#x201c;Fundamental Change&#x201d; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the 2027 Notes were not convertible as of September&#160;30, 2021, the net carrying amount of the 2027 Notes was classified as a long-term liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the 2027 Notes as of September&#160;30, 2021, and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability component:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt discount, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity component recorded at issuance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recorded in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair value of the 2027 Notes was $1.3 billion and $1.3 billion as of September&#160;30, 2021, and December&#160;31, 2020, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $1.9 million for the three and nine months ended September 30, 2021, which represented an effective interest rate of 0.2% and 0.2% and for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions (the "2027 Note Hedges") with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $182.60 per share, which represents a premium of 75% over the last reported sale price of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.&lt;/span&gt;&lt;/div&gt;As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#x2019; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0 million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzY_ee821ba5-a3b8-4a94-90b5-3297375e6cb0"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTAz_18c82480-88f3-49d1-8b0d-997e8ad4b8bf"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage
      contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzY2_fd9cb0fb-06c2-4542-aa5e-b13dffbf0914"
      unitRef="number">0.0050</gh:DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTAxOQ_b89b2434-2bc1-43b9-81a0-1b1e683b877c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTA2Nw_9f444d07-aec4-46c1-90e5-13f09a0a8627"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie7e64c2a858d4e9cb9e689c48a5d98ad_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTEyMw_9d0b8ead-c10b-46b7-bacd-0356664b7b48"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTI2OQ_adbf9f87-b393-4161-8dd7-61ac5bb66df0"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTMyMA_ae674e24-ad98-4532-9886-94234fa13b7c"
      unitRef="d">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate
      contextRef="i2e21ec1eed64401a8f8bcec23c5ddd28_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMTQ5OQ_07317533-e19a-4f4a-80f7-b8dc3b2245a7"
      unitRef="number">0.98</gh:DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if196b52749ca4701a0fa9abedbed7ded_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMjI3Nw_78a5b9ad-fc81-4569-a992-bf0eabdc6853"
      unitRef="usdPerShare">139.82</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzIzOA_6c3445ef-ee0d-4ecb-af59-b8c64b0c208a"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzI4OQ_fcdcd00e-6711-4af5-aded-25ab1eca78da"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i195c63f9a2e94d25811c7ff5057c6cb1_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfMzM0NQ_a71fe676-9562-4809-ab40-a7b7cd601e97"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzUyMQ_027818f7-5052-43f1-a062-92b6c960d1de">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the 2027 Notes as of September&#160;30, 2021, and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability component:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt discount, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity component recorded at issuance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recorded in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNC0yLTEtMS0w_0e9bba29-6ba9-4d54-aa54-7360632ea9d8"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNC00LTEtMS0w_0a7f5077-a5ca-4521-b842-7ddd11440499"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNS0yLTEtMS0w_34910eaf-505e-4e5e-94cb-554d190d6912"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNS00LTEtMS0w_571d5066-6737-43c5-8337-8071f25f0c50"
      unitRef="usd">331074000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNi0yLTEtMS0w_a1e71469-c8c9-4f7a-9335-62bba696bc9a"
      unitRef="usd">15820000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNi00LTEtMS0w_24e898fd-3592-46d9-890e-4e6bf7efde29"
      unitRef="usd">12634000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNy0yLTEtMS0w_3c11471e-c6d3-4339-8dda-b0e7cbd1a952"
      unitRef="usd">1134180000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfNy00LTEtMS0w_c9718e6b-9829-4d70-b8fd-754389e123c6"
      unitRef="usd">806292000</us-gaap:LongTermDebt>
    <gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTAtMi0xLTEtMA_48a47d4f-00cd-41fe-81c5-948c41b0a570"
      unitRef="usd">0</gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts>
    <gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTAtNC0xLTEtMA_0d0938ac-6df3-4ab8-a2dc-f3cbc2025da8"
      unitRef="usd">335667000</gh:DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts>
    <gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTEtMi0xLTEtMA_0703ed2a-e7f4-468a-b370-98de9d76e0bd"
      unitRef="usd">0</gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent>
    <gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTEtNC0xLTEtMA_6dc99527-1243-4a26-9351-f5753cbad520"
      unitRef="usd">5264000</gh:DebtInstrumentConvertibleIssuanceCostsEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTItMi0xLTEtMA_fee4e7ac-2f46-4335-9f69-4e5b2aba3b38"
      unitRef="usd">0</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RhYmxlOmFlNzUzOGQzYTk3NzRhNjliNmM0MDRlMTk5N2VmNjhkL3RhYmxlcmFuZ2U6YWU3NTM4ZDNhOTc3NGE2OWI2YzQwNGUxOTk3ZWY2OGRfMTItNC0xLTEtMA_c37ca35a-22d9-4be3-bdc5-61280da0ee72"
      unitRef="usd">330403000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib821d04236034791b8d3fa9b120448ae_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTY5OQ_a6f94cec-edc0-48b3-8483-41a6193f19ac"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iad5e0b1db685472892b3b4d4be7ab044_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTcwNg_58890d5a-56aa-47f8-aa52-9efb89a3db90"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i82ce7dd079ac4bfd882a6e3d866ee98c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTk2NA_fc979885-a64f-405d-81b1-7a8c5bbcd450"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i26bb0381128745be8004975327b5b957_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNTk3MQ_119c4079-2983-4806-a2ea-7f8662b12fa7"
      unitRef="usd">1900000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icd9648256b9c411694a641721c1541a0_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjA1NQ_d8b1a760-a313-409c-aae7-635d2b04455c"
      unitRef="number">0.002</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icd9648256b9c411694a641721c1541a0_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjA2Mg_58bd9cfe-6612-4e9b-9608-3794be82864e"
      unitRef="number">0.002</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <gh:ConvertibleDebtHedgeStrikePrice
      contextRef="id32f5d1807074b2793d40078426095aa_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjU2OQ_f75ed84d-139f-4542-8808-0418ccac50df"
      unitRef="usdPerShare">182.60</gh:ConvertibleDebtHedgeStrikePrice>
    <gh:ConvertibleDebtHedgeSharePricePremiumPercentage
      contextRef="id32f5d1807074b2793d40078426095aa_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjYxMw_be4e3459-0816-406f-9eaf-71095f90ad8d"
      unitRef="number">0.75</gh:ConvertibleDebtHedgeSharePricePremiumPercentage>
    <us-gaap:SharePrice
      contextRef="id32f5d1807074b2793d40078426095aa_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNjY4Mw_7a788924-f8f8-4a65-b05f-f8e04992c175"
      unitRef="usdPerShare">104.34</us-gaap:SharePrice>
    <gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
      contextRef="i96636707b48c4179884f86ea7ec8a02f_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83MC9mcmFnOmRiNjk3MjdkMWU1NzQ5MDg4NzU2ZjI1MTkyYmRmNDQzL3RleHRyZWdpb246ZGI2OTcyN2QxZTU3NDkwODg3NTZmMjUxOTJiZGY0NDNfNzM4OQ_9344ccbb-2467-44dc-8653-15b795e0a204"
      unitRef="usd">90000000</gh:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5OA_f3a52f43-0457-43d9-8cb5-86b95a55338c">Leases&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has&#160;entered into various operating lease agreements for office space,&#160;data center, lab and warehouse use, with remaining terms ranging from 1 year to 12 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  In July 2020, the Company entered into two lease agreements for additional office space in Palo Alto, California ("Palo Alto Lease") and in San Diego, California ("San Diego Lease"). The San Diego Lease has a term of 8 years with rent payments commencing in May 2022.  The Palo Alto Lease has a term of 12 years with an option to renew the lease term for an additional ten years which has not been considered in the determination of ROU or the lease liability as the Company does not consider it reasonably certain of exercising the renewal option. Rent payments for the Palo Alto Lease will commence in October 2021. Both leases consist of fixed and variable payments and are being accounting for as operating leases. The Company took possession of these facilities in March 2021.  The Company estimated the incremental borrowing rate to determine the present value of lease payments for the San Diego and Palo Alto leases using trading data of the Company's convertible debt adjusted for credit rating and market yield curves.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense was $6.9 million and immaterial for the three months ended September 30, 2021, and 2020, respectively, and $17.8 million and $3.3 million for the nine months ended September 30, 2021, and 2020, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are not material to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i993c2da446a34875acb1c40b068b3089_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTY3_41863c3c-be73-42d1-8dad-bfff5d220c66">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i55c4a05385cc4fc18d198385dd93c921_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTcz_d2027ecc-966b-4004-a338-55827039900d">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <gh:NumberOfOperatingLeasesLeaseNotYetCommenced
      contextRef="i8e71a02ecacf4adcb391e6c7f12702d1_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfNzU3_968b04d5-498b-42ff-95e7-4010a764b3fe"
      unitRef="segment">2</gh:NumberOfOperatingLeasesLeaseNotYetCommenced>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i2cb77ccae9a74814b7e00acb580b3aab_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfOTM0_662dac67-e255-4342-8b65-e4a65f8d9a04">P8Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="ia25c787a137a4bec9fd1a061e1adf313_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTAxNQ_67767046-5b6e-46eb-af84-4408397745b9">P12Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <gh:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract
      contextRef="i86f9ba8b79324beb88e8b7488d9694c8_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTA3NQ_37ff9c23-1ec7-413e-bb1c-b937d26651bc">P10Y</gh:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTc1OA_b3d80fe0-99b9-4f5e-b485-1442cd824c1b"
      unitRef="usd">6900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTgwNg_31fa2b62-9df8-4703-9e9e-63343b27f421"
      unitRef="usd">17800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMTgxMw_90ce8044-f1d3-4ac5-93ef-5014f0a5a165"
      unitRef="usd">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5MA_fe5dfa65-c30d-4825-a566-25536335e2a4">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMi0yLTEtMS0w_eda8ee7a-c249-45aa-b076-480c4b63702a">P10Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMi00LTEtMS0w_ae1126a1-39c1-4fc6-aee1-b48edf47b912">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMy0yLTEtMS0w_818aad37-d45d-40fc-b8e3-642ed982a40b"
      unitRef="number">0.0409</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOmIxYzViMWI5YTI3MzRiZDRiZjc3ZWRiZWQ3NTkwNmYzL3RhYmxlcmFuZ2U6YjFjNWIxYjlhMjczNGJkNGJmNzdlZGJlZDc1OTA2ZjNfMy00LTEtMS0w_3768da79-35c4-4e68-8d32-fa4176d52b72"
      unitRef="number">0.0807</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RleHRyZWdpb246Y2ZlZDZjYTk5OTcxNDU0MGI5NGQ4NGFiNGM0ZWM2MWRfMjE5Ng_89c05493-0988-4547-8a25-067ad97b0882">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMy0xLTEtMS0w_23ad892f-5c58-491a-9cbd-4f6b2f99a52f"
      unitRef="usd">2737000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNC0xLTEtMS0w_d2c0cf46-1278-4941-b56c-73b294287851"
      unitRef="usd">21495000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNS0xLTEtMS0w_46dd5f4c-8c83-4e03-88b0-96afbe1c49ba"
      unitRef="usd">28972000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNi0xLTEtMS0w_0b5ae216-bcd1-400d-9f21-42f0cbd3c707"
      unitRef="usd">31525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfNy0xLTEtMS0w_f7b1e6c2-04de-46cb-b163-b02438017819"
      unitRef="usd">32081000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfOC0xLTEtMS0w_4c100dc6-ab1b-4c2e-8a35-aeea767838cd"
      unitRef="usd">177400000</gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfOS0xLTEtMS0w_5d0ae08e-4abd-40e6-a01f-3d109f7e7234"
      unitRef="usd">294210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTAtMS0xLTEtMA_9c15df33-696e-4a14-98e9-f7cf2bae1851"
      unitRef="usd">52473000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <gh:LesseeOperatingLeaseLiabilityLeaseIncentive
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTEtMS0xLTEtMA_1d69f968-a166-4aa5-b0cd-7a05e04faffb"
      unitRef="usd">16678000</gh:LesseeOperatingLeaseLiabilityLeaseIncentive>
    <us-gaap:OperatingLeaseLiability
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83Ni9mcmFnOmNmZWQ2Y2E5OTk3MTQ1NDBiOTRkODRhYjRjNGVjNjFkL3RhYmxlOjVlYzUwYjVmOWFmYzRlNmU5YmZhYzdlZWEzMGUwZTEwL3RhYmxlcmFuZ2U6NWVjNTBiNWY5YWZjNGU2ZTliZmFjN2VlYTMwZTBlMTBfMTItMS0xLTEtMA_6e68fb6c-5044-4fef-ac25-2ea6b893a2ec"
      unitRef="usd">225059000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNjQ4MA_666bfde0-422d-4cc1-b37d-4f096d0f4b26">Commitments and Contingencies &lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Disputes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2017, the Company filed a lawsuit against Foundation Medicine, Inc. (&#x201c;Foundation Medicine&#x201d;) in the United States District Court for the District of Delaware. The Company has alleged that Foundation Medicine has infringed four of the Company&#x2019;s digital sequencing technology patents. Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license and non-infringement. The parties are seeking damages, injunctive relief and attorneys&#x2019; fees. Discovery in the lawsuit has closed, and a number of pre-trial motions were filed in September and October 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foundation Medicine also filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company. The PTAB denied institution of inter partes review for four of the six petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, the Company filed a lawsuit against Foundation Medicine in the United States District Court for the District of Delaware, wherein the Company alleged that Foundation Medicine infringes seven of the Company&#x2019;s patents.  Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license, non-infringement, and that the Company has violated Section 2 of Sherman Act. In December 2020, the Company filed a Motion for a Preliminary Injunction to prohibit Foundation Medicine from practicing two of the asserted patents.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, the Company filed two lawsuits against Foundation Medicine GmbH in the District Court of Munich I in Germany, wherein the Company alleged that Foundation Medicine GmbH infringes two of the Company&#x2019;s patents.  Final hearings on this matter are scheduled for December 2021.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Company entered into a binding term sheet with Foundation Medicine, which upon execution of a definitive settlement agreement, will result in the dismissal of all pending patent litigation worldwide between the parties. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company and Personal Genome Diagnostics, Inc. settled the patent infringement lawsuit brought by the Company. Under the terms of the confidential settlement, the lawsuit and counterclaims, as well as other challenges to the Company&#x2019;s patents, have been dismissed.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2021, TwinStrand Biosciences, Inc. (&#x201c;TwinStrand Biosciences&#x201d;) and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#x2019; allegations. The court has not yet entered a case scheduling order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;False Advertising Dispute&lt;/span&gt;&lt;/div&gt;In May 2021, the Company also filed a lawsuit against Natera, Inc. (&#x201c;Natera&#x201d;) in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#x2019;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#x2019;s Signatera assay. The Company is seeking a Preliminary Injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. Discovery is ongoing and the court has scheduled a hearing for November 2021 to hear argument on the Company&#x2019;s motion to dismiss Natera&#x2019;s counterclaims and for a case management conference.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i32f365a013324f7ab9a257ec6616bfe4_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzIwMQ_9042d187-0c0c-42bf-987e-01a224468045"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <gh:NumberofPetitionsFiled
      contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzYzNg_d45bd9e8-42ea-4981-a292-3fc53d72eccc"
      unitRef="petition">6</gh:NumberofPetitionsFiled>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzcyNQ_a4e49dfe-677e-4ed1-9caf-8b8e0c7575c6"
      unitRef="segment">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <gh:NumberofPetitionsDenied
      contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzgyMw_91df4695-1fa4-4df9-8712-68b1f91c50c8"
      unitRef="segment">4</gh:NumberofPetitionsDenied>
    <gh:NumberofPetitionsFiled
      contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzgzMw_4e1e6ff7-f035-422b-9352-630d73cd9fd8"
      unitRef="petition">6</gh:NumberofPetitionsFiled>
    <gh:NumberOfPetitionsFiledRemaining
      contextRef="i660c0774906b43d8862cee0a47049547_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfMzkyOA_b3490dc7-12ac-41a4-a23c-2d8c856216a2"
      unitRef="petition">2</gh:NumberOfPetitionsFiledRemaining>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i705721d0e67244739b045350d485c93f_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDE0OA_3ebd72cd-d3aa-4232-84fa-337b7a538c6e"
      unitRef="patent">7</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i9963f628118f43db994c73aa2c0b5931_D20201210-20201210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDUxNw_c98ef83c-5dae-46ea-88e3-45960279f0d2"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ib18022bf9450402f8ce4975ec504ea61_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV83OS9mcmFnOjYzODQxYTM1ZjM2ZjQ0MTFhOThhYTJjZjhiYTQzNmQzL3RleHRyZWdpb246NjM4NDFhMzVmMzZmNDQxMWE5OGFhMmNmOGJhNDM2ZDNfNDU4Mg_ecb2eb5c-e3fd-43a9-8597-46e8c3e857e0"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNjg4_bd377b7a-2d83-4a9c-bb59-9782dba1df9c">Common StockThe Company&#x2019;s common stockholders are entitled to dividends if and when declared by the Company&#x2019;s Board of Directors (the &#x201c;Board of Directors&#x201d;). As of September&#160;30, 2021, and December&#160;31, 2020, no dividends on the Company's common stock had been declared by the Board of Directors.&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,868&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,655&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391,148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,922&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819,223&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,568,420&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,344,620&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-on Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company completed an underwritten public offering, in which it issued and sold 4,312,500 shares of its common stock at a price of $84.00 per share. The Company received net proceeds of $354.6&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DividendsCommonStock
      contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfMTg0_38a38f3f-9f14-4b59-91ae-aa647069361e"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfMTg0_5c1e2a8e-ce8f-43dc-822b-c4bade9e254f"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNjky_70b7732c-3484-43f0-916d-368d56386854">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,868&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,655&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391,148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,922&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819,223&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,568,420&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,344,620&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i01b665c40a8f47ea8cd85e635363d20c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMi0xLTEtMS0w_49078e12-6974-4fde-972f-1815df4b5970"
      unitRef="shares">2516868</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5e8d9afb89dd4632a8f43a7e0dfca6af_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMi0zLTEtMS0w_eecb6cf8-87c7-4e02-afe5-f8ee6f928cfb"
      unitRef="shares">3101181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i85be72137c66452fa6b52b9f18871115_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMy0xLTEtMS0w_006c3aab-fb07-4d21-b82b-0db4a72a37f6"
      unitRef="shares">1128147</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfMy0zLTEtMS0w_ccfeddc4-3981-46e6-9dee-35d8143ea09b"
      unitRef="shares">1118655</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNC0xLTEtMS0w_a6f1eb21-c18d-45ba-98b1-32b2539bc1db"
      unitRef="shares">2260764</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNC0zLTEtMS0w_4beac3f7-48bc-4a0b-bf41-bca8fedf65d3"
      unitRef="shares">3391148</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNS0xLTEtMS0w_8b278a11-28cd-481c-b4c9-86c56e7a73e5"
      unitRef="shares">383341</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib51f14efceef46e083455712a43bf986_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNS0zLTEtMS0w_a4b450b8-3d6b-4626-b48f-cf4be218244e"
      unitRef="shares">377922</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i63475ab401474e89bee5f05a4a47acd0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNi0xLTEtMS0w_380aee71-c832-4f66-8b23-7798613555b9"
      unitRef="shares">5803707</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3fc5ee952cf84418b7016f83429f0aba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNi0zLTEtMS0w_6316fac2-d0e1-40ef-a19e-fd658e209a52"
      unitRef="shares">1819223</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNy0xLTEtMS0w_df78bcec-3506-413f-95cb-d776e6981f7c"
      unitRef="shares">1475593</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i940221e6cce645cfb6a90604dac8cbe8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfNy0zLTEtMS0w_80d4765f-3e32-47fa-b63d-1c8864115908"
      unitRef="shares">1536491</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfOC0xLTEtMS0w_b9ab4d53-a9a8-4a0a-b799-47fa05f98a40"
      unitRef="shares">13568420</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RhYmxlOjFhMWQ2ZDVkMDJmYzRiN2Y5N2VjNTc1NWQ3ZmJkOGEzL3RhYmxlcmFuZ2U6MWExZDZkNWQwMmZjNGI3Zjk3ZWM1NzU1ZDdmYmQ4YTNfOC0zLTEtMS0w_45b0b1e1-b89e-421d-8fc6-2cd7eab8cabd"
      unitRef="shares">11344620</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNDg4_878c655f-0be4-4f0f-9ed8-e30becd814f0"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ifa05344a7c40424eb0df008620fe83e9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNTMy_bc307a55-6ee6-494e-81cf-790887185039"
      unitRef="usdPerShare">84.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2541fd92030e4ebb86652edd804ac055_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84Mi9mcmFnOjlmZDY3M2ZkMDE3NDQzNDc4ZDdmYmQ5NWQ3MGRlZTRkL3RleHRyZWdpb246OWZkNjczZmQwMTc0NDM0NzhkN2ZiZDk1ZDcwZGVlNGRfNTgz_e4b729aa-5c57-476e-b404-c90d65fe7ce5"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNTE_6ba53f55-2d0a-48e8-85f6-7e676af914b2">Stock-Based Compensation&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#x201c;2012 Plan&#x201d;) and the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;) and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Plan annual increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164,147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629,246)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,117)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,627&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558,254&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,917)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,868&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Effective as of January 1, 2021, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $28.4 million and $46.8 million for the three months ended September 30, 2021, and 2020, respectively, and $77.8 million and $97.1 million for the nine months ended September 30, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted was $65.17 and $49.73 per share for the three months ended September 30, 2021, and 2020, respectively, and $72.14 and&#160;$46.85 per share for the nine months ended September 30, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future stock-based compensation for unvested options as of September&#160;30, 2021 was $22.7 million, which is expected to be recognized over a weighted-average period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,655&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,998)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,627)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future stock-based compensation for unvested restricted stock units as of September&#160;30, 2021, was $105.2 million, which is expected to be recognized over a weighted-average period of 3.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant performance-based restricted stock units (&#x201c;PSUs&#x201d;) under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of 4 years and an additional service period requirement of six months after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of 4 years. The PSUs are expected to be expensed over a period of approximately 4 years to 4.5 years subject to meeting the respective performance metrics and service requirements. As of September&#160;30, 2021, a significant portion of these PSUs are not expected to achieve the related performance metrics, and therefore, no stock-based compensation expense was recorded for the PSUs that were not probable to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,498)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation recorded for the PSUs for the three and nine months ended September&#160;30, 2021, was $0.3 million and $1.0 million, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of September&#160;30, 2021 was $4.4 million, which is expected to be recognized over a weighted-average period of 3.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units (&#x201c;MSUs&#x201d;) under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYwOA_1a96adcc-20aa-4c2d-b632-070a36d742ec"&gt;six&lt;/span&gt; to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$120 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted-average grant date fair value of the MSUs was $67.00 and the weighted-average derived service period was estimated to be in the range of 0.83 &#x2013; 2.07 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, Tranche 1 of the MSUs became vested because it has met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of 30 consecutive calendar days. A summary of the Company&#x2019;s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Market-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(572,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(558,254)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for the MSUs was $22.6 million and $46.8 million, for the three months ended September 30, 2021, and 2020, respectively, and $88.9 million and $65.1 million, for the nine months ended September 30, 2021, and 2020, respectively, which was recorded in general and administrative expenses on the condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of September&#160;30, 2021 was $26.4 million, which is expected to be recognized over a weighted-average period of 0.7 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AMEA 2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan (the &#x201c;AMEA 2020 Plan&#x201d;), under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to employees of the Joint Venture or its affiliates. Nonstatutory stock options may be granted to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;employees, directors and non-employee consultants. Stock options may be granted at an exercise price of not less than the fair market value of the Joint Venture's common stock on the date of grant, determined by the board of directors of the Joint Venture. Options generally vest over 4 years and expire as determined by the board of directors of the Joint Venture, provided that the term of options may not exceed 10 years from the date of grant. For individuals holding more than 10% of the total combined voting power of all classes of stock of the Joint Venture, the exercise price of an option will not be less than 110% of the fair market value of the Joint Venture's common stock on the date of grant, and the term of the option will not exceed 5 years. A total of 4,595,555 shares of the Joint Venture's Class B common stock are initially reserved for issuance under the AMEA 2020 Plan, and the number of shares may be increased in accordance with the terms of the AMEA 2020 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(826,667)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313,331)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382,780)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341,259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted was $0.33 per share for the three and nine months ended September&#160;30, 2021. Future stock-based compensation for unvested options as of September&#160;30, 2021 was $0.6 million, which is expected to be recognized over a weighted-average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 66.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 68.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 66.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company and the Joint Venture, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. The grant date fair value of the Joint Venture's common stock has been determined by the board of directors of the Joint Venture. The grant date fair value of the Joint Venture&#x2019;s common stock was determined using valuation methodologies which utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the Joint Venture&#x2019;s common stock, the methodologies used to estimate the enterprise value of the Joint Venture were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the commencement of trading of the Company&#x2019;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Joint Venture derived the expected volatility from the average historical volatility over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Joint Venture does not have any trading history for its common stock. The Joint Venture will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and the Joint Venture does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of MSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risky Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risky rate represents the Company's cost of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discount for Lack of Marketability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 &#x2013; 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.53%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% &#x2013; 14.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional 942,614&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#x2019;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock purchased under the ESPP were nil for the three months ended September 30, 2021, and 2020, respectively, and 60,898 and 58,164 for the nine months ended September 30, 2021, and 2020, respectively. The total compensation expense related to the ESPP was $0.9 million&#160;and $0.7 million for the three months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021, and 2020, respectively, and $2.5 million and $2.3 million for the nine months ended September 30, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No ESPP shares were issued for the three months ended September 30, 2021, and 2020. The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the unrecognized stock-based compensation expense related to the ESPP was $0.4 million, which is expected to be recognized over the remaining term of the offering period of 0.1 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDM_a9c34162-ca06-41ac-be5c-bf1d2dfe9f26">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#x201c;2012 Plan&#x201d;) and the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;) and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Plan annual increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164,147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629,246)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,117)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,627&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558,254&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,917)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,868&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Effective as of January 1, 2021, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(826,667)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313,331)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,780&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382,780)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Exercisable as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341,259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS0xLTEtMS0w_b416812e-5ddb-4d5b-adb4-e2dadb7f0f94"
      unitRef="shares">1819223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS0zLTEtMS0w_d1f3155a-077c-4121-97a8-64cd8743c0fc"
      unitRef="shares">3101181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS01LTEtMS0w_6f7df88c-aa0e-4f5b-81c6-7f41b31ad7e2"
      unitRef="usdPerShare">15.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if82c262f1fdc4dbd871f322b128c1392_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS03LTEtMS0w_ae34104f-468f-40c3-aa74-5cb4c429107b">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i78e4ce20d6fa44b99855dfa0287375ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNS05LTEtMS0w_9d1f5124-0f53-4058-82ba-3d70d8f4a32f"
      unitRef="usd">350670000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNi0xLTEtMS0w_25471479-8827-42eb-a350-6ac51b5ca47d"
      unitRef="shares">3689000</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy0xLTEtMS0w_5a1ee355-e3ec-4215-ade1-8b87402cb4bb"
      unitRef="shares">164147</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy0zLTEtMS0w_38befbce-7ae6-4b08-b241-cd69c11ec58e"
      unitRef="shares">164147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfNy01LTEtMS0w_d63a13f4-a7cd-4e52-b9b2-7baa08d8a325"
      unitRef="usdPerShare">122.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOC0zLTEtMS0w_52d0907f-b395-486f-8370-f6d01d1298ba"
      unitRef="shares">629246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOC01LTEtMS0w_f0832aec-484a-422f-a46e-2612e6fd3db2"
      unitRef="usdPerShare">10.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i72587a5483874cd0bce93b7f6a34d673_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS0xLTEtMS0w_b7be0468-391b-44eb-b95a-46f21d9fc618"
      unitRef="shares">63286</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS0zLTEtMS0w_b3dac8ac-d583-4d3e-83fa-806032ada546"
      unitRef="shares">119214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfOS01LTEtMS0w_f0bf4557-1a6e-417b-a575-68d8839b0a26"
      unitRef="usdPerShare">49.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTAtMS0xLTEtMA_4a68a15c-9591-4dfd-988d-682968a5f45c"
      unitRef="shares">398117</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i3658f81c86624cb7a01478db3da1a58c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTEtMS0xLTEtMA_095b6e6d-8c10-42ee-99c0-7bc217e99d7b"
      unitRef="shares">241627</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTMtMS0xLTEtMA_31435547-eb3b-4a8c-9c56-a53184459f2e"
      unitRef="shares">558254</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTQtMS0xLTEtMA_7b9a8170-8b0c-4ac9-942d-d92f8cb54315"
      unitRef="shares">52917</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTUtMS0xLTEtMA_5b687fe4-c3df-4527-98b1-b253bfe92ba1"
      unitRef="shares">47498</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtMS0xLTEtMA_8026375d-56f1-4ca1-8147-951870ce19d2"
      unitRef="shares">5803707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtMy0xLTEtMA_e7ee1f08-3da5-4cfa-8afb-68de29f3311b"
      unitRef="shares">2516868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtNS0xLTEtMA_59933617-213e-47cf-b1f1-9a17171a66b0"
      unitRef="usdPerShare">22.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtNy0xLTEtMA_b981e2e3-dbc2-4b29-8afe-eefbb9a62094">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTYtOS0xLTEtMA_403dabe9-124a-41df-8e56-10b4a63b6945"
      unitRef="usd">259451000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctMy0xLTEtMA_4ff670ea-2ce4-4933-be1e-7f9d3743f2f6"
      unitRef="shares">1943159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctNS0xLTEtMA_aa439630-b8f1-4c27-a964-183a595fe50d"
      unitRef="usdPerShare">10.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctNy0xLTEtMA_ce1d0154-c86b-42ee-836f-750648221909">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjdkMWE1YjRmNGU5YzRhZjk4MmRiYTNkNGE4OWQ4YmM5L3RhYmxlcmFuZ2U6N2QxYTViNGY0ZTljNGFmOTgyZGJhM2Q0YTg5ZDhiYzlfMTctOS0xLTEtMA_616eb1e6-e540-439b-8578-91195578e93d"
      unitRef="usd">222786000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzEz_25471479-8827-42eb-a350-6ac51b5ca47d"
      unitRef="shares">3689000</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzAy_7c283342-e210-4788-9ef3-4008f0e7dfb4"
      unitRef="usd">28400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzA5_11ceb661-53b6-4bef-b5e6-1069fa9e5db9"
      unitRef="usd">46800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzQ5_7978c4ff-c0f4-46f7-b887-70fcead20684"
      unitRef="usd">77800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzU2_7a465b34-8ee7-4a5b-8139-4a980ed4dea9"
      unitRef="usd">97100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODU4_2fd031a7-347c-4a4c-b0b0-64a116ce90ba"
      unitRef="usdPerShare">65.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODY1_8db0e89e-a817-4fed-9cd0-33235f1637d9"
      unitRef="usdPerShare">49.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfOTE1_370c92d2-7ef1-42a9-afa3-43e23e9f0d14"
      unitRef="usdPerShare">72.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfOTIy_e841f933-88bf-494f-b8f7-6acf7f568c57"
      unitRef="usdPerShare">46.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i95165abecdd04d43a21f2a1198ebe3f0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTAzNA_665cd398-2665-46f0-9634-91febfce04f8"
      unitRef="usd">22700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTEwNw_75653c38-2ce6-44d6-ab48-de50bb93922a">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDU_e3419835-4b4e-48b8-ab5f-7d6cced113fa">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118,655&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,998)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,627)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,498)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;A summary of the Company&#x2019;s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Market-based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(572,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(558,254)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt"&gt;Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfMy0yLTEtMS0w_0e709b57-68f6-44de-9deb-e4e88a01acf6"
      unitRef="shares">1118655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i619cc50dcce348cc8689f3c9699ad658_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfMy00LTEtMS0w_4f1a26c6-8e8d-4231-9cab-cfbb060f1bfa"
      unitRef="usdPerShare">92.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNC0yLTEtMS0w_d33ab799-8b87-4eac-829c-06e6c1d84d65"
      unitRef="shares">398117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNC00LTEtMS0w_9ade2a05-de40-4ad0-9973-fd7fa48e3fe5"
      unitRef="usdPerShare">130.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNS0yLTEtMS0w_01e79ae6-d2a5-4330-a69e-3be563fa6618"
      unitRef="shares">146998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNS00LTEtMS0w_c773666b-7fd7-40eb-8b48-6a98280cfac3"
      unitRef="usdPerShare">89.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNi0yLTEtMS0w_d0306c9c-d59e-48f2-bcfd-a8abdedce667"
      unitRef="shares">241627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNi00LTEtMS0w_1a2411f2-7654-40b5-a39d-b9f59b4933a9"
      unitRef="usdPerShare">94.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i85be72137c66452fa6b52b9f18871115_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNy0yLTEtMS0w_bc52a205-389a-40e2-b7c3-6e8591468062"
      unitRef="shares">1128147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i85be72137c66452fa6b52b9f18871115_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjJiODhmMWMwOGZhNjRkYWY5Y2U3ODg0NmI5MGVjYWRmL3RhYmxlcmFuZ2U6MmI4OGYxYzA4ZmE2NGRhZjljZTc4ODQ2YjkwZWNhZGZfNy00LTEtMS0w_98fe4874-8caa-4d12-8861-607a518d80d8"
      unitRef="usdPerShare">106.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i85be72137c66452fa6b52b9f18871115_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQyNQ_30bd69f5-8039-4c99-a17a-d1a554493c50"
      unitRef="usd">105200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i33b0256b34954c83af75fa48e67f0705_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ5OA_88aac20f-814c-4fd5-b40c-7f645afb427b">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTg1NQ_30611ca7-e187-42b7-8f6c-5bc450156f06">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod
      contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTkwNg_ef782f27-a7da-43cd-99d1-ec39fa0bd2c9">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i9acc7dad3e8449f5b0bfdd46d55f0e93_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjA1NA_550220f4-532a-4536-a27f-a8eda72e098c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5e73ee9eef8e49aab2ec36819934f632_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjEyNg_14007bef-ca03-4868-8226-5c48fe6b06de">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5e9815d0d7cb41b09b77791966e52c75_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjEzMg_bb49fa28-43f9-414e-bf73-7d03e3c891e1">P4Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib51f14efceef46e083455712a43bf986_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfMy0yLTEtMS0w_66456bb0-6664-4f1f-bb94-cb7074de3d18"
      unitRef="shares">377922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib51f14efceef46e083455712a43bf986_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfMy00LTEtMS0w_830a8b77-19ee-459c-a108-9e6bcb3a9e54"
      unitRef="usdPerShare">113.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNC0yLTEtMS0w_00323579-ba86-4e2b-b5c8-3bf048649a8c"
      unitRef="shares">52917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNC00LTEtMS0w_fea382e5-31d3-4904-9bad-99217e1dcce0"
      unitRef="usdPerShare">135.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNi0yLTEtMS0w_12983697-8771-4498-8b48-d3e020f046df"
      unitRef="shares">47498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNi00LTEtMS0w_8d207a6e-60fd-4ad2-be55-9b92cbf35964"
      unitRef="usdPerShare">113.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNy0yLTEtMS0w_5fb30d3a-9540-4869-90ed-b87771cf9429"
      unitRef="shares">383341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjBhMjRhOWVmZmVlNTQ4NGViM2YwZmU2MmQ3NThiMmFkL3RhYmxlcmFuZ2U6MGEyNGE5ZWZmZWU1NDg0ZWIzZjBmZTYyZDc1OGIyYWRfNy00LTEtMS0w_201051ce-1047-4806-9c34-e6c9fba4269d"
      unitRef="usdPerShare">116.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i565831a0298547cd9661d27b9d9d2944_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjY0Ng_129d6966-af77-4187-b8d3-b8475e39fd06"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjY1Mw_667521ae-f6ed-4dab-863c-e44d67de4c77"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i3e477370d1a64fd2a0fa21ffcda04720_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjc2MA_4d976869-d869-4ba0-b4f8-83ca0c58a4a9"
      unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i429067f5e77c48e1ac881344be65d0cd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjgzMw_1435693b-d5ab-4005-86f3-91360194a6ca">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="i11b69d916f624dad9b518cabc4589b73_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMjkzMQ_79a2107d-03b1-47f0-ac50-7e3f546564d6"
      unitRef="shares">1695574</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod
      contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzQyMw_7d049e99-8ad5-4ec9-90a7-7cce8b0bbf20">P30D</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMjI_ddf025ff-d5d1-4539-ad7a-2c62a69cf9e2">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="ie634a7fb83674c7d92b925a5d6a99ec1_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYxNA_37ec67ed-72b9-4924-9e4a-79b62b4d416d">P12M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzY_b1ee1bb3-c808-4cda-baf9-2aadff518538">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDY_1a1b937d-326a-476b-b5f9-c9b9db607688">The following table presents additional information relating to each MSU award:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$120 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="id1e7591cbb12410598b75394c40acba8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMS00LTEtMS0w_9346542f-d0e4-4e17-abec-5e021766c651"
      unitRef="shares">565192</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="id5c7f0c0ebc94b6bbbcfabf0a1fae5db_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMi00LTEtMS0w_bcfbfa1f-babc-4b3f-823e-111e0a57d3da"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="ic51021850ccb4f1fadfb3bdbae1f91d3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjU2YjhlNTQ5ZjhiMDQwNzhhM2I1MThjYzAzNjhiY2E4L3RhYmxlcmFuZ2U6NTZiOGU1NDlmOGIwNDA3OGEzYjUxOGNjMDM2OGJjYThfMy00LTEtMS0w_62868087-8475-4941-a35b-110716705403"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNDkyOA_f40c8f8e-0fbb-411c-9917-c8d7727963bd"
      unitRef="usdPerShare">67.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTAxNQ_3b85c181-c757-4863-9b64-963374243db4">P0Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTAyMA_d6c123cd-0988-4b19-9b82-3e2cd1699506">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod
      contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTI0Nw_7d049e99-8ad5-4ec9-90a7-7cce8b0bbf20">P30D</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfMy0yLTEtMS0w_36a133ff-dcbc-41a4-9841-3b9cdc0735e9"
      unitRef="shares">3391148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifd2b5342dde3448c8891ca3d99b1978a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfMy00LTEtMS0w_7db91cee-8028-4321-88ad-0ce969237f0f"
      unitRef="usdPerShare">67.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNS0yLTEtMS0w_a16f8411-bb7e-495e-a115-9604849b4927"
      unitRef="shares">572130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNS00LTEtMS0w_9c68287e-f9c7-4fc9-9727-0c082ecce539"
      unitRef="usdPerShare">70.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNi0yLTEtMS0w_94d6e005-d1e2-4208-ab84-262570449c8e"
      unitRef="shares">558254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNi00LTEtMS0w_0c710991-029e-49f6-b9bd-a5b1ed58e82f"
      unitRef="usdPerShare">70.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNy0yLTEtMS0w_ac7ceab4-c106-4004-b5a6-5c87303832fe"
      unitRef="shares">2260764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjA3N2ZmMzk3YWRlOTRhMjk4ZDJhNGUyZGZmODhhZWUwL3RhYmxlcmFuZ2U6MDc3ZmYzOTdhZGU5NGEyOThkMmE0ZTJkZmY4OGFlZTBfNy00LTEtMS0w_b53b7493-7da8-4875-bc6c-318e07707a45"
      unitRef="usdPerShare">65.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib17cb1196a064f4088f3fc6c035e9d72_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTU4NA_6cd2b749-792e-4d10-9ef5-7a2418996acc"
      unitRef="usd">22600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia097fb6e0e4d41ed842060e7bc5260e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjkwMw_9fc7696f-fdc6-4aec-8e06-f92e3047b308"
      unitRef="usd">46800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjk3NA_f63a3b89-5180-410b-b65a-d4013a0a1163"
      unitRef="usd">88900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b7a51301dcf41c98545f06434fe3b72_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjk4Mg_cd6b4d88-21d4-4c32-9f5b-c9e735383ecc"
      unitRef="usd">65100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib95921a37c5e43f49a9c3c37215251e7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTc4NQ_951af714-d1ff-4929-9335-94708abba68e"
      unitRef="usd">26400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNTg1OA_68553626-9610-4119-87a8-22b8d17fbe4a">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i32296f65f3ae4bcd825ff74ee3290303_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzA_7c8fbb10-8c70-4ccf-a5e4-b439b38f6f20">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzE0Mg_7533f655-faa9-481a-8717-3a5a755f82fe">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if0405cc654514f00be4d0af7bec65a9e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzI2Nw_855bd80a-5046-4067-8aca-a4da1cb3d698">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm
      contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzMyOA_faadef54-ea5c-4f18-9a49-84569253c8a1"
      unitRef="number">0.10</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzQ2Ng_46424901-55c8-4082-8f80-c1d9c53acc61"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie874ecff7bba4ddea894f749df7c5a57_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzU5NQ_0834f348-7a09-4e16-9e2e-672466b5710a">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7c382b53abce461ab4ceb209bd8a2229_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfNzYxMA_ba230c2b-f63b-415b-8660-d002865a9815"
      unitRef="shares">4595555</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia601d039561f4097b3df49643250b3bf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS0xLTEtMS0w_d7459af0-08cf-4c5d-b034-e440174394fd"
      unitRef="shares">542220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia601d039561f4097b3df49643250b3bf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS0zLTEtMS0w_ae011c27-0480-4550-bf50-7b8d45a995f8"
      unitRef="shares">4053335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia601d039561f4097b3df49643250b3bf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS01LTEtMS0w_40db6d1b-fe37-49a1-a2b9-2ff53f0ffaa8"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8a3300f2c9ff4ec6a29cf3cc30f0a698_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS03LTEtMS0w_ada1c4f9-e7c8-4a08-b883-31c069a12278">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia601d039561f4097b3df49643250b3bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNS05LTEtMS0w_2d0c8c3a-a38a-4121-9d50-b81bdbd14961"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy0xLTEtMS0w_d8b4c39f-72d9-4c52-905a-ebb892d89915"
      unitRef="shares">826667</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy0zLTEtMS0w_affd7d92-0fe2-4915-a012-1e77a9807f98"
      unitRef="shares">826667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfNy01LTEtMS0w_ad096325-851a-44dd-a9c9-0c31a9789d2a"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOC0zLTEtMS0w_e71d00a2-0aa9-450a-9eee-49dd11e10fcb"
      unitRef="shares">313331</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOC01LTEtMS0w_4436f0f2-4b81-4091-99bf-9c820bd0b80c"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS0xLTEtMS0w_73200141-97e0-408a-b85d-5b354a99178d"
      unitRef="shares">382780</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS0zLTEtMS0w_ce2508b1-1b31-480e-a7d4-d1194a34a41b"
      unitRef="shares">382780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfOS01LTEtMS0w_845177c0-238d-4d86-ac2e-d00f8cf07dfb"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtMS0xLTEtMA_8f158f00-5805-413c-876a-545aa2159053"
      unitRef="shares">98333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtMy0xLTEtMA_ebe7cae7-66ad-4cb2-ba7e-8d5de6823e8c"
      unitRef="shares">4183891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtNS0xLTEtMA_009923cf-10b9-43d7-a00a-f223ba51e8ae"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtNy0xLTEtMA_037c6b56-96c3-4bd5-b0d2-26f098510c02">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTAtOS0xLTEtMA_61fcdfc0-9fde-4a10-a64b-8fe7ec5eaff8"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtMy0xLTEtMA_1dd05d2e-7154-4e50-8eae-8953d8ed4aa0"
      unitRef="shares">2341259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtNS0xLTEtMA_ee69048c-c923-443a-abae-b85a5553fd42"
      unitRef="usdPerShare">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtNy0xLTEtMA_b2fd0939-cfc0-44cf-96c4-64b0e0d7d9f0">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjkyMDEyNzIxYTNhMDQxMjliOGJjNDc3ZDdkYjhhNWM4L3RhYmxlcmFuZ2U6OTIwMTI3MjFhM2EwNDEyOWI4YmM0NzdkN2RiOGE1YzhfMTEtOS0xLTEtMA_7188fb65-4add-4b47-8730-13a0d86ab32a"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODAwOQ_3d774657-1ca4-4c29-af94-f386ca76e6f4"
      unitRef="usdPerShare">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0f17ed5a12ca4a6abb0cea17b1730fef_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODAwOQ_91821abc-a9af-449d-8bb3-899eddadd143"
      unitRef="usdPerShare">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODExNg_02344129-de3b-440f-9dd2-1677713d2d10"
      unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if58ffec0307a44cfaa204337af91208a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfODE4OQ_fb717be5-6362-4f24-8a0e-dd4ef44a7162">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNDA_70f793fa-621a-4c31-a389-a4351e3de4f6">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1f46661f1f446eeb205375c1af434fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS0yLTEtMS0w_56876c57-22ce-4904-a607-08991b4c5f51"
      unitRef="usd">676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i62d04197610e4189a303bead82651edb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS00LTEtMS0w_1286242a-45e4-4d41-bf59-dc22c0b7b106"
      unitRef="usd">428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc36477bea5640ec874839095e170908_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS02LTEtMS0w_bd20bcbe-0023-4992-90f5-ba97545d556a"
      unitRef="usd">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f4b78122abd4e8eb313c8e1a7719f92_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNS04LTEtMS0w_07fc54e2-9ad3-457e-bec2-e463febe5422"
      unitRef="usd">1138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b7fba181b054fabb73999b47d483dbf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi0yLTEtMS0w_a92137d9-0d8d-4d59-b0ef-fd9a1bc36639"
      unitRef="usd">4416000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38f6cfe7e6404cae9e7b6b09a000b0cd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi00LTEtMS0w_10f7a5c9-4efc-4884-b5b9-2a1a836c3524"
      unitRef="usd">2369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd4023c5dcd0439fb73518c68885f959_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi02LTEtMS0w_ef8cb0f6-c882-4d84-8076-a6980ba98fff"
      unitRef="usd">13280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i007fd51f89bf4055aa793319535aa53c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNi04LTEtMS0w_d6eae337-e56a-472a-888b-fde213d7d152"
      unitRef="usd">7355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id22b70d2f2e34c20a09a9012c59cd21a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy0yLTEtMS0w_e3226267-e6db-4cfb-95b7-328c3da9cbf2"
      unitRef="usd">3991000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if66ec163b0d848a3a230072df877cf55_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy00LTEtMS0w_c8556d26-b202-4ee2-864f-4f8d61750c9b"
      unitRef="usd">2320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia23565c372dc4ccbb89ffb28f7af1b0e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy02LTEtMS0w_ca9d0b94-58f3-4b2f-af55-ded28bbca1c4"
      unitRef="usd">10309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i77295fc586c94e54a8fba5426ea17938_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfNy04LTEtMS0w_564d38ae-cf10-4fcf-8349-daf104339be4"
      unitRef="usd">6285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if994b46b023d4d5fa18a833907f95a23_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC0yLTEtMS0w_a9f54e4c-4cf5-4c27-8540-61db626ec4f8"
      unitRef="usd">25933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i62c5b239ffb4440f80781154268288d9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC00LTEtMS0w_1cf856e3-10dc-4d85-97c2-68b91f71eff7"
      unitRef="usd">50081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9ba431512174cc5bfce850e0b0b12a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC02LTEtMS0w_4ef2e752-91ae-486a-9af2-7ba3873570a2"
      unitRef="usd">98687000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b2e85ec40be47df923a27894e32515d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOC04LTEtMS0w_b39629e1-3501-441b-99a4-638e7832abe2"
      unitRef="usd">72573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS0yLTEtMS0w_99361a42-5422-417f-840e-a5c04690369f"
      unitRef="usd">35016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS00LTEtMS0w_bcb848d6-560f-41cd-9674-06638ba3175b"
      unitRef="usd">55198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS02LTEtMS0w_7701832f-4d7a-448c-952f-9d79f2b69a04"
      unitRef="usd">124592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOmViOGFmYWYyNjAwMjQxNDBiZjY3NjY4YTIyMDMxZjIxL3RhYmxlcmFuZ2U6ZWI4YWZhZjI2MDAyNDE0MGJmNjc2NjhhMjIwMzFmMjFfOS04LTEtMS0w_6519dad4-191c-46b8-9ac0-4be00c957415"
      unitRef="usd">87351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMzQ_c780dc8f-8aa5-40fc-ac8f-801118a6d6dd">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49 &#x2013; 6.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 66.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 68.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 66.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6% &#x2013; 73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3% &#x2013; 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC0yLTEtMS0wL3RleHRyZWdpb246OTRhMjgzYmNhN2M3NDMzZGIxNzIzNjlkODc0NTRlMjZfNA_6e118c77-e1ed-4870-acbc-b3ea36287aa6">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC0yLTEtMS0wL3RleHRyZWdpb246OTRhMjgzYmNhN2M3NDMzZGIxNzIzNjlkODc0NTRlMjZfMzg0ODI5MDY5NzI0MA_eb68ae23-2bee-4a63-b412-182c9c4d206e">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC00LTEtMS0wL3RleHRyZWdpb246OTZlNmZiNzI5M2Q2NDJjNWFkYmFlY2U1MjQ1YzUzMjdfNA_2f14ce3d-224a-48f6-9869-8a0aa3fe353d">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC00LTEtMS0wL3RleHRyZWdpb246OTZlNmZiNzI5M2Q2NDJjNWFkYmFlY2U1MjQ1YzUzMjdfOQ_79eeb905-6cb6-4bf5-aba7-588e9e06f82e">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC02LTEtMS0wL3RleHRyZWdpb246MGNmYTE4NTZhYWQ1NDc0N2JkYmY5NmYwMWY1ZGZlNWVfNA_36921610-3487-4ff5-8159-dfded6740632">P5Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC02LTEtMS0wL3RleHRyZWdpb246MGNmYTE4NTZhYWQ1NDc0N2JkYmY5NmYwMWY1ZGZlNWVfOQ_0f45860c-9668-48ed-a1ab-1d13438c13ce">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC04LTEtMS0wL3RleHRyZWdpb246MGFhNzA3NTBhMzc0NGNmOGI3ZmE5ZDEzYjJkMDQ2YTRfNA_a260ebf9-50c2-4265-9f92-1af09050c80a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNC04LTEtMS0wL3RleHRyZWdpb246MGFhNzA3NTBhMzc0NGNmOGI3ZmE5ZDEzYjJkMDQ2YTRfOQ_ecaf8ea2-93a3-49be-8b60-5c5d11461bf0">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS0yLTEtMS0wL3RleHRyZWdpb246NzAzYjdjMWVlOTI4NGM3YjlhZDY5OTllNWY4ZjAzNzdfNA_16628cfa-1517-4f8b-bee9-8b32fae71c70"
      unitRef="number">0.636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS0yLTEtMS0wL3RleHRyZWdpb246NzAzYjdjMWVlOTI4NGM3YjlhZDY5OTllNWY4ZjAzNzdfMzg0ODI5MDY5NzI0MA_cb512461-48a0-4cae-9727-4fd539111c99"
      unitRef="number">0.660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS00LTEtMS0wL3RleHRyZWdpb246YWFlZjE0MTQ2Y2UxNDM5YmE5YmFiYTMzNGY3N2E1ZGVfNA_20e1165e-25cf-4075-a1dc-2259e8df946c"
      unitRef="number">0.636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS00LTEtMS0wL3RleHRyZWdpb246YWFlZjE0MTQ2Y2UxNDM5YmE5YmFiYTMzNGY3N2E1ZGVfOQ_5aaecb16-6a68-4841-81a5-e45de404acfc"
      unitRef="number">0.684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS02LTEtMS0wL3RleHRyZWdpb246MTAzNWFiNjE3MDM1NGZlMGIzNDc2NGExZGRmZDAwNTlfNA_fa610f93-5385-4848-8f99-cf98f0af1da6"
      unitRef="number">0.636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS02LTEtMS0wL3RleHRyZWdpb246MTAzNWFiNjE3MDM1NGZlMGIzNDc2NGExZGRmZDAwNTlfOQ_c0de5afe-4072-4ac6-9d07-a6f6d60dc5f8"
      unitRef="number">0.667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS04LTEtMS0wL3RleHRyZWdpb246NGQzY2NiNzFjMDBmNDEzMzlhN2I0MzNiMjUyZTUyYzRfNA_0b6ebdf9-e947-4279-8df4-c1f48a674ebb"
      unitRef="number">0.636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNS04LTEtMS0wL3RleHRyZWdpb246NGQzY2NiNzFjMDBmNDEzMzlhN2I0MzNiMjUyZTUyYzRfOQ_66d2ec70-bdeb-45ee-a6d1-781b4f8385c0"
      unitRef="number">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i477964bc10504bb0938d30103ef7edac_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi0yLTEtMS0wL3RleHRyZWdpb246ZjQ3YmZkNGFhOWU5NDhlZGJmNzIzNzRiN2FjMGFkNzNfNA_71046898-60af-431d-8c7c-ed9f5ce10e4a"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i23e9f8931ea9473e8400905b9f3ae595_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi0yLTEtMS0wL3RleHRyZWdpb246ZjQ3YmZkNGFhOWU5NDhlZGJmNzIzNzRiN2FjMGFkNzNfMzg0ODI5MDY5NzIzMA_38f5fa04-6233-44bf-a4c0-da1f2d77062a"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ieada76793f944c4eb13d6f49d1d919c9_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi00LTEtMS0wL3RleHRyZWdpb246YTY3N2Q0ZTg2NzFhNDMzOTk3NTcxZWJhNzRiM2I1MzhfNA_0ace16ed-e7b5-4ddd-935d-e03bca322122"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if1104e86268b4788bd3ab46af5668636_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi00LTEtMS0wL3RleHRyZWdpb246YTY3N2Q0ZTg2NzFhNDMzOTk3NTcxZWJhNzRiM2I1MzhfOQ_2c4d335c-cfa7-4fd4-911a-b387165f71a4"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i58da51c726c84bb7a102eab630e19383_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi02LTEtMS0wL3RleHRyZWdpb246ZjA0YjE4YmVkMzgwNGMzYzg1YjVlOTgyZTRjOTgwZWRfNA_78a3c1f4-481f-42f9-9e5a-463d19143e67"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id3851733963a44f5b6ab5baa83678583_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi02LTEtMS0wL3RleHRyZWdpb246ZjA0YjE4YmVkMzgwNGMzYzg1YjVlOTgyZTRjOTgwZWRfOQ_ba20112d-fc36-43ec-9306-59a332a38be4"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia4486f177ee84c23bce912409a946b2e_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi04LTEtMS0wL3RleHRyZWdpb246MjIyMzE3MTk3MzE5NGMyMGI5YTlhMTlhNWViMGZjMDJfNA_50ea9350-d318-4e2f-96b6-5d5354c23359"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i878e7ec5e4d5477d814154f13bcbf670_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNi04LTEtMS0wL3RleHRyZWdpb246MjIyMzE3MTk3MzE5NGMyMGI5YTlhMTlhNWViMGZjMDJfOQ_8ed836c2-b94c-450f-87d7-11ef80b42ef3"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy0yLTEtMS0wL3RleHRyZWdpb246ZDAxN2RhNDk4NTE0NGE3NmI2MGM4ZmI3YmJjMTE5ODNfNA_4d688716-c839-4ba6-9aaf-e9919c9ea5aa"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic4668e47fc5d4e66bcc62ba0227681c7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy00LTEtMS0wL3RleHRyZWdpb246MGZjMmJlNmIxNzNhNDllZmFlOTUwMmQ1YTc1YjFjMzRfNA_7cd5a465-b716-4976-87d2-a40e24ba178b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy02LTEtMS0wL3RleHRyZWdpb246YTg3OTliY2I1NjYyNDhkNzg0NGE3MGEwNWQwODcwYmZfNA_695ec1a2-d33e-4b55-a435-adfda566e0b4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibf99460e0d7143c8901e2a82687f38ef_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjZjY2NkYmVhNzI4MjQ2ZGViOTJiNjEzMjRlOTJkZjY2L3RhYmxlcmFuZ2U6NmNjY2RiZWE3MjgyNDZkZWI5MmI2MTMyNGU5MmRmNjZfNy04LTEtMS0wL3RleHRyZWdpb246OGZjMTYyYTQzOWVjNDhjMDk3MTY0ZDgxODBlMGJkYWRfNA_a9a813d5-9dfc-4f55-a7dc-28c06e2d4e5c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ife34cbe919164cbaaec16da9320bc8fb_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTE4NzI_072dc7d3-cb70-49c9-9408-a62c8542b4e1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxNDg_89af3b10-21cd-4272-a468-6890eef3af3b">P0Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxNTM_af8250f9-80ed-4896-9c46-703963f407c0">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMxODA_6ae1c5f2-81e5-4033-a416-724107404827"
      unitRef="number">0.655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyMTM_fe7ee76f-41b3-4bb1-8516-84ad40b2e283"
      unitRef="number">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyMTk_20b2819f-7afb-4f36-91f3-2314f0209efc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate
      contextRef="i0ee315cd6efd4626b4bac9e4c560fa53_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMyNzE_40e31eed-18e3-4776-8b48-5de1ecc3a924"
      unitRef="number">0.16</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="ibf2aeb725ec642528a5e6e7b5b1f7998_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMzMjM_3772d537-9987-444b-9a59-9b76586a9b4a"
      unitRef="number">0.104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="ia39bf9037ad446edbd6302da93b341f8_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTMzMjg_e5e4974e-ce17-4750-9146-103a1559de47"
      unitRef="number">0.145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic36d7e888e844c6ab365df40d7c9fb62_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM1MTk_7e95da1b-5ce6-4c0b-a6bd-177975ad7ca5"
      unitRef="shares">922250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i439505c15efb47c09a20226584e2c489_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM2NDU_60006fc1-39cb-4fb5-b383-5e744897de87"
      unitRef="shares">942614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTM5MjM_2d0b50d9-ed69-41ab-bbf0-d7e3bf2c7cc6"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQwOTY_7f299e09-f476-443c-bcf7-6d56be56bbe2"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzNTA_c538abca-714d-4de1-9871-15033d3636a5">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQzODU_1d6467e8-bb09-4e38-8f16-7b441780a947"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQzODU_38fd94fd-f3ce-46b9-a1ce-f4bd47c74472"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjYzNw_a07b1abf-3550-41c5-8122-16d425a76e03"
      unitRef="shares">60898</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzg0ODI5MDcxMjY0MQ_9f7d01f3-a501-4732-b7d8-317fe24182af"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3102fe7237d84a8c82d30dfe4905765e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ0OTk_8c623721-400a-4d9e-96a6-864d602fc8b2"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49af050adba4445e8719cfb7cf09e673_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1MDY_f01452c0-09a3-42b0-bab0-47ca1da94932"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1NDY_8df388e1-9482-4b4e-845f-fb8ba2a9b976"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTQ1NTM_d15fc64e-a0c1-41bd-818e-87f2114d5aac"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNC0yLTEtMS0wL3RleHRyZWdpb246YjEyYTJmMGZmODc0NGYyOTg1NDUwNzdiODBkYjQ5ODBfMjE5OTAyMzI1NTU1OQ_5c5e68e6-06be-46bc-ba5c-4c228396f36f">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNC00LTEtMS0wL3RleHRyZWdpb246MTc3MjU4YTU0NGJmNGE0ZGFhNzhlMDllNThmZmIwOWRfMjE5OTAyMzI1NTU1OQ_3778eebb-70ca-429e-98f3-d48cd075b446">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNS0yLTEtMS0wL3RleHRyZWdpb246NTgzMWRlNWI4NjU1NGJkNzk1YzU5OWY0ODI0ZmM3NmFfMzg0ODI5MDY5NzIyMA_63737d03-97cd-400d-aba9-a6d5159cfc82"
      unitRef="number">0.508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNS00LTEtMS0wL3RleHRyZWdpb246ZjQwZWJiY2FlNzNhNDYwMTk5NmFlNjI0N2ZlOWU0ZjZfMzg0ODI5MDY5NzIyMA_336a0222-c8ad-4e64-bd9e-8a05fac6d870"
      unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNi0yLTEtMS0wL3RleHRyZWdpb246ZjFiYjFhYjZjYTQ1NGVjZGJhNmQ4NzZhZmJkM2JlOWZfMzg0ODI5MDY5NzIyMA_19de8809-b274-4e7a-ad2a-7d97ce3b814b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i226b2a1609f34decba63d9f7bdf51a86_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNi00LTEtMS0wL3RleHRyZWdpb246N2M2NTJjYmI4NDM2NDgxYzlkMThhMmJiNDY1NTRjNTdfMzg0ODI5MDY5NzIyMA_6cc664f3-efb7-4ab0-9eb3-fafb81e26902"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNy0yLTEtMS0wL3RleHRyZWdpb246M2MwMDY3M2RiMmUwNGVjNmI3YWYzMmE4MmNlNTEyZjZfMzg0ODI5MDY5NzIyMA_bff8a38c-a972-4fc3-9bd6-6cf27415031c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8b68835c972d41029ec0acfd75a26e8e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RhYmxlOjM0MGQzNmE4MjMwZjQyZWZhNjY3YTUzNjQ4MzNmY2MwL3RhYmxlcmFuZ2U6MzQwZDM2YTgyMzBmNDJlZmE2NjdhNTM2NDgzM2ZjYzBfNy00LTEtMS0wL3RleHRyZWdpb246YjU4MzJlYmUwZDk4NDc2YTk5ZDFjZDI2MWE4MTJhY2FfMzg0ODI5MDY5NzIyMA_bc15e89b-163d-46bb-a0ad-aa39091247f5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ic958cc4df2714adb8e2a85c3302cae4e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUyMjg_05cfa7d3-5536-4b81-a40d-fb77cf7e64c5"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMTUzMTc_db9bd134-c0c2-4f12-95c0-a11675922c19">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTIx_e5648c8c-ded9-45c3-addd-041d1bfeb634">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;(1)&#160;&#160;&#160;&#160;Excludes stock options of 4,183,891 shares outstanding under the AMEA 2020 Plan as of September&#160;30, 2021.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTMw_8bf660a5-ded4-4a83-9083-8b191aa56c88">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS0yLTEtMS0w_871af2b6-a833-4041-96a1-4818e4986676"
      unitRef="usd">-107526000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS00LTEtMS0w_d503e420-597b-401c-9c6e-db68d1af4b22"
      unitRef="usd">-71670000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS02LTEtMS0w_2113e4af-267f-459f-b464-b968d1f9626c"
      unitRef="usd">-312459000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNS04LTEtMS0w_87fe84f7-7ce4-4d19-8efd-dbf1fc1810e3"
      unitRef="usd">-153238000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi0yLTEtMS0w_f3e119d4-f9f5-4feb-bfd5-3afdbd85b20f"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi00LTEtMS0w_749f4ff8-6a22-4cf2-b99a-881220d0b919"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi02LTEtMS0w_47a648a4-d589-4149-b2f5-5365477bdd8d"
      unitRef="usd">2300000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNi04LTEtMS0w_b4834c52-aa07-4182-8f9b-57e006c71cb7"
      unitRef="usd">6800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy0yLTEtMS0w_5fb15a6f-99ce-48c3-9458-8326d07d546e"
      unitRef="usd">-107526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy0yLTEtMS0w_874ad18e-18fc-40c0-8475-233b2cc75eae"
      unitRef="usd">-107526000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy00LTEtMS0w_7cf8edec-5b3a-4ed9-bc33-fd74fbd6afb0"
      unitRef="usd">-77670000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy00LTEtMS0w_8dc8426e-3495-49b2-abd9-940fb6ad33ae"
      unitRef="usd">-77670000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy02LTEtMS0w_3be0f175-2ef8-4054-be41-1f693fdc6a60"
      unitRef="usd">-314759000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy02LTEtMS0w_da0bdad3-4ec1-4239-b438-526e1d366870"
      unitRef="usd">-314759000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy04LTEtMS0w_3bfae457-11d1-47f2-a894-526199e6ba38"
      unitRef="usd">-160038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfNy04LTEtMS0w_6a771443-e1a8-44c8-980b-3f6ac4a0489b"
      unitRef="usd">-160038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC0yLTEtMS0w_5e8f5e54-daf5-40fe-8053-de9221edde10"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC0yLTEtMS0w_e34d2365-82d7-4a0a-87aa-636ae63fcf99"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC00LTEtMS0w_3591fe49-89e0-47fe-a4c5-f6869b685ed2"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC00LTEtMS0w_83e47ca5-1995-4378-b87c-f29fe85827c9"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC02LTEtMS0w_3143a1bd-0fa1-4325-a914-b9e2191d59f0"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC02LTEtMS0w_85e3b458-8f5c-4861-b22e-18dc4a83b75d"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC04LTEtMS0w_7621e41c-04a9-4d82-9e2d-310264887c94"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOC04LTEtMS0w_9d92cafd-0d32-4843-b8ba-9eba258af409"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS0yLTEtMS0w_3547942d-001f-4f89-9522-43b8ed67973f"
      unitRef="shares">101420000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS0yLTEtMS0w_5036dc6e-bb14-4fef-850b-f10c73d98915"
      unitRef="shares">101420000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS00LTEtMS0w_08983a6c-b99c-4ced-840d-737f5a71a651"
      unitRef="shares">99554000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS00LTEtMS0w_cf6de157-4e44-4669-9ab7-a2e06d25892c"
      unitRef="shares">99554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS02LTEtMS0w_2a1dc424-e264-474e-ad8e-ac2aac3ddd5f"
      unitRef="shares">101184000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS02LTEtMS0w_5c25cd97-5ffd-4e1c-a043-bb3a1fd5fb96"
      unitRef="shares">101184000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS04LTEtMS0w_74fc4605-5672-419d-831c-43e6ab0cf64a"
      unitRef="shares">96659000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjc4Mjg1NmQ1NjhiNTQ1ODU4NDVhOGE5M2ZhMzI3YzM2L3RhYmxlcmFuZ2U6NzgyODU2ZDU2OGI1NDU4NTg0NWE4YTkzZmEzMjdjMzZfOS04LTEtMS0w_772ea594-c73c-4bfb-a0b9-e5a0b2538257"
      unitRef="shares">96659000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfOTI1_02b4e333-b4f1-4ac3-b46c-58652c53ccaf">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,220&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;(1)&#160;&#160;&#160;&#160;Excludes stock options of 4,183,891 shares outstanding under the AMEA 2020 Plan as of September&#160;30, 2021.</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id5e2eb5867bd4abdad9efdb23c03648e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS0yLTEtMS0w_62efed84-e1e2-40e6-954f-8b9758e9e3f8"
      unitRef="shares">2628000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4cd8dd76287347a8994cc91cb0f37e54_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS00LTEtMS0w_9b5bc1fc-c864-4a44-8041-44db36f93184"
      unitRef="shares">3662000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f1590c4a013498998b04d6183682906_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS02LTEtMS0w_ee33895e-b06c-42ee-b04c-7bdfd930a064"
      unitRef="shares">2753000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i563548405428432e9be4583d990c20a5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNS04LTEtMS0w_c22de784-81ce-4479-8e67-0de8380d8807"
      unitRef="shares">4021000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1764a9cb4164255b21e4e0410cbdd27_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi0yLTEtMS0w_2de635c5-2112-4623-81a0-fc9be61f71fe"
      unitRef="shares">1185000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i467c75e1f7b948f5a7efd31013b1df18_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi00LTEtMS0w_467eb1f8-f055-49a5-bff1-4955dbf06d61"
      unitRef="shares">650000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i59f3361b30354d25bc950de5b659ed29_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi02LTEtMS0w_f87fbf75-662d-441c-8382-54fa9c014923"
      unitRef="shares">1151000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61bba0a88cc44568eb34939ff6408d3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNi04LTEtMS0w_2135ef09-9ad5-4bfe-a2fa-389593c7428d"
      unitRef="shares">563000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i051dbab8706f4e6c98fecf9f6683eeac_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy0yLTEtMS0w_04fbb347-b3ae-4615-a769-7837ea086df2"
      unitRef="shares">2261000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie0255fd6f42d4f048e85959bd465c936_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy00LTEtMS0w_baad7cc8-671b-4923-869f-033dab293a30"
      unitRef="shares">3391000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8dae2902d6664783b4358b0e7fc11e28_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy02LTEtMS0w_04fe90d0-1e50-4874-9056-3c1bf511aaeb"
      unitRef="shares">2389000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iebaae8e37d2b469097bb427b4661df0f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfNy04LTEtMS0w_a5cb9038-fb44-4175-b39f-8dbcb2b3d619"
      unitRef="shares">1577000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c69dc8a627e4728912a6ed479ffc345_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC0yLTEtMS0w_d74a9d26-ed59-439b-b392-63ad0e76aef0"
      unitRef="shares">395000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i48e9f1511fdf4cfcb8763f4f23670aa0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC00LTEtMS0w_ded898d0-cc09-4c40-954a-57ac50b9d193"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9347e34e544e4e239b40143f08c828bd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC02LTEtMS0w_a370ddda-b6e7-426e-9d59-2c43f579a931"
      unitRef="shares">404000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68a11b9af24a42609ff2239dde8e7b4f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOC04LTEtMS0w_daa5dd98-9a61-4bdd-92a5-b363bd5a6a13"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib68413562a6147688552dc1e0f887f19_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS0yLTEtMS0w_1fadedbb-aa75-42d4-9cad-0d1790036f53"
      unitRef="shares">51000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8824d00a82d749e4ae56c26f8bf3f10d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS00LTEtMS0w_ac606696-b6f6-4f93-ac9c-5f6b3a3c7f87"
      unitRef="shares">38000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i181b6be341c14cacb65432c7b26b5d1a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS02LTEtMS0w_dcb3adbe-158e-4321-ba3c-5e2c2285e643"
      unitRef="shares">47000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i754a60ee0b734d8c8d484dab169687c5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfOS04LTEtMS0w_00a75b04-8fd2-4fa4-803b-eb318961a003"
      unitRef="shares">39000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifa67442147d24fb6a1c2a53972720ac1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtMi0xLTEtMA_d64f52fa-a845-4c83-996a-1155da6e4d72"
      unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iac62ba63e55f4ede8b1e77117a996888_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtNC0xLTEtMA_85b5def6-832d-454a-9eac-7839230f5786"
      unitRef="shares">17000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4779950a41b74addaabf2b2059d74b21_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtNi0xLTEtMA_d145173a-24a3-4b13-a671-c967dd38ba95"
      unitRef="shares">9000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i237f233fbe394afd8d627b2eb131fc5b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTAtOC0xLTEtMA_f432a02d-6430-4789-a52d-45c3ae12b410"
      unitRef="shares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i323c4b627b0a459fba3b36b35483f280_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtMi0xLTEtMA_3d095cf1-2090-4b5b-b0de-1c88c8d5711e"
      unitRef="shares">8225000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d16e8391a8340adbde54906d31ca966_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtNC0xLTEtMA_781b2d3b-e009-4334-8ad5-9211d314adc0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ca0eb25cb4e48be9a03dadf144d511d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtNi0xLTEtMA_e392967d-7a58-4524-b855-e521283c571c"
      unitRef="shares">8225000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i54d2bc7082434cad8d5831042bf6a66e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTEtOC0xLTEtMA_c78e0491-2695-4ef5-9cf6-d87f70bd7e02"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItMi0xLTEtMA_4b7e821e-d185-4bc8-80ba-e7d222011d7e"
      unitRef="shares">14751000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItNC0xLTEtMA_15527ff0-67fa-4b7c-a7ac-0acba1b3cf14"
      unitRef="shares">7758000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItNi0xLTEtMA_74f6544c-ab4d-4f4f-bb0c-4981ca617568"
      unitRef="shares">14978000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RhYmxlOjQxOTEyZGI3NzFlZTQ0YThhMDM1NDRkYWUxNzY2NWE0L3RhYmxlcmFuZ2U6NDE5MTJkYjc3MWVlNDRhOGEwMzU0NGRhZTE3NjY1YTRfMTItOC0xLTEtMA_c5cdd3b7-bdf5-452f-8297-b0aa48140cd9"
      unitRef="shares">6220000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8537a86f1af94a2daf05f30b67b193e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85MS9mcmFnOjUxZDY1MzBlNzM0MzQ0OGNhYThjMDE2NjgzNWJjZTQzL3RleHRyZWdpb246NTFkNjUzMGU3MzQzNDQ4Y2FhOGMwMTY2ODM1YmNlNDNfODY0_89dd03fe-ba09-4bcc-9ffe-20599db2cb3d"
      unitRef="shares">4183891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85NC9mcmFnOjc2NzI0YmM1YWRkZDRkNmViNTM3OGVhYTNhY2Y4M2M2L3RleHRyZWdpb246NzY3MjRiYzVhZGRkNGQ2ZWI1Mzc4ZWFhM2FjZjgzYzZfNjI3_8f3c0024-4031-4738-9430-23320d1fe239">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the three and nine months ended September&#160;30, 2021 was determined based upon estimates of the Company&#x2019;s effective income tax rates in various jurisdictions. The difference between the Company&#x2019;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense for the three and nine months ended September&#160;30, 2021, and 2020, relates primarily to state minimum income tax and income tax on the Company&#x2019;s earnings in foreign jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfNDM3_388a06db-fbaf-4e9d-abc4-c5a996d0c181">Segment and Geographic Information&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company operates as one operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and nine months ended September&#160;30, 2021,&#160;and&#160;2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, and December&#160;31, 2020, 98% and 94%, respectively, of the Company&#x2019;s long-lived assets and right-of-use assets are located in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfNDM5_e793a97f-e81e-4959-b994-f79855d92492">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and nine months ended September&#160;30, 2021,&#160;and&#160;2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="i7b784372c3354db186e4207099919653_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS0yLTEtMS0w_5bcb4e5d-8309-4422-94e6-3e061accfd82"
      unitRef="usd">90421000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibade6416d9d94221aaa09a5c56f76ec5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS00LTEtMS0w_c59f0e97-4ec0-416e-b869-003894b411ce"
      unitRef="usd">65613000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idac36981cc6c40c8b223afae0434d59f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS02LTEtMS0w_51db8b26-72d2-47d2-9a3f-f533905fd3e0"
      unitRef="usd">250589000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide1277ed3fdf429fb8b2ce51e59b628c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNS04LTEtMS0w_cd57ff8c-4108-4d42-91aa-3a7b821dec8f"
      unitRef="usd">191648000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1476a97484154965919c2e362fd4d837_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi0yLTEtMS0w_478603a8-6ae6-40e5-a7ff-3c62d89f6d6e"
      unitRef="usd">4358000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cd900800a93495eafddef1dfbea5516_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi00LTEtMS0w_f26a8c04-86f4-4737-80e3-9eca6356ae44"
      unitRef="usd">8956000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d20b34408944d6f96387d39fb1726ed_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi02LTEtMS0w_0243a2d4-cc5c-447a-a7d7-56f45ce4f42b"
      unitRef="usd">14956000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23bce519e74e4d918ca90a92c7c39f65_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNi04LTEtMS0w_7e533262-3bc2-4cc8-ba02-17ed15edaf52"
      unitRef="usd">16766000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87072388cc314ce488bc187e99179f36_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy0yLTEtMS0w_b6906b6e-b247-49e5-966f-77b72ab9a64b"
      unitRef="usd">94779000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fb8c7592b314d85bd9b6da0ac8d2aed_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy00LTEtMS0w_a02d1179-bcbd-43bd-b46c-83f693701ff5"
      unitRef="usd">74569000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy02LTEtMS0w_2992733a-102b-480b-aedf-9e8b39497741"
      unitRef="usd">265545000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id99d1f03db58476b865112b51f6b69de_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RhYmxlOmI4ZGZkMDMxNWZlOTRiZmNiNWQ3NzY1OGQ4ODFkMjhmL3RhYmxlcmFuZ2U6YjhkZmQwMzE1ZmU5NGJmY2I1ZDc3NjU4ZDg4MWQyOGZfNy04LTEtMS0w_4093fdc6-961c-4fc9-89af-5a6166c33883"
      unitRef="usd">208414000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if34f8da1addc4820a1cb6767365cb8a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfMzE5_0991db3f-9d26-49e0-93ae-5c39f07a8459"
      unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i818a62562a3c4a978a87e6b139e9bdc9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV85Ny9mcmFnOmI5ZDJhNDk3Y2U2ZjQ1ZjRhZmU3YjNiZjIyYWE5OGQzL3RleHRyZWdpb246YjlkMmE0OTdjZTZmNDVmNGFmZTdiM2JmMjJhYTk4ZDNfMzI2_f6dfc713-ba1e-405e-9c15-6dca403ad0ff"
      unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDAvZnJhZzoxNTEwYzY0ZmQ4Mjc0ZGI5YjExOWQ5OTFjMmIyOTkzOC90ZXh0cmVnaW9uOjE1MTBjNjRmZDgyNzRkYjliMTE5ZDk5MWMyYjI5OTM4XzEwMDE_48c2cabe-77a8-4c8e-a2a0-35bd5eefdf48">Related Party Transactions&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.&lt;/span&gt;The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#x2019;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDYvZnJhZzo2ZTI2MTliMjEyNjU0YjYwYWJmY2Q2YThlY2Y2NmRmNy90ZXh0cmVnaW9uOjZlMjYxOWIyMTI2NTRiNjBhYmZjZDZhOGVjZjY2ZGY3XzE2Nw_7d37c028-1ea4-4b27-a7b9-870ea0a4ede8">Subsequent EventsOn November 1, 2021, the Company exercised its call right contained in its joint venture agreement with SoftBank. As a result of the exercise of these rights, the Company will purchase all Joint Venture shares held by SoftBank at a price to be negotiated between the parties or established by a third-party valuation firm utilizing the financial and operating assumptions outlined in the joint venture agreement. Pursuant to the joint venture agreement, the fair value of the Joint Venture will be no less than an amount that yields a 20% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture. Settlement of the aggregate purchase price will be in cash, shares, or a combination of cash and shares, at SoftBank&#x2019;s discretion. The Company expects to purchase all shares held by SoftBank in the Joint Venture on or before the end of the second quarter of 2022. No changes to the fair value of the redeemable noncontrolling interest have been reflected as of end of September 30, 2021.</us-gaap:SubsequentEventsTextBlock>
    <gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn
      contextRef="i3edbb27baf14454882593f853aa8325b_D20211101-20211101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xMDYvZnJhZzo2ZTI2MTliMjEyNjU0YjYwYWJmY2Q2YThlY2Y2NmRmNy90ZXh0cmVnaW9uOjZlMjYxOWIyMTI2NTRiNjBhYmZjZDZhOGVjZjY2ZGY3XzM4NDgyOTA3MTE4NTQ_362e0c12-5f26-4dd6-8122-197aba49e5cd"
      unitRef="number">0.20</gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of September&#160;30, 2021, and&#160;December&#160;31, 2020, this balance includes $24.8 million and&#160;$35.0 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#x201c;VIE&#x201d;) and VIE&#x2019;s subsidiaries, and&#160;$3.8 million and $4.9 million, respectively,&#160;of liabilities of the consolidated VIE and VIE&#x2019;s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMy0xLTEtMA_94ce947f-babb-45cf-896a-1ad1b3a56014"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMy0xLTEtMA_7dc347de-26b1-4fb5-b71b-495df2bc0c0b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMTYtMS0xLTEtMA_7a737099-f379-4827-b28f-7928764dd9fa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RhYmxlOjZkOWMxNGE2NTQ0ZDQyMjc4NmIxNzgyNjJhY2I4MWYwL3RhYmxlcmFuZ2U6NmQ5YzE0YTY1NDRkNDIyNzg2YjE3ODI2MmFjYjgxZjBfMjktMS0xLTEtMA_e5a54e0a-82c3-4cb5-9a27-b590da549bba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV8xNi9mcmFnOjFjNjAyYWYyOGRhNDRlODI5NmQxMzZjODcxNGVkZjJhL3RleHRyZWdpb246MWM2MDJhZjI4ZGE0NGU4Mjk2ZDEzNmM4NzE0ZWRmMmFfNjE2_5fd23ad8-5694-4924-9584-fba27c6c8b1b"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796261010712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GUARDANT HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4139254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Penobscot Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">698-8887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,656,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258520200">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 832,370<span></span>
</td>
<td class="nump">$ 832,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">653,601<span></span>
</td>
<td class="nump">961,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,744<span></span>
</td>
<td class="nump">53,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,739<span></span>
</td>
<td class="nump">22,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,958<span></span>
</td>
<td class="nump">17,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,593,412<span></span>
</td>
<td class="nump">1,888,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250,226<span></span>
</td>
<td class="nump">246,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,156<span></span>
</td>
<td class="nump">62,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">196,436<span></span>
</td>
<td class="nump">37,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,698<span></span>
</td>
<td class="nump">16,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,316<span></span>
</td>
<td class="nump">17,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,225,534<span></span>
</td>
<td class="nump">2,271,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,674<span></span>
</td>
<td class="nump">7,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,838<span></span>
</td>
<td class="nump">28,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,475<span></span>
</td>
<td class="nump">22,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,317<span></span>
</td>
<td class="nump">8,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102,304<span></span>
</td>
<td class="nump">66,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,134,180<span></span>
</td>
<td class="nump">806,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216,806<span></span>
</td>
<td class="nump">41,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,424<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,456,714<span></span>
</td>
<td class="nump">916,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,400<span></span>
</td>
<td class="nump">57,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September&#160;30, 2021, and December&#160;31, 2020; 101,623,257 and 100,213,985 shares issued and outstanding as of September&#160;30, 2021, and December&#160;31, 2020, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,626,926<span></span>
</td>
<td class="nump">1,902,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(593)<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(916,914)<span></span>
</td>
<td class="num">(606,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">709,420<span></span>
</td>
<td class="nump">1,298,495<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,225,534<span></span>
</td>
<td class="nump">$ 2,271,781<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2021, and&#160;December&#160;31, 2020, this balance includes $24.8 million and&#160;$35.0 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$3.8 million and $4.9 million, respectively,&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256406344">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,623,257<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,623,257<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,225,534<span></span>
</td>
<td class="nump">$ 2,271,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,456,714<span></span>
</td>
<td class="nump">916,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,800<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2021, and&#160;December&#160;31, 2020, this balance includes $24.8 million and&#160;$35.0 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$3.8 million and $4.9 million, respectively,&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258551272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="nump">$ 79,272<span></span>
</td>
<td class="nump">$ 60,384<span></span>
</td>
<td class="nump">$ 215,605<span></span>
</td>
<td class="nump">$ 171,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services and other</a></td>
<td class="nump">15,507<span></span>
</td>
<td class="nump">14,185<span></span>
</td>
<td class="nump">49,940<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">94,779<span></span>
</td>
<td class="nump">74,569<span></span>
</td>
<td class="nump">265,545<span></span>
</td>
<td class="nump">208,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTesting', window );">Cost of precision oncology testing</a></td>
<td class="nump">29,665<span></span>
</td>
<td class="nump">16,699<span></span>
</td>
<td class="nump">78,142<span></span>
</td>
<td class="nump">52,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostofDevelopmentServices', window );">Cost of development services and other</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
<td class="nump">11,348<span></span>
</td>
<td class="nump">11,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">70,968<span></span>
</td>
<td class="nump">36,245<span></span>
</td>
<td class="nump">190,200<span></span>
</td>
<td class="nump">109,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">50,228<span></span>
</td>
<td class="nump">25,095<span></span>
</td>
<td class="nump">132,282<span></span>
</td>
<td class="nump">75,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">50,055<span></span>
</td>
<td class="nump">66,294<span></span>
</td>
<td class="nump">166,366<span></span>
</td>
<td class="nump">123,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">202,067<span></span>
</td>
<td class="nump">148,821<span></span>
</td>
<td class="nump">578,338<span></span>
</td>
<td class="nump">372,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(107,288)<span></span>
</td>
<td class="num">(74,252)<span></span>
</td>
<td class="num">(312,793)<span></span>
</td>
<td class="num">(163,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">8,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">2,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(107,430)<span></span>
</td>
<td class="num">(71,602)<span></span>
</td>
<td class="num">(312,170)<span></span>
</td>
<td class="num">(153,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(107,526)<span></span>
</td>
<td class="num">(71,670)<span></span>
</td>
<td class="num">(312,459)<span></span>
</td>
<td class="num">(153,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">(107,526)<span></span>
</td>
<td class="num">(77,670)<span></span>
</td>
<td class="num">(314,759)<span></span>
</td>
<td class="num">(160,038)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">$ (107,526)<span></span>
</td>
<td class="num">$ (77,670)<span></span>
</td>
<td class="num">$ (314,759)<span></span>
</td>
<td class="num">$ (160,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)</a></td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)</a></td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)</a></td>
<td class="nump">101,420<span></span>
</td>
<td class="nump">99,554<span></span>
</td>
<td class="nump">101,184<span></span>
</td>
<td class="nump">96,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</a></td>
<td class="nump">101,420<span></span>
</td>
<td class="nump">99,554<span></span>
</td>
<td class="nump">101,184<span></span>
</td>
<td class="nump">96,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostofDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostofDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258038440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (107,526)<span></span>
</td>
<td class="num">$ (71,670)<span></span>
</td>
<td class="num">$ (312,459)<span></span>
</td>
<td class="num">$ (153,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax impact:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(513)<span></span>
</td>
<td class="num">(1,721)<span></span>
</td>
<td class="num">(2,097)<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(626)<span></span>
</td>
<td class="num">(1,530)<span></span>
</td>
<td class="num">(3,290)<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(108,152)<span></span>
</td>
<td class="num">(73,200)<span></span>
</td>
<td class="num">(315,749)<span></span>
</td>
<td class="num">(150,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Guardant Health, Inc.</a></td>
<td class="num">$ (108,152)<span></span>
</td>
<td class="num">$ (79,200)<span></span>
</td>
<td class="num">$ (318,049)<span></span>
</td>
<td class="num">$ (157,287)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256793960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect adjustment for ASU 2020-06 adoption</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest</div></th>
<th class="th"><div>Common&#160;Stock&#160;</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative effect adjustment for ASU 2020-06 adoption</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>&#160; Accumulated Deficit</div></th>
<th class="th">
<div>&#160; Accumulated Deficit </div>
<div>Cumulative effect adjustment for ASU 2020-06 adoption</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">$ (6,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">798,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,150,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="num">(352,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">7,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">87,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax impact</a></td>
<td class="nump">2,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(153,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,897,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">1,092,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,601,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,862<span></span>
</td>
<td class="num">(512,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 798,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,150,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="num">(352,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,298,495<span></span>
</td>
<td class="num">$ (325,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,902,389<span></span>
</td>
<td class="num">$ (330,403)<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="num">(606,592)<span></span>
</td>
<td class="nump">$ 4,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,312,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">1,114,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,544,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,392<span></span>
</td>
<td class="num">(435,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">3,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">55,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax impact</a></td>
<td class="num">(1,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(71,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,897,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">1,092,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,601,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,862<span></span>
</td>
<td class="num">(512,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(2,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,298,495<span></span>
</td>
<td class="num">$ (325,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,902,389<span></span>
</td>
<td class="num">$ (330,403)<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="num">(606,592)<span></span>
</td>
<td class="nump">$ 4,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">629,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 7,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">5,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(82,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">124,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax impact</a></td>
<td class="num">(3,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(312,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,623,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">709,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,626,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="num">(916,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,265,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">788,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,597,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(809,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(7,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">35,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax impact</a></td>
<td class="num">(626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(107,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,623,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 709,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,626,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (593)<span></span>
</td>
<td class="num">$ (916,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised Early</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796253007736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">$ 1,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796341931896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (312,459)<span></span>
</td>
<td class="num">$ (153,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,181<span></span>
</td>
<td class="nump">11,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NonCashOperatingLeaseCosts', window );">Non-cash operating lease costs</a></td>
<td class="nump">17,782<span></span>
</td>
<td class="nump">3,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">Charge of in-process research and development costs with no alternative future use</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Re-valuation of contingent consideration</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">124,592<span></span>
</td>
<td class="nump">87,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="nump">9,546<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Credit loss adjustment and others</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(7,445)<span></span>
</td>
<td class="nump">11,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,023)<span></span>
</td>
<td class="num">(12,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,758)<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,226)<span></span>
</td>
<td class="num">(7,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,939<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">10,558<span></span>
</td>
<td class="nump">5,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">10,484<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(3,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,233)<span></span>
</td>
<td class="num">(4,940)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(132,029)<span></span>
</td>
<td class="num">(44,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(334,082)<span></span>
</td>
<td class="num">(580,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">627,110<span></span>
</td>
<td class="nump">307,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of non-marketable equity and other related investments</a></td>
<td class="num">(39,076)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(50,410)<span></span>
</td>
<td class="num">(28,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets and capitalized license obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,886)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">203,542<span></span>
</td>
<td class="num">(319,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments made on finance lease obligations</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">7,065<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of common stock under employee stock purchase plan</a></td>
<td class="nump">5,401<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(82,157)<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering, net of underwriting discounts and commissions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">355,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs related to public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of offering costs related to borrowings on convertible senior notes</a></td>
<td class="num">(784)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(70,604)<span></span>
</td>
<td class="nump">363,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,193)<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">832,977<span></span>
</td>
<td class="nump">143,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;End of period</a></td>
<td class="nump">832,693<span></span>
</td>
<td class="nump">142,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">171,068<span></span>
</td>
<td class="nump">10,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">9,589<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquitySecuritiesFVNIIncurredButNotYetPaid', window );">Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases', window );">Property and equipment acquired under finance leases</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">832,370<span></span>
</td>
<td class="nump">142,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; included in other assets, net</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 832,693<span></span>
</td>
<td class="nump">$ 142,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ChargeOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge Of In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ChargeOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquitySecuritiesFVNIIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquitySecuritiesFVNIIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NonCashOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Operating Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NonCashOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Acquired Under Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796253009976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of BusinessGuardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a liquid or tissue biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company provides its Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. In February 2021, the Company launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, the Company launched Guardant360 TissueNext, the Company's first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. The Company is also developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's tests, the Company has also developed the GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#8220;SoftBank&#8221;). Under the terms of the joint venture agreement, the Company holds a 50% ownership interest in the Joint Venture. As of September&#160;30, 2021, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span>) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254553288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable securities as of September&#160;30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the coronavirus 2019, or COVID-19 pandemic, will ultimately impact the Company&#8217;s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of September&#160;30, 2021, the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2021, and 2020, and cash flows for the nine months ended September&#160;30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021, and 2020, foreign currency transaction gains and losses were immaterial. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of payroll withholding related to the Company's enrollment in certain voluntary disability insurance plan. Restricted cash balance as of September&#160;30, 2021, was $0.3 million, which was included in other assets in the accompanying consolidated balance sheets. The Company did not&#160;have any restricted cash as of December&#160;31, 2020. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investee. The Company's non-marketable equity and other related investments totaled $39.4&#160;million as of September&#160;30, 2021, and are included in other assets, net on the accompanying condensed consolidated balance sheets. The Company did not&#160;have such non-marketable equity and other related investments as of December&#160;31, 2020. Non-marketable securities are subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. Pursuant to one of the investments in non-marketable securities purchased by the Company, and subject to the Company purchasing additional non-marketable securities from the same investee, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022.  As of September&#160;30, 2021, no impairment or adjustments to carrying value of non-marketable securities have been recorded. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0&#160;million. The Company has evaluated and recorded a credit loss for the remaining $7.0&#160;million considering the third-party's credit worthiness and lack of financial history. The following table presents the receivable and the related credit loss amounts: </span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to (Reversed from) Other Income (Expense), Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassi<br/>fication</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousand)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of September&#160;30, 2021, and December&#160;31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are presented under accounts receivable, net and other assets, net on the Company&#8217;s condensed consolidated balance sheets and include balances due from commercial and governmental payers, and biopharmaceutical customers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of&#160;September&#160;30, 2021, the Company had contract assets of&#160;$30.9 million which was recorded in accounts receivable, net. As of December&#160;31, 2020, the Company had contract assets of $15.6 million which was recorded in accounts receivable, net, which included $8.4 million of unbilled receivable relating to Guardant360 CDx.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;September&#160;30, 2021, there has been&#160;no&#160;impairment of goodwill or IPR&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6&#8212;12 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended September 30, 2021, and 2020, the Company recorded $3.2&#160;million and $11.4&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the nine months ended September 30, 2021, and 2020, the Company recorded $17.8&#160;million and $21.9&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Kits fulfillment related revenues are recognized when such products are delivered.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of September&#160;30, 2021, and December&#160;31, 2020, the deferred revenue balance was $7.3 million and $8.6 million, respectively, which included $0.6 million and $3.0 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the nine months ended September 30, 2021, that was included in the deferred revenue balance as of December&#160;31, 2020, was $8.0 million, of which $3.0 million represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;Revenue recognized in the nine months ended September 30, 2020, that was included in the deferred revenue balance as of December&#160;31, 2019, was $8.8 million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Precision Oncology Testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the Company&#8217;s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020, from additional paid-in capital to convertible senior notes, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796253013000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Joint Venture</a></td>
<td class="text">Investment in Joint Venture<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to 89,000,000 shares consisting of 80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non-voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SoftBank held 40,000,000 shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $0.05 per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#8217;s 2020 Equity Incentive Plan pursuant to which 4,595,555 shares of Class B common stock have been reserved for issuance. As of September&#160;30, 2021, and December&#160;31, 2020, 313,331 and no shares of Class B common stock have been issued and outstanding, respectively, and no shares of Class A common stock have been issued and outstanding. As of September&#160;30, 2021, and December&#160;31, 2020, 80,000,000 shares of Series A preferred stock have been issued and outstanding.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#8220;VIE&#8221;) and the Company has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, and December&#160;31, 2020, the Joint Venture had total assets of approximately $24.8 million and $35.0 million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of September&#160;30, 2021, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put-call arrangements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right, the Company will choose the form of consideration. On November 1, 2021, the Company elected to exercise the call right and provided its intent to purchase all shares held by SoftBank pursuant to a time-based trigger, see Note 17.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254393704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Condensed Consolidated Balance Sheet Components</a></td>
<td class="text">Condensed Consolidated Balance Sheet Components<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $5.0 million and $3.8 million for the three months ended September 30, 2021, and 2020, respectively, and $14.6 million and $10.0 million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued tax liabilities   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued professional services   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials and studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued legal expenses   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued royalty obligations   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accrued expenses   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252716008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements, Cash Equivalents and Marketable Securities</a></td>
<td class="text">Fair Value Measurements, Cash Equivalents and Marketable Securities  <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,828&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. As of September&#160;30, 2021, and December&#160;31, 2020, contingent consideration liability of $3.1 million and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the redeemable noncontrolling interest as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 3 measurement. The fair value of the redeemable noncontrolling interest was determined using a of the income approach and the market approach, and estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted-average costs of capital and future market conditions, among others.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments for the three and nine months ended September&#160;30, 2021, and 2020:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.076%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the fair value of the Convertible Notes as of September&#160;30, 2021, and December&#160;31, 2020, to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to the fair value of the Convertible Notes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and nine months ended September&#160;30, 2021, and 2020, respectively. The maturities of the Company&#8217;s long-term marketable securities range from 1.3 to 2.0 years as of September&#160;30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257495864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent License Acquisition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Patent License Acquisition</a></td>
<td class="text">Patent License Acquisition<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#8220;KeyGene&#8221;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#8220;SPLA&#8221;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#8217;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated $9.4 million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of 6-12 years. The Company allocated $8.5 million to IPR&amp;D technology, which have no alternative future use and was included in research and development expenses for the nine months ended September 30, 2020. The remaining $1.2 million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252781576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net and Goodwill</a></td>
<td class="text">Intangible Assets, Net and Goodwill<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets was $0.5 million and $0.5 million for the three months ended September 30, 2021, and 2020, respectively, and $1.5 million and $1.3 million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257495864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company issued $1.15&#160;billion principal amount of its 0% Convertible Senior Notes due 2027 (the &#8220;2027 Notes&#8221;). The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter (the &#8220;sale price condition&#8221;);</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the five consecutive business days immediately after any ten consecutive trading day period (the &#8220;measurement period&#8221;) if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon the occurrence of specified corporate events</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company&#8217;s election. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $139.82 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a &#8220;Make-Whole Fundamental Change&#8221; occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company&#8217;s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain corporate events that constitute a &#8220;Fundamental Change&#8221; occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company&#8217;s common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the 2027 Notes were not convertible as of September&#160;30, 2021, the net carrying amount of the 2027 Notes was classified as a long-term liability. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the 2027 Notes as of September&#160;30, 2021, and December&#160;31, 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component recorded at issuance:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recorded in equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of the 2027 Notes was $1.3 billion and $1.3 billion as of September&#160;30, 2021, and December&#160;31, 2020, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $1.9 million for the three and nine months ended September 30, 2021, which represented an effective interest rate of 0.2% and 0.2% and for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Hedges</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions (the "2027 Note Hedges") with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $182.60 per share, which represents a premium of 75% over the last reported sale price of the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive.</span></div>As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders&#8217; equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0 million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257217608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has&#160;entered into various operating lease agreements for office space,&#160;data center, lab and warehouse use, with remaining terms ranging from 1 year to 12 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement.  In July 2020, the Company entered into two lease agreements for additional office space in Palo Alto, California ("Palo Alto Lease") and in San Diego, California ("San Diego Lease"). The San Diego Lease has a term of 8 years with rent payments commencing in May 2022.  The Palo Alto Lease has a term of 12 years with an option to renew the lease term for an additional ten years which has not been considered in the determination of ROU or the lease liability as the Company does not consider it reasonably certain of exercising the renewal option. Rent payments for the Palo Alto Lease will commence in October 2021. Both leases consist of fixed and variable payments and are being accounting for as operating leases. The Company took possession of these facilities in March 2021.  The Company estimated the incremental borrowing rate to determine the present value of lease payments for the San Diego and Palo Alto leases using trading data of the Company's convertible debt adjusted for credit rating and market yield curves.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense was $6.9 million and immaterial for the three months ended September 30, 2021, and 2020, respectively, and $17.8 million and $3.3 million for the nine months ended September 30, 2021, and 2020, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes). </span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of September&#160;30, 2021:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:81.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252787752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, the Company filed a lawsuit against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) in the United States District Court for the District of Delaware. The Company has alleged that Foundation Medicine has infringed four of the Company&#8217;s digital sequencing technology patents. Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license and non-infringement. The parties are seeking damages, injunctive relief and attorneys&#8217; fees. Discovery in the lawsuit has closed, and a number of pre-trial motions were filed in September and October 2020. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foundation Medicine also filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company. The PTAB denied institution of inter partes review for four of the six petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, the Company filed a lawsuit against Foundation Medicine in the United States District Court for the District of Delaware, wherein the Company alleged that Foundation Medicine infringes seven of the Company&#8217;s patents.  Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license, non-infringement, and that the Company has violated Section 2 of Sherman Act. In December 2020, the Company filed a Motion for a Preliminary Injunction to prohibit Foundation Medicine from practicing two of the asserted patents.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company filed two lawsuits against Foundation Medicine GmbH in the District Court of Munich I in Germany, wherein the Company alleged that Foundation Medicine GmbH infringes two of the Company&#8217;s patents.  Final hearings on this matter are scheduled for December 2021.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a binding term sheet with Foundation Medicine, which upon execution of a definitive settlement agreement, will result in the dismissal of all pending patent litigation worldwide between the parties. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and Personal Genome Diagnostics, Inc. settled the patent infringement lawsuit brought by the Company. Under the terms of the confidential settlement, the lawsuit and counterclaims, as well as other challenges to the Company&#8217;s patents, have been dismissed.   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, TwinStrand Biosciences, Inc. (&#8220;TwinStrand Biosciences&#8221;) and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company answered the complaint in October 2021, denying TwinStrand Biosciences&#8217; allegations. The court has not yet entered a case scheduling order.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">False Advertising Dispute</span></div>In May 2021, the Company also filed a lawsuit against Natera, Inc. (&#8220;Natera&#8221;) in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company&#8217;s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera&#8217;s Signatera assay. The Company is seeking a Preliminary Injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition. Discovery is ongoing and the court has scheduled a hearing for November 2021 to hear argument on the Company&#8217;s motion to dismiss Natera&#8217;s counterclaims and for a case management conference.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796253012168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common StockThe Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of September&#160;30, 2021, and December&#160;31, 2020, no dividends on the Company's common stock had been declared by the Board of Directors.<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,868</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101,181</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391,148</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,922</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819,223</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536,491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,568,420</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,344,620</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offering</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company completed an underwritten public offering, in which it issued and sold 4,312,500 shares of its common stock at a price of $84.00 per share. The Company received net proceeds of $354.6&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796253056504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819,223</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101,181</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,147)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629,246)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,286</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,214)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,117)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,627</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,254</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,917)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,498</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,868</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,159</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2021, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $28.4 million and $46.8 million for the three months ended September 30, 2021, and 2020, respectively, and $77.8 million and $97.1 million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $65.17 and $49.73 per share for the three months ended September 30, 2021, and 2020, respectively, and $72.14 and&#160;$46.85 per share for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested options as of September&#160;30, 2021 was $22.7 million, which is expected to be recognized over a weighted-average period of 2.8 years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,655</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,998)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,627)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock-based compensation for unvested restricted stock units as of September&#160;30, 2021, was $105.2 million, which is expected to be recognized over a weighted-average period of 3.0 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant performance-based restricted stock units (&#8220;PSUs&#8221;) under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of 4 years and an additional service period requirement of six months after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of 4 years. The PSUs are expected to be expensed over a period of approximately 4 years to 4.5 years subject to meeting the respective performance metrics and service requirements. As of September&#160;30, 2021, a significant portion of these PSUs are not expected to achieve the related performance metrics, and therefore, no stock-based compensation expense was recorded for the PSUs that were not probable to vest.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,922</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,498)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation recorded for the PSUs for the three and nine months ended September&#160;30, 2021, was $0.3 million and $1.0 million, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of September&#160;30, 2021 was $4.4 million, which is expected to be recognized over a weighted-average period of 3.4 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units (&#8220;MSUs&#8221;) under the 2018 Plan to each of the Company's Co-Chief Executive Officers, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxNjViM2RkMmNkNjQxMDlhZTY2MzAyMWQ1NDE0M2FlL3NlYzplMTY1YjNkZDJjZDY0MTA5YWU2NjMwMjFkNTQxNDNhZV84NS9mcmFnOmEwODhmODBiNDc2YjRhMTE5OWM1YjgzMDJmOTI0Yzk2L3RleHRyZWdpb246YTA4OGY4MGI0NzZiNGExMTk5YzViODMwMmY5MjRjOTZfMzYwOA_1a96adcc-20aa-4c2d-b632-070a36d742ec">six</span> to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted-average grant date fair value of the MSUs was $67.00 and the weighted-average derived service period was estimated to be in the range of 0.83 &#8211; 2.07 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, Tranche 1 of the MSUs became vested because it has met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of 30 consecutive calendar days. A summary of the Company&#8217;s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Market-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(572,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558,254)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for the MSUs was $22.6 million and $46.8 million, for the three months ended September 30, 2021, and 2020, respectively, and $88.9 million and $65.1 million, for the nine months ended September 30, 2021, and 2020, respectively, which was recorded in general and administrative expenses on the condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of September&#160;30, 2021 was $26.4 million, which is expected to be recognized over a weighted-average period of 0.7 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMEA 2020 Equity Incentive Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan (the &#8220;AMEA 2020 Plan&#8221;), under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to employees of the Joint Venture or its affiliates. Nonstatutory stock options may be granted to </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees, directors and non-employee consultants. Stock options may be granted at an exercise price of not less than the fair market value of the Joint Venture's common stock on the date of grant, determined by the board of directors of the Joint Venture. Options generally vest over 4 years and expire as determined by the board of directors of the Joint Venture, provided that the term of options may not exceed 10 years from the date of grant. For individuals holding more than 10% of the total combined voting power of all classes of stock of the Joint Venture, the exercise price of an option will not be less than 110% of the fair market value of the Joint Venture's common stock on the date of grant, and the term of the option will not exceed 5 years. A total of 4,595,555 shares of the Joint Venture's Class B common stock are initially reserved for issuance under the AMEA 2020 Plan, and the number of shares may be increased in accordance with the terms of the AMEA 2020 Plan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(826,667)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826,667</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313,331)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382,780)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,333</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183,891</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341,259</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $0.33 per share for the three and nine months ended September&#160;30, 2021. Future stock-based compensation for unvested options as of September&#160;30, 2021 was $0.6 million, which is expected to be recognized over a weighted-average period of 2.5 years.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense   </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense   </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 &#8211; 6.10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 66.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 68.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 66.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 73.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 0.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 0.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company and the Joint Venture, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. The grant date fair value of the Joint Venture's common stock has been determined by the board of directors of the Joint Venture. The grant date fair value of the Joint Venture&#8217;s common stock was determined using valuation methodologies which utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the Joint Venture&#8217;s common stock, the methodologies used to estimate the enterprise value of the Joint Venture were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Joint Venture derived the expected volatility from the average historical volatility over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Joint Venture does not have any trading history for its common stock. The Joint Venture will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and the Joint Venture does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of MSUs</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risky Rate</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risky rate represents the Company's cost of equity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discount for Lack of Marketability </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 &#8211; 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.53%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% &#8211; 14.5%.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional 942,614&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock purchased under the ESPP were nil for the three months ended September 30, 2021, and 2020, respectively, and 60,898 and 58,164 for the nine months ended September 30, 2021, and 2020, respectively. The total compensation expense related to the ESPP was $0.9 million&#160;and $0.7 million for the three months ended </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021, and 2020, respectively, and $2.5 million and $2.3 million for the nine months ended September 30, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No ESPP shares were issued for the three months ended September 30, 2021, and 2020. The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:73.378%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.940%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the unrecognized stock-based compensation expense related to the ESPP was $0.4 million, which is expected to be recognized over the remaining term of the offering period of 0.1 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254973560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,526)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,759)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.66)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,554&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:39.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,978</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220</span></td></tr></table>(1)&#160;&#160;&#160;&#160;Excludes stock options of 4,183,891 shares outstanding under the AMEA 2020 Plan as of September&#160;30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252789832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three and nine months ended September&#160;30, 2021 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the three and nine months ended September&#160;30, 2021, and 2020, relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252985912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates as one operating segment. The Company's chief operating decision makers are its Co-Chief Executive Officers, who review financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and nine months ended September&#160;30, 2021,&#160;and&#160;2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, and December&#160;31, 2020, 98% and 94%, respectively, of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254536552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span>The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#8217;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254534008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn November 1, 2021, the Company exercised its call right contained in its joint venture agreement with SoftBank. As a result of the exercise of these rights, the Company will purchase all Joint Venture shares held by SoftBank at a price to be negotiated between the parties or established by a third-party valuation firm utilizing the financial and operating assumptions outlined in the joint venture agreement. Pursuant to the joint venture agreement, the fair value of the Joint Venture will be no less than an amount that yields a 20% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture. Settlement of the aggregate purchase price will be in cash, shares, or a combination of cash and shares, at SoftBank&#8217;s discretion. The Company expects to purchase all shares held by SoftBank in the Joint Venture on or before the end of the second quarter of 2022. No changes to the fair value of the redeemable noncontrolling interest have been reflected as of end of September 30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257055064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents and marketable securities as of September&#160;30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-</span></div>marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. The extent to which the coronavirus 2019, or COVID-19 pandemic, will ultimately impact the Company&#8217;s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of September&#160;30, 2021, the condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and nine months ended September&#160;30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and nine months ended September&#160;30, 2021, and 2020, and cash flows for the nine months ended September&#160;30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign Currency The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and nine months ended September&#160;30, 2021, and 2020, foreign currency transaction gains and losses were immaterial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div>The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0&#160;million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0&#160;million. The Company has evaluated and recorded a credit loss for the remaining $7.0&#160;million considering the third-party's credit worthiness and lack of financial history.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of September&#160;30, 2021, and December&#160;31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are presented under accounts receivable, net and other assets, net on the Company&#8217;s condensed consolidated balance sheets and include balances due from commercial and governmental payers, and biopharmaceutical customers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of&#160;September&#160;30, 2021, the Company had contract assets of&#160;$30.9 million which was recorded in accounts receivable, net. As of December&#160;31, 2020, the Company had contract assets of $15.6 million which was recorded in accounts receivable, net, which included $8.4 million of unbilled receivable relating to Guardant360 CDx.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionPolicyTextBlock', window );">Asset Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets, net</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;September&#160;30, 2021, there has been&#160;no&#160;impairment of goodwill or IPR&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6&#8212;12 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.</span></div>In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precision oncology testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended September 30, 2021, and 2020, the Company recorded $3.2&#160;million and $11.4&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the nine months ended September 30, 2021, and 2020, the Company recorded $17.8&#160;million and $21.9&#160;million as revenue, respectively, resulting from cash collections exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development services and other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Kits fulfillment related revenues are recognized when such products are delivered.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with multiple performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of September&#160;30, 2021, and December&#160;31, 2020, the deferred revenue balance was $7.3 million and $8.6 million, respectively, which included $0.6 million and $3.0 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the nine months ended September 30, 2021, that was included in the deferred revenue balance as of December&#160;31, 2020, was $8.0 million, of which $3.0 million represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;Revenue recognized in the nine months ended September 30, 2020, that was included in the deferred revenue balance as of December&#160;31, 2019, was $8.8 million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock', window );">Costs of Precision Oncology Testing</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Precision Oncology Testing</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostofDevelopmentServicesPolicyTextBlock', window );">Cost of Development Services</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Development Services and Other</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company&#8217;s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options granted to the Company&#8217;s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div>The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company&#8217;s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Adopted</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the Company&#8217;s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020, from additional paid-in capital to convertible senior notes, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostofDevelopmentServicesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostofDevelopmentServicesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTestingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Condensed Financial Statements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254240408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Customer D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;less than 10%</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock', window );">Schedule of Contractual Receivables and Related Credit Loss</a></td>
<td class="text">The following table presents the receivable and the related credit loss amounts: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to (Reversed from) Other Income (Expense), Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassi<br/>fication</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousand)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254278696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Leasehold improvements   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer hardware   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Construction in progress   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Furniture and fixtures   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Computer software   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, gross   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Less: accumulated depreciation   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Property and equipment, net   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Operating lease liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued tax liabilities   </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued professional services   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trials and studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued legal expenses   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Accrued royalty obligations   </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Others</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total accrued expenses   </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796352477768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:<div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,828&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total short-term marketable securities   </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities   </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total long-term marketable securities   </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Level 3 Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities for the Level 3 financial instruments for the three and nine months ended September&#160;30, 2021, and 2020:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.076%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesTableTextBlock', window );">Schedule of Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Money market fund   </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">U.S. government debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796341997704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of purchased intangible assets as of&#160;September&#160;30, 2021,&#160;and&#160;December&#160;31, 2020: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:43.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Weighted-Average Useful Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;padding-right:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated future amortization expense of finite-lived intangible assets&#8212;net:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254545336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instrument Components</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the 2027 Notes as of September&#160;30, 2021, and December&#160;31, 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability component:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount, net of amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net of amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component recorded at issuance:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recorded in equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254245800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of September&#160;30, 2021:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:81.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254545336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,868</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101,181</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,655</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391,148</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,922</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819,223</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536,491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,568,420</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,344,620</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257904024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819,223</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101,181</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Plan annual increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,147)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629,246)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,286</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,214)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,117)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units canceled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,627</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,254</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,917)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,498</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,868</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,159</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Effective as of January 1, 2021, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:30.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Subject to Options Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(826,667)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826,667</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313,331)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382,780)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,333</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183,891</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341,259</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118,655</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,998)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,627)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,922</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,498)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>A summary of the Company&#8217;s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:<div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Market-based Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(572,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558,254)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260,764</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt">Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of Performance-based Restricted Stock Units Vesting Conditions</a></td>
<td class="text">The following table presents additional information relating to each MSU award:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Goal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,191</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development expense   </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">General and administrative expense   </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49 &#8211; 6.04</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 &#8211; 6.10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected volatility   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 66.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 68.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 66.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6% &#8211; 73.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 0.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 0.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% &#8211; 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td></tr></table></div>The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:73.378%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.940%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield   </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254926552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:13.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,526)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,759)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.66)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,554&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:39.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,391</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,225</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,978</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220</span></td></tr></table>(1)&#160;&#160;&#160;&#160;Excludes stock options of 4,183,891 shares outstanding under the AMEA 2020 Plan as of September&#160;30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796255048936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and nine months ended September&#160;30, 2021,&#160;and&#160;2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254526376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796261149320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; included in other assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Non-marketable equity and other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue', window );">Impairment or adjustments of non-marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLoss', window );">Other receivables and other assets due from a third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesTerm', window );">Other receivables and other assets, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ProceedsFromContractualReceivable', window );">Contractual receivables, installment payment</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent', window );">Contractual receivables, credit loss</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue from cash collections exceeding estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="nump">21,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gh_Guardant360CDxMember', window );">Guardant360CDx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ProceedsFromContractualReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contractual Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ProceedsFromContractualReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gh_Guardant360CDxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gh_Guardant360CDxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796255602248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerCMember', window );">Customer C | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerDMember', window );">Customer D | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258164248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent', window );">Financing receivable, gross amount, current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent', window );">Financing receivable, net amount, noncurrent</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward', window );"><strong>Allowance for Credit Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent', window );">Beginning balance, financing receivable, allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossExpenseReversalCurrent', window );">Additions: charged to other income (expense), net, allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossReclassificationCurrent', window );">Reclassification, allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent', window );">Ending balance, financing receivable, allowance for credit loss, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent', window );">Beginning balance, financing receivable, allowance for credit loss, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent', window );">Additions: charged to other income (expense), net, allowance for credit loss, noncurrent</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesCreditLossReclassificationNoncurrent', window );">Reclassification, allowance for credit loss, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent', window );">Ending balance, financing receivable, allowance for credit loss, noncurrent</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent', window );">Financing receivable, net amount, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent', window );">Financing receivable, net amount, noncurrent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, After Allowance For Credit Loss Net, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Allowance For Credit Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss, Gross, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossExpenseReversalCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Expense (Reversal), Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossExpenseReversalCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossReclassificationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Reclassification, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossReclassificationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractualReceivablesCreditLossReclassificationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Receivables, Credit Loss, Reclassification, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractualReceivablesCreditLossReclassificationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256989816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,568,420<span></span>
</td>
<td class="nump">11,344,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,623,257<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,623,257<span></span>
</td>
<td class="nump">100,213,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,225,534<span></span>
</td>
<td class="nump">$ 2,271,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase', window );">Fair value of joint venture threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payments to acquire interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,331<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,331<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,595,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock dividend rate (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A | SoftBank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A | Guardant Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | SoftBank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue', window );">Redeemable noncontrolling interest, redemption value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | SoftBank | Series A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PreferredStockSharesIssuedUponConversionOfCommonStock', window );">Common stock reclassified and converted into preferred stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2021, and&#160;December&#160;31, 2020, this balance includes $24.8 million and&#160;$35.0 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$3.8 million and $4.9 million, respectively,&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Joint Venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityMethodInvestmentSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityMethodInvestmentSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PreferredStockSharesIssuedUponConversionOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Issued Upon Conversion Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PreferredStockSharesIssuedUponConversionOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 24(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gh_GuardantHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gh_GuardantHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256949896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 155,440<span></span>
</td>
<td class="nump">$ 97,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(49,284)<span></span>
</td>
<td class="num">(34,345)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">106,156<span></span>
</td>
<td class="nump">62,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">56,553<span></span>
</td>
<td class="nump">40,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">35,681<span></span>
</td>
<td class="nump">34,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,067<span></span>
</td>
<td class="nump">10,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">42,295<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,598<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254462440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257589688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 8,253<span></span>
</td>
<td class="nump">$ 6,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued tax liabilities</a></td>
<td class="nump">4,077<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedClinicalTrialsandStudies', window );">Accrued clinical trials and studies</a></td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedExpensesPropertyandEquipmentCurrent', window );">Purchases of property and equipment included in accrued expenses</a></td>
<td class="nump">7,144<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty obligations</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">4,762<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 40,475<span></span>
</td>
<td class="nump">$ 22,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedClinicalTrialsandStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials and Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedClinicalTrialsandStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedExpensesPropertyandEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses, Property and Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedExpensesPropertyandEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Litigation Liability, Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EstimatedLitigationLiabilityLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256025512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 735,719<span></span>
</td>
<td class="nump">$ 620,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">653,601<span></span>
</td>
<td class="nump">961,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">250,227<span></span>
</td>
<td class="nump">246,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,639,547<span></span>
</td>
<td class="nump">1,829,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">653,601<span></span>
</td>
<td class="nump">961,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">250,227<span></span>
</td>
<td class="nump">246,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">903,828<span></span>
</td>
<td class="nump">1,208,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">653,601<span></span>
</td>
<td class="nump">961,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">250,227<span></span>
</td>
<td class="nump">246,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">653,601<span></span>
</td>
<td class="nump">961,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">250,227<span></span>
</td>
<td class="nump">246,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796341950424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LongTermMarketableSecuritiesMaturityPeriod', window );">Long term maturity period (years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LongTermMarketableSecuritiesMaturityPeriod', window );">Long term maturity period (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">$ 3,090<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">$ 3,090<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LongTermMarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Marketable Securities, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LongTermMarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796255603016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details) - Fair Value, Measurements, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="nump">$ 59,400<span></span>
</td>
<td class="nump">$ 50,400<span></span>
</td>
<td class="nump">$ 57,100<span></span>
</td>
<td class="nump">$ 49,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">7,407<span></span>
</td>
<td class="nump">7,852<span></span>
</td>
<td class="nump">10,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod', window );">Net loss for the period</a></td>
<td class="num">(1,920)<span></span>
</td>
<td class="num">(1,407)<span></span>
</td>
<td class="num">(5,552)<span></span>
</td>
<td class="num">(3,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="nump">59,400<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
<td class="nump">59,400<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="nump">$ 3,090<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="nump">$ 3,090<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796261178040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 832,370<span></span>
</td>
<td class="nump">$ 832,977<span></span>
</td>
<td class="nump">$ 142,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost', window );">Amortized cost, cash and cash equivalents and debt securities available-for-sale</a></td>
<td class="nump">1,639,468<span></span>
</td>
<td class="nump">1,826,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue', window );">Cash, cash equivalents and debt securities, fair value</a></td>
<td class="nump">1,639,547<span></span>
</td>
<td class="nump">1,829,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value, cash and cash equivalents</a></td>
<td class="nump">735,719<span></span>
</td>
<td class="nump">620,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="nump">903,749<span></span>
</td>
<td class="nump">1,206,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value, debt securities</a></td>
<td class="nump">$ 903,828<span></span>
</td>
<td class="nump">$ 1,208,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Debt Securities, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CashCashEquivalentsandDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796342032888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent License Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">In process research and development expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember', window );">Patent and Covenant Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember', window );">Patent and Covenant Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember', window );">KeyGene Patent License Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentInConnectionWithaLicenseAgreement', window );">Payment in connection with a license agreement</a></td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionTransactionCosts', window );">Asset acquisition, transaction costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">In process research and development expensed</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement of prior dispute between parties</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember', window );">KeyGene Patent License Acquisition | Patent and Covenant Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ChargeOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge Of In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ChargeOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentInConnectionWithaLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment In Connection With a License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentInConnectionWithaLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257734504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(3,888)<span></span>
</td>
<td class="num">(2,431)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">13,098<span></span>
</td>
<td class="nump">14,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IntangibleAssetsGrossIncludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">21,876<span></span>
</td>
<td class="nump">21,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">17,988<span></span>
</td>
<td class="nump">19,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">11,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(2,194)<span></span>
</td>
<td class="num">(1,367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 9,692<span></span>
</td>
<td class="nump">$ 10,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted-Average Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements and other covenant rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(1,694)<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 3,406<span></span>
</td>
<td class="nump">$ 4,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted-Average Useful Life</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257660472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796352662232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">5,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 13,098<span></span>
</td>
<td class="nump">$ 14,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Amortization Expense After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257009288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ConvertibleDebtHedgeStrikePrice', window );">Notes Hedges, strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ConvertibleDebtHedgeSharePricePremiumPercentage', window );">Share price, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges', window );">Purchase of convertible senior note hedges | $</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Conversion Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage', window );">Maximum special interest rate percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.0071523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 139.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible Debt | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold of common stock trading days</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold of consecutive common stock trading days</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member', window );">Senior Notes Due 2027 | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConvertibleDebtHedgeSharePricePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Hedge, Share Price, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConvertibleDebtHedgeSharePricePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ConvertibleDebtHedgeStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Hedge, Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ConvertibleDebtHedgeStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConversionAxis=gh_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConversionAxis=gh_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796341942680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Convertible Senior Notes (Details) - Convertible Debt - Senior Notes Due 2027 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount, net of amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(331,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: debt issuance costs, net of amortization</a></td>
<td class="num">(15,820)<span></span>
</td>
<td class="num">(12,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">1,134,180<span></span>
</td>
<td class="nump">806,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts', window );">2027 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">335,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent', window );">Less: issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Net amount recorded in equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 330,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Equity Component, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Issuance Costs, Equity Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gh_ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256026472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office and laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberOfOperatingLeasesLeaseNotYetCommenced', window );">Number lease agreements, not yet commenced | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract', window );">Renewal lease term, lease not yet commenced</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office and laboratory space | San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office and laboratory space | Palo Alto, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberOfOperatingLeasesLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases, Lease Not yet Commenced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberOfOperatingLeasesLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gh_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gh_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gh_PaloAltoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gh_PaloAltoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254471720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Information (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">10 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">8.07%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252763064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Liability Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 2,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">21,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">28,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">31,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">32,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">177,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">294,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(52,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLiabilityLeaseIncentive', window );">Less: lease incentives</a></td>
<td class="num">(16,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 225,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLiabilityLeaseIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Lease Incentive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLiabilityLeaseIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256939096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2020 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>segment </div>
<div>petition</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, patents allegedly infringed upon, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member', window );">Foundation Medicine, Inc. vs. Guardant Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, patents allegedly infringed upon, number | patent</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsFiled', window );">Number of petitions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsDenied', window );">Number of petitions denied | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberOfPetitionsFiledRemaining', window );">Number of petitions remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberOfPetitionsFiledRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Petitions Filed, Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberOfPetitionsFiledRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPetitionsDenied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Petitions Denied</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPetitionsDenied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPetitionsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Petitions Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPetitionsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_FoundationMedicineInc.vs.GuardantHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796257443544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,568,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,344,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share)</a></td>
<td class="nump">$ 84.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">$ 354,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares underlying outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,101,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,391,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember', window );">Shares available for issuance under the 2018 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,491<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256303272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant (in shares)</a></td>
<td class="nump">1,819,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable', window );">2018 plan annual increase (in shares)</a></td>
<td class="nump">3,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant (in shares)</a></td>
<td class="nump">5,803,707<span></span>
</td>
<td class="nump">1,819,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding (in shares)</a></td>
<td class="nump">3,101,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">164,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(629,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(119,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding (in shares)</a></td>
<td class="nump">2,516,868<span></span>
</td>
<td class="nump">3,101,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of options (in shares)</a></td>
<td class="nump">1,943,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 15.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">122.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">49.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">22.40<span></span>
</td>
<td class="nump">$ 15.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 259,451<span></span>
</td>
<td class="nump">$ 350,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 222,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(164,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">63,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(398,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">241,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">558,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate', window );">Risky rate, cost of equity</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(52,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">47,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796245862968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, grants in period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.17<span></span>
</td>
<td class="nump">$ 49.73<span></span>
</td>
<td class="nump">$ 72.14<span></span>
</td>
<td class="nump">$ 46.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,016<span></span>
</td>
<td class="nump">$ 55,198<span></span>
</td>
<td class="nump">$ 124,592<span></span>
</td>
<td class="nump">$ 87,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,568,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,568,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,344,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B | AMEA 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, grants in period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Total market-based restricted stock units approved and granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,595,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option term, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option term, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm', window );">Threshold percentage for individual's combined voting power triggering five year option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (as a percent of the fair value of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="nump">$ 77,800<span></span>
</td>
<td class="nump">$ 97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,101,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">68.40%<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod', window );">Additional service period requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Total market-based restricted stock units approved and granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="nump">$ 88,900<span></span>
</td>
<td class="nump">$ 65,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod', window );">Market-based restricted stock share price goal</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,391,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate', window );">Risky rate, cost of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Total market-based restricted stock units approved and granted (in shares)</a></td>
<td class="nump">1,695,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for post-vesting restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for post-vesting restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (as a percent of the fair value of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate, ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">60,898<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityIncentivePlanTrancheAxis=gh_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityIncentivePlanTrancheAxis=gh_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityIncentivePlanTrancheAxis=gh_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityIncentivePlanTrancheAxis=gh_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796256453688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">1,118,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">398,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(146,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(241,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">1,128,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 92.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">130.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in usd per share)</a></td>
<td class="nump">89.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in usd per share)</a></td>
<td class="nump">94.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 106.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">377,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">52,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(47,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">383,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 113.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">135.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in usd per share)</a></td>
<td class="nump">113.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 116.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">MSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">3,391,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(572,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(558,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">2,260,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 67.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">67.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in usd per share)</a></td>
<td class="nump">70.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in usd per share)</a></td>
<td class="nump">70.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance of options outstanding (in usd per share)</a></td>
<td class="nump">$ 65.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252847464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Market-based Restricted Stock Units (Details) - MSUs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 1 - $120 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 2 - $150 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 3 - $200 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796255582488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant (in shares)</a></td>
<td class="nump">1,819,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant (in shares)</a></td>
<td class="nump">5,803,707<span></span>
</td>
<td class="nump">1,819,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding (in shares)</a></td>
<td class="nump">3,101,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">164,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(629,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(119,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding (in shares)</a></td>
<td class="nump">2,516,868<span></span>
</td>
<td class="nump">3,101,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of options (in shares)</a></td>
<td class="nump">1,943,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 15.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">122.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">49.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">22.40<span></span>
</td>
<td class="nump">$ 15.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 259,451<span></span>
</td>
<td class="nump">$ 350,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 222,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember', window );">AMEA 2020 Plan | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant (in shares)</a></td>
<td class="nump">542,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(826,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">382,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant (in shares)</a></td>
<td class="nump">98,333<span></span>
</td>
<td class="nump">542,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding (in shares)</a></td>
<td class="nump">4,053,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">826,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(313,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(382,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding (in shares)</a></td>
<td class="nump">4,183,891<span></span>
</td>
<td class="nump">4,053,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of options (in shares)</a></td>
<td class="nump">2,341,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">0.58<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796346955320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 35,016<span></span>
</td>
<td class="nump">$ 55,198<span></span>
</td>
<td class="nump">$ 124,592<span></span>
</td>
<td class="nump">$ 87,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember', window );">Cost of precision oncology testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,416<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">13,280<span></span>
</td>
<td class="nump">7,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">10,309<span></span>
</td>
<td class="nump">6,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 25,933<span></span>
</td>
<td class="nump">$ 50,081<span></span>
</td>
<td class="nump">$ 98,687<span></span>
</td>
<td class="nump">$ 72,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258038440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation of Stock Options (Details) - Stock options issued and outstanding<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">68.40%<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796252757240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Shares available for issuance under the 2018 Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796258451464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (107,526)<span></span>
</td>
<td class="num">$ (71,670)<span></span>
</td>
<td class="num">$ (312,459)<span></span>
</td>
<td class="num">$ (153,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders, basic</a></td>
<td class="num">(107,526)<span></span>
</td>
<td class="num">(77,670)<span></span>
</td>
<td class="num">(314,759)<span></span>
</td>
<td class="num">(160,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">$ (107,526)<span></span>
</td>
<td class="num">$ (77,670)<span></span>
</td>
<td class="num">$ (314,759)<span></span>
</td>
<td class="num">$ (160,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)</a></td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)</a></td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)</a></td>
<td class="nump">101,420<span></span>
</td>
<td class="nump">99,554<span></span>
</td>
<td class="nump">101,184<span></span>
</td>
<td class="nump">96,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)</a></td>
<td class="nump">101,420<span></span>
</td>
<td class="nump">99,554<span></span>
</td>
<td class="nump">101,184<span></span>
</td>
<td class="nump">96,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796255581000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">14,751,000<span></span>
</td>
<td class="nump">7,758,000<span></span>
</td>
<td class="nump">14,978,000<span></span>
</td>
<td class="nump">6,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">2,516,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,101,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember', window );">AMEA 2020 Plan | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">4,183,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,183,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,053,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,628,000<span></span>
</td>
<td class="nump">3,662,000<span></span>
</td>
<td class="nump">2,753,000<span></span>
</td>
<td class="nump">4,021,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,185,000<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
<td class="nump">563,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">MSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,261,000<span></span>
</td>
<td class="nump">3,391,000<span></span>
</td>
<td class="nump">2,389,000<span></span>
</td>
<td class="nump">1,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">395,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember', window );">Common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,225,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,225,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gh_AMEA2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gh_AMEA2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gh_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796261216040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 94,779<span></span>
</td>
<td class="nump">$ 74,569<span></span>
</td>
<td class="nump">$ 265,545<span></span>
</td>
<td class="nump">$ 208,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember', window );">Assets | Geographic Concentration Risk | Net Assets, Geographic Area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">90,421<span></span>
</td>
<td class="nump">65,613<span></span>
</td>
<td class="nump">$ 250,589<span></span>
</td>
<td class="nump">191,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 4,358<span></span>
</td>
<td class="nump">$ 8,956<span></span>
</td>
<td class="nump">$ 14,956<span></span>
</td>
<td class="nump">$ 16,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139796254382360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | SoftBank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMS#7Y'%;[WBB1)SMC*V$4B+,#K><>5SJ!^#^6@AU/M$OR#=7A_\"4$L#!!0
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M)#.5BA>ERR 4",39MZX824DZ!+/C&3Q.- >8!S+W0G0Y(PS").I#]% +B>E
M%D0Z9B'CS/+$5QR640[I&B1$C7>NB4L3"<5)#Z%'*HVB 1^2CDO(.)><YQ0G
M:]V+U,,H :%!?UEZY.(X#8:\>5*HC#,*E&H[X&FQ3R@J(16JI.;#L9%X& -#
M)I3V [A', UBD@UP->FXA8QS2Y<,F10#=E*U1@6'@OVBKUU*(1B<V(_K'KD0
M0L4 *9*.>\A;N*<XPK\$UZ47&A)G87A(*")#B[CC(/(6#OIY%.'#!1L#1$1<
M?L$A1&+L#,T5S" [20=R?M+Q$!DOI;[PG//2)M&5K):RTDH6A5E'HH*9X;5_
MY;OE4Y2%@;/N/6()#H9FI.,XDHR2Y[.6RV\;6>1<U3_^D!*<W-C$6K^.<2CI
M&(J,,]2C+$M9H=IT,P4B56C'BH8CN4)7P2R 'XQ@OZ%ZPQ2_030*IM!F?O=-
M4/@U&FI_\3O$9E8;O6>^U;Q<</7C#S@.;@[G,U-;%#Q!M7WRK3U\N4$XP-.8
MT"F)$BL'KIL23*=9&ATZ$G5M2,H6FHVN(2?.S>3]Y4ZGP"7UEMMSP\);7Q-/
M8=>?]S&1\SGIZ)A<H.,\%R93@*UH:NQK4:$EVPK8FEZ0+N/BF,294_3Y!#-@
MG72 3FA'SG2<G"%_:,JFL =_[1D )#R*;\SQ[H[#_H)W+V53EXROH<3N'UFY
M4C# @6J5=I1-QRG[%';.5V(IO!& NB1\#1$I<R*73S .H*X>(#_:\34=Y^M]
M7/;%@I]L+/#"=IDX";*0..>!'FHG61IF \Q'3PXOQRG;89,I.HG!_SZ/P9_:
M&&PW[)\<J7NDZ:]QO((C-0XU)'_>TE$I_2LT^'!!Z^-Y,$/^.(:Z$*8WHD:+
M]K =]EG1Y! JKT@X2U$)I;B]&@'5*QK-@F,+]'$HAD]CH#''- 2;"BTX:LRA
MOJR*5Z0E9(E:PZ3)12'6MHRQ0&&OPU8_.?;?,27L[!XH%4$V#-.&WIEIA$#_
M]=-/]@G?O+>XVG>8X!K5S:(6N0 39JGL4?>'$<ZR0T,?.^ YR:V\\*"W"[VN
M(!5^V8CEQB@+"&10<P@M58UR:7)DM&$0T!2'RE-![@F>,9VL>04Y:=%*'[H&
M;MVRZG4&\VF6N^:(3I$YT*VU.18SEQ__E. H]!7>&L71S$?I\Y.[F9*KM;WC
MJI$M??<W"<?6XSW:@[UNZK?3\,,C#3U?8%7"%WNS->^ZV%_<_8NIM8#9+O@*
MN@MF"2Q@M;\+V[]HN;6W0PNIM2SMXX8SV+E& +ZO)(R\?3$='&\D[_\ 4$L#
M!!0    ( !2)9%/0^E*O1P0  -P,   8    >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULI5=;;RHW$/XK%HVJ1.*P=RX)04K(.6JJMHI.>M*'J@]F=V"M>&UJ
M>^'07]^Q=]D06$C2\@"^S#?^OO'8'L9KJ9YU#F#(]X(+?=W)C5E>>IY.<RBH
M[LDE")R92U50@UVU\/12 <T<J.!>Z/M]KZ!,="9C-_:@)F-9&LX$/"BBRZ*@
M:G,+7*ZO.T%G._"5+7)C![S)>$D7\ CFV_)!8<]KO&2L *&9%$3!_+IS$US>
M!:$%.(LG!FN]TR96RDS*9]NYSZX[OF4$'%)C75#\6<$4.+>>D,??M=-.LZ8%
M[K:WWK\X\2AF1C5,)?^#92:_[@P[)(,Y+;GY*M<_02THL?Y2R;7[)NO:UN^0
MM-1&%C48&11,5+_T>QV(]P#"&A#N 8+X"""J =%[ 7$-B%UD*BDN#G?4T,E8
MR351UAJ]V88+ID.C?";LOC\:A;,,<68RE2+#782,8$M+SC)JL'-+.14ID$?K
M6)/S4M R8SAS0<X?J )A<C LI?R"?"+?'N_(^=D%.2-,D-]S66HJ,CWV#/*S
MJWAIS65:<0F/<'F$98]$?I>$?ABTP.].P^\@17C@X/YKN(=1:4(3-J$)G;_X
M:&B* C,3MR!][I(E561%>0GD'%66.B-+P/.38S NVJ16O@?.MSU\JTD G_QD
M[*UV%;UE]8IXU!"//D#<4=2$EB:7BOV#FVL%5*.MS"OGR0ZG*/&KSQ[[]UB^
M4A W"N*/*\!;2QO,+"86;TF(#X@%?M /HS 9[$EHL\3LBT;#(YN0-!*2CTM@
M6I=O;T#R;O9MEB?9]QOV_9/L;[3&<]]"[O8T[L_@KS9%%:B_PS,,PR2)XCT]
M;7:#8# ,VM4,&C6#DZQ^873&.#,,6B6=!A^1-#@,?9ST!\&^I$.[4= /AOUV
M1<-&T? DJ2>J4!,'<B\,8!X9\ED89C8GKKU1XWKTW[9^.CJ0$L;#@TOAT,I=
M"NUZ __EG?+_QQY.:_1NZD2'W%JLXM%1;O8-?3WR\G0$I]^.]J2Y?0-U@Y?<
MG. S:*"8X>NR?0N[!*\]@N];/5R_<5UB<J:Q[*G>:B927F9XRYR%<6^(Q0+G
MKK)"Z%F4]/QF!->@;I.[6+GI);C2BV^L.VI(2@69 ;YP>%%)P3?$2(+&!I--
MSCA;4%NO.:)8 Y!TMVI8;;.2;;,27%:2\Q]_&(:A?_5T_]FU@JL+QZON!X,K
MC97G3+.,H0O0W9KUOHRX-]H.['-'/OPE15KIX6IOK(IU-%GG+,TMF"F2*L"J
M1RI-,DF$-"2G*\"%4UDJ#38R=I$%"%"4U];;I?$!6%*QZ>%^ OE-&B!1%X_K
M"L."=;.QM=+/$@-%GK!7*B"]ML/K[91V!:B%*Y$UZBJ%J2J"9K0IPV]=M7HP
M'EQ.@[89S$J<<06K][)$5??_2M6"X6YSF.-R?F^ YUI5I735,7+IBLN9-%BJ
MNF:.?S] 60.<GTM47G?L LT?FLF_4$L#!!0    ( !2)9%,WQ/[7SP8  (,>
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULQ5G1<ILX%/T5C:</R4P2
M(PD$9)+,-+:W[<QVFTG:[3,QLLT6D!<))_W[E0 ;1[HP:7<[^Q(#.;K2.=*]
M.J"K)U%]DQO.%7HN\E)>3S9*;2^G4[G<\"*1%V++2_V?E:B*1.G;:CV5VXHG
M:=.HR*?$\]BT2+)R<G/5/+NK;JY$K?*LY'<5DG51)-7W6YZ+I^L)GNP?W&?K
MC3(/IC=7VV3-'[CZLKVK]-WT$"7-"E[*3)2HXJOKR5M\N2"A:= @_LSXDSRZ
M1H;*HQ#?S,V']'KBF1'QG"^5"9'HGQV?\3PWD?0X_NZ"3@Y]FH;'U_OHOS7D
M-9G'1/*9R+]FJ=I<3Z()2ODJJ7-U+Y[>\XY08.(M12Z;O^BIPWH3M*RE$D77
M6(^@R,KV-WGNA#AJH./ #4C7@-@-_($&M&M 7]N#WS7P7]M#T#5HJ$];[HUP
M\T0E-U>5>$*50>MHYJ)1OVFM]<I*LU >5*7_F^EVZF8FRE1/.T^1OI(BS])$
MZ9L'I7_T>E 2B17ZM.558N95HI.Z3.HTTYA3=(Z^/,S1R9M3)#=)Q27*2O1Y
M(VJ9E*D\0V]>W%]-E1ZNZ72Z[(9VVPZ-# R-HH^B5!N)%GJ(*=!^/MX^'FD_
MU3(=M")[K6[):, 'OKU U#M#Q",8&,_L]<T]B,Z_ZWWQT[V_$(,>%@YMXM&!
M>/=\Q\N:7XZ$\@^A_":4/Q#JKN++K*D\HM3K6:R_(\6ERLHUM&C:6*R)9<K@
M[B:,24BNIKOCJ7!1S*.1_Q(U=U$$!\P+7L(6+@R'F)E9V &T@P/M8)3V7"N8
MBZW),B1YM<N6.H5TJB"A-KR"J+?Q@N-Q!($76M0!E(\CB]/<1?EQ['L6<Q=%
M61A3F#@[$&>CQ#\+E>1ZEVD6$,23.;W&?AC&%D\7%?H!LU!S%T58$/CV% ,P
M+_*Q#S,-#TS#T229":FZ.6U+:+E&_'EK"JX<RYSH$#\:5=+$-P5Z^T,9%+E<
M8\8L168N"C,6V_*ZJ##"OI6-"Q<5D.-8+\C'!_+QJ\BG/YQ'L4L-!]CB[X)\
M/XHL^E DZENH!83RR0!][/5;MS<JP#V7/*F6FX;LL0K=$@.W7,^=,"]FUHAG
M (PR8F?-'(#A6.\O=AF!<%X<1-Z !$?N!8]*\)#DW61KF_N-'R<8R!Z["]$C
MQ&'OPDB@QVNS=V&8ZFCVZ@=P84!(,$">].3)*/EWO-1%)6_H)ZDVAYE4ILCL
M^*@&!-# "^ST!V",D=C>00&8+A.4,5L# $<H84,B]#8$TU=L)LN10@N*0(%Z
M3SQF[Z4 #NLJ0+ M@XL+PHA2NQ( .!H2'$<#,O06"H][J-^%E&A5B6(O@#;K
M(''?&< Y]D)B5[89! Q]$A";.8"CF!R;A(XZU#.C832PQ^+>1^%Q(_6A5%R_
M?BC]OK$4!;SH72/#(MM0 "!",;4) YZ(A*'-UD5%)!QPC+AW3GC<.AVHCB6X
MZV7.F>_;9 &4O;M!&!Q3W^8*P.A0:>^M$PY'J7XRNW<WI>BDXWMZADJN0-8A
M,-;(R6<71=U=#0@5$F=/<U'$'WHGP+VCP^.6KDGD1[X2%=>V3NQ:6Z=O]U*H
MY'F@IKDNRZ2V3SU;! "HWV<\)[4!G$YM'#I20#T'&DH&U.@M'A[W>'<_IH!K
MM&)FDW<QMON9 QAB5XL% ,*8P81)[^G(N*?[@RN4ZR4 T2.NBS(3K*VTQ1$"
MZ@FVYVT.X?2L^8'-%>PYH(0.[%ND-W!DW,"]3?^JI6I<J[;R%4\Y+Y+'G*/2
MO,F4JA)Y;C;SK"M\H"ZNO[*7/  Y9Y[M4^<0C%#'SH+1(F^@Y)'>T)%Q0[>?
M?)0H566/M6J44 *]JY,J3;1&[WF2J\T9^E N+[3I*0J=&5*)Y;>-R%->P<O&
MM5X#RP8 AB&P;  <Q7[H+ANH9RW[X++I71\9=WV_2"GJ?.@94 H @DH!.%@I
MJ.<QI7IC2,:-X4$I;0O;[[0_K]F9^2:?+=%)5J):IGW(4U#-=F#1"TX7GJ,E
M /,N0KLF0S!Z@;$M)-@I&ZK+O<<DXQ[SOY4QS?+:?&9_I9#!ZX0$8)"0  P2
M$NQT4,C>P9)Q!_NU.;KAZ7FRT^\I:[X_.ZC-&8260^NUK9OWM_(7K=RV0UAI
MU\EB#_NV]YL!N#@. OOE& Z'[<_0"R@<8\' !R+26V@R;J'_+ZV/E_>8VJZ#
MAM5V<:#:8#A ;2 <H/;TZ%"MX-6Z.<V4FG!=JO:8Y/#T<&+ZMCDGM)[?XLL9
M!I[/\>6B/0_MP[?'LQ^3:IV5$N5\I;O2.:S'6K4GGNV-$MOF2.]1*"6*YG+#
M$RV^ >C_KX10^QO3P>'<^>8?4$L#!!0    ( !2)9%,_]X.N!@0  'X-   8
M    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULI5??C^(V$/Y7K.@>=J5E\XL0
ML@*D7:"]D^[:U=%M'ZH^&&*(>XE-;0?V^M=W[(0<)";=:U\@=KZ9\?=Y/)Y,
MCEQ\D1DA"KT6.9-3)U-J_^"Z<I.1 LM[OB<,WFRY*+""H=BY<B\(3HU1D;N!
MYXW< E/FS"9F[EG,)KQ4.67D62!9%@467Y](SH]3QW=.$Y_I+E-ZPIU-]GA'
M5D2][)\%C-S&2TH+PB3E# FRG3J/_L/2-P8&\2LE1WGVC#25->=?].!#.G4\
MO2*2DXW2+C#\'<B<Y+GV!.OXJW;J-#&UX?GSR?L/ACR066-)YCS_C:8JFSIC
M!Z5DB\M<?>;']Z0F%&E_&YY+\XN.-=9ST*:4BA>U,:R@H*SZQZ^U$&<&X,=N
M$-0&0=M@>,4@K W"MT88U@;#MT:(:@-#W:VX&^$66.'91/ C$AH-WO2#4=]8
M@UZ4Z419*0%O*=BIV9RS%+:=I B>),]IBA4,5@K^(!^41'P+KPK(PDRGQX&@
MCUQ*=%,R7*84L+=H@%Y6"W3S[A:]0Y2A7S)>2LQ2.7$5K%#'<3?U:IZJU017
M5A.B3YRI3*(EK"JUV"_Z[9,>>Q>4:>0)3O(\!;T.5V1_CT+O#@5>X%O6,W^[
MN6>C\_^B+_]S] LQPB970N,OO.;OE!3=G/C -KP@Z/?'M50"#O\?/>&&3;BA
M"3>\$NXG*),YY)HMC2K+D;'4M? P&_A>' 6CB7LXWQX++O9'L7<)6UA@H1\,
MH^02M[2%C<(@'#>X"Z91PS3J%?9GE1&!-A>*TDK1&ZW [1UBQ*BN\"NBQ1X4
M?NA1>-3$'?4J_,+@;LGIWW#@=W"GU,&0KM\'3'.\SLD [J*!Q#E!DFQ*014E
MU@VI D7GRD1^V-H-"\B/=69?;(8%%7A)W-J*+BJ(_,"^#W&C1]RK!UP]<+$P
MJ+M"$+;YBB"7F<QQ=:6E?T(Y-C71)D!LX=81H ORDS9]JZ.DY6G9105A8F<_
M;MB/>]G_:Q;::(^[JQUU3J$%!,>F?0@MJ#!(6JAE%Q7$D6]GGC3,DU[FE[7L
M6LU)+"R\L1\%+;867!Q"X]:B:X&%?A0/VS7'%C;RAN/8SMGWOMW\WG>POMAI
MA)42=%TJ70*0XM 2I@0Z5#UB')!,"9Z#PQW8*2*(5-;+WNNLO:7"W (9C+R.
M6#98$+9A2ZNW\1GL4JJS)LG_S@3I*/1CB46*X6Y\#R5597?Z2KRWBN+;[BY+
M'MF <=)-)!LN],=>)Y.LD:,XZ*22>]9/%D3L3",OH3243%7M0C/;?"P\FA:Y
M-?_D/\Q]R_Q"?UR8_O6;^^K+Y!,6.\HDRLD60GGW,>REJ)K]:J#XWG2S:ZZ@
M-S:/&7P@$:$!\'[+N3H-=(#FDVOV#U!+ P04    "  4B613WE$NMQD+  #2
M0@  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;,6<;7/;-A* _PI'[?22
MF2@BWLG4]DSDR+4R;2\3)[T/F7Z@)=CBA2)5DHJ=?W\@10LBL 0M6<Y]B?6R
M6.X""SR[2RHG=UG^M5A(67KWRR0M3@>+LER]&8V*V4(NH^)UMI*I^N8FRY=1
MJ=[FMZ-BE<MH7@]:)B/L^WRTC.)T<'92?_8A/SO)UF42I_)#[A7KY3+*OX]E
MDMV=#M#@X8./\>VBK#X8G9VLHEMY)<O/JP^Y>C?::IG'2YD6<99ZN;PY';Q%
M;]X']8!:XJ]8WA4[K[W*E>LL^UJ]F<Y/!WYED4SDK*Q41.K/-WDNDZ32I.SX
MIU$ZV%ZS&KC[^D'[1>V\<N8Z*N1YEOPGGI>+TT$P\.;R)EHGY<?L[E(V#K%*
MWRQ+BOI?[ZZ1]0?>;%V4V;(9K"Q8QNGF;W3?3,3. ,HZ!N!F #8&,-HQ@#0#
MB#& =%V!-@.H,0!U78$U Y@Q (N. ;P9P(T!G;,DF@'"G"7>,2!H!@2F2;AC
M0-@,"(T!HFN6D/^P<GX=09LEK^/E751&9R=Y=N?EE;S25[VH@ZX>K\(D3JO]
M<57FZMM8C2O/SK-TKJ)=SCWUJLB2>!Z5ZLU5J?ZH;5 67G;C?91SJ;;E=2*]
M/[-TEJ5EGB5*TZTW34N9RZ+THK0:E,V^+K)D+O/BEY\"C,2OWN2?=5Q^]UZL
MTV@]CY7JE][0^WSUSGOQ\TOO9R].O4^+;%VHX<7)J%0.56:-9HWQXXWQN,/X
M3UD9)<"P<_>P\_5RG435OO3DS8W:J%XT_Z^:[,I?3QTYWMNKSQ[VL3_TN?HJ
M6U4[&;C,._=E^F<-T#EQZJQ.RS?%*IK)TX$Z#@N9?Y,#M8;+99;^\A/B_J_U
M&FQ> MHOW!:_G:LE4KY&B?<ABN=#M3KGT2J&)_FW0W4=:_HO>PR8S3874N'\
M[W(A<Q7A2S5IB^IP5]>>JB592N_%[UE1O 343P]8B<W$>[N7?B=OXED,+?7[
MHU[@"+,Z4F?']@#!VP,$UV;2CFD>R]LX3:NHOHZ2*)U)+RJ53;/7'D&OU 51
M".V<C4Y>ZZP0_NV,AMSW3T;? %/(UA12#R,=IJ@552E"H=947;]^];(^8.1R
ME>4*_@^'T9>/:A]Z"J]W43[_VS$'='MAZIR#MWJFU6F9ZWV?MO=]W+WOQ]2:
MD2$/=F9D,V\;*;8C90M-^U2U?&1;'YG3QTDZ-Q;Y2J[4(ONOZJB"%IE9QC).
MN^S@6SOXGO'V0JUQL8C4Q+Y\3.Q-N&562#%'%%'8,K&U3!Q_)XR%98T( Q*2
M]II.A+6FJ"UQ 4@@YONA$1V7D!PRE$UMJX:$X< /X2D*ME,4'+)#=Q.'?^V]
M2\/MQ4/G^DR+8ETOB]JCLQJ97E%=N+)@M;Y.XIGZYD;F:@5?>:FL]_+#!VI
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MHII@U-T7/J S1>U>+MR9HOTW82%=8&<*$ 0Z4X"4LS-%-6JI&[5]/0XX?Z0
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M>5-FJ_JG\M=966;+^N5"1HKPE8#Z_B;+RH<WU:_OM_^-Q=G_ %!+ P04
M"  4B613ERK97W8"  #_!   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;'U436_;, S]*X17;"U0U(Z3?JQ+ B1MA_70(6C6[3#LH%A,K%667(ENVG\_
M2DZ\#%AZL42)[Y%\)C5<6_?H2T2"ETH;/TI*HOHR37U18B7\B:W1\,W2NDH0
MFVZ5^MJAD!%4Z33/LK.T$LHDXV$\F[GQT#:DE<&9 ]]4E7"O4]1V/4IZR?;@
M7JU*"@?I>%B+%<Z1'NJ98ROM6*2JT'AE#3A<CI))[W(Z"/[1X;O"M=_90ZAD
M8>UC,&[E*,E"0JBQH, @>'G&*]0Z$'$:3QO.I L9@+O[+?OG6#O7LA >KZS^
MH225H^0B 8E+T6BZM^LON*GG-/ 55OOXA?7&-TN@:#S9:@/F#"IEVE6\;'38
M >2]/8!\ \ACWFV@F.6U(#$>.KL&%[R9+6QBJ1'-R2D3?LJ<'-\JQM'XRAK)
M$J,$WGFKE13$QIQX8>W)@UW"/4KD7EAHA*_6%-:0LYJ95G!K"!UZ F$"R!:/
MI=42G7__[B+OG7^"FZ=&T2L<-D8T4C'U$1S.A&/F$DD50A_! 2@#WTK;>";Q
MPY2XK)!<6FQ*F+8EY'M*^ AWG%'IX89+D?_B4Y:CTR3?:C+-WR2<8WT"_>P8
M\BS/'N;7<'AP] 9MOY.Z'VG[^VBWF@9)=[7ZL%7IYV3AR7&C_GHCW* +-XCA
M!GO"3>1O;I_V'Y(%(5E^G@.AH19*!LT+42L2^AA\2 :4]PW*X[@*4R 4UM-_
M_T<;^"P&#E/_/.[U^MDP?=Y--]UIR@K=*HZ>9]+&4-N?W6DWW9.VJ?^ZMT_#
MG7 K93QH7#(T.SD_3<"UX]8:9.O8X@M+/#!Q6_(+A2XX\/W26MH:(4#WYHW_
M %!+ P04    "  4B613YF5RU*<)  #X*   &    'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;*V:;7/;. Z _PHGMW/3SM2UQ!?+[J:92=-VSQ^:9I)L[S,C
MT3&OLNBEI*397W^@I)BV^.+T>E\:60)9@ #Q )1.'Y7^7J^%:-"/35G5[T_6
M3;-]-YW6^5IL>/U6;44%3U9*;W@#/_7]M-YJP8MNT*:<XB2933=<5B=GI]V]
M*WUVJMJFE)6XTJAN-QNNGSZ(4CV^/TE/GF]<R_MU8VY,STZW_%[<B.;/[96&
M7]/=+(7<B*J6JD):K-Z?G*?O+A@U SJ);U(\UGO7R)ARI]1W\V-9O#])C$:B
M%'ECIN#PYT%<B+(T,X$>?PV3GNS^3S-P__IY]L^=\6#,':_%A2K_+8MF_?YD
M?H(*L>)MV5RKQW^)P2!FYLM567?_HL=!-CE!>5LW:C,,!@TVLNK_\A_#0NP-
M@'G\ _ P (\'T,  ,@P@G:&]9IU9'WG#STZU>D3:2,-LYJ);FVXT6",KX\:;
M1L-3">.:LPM5%> 442"XJE4I"][ CYL&_H"WFAJI%;K@]1I]!H_7Z%5;\;:0
M(/,:3="?-Q_1J]]>H]^0K-#M6K4UKXKZ=-J 9F;^:3YH\:'7 @>T6* OJFK6
M-?H$VA2'XZ=@T<XL_&S6!QR=\$9LWR*2O$$XP:E'GXN7#T\BZI#=*I-N/A*8
M[^O5I^OSV^7E'^C\XG;Y;7F[_'3S+C(OW<U+NWEI8-Y+V.>EJKTKWH^<=2/-
M9GXXFY 44[8XG3[LKX1'+F4$D_E.[D UME.-14T^+_X#T=N'4*-@Q^>JRF4I
M4#7H;.Z:Z]P$5VLB$&((TI/FC:SN^_TM&RGJV$+-=MK,H@OU44"2RR7O4T=5
M(+Y1NI%_=S=\J]=/Q_96)9VE\W2T=AZIE,ZP?^6RG:Y9W*FJFG2+8A>C%)"I
M4*[JQNOJS%4CR^9XI*PK10A=^'6=[W2=1W6]6'-]+TR.D-5DJU4NP+%:U(+K
M?-TM="$>@!5;$PB] 9#@FC6J%.)E(W3%31I'J[9IM3!AX+-O[FB>C&QS)>8L
M2?RV+7:V+:*V78O) R_;/F; 0@A@XXS>$.!8T7G''SX+UR-SRD9*NT*3% >4
M3A.;T).7A0^P(_\^,8PK0.$-@+\.ZCO,>:"PR17C&/+(S3/"TH#2>Q1*HTJ?
M[VU'L]:%N&N0K.N65WDD\(=9#]1>8$=I5RJTRM@JC']*84@O&]ENT*M"UKEJ
MJ^8U@@=0&7T7#;^#M%>+O-5=/O,:@AT5%XS.QH:X4NF,S *V6#BE)+Z)M0"B
M]TF9[])VMWM5LQ;:KS%Q(V&LKD<D82%U+?-2&B4+Y!S8A?4(%W4M(+<8G4O)
M[V1Y%!VI)5G*XK[..X^:Q)8+^6#<^<:@R[LLS-W4&76VOD<L3=D\M(\LYM(X
MYY;5 [A.Z2>O;BZN)E#@D+%N'K$4,Q;:,Y9K:1QL5UILN2R0^&%RD:AMA$&E
MJW47<YT;O<J[^)JPC#DQYXK116A9+>72..:^=DI&E'/Y,R$8._O7(Y:Q+*2>
M!54:)]4N0+?\R42G5T67-K,%&1>#'JDY#>Q8;)&$XT@"_73[ @IA#X42YOC8
M(\;H/!">V#(('V'0H*4G//=2BE=O#X82.J=CO5TQ*+53&E#<L@C'6?1U5"<>
MT]:E"';7V!6:$+:7*PYUM:S!<=9\%"L!6[V 7 J9JO6&*G:Y 0F(C/.43XPN
M:"@.+%_P\:;J:%/BU9MZ]":08<>[S"=(:9:$(L&2"L>;KN7EMT\W/]%G8@L6
M' ?+50L%/3>[ HJ=%Y<UV(,2:#H2IS?Q";)YDF:!7@I;Z. X=+[PQBCX]'-Z
MNQ29X2Q-QVV'1XXD&22C@-86.#@.G.?E-EI74-#O:2[^:HTY-CEI479G-A+8
M/W3<7IM\C%HDV1A2'KG0EK* PG% '40/M(FPH083C#5=<^A5V=,AL82Z;O#(
MX?D\Q'UBP47BX-IW@ZP:J#NE<<%>L9GSK6QX*?\6IO#,#3B0NBOE?0<YKR.(
MBZ^Q01Z129K-YP$2$\LX$F?<+K>!$QZ@@RW0W1-Z-22ZUT,('<]TQ"493@BC
MXVWMD9N0%')TR#.6>01',]WGY>7YY<7+,QW9.ZJ+$^J*/_6G5AM>"-/$K635
M=:$]7(\YU\NN,0#\4BRP*)9<)$ZN*W, (XH:K;3:V/:Y.[O8;,"4[D@ M5NX
M%#^$SF4?VOUMM0U;Y0(K2V;CIL8G11:!$R9BH4;B[9??JMHUJRH@&XK-ME1/
M0@PWM\\[>%MR;\U)W$Z,[<?G8)HK11:A5I98JI(X56_Y#V&J=EGLLOAP*EJO
MN3:4:IJR.X<WUFK8FUKF1NK98NG/]<2#TSE.638VR]<18IH%[++0)<<ZO7V7
M;5O8,SE8 *4?Y):N=S;V= Y[-!2&A/-\;C*D57 L>#H8CRYWG13J03-C&0FP
MC%@TDR-H[O.#,>#9HN%@<\^%(Y.]-AP_U?2(3-(T:(+%,3F"XY>8<*<T3 R/
M:I,$<P5HT(WL:Z=**@UU21.@@P?'F=,->:0"AE'+:WKD[/,9;Q9I^Z#K,_EQ
MO%$/?B'?)6,3/')D1M@\T"51BVEZ'-,"/)-W/EHI+>2]2=EY=_2%H!L1*!^.
MP8QSP.0WO>&FGGK@I7C>2'LYPSSW6NMK2]/%N-WRB&$22.[4<IS&>U=CJ:QR
MW;%5_K(IGJX5.Y'GEPHYS18.],@QJE&ZKPD/M?_G/R#WXM\_B'M952;Z3!$,
MNTX57AL\IZ8$+[)Q[O;(I91@'.@]Z-X[Q7@5<?%B%PR&?3*M2-0DMS  DV9N
MB+ER*<4+&BB,J"TA:+POOFFWVYZCO$0?@32EJELM#E]NHV75?Q8!U(F^G+5X
MIW&\1PYF$->R-D\Z0JJ[ALLN-+3Y[&"B5A-(8)$#1^IY\YBER6Q\C..32^@L
M%.L6\#3[GQ?T4E5=\"QM,P$!\GF7>\]?]&:76B#3E_7*D>;2I)BR+?KC'#XZ
M+>W?!X\._[R+[N)XP>;.^W17BI)0PT,MLVF<V<N#EV&'M<8OG17\G];&I3EQ
MWE]YA +(9Q;Y[$B+[G<XS^'2G#/V7<%!#^<U@+DLW_\&HC? (Q0JEIF%/4NC
M>^EZ^#1"VC?-+\[ L1W$+(19',)!<GD7RJ4G)'.2C8M7CUPLF3/+61;G[/7A
M$J".0NGO!W&L]E[8!-_5,9>@Q'D;YA$*Q:PE+(L3]E:9M/EKI0YSO]OQ,M4C
MYW7#=.\;LHW0]]VG=37JTD'_W=7N[N[SO?/NH[71_0_INXO^(SP[3?]-X!>N
MH0*J81.N8,KD;0:+JOO/[/H?C=IV7ZK=J:91F^YR+3CL7R, SU<*6H[AA_D/
M=A\[GOT74$L#!!0    ( !2)9%,B)PB=R08  #,/   8    >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULI5?;<MLX$OT5E+9V)U.EZ.9D)CNQ7>7+>$:IV''9
M2?9A:Q\@LD5B# (,+E(T7[^G 5*FO(EK:_?%)JA&]^G3IQO@\=:Z!U\3!?&U
MT<:?C.H0VE^F4U_4U$@_L2T9_+*VKI$!2U=-?>M(EFE3HZ>+V>RG:2.5&9T>
MIW>W[O38QJ"5H5LG?&P:Z7;GI.WV9#0?]2_N5%4'?C$]/6YE1?<4/K6W#JOI
MWDNI&C)>62,<K4]&9_-?SE^Q?3+XK&CK!\^",UE9^\"+97DRFC$@TE0$]B#Q
M;T,7I#4[ HPOG<_1/B1O'#[WWJ]2[LAE)3U=6/T/58;Z9/1F)$I:RZC#G=W^
M3ET^K]E?8;5/?\6VLYV-1!%]L$VW&0@:9?)_^;7CX;_9L.@V+!+N'"BAO)1!
MGAX[NQ6.K>&-'U*J:3? *<-%N0\.ORKL"Z>7Y NGVL2078OSZ&'@_?$TP#F;
M3(O.T7EVM/B.H[^+:VM"[<6OIJ3R</\4H/;(%CVR\\6S#N^IG8BCV5@L9HOY
M,_Z.]ID>)7]'W_'WP572J#\EISH6%]9XJU4ILS9,*6X=>3)!]E1<*2--H:06
M]WA)$&+PXI]G*Q\<I/2O9Q"]VB-ZE1"]^O^Y_Y\<_1:E*Z4)XG>2.M1CL33%
M1+P(-8F__>7-8C%[>V&;5II=6LW?_BB4%U)H]+8RE4"3%RHUGS60F:UVHLCV
M8FTA32KQ@ZA)MVQ=6/,EDA,%2,._2MN5U'HG0NULK&H!>\:F0&+K;.L4!0P!
M$<@'/Q8;Z8- ,:3P! NNARPW[ H/1NI=4(6?B(^ _D#89?MX*70."?#1,&@J
M42O>6!1@@8TY:F,Q":*6,#1YF'%J'3R,*P&XP@=,(L] F:52>4+'C\6V5D6=
M7G6,"3)RI6&YVC%CZDM48,.)H+R/)%;*MGZ7\3ZI@OC0DWFK96 @#+PDKRH#
MS "K:4,.,(;QN$+SG]]ZY-K*E=(J* 17P$]%;9*_L2B@"U5 L"4\:-NR9,>8
MG!6R#A9D,ZV.5+.*SB=!<[C282QR91MR2>ZRM&UN$B90 TL %2Y6AWY5@SIB
M9PLBV=4^.KB$-\I5Q-!':>J4>B$=!T+!)Y"B:($BJM"KHK+8"SP-ZHWDNZ+*
MPEG4\)G:#*O"B%3)S,!A3_S13Q@B@X5X?_GQ\,7%Y==Q0MN__'!]L^RKFFOY
MDD=_F>4*^;M'>298'=R4UQ6M7&1M\^ ZQ*=E-#A6RP-\X@ZT(O?GXV$ZJ3)R
M>5(1B^B&V@=O:^700[(L71(]HAKB2(;G%Q NER^7RZ5@\6%[@*<!YG?1T'-X
MAVQ]3!J_H:_AP/@'WT'(/3!(H&N?K4(15R32Y."FY#95ZUVO( \+],>>V"ZU
M;<V:V&&GH37DLG:V89)PAW@@]S(W,WO$G21D:0Y+R8COR+>8]_0=( V$%"%-
MD@X#2YD2,N8&2*.C!_<#5R![P=M],!%;7J?#7VR)'GQRH[@FM32/FV@C=<PS
M![,Z8'))KDTZA$2(C77=?.NYYUFLO>V;CHO=J8$)8 &]_W1S=L>:KYQLNMRD
M:A+LISI(?9,3' KV"?>&K"S_B!M699[!W>(QW_V%:MR[ '<;M0'^[(.7!(;Y
MQUP*Z7=-BXL,0A6)WDU2,IC2JE(8HTG@O;?"$1G.EK<.K24PB1I$P\HI_Y!V
M#=CI]<(@<J8EA8QU(CYY-DDG##J 4T#M$Y.'$N[.HV$3U/*P$BR:P5Q?WEQ]
MN+L6;3_-N16C"W4:7OOY^8W#].E(Y;.$F[^6.)P*BB%-TWSDJGS4V/4Z'WEP
MWX @\//2XS0H+ L-24,!WP(2C;;% ZP]ZY0/#M8PBPZZM#KN+T&/=>9Y Z6
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M$9GUIG0[>A06V-5U0=(34>Q06 !:"4Q0"Z;:.?R3*7#%"NT$3PZIZ(!G+IL
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MXDN0_ 4$R2V3YDB;2>CJ7KA"^9[WSE+]<&DG-(2&(4?DTOM;NM ]=;P9<Z$
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MJQ,M\2IK'"50KC@V'N:7 ,MF60SBVHNI'R-)]*A42XZ& U%NG!J/'CD^1!&
M; L@14$6:!_T%.PFUPSC*[@AQ@N<S8T.,$OD( TB<1.56+3K2%SC#+28,N5F
M,I<;I!Z; 3) .LJK84\:.!;EABWH=FW1<W*.=Z7]V;)=%\8&B@^US+R7OBTV
M"-_4X"EA%!ZBCU:=%'6K;>,Y!PS/T:2Z@TL1<OB#J%(XS.)HYXB-Q/KXM!_Q
MB"B53:Z(A=0CFR/[35G9ZKA!YI$:2'2J8RB4;Q3ECK_X%I6)LDF$AF1'7,JT
MRYJ*T)L*E\'<).#>+$K!W OAT2*BMT%75'0KI'I ^<.'.E.3'GE*.,AE0L9E
MLN'$W$00#]'V0>VH@.":;S1=/*5M";7A[WATB]V34?"6&_V&JC0MIQV*Y1 .
MY!YA5ATGEIVJE:3)F89@2">=-T"TR0L6ZKL[B+_$1RF:B@))6Y[J9UUB$&@Z
M*I9<^R[ I%HI>7P9+1FB55@T;[PVROM80F0>>%>J'L2#LYE08H[(A/6XLF28
M<G0WPR+[J-!TO&)?84$/.K4C +WS-?RFW8/.1Z'3#<30)+J^03=C*RA \!,<
M->G&1GQIC;K;3QV@=E)KXK@46BL6@)8&?H^">SZ<$VS6S$6@,5VU +ER125*
MC16N>8D((H0<TU9!%K_G0DH;4 /B" V\FV$5"!X34BGB0)5:=7"VW)(1L=9S
MZA3PB,%1SJ?YG!D(7S+OOQ^ L7$P;.8>$$I1VY+2'\@@32TM^9-/]"]I/XR%
MM7*3JG/7W[,O.=(09'M<DWV\M(IRRQ']T^GN ?9C).G"E,LU(V@9D_MN-*8I
M+'J6^IN3[=A<:L^] XDD8MQ0N&ONS4L3;Q288+=3;71U5^7@'YGJ#7K[&!L>
M4N)K)%,L&V[P2*(V9>(\*.FJP^6'T1&WLHS+T2U1>>G^#NV\J>+\QIYJ+T&9
MHW,]2%>U6758*K-$3LRECU_3ZKQW84/0:XF^0YW8%B(3OT,/1LCXC#@Y=T@2
M1[5"W(6I5U67=MW3-94.^0A)]GNJ5W@&3H_73,SPP(C*/)'C%A$7!!%TWF#@
M[]5-' 7\.+F9*TK4GIOC+-&F*6*=:RHU2L:%LQ44@9[=K$")X/)-L]VN6H(E
M98@Y#6C_&#OG"7X#\?W&T38<'VE@UV(F(P[8-7&32[UA"4-K*@P9DZ*R#9\*
MZ]8:S8?ZZ<GTN^@_9'UW>>$4I!)PQJ)'L9BLB-=%:<C3_(Y W=OCQP("D^0-
MA03/^.Z9U2*+P0TSI7+?7J_<*QY3@"=)'#8<I%T+ :%P3.&9&5!$MGS?21TZ
MON,A'?VXS_4\HFZE%K"-DBMZ_HPN@!=[9 W@N\T%CB;3\+GJ".V 6@PO/[^5
MB&'*B.]-@,I0G4;\I"7.1K!3STQO .B<GDU)Z7_XOG6M\["%D@I\&K2^UWQZ
M]Q+?SJ#[;SP(F6JY'H/H[G71'>>EVPJ^MMBLBQ49$S_V@J<1JQ(-0-_HKGLW
M\R1/"UX9C7/C98UB*D\YW[T-XIO3S2DJ7K99$!B=SNU?,FF_T\$&;:O7H[;W
M/N,63VR)'L\30R$7.&47#P(F>MH'ILTE,.5K5EB;,I-9(M\M&WJ%YM*MPGWU
MUS:C'NX-*N+^$WXQXF=,RUP7L[$AE%_7QUKJ&/[0+,ZP;D;5(787,S)RQ/38
MR=#^S:CDL>MP'E]80/Z2J*E7"FJBQF;/8_(B>Q*K*Q,LQINM'=FT"L, \@0F
MYJ3@9AY1N4J<8*%D?,7<]5N:F-&9> ",+&I/(V-F21[HNE_O:K_W1A1TIY*&
MW)(R-HD<=,!TZR3XYP.I3CM]DY(;2Y($LD-5S*KWN26W;!#*C%HV4S6&2#'7
M"T0H)K8D/,=2%>\+*OH%"C,?M6":';%(XK/3MY*I"&.+[W*J0_.L5'25$J_F
M2J0@'UFV%Z$/T_KN2 ^/1?K-V[EB#O91T=K>$;!M9VY/]_G]Q![V,[[1H8O!
M'LST7DN.CUS]VK$\$<E%2,/>MPP;YKYAXQ'CT6#@O_KXR^#VMQG<KB3,[=^L
M;+TPW^!#Q_]C8G?S5Z_08J_3%0TH\4XS!@,69,A.SL&.8^\KTWBEF8(6PQLS
M59F\]813W#]A:TV#<QZ5SJ1S:WHX8!0/*"!-=\>.WMCGOS?,XMK>B$0W]**5
M(HU,)U3&V,NW^2SQP>DN(N:E<0-:T]LCN>RTA',-\CKCN[^=M^-$0"7SJ3%<
M^7SUOAT:MTZG844KW]T=F8V%5!@MF8EW.ET@(B_N7MOODK2'XO.D%_&>? XP
MCDU)<4=TF:>._1SHN/<3K$JY)?_0C# #BL=?8W5/N]^R7<:?<&V6QQ_"?9!N
M22VD5 MLG1X]/S^("-%^"+;F'W3-;0BVXC\+!:[A: &^7UCTKO2!#NA^X??F
M_U!+ P04    "  4B613$K><,ST$  #)"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6RU5MMNXS80_96!D(<$(&S=)0>.@5QVT0)--TAZ>2CZ0$MC
MBUA*U))4G/Q]AY2M.-LD0 OLBT0.9^;,# ^'7.Z4_FH:1 M/K>S,1=!8VY_/
MYZ9JL.5FIGKL:&6C=,LM3?5V;GJ-O/9&K9S'89C/6RZZ8+7TLCN]6JK!2M'A
MG08SM"W7SU<HU>XBB(*#X%YL&^L$\]6RYUM\0/M[?Z=I-I^\U*+%S@C5@<;-
M17 9G5^E3M\K_"%P9X[&X#)9*_7537ZN+X+0!802*^L\</H]XC5*Z1Q1&-_V
M/H,)TAD>CP_>/_O<*9<U-WBMY)^BMLU%4 90XX8/TMZKW4^XSR=S_BHEC?_"
M;M1-2;D:C%7MWI@B:$4W_OG3O@Y'!F7XCD&\-XA]W".0C_*&6[Y::K4#[;3)
MFQOX5+TU!2<ZMRD/5M.J(#N[NE9=327&&FADE!0UMS2YXI)W%<*#)\:U:GO5
M86?-<FX)U)G.JSW U0@0OP.P@%O5V<; )P*J7]O/*=@IXO@0\57\H<,'[&>0
MA SB,(X^\)=,%4B\O^0=?Z]3O4?I"W C3"65&30:^.MR;:PF_OS] 5PZP:4>
M+OUQ!?\0P)WB<]/S"B\".J8&]2,&_Q45[C0=>VV?@7<U?/HVB)X.HF7P*ZF]
M6L.7M8[6*O(NC 6U =L@;)2D4R^Z[3G0MEELUZBGO8,;K/:2R$M".!TZ/M2"
M0CN#4]&1#S48@C%G<,NKAC+5W\'""60YR[*$!FG(XBB'7Y!.::-D#:+MM7K$
MUJ>49"PO(TA2%B:%SW6PA-UP7>^X1HAR%N8%1"$K\]B7R>IA;!T4"3G:4C4-
MI#&+%QD4K$P2^#SH3E@BB0]J(YZL)TS"LD5)WS!-7H",VM@1B,5I3M\HR=^M
MY58KPCJ!*,M8FH8T6A0LB@M*SIASZF75T XC4VND;:X$]Y&>I@L6ERE5C_),
MTNSLP]TB_V'.HBRG41ZSHHQI3XZ\X5/O2$/-=X2RRM7A#7>PXQ1M-@NI14GI
MNRTMGR2S<A+0_>$I81N-".W8$]#UA#>HP;R]HP0C<-.C[]WR>92?1.DL?XT4
MA4?8!ZB.^/)_D69P655Z()M/8Q',),"#X,>1_0O5F+:@VX)T9 8I^%I(804Z
M4I0L]GS/69[$4UB6/[W2(YX7!7WS))UT:/<V1" J$I?@6H.H2#-G990179-%
M,6E6U%9$15I6"RZ-KY*Q%*ZG=Y)%CL;YBV>)6U*>2I.QLB@AIF\&=X.N&NZD
M5*AW^".Z2@YNAX2[J+^K,S$_3=V!(:(>\+1ZYI+<J+446\]6 Q&=RXB.UA?:
M#>T*4-!!CEF69/";LA3>OSS[GI%2C"<0QU2I!;S5X>='UVN+>NL?$6[[A\Z.
M-^TDG=XIE^/U_*(^/G)NN=X*"E7BADS#69$%H,>'PSBQJO>7]5I9NOK]L*&W
M%FJG0.L;I>QAX@"FU]OJ'U!+ P04    "  4B613T/SJQ<0*   ,(0  &0
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MJ328(*16*W1.0LR=JE>PDR9YR'8L!:<.>]]PDH:B'? $64S8GBQYL1 PC$S
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MB=/-?NZX)\^2,G/>4AI2F)I1A'/N%;2K[@5!11D12,IBAXBLC&LUXD'_B@+
M[V!,MPN\9.%NJX5@,ZUXZO5CR#OF*H/.S#G[Z%369Z?LGZ4BP9RK& =+5X\$
M['A,>&3A&B%6M,TL*51Y=C'8?0CW<1$&EBCJHYQ9"$7-Q2(FI"-,)11IX0AT
M6%&]12C)'++8]RTA220C<YEQO5^@BP<;9%%?IY:B4#9<]8)V>X&#!O>(2C1
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MIOUO[_[%JI7[O1M]GE6Y>URBVQ&:"/#]7,'9PPL=4/\'B.O_ E!+ P04
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M#[9LE8&@5*;YEP]M'GH*9Y-G%))6(8FX&T<1Y3L9Y&+N[%8XEH8U_HBA1FV
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M6 #G:XN+H%VP@^Z=N/@/4$L#!!0    ( !2)9%,&GM7<000  ( +   9
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M$ K,C45@]'.'%RB$!2(:7S:8WLZEW?C4WJ*_<;%3+'.F\4**3[PPJXDW]*#
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MT(>D&\$':9C8<QX'F$+8]S-B=1(3N>$IA+$?9,,]D5;2'([VZOKF%2OKUY=
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M"S<1X36O=:@1Y-];A??N8'.+E2#.JJB4"5/<_XDCW(8;S/0H)6&\)T@3X'S
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M*W]<*HG<TP#\OC!(0_>%%NC_/.;Y_P!02P,$%     @ %(ED4Y[06SIK!@
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MRU*&2O+& 5]V[.]*QD9JU'/RNT- \FGI)R71YTGIB7,G2H>:$JW*=F@/A7,
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M@?8-Y>/5?"7=G,"$Q=62G^>47XZO5CD_+UCK,I?U)<WS\?1RQL\7_0&,]&Z
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MF7+9+SLXKN*4%$9B\[8#'L-F&U[D![2C_?^LF"E3?3\C?1\Z4C88\ F7T",
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M&X$>QM)A8U7G1\&ULC18^F5#DSQJ=X'>;Q19N-\X!<?_!HN_ %!+ P04
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M[V>+OF/ 4B>ZIO+^8)$XP.#@5"44+)5"1EH;% =0+R7L14RR,[ +"@#6D?C
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MZGKU\D4V-?RR"79(#TEI YZEM.SP/T!<%,!]8VU8-M' X9_%]B]02P,$%
M  @ %(ED4X:E <=B*P  +IX  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&ULY3W;<MM&EK^"\J9FDBJ*EN2)X\1)JF0GF?'N9.*UDMFMVMH'D&B2B$&
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M6EEF/\$LP-FZ9OU^UU2%:[U '9;1.3@86A"M93 N_.=W,*#^_)@MYA[88.&
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M%\./CV-<(SZ+;!'.$(@&*!H@4X-ZM!>DW^?O@6NXM@.%*W.ZB$7V:U]L]X'
M<L"W_8$)FX@SWVQ #2*(PU(!#6 Y^3YP27C>R:M5R2=:*I.@5RK:0%'Z-2!H
MC\O*NT@?S>:QS&R!U'X+NAC^.[>JB,:P#G=WP+$![8%?  KA2TRY'L&/LA I
M+.%/.3Y/?"F<%AS0#O"S03E4T: M\),UL_R&^#ISIS-_<&ODH5G3R@\ !G>#
M+'4$WK(SS+!!5@4:L@?D118''$F8R;ILU_T>H( L>&EP"'E$[YGA>A@%Y"E^
MEZM<@PTOLE7?$8DA>T9(=<U"-R9X=Y.W)4U)5%@XQLCA4VN0(K!@Y32XG"*O
MD/>!LER)=$>( ']=\ULB754@D%+D&5GWH/ZB(H"'048" K-95>667H4)MDU3
M$ ='$)?(L "LM$P037F]+?$C8^""A>H9GAQBT1[/7#8!:V@)>0 VJZ8%PL>E
MMHA_&SRBP%R0K^/&F+N">H+*W"(035D?>J([."A"HK:Y*<G(P&%@EF8/7"B_
M(RZLT \D@)C6WN!O(-#Z %.0QF<GV-/SP)Z>GV8N=0[3X3QO4&J7>\!EI:D?
M AE=!S*:8E\?=X8':V6B661L2\[+\A.,PG!%%,8'P5]/!X/O@?!V3*DU;"O;
MLTF!0K"8G N?A$_GCY@5-]JZ'9J=((R01OXW9[]?OZ-1IS1/%!<@0'[_8H/6
MM@'U*N[^0X:QLJ,4=)N!0R):D!LJGD[8!>&WCV#CX,!H( #F1MG+C(#7&\<J
M:W:"D#.AGGP;-US6K$BQ=&@R=!YD%^=G_TXOO>OA;.&O\PL\[W=NVU<\XO79
M?ZH<O8XZ\14(;?CVXLMGSTADYGN&_:?XG%A1Z>/1GKJBQ0' JB.AX#$K&A(@
M:BL!@]<IAWN#QYQ7'02(^Q@!@P=1.>2Z$U"FT_+N X_(+BPO?NU])\J":)5X
M^$U='9GCPGHK6")JE_@#G$7;YY5(Y&[*3D'$JAW(7H\N#[06\K*%X6@)]$I<
MUJ$133<BL@=1YQ5B0]W8L*L)"E)L4HUE!O.6RI7/Q"C126GE<'2Z^A)67=9%
MB?+YQC'K",LS2\'S2E>2@XD$X"4S!_\$^*!I"R?MU%@,Z_R=-CE8NGU5B#:D
MNL.O?<W^N$ P0T@JYDQ;4P$Y425S;#<%W61JN*NZ!K0 4B/K!R96@ORWP-L(
M&$Q8WP& F:==$$\[/V5U?!'$^A<GA2[,Z, BSUZ3(;0^3HGMQXU ![,14**)
MI-\+=@9O1>F\4<_G_!TE*^&H[\6QY/2G38.I>1!)R40,'+_)?EE>+__P+Q?/
MSU\6(,GRE@P'=[?>@>+G2'LC8G!LG^!O^7HW4"9PQ8N(+XSI9 /(9$2FD5\@
M4P#2(A49\-VS;>:(<X&:6Q-+!:SN]SVOE-7["=&/<Z)*/BMOD6!)830F2O0_
M#0""=ACJ]K#Q 01&-LTRTQ,/)VN\-=D6%%DY$]+B#4PV;;-//3M KXUQZ.0&
M66C?P"^9<J;P";> X-S6Y3\BC3U2@:/=/%PM87R94BHVCP+*K4/4WJ.)!7;1
M2?_!BT#)+T[2(2C+:X?VCRK^[TK_?HJ</V"8Q'8%B@3:^I6,]D9-MA:?H@-&
MHQ;YV09@WY#>.O2S[5Q%&(=V'6#HWK7$2E=Y_5ZT%Y"(7?!!3+KD4G.:[$ZQ
MI^\.I*N9M0G,5T<9F956/&%WE-').>>C"XZ8 Z^(B'M7PK>Z5;+ETA5$=Q5N
M%CU&HA<@  I'$ELV3N/AR*(.X,.H%91[AZM?.Y0OKA#'->!-CVH.[W"1[9I;
M-,(7<WNE<Q!20!^%+(!"00B!5)- A;#L>C:DO3'?^?V[3CF2>#X"]VI.$EO"
M(P=');8X+#Y8J8%EDT*.'$XV0_8_:5;TNY]9.NFRM'9VA])BC3M!P90N!/2Q
M1A""T"QBW=FVS4'5*]RJ$Y4Y"OA=CMA=E>N ="JI95J8;YWK:,348"[$].YX
M(&U(<!@47SSL0T<#&%\S.V11 =KV(!Q ZV$ME\(6B)7;!A"@QB7QAK8-JI8S
MNE_<E2P;/0<9'F*+KQR H_-BD)OFN!MT7?NO,I]O'!AMN.<#>Q8"1Y (2\YN
MDP(.K/7DTM<'$ E? GR Y@L*4VP2FDY]Y7N4HT$35,6>GGS)'D/VML!I(VJ0
M__NLR^_8OT+J)2@*]3+[A9Q9Q ?&F^[&W$*1FI\6#U</(MX<!L ]H?H%D&LG
MQV=FH;,EUH6'U[(]))(OG5M\T822H@6@FFN"(FO+@+U!X\ABIVA!D'3Y6%8=
M- *@;0<L&M@LCQ&#3-.8-?$B(%&)G%87:1Q8A#9N+7^ 8E(U6]@WH%6I,9\"
M8P3-@0":_,"ZP&3DCO"CQ8G*/9L>S%[+YK#+P0I;.^ 0I#G2ZO%('\3/B<[E
MH,0-6V0<#&")';4;5J  O!$. @&T@F[*HB>E!</E0"<+(FR0,@<^6OT^G;UH
M'$\OU #+KW >D E+#8 / .\B<\[1&.L$OT^I%E\&U>++DSI!F/%=F'&1_<UU
M4]K%AXTTN:G6B?<<'9HER)@J+T%PY*1-=:<.>4'.T+P%8E8Y(<A"5F2=BRY9
M@(1NRU7?-<,3$.G$QAR!'XA( TK(SZ9))V/W<.K*E[<I-@6Z8>$7 S&,8K0,
MW#4_,N?*VZXFC&$%GM9=!7T%-,NF]<*?@<H*)T9TS=%'$L#XQ:%!*4[3I.J0
MKC1&<0)MKU!V:61"&4"4JS#ABIWY=D2*(<ZX5G&9(_LUY8P[M,.#1CS81+IT
M0W2S+.RUQ *"E4A<0H(Q$OB8>''!I!.XCCK_\=MFVHI_D!(DR,=.I!#J+GK'
MK,*HP?A@%/'H[LF/ 0TF<#YRD.&6107UACLVFZ^R\K,I5MR)8APB6R@P@'S3
M221DEUI>%.,M7(6*0! 7.%[P_)":02.BG(_TP *^A!7=P_SMJD[ 8'YY'"??
MH;-M+TJMB0I)5&=? N_N0%GS%-$*JR9EV*,)4OJ=O@Z\@-S?+29734"?5T'N
M/5#ZP79/L)TQ#B82<A>1,88X"0QZO41U\J8AR.!0I^! +YCMD';'VR\6[)]:
MT2(J6&VY.:J)'S!3L#+=$FHK4[0V3_=# A^."*]]\NQ\^26NM2+7VZX$IGV;
M&UM#'))3A*I3/X"U3,U\\?GR^0?.O)#G@XOODQ?+/X6Q8/"^1@2AL)P1:!7'
M 0&0FOWS[/EY]OJ[NU-B^N(\9LR=GQ:ON#>0I: TL(MX,AWND6-@R@5*%?--
MP]_0DZK/F&!]4%](MZ=8O -I%]\%\O(PK1=):%TE9>#G: >C0/-Q+KL&4-N"
MBR@.B)QT5=:2$G0U]:)1KI [J6(I'$/7F(2&[0(Q(84)2I(_B,F@69BW771H
M^O!Y%DRTJ);B2./Q.<(M0JX^ Y&+[O6HUPPUYLZM=S6S<M)P:TPXXLRNBE4>
MBN,C?,492(NFU)Y68UE=T[$Z$D/T="!V,;@EC.8WO1]'R<.>,DK["08]1C,H
M+$T:4HGL$B7!(2_5^5Z+AH2,N8<-YIS,\LBMD[T]<>:ER<10URD'E]0AY./\
M#W$C!L<6A2].4J_)=[TX27E_MBCW)H+V*NH@D_3\NT>U7\LY6A7K 4? 2*O)
MDV_>OOM#OC^\_$XC?A$MRCEB98H2S..)5W@^PCG<&:H7J+AU924G1,$^.C/@
M$BM84E/KT0C=-:!1:6K$Y+K=!E@,2F_B<2*G[0.E#U'%Q7!4 =6MAI(P0,[!
MH;A>&I0>Z'#H%:G1;4<\(VC@\%.).@[F]1"YJ.I=(,EN>K V25>@X&&.3HVR
M9KY5[D'\O@W:E0&)>M1.;WP1.90?GL 0]LOL.XT%(#E1,"!YG[ ,&6NZR[X+
M69(=.UHH[ BBN6SYO)AH.1A&[(%U7=?=8DQ<?NC84;?);C%6SI&-6UPR":,C
M>SM!KJ\UZHIF T4R.)/-)C@Q&/E<)%;IB%T5O4@A"3M$MB4 #:B-1A Z5M!8
MDF3/] S7>=N27B5^IF46*#$8ME[\K$1<,D/@?ISJA); Q%J0:I.$I>E@F)F4
MR#^L7J.VZ3E15&CRC&)2*IT&F!(F,+1I^A9$SJ;TJ(7^!II-ATXP'&$S 'R
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M6='V6RYD,MG<WIG!V?^2H*'ZGP+(DJ+ @%7LG/6VX>&<HQ19KT'"V?2 5*;
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M9Y;&E$U2P(UU.;33TVG\NCD$:0"L8%O67#O%;N*)I$UC;(>@]QR2C26H:"@
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M/^' BO[1-0<<$BN_NF9/'W=@X[@6'X#?-PV<O/R!$V#4G9;W[?\ 4$L#!!0
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M$+T.[[0PL:KV;Z.ELJAC/RSPM.7:&6!_I93=3ER [K$\^0=02P,$%     @
M%(ED4Z#PDFL-!   #@D  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MM59-;^,V$/TK R&'!" BB?IT8!O(QRY:8(,UDFU[*'J@)=HBEA*U)!4G_WZ'
ME*TDV]CHI1>*I(9OWLR\$37?*?W=-)Q;>&YE9Q9!8VU_%8:F:GC+S*7J>8=O
M-DJWS.)2;T/3:\YJ?ZB5(8VB/&R9Z(+EW.^M]'*N!BM%QU<:S-"V3+_<<*EV
MBR .#AL/8MM8MQ$NYSW;\D=N_^A7&E?AA%*+EG=&J XTWRR"Z_CJ)G/VWN!/
MP7?FS1Q<)&NEOKO%[_4BB!PA+GEE'0+#QQ._Y5(Z(*3Q8X\93"[=P;?S _IG
M'SO&LF:&WRKYEZAMLPC* &J^88.T#VKW&]_'XPE62AH_PFZTS8H JL%8U>X/
M(X-6=..3/>_S\.9 &1TY0/<'J.<].O(L[YAER[E6.]#.&M'<Q(?J3R,YT;FB
M/%J-;P6>L\M;U=688EX#SHR2HF86%S=,LJ[B\.B%<:O:7G6\LP;.O[&UY.9B
M'EKT[C#":N_I9O1$CWB:P;WJ;&/@$WJLWY\/D?5$G1ZHW]"3@(^\OX0D(D C
M&I_ 2Z94)!XO.8+W/N8'+GTF[H2II#*#Y@;^OEX;JU%(_YQPET[N4N\N/48?
M^ZL>) >U@97&+M/VA< *.5A@70V??@RB1_G;CU)]$MHU\I7I6<47 7:JX?J)
M!\N##P_.#^ $.@RVPMH+8QT5VW#8*(G-*KKM%6"2+6_77$^9ACM>[7=BOQ/!
M^="QH1:8K@LX%QUBJ,&@&W,!]ZQJD)W^Q2V<09:3+$MPDD:$QCE\X=A<C9(U
MB+;7ZHFW7G!)1O(RAB0E45)X)0X6?3=,USNF.<0YB?("XHB4.?4BMGH8.QZ9
M(- 6,V @I83.,BA(F23P>="=L%A23VHCGJTO;T*R68ECE":OCHS:V-$1H6F.
M8YSD<"R76ZW0UQG$64;2-,+9K" Q+3 X8Z[P$U0-[3#JJN98FDHPS_0\G1%:
MII@]C#-)LXNC'ERU$#_*29SE.,LI*4H*)_2837K,_K,>KZM*#TCRBV!K(845
MW'RDPI. 'ZOP@,R?>_?9,?^C]+YB C&]W1:DDQ;(UV P<26A7GTYR1,Z!6S9
M\SL[5%U1X)@GZ62#FMI@.;%N3((+2U1HF9,RSE \R:R8+"M,B:C0RFK!I/&U
M-!;I>K$E6>Q$E;\B2[Y%XRDU&2F+$BB.&:P&737,[6*B^@_%@7JOY(#?5B=\
M]FN>48=IZN2+LCGXT^J%2811:RFV7HD&8NR2&(7^%:NA70(*;"M*LB2#;\HB
MO7\A^PY.D>,94(J9FGVHQO#-'=5RO?4WL2O_T-GQNIIVI\O^>KSC7LW'/X5[
MIK<"J4J^P:/198$ZU./M.RZLZOV-MU86[T\_;?"'A6MG@.\W2MG#PCF8?H&6
M/P%02P,$%     @ %(ED4QPZ<Y#7!0  71(  !D   !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&ULK5A?<]HX$/\J&BYS$V;<8!ML8RYAAB1MKS-MI].DO8>;
M>Q#V KK:$I5D:.[3WTHVQ@0PI'</('FU_[3ZK7;MZ[60W]0"0),?><;536>A
M]7+4ZZED 3E55V()'%=F0N94XZ.<]]12 DVM4)[U?-<->SEEO#.^MK1/<GPM
M"ITQ#I\D446>4_ET"YE8WW2\SH;PF<T7VA!ZX^LEG<,#Z"_+3Q*?>K66E.7
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M*0A\4KBL<WC/EPB]NF1U1IW-#J''2]!K42L"JIKA'3))YOFS*E6]^(T4 [0
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M:&5E=',O<VAE970S,RYX;6R554UOXS80_2L#%2AV 342*<F64\= DDVQ>UC
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MJ<'9;:)_3+C<,*2Q$.@E[F)?[:/5=G\(EN_$WD8@VEX^[LF/!L(%@ %4L!M
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M4DD8KY  GL^UKOL;W&#XYG3];U!+ P04    "  4B613C>]P$8@$  !%"P
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MV.=2:3;@^D:@A_N!,=!WSO/_ %!+ P04    "  4B613U2 I#QL#  "/!@
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M[/Q:;S,CC*>M^*"E^949/SUYR%H0B05Z8$O.%BR@7*/+(! )UXPOT9V(6,!
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M%JG^(IY_8K5#H=$7B525?]%SW=?KH:A06F2U,"#(>%[]IW_6@3A$ -<">$L
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MO*#YRP#&DZ'_""AJ21^Y#E!TKO_#M<,:&9-/Y;$:!7X5N:X^D#>MS=&=Z_+
MRE;[U/]XXW>T7X7DXVU(.IY ML*3\FC*T)JNSA#=4_G$(0M2-@<8WN ,II2L
MCN54-UHLRF,D,Z&UR,K+A-&82=,!GL\%1*2^,0::PU&7_P=02P,$%     @
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M!)XLI*JIP:U:^KI10$L'JKD?!<&57U,FO"QUMGN5I7)E.!-PKXA>U355O\;
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M4OU)/OXIZH18V=Y,IJKZBQYK;#! LXW2,JN##8,LR7?_^8^Z(UH!.#P00.H
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M^WRLBT?D5RCY0/%M=@NQY$KQ.'O<  U!& $]O^)<[0?&07F1-?L74$L#!!0
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M%EEYF3 :,VD&P/=K <5;WQ@'S:N9Q7]02P,$%     @ %(ED4]..', ( P
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MI#4P_R^$T*\3ZZ!LJ ?_ E!+ P04    "  4B613=\,HWRD"  !R!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R5E%UKVS 4AO^*,!0Z6.//)&UQ
M#&W"6&&#T+#U8NQ"L4]B45GRI).Z^?>59,=DPS'LQOHZ[R.]QSI*&ZE>=0F
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M0,%D/O6(:BN\':"L79%L)9J2<]W2/(J@;(!9WTF)IX&MN_Z9S3X 4$L#!!0
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MU;P\<&K<E.=?L"!N8JY0PM;@TKX,@)0LCY3*&RVRX@CD46@MTN)RRRA,&6,
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MAN??9>"QJ0%?1E7C=3B@B!#B=LR"Y&.H)^11SM>=6!)CYH?9O "%8W =33A
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M-Q$LY!OX])5*4I3B\\272D-CR9]W_F:M/V3QEX%;5LN5 -_JG.:'_7VEO1\
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MD&_TK7DF[2\Z5%C/0>N]5#ROA+4'>5J4_^RE2L2)@-;3+4 J =(4&%P0H)4
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MA8AAH5+Z.0QS];V!AS03ZH@(+@>6N8X2RH.E8!*N[M$R+LPU):X2IM$ VU.
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MU$4"?=\H94^38H&Z,T]_ U!+ P04    "  4B613[1G9*P($  #"#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6S-E]^/XC80Q_\5*]J'76F7_((
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MU!I9)&);FJ?ZBSA\8%5" ^,O%*DJ?LFATCH6"7.E1589PPRRA)?_]%L%HF$
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M-I-& ,^W0NCCC0E0M^VS?P!02P,$%     @ %(ED4R_<G-7J!   D1D  !D
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M%(ED4_8G[-CN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ %(ED4YE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  4B613<9#M
M9D %  !H%0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ %(ED4_Q"$/BV!P  G1P  !@
M ("!@PT  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !2)
M9%/0^E*O1P0  -P,   8              " @6\5  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  4B613-\3^U\\&  "#'@  &
M        @('L&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ %(ED4S_W@ZX&!   ?@T  !@              ("!\2   'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !2)9%/>42ZW&0L  -)"   8
M              " @2TE  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  4B613ERK97W8"  #_!   &               @(%\,   >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ %(ED4^9E<M2G"0
M^"@  !@              ("!*#,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( !2)9%,B)PB=R08  #,/   8              " @04]
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  4B6131"^N
M]2PF  ".A0  &0              @($$1   >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( !2)9%/GRX(=10T  .TG   9
M  " @6=J  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M%(ED4Q*WG#,]!   R0D  !D              ("!XW<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  4B613T/SJQ<0*   ,(0  &0
M            @(%7?   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( !2)9%/' I<$<@0  #,*   9              " @5*'  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ %(ED4P:>U=Q!!
M@ L  !D              ("!^XL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  4B613*6+#V;(+   J(P  &0              @(%S
MD   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !2)9%.>
MT%LZ:P8  /\.   9              " @5R<  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ %(ED4]Y!%THV"@  =!L  !D
M     ("!_J(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M"  4B613(AGJ+QT$   9"0  &0              @(%KK0  >&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !2)9%/&N=8NC!8  (=0   9
M              " @;^Q  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L!
M A0#%     @ %(ED4W#,C,^/!   )PP  !D              ("!@L@  'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  4B613Y1/! ^L"
M  #N!@  &0              @(%(S0  >&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;%!+ 0(4 Q0    ( !2)9%,HTY+KTP,  '0(   9              "
M@6K0  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %(ED
M4T1NHQNX @  (08  !D              ("!=-0  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  4B613T\84([\#  !E"   &0
M        @(%CUP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( !2)9%.&I0''8BL  "Z>   9              " @5G;  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ %(ED4^1%%3-7!   . L
M !D              ("!\@8! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  4B613H/"2:PT$   ."0  &0              @(& "P$
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !2)9%,<.G.0
MUP4  %T2   9              " @<0/ 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ %(ED4X!;=IM2!   KA   !D
M ("!TA4! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  4
MB6132&C ;A$#  "8!@  &0              @(%;&@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !2)9%-ZM&@'5@,  $('   9
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M970S-BYX;6Q02P$"% ,4    "  4B613-#I)$ 4"  ! !   &0
M    @(&;-0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M !2)9%.ZVN3JEP4  (\8   9              " @=<W 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ %(ED4X=Q[:=1 P  6@\  !D
M             ("!I3T! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  4B613B.A(RLX#  !K$   &0              @($M00$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !2)9%.-,_S2J <
M "@E   9              " @3)% 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ %(ED4X(" 9RM P  V@X  !D              ("!
M$4T! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  4B613
M43S*R)$"  #+!@  &0              @('U4 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( !2)9%-),NNY5 ,  /X)   9
M      " @;U3 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ %(ED4]B47'DL!@  Y2<  !D              ("!2%<! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  4B613^K[JXB\#  #@"@
M&0              @(&K70$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( !2)9%,U&S_@+P0  +@/   9              " @1%A 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ %(ED4VDZ<)OG
M P  A \  !D              ("!=V4! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  4B613R>BT!@X$  #.$   &0
M@(&5:0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !2)
M9%.:D32!=00  -02   9              " @=IM 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ %(ED4[UEC\=_ @  Q08  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( !2)9%-WPRC?*0(  '(%   9
M  " @1&% 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M%(ED4R<O_DO5 @  *P@  !D              ("!<8<! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  4B613*;E#5N@"  !%"0  &0
M            @(%]B@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( !2)9%,&K_\0EP0  .03   9              " @9R- 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ %(ED4[%(<P,3!@
MG!L  !D              ("!:I(! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    "  4B613.+&^# 0,  #>3@  &0              @(&T
MF $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !2)9%,'
M#@:BLP0  -86   9              " @>^D 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ %(ED4\YRJ6R> @  ^@<  !D
M     ("!V:D! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !2)9%/M&=DK @0  ,(/   9              "
M@3*^ 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ %(ED
M4R_<G-7J!   D1D  !D              ("!:\(! 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    "  4B613RR:F%',#  !V#   &0
M        @(&,QP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( !2)9%/4A3._* (  /H%   9              " @3;+ 0!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ %(ED4[ 7H<HL P  '!,
M  T              ( !E<T! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  4
MB613EXJ[',     3 @  "P              @ 'LT $ 7W)E;',O+G)E;'-0
M2P$"% ,4    "  4B613MV"4[4D%  #Y+@  #P              @ '5T0$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %(ED4[ % +TV @  '"H  !H
M             ( !2]<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ %(ED4^'+1LC] 0  /2D  !,              ( !N=D! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $\ 3P"@%0  Y]L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>317</ContextCount>
  <ElementCount>445</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Investment in Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentinJointVenture</Role>
      <ShortName>Investment in Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Patent License Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/PatentLicenseAcquisition</Role>
      <ShortName>Patent License Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Intangible Assets, Net and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</Role>
      <ShortName>Intangible Assets, Net and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2158115 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2161116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2162117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables</Role>
      <ShortName>Intangible Assets, Net and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2354309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2359310 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/DescriptionofBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Investment in Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentinJointVentureDetails</Role>
      <ShortName>Investment in Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/InvestmentinJointVenture</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Patent License Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/PatentLicenseAcquisitionDetails</Role>
      <ShortName>Patent License Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/PatentLicenseAcquisition</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Debt - Components of Convertible Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails</Role>
      <ShortName>Debt - Components of Convertible Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Leases - Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesLeaseInformationDetails</Role>
      <ShortName>Leases - Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails</Role>
      <ShortName>Leases - Schedule of Operating Liability Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStockTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Market-based Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails</Role>
      <ShortName>Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationDetails</Role>
      <ShortName>Segment and Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="gh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463435 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SubsequentEvents</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gh-20210930.htm">gh-20210930.htm</File>
    <File>gh-0930x2021x10qxex311.htm</File>
    <File>gh-0930x2021x10qxex312.htm</File>
    <File>gh-0930x2021x10qxex313.htm</File>
    <File>gh-0930x2021x10qxex321.htm</File>
    <File>gh-0930x2021x10qxex322.htm</File>
    <File>gh-0930x2021x10qxex323.htm</File>
    <File>gh-20210930.xsd</File>
    <File>gh-20210930_cal.xml</File>
    <File>gh-20210930_def.xml</File>
    <File>gh-20210930_lab.xml</File>
    <File>gh-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gh-20210930.htm": {
   "axisCustom": 2,
   "axisStandard": 33,
   "contextCount": 317,
   "dts": {
    "calculationLink": {
     "local": [
      "gh-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gh-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gh-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gh-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gh-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gh-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 611,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://guardanthealth.com/20210930": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 9
   },
   "keyCustom": 69,
   "keyStandard": 376,
   "memberCustom": 25,
   "memberStandard": 53,
   "nsprefix": "gh",
   "nsuri": "http://guardanthealth.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://guardanthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Investment in Joint Venture",
     "role": "http://guardanthealth.com/role/InvestmentinJointVenture",
     "shortName": "Investment in Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Patent License Acquisition",
     "role": "http://guardanthealth.com/role/PatentLicenseAcquisition",
     "shortName": "Patent License Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Intangible Assets, Net and Goodwill",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill",
     "shortName": "Intangible Assets, Net and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Debt",
     "role": "http://guardanthealth.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Leases",
     "role": "http://guardanthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Commitments and Contingencies",
     "role": "http://guardanthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Common Stock",
     "role": "http://guardanthealth.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Stock-Based Compensation",
     "role": "http://guardanthealth.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Income Taxes",
     "role": "http://guardanthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158115 - Disclosure - Segment and Geographic Information",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformation",
     "shortName": "Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161116 - Disclosure - Related Party Transactions",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162117 - Disclosure - Subsequent Events",
     "role": "http://guardanthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables",
     "shortName": "Condensed Consolidated Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables",
     "shortName": "Intangible Assets, Net and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Debt (Tables)",
     "role": "http://guardanthealth.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Leases (Tables)",
     "role": "http://guardanthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Common Stock (Tables)",
     "role": "http://guardanthealth.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359310 - Disclosure - Segment and Geographic Information (Tables)",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationTables",
     "shortName": "Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "iaacefe81c0f14186af54df7f09699324_I20180531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://guardanthealth.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i78e4ce20d6fa44b99855dfa0287375ab_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ib22d1864ebff405dbb4e00d7c35cb73a_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenuefromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
     "shortName": "Condensed Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenuefromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i78e4ce20d6fa44b99855dfa0287375ab_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i78e4ce20d6fa44b99855dfa0287375ab_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Investment in Joint Venture (Details)",
     "role": "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
     "shortName": "Investment in Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i60c5b60ae7664a06b84d4cef96e2d5a2_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:LongTermMarketableSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i7dd285febee1461b9eb54caf6d2575e2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:LongTermMarketableSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i06071e62b6544aba8290bd086369fa36_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i06071e62b6544aba8290bd086369fa36_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gh:DebtSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Patent License Acquisition (Details)",
     "role": "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
     "shortName": "Patent License Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i2d2672bc23d34d2783b636a52ec86105_D20200301-20200331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Debt - Narrative (Details)",
     "role": "http://guardanthealth.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id32f5d1807074b2793d40078426095aa_I20201116",
      "decimals": "2",
      "lang": "en-US",
      "name": "gh:ConvertibleDebtHedgeStrikePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ib821d04236034791b8d3fa9b120448ae_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Debt - Components of Convertible Senior Notes (Details)",
     "role": "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
     "shortName": "Debt - Components of Convertible Senior Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ib821d04236034791b8d3fa9b120448ae_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Leases - Narrative (Details)",
     "role": "http://guardanthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Leases - Lease Information (Details)",
     "role": "http://guardanthealth.com/role/LeasesLeaseInformationDetails",
     "shortName": "Leases - Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)",
     "role": "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails",
     "shortName": "Leases - Schedule of Operating Liability Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i95165abecdd04d43a21f2a1198ebe3f0_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i9be8ea22fbbb409984f67bfff4ce6a0d_D20180701-20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DividendsCommonStock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Common Stock (Details)",
     "role": "http://guardanthealth.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DividendsCommonStock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i32e0e7a381cb4c54b6fa6ca304bcfb9e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id99d1f03db58476b865112b51f6b69de_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ReclassificationsOfTemporaryToPermanentEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i78e4ce20d6fa44b99855dfa0287375ab_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i619cc50dcce348cc8689f3c9699ad658_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i619cc50dcce348cc8689f3c9699ad658_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id1e7591cbb12410598b75394c40acba8_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id1e7591cbb12410598b75394c40acba8_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i78e4ce20d6fa44b99855dfa0287375ab_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
     "shortName": "Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "if58ffec0307a44cfaa204337af91208a_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ic1f46661f1f446eeb205375c1af434fe_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i98a90cea546b4b58808f7b4f200670b0_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i477964bc10504bb0938d30103ef7edac_D20210701-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i7e20e83cdbd44af1990d7facfd58b988_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id99d1f03db58476b865112b51f6b69de_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "id99d1f03db58476b865112b51f6b69de_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i87072388cc314ce488bc187e99179f36_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Segment and Geographic Information (Details)",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
     "shortName": "Segment and Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "if34f8da1addc4820a1cb6767365cb8a3_D20210101-20210930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463435 - Disclosure - Subsequent Events (Details)",
     "role": "http://guardanthealth.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "i3edbb27baf14454882593f853aa8325b_D20211101-20211101",
      "decimals": "2",
      "lang": "en-US",
      "name": "gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://guardanthealth.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20210930.htm",
      "contextRef": "ia4c2d9dd95e64738b2966fbfb6e9e159_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gh_A2018IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Incentive Award Plan [Member]",
        "label": "2018 Incentive Award Plan [Member]",
        "verboseLabel": "Shares available for issuance under the 2018 Incentive Award Plan"
       }
      }
     },
     "localname": "A2018IncentiveAwardPlanMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AMEA2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMEA 2020 Plan",
        "label": "AMEA 2020 Plan [Member]",
        "terseLabel": "AMEA 2020 Plan"
       }
      }
     },
     "localname": "AMEA2020PlanMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AccruedClinicalTrialsandStudies": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials and Studies",
        "label": "Accrued Clinical Trials and Studies",
        "terseLabel": "Accrued clinical trials and studies"
       }
      }
     },
     "localname": "AccruedClinicalTrialsandStudies",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AccruedExpensesPropertyandEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses, Property and Equipment, Current",
        "label": "Accrued Expenses, Property and Equipment, Current",
        "terseLabel": "Purchases of property and equipment included in accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesPropertyandEquipmentCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges",
        "terseLabel": "Purchase of convertible senior note hedges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AssetAcquisitionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Policy Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Transaction Costs",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Asset acquisition, transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CashCashEquivalentsandDebtSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "label": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "terseLabel": "Cash, cash equivalents and debt securities, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsandDebtSecuritiesFairValue",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ChargeOfInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge Of In Process Research And Development",
        "label": "Charge Of In Process Research And Development",
        "terseLabel": "Charge of in-process research and development costs with no alternative future use",
        "verboseLabel": "In process research and development expensed"
       }
      }
     },
     "localname": "ChargeOfInProcessResearchAndDevelopment",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, After Allowance For Credit Loss Net, Current",
        "label": "Contractual Receivables, After Allowance For Credit Loss Net, Current",
        "totalLabel": "Financing receivable, net amount, current"
       }
      }
     },
     "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent",
        "label": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent",
        "totalLabel": "Financing receivable, net amount, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 2.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss, Current",
        "label": "Contractual Receivables, Allowance For Credit Loss, Current",
        "negatedPeriodEndLabel": "Ending balance, financing receivable, allowance for credit loss, current",
        "negatedPeriodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 2.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss, Noncurrent",
        "label": "Contractual Receivables, Allowance For Credit Loss, Noncurrent",
        "negatedPeriodEndLabel": "Ending balance, financing receivable, allowance for credit loss, noncurrent",
        "negatedPeriodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossNoncurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Allowance For Credit Loss",
        "label": "Contractual Receivables, Allowance For Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Contractual Receivables and Related Credit Loss"
       }
      }
     },
     "localname": "ContractualReceivablesAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss",
        "label": "Contractual Receivables, Before Allowance For Credit Loss",
        "terseLabel": "Other receivables and other assets due from a third-party"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLoss",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 1.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current",
        "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current",
        "terseLabel": "Financing receivable, gross amount, current"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": {
       "order": 1.0,
       "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent",
        "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent",
        "terseLabel": "Financing receivable, net amount, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossExpenseReversalCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Expense (Reversal), Current",
        "label": "Contractual Receivables, Credit Loss, Expense (Reversal), Current",
        "negatedTerseLabel": "Additions: charged to other income (expense), net, allowance for credit loss, current"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossExpenseReversalCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent",
        "label": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent",
        "negatedTerseLabel": "Additions: charged to other income (expense), net, allowance for credit loss, noncurrent",
        "terseLabel": "Contractual receivables, credit loss"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossExpenseReversalNoncurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossReclassificationCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Reclassification, Current",
        "label": "Contractual Receivables, Credit Loss, Reclassification, Current",
        "negatedTerseLabel": "Reclassification, allowance for credit loss, current"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossReclassificationCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesCreditLossReclassificationNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent",
        "label": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent",
        "negatedTerseLabel": "Reclassification, allowance for credit loss, noncurrent"
       }
      }
     },
     "localname": "ContractualReceivablesCreditLossReclassificationNoncurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ContractualReceivablesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Receivables, Term",
        "label": "Contractual Receivables, Term",
        "terseLabel": "Other receivables and other assets, term"
       }
      }
     },
     "localname": "ContractualReceivablesTerm",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConversionPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Three",
        "label": "Conversion Period Three [Member]",
        "terseLabel": "Conversion Period Three"
       }
      }
     },
     "localname": "ConversionPeriodThreeMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ConvertibleDebtHedgeSharePricePremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Hedge, Share Price, Premium Percentage",
        "label": "Convertible Debt, Hedge, Share Price, Premium Percentage",
        "terseLabel": "Share price, premium"
       }
      }
     },
     "localname": "ConvertibleDebtHedgeSharePricePremiumPercentage",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_ConvertibleDebtHedgeStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Hedge, Strike Price",
        "label": "Convertible Debt, Hedge, Strike Price",
        "terseLabel": "Notes Hedges, strike price (in dollars per share)"
       }
      }
     },
     "localname": "ConvertibleDebtHedgeStrikePrice",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gh_ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2027",
        "label": "Convertible Senior Notes Due 2027 [Member]",
        "terseLabel": "Senior Notes Due 2027"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CostofDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Development Services",
        "label": "Cost of Development Services",
        "terseLabel": "Cost of development services and other"
       }
      }
     },
     "localname": "CostofDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostofDevelopmentServicesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Development Services [Policy Text Block]",
        "label": "Cost of Development Services [Policy Text Block]",
        "terseLabel": "Cost of Development Services"
       }
      }
     },
     "localname": "CostofDevelopmentServicesPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CostsofPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing",
        "label": "Costs of Precision Oncology Testing",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostsofPrecisionOncologyTestingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing [Policy Text Block]",
        "label": "Costs of Precision Oncology Testing [Policy Text Block]",
        "terseLabel": "Costs of Precision Oncology Testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTestingPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer D",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Equity Component, Gross",
        "label": "Debt Instrument, Convertible, Equity Component Before Issuance Costs",
        "terseLabel": "2027 Notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Issuance Costs, Equity Component",
        "label": "Debt Instrument, Convertible, Issuance Costs, Equity Component",
        "negatedTerseLabel": "Less: issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIssuanceCostsEquityComponent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate",
        "label": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage",
        "label": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage",
        "terseLabel": "Maximum special interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "label": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "totalLabel": "Amortized cost, cash and cash equivalents and debt securities available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DebtSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities [Table Text Block]",
        "label": "Debt Securities [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesTableTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_EquityIncentivePlanTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan Tranche",
        "label": "Equity Incentive Plan Tranche [Axis]",
        "terseLabel": "Equity Incentive Plan Tranche [Axis]"
       }
      }
     },
     "localname": "EquityIncentivePlanTrancheAxis",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_EquityIncentivePlanTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan Tranche",
        "label": "Equity Incentive Plan Tranche [Domain]",
        "terseLabel": "Equity Incentive Plan Tranche [Domain]"
       }
      }
     },
     "localname": "EquityIncentivePlanTrancheDomain",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_EquityMethodInvestmentSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Shares Purchased",
        "label": "Equity Method Investment, Shares Purchased",
        "terseLabel": "Equity method investment, shares purchased (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesPurchased",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_EquitySecuritiesFVNIIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI Incurred But Not Yet Paid",
        "label": "Equity Securities, FV-NI Incurred But Not Yet Paid",
        "terseLabel": "Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIIncurredButNotYetPaid",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value",
        "label": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value",
        "terseLabel": "Impairment or adjustments of non-marketable securities"
       }
      }
     },
     "localname": "EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_EstimatedLitigationLiabilityLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Litigation Liability, Legal Fees, Current",
        "label": "Estimated Litigation Liability, Legal Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "EstimatedLitigationLiabilityLegalFeesCurrent",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period",
        "terseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FoundationMedicineInc.vs.GuardantHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]",
        "label": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]",
        "terseLabel": "Foundation Medicine, Inc. vs. Guardant Health, Inc."
       }
      }
     },
     "localname": "FoundationMedicineInc.vs.GuardantHealthInc.Member",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_Guardant360CDxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guardant360CDx",
        "label": "Guardant360CDx [Member]",
        "terseLabel": "Guardant360CDx"
       }
      }
     },
     "localname": "Guardant360CDxMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_GuardantHealthAMEAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guardant Health AMEA, Inc [Member]",
        "label": "Guardant Health AMEA, Inc [Member]",
        "terseLabel": "Guardant Health AMEA, Inc"
       }
      }
     },
     "localname": "GuardantHealthAMEAIncMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_GuardantHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guardant Health, Inc.",
        "label": "Guardant Health, Inc. [Member]",
        "terseLabel": "Guardant Health, Inc."
       }
      }
     },
     "localname": "GuardantHealthIncMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_KeyGenePatentLicenseAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KeyGene Patent License Acquisition [Member]",
        "label": "KeyGene Patent License Acquisition [Member]",
        "terseLabel": "KeyGene Patent License Acquisition"
       }
      }
     },
     "localname": "KeyGenePatentLicenseAcquisitionMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract",
        "terseLabel": "Renewal lease term, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_LesseeOperatingLeaseLiabilityLeaseIncentive": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Lease Incentive",
        "label": "Lessee, Operating Lease, Liability, Lease Incentive",
        "negatedTerseLabel": "Less: lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityLeaseIncentive",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_LongTermMarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Marketable Securities, Maturity Period",
        "label": "Long Term Marketable Securities, Maturity Period",
        "terseLabel": "Long term maturity period (years)"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMaturityPeriod",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_NonCashOperatingLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Operating Lease Costs",
        "label": "Non Cash Operating Lease Costs",
        "terseLabel": "Non-cash operating lease costs"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCosts",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_NumberOfOperatingLeasesLeaseNotYetCommenced": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Operating Leases, Lease Not yet Commenced",
        "label": "Number Of Operating Leases, Lease Not yet Commenced",
        "terseLabel": "Number lease agreements, not yet commenced"
       }
      }
     },
     "localname": "NumberOfOperatingLeasesLeaseNotYetCommenced",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberOfPetitionsFiledRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Petitions Filed, Remaining",
        "label": "Number Of Petitions Filed, Remaining",
        "terseLabel": "Number of petitions remaining"
       }
      }
     },
     "localname": "NumberOfPetitionsFiledRemaining",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPetitionsDenied": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Petitions Denied",
        "label": "Number of Petitions Denied",
        "terseLabel": "Number of petitions denied"
       }
      }
     },
     "localname": "NumberofPetitionsDenied",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPetitionsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Petitions Filed",
        "label": "Number of Petitions Filed",
        "terseLabel": "Number of petitions filed"
       }
      }
     },
     "localname": "NumberofPetitionsFiled",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_PaloAltoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palo Alto, California",
        "label": "Palo Alto, California [Member]",
        "terseLabel": "Palo Alto, California"
       }
      }
     },
     "localname": "PaloAltoCaliforniaMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PatentandCovenantRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and Covenant Rights [Member]",
        "label": "Patent and Covenant Rights [Member]",
        "terseLabel": "Patent and Covenant Rights"
       }
      }
     },
     "localname": "PatentandCovenantRightsMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PaymentInConnectionWithaLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment In Connection With a License Agreement",
        "label": "Payment In Connection With a License Agreement",
        "terseLabel": "Payment in connection with a license agreement"
       }
      }
     },
     "localname": "PaymentInConnectionWithaLicenseAgreement",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Restricted Stock Units",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PrecisionOncologyTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Oncology Testing [Member]",
        "label": "Precision Oncology Testing [Member]",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "PrecisionOncologyTestingMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PreferredStockSharesIssuedUponConversionOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock",
        "label": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock",
        "terseLabel": "Common stock reclassified and converted into preferred stock (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssuedUponConversionOfCommonStock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ProceedsFromContractualReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Contractual Receivable",
        "label": "Proceeds From Contractual Receivable",
        "terseLabel": "Contractual receivables, installment payment"
       }
      }
     },
     "localname": "ProceedsFromContractualReceivable",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, Acquired Under Finance Leases",
        "label": "Property, Plant And Equipment, Acquired Under Finance Leases",
        "terseLabel": "Property and equipment acquired under finance leases"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAcquiredUnderFinanceLeases",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RevenuefromDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Development Services",
        "label": "Revenue from Development Services",
        "terseLabel": "Development services and other"
       }
      }
     },
     "localname": "RevenuefromDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RevenuefromPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Precision Oncology Testing",
        "label": "Revenue from Precision Oncology Testing",
        "terseLabel": "Precision oncology testing"
       }
      }
     },
     "localname": "RevenuefromPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period",
        "terseLabel": "Additional service period requirement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross",
        "terseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "terseLabel": "Number of MSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate",
        "terseLabel": "Risky rate, cost of equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross",
        "negatedTerseLabel": "Granted (in shares)",
        "terseLabel": "Total market-based restricted stock units approved and granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "terseLabel": "Market-based stock units holding period during vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "terseLabel": "Market-based restricted stock share price goal"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term",
        "terseLabel": "Threshold percentage for individual's combined voting power triggering five year option term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available",
        "terseLabel": "2018 plan annual increase (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_SoftBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SoftBank [Member]",
        "label": "SoftBank [Member]",
        "terseLabel": "SoftBank"
       }
      }
     },
     "localname": "SoftBankMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "label": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "terseLabel": "Vesting of common stock exercised early"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedEarly",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Two",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "label": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimCondensedFinancialStatementsPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase",
        "label": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase",
        "terseLabel": "Fair value of joint venture threshold"
       }
      }
     },
     "localname": "VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "label": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "terseLabel": "Threshold percentage of fair value that is no less than internal rate of return"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
     "nsuri": "http://guardanthealth.com/20210930",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r117",
      "r284",
      "r288",
      "r293",
      "r479",
      "r480",
      "r485",
      "r486",
      "r571",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r117",
      "r284",
      "r288",
      "r293",
      "r479",
      "r480",
      "r485",
      "r486",
      "r571",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r115",
      "r116",
      "r300",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r122",
      "r129",
      "r135",
      "r236",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r498",
      "r501",
      "r503",
      "r504",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect adjustment for ASU 2020-06 adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r122",
      "r129",
      "r135",
      "r236",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r498",
      "r501",
      "r503",
      "r504",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r122",
      "r129",
      "r135",
      "r236",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r498",
      "r501",
      "r503",
      "r504",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r204",
      "r382",
      "r387",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r299",
      "r345",
      "r400",
      "r401",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r651",
      "r655",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r299",
      "r345",
      "r400",
      "r401",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r651",
      "r655",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r204",
      "r382",
      "r387",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r200",
      "r382",
      "r385",
      "r611",
      "r650",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r200",
      "r382",
      "r385",
      "r611",
      "r650",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r299",
      "r345",
      "r391",
      "r400",
      "r401",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r651",
      "r655",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r299",
      "r345",
      "r391",
      "r400",
      "r401",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r608",
      "r651",
      "r655",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r115",
      "r116",
      "r300",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r382",
      "r386",
      "r653",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r382",
      "r386",
      "r653",
      "r669",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r206",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r123",
      "r124",
      "r125",
      "r126",
      "r214",
      "r215",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r283",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r564",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r26",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r619",
      "r637"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued tax liabilities"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r43"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r43"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty obligations"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r273"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r61",
      "r62",
      "r63",
      "r640",
      "r663",
      "r667"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r484",
      "r658",
      "r659",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Remaining Weighted-Average Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Balance Sheet Components"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r446",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r443",
      "r444",
      "r445",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r402",
      "r404",
      "r449",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r359",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Adjustments to additional paid in capital, stock issued, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r404",
      "r435",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r82",
      "r99",
      "r319",
      "r545"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r99",
      "r255",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r184",
      "r189",
      "r196",
      "r231",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r479",
      "r485",
      "r520",
      "r572",
      "r574",
      "r617",
      "r636"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r54",
      "r112",
      "r231",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r479",
      "r485",
      "r520",
      "r572",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Member]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r218",
      "r244"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost, debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r216",
      "r219",
      "r244",
      "r622"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r405",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office and laboratory space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r98",
      "r473"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Re-valuation of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r470",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Initial fair value of contingent consideration at acquisition date",
        "verboseLabel": "Contingent liability from business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Patent License Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r35",
      "r101"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Estimated fair value, cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r101",
      "r105"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r531"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r109",
      "r112",
      "r139",
      "r140",
      "r145",
      "r147",
      "r149",
      "r157",
      "r158",
      "r159",
      "r231",
      "r284",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r343",
      "r344",
      "r348",
      "r352",
      "r520",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September\u00a030, 2021, and December\u00a031, 2020; 101,623,257 and 100,213,985 shares issued and outstanding as of September\u00a030, 2021, and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r79",
      "r626",
      "r646"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Guardant Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r78",
      "r477",
      "r489",
      "r625",
      "r645"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r204",
      "r517",
      "r518",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r204",
      "r517",
      "r518",
      "r668",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r204",
      "r517",
      "r518",
      "r668",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r162",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r168",
      "r169",
      "r204",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r165",
      "r168",
      "r169",
      "r170",
      "r517",
      "r519",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r204",
      "r517",
      "r518",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r370",
      "r372",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r370",
      "r371",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue from cash collections exceeding estimated variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r370",
      "r371",
      "r383"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r299",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt",
        "verboseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r166",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r313",
      "r320",
      "r321",
      "r323",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r111",
      "r117",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r330",
      "r331",
      "r546",
      "r618",
      "r620",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "totalLabel": "Net amount recorded in equity"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r298",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r46",
      "r298",
      "r360",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold of consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold of common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r296",
      "r328",
      "r329",
      "r544",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r311",
      "r328",
      "r329",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r45",
      "r327",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r111",
      "r117",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r330",
      "r331",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r111",
      "r117",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r328",
      "r329",
      "r330",
      "r331",
      "r360",
      "r364",
      "r365",
      "r366",
      "r543",
      "r544",
      "r546",
      "r547",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r309",
      "r543",
      "r547"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount, net of amortization"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Debt securities, short-term"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Noncurrent",
        "terseLabel": "Debt securities, long-term"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r39",
      "r309",
      "r545"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: debt issuance costs, net of amortization"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r99",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r99",
      "r182"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r367",
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends on common stock"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r80",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r136",
      "r139",
      "r147",
      "r148",
      "r149",
      "r153",
      "r154",
      "r504",
      "r505",
      "r627",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r80",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r139",
      "r147",
      "r148",
      "r149",
      "r153",
      "r154",
      "r504",
      "r505",
      "r627",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock based compensation not recognized, period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for issuance under the 2018 Employee Stock Purchase Plan",
        "verboseLabel": "ESPP obligation"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options issued and outstanding",
        "verboseLabel": "Shares underlying outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r124",
      "r132",
      "r134",
      "r156",
      "r236",
      "r359",
      "r367",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r503",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r658",
      "r659",
      "r660",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage",
        "verboseLabel": "Ownership interest in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Non-marketable equity and other investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r311",
      "r328",
      "r329",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r507",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r506",
      "r507",
      "r509",
      "r510",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r311",
      "r392",
      "r393",
      "r398",
      "r399",
      "r507",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r311",
      "r328",
      "r329",
      "r392",
      "r393",
      "r398",
      "r399",
      "r507",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r311",
      "r328",
      "r329",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r507",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Level 3 Activity"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value \u2014 end of period",
        "periodStartLabel": "Fair value \u2014 beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r311",
      "r328",
      "r329",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r512",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r551",
      "r556"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments made on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r322",
      "r357",
      "r494",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Intangible assets subject to amortization, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r256",
      "r259",
      "r263",
      "r267",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r263",
      "r613"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets subject to amortization, gross carrying amount",
        "verboseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r256",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r263",
      "r612"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets subject to amortization, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Gain contingency, patents allegedly infringed upon, number"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r167",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r249",
      "r250",
      "r574",
      "r616"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r253",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r99",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r184",
      "r188",
      "r192",
      "r195",
      "r198",
      "r614",
      "r623",
      "r629",
      "r648"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r454",
      "r455",
      "r456",
      "r459",
      "r461",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r133",
      "r134",
      "r183",
      "r453",
      "r460",
      "r462",
      "r649"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r98",
      "r609"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "gh_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r254",
      "r261"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r181",
      "r542",
      "r545",
      "r628"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r53",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r86",
      "r180"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r112",
      "r190",
      "r231",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r480",
      "r485",
      "r486",
      "r520",
      "r572",
      "r573"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r112",
      "r231",
      "r520",
      "r574",
      "r621",
      "r642"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r112",
      "r231",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r480",
      "r485",
      "r486",
      "r520",
      "r572",
      "r573",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Financial and nonfinancial liabilities, fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Acquired license"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Settlement of prior dispute between parties"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r310",
      "r325",
      "r328",
      "r329",
      "r620",
      "r638"
     ],
     "calculation": {
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails",
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r10",
      "r42"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetAssetsGeographicAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Net Assets, Geographic Area [Member]",
        "terseLabel": "Net Assets, Geographic Area"
       }
      }
     },
     "localname": "NetAssetsGeographicAreaMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r97",
      "r100"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "negatedLabel": "Adjustment of redeemable noncontrolling interest",
        "negatedTerseLabel": "Adjustment of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r136",
      "r137",
      "r146",
      "r149",
      "r184",
      "r188",
      "r192",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "netLabel": "Net loss attributable to Guardant Health, Inc. common stockholders, basic",
        "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r138",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r149"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to Guardant Health, Inc. common stockholders",
        "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements and other covenant rights"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r188",
      "r192",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r559",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r558",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r43"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, net"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r529",
      "r530",
      "r532"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r68",
      "r70",
      "r71",
      "r73",
      "r77",
      "r359",
      "r533",
      "r538",
      "r539",
      "r624",
      "r644"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss), net of tax impact",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r68",
      "r477",
      "r478",
      "r483"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income (loss) attributable to redeemable noncontrolling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax impact:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Credit loss adjustment and others"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs related to borrowings on convertible senior notes"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r94",
      "r225"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchase of non-marketable equity and other related investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets and capitalized license obligations"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Payments to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "MSUs",
        "verboseLabel": "Market-based restricted stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r405",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount per share used to calculated dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Preferred stock dividend rate (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r11",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets, net"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering, net of underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r90",
      "r438"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuances of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r64",
      "r67",
      "r72",
      "r95",
      "r112",
      "r123",
      "r133",
      "r134",
      "r184",
      "r188",
      "r192",
      "r195",
      "r198",
      "r231",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r477",
      "r481",
      "r482",
      "r488",
      "r489",
      "r505",
      "r520",
      "r629"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r272"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r274",
      "r574",
      "r631",
      "r643"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r340",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Adjustment of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.",
        "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value",
        "terseLabel": "Redeemable noncontrolling interest, redemption value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r452",
      "r610",
      "r685"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r105",
      "r615",
      "r639"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r13",
      "r19",
      "r105",
      "r670"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash \u2013 included in other assets, net"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Shares underlying unvested restricted stock units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r367",
      "r446",
      "r574",
      "r641",
      "r662",
      "r667"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r119",
      "r120",
      "r121",
      "r124",
      "r132",
      "r134",
      "r236",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r503",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r75",
      "r112",
      "r178",
      "r179",
      "r187",
      "r193",
      "r194",
      "r200",
      "r201",
      "r204",
      "r231",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r520",
      "r629"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r557",
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r168",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r47",
      "r117",
      "r328",
      "r330",
      "r360",
      "r364",
      "r365",
      "r366",
      "r543",
      "r544",
      "r547",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instrument Components"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r112",
      "r230",
      "r231",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r256",
      "r262",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r256",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r191",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r191",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of Performance-based Restricted Stock Units Vesting Conditions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r405",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r410",
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r109",
      "r157",
      "r158",
      "r333",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r352",
      "r357",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r334",
      "r341",
      "r342",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r165",
      "r168",
      "r169",
      "r170",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r174",
      "r176",
      "r177",
      "r184",
      "r186",
      "r192",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Weighted-average derivative service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Market-based stock unit vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of MSU (in usd per share)",
        "verboseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending unvested balance (in shares)",
        "periodStartLabel": "Beginning unvested balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Discount for post-vesting restrictions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate, ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending number of shares, available for grant (in shares)",
        "periodStartLabel": "Beginning number of shares, available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable, weighted average exercise price per share (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, grants in period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r412",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending number of shares, outstanding (in shares)",
        "periodStartLabel": "Beginning number of shares, outstanding (in shares)",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r403",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche 1 - $120 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche 3 - $200 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche 2 - $150 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r405",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option term, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (as a percent of the fair value of common stock)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price of stock issued (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r109",
      "r112",
      "r139",
      "r140",
      "r145",
      "r147",
      "r149",
      "r157",
      "r158",
      "r159",
      "r231",
      "r284",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r343",
      "r344",
      "r348",
      "r352",
      "r359",
      "r520",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r52",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r124",
      "r132",
      "r134",
      "r156",
      "r236",
      "r359",
      "r367",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458",
      "r503",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r658",
      "r659",
      "r660",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r156",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r359",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r359",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r112",
      "r210",
      "r231",
      "r520",
      "r574"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r540",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r540",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r540",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r540",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r575",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r49",
      "r112",
      "r231",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r322",
      "r357",
      "r494",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common stock subject to repurchase"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r160",
      "r161",
      "r163",
      "r164",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r479",
      "r480",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r138",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "24(b)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r686": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r687": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r688": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r689": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r690": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r698": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001576280-21-000105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001576280-21-000105-xbrl.zip
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M-YAYW2HR+DT[SE.&@T*PIW>=,B@T19A+BE0-9CDEEAD<>OAZ8+6,@5]CCH+
MIM"?L\=DSR>/N?&.F-N9"-:@MSN%[(Q 0.U4, 06-2JER)74 "BQ\$.TP6YB
M$7G HJ!C(86=8W+=-"VN P<2%W\/X7NB*X6CH^3;PJ LUQG@S[AB( P5[F%
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M<AL"&8^Y,53/4"2E-QS67=%IX!X#8V!)Z2H^K($"L=!0X4$L@^E@">.:3,?
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M[.:4;[PP5W[Z=_?<6X2G_P%02P,$%     @ %(ED4S#M&MR<!0  &Q<  !H
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MX;:9-BTX[LZ%HM<[F^X]NIEK6M"4I:'66*]S4[)1V7*#_#?&-CP+S8SQ!OU
M0XP]UTEP'=8)Q6>)!#NB*,D$RW1:)$:^?;.IKZ/<%9$1I\IZ8<2N:(8$F^]8
M8/SB:']!5D8]J"),*NWWY-SMRW-SRS7ICI#=:U8,M6T'^I)R8N"^=_%Z1=6M
M3O]J"UDB$ J]O^43=[759WEM;"^P1_\"4$L#!!0    ( !2)9%,&.7,AG 4
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M=.5'A;RZ[M.QC\W,GYT:VEI\>L3%D:OO5P]Y<*VCKNY3K>^LTR95A28?NV'
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MGNQ:"A&2#3)ZRLZ"2#&B)I$*LW93?+I<S+Z4\+E=L[BLZ%T6W#A"R. 5.1+
M_Z)C_"AG^+N*SB\Q _K!!2=E]M)X*]$HL-JB\5FJ)#03(716+J!\8I.CP"^7
M8MU)7<<ODT!=9$4,UD4(R4:?V71+,$*0<]JMGD 7MDSV[H7+HI6),F55EYY
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MTU2K4VP/^=+#,4V:XJ0P1)V]E"$+!\K9Z).+45D;51V ;,#BOV67U1PC*A$
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M&T8SYUA5($5 Y@[>&0<DL]>J4))44D1*-BP_>'\\JH=>QU*$M"HB"%4\&@S
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M3HPG11#E/CM9%-S\&#T"_QY++H6A6M0+H7790:[S]N!H+@W<5Y:5;3=.;2O
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M7.NF\X.C,[CS)U:><!>;I6P-3<MN)+/"=3-QG;]4A (&2U.<CT9SASC5";D
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MJVC.N1,I5["3B'(S/O@I$6254\E%XVPTU;Q@*JZ7LA<.>.(<L("42N& %7'
MQ!%02<D@N,OUG@)Q1RRREED4J..6>1$DC1!A$=I4AA42*"2P\-1*(8'5D,#T
M.1A!E51&(>Q$/M3F%((?,$H0U0GK6)[3E8O+6%/IZ^6B]2.!99>HK *ENX#"
M7NP/&JT* F4(2,T+1RX3V&[G,\@N=PH:,=BY- N+S<1B?TWG-+QC-/CHP(NQ
M$,XP$<&ID1(E'!2+6'LKW<:6U'5J4%R0NM95'@7&"X+Q5%8BI.!)+O0 "8(S
M8C5%SL6$G-?48D(2B[G4J\G(]7BD /G1 'FY%1L%R(L"\L0>2RH4!3)&DEF+
M.+8869,L MW%EBG!/>8;6ZQ)U:(J-@N0:PCDY59?%" O",A3Z8$0L#28YL-F
M@B(N(UCDH#GR-$(H9)F3!&]L:0!RG<;H+;O,8J5)@*M-+\K1NYK6/EQEJY'\
MRG&Z^Y#4N^GHWU*;F_DS1+53B <ID,$JH" DEU0%X;V Z)\O('^YIOL4CQR<
M"XC\"S@7"<[I2@,91%*>(7#\ )R,1Z2#2RA@[HFQB22JP8,HT'R<T%QV+%]P
M.Q=NIPY?8*%"L )YY3#B2DMDI8T(_L^ED$(1G,?^-0TK9O618G<!X7N!YR+A
M.1V8FV"IP1P934R&)T'6<HHD8UXEYKC1;F.+79^.L1)L/H5=^8/!4>R-M^0;
M/XVC\I^;C4X<E!WZNL?F%Y5(5XJ-LDSWNYWNY:*CPE_WX2\_';,'3(0ETB(I
M8VZ,G[?Z(M.(268%\93($,"]T-?W!^Y.8&5KH+Y; PL/V0M4%PK5J0B>"RYE
MSOR3@#5$\$HC9QA!$-)9[R76TN63F/-/RBQXK;&1763-?T'N0R)WJL*?4>J3
M%$AZ$Q&/2B$;-4/82D^HU1#*YR;W=)XHH8"VOD9VN?OO!<<+Q?%4L.]%TH*+
MD.M9(=C71B&-HT->!$XMO.:ES75Q?&$]D-9Q%WZMFQVX"$B+C=->]W.KGV$-
MOYXG$P;VZUP=),N!I]JE&6;:TS@_Y_2RUSUY#G?4Z@QAF0\N.F/\5NG.Z'.'
M65=VO@YZ%B35ZMC>V>X@GO2!EO.S]+K5+*%2&74O3OXXG< @C%BFJ46$6(%X
M;E+CDDI($9*TU\Z1D$9M%/@BLK!/ZO3D8V>2%?50*$Q2'R:9[G$)HD])$L1X
MX(C+1)&V7B"6I 7M2."0<8C22%/BA^S%\.A8Y D0R8H:,10BJ1&13%P2!L9#
M)\V!.7)#!U (9+W4B%@3/),T<)M&#1V(*BY)(9-Z-'0H9%(?,IDN,"$:RP#L
M8;C/9"(",N">(DL<%5PYCHV&^$:P)J'KT"*J+K-+ZIZ-^N,A,E E8[^Z8R9C
MUARGX7^+G9A:A1EG8\9/TYD?120(A GD C,0KRF.G#$&:>$)CL$'@?W&EIE[
M%%O96:LO3A_@Q$G!Z2)P.I57L59+G ^A"\<UXI18!)ZMS75FB6N!:1)54YB"
MT\>+TP4D2 I.'P2G$WN:!$M*1X)2TAAQK!4R>1JB8-R0()3F*6YLT=*\Z3$#
M]0'.FA2@+@*H4RD!$GTRDC,$E,H1MY$APZ-"1& <B2921KRQ14B=/-]2A'(W
MJ.['0:/=[9<RDY6G85=49O)'KPOT6-KISDJ1Q]O3N0%A@E-<)825C(@++)")
M#B@R4.I=\L3A,*H*$?0Z3=8O:UJP_Q0*0PKV[XW]Z7P#)I0HI9&P7" N'44F
M28N49C(R9;%2:E3'479?"_1K4LI1H']_Z$]UH I,<BLY@O U%^AKAPS3 BD0
M4W+,>)'"J/*"B^MIC(+])X[]%55>%.S?&_M361'M@Q $''WGI0*S+S'22=A\
MW,X$KSR$ V94*$%OF%)</^R70HF[ 7P[' ]'[68;W=3HQ1#CB77MV.A<JD5J
MM,;%2*5\8BW*)Z;Y,[6^QH"^Q5[W*G7NQ\&D;FU[,.BUW'"0I7_8?7.A":4H
M;0%<NS.=7DDL$F("1\DD"+%2=,BE(!"S*;@<+U.<-K;^S[\T)?37&F6A"]!K
MF"F9P5,J<%\>W*<R*HJ;Q%/22%I*$?>)YDHKB[0FE.* G2'@6LDFJ&7I8/ X
M<;[<_J$%YTO$^<2L<V4EUY:C(+1!G'"#' 4#+Y@47"D7@@[5W)^"\\>*\^6V
M*BDX7Q[.IU(ECFO&O:#(6JP YYHBG8Q#0D6,I5?$.Y7MN:X+SDOUR&S5(PT[
MA:7&H-MX-;2]8#N#QG^B;0^.F@V W28LY<E)-]]DUW\ZZK9#[#U@W<G#)IYK
MUX;V?QXLH3@#>.IN;5948W/9['RVK?;(YCRO\/!V"@XO6NWA((9B;&8R-KO3
MN2(FI95*"Q13D(BKJ)#3G(&Q(9Q@+R&<E,M.+CZLTOQF^RU?5.;^*B,XJ(EG
M%C&;^R7RF-NK6XE8B@YK80,A]O;JK378VRDFM9C4^B9DBTFM(S].=X(F."5+
M".(V;W ;Y\&D!H54BH$;%JRS=-G'*(M)K;7*>,&UM1YT1$K0&\T= A$GY'B2
MG@E&9-0;6TK=6!19+&JQJ$_7HJZH(K18U >GQTG$@3FUW :,8O0)+*KT2$N;
MD)5&LH"%E&8VBUI[I2D6=4Z5$4Z!3$%'I-<>@?XP9)T(2))D$L,<*T5RK3%O
MJAMJC8M)+2;UZ9K4%15:%Y/ZT/PXM<G( TW8:HHDE@XB52O F@80*',NUQ.8
M9,6R6Q,4DUIKE?$J^J 3V-#@ N(XEYB!I)$WQ+*8'(DZ;FP1B9OXAA+^-3"I
MI:9_QGWLT]AK](]L+]Y_1[O9<!F7#=L)C3"B]8<[ O"COYO2, 8Z%+K#_#A/
MP=N9?0'6V-WY(_;>9JU=[,XEO75TVX[M=6#=^N??>]D2X6*)[F")]J9W('40
ME#%MD 1G!9P7ZI!5S"(B%$N6>A?SI*<ZJ\!5#[8HP<Q*$$P>N<DMDM;IO,V2
M"^; .TF&!V]YXH8K<$<V\4+WH&<FRA47SQ:35TS>[7PWY\YB,7D/RW;3;5,,
M4V#G) J^2H&3B"!$#PA;ET_Y6"Y!-/<Q>4M3@6+RYE8"S\"R)2Q0XHP@SDU
M1C**F//*,ZE!+!"!XTVUT/"[F+QB\AZ/R9MSZZ^8O =FNXF#'QFA(5"%5*Y/
MY@[^L=I0Y'T(47MFHS3W,GE+4X%B\N97 L-,DB%O^*N(.!$:.9 ?BH);1S4A
MRN5I79OD^DSG8O**R2LF;_ZMN6+R'I;MIG=E/3/8:H94-![QB!DX^(&!*GE.
MP39Q8OR]3-[25*"8O+F50-DHJ T460K6CN?2<>M<0MH[!2X/5UR*G-B4ZYG8
M+*>%[\;T_U2_Q( L/)G]&$<[K?W&L!]#H]7)FZFGPT'NG=:I[7[LXCM?CL1Z
MDV[.Z>/4S]3?2O,C17C8IFX_*+LY5\[MD6[N#T]<[!VD,?M7EJ!_,!ST!Z!'
ML.RE[&8F<_#GI1.Z@BO#:4!@GA/B21MD1&[TQ)R.02JC6%I+9;FF):5":TY5
M$9A!J"PC<H[PW/@/G :!'4H$>\6"T89DSP&3)J=W.$<T8R? Q1/U^C5F+N;I
M%L99;B?"PC@/R3A3.U)8&\VL]+GC( 2L'MQ5S7% BJDDK"(6XLRU5)7BR2Q>
M67R2(1*A$(^<YQ[@X,E8!]$MC5@&"'8-S2.!35,(7JQ3L4[+LT[+[9]9*.>!
M*6?B$5-+@N>4HT@E4([B$=F@X1]/K?4LA"!F#IYJH2S%E5FTJ@A/A0]&(9%2
M !-%/+*8,XBEF"4)],09.0J>B"[FJ9BG)9JGY;9]+>;I83EG>JN')\\E%DA(
M11$G!L(G!L3#693687"8^?<.,M1768IY6KBJ*!JM,!QYQ4!!P-T \^0,B@+^
M0P735"@(GF13WJ6?P=I:IVKW\)=J7^M\1VIJ@^_$]CZV.N<WJ"]; 1]S<^J'
M(_SJBL]: _@V_WT30+,).#R*#>OS+I[MG%7;>-T!?%^U>]>IYB%][-EVX]3V
MJM%)@Z/8CQGI(<]IS_:U4YV M0"^1FIU;,>WX.. MT',XY;ZFY?W[>ZU2EO_
M=KU?MM;H0N,59C)O[G;[K:SLSWJQ;0>MS_'7+ZTP.#JWP%-_-?Y>//D3ZV!Q
MP=S=^B?C.\Z:+I>K9M]5*G%ELW;JWWSS%>E&(H6#T(?Z(#F$)S9*R2!0"8(3
MSFS\0',SG=$?'?4F>^<?(W*]:#\AF^ !G]GV%WO6W_CE\K+ FDS+X.KRW;HJ
M*=UG5?0=%F4D&S!?W9ZM9 N\%GOY4W!+MBZWTCCJ9>O]KQ]+!UC^L-K6!U)X
MG@T_8/W?O]BMFR1?%VH<KXFZ46=OK$VX%>%UN>OG%TS\?)J)WU[P[T@^)Z>]
M> 2? _IIY!85C9^&'3L,+?CLS[5_QI]:'; [W2%<(_1OO]WKJC7%CJ**"D>%
M*!=T6WD)\!1M>]J/S\Y_^#6T^J=M>_:LU:GNI?JC7R]?/1?H7'$0JM4:O3WA
MFTT\XIQQH='XF\=O;U9O7?%Z1N]QOLD)O?5MO$GN^9[$]_O+[]TL(9N*WOYV
MN=DG=+/\3I?]0?'=#Y,Y,WS47/OH#9F9$;TM)S5C?L1Y>.26]V)L[,'GCOJ-
M'>#X4'F<;^,I\#K$M@V&FU?CIB>T//OPRBRKLT2%FTI6SM IJ-[+G3<0[J!M
M=WK@I[9P>!$P?:1K4Y1J(4HU9K>KV8>1RULWPBM?N8RO+$WD9FLBM[IN;T_@
MV.-C.=A8CQE3?_2ZJ37(69RZ;&2=[;7.-[+>P]]]PON'[S_M?6L?[;WXD^Z=
MO!,'_[S[\NZ?-ZW]D]_;>\?;7]Y]FVQ*'>2-II-=^ S\_L]?Y.#PS[.#%_ W
MAQ^_O:-OC@\.WYT=O'K??G_\\?I&UC\[]-WQ)_'^U4MXEK_$_HM=O@^_'[S8
M/W[_:D_L'^_R]R=_GQR\:*>],WQ6;6*]Q5\^N("5L=0B)JA!/'F-'+$."9LT
M%MQJP>GMPZ/6>8QMH:/'2D<KFL]3Z.B^=(0OZ,BFR (F!&&//>*!!^1D4DAI
M&PR6T1MO-K84N7'P3F&C.B&VL-%*9YL4-KHO&]$+-@J:DD2=0('RB+BP NEJ
M<DG^G=A$'-9Y: EM\AN*? H=U0FRA8Y6.A>BT-%]Z8A?T!'CQ"0?!(J&.,1-
M3,A%8"<&)*4D!H^7Y [+@C7I#0,?5D)'I;G(W1!\,#B*O:J%R*0\I57-46G\
ME+-R/S>KKB*Y[M!^;;1.3D&HSY;0"*1<XW%=HR[9<(HWJ:@Y)O_J]"(\SK<8
M&A]MJS,&8@/,JSV?:X3  J*^S:54T0][K4$K/F "_4Y'>.[JH*VW%[/(C/-E
M1Z5BXDMU@J-Y5A-M^$^WG9?V%>A$]F<..F\O9+_=:_7AK1?P:^?C'[ ,W; ?
M!P?IT'XM;L\,;L_^VZD4M0R6818Y\E'D+ML1(YW[SA*GA.#.4>SQQI8@K!XN
M3P'[(\GG%B:H!Q-,LL,T,<  \<@K3A'/.U8.*X\B88)JG""VS1/OFHI>[SY<
MN.!1<,&*LJF%"^K!!9/<K/&<JN@I,@Y+Q/-H:1.,1M9%I16-*FBZL46;V*C"
M!>O#!<O-9!8&6#L&F*1##5761$D0 5<0<>(YTKE5B HV6.E"),%D!A"$SGO>
M^A%F1 FI,C#+ASG+,'_9[<&OG08 I!<[_JPQZ,'5VM4IS(8-Q\/^X&1TD+(.
MO8[7D$?KG4P9B__Y6/J'6?BC^]SNA,.)*IQS:>'/!?%G:RJOHEGD05B)E'8)
M06#-D0T,?HK2@O?D-68>HJFY\BHWD]>Z]$%:0]PO-ZU2T%YSM$]R)]AS&;S2
MB/OD$,?&(4><1LP[S9.UC)$ :#?7,R?WZTU3(%]'4U^S]$EAAI4QPR23(A,5
M-#*)I, ,<6JKK"I!B4.$I1FE7F9F:!)3/($UHH7E9E(*WFN.]TG>A&L(\;C*
M';^Y0)P9BIQ( 4EN(!Z@D1IL-[8HNU[1NCI/8$%U*]5WLW'M24VK5=F=ZL'N
M<E[\(5/+=SY$OB9L6>]\2>;"0GSW(;[ILXXJQ"!]) A;$1#72N:SCARQQ(FR
M26O+S,:67,0YQUEZ+*S+;M)3AGS-2E *']R?#R8ID1 XPXXR%(,R^;"A1\9B
MB;0PGG 2!8XN!SZ"+>"L86&$Q\4(-<ND%$:X/R-,I4*DH4SJ@(++&R&"2V24
M2XA$Z;$C5!(A-[98$T*DP@A/@1'6KARE\,#]>6"2(E'1)P]B0T%$C;CR EE"
M!?PJ:$A:6$]D+BU18N[MDF6105WJ3NI^$N]RB^@Y.V+]( /]H[^;CTWKE-2:
M\0CVS,]?;RNR!KVT;C EYV8$?FL/\U+_T>U5J?JI6?:'W?UN)]]_K]N&Y_ZX
MFUM$QOZ@F)X93,_!\ZDD%3=>>"<8XL19Q*UTR&KED8HB1$,Y@P_DAERZ2<3U
MNL:9]^-JXX06JBQ4N1Y)N4*5*Z7*2?XN49F8#@DI+3UXZ50B#9XY$L18QX,D
M$9.-+07A.IXG7"],69ARS9ER1<G*PI0K9<I)7A.+A%/*I^.DIOFP7$0F.(SR
M%%TN,;>1L=S(3#05GZ>16:'*0I5K3I4KZH]6J'*E5#E)_09KA4J2H2A9+A*)
M>0LH6"2Y,T():8FRN<D:;G(]S\GB95%E73H^K5?>]U*M7<-.(:XQZ#9Z,<1X
M4OW6N02_:DQLQE\]FD ]G3'M#Y)'G:;OU/H: _H6>]W[[,05YGX@YI[N$Q6Y
MLD&&@!@H-N(Q6J03]HA@SE66>K1^8^O__$M30G]=_+;= PW8+K2Q=DG%!6_C
M%_)X,/*8Y!*)"2EB+)!41.>3$0[E4<\@8TF],\: I#>V9!//E4HLK/%(66,!
M";;"&NO"&I.\6J8,Q@E'@0:!>" 46>(X(H9CD0CE(:A<)\0*:Q366(>2P<(:
M#\8:DQ03Q*-6"FX1P^!F<)W/'8@\8"0DB:U1"6*5[&OH]6"-4EEXW\K":XFE
M5T/;"[8S:/PGVO;@J-D A&ZNO/YPM/(WJ4_9(%G8 CT>JU:_"L9BJF89.7.X
M/=AKX:^5N=K^0)7TQAJ&E!6Y;Q#C".(<CK3%ED.@(UG$BZ]'7 "BUF-ON7!K
MX=:U+GDLW#HCM^X_O^!69X,E-(+[[Z5 G,L(M"HTHBEP;3QA-O&-+6466L!8
MJ+50:Z'6=:B1+-0Z*[5.W%:5>]OZJ)#S*2">*W@L"PP1*4W0#*>J.3@CNHD7
M6/%8N+5P:^'6=2BJ+-PZ([<>3-Q63(AVP*Z(:<]S/^& '-,"6>=HU,98@7DN
MD51-NL 2R15R:Y7A_J7*TIZG8:>2T">V]['5.;\_?9G0?,S;)0\'T>J*SUH#
M^#;_?=#2#-K#H]BP/O<5M)VS7+#8Z0[@^VP/7NY4U8L?>[;=.+6]T;#9H]B/
M&<H!,!2SA>E4JVL'\$MJ=6S'M^#C_0&\4,UKN)*LOM<J;?W;]7[96J,+C5>8
MR;P!T>VWLIH_Z\7<RO1S_/5+*PR.SNL7I_YJ_+UX\B?6P>(.![?_R?B.LZ++
MY:K9=Y5*7MFAF/HWWWQ%KY%(X5@(U ?)P7FV44H&;G00G'!FXP<J-L[_Z*@W
MV=_Y&)'K1?L)V00/^,RVO]BS_L8OEY<%UF1\0YQNJKSE<W4%;Y?C-6DN?U75
MC:MZXUY0XU8EO*?NUN5IGU]PS/-ICGE[P2R9CMY,ZJXO[TDWSC>E@<7R'W7]
MIZ-N&XQ"ORKW5+\V=OX[; W.&C\-.W886G#IGVN_)#^U.D# W2%<(_2;C?C5
MQVS=CC)9P^K8VY_@.K--,<=HZ,]HR_&"BBH#"@_6MJ?]^.S\AU]#JW_:MF?/
M6IWJ]JH_^O7RU3/:KAC/:@%';T^ N(E'8!QO%(^_>?SV9O76%8=@]!ZCFT+J
M6]_&F^36][YW6;6I^?VN^OWWF##E7LN]+OQ>]2;1?$WN=9W6%>Y5W&U=?U#F
M\L-B.&:N??:&!,C(XBPGT-<_,D-X%#+T8FSLP>>.^HT=L-)@8,$0Q1,7>PV&
MFXV<#;T4TXU7ZHI[3-G(\-QS]38:O>Z7:V6%ET+#R\'?[6'A]RJ/EIAGN=OR
M_]CGN4LK^!\NQ:T+;V:XR%KH\_/NR4FW,SKN4WF*-Y_\6>PJ/EGUW89;S<&M
M;3>J0.0/VPH('-OJE^?V-&<NOK?TMZ]:$<,L8O!^>#)L5S'5:+;$2 "72A)W
MQX=>7_]HP$01RD*$,B:>+(AI^50OO(BIY5O?Y?8BA<7X-UV@H._D#.[@VA Z
MIVLS^T?O)YAUD\W;G.SHSV.:[ZK[3VI9MT^ZP\Y=_,8;5VX%'246O$KF3AN<
MO]FV[?C8L%7N\?=A)XX(^UK,<ZDN?X;S&-\AS15OCM]M@>Z^-S[;LZ\(.W=[
MZ%EVO0D+&!O)B1+<:V^4\#)%DJ)@*E#S8;<J)))SG>HZC">GW9[MG8VLU7/;
MZ^6-O1'$[],ZJ%^;K?']M^.M\>./]-WQ;ZW]0R_>??O[Y/WQG^S=X?O6_JL=
M_.[DY='^/WO?X.^^O3_9;T^VQM]]V:<[_-WA)[BGO_B[;W_"9WYOO7_Q=WL?
MKI>WU??I7U_WZ%_DVM;X\39<_^CHX'#GR_[AT?'^BSVR=_+[IWVXS[R]_A[>
M?W^X\^W]X=]I[VR\+5ZU67,41X<]2DESQ+&-R#$K$:?,$9<U0(B-+6&:_(9Z
MS@7WC7\$!T)GY<?UX8IJ$Z=_A2Z\(UI;QQASD0>/M3->5*/)@@;:T#?3Q>[^
MRYGX8N12'0P'_8'MY/6\@#LN<+\+W+]-3G\G"^JC+(J4.L1=XLAZ%5 *(0B1
MC%11Y*,QI$FE:)*GA?GB!Q4_:"YBNSY5>#I&'WD[Q569C;O(!7>!")@.,8&K
M$A7B/!)DF*?(D60Y_*239<!=A;$*8SU!QG+!*4! E%IIKG34/B@L&(Y!!2LP
M64CD5NAL7CICDY8:1&/!C4 D)(&X!R8S/&%@-RHXCB)2&:I1GD8U.9E[LGFA
MM4)K=7GH61)2,@CIP!?#'G//O79,1N:--$%2F6AQQ);%7&+BB+'@*><6"<H]
MXD;G9D V(8J5%Y(3AYG;V&*L4%:AK,="6;,<'?,&HD;CX-$5XT(R0WCB!L(4
M$S25_CNNV'U.C!5FFSL;#JQV?E",J$!<9 8%SC1PFV.Y=XQ 4C*O,,$67+.-
M+8U-DVG]@ .5"[<5;JNA.Z89#WF>L!/1<N^BEM0G1X)W%O@NNA)EUH31SBX8
MC6M+-4\6R:@MXMAK9(P,",N8J,<T>4$WMI3632S%6KAL/ZCF.#\!!(\1O\^$
MY9/ED_<N$7J@EJ 4;])E= "]FVG8[?>'5451-\&JY"ITN %@Y\;P%'Z,7V//
MM_K5NZ.7NZ>9-7XT?_Q[>^HW+.MZ[)R/IW3,2)@W:]$JVZD\;BG-5M^@?8A2
M$I(BX=QKI:-(A"N#59)"4O&#OJ S%SID#&7(Q?!BV,LU4/",W3"J?ZC>/!CA
M:V<,O% J(69PC/;?3E5"6$>-=QPC2:E /!F#G%("B42=(XJS1,+&%A6J*=C<
M;E%!>>'B(J4YXDX3=.9=J95SW&&KG;51.Q:Y9(%&/.-HM/OQ\-^V/8S?I^$2
MG]Z)AB>[H(SI% WE*"9.$8?@$9F0&**42Q(,"5KZO LJU?6V3 7>M89W(>$B
MI2*EY:=H%SM%M)C*U9K*Z52N ;$*[A,"B3+$F2;(,A$@A.$X:JVYMK9^QK(N
MXYSKE5G[._8'N25&-S7R$:9>R^>#U./D&J![GAS:#0NX'C1W/V-TL[ZLR^FA
M]9/2^N;0WEP@K?K8]A?;"U5[W9?=7HJMP;"Z_9)2N[N!:DVEU(R*A&$6D7$L
M(>ZQ0R!,@9P(F/*DA$W9/&'<E/3ZW)T"^EJ#OE!SD5*14I%2D5*14I%2#6?)
MUC:\O50W<EXR$AK1]MIGI5"D9%R+E(J4BI0>LY26N]$_R@=]/)I];V(GFZ2R
M03%+_F?Z1+,(1C,N-?)*>L0Q9RB?"D".8.89(U9BO;%%YCX76.!;2+9(J4AI
M':6TW(W\8@J7:@JG]^J94-Q;@Y$+).5#\@09+"QBTAEEE>3!LYH9PW*NJGQR
MX9]<4/5'I="43*6XIE)E5U->=2+\0_L5KG5J6Z%1S5>,H3'H-CKQ?"Q:/PX&
M[6I>W!U*04I&M^3=BY2*E(J4'I649FDNL]R3,-OA>-@?5--,WXRLUV$7+-H_
MK<%1;M  R_RRVZMJJWZS$#7DX3RQT[?Y(4KP,$/P<#!])H8FHB!RP$@J :&#
M= J9Y!**6#MJ2%2&ZHTMU23F>E? F3O0%) 7*BY2*E):*RG-8C"7>QZF&,RE
M&<SI;)LT$1/%*=)24<0=(<A%Q9#7*0D3C8C4U\ID+JAJ:(16>G-:I$: K7+,
MR&65S_5 %SI_K\S&VB;_RQ9-D5*14I'2TY'2.B0V#KO;X7SB<Y[UO-L9#WFN
MW#1WU4U[$_\[;/5;@_@V]CZW?!SMI+Z)OONQ4UVEVE0MSMPL'2L/MP?[4QTK
MDW(84XJD3A9QH7UVZP)**B3*&"=*J8TM)IJ8R!IMGQ9"*+1=I%2D5$?CNK(D
M2#&N=3"N>X=[@U&3^^T/QGGEC)6("*'!NLJ -!=@9[57C&+BJ= UM*ZE.*E\
MLM;%26N0A3L8',5>E7_KQ2.@W-;GV&AW^_UF58_438V!_=IHG9P"V$O)4=GU
M*5(J4BI2*E(J4EJ'?6XG+%::.VV4XXXJJT0(+E@=L(HVZ3N$>!?CQRZ'<Y7;
M\'S::]CM@!,17X/K4'7/.K1?2T@V4TBV.SB8S!SSP4E#-8$0C 3$B8H(XC.*
M$K:,Q\ A>.<;6Y)>#\=*M5==D5OX=1VDM.0ZHL*OR^/7Z907DX13JS#R3+"<
MZ$K(8L%1, (;([ST@M6(8)]8;1"H>)6%*+5 98NE2*E(J4BI2*E(J4BI2&DQ
M@8OB3CB.$S'*<T>=EB)J)[WFQ'!B9PI<9B@"^*/73:U!CF%*[#)3[ )QR^@D
MX&B[/DH0H!-(@H005]XBG2Q#5G$2DJ :$YJ;JJNFF"M^*0BN+X(7F7HH"%X.
M@B?9!V=B2E0;1",QB OXQX@\;M3HY&,(%&M>,P2O8&3/2D#XFVU7TZUM/U<_
MO(VG@WCB8F_D_##<;&0XW=RC^$=+X;J]$'MH](C/& @B=(>N'1OYH<[?'71/
MGV49];OM5AB]\T,FJUOZYG]F39$M9&5JS>TS4'O4'(A<8D:\Y(1(AVE(D5J>
MM$[,^@^["ZC'/(PGI]V>[9WM_'?8&IP]M[W>&:SD]@E(9[#;\>UA7M@_NKU\
MM]N#0:_EA@,+(CGL[G<[^7Y[W38\YL==N//<HJ@8A-D,PI]C8S">XB:2C%P@
MP(,'>Q "F )+$2.68F>=<\IM; G3!.5:T)2<14!NC3:B'HQ[UX=I;AS%%:FB
M''0M86ZY2$DK@5EDC 6+573A9K*9>0)7]=4'PT%_8#MY/<M$K5G)8G(6BF#-
M@N<2<685XC0*9!*E*&A'.!;"$Y/G(V/2E)0UJ9A[\./C88SBH14/;1$>VKU(
M<])]]])@PMP#)/;Z(S^L.%$S\N+^Q(G"TBEM%476.(UX-!Q993S2( +J9>#8
M!.#%PH:%#0L;+I -N7 Q<LH-"9$GX36-P427 N:<>"T6$J\6JIR?*J>FANOH
M)$@(.3!AX$<ZBIP3$C'KE4C$<.%=-36<RJ:Y(0-9*+-09J',.;9O(K8LAL2-
M")K'O'N7L(LI$F6QQ]K>SIFW%(P6?IR;'Z?*[XTW5G/__[/WK4UM)%G:?T7!
MNQ]F(Y3NO%_L#2+<-NYE8P"W37>'_:4C+R=-N87$E"3;^->_F26!)"XV0@)*
MD#,Q'E"5BJH\=9Y\SIV@R!,T<LP=,LYCI,!0G?8Y27W(_KC+HQJ6S@XMH%A
ML8#BI-T3EMZ[ ,HD!A*Q=@Y'C2.6(+F,!M\ % NCO%>GY%Q2"HE N:0**1H)
MXI:K'-*V2!@!U@HJN(2M;4,2H22\P&:!S0*;:VJ2)X@4UH$/R> .G%E*(K6$
M9!L/$JTLYG=;P'(N_X<I;+CVR'.>^"5-1KA)_T'*I-^MMD(ZN[6=SNFF8X_
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MG:LX#X'YH#QR))N86F#DG+?(4BL<90);VBX5?V+91P>C(ZB;O*,:CJ _K+Y
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M\Z*7!8NY9H \,!N2R6<2Z4=<"H,LT8 <T*",39Q/BZUM8[II#^D2O:Y"]T<
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ME3+DM%<(.^,A>&:\M!.[I>J/(;S,5@>-%@B1# @8SA38)"!K+.84:Z<MW>I
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M.KA2*3^@4U>_2?ONM;=F=&G&".MNP<[;1AZK%\#A,Q3"CP_4A$>?]T]DE,2
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MCB96!0V2Z[O@X[:,JM*$&#&:U3W+8JS-@<]-[Z':Z6BNAL%VE?=V[[5-;!:
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MDXV <8"2Z@$CHJUL::R+!*0K:MI\@;J\(A>,&L"S3EA@I*+IB2"X/#8W&<6
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MQ3I-6,-/[5.A#--!J_JB7=.DMZ@9P&PX.SJ76##D& H4KJ2SD1O(=AN;;NW
ML#PK:^%CG=7%M;IR.(?=6=5H362)Y8[49"V[]A]P2TNQTM]>HA=LR'=?NQO/
M0Y00KURCCY%[7;M-=2U_-45>[ZY(8^P-,,*L3="[U+94:];98+544YTC:B%J
MKPBM;WX@).>FXP73>5KE<NI0.Z9:ZBQ6:_!4C6R7LP?P])F7!NFHHY"G@-5
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MOD>SCP)JE[9 V[3?X6<Z5=%5J1H_YO8Q$*9@N[5,KSD1N!WLH]V<MKF4-O.
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MVG+3S[;#5OOBLU?AMOUK'8\Y>['GI1]^M@WL75+N[OSXO<T/C%\C+>QM[PF
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MX"RF(2,RYWE!!&4L#92,:1XP$HH\$J@:PSQ(M&K$'[ZHDZPK67E3[7,-=9W
M.9AK7K"L<&_ZMGUK90IKB$XR%J5 ?^JGV#^$ *CS69SFON 4H%Z6QS1-GSPM
M+FMOB!)I*Q.8>,G7Y8.#HY?78H33LRU(2H=:&Y?XVW7N"QX=!_SY^20-8A"$
M"JP]$B4^B<'B FP5^5E(6)KE69*&T9.G))B (%IG@LU14CW#9RM/F!CKN#4N
MA47(/.2!"DF8IU0E1*A,!45:%'%$L+GT%E:X#G@^/I^#/796+OYHVT6TQ^Y'
MC^[<^><3$E)):,K]A$3,)SG Z2(KE)_!20@19DHP\N1ILG[F_XW>54/,UJ,R
MV9@KWB7T;P8]VHF+>$7>3(](AC,HF.0Q2 R5A30%:4*R""!VFA1%MIE7;J@^
M7DD!2@^1ZA$VYM%]9W#HC],BAL_P4R;]_U^84O=XE<GG=^<G(4\H)V'A,Y90
MGPCX"6<$@'%64+C/F<A2L*Q(^'6UB50DCV*:)!SCG[$H: 8")))1P1)0+LE.
MFWPS%HA/@/ Q [O53SEV)R&,^#0+E2^C1.:9B -*@EMI$Y0BQI:XF5ZYG:S8
MZ97;N6?VXY,D(DI&8>"+6"B?1('RF<R%+^"_/$M$GH?I%^H5/1/QGZNYM%Y1
MM*IGIFNU==DO3>$,^D&U.]?D.H,8KQ?5<'3A6&'95*:/79.4:]96F6[6H.9<
M@RO\Q&O):[G$UF:H]Y9V(?HO[A_/P<0];WWA-]['8.@K!D/FITT7US#:MTMJ
MHV"S5[5V+6S);P/#^&;BEXD(P'R212$/P7Z(J(RB*$Q5%,=Q06ANIH($Z; 5
M]W6E;M>+&]>HTR"-O-UO=_)H!>[AFX/SPS]/<A&$,@ ,)T,]$X0'H' CXHLD
M)%G&\@Q@_).G>8$B]U*Q:YL,VNYD-S3I$B&X2%7...#)3%(0L44N<Q+$B0@3
ML>.".^2"BZ,_3T)2%$6./=<3&6!+4 78JR"@@@7JORR*90Y<$%S)!5A\@W$P
M;W\H&% BW9 G1%*H%*!?$0>$YU$1I5+Q+&<J2O.<93N>N$.>B [/3X0J8JK"
MW,_B B1#%!5^(>"?@A2@HS.I: PFWM6"H66)W[R?L"_RQPJ%Q,\#_OC5^+<[
M_7(S7@D#)B7/PB*0#!::@]4?@$0I,OA])//TZ_#*'[7M,;-CER&['%X<G9ZD
M%&!;'J=^D-/$)T&: [O0U,\E23B)520B=5T1\EK6F+VPCVD<MJV/9I,]K+<?
MY'#? O&8,A^=\SR&+V=R.NYN=X43PO8FM:%_NQ#YR624B%O8HVG,HHC'BLN"
MP44#8H9IBMWI)0C!H/A"0 1FZ"8N/M!9-&\7U?Q9FWIPK'JR\1$S]]O@:/\D
M"E*F* ?AES,T3*/ +U0L_#!.@A14)T\3\>1I>'N^WN_G]&D.'4;@-K/A#?JS
M/_IJ[F)7S?W=E_(-J[FOS($8SQ,141*#[9DH@! %ER!R"Y;2M(C1.LKNU5R0
MRSM*.=6DE=D-E4^1<MAK3&@*I&(Q *D\$TE* @FF6:KN#D<9#?2(U<R[$(SQ
MD-* RCCRP0S&,;T!F&%@]& \%7Z;15G*TB=/;W:FN2JHHF%(8Q63B*5Y"/=!
MA$RHK%" EW=G>K=GFM(@ =R6^2I18$:E8%H7(?R41WF8Q2Q6>1 ZG_9&_' [
M0('N0%>V=\D'3=-.3*&:NJQGW?>R[1/5N#YPM<4<EX;:7#GZB <C0$T1+\ P
M8 %A)&&$T5#(1(3P0\*%G;R7NLE[FYCQ,GY[;A?["M8(2WB.(]OJ?9UP^XC9
MC\?'?YZ $0RV& M\0;GT29*F@&P(]4'-BI@019)<3WH.DG4^ZXI#2Z4!Z/F9
MQ-&^8.[4-_9PC]WN-_AJWS&@,;"M=MGXX397;7O;MT$EL,GGOIE,S7B<1RR)
M*>.2I"%EA$L6!043.04,47QUW]0SD]5GY"JVX:T_2O&RJE_JX5 '-O_[\?+Z
M^_U/(&H9C>* 1\Q78$7[)$R8GZ<IL'X01'F:T"(/$Q"UDZ1()DFR@>'7/59#
M]T!;:%W;(] &ODN_UU:<EK5V]JD=6-H.D#;]M3</@[X9 Q8\"Q/..2!;"1<Y
M+[*HB#B3H8@+!6I=,^#:K-_@RURCCUV?O]]/CDY/DC#(L@ADJ:!Q# *52#\/
MX:<XHB&H>07'>F.,]EV.\[AK[O#HSY0&>293[N<\4CXI:.#3.$+<'09,)'&2
MX6#(.(PG<1Q> Z#=/-H!V(BF(:B/C.:$BXRR M@K!NR8PBLC:C1*& T3#48<
MH,I/4OB?95WM[O)5Y_[B_/#\) 83&A6X'ZDL]\'*Q?'<0>%SQ0&54I$'JKCQ
M7?[&)[F[QNUQ@JF5*D!A8#D#S"5IG/DL5-3/$CC+K$C31*HG3^?5C4RL*Y"
M*T#%F0G=24QZW:BQ=/+F D&!'@#^"RG\?Y*!!8E>F9RF5* )*<FU5,*.C6[*
M1O'1GR>1C(2,0!:D 2,^ 5#ITX(!JB1Q5*09BRA);BH5OO5Q[N0[GF0:%CSF
MB?(9F+EPDF#W,E9$?IJ32"1!DN6ANNE)TAAP7I9*0G)%B* %%6&41\ ;DE-)
M^4Z^W]EQYCRD@*\SOY#8U"^5S&=!!JB-\"(M0L5%(._[<>XN)IXD$#E,(EE@
M$ZK )X(I.$05^7F1<BE8G$1Q=CU-?0M=OG\S7?X-S?H@X*$, #YRP4C*.$N5
M+,"Z!+TA6)K1S5IBYZO_"FQY$!WNGX2<9O _[A.><Q0P8 ?F(4B9E&1AQK(B
M#+,;:_Y"1DK%>4*2F ";494(GH#ZSY(PAX/8+&"^QIGN-$=[L'$8!J'*8S\+
M\L0G$9, Z0CSLX@F81Q':9[PFQ[L][NLNX-M#Y:'81'H@\UC0'@JR7P: T(
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MO?_%:$QY/HQE,EK$!1@-QAB%)*,AR$1\)&3C%1,_N#A^/EY?)X6<@"Z90#M
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M@I"WN=FZ^SJC8VT(OOXB#=$T48YP2/D:B0.,5$:B0'B$_6?6&/#RN=FDFE_
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M>G\HG9O523(C<7+(.1<03S(B&U2N-@8N,XTF!2[ K*:;\-R3@=(;]%&ZO$5
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M=B.(Q]YQ"RZR5D+Q2()F-$5/8O+.1B]-\8Z;B_.=A>B=8-G(!.\X>0'>,0Z
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MW]8<WU:2$UR,N < N84&)));:YDB*%K)$>@EC1RF'"G)<$I&$VM6=XY:0*Z
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M/^?SVUY81MM9"E_!T]OAZ3Q>++4"W.092KW.!1(E,E)CI(FSD1HE:4XLK@,
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M/[R;LL8Z_&-QT"/+"T2"I?0I:)8\#\&9W*2#2Z\T9B&96_4E;O("]Z6ZT[Q
M5%(Q"I;7B9P7""&"Y74&!:4)#L1PI_"SYWQCJ27'C^4%KLZ3W8Z?5E=U)^N<
M%R@4M2N.TEU0RO4#:8$[Y/?^,1:;1^V9&$&DL"[Z$# /X)M0DJ@EQ.CH(DM-
MJ<?: =SVR]E2#TJ#X=0BD0#6.+$4&?!#P$&)DFFGN=3@FQ#9-G=6ZK$VW%8-
M -Q)NN&A$:!)-]P))DS3#;!R"CONP-^A&##!*&2]EXA9ZYR16&H7<[RBM?[Q
MJHH&#=8?#1X1&#2)BALK_C1103P-"7.,O+8"\<0CTD1&Q"CS-BG/$]7@#+ V
M-LN:_T2<@=O>X[[WAM?C $[N\WWE(9QU.N;1W&,][_'4CM],6G;^C',W-_%E
M?FUW!5XN,.VYPS%P\%D<\5$:*@63C&KC[L1=N:*+V.OO-9?!N#M>X\#<P(&!
M\9]L=O#WXL2\V N12BUT0AY6%'&>('8QA""BG?0A9^.Y+UNE/UX#L<8UF+^F
M7A<N'?I'LTSKO4P-_#XQ^-V:PJ^)3#II)$I" _SZ?'+0<H^,)0#*5L> R:\/
MOP\<(SX:)W?:#O@G1H)/OG;H7E)R#7C>"CQ?S_JNSEC&\ODA;S,O%K<,V4 ]
M8AH6$$?EE< Y[TY-4[_[V/3U=KYKLTP-K#:P>AM8G?%)+5>&&4;RK@9#G(2$
M-+$.:16X@<5++I)?'U8?./'ZP[5KW*Q1_['+2M<NZ0?_\XK5KKG-5G=M9R"3
MH3_* QO/RH]M6:]=9''C=@)W.$&-A;LF!]S*4KYWO28=\R.F[]UL1*%M( YK
M@JBF G&=J_N8-DB8$+DTAG'/GCVGI*W5'5?WW8$BK7F/E092&TAMBB6?*LAN
MO9SFO)W56$N,F+06<48"L@IC9'0(,6G*(Q=W72[9P&L#KT\%7M<-75>4G#9.
MZP_CZ=1IC0HSBXE 3FO 4ZPYTL3K[+E:;Z42)K,W$M4V*P#UB3NM=[,%^<]"
M]?;\AF1S"^Q]#=E<0S;W:/G;'M5@&[*Y.Z+@&)-OML:\FPW77,,UMWXSV7#-
M-5QS:S>/#==<\\@??V1#F':EHC6$:0UA6D.8UMQCW>_QU$YL-H1I#>_'K3<N
M<"1!*6PQ#Y;+A!UGU&&J>7+$2*_*Q@4FE)&FB]85FQ:'[S!\Q[:./AQL?O[0
MV=YY?[[]ZCT\ZSW]\ODUC.%#=_O5GU^_['0[BYL6\"R\N^/IE[>OOW]Y^TYL
MO=J$9\![O?K2W=WY=V?K[2>^^1:N__Q7VOHXTT4+8R*T=A$YJASB@GCD@I)(
M&>Z\#()B'1K"M :5UN'=;E*M\M"P]$M7J]P?4$U;>_FD2"(X(,*51=P3C2P!
MH"(LB&1B8([%?#Z32=40IC40U3A.3Z;?V/VAT;3?6)#&ZJ@)PD%RQ'/1G-8\
M(I-,XE%IPU5NUH';@IA?SVVZH],TCZPS.J7),.*IE\ESK[3%V#C!P6].7'CE
M2V=T/.Z,7FMNTQE]371WVAG=1\\D<11Y'<&34($AK2 ""E82D6!-/2^,:?H^
M&-,>39)H->M9T__@9[H($)F+%(*V@EAN2738*^= 3GEDX"Z8)K>R=D S2T:/
M(RR2M!HYDSSBVB2D!9$H",^H(@H;C1M6L\>IQ3<B;W]@-6YR$7>BV#.Y"&X\
MP1IT6C**N \$&:X34C[19$&KB2BL9E@VK&:/2*<?D4HWP?N-U9?.4",)H4V0
M2+B8$$\"(XN%0#%81K PFD;U[#EO8]:PFOTBL;O@GB5"G<&><FJ9C1+B=^J"
MHM8[(9K8?9U5=QJ[.QXDY9HAJK5!7&".C \181>T",(Y 0OWG&^8AM6L835[
MDC0F2D?N(\5!)LNY,T8+$1)@G59,">N:G,': =PL$[KA)KA<A2$MR0Q&22'-
M"$'>97O%98*_-*QF3PX ;I)N>&@$:-(-=X()TW2#5<1I0SC"-#'$J>>9&2 A
MZQ2L-29!)_GL.6US1AI6LZ> !H\(#)I$Q8T5?YJHL(X&!_J-(E8!%%\0Y'+>
M FR_,EQKQRT&9X"WA1!/U1EH6,T:5K/F'LT9F9]L<AM6LWMQ5[@0V#LBJ)"*
MZT"M-LXH@3G37CA.[L1=>9JT.O?DP&S/GBZ)X&8JG3"20CO$I:9(>RH02<)2
MI; 2PO[ZI#J_IE8WG&:/8ID:\'U:X#N-'KW$)A";4/#.(DY$0-8&@RS'VO#@
M8N+LUP??AM&L831;'XB]EW1< YVW@,X%-EZ2/,-$)!25B8@[JI'3+*+($Q9,
M$DQ9PVCV2/6U831[%,O4P.HO JLS';(5@0A#.X8"%Q1QS1QRG >DDI=&,1IP
MQ3CP:\-JPVAV3V5K#:/9&N!XPP^Q[A;NB3&:W9OIF^-(#LJJ8*5$V"6">$P:
M&9G)/!T++GFJHI(-HUD#J0VD-H62#<C>!&1G&,VT9Y1PCA'6A"-N>$0V%U(+
MYYCEN2N+TW==*MG :P.O3P5>UPU=GPZCV7WBZ0P#??3)*.(!175"7(F '$N9
M*](RK2PFG/)GSXEI<W['%:B/'U7O9@MRGM%LZ53CBK]G+>ST1L67F,OAC&DJ
M9,[=](>=4O4YB." @'=2DY#5:CYS5;T0>'J)=3#GHY.++YFA5I,74*O=,WC1
M/$0J%I(^,_\^&$PS7?L1N4&T7Y%-,-C?;??4G@V?_7/^%>']9N=S<2HN?,.4
M;O.&^AHO6,TS &5_4!7T@IC%0?X5#,FNRU!:!X-L'OZC$XD4$/H&ZH/D!!L;
MI628DB X 7B)>^K9\YU"P-=/K9?9LI1^4_;YJD5<$/L:Y\'N!)J2DT%Q%I6C
MQBLM/8DD>)>I&&_+$'@X&IYTTMD#R?%LL) GIRJG0=T<8ZPXJ7MJAZW_O('A
MU@HKRK3VGA&PX/F<@2=:16.(,HG)<E:>8%6=E5_F)!4WLN"S+[.=%NWYQ';+
MQVF[N_%_/YQ]^1R.'>5R>V?W;.M5Z.S2]Z=;1V\.MM["?P^_PK,VP3[OX\VC
MOP[@\\Z7HP]@A_?IGO.),1,-<H&!S37>(1,,F&!M/.:.Q9! 2?#&LNEM@=AU
M\SK;7KC1XK/DM%?"4 >+'[1PP8#Z6&Q]+@B+H6Z44"\^;A;_YRS^U_,]3Y7A
M7&)DI ?7"RN"'(D0V4;L8HJ16DFN6'Q8B=;)081_!C&VCF"=#X:M"% <6A_C
M\4G-&(@+8R!I%UG)B]IN#>+P./KL%G3/VC>6(<L]!3$-1D3)%=. NU(F!S@<
M323"U !"&@#YF3)TN'F^AQ4C,G"&(/#RB+NHD%9!(#"*40&DTTAR">!= D@P
M)I"$67!"<R6=EH(0Z@1)TDD3XD*GE6;Q?\[BOS_=$XK0!-J%0 UE9J..2%,1
M$:BB9LD+PFVF=MA@5P-(#WR0V^+'QKR_=DF3GEOAQKP\?/0',8RZL9\NR;N^
M&9V,!G%6=%Y_/\[$-\7=W('Q_-GM^Z]/36;.]]D>=D)HJRDRQBG$J<V^!Y%(
MZ;PR@!W@ CYK15"K8YCUD\$H7N5$KXW7O -RG/K=;O\T4SW6U-ZC(Q@QW 3$
M&L9V5(A)4Q&/N;.1K5@)R-7>=EU;UHLG"\QCETT2S,C]4HU#G+J!JUCUIESC
MFF](INZ<9!H>J6]'77T%R;36UQO0-?D;'S1]?3UVP=UH!ZW7O3S<UBPO],\A
M7+Q1@=+]$WFN20N[:_)"CGIV% !=PHV((9N9NXQ:] %8-1]F;Z;B,08%RU8J
M.T@_C_KRAZN-'_&6WZI7_&4V[8P@4E@7?0B80^!H*4G4$F)T=)$E7#;MEB-V
M=I.JAV6_>R*YV^"VYY!MM[39_"6V[5ZS[5?O3C??OH:Q;+(O.W#]X2[?I1^.
MMLYWZ>[.7]U-^I[LTM=B:=MNQ_/-PQ>GNSN[YYOGH9L=^:W#@\,O;W?9UN&7
M@\VC3^=?7OW[<'>GFS9G>\A131WU/"(B(T;<4(DL9P$YH[T5DE.3"2ZX62Z!
M>+@2Z_LN;7X(/035H4W[B/6$KSNJZ%K&MBT8W,YI['Z+FR5_TL#:#6!MZ^4,
MK'FOL8G2(.Y%1%SG\\R,4V0),T)@+$"]\GEFPY<9 !_N//.OU6?J0F!CS;GA
M)P9LV4?;.>TW>'83/)MMCA,,"4H*@;R+ H%71I'QDB%#N6)!>!6=O",\:QRU
MF^(9;QRUIXAG>:.\0;2;(-HLX5D@5"HC% HX,,2%M,@FX1 $GU[12#7VI=V7
M$<M[CHV']I,1330>VA-$M#?]49-)NQ&@S6;2N-&:B411$!G&@O7(>1U19$YZ
M3#Q)4F= 4_B'J]\?L8OV8#L>H%&R5)V<',1!+-7:Z\$_TT#=K:%N_^"&*/<B
M+WL#=;> NNW9[)K#7%'M!6(X1,2)U,@H;9$4RACB:5(T9+):?&>MYM?(=WLT
M7?I*6Y.?X<A==5US!/3^)J@Q% WYR,,8A-GT)&4^T!0H$MX3Q+%3F>28HR05
M2T$0SH@"WY>UL=%WY/P^_-'/:QZY7#YB663KZB-M^-G%]:#EK>A,7ZV*(W)R
M@G+<5RM_<N>Z3Z\JLRHUM'JC]9,+N%]%=_*J,_3=_G T6)=:;+;YLE;>HP^@
M/%_9YF'XNOGY$]DZ?P^*N\^WSC_1+X?OR.;.U[/=(U#*5^_/%VNQO[Q]1[=W
M_-D6??_]R\XGMO7JZ^GVJWVVM?/E://PT_?MG;\ZH)08GIG@?M^W7^P)ZA/%
MT2-B!$;<4HUT$@E9K8,46(!2T@IR01AC>)$!4PF:B#;6B,"X@@"66N:QQ5XP
M*C1+B]7;><(O)$N]^&SEU8^9'Q9+&4\448QJSJG/S0&,HD8XZC)E^AJ?Q2QW
M_+T#CE?'7T-'7O9[!6(R;GV,O4Y_T-KJG\3A]<O!UZ=F_ET/QOZMJB"N3G;D
MTR O^T<PEK-69SB$Y;W1Z:!$C'2"@L!XRQ4F%L/B@X<0X/\JQ% WA2 +'H&Z
MD4>01?I=;PCR?02 ^<;Z?-9CU)OZ N;)P<GN7HR:$F<%LLQIP!+#D<$.PCUJ
M<C^.*+W+7&(;Y*+PSM5G@HX'G9[O'-MN/B$!LYJK33LGP]:%4@"K!?)S)X)
M+U_J=[DL.0Y//MB3^/$D'^;X.PYRL;+=G^[J(/K$5A_&<KY'M->4:XRTSAR2
M)A"D'0[(&!6U#=QIEYX]7VZZ^E^MB_"L%48Q@X)J_99!(1]\H?B/\D'YOGQ
M_OC'1BN?O)E^#CY=H2%S^9A"IUZQ]CB-MU*\\N?5M;F?2[G:>C^()W&C];_]
MTPCC:[?RB;-.155=;EGNF#VI_!ZSGQ_9LW(Y#+_?*_>>&9R%ZUH#$)W6,6">
M[8'PEN?%[^"BEB,5]R'G;"8;-B_BF_9[YVAT-"?IU8O/?M2(/8@]!$9[*1C
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M$)& G8XV($]PIM9T"CGK \),2"FY4X[K9\]70,:L%,R+R]1(32S2S/=CI.F
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ME 06RDOO2%-2<&]E;^_.MU_L20^2*F)",>* >/0NM^(PR&DON<.>8FUO6E(
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MG8<%'\1>/-UH@;M?T&)8;=18N' <9,[OC8%$##LE !SC38)5ZN?'CN B\(L
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MPE98(L6SYVS52=S%;=;K'=:Z"#+FTII#<!7&7D]UM*/?0Y.\5[5Q/FS]=CR
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M=AIC=:"T]?=HX _RH>Q;6_-?/TKP1FCO>4A4$6Z#T_D,F/",8>IMY+&QYH\
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MWX&Z?>ELO7W]?7/GJ]@]_W=G^Q4\\VA7;!Y^.-S>^9(V=SZ=;^V\WI/."I8
MHVF 4)KKJ)$622(5I9(V&<(=7>S9J93"43G'+<$\!:>YSF?-$OB(EGJM%GL]
M%0!$9=I;LRMS>1?4E>V_KG[TPE!Y""E1$1P-8."U=583^)^21$0P3U<THEJ;
MJ*':Y-LNS2PR$UCG6^?D;&F^[J?MV42'9M>R#/#_L_?N36TD2_KP5U&PN^^>
M$T'IU/WBV2""&6R6B9_$L0>/ _XAZ@K" GDE,(9/_V9U2R A"9 0($'OB?4
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MA4_4S]E/#'LS:6!U:K@XQ;P]-0R26<(21U;EP2M14.2,HT@Y:[$.VC(J,O<
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MYI]/;>OL'/X_&W) )G#I'5CUS#G4C2&"PIP6K]T%OR)ZM8]E)*74@(T7">2
M.Q\T%2DI'B.#*(#AR79^@K,?[-4B;'KQUW_G6]F&.WF?O&K7GZ_ BU<!<Q/S
M1&@;!.+1YU,RJY#R/FJ'G4L4 ]".,XUF2S:PJMD9.@NV6X/'T[=V8]+B06OZ
MM&B9DO(<U*,&#W3 7?,2PG.'FZ_B,UH .=_7Z\;)SF$(">>' K%@()D(S2 ;
ME$742PK@[).)=&VC!W[5&<K1WY@T3:#(2]W.:2$:(;M'@"]%A%&O??T!:-8'
MPC(T*3RK4P#H+&#'L1W&H6D8M+,XH-8O=-P*(9Y]>#\/ZWK_<G?SD%BPE<%[
MT)5,6N]I0$XRBK#"ELF@.(V^8%+LF^6'J,:B9-RJ!#99*NY5,-09*JP(TAH3
M/9E3.Y\"[__;:8<;G=PJ0*:OIN]-/Z_W?S4W#YF*7JH8D()G@[BA'!EPHY R
M3E+' R<RK&V<7\;VSSB-/S-$> *A<#[.RN.RC."@6P.?Y+)U?MPZJ\!\=84E
M@_GU_J$C,1+G&/+@+0- ! OA;S*(6O"CDR!:,#TCF)<^P9#W>@/;V2V 0+I(
M+9]W6T='$9S.VD7&>%OSQ_FIU4"JL@AU.^U:_M+SDOAW-$Z'-\=N]F(G?.C6
M"UG/[NWE<3PKZ>8*RK':_UV BY^N"D^D<';+B />V1?G\DOA2T*TY\?YA=#J
M6==JM\ZOZO<*N\WP:D(P(DJNF'8@^S*YY"3$'T28B3GN.P(-_GVX:,?=-+=H
M#Y$U%:\52<ERNO'F6?C8S^_O=?*?B@!M#V[@]S;$"^]0 YI;^V BB3-,!<2H
M!!.I9.Z%! WPQIG@)%92CY$ &LZC58*&Y"T7$*!*08CP$I, %[-IK19[WOZ
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M<00+<]GL1_*>/)OHE6?JGSK=_I_R^]X?(<H1V8480@O!X+DA(TFVZ<0@K2S
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MG_C=!R%<@=#K@!"^ 2%"M:2<6L1%Y(@'3I!+PJ#@ 96P4XY@N;;!Z1OD_*A
MZ(V"D/-,<J4 =X3D.'JMN&8&&Q&)P@;K!\HP[Q9R/U"A5"'4<R 4O4$H%RAV
MWD6$<>[R,B8/8DT".6N4X"(((6W11$HJ1ZG"J%7!*)JX4YI0:EW@44?'"/,Z
M$JL4,<G0OJ-$[G&4*HQZ98SB-QB%5?*"1T F&P"CA(K(14]1Y)*EZ*+@E*YM
MD'7"ELF/>F2R\[TDYK[$7K1=?US4*X7X,[8[/W(!W$TUT@QIN1DF%+RQ001W
M<,XXE9PEFC@L>++.*6:,<5P%\,F">ZCUH<*Y5\>YUE#*RAI*F H&X5 ,%8!
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M^<H,48QGR[TQX)>?0<1;"\2!$]<[]G6]48_!K^>SP\D4.(G^G5&6##8^?TV
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M([Q\/1Q.%*YYM9FQZ3=6HV'RNZ'A[H=P9_?;5ZX2.! ":!>& LR(S 19(I*
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M.BI_BE3>>$$DXY2IF 1"A"E0.2<!MYD,XM2$8:+22,D493E_*E3^T'E#E_E
MGHB[HTHSNGT-5?]\C=;]-3.\ZKYKY^7^HJ[RZ^__UY$TCY3SM"AROHM\Z.6-
M+_)MU_BZ*M=.S-Q$S+2:>'V-K8QBD=@@RY0)&,>V6RSF :<DT6&J8Y:8AW8G
MWB_"E.70'<K<%F5XRH2.N DB;E7 0A4&H(3& :%4$J72V AS<2[=SP=L;E(>
M\I2#RYTX_?W$Z2/E['7B]%YY8\L#JRP'DU@%L:0B8-@F12I* ZM39J5.A)7A
MC<3IDT>83IS^),IPK3@CB0DHR^* 91),?CAE4,-"*Q.A*45QFJ8K<T$[:=I)
MT]]7FCY2SFG''.^9.3:Q#BI-:",T+HSE8&O$+)"&14%DDXQ:K1*1W$R>/GF4
MZ12PGT(84(VD!J$)NI>* D8H*&",\@!,41-IFB1N)ACH4OUT12YS)TX[<?K[
MBM-'RIGNQ.D]<T?6$J=6&!:G011IX(ZI!5N#9PRY8Y1E)I&"\AN)TR>/,ITX
M_2F$242:1HS1P$0"]"^F>)#Q4 ;4)D(Q$3*>R;5741+VPQ6Y^,] G#ZES/VG
M%K6^@QZ@=QN_OB)!Z*K[6LA$ 5WT9([;^1V4FIL#X!EK-57_X[L-3)*6I+J\
M1?BBR D[D7.ER-EYTXY(&VYC X:^%EBQ$%H3\#"FH IDA$1&:Q-=8?(_-@(L
MJZD="MP0!0QEFM D#CC1./8Q% %/A0@2F@B34*MLEH'6L1[>:7CYQDSRD?-A
M.W'7B;N+N=U/!@X[;G?/W*X) -(XBZQA6< S$Z)1;@+!5!S8A"=P9CPVFMQ*
MX#T8"G0:ST\A *>&I4K$091A!)BF/) \58$EF34\YB15;G)0>J<6=B?N.G'W
MZXB[GXSK=;SN7GE=*Z"+(\HBJ8/08OM%2N) 9!'V&C(DRB(=9_9VUMV#(4"G
M[_PD"H!"0Z7+,;>Q"AA/HD 2@NG$6N%0)IG&>NT578^B3MQUXJX3=ZNXW4_&
MW3IQ=Z^\KHF?I0F)#(M4$#*1!6"$D0 $G0YH%)*$<=#R,W8K<?=@"-")NY]$
M@4QG1 D+&H^F!,0=HV#=20%X( 6)N; L=,[,Y'DZ,[NRWW,,_8O[P^A P";$
M@?%!U*(WQZ'F^;B<Q(A]SNYRW.*#E@I?JQ?#8@R_G,>X @U_4I5Y>A+]0G[N
M$>%^&[!=D3I3(>=KCYN#.4YAV[$EFW<LO]B9SXH9X!& O4N=N0G?;X\<H#%+
M,P:R'J2P#9CE69#%V):)2FYTDF8IM<\25<[A2)=C]5.($H<TT=C]7<J(88L^
M&_ XE(&-0I52G?$LBK&>-NHS<HT*H!OV[+M[)OW(F<V=:+H[T?2P/0,[?G./
M_*8)-X4\XU0D"GL#J@#$B XX"W60TM3&(HT$F)+/$E$Z'>:N44791)LH3@-F
M&(BF) $=1L@T$,2$B0;K%4S;M5=9UH]CUDFF3C(]G&1ZV#Z7'<.Y5X;3&D4B
M(JT888$A"3"<E)E : X_%!%"4:UU?&.CZ4F@2J?$W"VBQ(K$2F=I$%NK03Q%
M*A ANE8E%9$%+)%9XHVFB'>BJ1--#RB:'K8Y:R>:[I7CM$)YS"J6A'$0)RD)
M6)2!V42![3!J$B%#4)69>):HTHFF.T:4E!@19RQ0*07T $4#1)/, A/#/R2F
MG,0I&$U)/[E.!X)G*YE<8/"?+HY51Z#\W@#Q@ ^KA5C>2$P/\G&U8+XH$7!H
M4&Y/'Y[[$^3^G_*Q,KW9H>F]F8S@_:>]$U%@'$^4L;M)D3M:!U+LB>$0@WGY
M1,,70%8X$%Y7H;F[#/?U\L*MJ0 2[\%ZRI#?'8<4A7\)0& X+W"/$^NW.)G!
MSG(QK&*;\'G[ ;U)PTYZ)Y/Y4/<.Q7?3D\8 W.#.P*TW_V[6>_]:P(H[T-T7
MN=XG=6CT?&AV[&MX;_7:3T;-IW!LIMC\ 7O31K^=3D9O7&16X&GNV.5,B%U8
MU1]#V-SS9(A#\[\?3_>_Z&-)6#+8A6<>?3[;?O>9PGUG@XT/;(^\!:8([X-U
M[FQL1WNCP1#>:7=VMZ*O(9',4 H*-K-1P, 6PQF1*HA!9!$54Z6$]<(M'\]!
MQ*!$"H5)&8X<8DRR--0BX22C.M89Y<I&<+T!&7,,9S6;SLW:JUW -#L9#B<G
M#FN6H^@+^&7^,\^_@WP:SPJX$I#<E,?8LW".#FF!,:GYT!TFHN=]$(@C>7S7
M.9(O*><4T!Y^7\+Y'K!HHV8OSC'$Q7@]?%D"5'C9T.*7)8>B"4Y\*QG0BZG!
M[7XW+T]R/3NLE-?6725[#9M;A"PF")<+;RD9,PJ*9)$K*]SH])&8,DV7@-7Z
M>3AM,D0.3""G1GP+A(7%OA##$W%:K/US<8NPOS8\ET%QX0ZMO<T.^34VZ.$,
M>MQDZL[^!8AX,\6K8$GBJ2RE=SA%+OU?N8F26%*MB=() RXL3))0X,<Z9ICO
M;;Z"PK/KJ L(\0TR>*#;?_U3+&.\^WFA5D"=R;I$%9X7*RHUI]1RGF"[)RO"
M2!MJ%$^)B.*(+;,FEI(0U*_09B)EVEHI2&0E9T2$6&&J+GK/U2QM\3V::YO8
M-&)1G#(EB1 RHR3F8<@D)P1]69[KU 3JU#(XV*$X+LR+ZI>7.B^.A^+T13YV
MY^-N>KD('ISSN*21N:/S7Y=8G67K29HA8I<Y6^6+2YQ?=SB_I&7Z[VBV#H=Y
MX=?A>G3+[S(2W^K.RQ8;D77.TWM8;!+2;K'/:K'9]19T11[CE8ZS&UR:G;MT
MA1?,2]>'<8-E2V(@7>D%VP5N;WK;<-UAT=L$(:#_):?_?/7)',\,>A)Z-.PO
MVZF_$7@&\,E-H/. "-=R#-^@G]+3!C>:>]? MFMM^'<#7'@79/J+PJ9#JCM!
MJI*[+9NK#B)/CN%UKWR(5SZ@P"/1\]0A_CX?B[G.9T;_X[%TA6<+NGS<FQU.
MYO (7=P(>O=1HO0X<>I/WO5^C/X*#! 4<W1$CO6"-[X"S9TN,%F/K['"%9Y*
MY!\!75_ANY"B,-[A]??H'P]0R?1S"/'LDQ9B0XR,>9)*S02V4,^,U9)0%=*$
M<7.WE24_&8EY/8+#^55FRW[XL;.[>;K_;HL.SMX.X;L0KC_<WMB&-7W\!N_\
M,3C;(X,OF^&Y"/7&9KR]^^>WO2-%M[_\-83K,:I]LGWV.1R\^PC[VZ2#(]C'
M[D<[:%><),18HSD+3&1(P$*3!%G,;,!EEL;<9(9:CA.D$[*JX]#5ZG%'@[>B
M0:8TUSH%J*>4I8)G&5,JBY0,+4U-S.XVB;ZCP4>@P2:U/I.Q5)%5@>*8Z2H8
M"WC(HH Q+6EB,QIQMO:*]I.$=#3X<#08VRC.0FQM'E&6 0ER&3*=1)QBI"=,
M[C99N*/!1Z#!)HG8&$IY%IM AHD*&#'X&U,!Z$!6P\F*,&$H!].8=C3X@#28
MT)AQ'/9$.*/$9-*PF%.= 6&24,1WFQ79T> CT&"3+:D(T28%791'.(":I5G
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MI><_<7-SX4=%#R,Q/<C'%3%RP.V2S (T_%]$?)'0CN;%++>G_J-\K,UX]B+
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M4LY%F&@9@+ED V8R'0BI6*!B+"+3H8IXM"Q]:42T$2 4(TQ82,'<LH;'1AJ
M>\;Q^D7I6X+>$=@[,SF8BN-#..&ML;=<7+.H&\OD*Q>Q0#-/@>%%I&1X)4L!
M8]%X:8>J/; W_S<: 86'F)=VY>7_4_3486YLZS*T\@J$R$A\,U-XSA2XZ:R
M.X(W[M+-'T8YCT]OQ]H<A _(F)-#K('^GL-^;#X&R9*#[,N;LP!N:0IX.;!8
M%#]X]LX?)V9>O(-<K-CS\7QZ/"F\@(<EX)+.+P[%&@BHHL /FS?"=>Z53K(!
M8J"<4_Y.>/]D/@6!>%ZD^4-[]2\Y_>=Y)+E/[J$.C9X/S8Y=YB,M+ ;CV7_Y
M&W.4^*M),RJRU :&1P;G>F:!S#(6V#3C<:PSPC*RS"&:HWT,>K03U+$0\[Q^
MA]H4XOCL<*4& ,1C@!?VY&GOH.%F0'M QE[]+54'!9P&M(EI4=[:\Q@.)/'B
M*ET-17GLI'2YI-*][OWD )RA."[,B^J7ESHOCH?B]$4^=EMT-[U<5!30M;;D
M+'=<T7_]\B37LT/T8Z^'WI==IA:5;RZ_7G=?50& A>\H7\\2=N'7X7ITR^^2
M\'9W7K;8B,(V2;?89[38C-S38I-K/?:*=+L;Q,BNO#0[=^F*Z)="$3U]F/!7
M=I5N[W/TG+&V[6VT3;31G)BN[;0>F&C7"$/^JN 9H 5[ ^@\(,*UXK<7!6*O
MB,4^/7"C)G>=H/=U-OR[ 2Z\"S+]16'3(=6=(%7)W:IEE!=3K_(^-8;7O?(A
M7OF  H]$SU.'^/M\+.8ZGQG]C\?2%9XMZ'(TRB=S>(0N;@2]7Z+)Q.<Q8DWO
M$P8_[J6SQ$V %?:> \C^M@RF&VWQF68JS@N]W$%6IIS1E"A*8Z9EQ!/#2)B&
M699%61+3NRWQ^>B=:\63R32\I0_59QJ.MMC^N_UOVQO;/P9?]H<[NQ_S_=$@
M'WSY0 =G>Q%<RW8VWG[;/CH<+6<:[AT=?ML??3C9/MN,X!WQX-V?HSVR%>UO
M*#HX^LSV-PX8[.UTY]V^';2G"<02B[EC'7"*24F,D"!C)@FH"9-(*&4U)VNO
MLK#/R/F,I#(4]Q.(7Y44WH  .C;4L:$KV9 4VB0L2G2F,\#I2 @19B)6<6+3
MQ-2-K.^H5*EC0[=C0\W !15G-C19&C"CP@ .S@22)UD0AI1G3+(H4F;M51+W
MDXAV;*AC0\^$#6FA:((%-RI1+%1<$D*%%29DE&E ^;NMN>K8T.W84#.3(HZT
MA$-*@I1@O_P4?F2"VL#&E&9A;#6H16NO2!SV8WZ^XV?'ASH^]$3YD(E(FAI-
M<=0RR2PBN3)Q9.),)H2KNRT>Z_C0[?A0,[=#Z3BUEBO0A$(>,,V #X$.&U"1
M2DXB@#NW:Z^B+.HG['SUYN/QH6MZ%F_*.1XCW\>1V!;Z)<<N"T<,ZWJ8AZYB
M\Q[)Z!]+J<(_XY9=>20K6?JSYGLX\%)D*>,LBEF6Q%F4*6)H0JQFFM.T\T8]
M/M_+6]XHEO(DI(('B3!)P$(3!P(884!50C3/;*(3@R5R=$7+B4NYWOTI61VM
M5=/DE<["D(>AR"C+8B.LUL9&VDHCXCBZ:7_6CM;NA=8:EXLEB> *9X,EEF$E
M71KPT- @,THD- 8*9 R[.V;Q^3$]':T]+JTEFH22,A;RC#&=V"RA/-44%/LH
M)8FYXT:L':W=CM8:OT)(&!4XJ5FI&)1ZE@J0:SH-8B"]6!D&1IGTS5@Z8GMR
MQ$:H1%LY,RDS3&<15R(#(4=4JH#BDNL,Q>R([=Z)K3&>4Q-32A(2P+F1@"G%
ML>,"":+4Z"@V6MB8 +$E_31Y!&)[Z/21Y;*VLJR3I/=0U7F#[JQ57<RU;=H[
M=V9>VF,JO*S-U'(^Y2_J"KU# /TRLN!A.]AVLN VLN"TY5"0218F$J/)A*4!
MRTP<8#5GD*8R)4)F(F&@>&6LGZ9W%<^Y.[)YXM&@CH%V#/3&#/1A>PAW#/1V
M#+3Q$N%0O@AD6R"5U &C\$.R1 6<VB2C<$S6QFNO4M:/DXZ!=@RT8Z#WS4 ?
MMHUSQT!OQT ;UQ_),I)2*H(H)#)@/)0!B#D;9(9+FK$L35FT]HHD<3]FY\<H
M=1RTXZ =![WC9*@'[:3=<=#;<=#&G\O@!*Q6"5CND0J855G ,V&#6"11DBA*
M.:=8,\S[+&*_# ==[-O]J_7DOJ1']F#2P^9? &N%3>2GIZ[A<:Y-U1ATH3BQ
M)Y2[##[ /F.CR13[0,*.HO"_W0UM9W-/SZ>N<=,MFT7Z/^$>_TO5-K(X]HU#
MAZ<KNCFV^]0]CRZ;KR]K'>T;9FX8U?XNZI<M-"_DPN.R__<"([:46:Y%!)BK
M&">AB)1,TB2E2:PD%_0*598LL]HWDS%6$D]=OM['O/CVWDSQ W%@HIK]!N1Y
M\M];MUD#?AM_#;,LTI*"VJE)@G[0,,BH,$&,(<PP%9S%V=JK['Q6U7^[\[[9
MN?*(BX3$"1%4,9&E7/#4)#*BF<FD5MF2@(T(C;ISO<6Y;I&O-M%6I1$-I,#V
M>6%L@DQ%<9!H)5A(A0ZM1?_V^7-=9%S]B[HN#R<H4^ :738.=OC@Y%<PL<&\
M,/7GP'E=RSJ#C7'/<^H[['0+*M\OU^HV>:Q6MQ]=VV/]7DQGI[M3V(+'D.+)
MM;R%9[W^OC_^\W#_;/)CL+MYLG>V%X)&R;:/5+C_;BO>.]K\L?/E0[RS^_9H
M>[1UNK/[[6SG31;N_[_#4(W^&HLOV7SG:#/:WOWC:'#T<00:Y^G@[.,WH+I\
M>W<3J/9;O/UE^W3O: N>L<W^W]GFR?;&YE?&%5%"FB %1ADPQ4T@B @#&DL=
M@[JH+>/+76\%%RK$3K,Z%DSS1 BX68<9B1(P/2*UW-.R/(6>.X9>^QPN[W9[
M<Y5B97_<JY>[N#V2Z%ARGH7,*"83N#T#$6*M1@0$4#V>ZJ(!;>=%X9G08#(S
M/=J_G\S]9DWNB2]RT#1S=8U5;HV_FV+FFAS#&O^<Y/#+7_ 7D-H]+_329?7;
M L!WV1WWA+7Y,,<>Z*@33NSL#S'^YNQ?E AP#2"QV_B9\4WR%[:#'=1!03=#
MU[H8<&@$.(P-??,SCWSP4&Q!?#R=Z+F:N3;IKXM<^*5LYUJ#&; I"M\-^K4%
M_!<+;8Y[AZ)8[#F,-[;Z!D^*'%_DI-U\.'.J;=EU&"?O^!T4AST[G)S4HP<6
M]P!KPC4V#W4]X?'XBJH7,5PS@XV5:Y)BB(V*"UC<=YPY8,8],\Q'<'\I&YL%
MPR(:N7CU**:J\15*KFIK+US?>I#035/6_U[,^RDY0MC<(B2\?SZ[^):6X$R.
M5_3J>23ZIGQ)B6C]/*S;@QV#8AC(J1'? F%AL2_$\$2<%FO_7-PB[*\-SV50
M7-P\^CF-3%C-[J]FW[M+K  IH)A+L,-S,<UA?2,!2F.IYTVFH%4)L-3!%)\6
MCE7(.1CQIBCZG@AF+8'6.\EGAV!"U*P%?<7XIMSW!C\YS-5A/?OB KU4YU/0
M72=E&_/67V/]S\FT9^I6YI.RE?DBVY! D :X,/H*9K Q>.'"$O&A95_F0N"(
M!S,=%;T#,\;9'\-3?*K!@1KRU-\\@2NGK6T W_,? ;6XT7F>[.'KJ1\*TGK9
MXLKT!"X>3V:.2>35="?A!NKA4[Y/AM\]%SF_:GBK-#V<HC+U;=K]3 L\=O@*
MC[ ZEFK62/,W GKE5LKN[8[#@=BJF60#\VI1*\=*+2LKU]7PDUMI^(^EO:?K
MO<>:5 %$:?XS!SS;_(XBZ>DHZWN5LD[V=[?(]BXHV4>;IX.CS^'>T=[)WA=T
M_WX@>[N'PSVR1P:CCR,PH9>4]?WA]M$>*/5;I]OPC,'NQWQP],?AWF@?WK]_
MN//NKZ/]HSVR_VZ/@K).!B=?4TU3%1(>1$:P@$F2!B*56<#3T(A0,*/->5V=
M$2J%92&A,6/<2)7$"7+$3-A$Q?S<A(H:Y#T/\VNKZ$]!++A&]A=8 5<!XM4.
MZM3??0OBJ/((MM5&8+R@X#GU&UB%0MW(.0L<R(4;^E3J4T=.R?I>*EGB8&J<
M3N6E0Z5IKH,ZV!.E\E9QGNH=Y=_PBWM%L;B2DQS>?3R?*E 1C5/2%M6Z<IK>
MH1DZ-E[KMB /!,X 4J;DIV-S,)EY.=6>'P6L?%;R1V"+P-7SXM!+! '?YU,=
M'#M;KAG.9//IJ =2";3?R@O=*)4H9)MQ&*(HYJ-J.N1\-JP A_=< +CUWGL0
MOG,!W\&Z+[G0@\F*?.K69E9KO0Y\N/M);P@"PCO5\?].$GFY>9H#\/!\;N8?
MI$9+($S M(BQF'%.XHQ:'E,A."6Q]%POJK@>_K+2/WAP^.(O4$90H&Z5TFD3
MQ>TI]A8O#B=#W3@*)_8M;/@OW"\N/2\&DW_#MG9A5V61]_ C'/'$?C2P_?&3
M<2L^ A_=9H.-@].=W==T>W>3P5J^TH284$4DB"UZC[5. AX1$D19*J3 K%JE
M,0*WPGN<E\#U4]( TZ8.OJA<&5'J+^K0?5-:DJA.P$F:):HL==!::2PJ<EA
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MX%URYP0/<B^7? ;7M^5/@0Y-57IW'$FZM+S+BH1/<&NZ3*MQJ3,&=$U04NI
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M*%E*-?"\;> KMZ5K]3-7J$P<SUUQ+O;(<C3;]*<M2^>O/#*UH//XX\,LZO,
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M)GF6)TR>4D">.2P:B1'SS0NDX;1'_J7PJB3(%C*#NAA(;%[Q2OS:C1;\Z(R
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MK1>+,U#K;0R3,7YW[]:AE5[P7K&(9G6Q-WF)1D*0DM*'U<BDKF>%K@_*3K-
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MX"\8P4CJ)518/@5[^8I\^*K,YQ?$OZO!4=[V&;L!)[)2-7T5(N;P\,3.1OA
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MN'ST.J*Z[+!=,[.?&(G+9C1%>DC*MN;7;X*4K,.4Q .@7GF[HF6)HO@^B7R
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M[UK??\7%.(Y\42(CV?W"BP:5'7$U4:AB2V2614/14)_$SQV!-G0^A2U,BL1
M.$\B!]00M.501"E,2<=2[N-Q/W;G<W?&W.%Z[J*%0;B>#D/TEF,5U ,AY."B
M3\"T9!@U+?6\S_GV_W^NY^%$.Y:B^QEMQ8Q6.FO00;MZ1]P#N;P*,ED-[G-P
MJM,9TMU&>WO)/GY:?]2LO)WG.*X5/-_0>$]F'\\^T##7>_!*R<(9<Z#))I*+
MSS5XKR)P[2FP($<I\!LK\<T]I_L?,J2E]B E7U"\\;@>S.!S/+/R@KS>R6Q5
M].M]GG\91Q(P&R99U!*2* A*>:3@T05RJ(KAQK/,F=E*PQL_?DCG52UU>_A8
M-KRHN,CT,351\0JF<R%'EA[I-1%-(%?D+]>[Y4'6[727I15.9];K1N(=L(9T
M2M6$%NV5T>Y.85X93T*TSE:D[R_PI*BR]R&#M3;6^CXD:0B<EB*45ML<1.Q#
MCMLQ#>E,JBDS&JFA7>VT/*7H>D)XGJ63\72\6-98^TN^ (4"30Y)U7Q^DE5:
M#T$F 2)$C=$$QWV??/-[@ TI.ZPI05HJI&75UHMPT)-KO;I[SU0M$2K(N#EO
M+6!A/(6<BU%]RD_?%I3ODP-[$7"\(EW6,^+Q])0FXN79XZ^YS.;GA5H^X+>\
M>/F-U$"T&D]Q?O::V+"X)28)7ALA,P>NZBT;ZPR$3"$S]XP;EK7%FYYRLY3:
M;D(-R3/?DXD_IN<.@P(-\[K/@9ZO$[_2,D(#-<)20JD0#(T6*!J8>DR#D- [
MB<&7@'W.X6X!-*B-CJ9D.FSL&\8!YT<:*MAD%29ZIJS[=H:3EZE*S;24SJ>8
M4Z<Z-9L/CG:*4\\_HFKLUMB9B<"DB@C22-)89@:<E9Z^")7(DRKY9FVJ#1'K
M%@\:TNJWEW*OQ*RMQ[7%GL053)N":19E4N0 @U\%TT+Y>D9'\]0)+C5/R$7<
M1<T#WYUHJ.%#1[.Q;>IC;$6RR1=A:T,?3ZXVA='.%@]))2[06=>K//S1_*TV
MN1&JF!Q36)7,$J!T8N 3#1M7!34J% K[Q/CWYD8\[(HZ%&[>6HIA3QTVO3"X
M6-9%9(WDNW1:6F,B/=[P5-.-*-QU)B.M4ED$Q1C'V._RX"9$0UK&ATJK)MIL
MV>-A77GM?&]#A]JI36<(053KE) ([@I(D4,P(NED>@7/UX#LN"_=-T@9+I7V
M5U[;TC DW.SZ<GF!*7/FI'4!A'?5B;(*7- >@D\D.<5UCG?*"+P3UY!VMX=*
MKX::?>A+&]>J/]>1[GEWXXZ''>D*Q[;B-KK)L:&V]D5=;?IIW9_F[6R^FE[7
M\DMN(RW7&'F6P()PH*+*X'*TD!S65*BZ^=YGQZRQ( WW_'4T/H;:7-4P<CRE
MIJ6=,YIQT4KEC!:B]#D$&F8BWD,R[HY$O5VTU-8 WU?>WGBO>*3%6MM40!DN
MZL7=!-')'$NM@-$IK[E5&X+CY:8,AUG--=LP!>_642*7@TMG J_GY_2%L03!
M,82(@B0.29.3>NS5NZ.\>[%"TDK!ZI&$0%F[391:$S D2(C9>16+=7W"K*X6
M;K V82=.;NA.]&"Z/ZJ1V$4(5630FFG@,;A:U#N SY8B#.:TY[3R>-7G+D1C
M009U&-J+P0^I_..Z.3%X+(F@9,L,.6"2K*VI^3G,Z.2C<['3]M7N;DZ[$?AC
M.J< <?P_.?V?V635"Q3'T_K@-]/+8HC/YN,%_>H%_4C+59Z/9^G[J"4;);FH
M#GA.%,D7\EB]9[0VD2O+%>.:/):CCMJA$@W)+#7G[;:S^ZBTZ#[-7\WFI*WI
MNF)(//LPQ^D"XTJGT[3Z::WA"R'O$@R+3<IK6K"L('%0)L#H$80/3'F5-"_'
M#88:"C>D6.K!J/]09'GP;4Y<?'HUF7WMN[WYXT..M:UYCWCM"M/4)[V=S[Z,
MZ=-^/?N#,+V>K@_N:N8X,>G+NJ*[H=A;%_+%G"GDE=G(P8=4F\ I%\DO2UST
M.=/?'N/!FY!XMAK^#[-G\;]/Q_.\J=3R2!DI7' 9I%%D*R(9#)J[!JS(S.28
ME9:=JM1L V]'?Z#[W<X>]/IA6[*YWEKFLL><T^JXZSU.\NHJQK)".GM3-L+T
M61E7L@<1:_&=6F@0I9!@K)3%F:Q\I[HB.T,=DOT]%M.ZJK,=ZVY.B'5#L4M8
MK[[\/A[58CFF]E=7JI:B2\R"M[4R'?DC*2:K=.ATT+(-O$&E13S40G:PWOI1
MBL;B<YXOS]Y.R+^I]Y'HU57ZY\BZY&D$7"UI8LF-+ (<^GHE(0;ME6)>]]DP
MVQ[CCCD1/R>YVFBP'\->3Y<X_5C;AZTKEH^<1U$X!D@2B?W,2'!*KUI<H%:T
MJO;J)7$OM!TO"/Z<?#I(7RV+N6R2_GN*ZQ7I@Y4BU[;9F=5VG2E$<)(('Z7U
M,6H3@^C3SVM[C"WS*J2FF<P+..U7%X1JVW>.("-&*Z-B*G1:E@>95]&))W>E
M3.R@@(;EYS_7NS>K$:'O)_E\:^C923T%^9_5ZR-NF"0A:1E0IJ;.<06XDI>F
MJS3),)%ZE9^_']TC"#-:DZ:YTEI<G?I]-JVR7V_;N+J-/O):.>,S@@LUM"XA
M@<]2@93!H'52"7&#/QNN3=W^^4.JW-&9 >W&N4D%GT\X_YC?E-?35>"[6&PN
M-3)*C)ML, (/TI$;86EE8_7*EQ7!VL2DT.5>_6_YL"&E,_<G0P\--+,MOYXN
MQE/"]'QV$L;3U8"M4[H_$J2ZLTV#,C_7S9Q<P_7F-HE$W[Z>KGO>ORFW_,GW
MROE\M'(646 ]A,]D.)6'D+" ".2L,BY*M'VVQ(XDX)#*BQS)P@V1.NVJ']&D
MS;_BXGI?F9'-'&E<- A9;]053I%0E 5T9,706+L8^^RW;<:S#>O,S\6Z!HII
MU^#GBB_WIKRB23"-).G:T*<<A18!07NK:H-T$C)37*XTN76HF&>^S[6 NU!M
M0QC[<Q&FF9*:]H5:AP/7H+T8+]8MS\@O>#O/)^/3D\7E]<O%2(3,BC<%@LJU
M"AP&""(;8$RP:+CEJ=/=M/WP;D,U]\#[:<VYUE^SS6]"1AJ7&U?E%!HKD@7I
M:YOVDB.@+1**P)30>YH;?2IVW0II&R[YGXQ+;?33LB;'O$:Q+_+Z7_+@?NA5
M/,HUM5>R2%"(S<I[A" MQ;I*>:D1;>Y77.->=%OM7+*?C$7-U=:14!<MD*O,
MTBH10@Y0BPN!BJ%61,P()BCR^;G*0O7I8G(GK*TH]-"I.?TIM*^B.G+GO$WR
M13/0C>V21\68@JGNN&&-)",3$+CD4+3B7"2#5O8Q;/OAW8IMQRSR_S!L:Z[:
MCC1<0;H<DC4V9%A;%@>@D"* $M;5T@,66(S99,=MUGT<]^WP;46SAT[3Z4^S
M@U5W!%?KO!GV*++L*300)"^KR1U"@+>Z0-9")F>"S++/E8![H6U%II]D;[^/
MOCK2Z.7)Y\GL+.=W>5*3U:_TSAT%482,CD'.FE-,$15A+0I,TL8P9:6^>?S3
MC5&WH]R*7#_9+GLW+?9=KFYTW+ZPUI<GHE=0VZ"9*/5V:*CAAW,6$%FM"Q5=
MB5XY9HX8->Z ?"L^_F3[[T?5=HL#\ V6_MJQ_%5L&J4,4A%11&VOXZ*$8!Q"
M(7NO8Y1*AGON(^WVP*T(])/LQW=41<>E[,Z&\*.D:T<[&P$-*E#>$(VU+X!<
M<QY0J:#[9+/N"'0KGKF?@V?'T&7O3-?OIU17Q@*Q2!V1 $53N[WD#$AS ((3
M*B5K2I)]K.3V& \=C?5'YM5:\'8^ID__C).+'.41VN"3SQXBCQ2+L:+!);(>
M@J,R%HMRH4_0<R>LQW!9[U ZW9Q:[?34YY)>;3CYYO.J%N7+;WD>QS0*(ZY+
M-!5'L84$EK7_>,V31R?0J<"\[M<<]FYHCR [MC6#VJJK'XOJO9K%J#AKF5&9
M7%9'ODA.M7:HDU#((8DBJ*!*G\.(S7@>02YM=[[LKICFEYS.X^\/LP_XK;H4
MG]9U2U[-YK?D*'$KD7L>R,/@HG;Y(F]&\001LXFJ).]UIQ5H3\2/X8I=<Z8=
M0[M=%JS7B\5I-<LUI_)[W^619(IA00D^<005(\'22D#6V3O/K,'<QVV\%]HC
M2)GMN8P=KJ[F*]J;L@)Q@6R=(J=2B0K10Y&<@4(*Q+RG'YD.29,OYV+N9/SN
M0+5CXNM/M3(=K*4.O'F1P_(Z("%]5-%*"$50Z,YH)42)&9@-Q4?-A"B=VC[>
M#FK'[->?C#6'Z:A=,5X2NOZ_7E7_@I.UK5TLY^-(YK;^XMDT77_ARCO7U:Y^
MW-HY+VSZ\EM<72]X1Z;[92DY+D?>:B3N1XBB%N\HY"R25Q@A&):\BH;6U#[V
M[[AR'O'*=4:AN0P<,JLEQH3V@ PU",Q).@K;BNUS"7G?*]</7.AWN'R_N59T
M(D'OW=)-51&<*T$&7!T:U)NU24!@JAXZ\9 \D\KK/A=U]BUU]L!UY!\]20\E
MP4-LZ2=TWI8L0!IKR?XB4O!8/,C" H4)A%T,:TO_8?>:'C])#R5!,Y*N17Q3
MKHK]9GK0 (^*+S8C6BB*)5!!.?)7BP3'$L_<25$Z'5!U$&9(-]0?$>T?FE;#
M"%)&6=I209.UT75*JUKM(3"HO56L<<[QV.>DLB'G]QLS^OP;G_J,%L+Y_(RX
M]A\X.<TCQRG6Q,S(<4QDDPW99'01H00ALRU>.-NG8--6\'Z:P&$G#O[00Z2Y
M)AMVJ[\J<+T>MZJ:O1RA"VAP5:0SUOY^28/3UM6+O;(DPV2O[(#;$/TT[OU!
M5&JBK\Z%RM_749R?S<K[\<?IN(QCK:6XSN!>-<N9C",Y:I?WY; .UNITZ/D\
MIW5EL!=YB>/)XCKB;0J8MWQXF\+FW8;CP(+GM93.>0;7*4XNG[]X5I9Y_FPR
MF7VM6YNO9O-+'-4//R><R))%1]Z#+IK\B.I,>",]&($B>"$L\?K>W,X# !Q2
MPVGC4]=M5C<_]A]S^O)=<I%%]=Z UZFKF!$T?PN"5\YF$Z)//NPI^;88AF!7
MC\B?J]6?CJ>[)N7"-H_01J 7&,D$Q&1X[>G'5STQ)/B8'3@E8Z1P06L1]YU9
M=SUX$-VPAL2J=FKJ2*4[A^6*@^"9Y#F@ Y-J+VCM:WMP%L%HGFWR+&-R7=;K
MVURX8RS95^0OKK#B*0XOJ<[\Y"-->AO LL2<2$5&97NMVKMYL0-=N/?DTN%K
M]YY*//;R?16FD,:1XPTY&D561I,SSG2 9*VT5AG#U?WW7O9[]F->Q'LQK*F^
M'J++TZ\XJ?#??\IDZ68GGV?3U5[DU6+U>*58_=[!4\N'=^P*U6(X&G6+NK5A
M -%Y9,G1)(\@0C*AUJ%*M3:M4V""J!G]+@9WP^2VRQ6\%56#%,G-G[U:JT?*
MA*0R3249ZBY6R+;N+$>PG-',Y3&77NEM=^(:@MUMSID-Z9"M5-.R.-_IR>EJ
M.V.;$MZW-^!(*6+A3D)BH195$@*06PZQU'K/7B4C^S1;:R7!("QS=PX^B+Z'
M8Y//+V^?%]79?QOS\$<>W?YN(WHCJ_OC%?F+H#P+A1F5!M1$'14P0O#&0'&L
M9,\3]Z;/L<6MD ZN*[GQ2O?9]PT/[4IP@N9JS!D4>@>!1XJ-9"Q&R"3RS<VB
M5L4E[\0U)'O;ABT_U)-LIY>FE7!/:V),+6_Y ;]=2LI+R;DD#5DC@<@JUYO?
M$DH4:+1$R7V_8K<;(0WI/*\/0]IHHS4Y:O>=O%C0H.#D5;XBJ;'<6R9KJ4J^
M;J014#/0I7C'&:+NU ;^;EQ#2ICK2I,6>FFQY74.YSG]:DS#_6$^QLF"PNGW
MR]-4\^NB%E*E+(#GVDQ#$C+/G8$4LE<A>'3V_M.)>QXRI'2QMDIO/, M%/YR
ML1R?K"M?+<<?KW>+^"U_O,Y&Y$()"AA!&%5J7P"L!3W(MNGBG#6$+O-[M;_+
M$X=TJ[$Y%;H-?<.%X,*?OXC4KNZL74 +,;. P4 FPT;B&P$A4.@H58[6R(@L
MFVW7A"V>-Z0V';V6A];#WMJ->#<[HTCQBK@L)!L%6:>XNFD;:,7R/&J0&- 2
M%EE<GQ[PMP :4FN.KH[#09IHV_[@=CFYU*M\9P@E>E!)&W N%D";-.:(Z+!/
M9:^[<>W85.,1DJ2A7CKOLKW"\7R5"?M/"JA/Y^?MK:[G3F)M+O]C2_GSOTBS
MZ;OZVIRB\E]Q,=Y_^ZTCEC;[<L<:K$8;=E>8]QUY[>(RF54HH\B"+1')QRU(
MKDT@)\<C49%3H%-0R^!U']MQ-Z[C-0.\+)LG*?X7DFF2O=ITQ1W-16' *)ZL
M,CJX3N=G>X =TB9?0X;MWYAO/S6V<\U61=8WB2\UFJ)<AM5:KZ2JR>=) C>>
M<1,+8]CI\.PV2'UNQVR2'9/#(@E:"H:3[)R\Y.P%(>7"*<>]X/UN#VT%<4CS
MJ V'MKL!<ZBV&G8$#\M+ _G=-W))U0MZ('-FM9P'^4;>KZI[( GN1+\6X!O@
M#&J_O M)#M=")T)<R13CA6O)<P'!96U@X3UXH1/8F+VC8#PRW>>ZW6V(!K4_
M?@1:[*F+X<8NV[WK(2*9W9 ]>%QSP$"V2DOX0A]='U>K&A**Z\P]3WNIJ12+
MY2KB&H4<LJF499Y%BKXIQ/>\-OL2C@=ABTJECX79%>G!GNG=S[O,&5IEJOTQ
MG1,M*H!_X'BZS@__@-]&T3"6T&I0N4YX'PKX6C/'<UF$*U:[W*<&6A/X@ZIL
MW96J/VQ4'EW[[4*J/:'7!/-+Z+YH6W2A\"^I1(,G(F#6$DJP:*PU(?0*OUK
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M?#;]D@G]ZLK4=#R;_SY;'G#Y;+>/;[.U<H!(K8I=S*8?/^3Y244R<FAXD,:
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MJL4LSEH6A8K,14O"2%8);)/MT@W?<5.I@8X:I-*L03E/Z[T!*0D)RL!9CIY
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MO/MSA)/IZ? SO2Z)OH<3'$0I9'%>,FE0UZZ.) HYOZJ6(I4<DA%MTBXZ0SQ
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M4TQH)8J.  \P:+T-CY8WLQ8*ZO<&=/7R/YX"H7Q_,4FG,,4\D+9HEY)F.<K
MZL3)6KXD6,I07+9):)X?WMBZ/NKHJ-!$QLU&ARV#?/?G""?3T^'GFS3+ >;D
M!5A.1K^1M3(IL9 \,I6C4=F1\<_;1',[0SPZ$K554H-KHP]D$N!YM=[F]6YD
M+([/Z'=/KO:_Q4+J;YU_KII93*L*,IG@HV ^9\NT+8H%,B&9\M8[R:WS@C=A
MUE9PCY9E[977)$)X?CX>?9R-TS\7.^N+"Q+.9-%ST 49:NL73.#JX.7(@+O(
MK$@VV.Q+<JVNK]>".EKV]*6('B>(79MCI%N<3#"O1L=S"EQ:(-NKT E,7BKS
M-91NO.+&T.FL39N>+@_C.EJF]*B.OB>-W0?V9CJ]P/S'Y_'HU7A4)Q.1!FJE
M]S79R8!#:S%SQM$BTZ'P&O5(#+6B'3'D@DD^:B1O]>BC8\A>=-#C#+*'&+T
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M4[]G[1VH'J4+Q._U*+TH>(MZ@FVT<Z!Z%,N# \2:N)Y$[0Z=:'-6EM5^4PG
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MZ JY%\;[G,DPC:VR G9 ?804VYL2&_3L>S.Z5,%JW+_\E<XN\G!T<F70#E+
M6B8BF33D1VF=//,R:98A:C FN1#;D&Y3I$=(M*;*:I"1?8W#HS&Q)H6#TN1
MQQ08<)=HY;2_^@RZZ#8E&D=,AJV$VV."]<GI/=]W;MR_&2VSL#@>D ?'C+'$
MPJ (H$!@(D@;8DF*+]O.*R[DNCWKB/3<1KX]MJR[V97NF57W,4;+193TCF*J
MPT"4%<Q[$9C(JA0O).>I3>I2%W1'Q)IF2FG0S.[F<O,!<2RN-;G@EO,@6 R5
MXI''6E8660'C72JV>&@3N^J.<5_E&,VITT@M3Z4@8Y-T&@C)*A<ULS'0"Q(T
M,MI0%3,8$@0>:</]GG#9,TUV2+7<1%U/(.NM"]SOJ9;-"+!C^MLVVGL"I"O:
MZ9P<,N&D9CK35X!"LJBXYD)H;_8?>?PF4RWWR;5-E-: 8XO:B3HY]ZI)S%5*
MH 2,SJ%G0M:\0"45@V0S.:!<N&C)FE1MKD760GI2MOSNRKQ7:-V')AI<J?T^
M'J7Q^6><X3UDSDL$KS-+2 >_=@5J 3AA- F]B8!!M#&BUF,Z;I+TI(L&&\DC
M <S[>ZS$*+/T+-;PAI:%'-3"$PM9::UMB%JUF0J\(= CM\%;JJW!I=HC<%=;
M<QT@-[7%MP!]&'N\*1DV(UYOFMS_5K>Z>DL&U-KP.BFSIL5$>D>])^C"1JVC
M%%RWB7(]&?(]8I\_=>YMHL FG'NP0=.E#9#(& PB9A:US/4DJ,-M1&;<Z"2C
MR)[+-I=QG>#MWS1KKNA[Q.I;2_N:GEZ[%/\.DPG,2%!;9Q"O_)1>\H$?Q[>4
MW9M$$=SY&+CQFOL8DRHV1<AH54[2#%9^XNXC?&X:2=^$['4,Q=&#&4BK:C].
MS4C-FKEDG+>.&^?:N$EK /4QJNCF8U]#PA?GXXO1;  Q!5 >B<IU7IN)M&0-
MAF7+I2>_-479)@*U#M'^MYP^.+!J$-'.\FX0&;B+BW97G.!T]@%F^'%6LS;?
MD[M3BTY/<."C]71@ T.D0UJ[6F?AA&#%";2(3F75QO[ICO$8N=*;3OH?KGT#
M\K(BYP[6S[CHRG_SHUO (0NC=5$LE=J93M760"4[EDUQQ=D<.3Q>!KX;AF^;
M+/M508,XP%WTK\:C+SB95</N$^E[>CH^N\7S=^7C;)S^^7XR3/AI,CPY(1.L
M2,TMEL!DA%@[5RH&7"KF59*U'U'FJDVJXX[ OVW:'4)[#1)K'X?_:0(U&^=G
M^#H=Y*RYT/1JA#H$20-(%K DE@7&HKE6K1I";@3SN1!K6\TT2*%]'"S];(KI
MHCHHMW"+@<2@JI/(P"176W;05UX!TP&B!QL5B#8C?[:&_%SHU8?&^DWD78OY
M\LB_O=.^GXSS19J]*V^!#GS\/)Z0P5AG7LYWWSJR>_[/:SROF@,#+":0V9BK
MOZ'K"T0&I%>>&6^,!AG1.;FA'=8KP&^;=4](>0U2B]<N[0[,X5@,!#J=N0!F
MLC=,YSJ(RP15HW(\)*="\ON(GCP \=OF65N--)J4_0C0.>?%(%OA!63),,R[
MB](&7 <_,Z5X<3(8![[-1./.$)\-=;;0R'WJ^+XCEU>SWPVWCBA<F%0U71Z<
M95$B?8LI:(O"6MENL/H*0,=(B^VD?9\$8>?*W%O%Y-<C($<GB]E92B 99%HR
ME3DY!28@"]G[FF-OP#GG,8LF3'@(U7'0H3>YKPA&-HQE_U)*G:GWY7;X*UM=
MT"G-I-:":9T3"XDL**-22KZ0D%*;B]:-8!X';=II9@6/=HEJWSKW*N9_QWR"
M'V>3X3\7)OB %U$P)L4""(+FN6$!:0,44J(747 ;_*/NTB,/^;95WK,05^AW
MZ\CS.FBG,%D@>S_!\^%MEVQ0DG+S%KTQS3NK(CG]H V+6@>?> +)'[E/W_RA
MQZG_GH2\@@\[!X-OL UJ3@=(E9B*,K*:=$ >M;&U^M)YQ:52H8WI<(/AVU;_
MCC)=H=ZM@[1US&K^KXOI;#$M?/PBY[D@X>P]#/.;T2OX/)S!V2__?3&<?7TU
M/O\\'M$OOBNKZ#L=Q)*X2ZKV[@:@34L'5H>(LUB4T!FAV.6 [:KAMKWA^;99
M<CC5K"#8SD/L[DIFD=!MR"7B,=.A5H=LD@F3681 )HWP,A#M?9+[B._OM?:Y
MO>6XN6R?2EWSW77,TU\C>*U,\@QM#C5W@\P@2>Z2U"HY<$6EY7'932ARR J)
MG;7[(%LVEG*#I-^[B&[EJ';!U;2D81VRP]0M[*JY!XFPH]CW28L"A7/N,LNB
M=D?T1C'0M&OZPM&"CXI^<@1T>*228%]LV$3:_:;/W;)D/N)H.)[\/I[A].<+
M)/6XJR$!PAA!/A%S-GK:"<EP]@5JI\P@:X6@,MD]:G)V>-"A;<EM%;+2X^Q%
MF@T2;=^.1R<SG)S7I7^B?S,GM:;C3')!F$(@RU4)SKQ5=/2Y**4A21ALXVZN
M0G,L1L#.DFZ0[+B,Z9+N75 U-0)6XSJ,";"[WAXAP@Y";]&V834Z+V@K4L3W
M4"%JU*DF1@I&7]BDHA,HVQ15[Y,*CQS_^V+")K)NP("E:,;E.:4UKSVP#=/"
MDJ&3A&<@A&&8O,BT"1I7VMQCKX2S?]N@#UV-^Q9T X/@EJ%RU23$01')2E:
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M,SS!?/;US:A,ZE_E/SZ/1XN,/#)?,#N#D2GPM04OK3](K9DBAT=RM!A]F^2
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MT/HFDNW74'\]OACE.:3?, ]3/>M&Z6]?IG_[]3)B\^_SB$W]X550+)N$\PX
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MTO)&UV-/')[1Z3.,&+\)=%J-,>C&9O^91Q\_5::_Y E^S$O/8MZL7R^ LK@
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MG(48690BI*SYP)IPM[%T,96AX:95IO.(,V"]8[GN#.!7RF<GI!"0):]G@)2
MA@O@/DLC-:OSZ =YWQS [,6(S@=KK7*<W;#\^-P@SIAE,3,Z.'+)=7XW!Q^2
M &,*9I%T,"UC_"8\78QE<,CI,,@_IN?T>QQ-YM2_F4YO/]]Q^.UX.GM7WO[[
M=C3[BUC,)/G9>YSE*V6"$T)[B*46JD:=P&E.+B?1(I/PQ?,G6<@N&Y#W(?6,
M ']<[#Y(W3_'MNEP;<G!3PR+A<7%>(L^@A?2U'2<!5^,GD^SE%RKZ%*C5'I7
M+/2U$N74Z:B3J'R8VU9D=$P8Z8%S88&$5O>PIPPL6!.-(MM[.OKAA6Y;Z1,)
M&W>S[*.1016I;9CNN0M/E]TLH_UWL^P%EC[66QRBZ7-!L<W(0_0!$OI:$I =
M>2I6@3/DD =KN;1#*_KJ&[U[[689''CW47"K/:V/EGQ0N!FU3 9R]$@2L@PP
MD*M,CK$52?FB7</>Y!>XBV4O#:]J/#Y8/>UWL"R7>'A3N P!;#$15/ "7/0)
MA+#91%U$Y&U&DZPDYX*;#M34XZX5FSR3%<-)"D>0%@&<< 5RTBDPKT1J-.3C
M9>]:.08_7:CJ9+M66%&%LSII39AYYK+467)UPQ#7D7DOE-D^6O#5[5HY!"[M
M]++VE:67_0@_(\FR+@;I>"O"L\]MN MA,P]/-B"PP+#4ZEMCBPI.H/+19!0N
MI9*+$&LV(#S[CI/O/2C&ZY@#8;<$#8I #>ARAJSJ=*SZE"$&5M/ZX[%[#SJN
M_OQ:J_YA/*LSE!\5(N@D1)":0PZ!7 @9R/U4+-&A8771666TPZR.W(6[ 9[D
MW2*^4<%P=Y 9TD*%7?H1YW_X'<[R_?/355T<I&4D_JSDH)RU@.@0&'E+GJM0
M<JLGF7X9O1C+@(#4<FMOGGP9+<* YP[ ^.;+W6B6RNAT;OX/_[R^P/X\GOUW
MGKW/<?SQ9O3_%G[A0B97*1DIF,I@ZD1JI0N'X#R"]])&)0L/23>QEE[8>W4V
M,CS0-*B&;,;DW<GP_7BR^%']>_PJB^QCI)@L8+2@<J&8K,0(7,62<PXQQC8-
MJ?WR>;&5X<"H08UCNY/A_I/N_M$[BH\G'S[AS?*T*#):64@S1;+:;NK(_]0$
M>,TX:H\J"BG/RWZVL7PQI4&":R!5DE^K41?B6DSN1!YDX-R#]4@*8*(.T3.%
MT(UUR@,7SFY)>C6@ZM5 ^=0:;=6E>! _]3_O\[]O1]/1+#_BB5\Q(WEPQH+4
M >OT  DN6 /,<QN\*T(WBAB:L/-J\#T<4+0HZ#V*J3K)]'ZF."?IEE#('2-'
MS=<)RH%XD72O.!="\,&F^/3Y:A  ?\S%!==]0> YG.W1Y;K7\[_ST/UYR%2=
MP7LSS5>%?!RIM854JTZ5,!2!\Y!!&!_)"?(8$V]3Q[L3?:\.@@W4]AQ<;BB[
M+[E)643EH5A--L+)_7:9%T#K(W=.J)!B.W?UO/>[G,Y5/5:3SP'I3P'(^4_G
MPW#^/L;KI;OM$*T(!K)FEOA(2.<WRMI%6G2.L0COVB%R%4D72/:ARQ6/+P>_
M6A[#R#_&U^G>B;C;4[/P*ZZJ0"VW),2Z&$F56,![X\%'RV0@AX(SU0Z:ZPF[
M +0_O:Z Z>DFI2R;,J>SR>V\8NUI9FW?U]+:K^],U"!K[[0*)H(3+%4=65OK
MF&(:V'*BKD7P:FQI<)+?"WPKS/!T\UDH)AA-YG]Y<>\%C"X9[T#+>J HRR%H
MJ4"+2.&!=M:I@<V+>,K"ZS2#WI6_ L8GV3C_@5 X_40W)/$0Z8=DH-^/)S_<
MI-&74;K%ZRE]7B YI]_'\PS+^'_(TB>CCQ]SO4>_'WW)_YUQ<F?W=1C,E1>!
M@N#D 9.M&X3NMJA:8#ZHPI(0V3=<3-\U.Z_&&H8D]+TPM,*0NIF0>LB1\,OM
M)'["Q9S7=X7^]>?QS;SV9B&:JQR5H3#=@,?*&E+$[E5FH)7&J$24UL9A71!;
M>7HU-C(P>*Q _M%OC@](^A;_&,WP>L[)]'V>YLF77*MBOK^M$]GK-M?:M'(5
M95+%(()TM2-8T*^"(EL5W*%E7B3CVE2T[TWJJ\-I6V6N@-_I'@)7C2]:[CK\
MKEY#^2;-1Q?YDJH0JP#K$!I4'EQ6&K)CJG!9F&4#>_[>E;57!^]A@66%.1S]
MD-B$P]_'U_0QUQ3!SWG47LOH?0;,$4%I3K]"BKUU]<<-LB#BP$;J[L[<Q21.
M#)@51G'P V@3'M^/IO_Z?I+SH_%V22<=HD-P=:V*\L$"\I@(R&3UR)%%,;!<
MZ*ZL70SBI&!980XG>7[=:]BC"#FQ^;@"%C,%XT*##R: #CY((X,+ =LE=%[\
MH,^^DS7-=+^B4^ATS:>KN*S#@\>W-S,*>WXAAK_<O0$N!R[,R]%]%M%R:8#K
M^A"!04'PSD%R7CH?M<],#/_DW\[HJ[&4<P#2"L,YW</RS[=5C^_*@YKX><[@
MS>WLTWA2>SJN8DHJ(/$69)V;*=&0'I #CUD)F31:/C CV<[4Q2!.!) 5X&^_
M6'@=;S_AGZ//MY_OVZ%NPS1.1G.COPM]+.?6I3HM+@<2>&+@1'% LD9>M!8E
MMFF%:\71!?:G@,8*S)_D[??^.>+N^5HEQ@RW KBL5?/&)\"4.:!W0;OB@G&L
MG:/_F)A7 \P3Z6\%!(]_-:T/#?4I(2^J[.[HNKL>[@UG_MJU)/P:R5=2L7B,
MGA/)PM?E3!I0FP2%<1;KMN&8V\PO/)#@5X/-/A6[ I#'-U!V-RJ>@MYL683B
M%,7!)M0UV$F#R46[K)S4JDVKSFO<$W$45$^B\F'NB4A6NJ#J.G3#!*B0)*#B
M"D0H*'V,LM5^ZD=DO( ]$?L@8>.>B'TT<BX3]G?AZ;(G8K3_GHB]P-+'J/U#
M-'TN*)9<UB5R$G3@Z6Z#H6=>@+ *&0IA4\17CMZ]]D0,#KS[*+CE-,!G"PE,
ML@*5D9!8K?BK%PM:2U=<23X+72>RM7EL7DO2 ..;YAI?-Q#I*'6UWQ\Q'P_^
M_M??E@L*0D++?82ZXQL4*Q:\\ 68C<9Y59QK=(IM).N"IP[5UN'9M-_T>93<
MEH02&-$*RI,@7"IUAF1PD7AW]..MV<%7MQ7@$-"TTTN#89[K-EV48B2&2%&2
MT5@;P!,XQA+(X#!KHX,5EZ4D_1Y"7:BJY63+!YMVDF,RJE@@BEI4Q:(%%,Q"
M\FA=B$KGT&8AT@IB+L@Y6D4=3FZ<3F97[ZL<YF&&R<71?:F 6"-OC&D//F'-
M-:OHR!_+F'=J/J%/?8 1^MU3?#SZVM>9TCI<\AU>._=$+-WQ'<C8)_NT.Q"Z
M/QRV)XJ.4,%3)1XAOPY=T*?D6!V9,X3+$)(#A76]I'(9(FHM=) I[U9Y/0PU
MKLF8=*_%?<36L?9^(DE]OOV\=$9]R5PD 10BTR4CBZ!+)BN0DBX)Y:Q$L].L
M]9WT]^BK^[NECQ+^N O)=9A7F!-R5]JR/!'JO2ZT Y9% :48^0G*D]N0G93H
M@HQVI_TKNZGPX5>?H0H/EES'5OAA-*MNP=>6^[LD;(K<&R= 6D6AH4@9D$X5
MB$Z14R]S,:H[5:XDX?5Z2L=KI,-0:R5!_QS-/KW/UW-Y3#^-_O@P?GLS&\W^
M6K[V[$!JYY[5GD3V[WUUH-9-(&F@D]8GS1:2?6:1::-!>$M'J_(1?*PK=)-G
M(08?A>DN0AL$?#9X?:=%SSZJZ!@UWWX:Y?+VSQQOZ[;+=Z6,8IXLKDVM$T\V
M( 1+7K"JDW6=B!HPNVQ=*G5D<V<(V4!(O^Y'4^6-NY=\QS[GUPOZKNOLISS[
M-$X_S#>,U!OX^4]SKLFLN<&@2HK+%"#*ZJ[5?2'!R5IKG7+R63JA=VI9WPDQ
MQU#Z>MV?WO3;<6IQ'5T+*]R%LLZ=HLTT]>\#]:?;<5/%='S';:&P6,YT'9N0
M+(672GH#SM&)ZPL%^\P)X45WCM I(+/![QDB8O;11[>/[G]?["'_QWP/^9N?
MWK[YX28NKN2@K/5*)T!=E_T*%<!+D2!QSWCFUKBP?2K_AB_HU\GI4@7CSN77
M8EGR#&?S:_7;:YQ.Z?JM#V9S%$=F$RJC@*O$ZJ1I X&+ EG+$@3]J3-M7C37
MDO0ZG9-N-=5@Z]=#>A9VL@M%34NLG]-TF@+ICI3V=$Q>-Q)O4#6Z@K*47!%2
M9)"H"?/)%$"4&HIER(1FWJ1&XQ9[PL"6,N/>(+"/H%NH?CZ[<4[7-\MP7057
M1V]!$,7<;;7R4FD0(DM6EQ78TF:1\7-:^J^).59#*T=C'BS>!J[#LEQGCF5G
M32E!R=KS%D"%H@G+W$")R+B-*FK?IM_P(16OVT$X6!\-]B,^*>7:A9JF_L 0
MFJ4.U\\:11\AW ;G_Q.J,IH2;!00??9TUBD%CM,U)X5QVBOO)6][()SPRF^E
MZ7UDVFT&H,:L)&]6"5K</LX;9AP14Z<X@%)TCSG-"SBK59%!HN/;EY\]_]S^
M+^ICA#SN2D(=WL]$S'(P7IW0/OHR'V[P@:X@NJ;FD)3D63)R,.ENR41=J:4[
MEFX9Z5!FEHJ4>;OJ-G_'Z[R*NQ5]AXM>-Q*VK+?>@;35E_1>Z#C%%=RQ7G;1
M]A%"[?;HWDJB\'0?*92 (1")G%OZ5:+_Y!(,SUAX+@/5]YI[^'3JWD>6W:IY
M0<>[FV6)H"I&&T_>AN/6U'8')"H$0IBS%[*G4VRK6I]^:G^W<^?2'G<CJFXO
MZ@4I'_YGO"0ED<O *9QW\PE$)F?R&7RL!0_HE94Z9KVKUNX_]25I[3!1K;6U
M__VW)S+YD7X[_X/YSRO/[W/YC_J_O[W_X5X^'Q<O.I_F+SK_%<>?_S87SSS;
M\\SI>-(,^2:28&JA3)[AZ'KZF,;IZ/,?UUL,\Z!O^=M7KAYSN_BJ1_IOQU_^
M<Y9O4D[_^1^C]'_^<X19>IF-\S&2@QP<)J^S2"R2*:+"='70-YYH&N>/]Q.A
MF&)H69VF*X(%<A8%..(04K AI9*C%P.;NWE/^W WQ/X\OGN13>_'U]??CR?U
M'UUE'X/1-5QS5M'9S1VX)#3$:(0M1NB2!S;;]R ^!]C3V:T5]+?K]6@8M7B&
M;\_MW1CD*Y=X"ED9$*;J1/( H6A179_,I-5!-DK4]\;B&9E*#UCMWZP. -HI
MAFYUM"OZJJ ./)8 W(<$RJL$R%4 K:3(:',QOM$PV)XXO-C32>SI")@UF)K2
MCL_?Y_JXYY-I)[Q XHY" E I!_#!>N#::8&H%46-9V9.CSF\F--)S.D(F#48
M(=..3])"R:.'K&*RCJN"P**I@_ZS 2]-?8\,WD2>@\P-%SCWP^3%J$YB5,>!
MK<-.F!.XMQ33.AD"2,,+Q;;6@L\R0I3.)E$B\^S<W+Z-<=0@=?'#S6PRNIF.
MXGSAU4-[X:8XRS09B*FUE=YP0!4DN*@CHK#<I!.-QVW(]1F=@F>3).H&8F<5
MX-[S_L\\^OB)_O?-ESS!CWD>D7R'LWR_8JZ>@C+.JR*8\J"XU>"(?U#&V&1T
M*DJ?[2FXE?LS,K?>\=Z_H78+UK,RV,>I@NV"B (#VE2(?5^7I%($A,XZ(%.S
M4K/, I[;F\F>(KB8[@!,MR5LSS@%MET0V3!CG U0F".7*:$"#*33Y%F,H92@
MA[;5L6L17.QW /;;$K;GF'.[G>3I=BD8D=%IE4"%2+K4.8%'BG?(!4E!*NN-
M/[?+=Q_^+Y8[ ,MM!MCS3.EMET%2S)!5<6*_+HC./(,7SD!@6BDAF$XJG9G1
M'AKG'J#!SGHRE(P\1UX7<\OYV-,$*'4"H="RPK@UOM%,BE>XU?*HQ-Q)5#[,
MK98VEFRDM1 E24\E7< [5NHCCM'":*E,FQS9"]MJN1<2-FZUW$<CY[(/<!>>
M+ELM=VK4/@(L?2P&/$33YX+B4#3#$A"DB[*VS)*['%R"XCB3*%%C;#,QY'S0
MN]=6R\&!=Q\%-P#MYK5V,@BK;4S =.1UKU2I"0JZ:[@OAL?DR?EO@K[7L(UP
M+\WOM8UP'[5UV[ZWQ]8[D0U+(CNPI@X#B"Z 3S%#0!TP!X7";F_'?'7;" \!
M33N]M)B:LF;%'==)Z3H^U"$C)#O,Y.QF27)PRMA 'K!J4[_RLK<1'G,(=:&J
MM<]2O?2A_H23?^596&<1'?>C[OAM#?M2#^'W27^J=59KZURV.JN"=4<XE]$J
MF8-P,NLU_:D[?O/)^U31&.5S34^[DD%9'0"-36"C5B$;DQ%W&DQ_1GVJ=#VT
M2ZJ^_?./7%7]85P?QZXD"T+9Q" I'L@?40J0"0&!''%!$M:.^ZV7?E_4#O"(
M[Q; #QR$02*@15]I9]FW4JST43"(*I"3[3C=G(PAH)4\T&F(439ZMGR%J?=#
M4'U:E0\S]8[.%?+M"5:&>Y(CL>$]_4JC5$ES8HNW>;9[8:GWO9"P,?6^CT;.
M)6FY"T^7U/L!J?>]P-)']O(039\+BIE.@B)56T=28_54ZI8M9R$513PJ&7TX
MT6"(P:!WK]3[X,"[CX)[S'0Y+6T)*H.(/M;ZF@@A:@XY&\XQ%RY9F_;4EYWI
MVDO;.V:Z]E%5@V"F!E2CFX]WNQ,*\:9=W<0C'"A3IRJ'XJ$2HCDFRX)N@IH'
M1+QNO^Y0;32HS%^0LER%L@,Q3=VQ1^2<QH\Z6#FKE7R$9!O<)(^)TH7 &T."
M@K4\%>LH5^4U>%N\2C(:QMHT0_2@YBT.1QLM[R/0_IS;^:'U='"KBR*(X'1]
MZI7T'T%'%[?$=,C::&:RS;VFKU<1V;\_<80Z=_-#C]9%?Q/T'I#Z=7(LX\YI
M4T=3%"= ">\A>.X@U)7%@53N5*]51JN(?-FP.4P7)SEM/A "EAA'7;3E) 66
M# E%, M!6%[;B*5B2@6)Y53 ^4KF"X?.@?HX[=/[<CW(BNG8'3^[[_!-#9_<
M]^7SR7-[L45$ID+PP2A;G'.<XE@FI"\A*LO7/+?O\*TG?VKGQ5N?0YV'R3*H
MC @^A>J@>:U%"=8W6H9W^J?VL.'+PU]?_\K#+[]+/+SY0LJKH6H93^:-20][
MZQBYM-+7V>_6(Z@D)'D<:, X)[BT/*#CFRVH+8$#S"1U"].G#^H#T/.09C/?
MC=%:9&F^LOC]@D4*V81,MA2ZO7+=,$31FO>\0%!*RR"YB+97;^)HCGK=,S$8
MQ'75M=LE7+K=+7,P2X\G?/Q],IY.KYR7$44N($KUV631@$BBCJG()!#)16Q8
M$[6"HE>-VE-JM\-,\#%L/+.T!]WQCYFSS)F4,$"*OJX&U*(NK5%@K7;.:R.#
MW[XIJSV=%T /"@E#&F6R[8[1S!BZ8LAR#0I0,=LZ%IGX$MI%K;4WV9ZQ2]*C
MI!?EH.]N9],9WJ31S<>'R$Z\-IW0X<B4H[L\EKJZNUA@4:O$O<O2#&R>Q$9^
M7DVD,R!8#&E"X7.N%E.2A4/KC$O C.6@,$EP@4YPIG/TTKJ"86##CM:Q<D80
M[Q!C[6!_ $ &B/A5+K#7T2,:7B<$T1WJ@@"7C87,DT]*L\#MP!)]ZYFYH'X
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M# C-> [6.N$;Q7VO\&'A&&">1N5#>5CXX8;NX7SO7/]8_T%ENCK6BI/EN>R
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MIDGR;12>*.$]%$CL!-4C]7D*W$4ILY/UP8II\I6<C^0K%0=!(3><_D2XG7H
MS@1OVU+4YPJW?=38:ZNOE-)0N.DAJ5 [)9!!L(Z#MMP%4W_/W4MO]>U6>SNW
M[>XC^C9#Y6>34:WXF9/V&TEY^O[7W^Y7!&=$SQ"((E7[</+=P"2N(TJF.",#
M:8*+C62],&QTIX(6:]/SI(PGG_$FYOGA.5V0E>OX:<^)PSS? (D)7-&:/,BZ
MDT=YSFR;10-K"'IAF.A"[!W6I=;=&%\IFN=X5J%V0:0SQ3F;0LWG$&0%%\1S
MR72NQ41P54Z5)Y76JQ:.[/Q]+T3U[63<H"1SU2-K0LEC+A(RSY9(T@7(F8K
M64'+>7:AT<[=0;R#]^<^'"#NYPA0QR+@PR3C]';RUYRDNR?+)6$VT\64"A'&
M/:@@!9U1]%L?-/K@:PMOFV!E+4DO# W=B/XY)O3Q*V=N1N/)S^/9_7U5B!65
MBP9O)853/#%PTC)@CJ6DK5)8V@06STAY81@X3M3/=6^.=A07%3SS*#IYGY73
M"+H6?*NZ) NM(275IYTZB4@TJK-_2,4E5WNX4AKT-#TI\=J%FJ:IU"%4"A^N
MGS6*/D*X+8+'QU0Q$:0-R8/01(OBCHXZ+A/%,C$@Y\E$V:8N: !EM:TTO8],
MN]TZ^>:GMV](WJP2M Q*@D?!F*Z=PP643P(P2 _%"6]=,-;9)\?^BL#O^>?V
M?W4?(^1Q5Q)J4=BSW%CV[35.I^_N%DC=C<5D6N=<\TJEQ#O/$8NR]:KA2AOI
M.6O4&;>.I,OUW9&Z&H3_#^E9SN#=@:*F]_ESFDYSIW>DM'$3B3>XY%=0YI1
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MEU=T7E1+.0 H!%!J *4'Z"CR%[./V=8<Q]EN0)"'YL(NOGL!!5]68CL@A9Y
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MB.88F*E6FH ?5[K\I*RBU0%K?<#EQC8=E2Z 5&J0%9$C@)WZ/N?*-*J;Y C
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MA+,!48MZT42&5: CK3OGV1 6I^[SJ3%'=: - =AVH4UOZYT;6SSR6SE?ZA/
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M6")75;%(K.AQ&FI-CGM5-,*\+>"RK%AOOIT&O*]>Y66H=V'H?:71:L!T +H
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MK[*=Z>&H]7(-@OZ]'8F._)*8L?%T33\PK>^/WU;ERM8FUK]49M_^V8L;&A#
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MW@.39:.!"J!N=0!:_HOF/^!C:X.W&QLH7=2IRDH;=[QY)II.B;.O+*,RYYF
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M2.;T8HA%BJ%RL4(>>A$A5DLS:PFF1IGRO44.6A4?!=V,]P:%<F#6.]R>>*7
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M;VP@\:=&B2OA&/@Q7X!EQ38>G6'QC5=Z#<[R"B=@W!$=RT.E-JL3M39;""[
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M#C%V4=X]ZNVIO[OOJKZ=4)D.<L?S3SAGUXNW^"FO\7S&D$@XS4*(2<#4\4(
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M*8F61!&@0)K;WM-L8I/$.1?("P<'YR7C'*4PTVF-[+NE' W7[5@#^KE+R8:
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MQJ%EW!=X<V3"><8-7#A);@;VB-"/:#CO#.*&S3Q07$(8_,+&+UPHT[AQ#F$
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MJ:C622ZX\/*U=(PW->?(S5K)^29Z(6UDQ?5;+KM0=EO) F(W\"*S"_,]!FX
MYZ\C+D&)N&O,43G2$8!#^G*]K1^S&-*;%Y_T06&(Y\-R1C2G$++4[#>%38C(
M% )4YHG9>68TYV;?J1/D0S!NPTZ-9TJIK;'^V3QU>[KJQS&.>+M137@4!V:<
M'8![D:^BNIS4H&6E_) *RD&.0X]*17YP'#*2Y]T]L]C56J_6]W9[7*5Y;4-R
M&"<$XPR0S)YL:Y$ @O,<Q"G4>8Z95E#[!3*WC.3SV8P3R/PK6_]#;>K=GHV
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ML?77/U>SA,:Y2"0'6$ ,H"0(<"7-ZT 4(2G-%/$[Y.TEQ=2<B>:;R+Q+;O<
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MR*G.80II)E.@\C0&,*,4\%Q*D!,H-,$PQMBIU[/_T%.S+YHE &K9^Q]O>,R
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MD71_C:ZM;: &:]+:.H#WR5WO?N7_OEK8;C75^&\?;8VE/U1AEY\9%+G6"4R
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M<<]9'"$X.FIQO:\?R]A2H4I]>E"VG/3R[H-BQ:[2TG.=J%&\?52S1),4&<,
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MNNQ<VU43L_5!@6N:W4HI6Y2RG/WK%R IB:D+!5  D[WOQDR[TFD2..<!^?
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M<'J<G#(L+H!P/EGBW(VCY3U<L+R;PG#ITK!*KD8<\[U^%F84HRREA0(XDP6
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MJ"FA)H.+#8]"![;N;0G!^OIAG['MA_';\I;_<U.NY"G!DQF#,2)%G@-:Q!#
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M$UMV.%Q]>NM"-Z.=Y+)SMWNJR_*.@;,H/=2=QU;/BAC-"@08IQQ )BF@:5Z
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M8I:QUS <0L=22_/? $* )]SU&^9TVA\W;#EV["@,.7&)%SF.3C$_*B@J,IX
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M GW7#MSS+A?E6GXLGTPF]<OCNEUJ>??#I.;(_Y9T9>HCR!D5*LMSB$$JX@Q
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M^'PCI'BOW3 "-)MFAO!9O:.K1;FXK^YD$Y5]+!?RPUH^5#,,<2)TC 24Q K
MHE  %YP#2@J>)0E!LG#:^?%EV-3HJ^M7IU!HM/4L,H].U/'-!%Y;[\S*9#L3
M^M-X&-4N.K*=MR&W8\77&,C [#GJ&+J?K?8,N-_#V+Z,&_?TMF=(CXY[^VY_
MX.[?T++TGQ_KJ5[G&%@WD5RDE!99+( H3$(LRA- BB0#%-.<DKS0T^K<:4LP
MB)E3^U T>PG1UPW[N^1K,S=LS;<Z CGF^%IN&K[ZJ(7>2336MWF171>CCH\1
M>XZZU[5^;C<46U=?G'(-=@0A[(#XW78,8^JX>Y%!X3[:H S;F]OWI5JMS3RF
M6LY+8=8MZY5?_8%K9]>)))C 7(%$(K,!23. <Y(#*@N>4$:2!%D)!?1W,S5^
M[UH:;4UU7,"X &P_,?N#*_QBQ1"DK G1#H@^0M,M=,A,_^V0R"YT,0H1V;FY
M)1++JP?NPJR6CW*U?K[3X[R^70AS)NO14-!>HY["K*B/61#*8DT*L0(8IP7(
M14;S%),TMR,%^RZG1A#=&@);ZV^BVOYZWV7G@>,.RV7L+;=8O"(:>H^E#\"@
M!0#L8?*[WW*YVW$W7*QA.-IQL;]S\)'UY8/\JF?7=63TT0RIJ3C7?$2)2G)9
M9!B@S,@E0D4!SI("%*E4BA4X9="I8'=O;U/CH%:0?V=MM#5WX$Y+/]1VO.,-
MP,"4<P5V0XZ37\;$]_GQGA['/C!^V?D3)\0M;AI:WI:M]\MXMT^TG)OOBTEE
MH7-9?VMF%*<*)Y2 C L)(!<$8$9- 25.8D5SS*33*7&+/J=&+L;DSO+Y3;2S
M&JCE"E3:[O;+[,@R-OC;<8UG5 ,SC@] !]2ZM8;(<ZG;R_V.7.G6&HCC0K?V
MMPY,*Z'5]_?SY5^?M"_Z1Z,R71]#T?%4*P6D?^;K\JF9Y)45GR]-]:2]JH5@
ML62(@)1 "F#",,!ID@$D8HAPD@I)W=0<KS1H:F3V=?/X.*\_)70>[<VMS.RM
M]3':.5E//W9N1GL_'44TKAY5.Q8<<ZQ"KR69<3"^W#B,2F<\@XA[^,+7;_K,
MM4:-FU[C"<*C]!M?[8Z\(_MI8TZ#?E:W0I3F%CIO]A-O-^OORY7)U9UA& O$
MH=*,7C  $4\!ID4".*&$08HPSXM1MF4OVSHYLF_V9NG.P"O.; 8<X< ;LW['
M;?J[LXV_YH.^][@](QKM?9[ !JW]P$QCE];"WG^/K5I[X+WMUSIT.53?CAM]
M@5*5S0I)]5GMM/2^+>^D41K1QC2R>C-(D(*QY(!E^AF!,BT (VD&5*80I9)F
M@CF*WSGT/K7/Q*WX^Z9:UQ12G_874C[4&PT+_1P:5?[E?&XBS;(]$>6JH.<R
M,';?@F!P!V;W([L-X'LQ3U,&=6M[J^SI4YIO &:>=?M<+!A9U&\ .,>*?T,:
M\;PU;<JY2(X4420'(HL5@"J/ :6( Y(7.<2)4M"MD'-?9U,CLZVM]2Q9;@V]
MB1:N!7-Z$=9((E+$",32*$*C@@!2( AHFE 2IPC'63Q;+]=T/C+"NR[_W1&^
M<G-_6B6)>K?U:X&6$3;R0Y4=ZNUP&IOW/66'K.YQ5C_9%C/:T+G^*LCRR<13
MU2]2+5=R5WKJ_7+5%)XR=:=FE&&:09:#F"924PH2@"B< BF+7!2*H9A9*5(-
MZGUJ+%[7%->AZ,[X^I59UK]MSW2+C6P.L-!H_;U<"?!(5SWQDH<1ZJ>DX+B'
M7G+>&Q]UK+^)&OL[%=/>6U9,\P"YM2A)6.A'$B#Q/P0N.B/#(3RK*3*@R;'T
M0X9[V]$*N:*186%_S8L?2\K*>;V2;];[V[JN)*9(%DD"$B4S #G. <L$ UP5
M%&:(<)DZ';@_W]4T/Q;SY>(>Z.X>HOG>:+> M ==NW#4#V:!B;Z!JV-EL\?H
MNW;N92R\1J$]W8T:@UYV^S "M;ACX*Y<FYG]69G$C6YQI5T*=8SC.&5I#I#$
M9G--0E,J (&L0$5&A(8Z=UH'O=SEU,BCF[[^<4<A=8K2WOQZ*V9I%F\<&<5B
M""QWO[P"&WH3RP;3*F@ZNSU>?O>6+G<[[A:1-0Q'.SWV=U['3DM3Y*U<RX_E
MDQ2'*D7O-T9E[?9AN5J7_ZJC[W<_S+93DVRV?XD*E&(J8@QDGF$ H1X9C$4.
M%!(LDSBGA5LQ(Y_&39GQ&N] [=ZQF-=-U+@8=7V,6B>'$:&7T7:CS+''<$1R
MO6+X1F%?G] 'X6DO!KX*H_N$]ASW>^UC^!F%_<?GXT[4)X4H36,I01['%, ,
M*\"0GOSJ*3#$:2Y@DCMM<9WI9VK<?1B7#I=7.@>L';=Z@"LP30Y":M"I@AX<
MO)\D.-77Z*<'>AP^=6*@[_)AI' H++3+$\<Y3W+!!>"<*AT&H@20&'&0$P@S
M4<0$IDZYHN<ZFAHMG!+MNIP [H:M'3'X0"PP,PP#RYD:+B'AE1O.=C8J.5QR
M^9 =+EX_5)MVKO^Z-%J43[*3F]B6L-)Q X2"09 P2 "4"0,,YQCP3!4Q+B"B
MRNV(4&]W4Z.*%]9VLXI=M6A[,;8C"W_(!=\;/0-:D.IA-J!XEJ#M[7)D 5H;
M]X_E9ZWN&I+'\:1?2CVY:2KG?/MKV3[AL20%*W24026$ .8" QU=()!CP15-
MB$IBJPE(7R?3XXZMH6WMJ4B;ZK+]?P;+?K;PA5!PCC@!CGN]UO,HN>1"7(_6
M>"D/#H^48SI#/PI]60MG[APQ.:'?]I<Y"!>N]9QA_.O*9.84*<Q5D12 Y H#
MJ+(4,,XX@''!4"QQIG#J)<>X[FYJ3'@N!_9^99T098FS723E#[W +'DA$_;7
M7OS\Y<*^@&6<;-BFRVGDP[YPWSHC]N5=;JPB9#E[VWY2_N\-7>F7=/[\13XN
M5^M9GL0Q@D3J&1C55(()!S0N8B!BGA/"8I0B*TW^GCZFQA];,Z.=G5%CJ!UW
M]*'93QB>, J]>.L,CS4U6 !P@@\JR?]VOWSZ#WUW0P7ZAYH!ZG>_K\U17G@+
MI[9ON<VE@_7I5I)6\JUL_OMA46<V?=9D0FLM@J8P5D906A 3+DBD )0Z>B!<
M(%"(+%5)PG@>%P,*E]GU;O6,CU^][',GL=U9J<X&=+LHPB.&HVG7U89&/VU-
M_CDJ%U$#Y\YL[Z7)W'#RK6=GT_78PG8.<)Q0N'.Y>^CI\">YV,AJIF)<, $I
MP#35[,.4U.P3YWH"$],\YC%$*G$YN+=MV"G &.&0WC?31[1JK',]L-UBE9$$
M)9@R@#)) :28 9SA A2)3'""J$"ITQ[[(*Q&8%\?6-D1[! $ E/HUB2?!\U?
M.NGY#'G;^,C'PU^Z='SR^^#?G1>:/TI-<W)'>A\-$VYSPI^WQ1S?;N2MTF_$
M?TNZ>J^?@)F"(BX81R WQ[MAIGF-*4H!@I@7G-&<)U:BOT,-F-J;K!^:HEY2
M,%\028VIU@NOPT;@XM)U<%P#\T-C_TTGFJI=N-D=(#%+.:T;-Y%V)*IACXPK
MD?$E\ !8KXH''XB15LS##8C+ZOI5:)Y=>1_6ZEBK\E?YW%FQOZX=KPI]1IKI
MVXHN^/>ZE+ELMYJR+)&4%OI#@@I37)P(P&($02:XGK1+R1!//&CNG>Y]:A^5
MUL(HBT#TO^JN(SUPC8B>%PF],T-@%U & S;P5^6D?-U^V_XFVH)>FQ\@RV(0
M<&/(T)VQ8 K"<OW@6$K%76CDU2M"_I<L[[^OI;A]TO1\+]_]D"M>5O)N57(Y
M2TA*62852+'* 8RY.6--..!209:FL5)"S![K;=BO:[I:7\6.OJUW>?T/?0C'
M!+_(^W)AL@ C1N>UML%21<NVA.2R4U_02)=N*K%GW[$43!V?$80YPUDF0))P
M"2"F'!"!<D"94CR!!2J*HGU&WBW$O_D3LO4@W//QKAG]_X\\'%=]U5]SN$>,
M!SP6);V)MOY'+0#1%H&HAF "*KC#QFP:BKB.MD\AB DU( $KFUIU?X6>C#;P
MH:SU7ZN/NW-@/,[S-,D20+"IAETH"!A#,4@RQ$@2)RGGT%E.YE1/4YON-9N'
M'4NO.&1W'EZ[#X$7T )3]T"\ANG)]&'A7T[F9&_CJ\GT.7U23*;W!O>\K7>F
MINJS:72Y^+I>\G\TTMT=AIIEBN<9-S,A)F( 35EDPO-8SY,HHAE$6<R$;0K7
MY>ZF1AF-Q5%C<E3;?+-5W.^8;9_;98%X/X'XQS$PBUP+H5/^ESTR@U+!+)H?
M+2O,WM5N@IC#74./Z%7KRN26-I(!U>Z4:0&S7.5%"IAB2(<=T!RKB14@^K'!
M&)DC-HZ'\TYW-#4*J>UL1$YW^SJRM=FUVM8Y;.UB#A^(!2:+/5A;(\/4N[J
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M *<ZVHQYG,?":=[9U]G4(JE#:A1F(;JLJDVM=LJ-R8X4V(>T)=%YPB\TG1U
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ME9T7G3PHRQN&2@K7&5;</!L?%IK"[_4S4;6[\1)Q(83,0)'%A<EHTE%C3&/
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MV*1!RV,7GC0'XT012HL/GYL?^SVK9M6?/W[7_$9]T<'&C]_]#U!+ P04
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M 80^XI%UG?HS2WO!A"&WO%AOP#F+9+'10_1DL;/UT5A&\GGPNNU0Y-P@9UP
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M,<G"N-2-ZM/N):D;]ZE=N#>,.CHP1M?O#2],ZQ6&@E4A2^) 1W2@E-6U,D:
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MO[JJ+1\,/[#8L=X-[\KO\-UTM[!^-L]W3#&XP+BTM7]%(==-^CK!H'"(-G!
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M#PZC!9:C+49S$52CZ+^_.78CUKP]10V=E/#>46F54(M2FR=F69LKY&P@Z"3
M*!DQD#?,6,-\_-,KWO@_ST71_HH8%$X_6^?>[?"&+[B>IC"[+I$.VOA>I^[G
MZ.G[@$2/V^ W^6@X#U 13UM T8YR9& IK' NH\RQ46'D41K\[A2,7>;AZM<P
M3_A\4=^+*.6+YEZ#2U4TPI%U<&1V9% ^"0RYV#9M@@ZANI.GR(-A;J_P>@B-
M#N:&CC#^-JR^O)HM_FP[]O;V(D<;=_L(?\,;T(L5+S"LM$;M/*=@QDM0,2.$
M),D3+4E[]$(Q+*WMYBVJ#C67%.+7SZ3 [=N4Y/?;CS]("Z_G[\B%";5B^UE:
M3[]MQ^Q=R,$Q$>IU;\%2QRP%#E'2YF)2&^\$.G+7F\CAZ;1V8QH/0]--B]A8
M:1V$XU<2"<HD[X6S8%R=ZF5=A)@DAV03L9%,<:6/#$XK&+76]OTYG*>(O@/0
M7',4:A)]GJ:S.K#E,J/Y:?%44<;(<F("P7!34Y_20$0K $LPT=K$'6\#OQ;<
MC/O:[<A 'AT.'6R)%T@KI^E&Q?3]#,\F?CX[J<_H_W-[-2N",CPP"\&;^N[*
M:?!8#*3,>,XQ%Q/:'.B[4#>N[1T?0XO&"AVW+O3M8EZE=R&M-S4EN(W<BK3<
MQV(!92TRM-R "QA!)QE%E+DP$Q\.:![\_'%-83>X&DX'XP+I^9>P_(QU)!Q)
M+.&J%E C$?.%]L8+_(:SQ=<J[4DR04<C&,ALR??VBD'07).'(TA4W"9=U*.H
MVG&Q<5_X]@2Q%MKIX'3][70UG1,WSQ<G<3K?:/;Y8O/0F9BIJ0P2Z_),X<M
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M>I-[JJAGU%6&SA[=&Y&-C=+6#J<:E,,(D3N$@,HZ[7E&W69LYP[$C=R=8&A
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M^_FL#C'&NK1LMISF]5#C.R/Z)M6*(M<.3%!UQF/,X .O<VD2#ZB22;R-1SR
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MP!4=N*%<,F[.\MZ"K2>_8MS4O@=(#:>!#H[C72I^,@8CLE$0=-VIB"& U]:
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M8B*Z IX8*EZF;!/[^_2/#*[X'3M#]M%"!V :M+8W>A_)( LPI2F7CKQ D$:
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M>OIVG.M:IZ)$E#$!>D4"I", ?)*UQ-VH()TU6+HM0&OVGMF%(]Q7._T^,/V
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M9&W>QPX@=N2-%D/BK:VB>C^CCM]+^\CG#'ING60W[0:J"EKTB5R,CC*""E%
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MP.E20*T%63>CYL1BB<5*+]I<SNQ+Z=@7Q:-@<&\5=?CDM86U5X6^[I8_*6-
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M&X%B&)'V?;,\G_VVJB\(!]T<W_SC 6^&M](ST,WOU9+5.Y=T)BMG QAAZO-
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M>,GZO ':D<$SM<<^+EI;@.@%G'6O<I[6WX2+VX&LMU-6<\"BC2O@75TER=&
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MTI8P/ <U'<CY3SE$;H,#'W4B&5IBBU0)0I':EI EP^ZS$B<KY3GD*KI0RA%
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MUZ:3@?-:]Z9[:32A/&,E:!!218H2=03/2TU-RZ*E#-K&D2::_NWSK]UHTLG
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M@D>GH@MM,B=/4=.I23D$"<^8E,.9WD& _G --PGPE%D(6A+=W,9:8H/UQ*&
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M,3$N:'1M4$L! A0#%     @ %(ED4X4@V29$"   .B@  !H
M ( !@@@  &=H+3 Y,S!X,C R,7@Q,'%X97@S,3(N:'1M4$L! A0#%     @
M%(ED4S%\+958"   H"@  !H              ( !_A   &=H+3 Y,S!X,C R
M,7@Q,'%X97@S,3,N:'1M4$L! A0#%     @ %(ED4S#M&MR<!0  &Q<  !H
M             ( !CAD  &=H+3 Y,S!X,C R,7@Q,'%X97@S,C$N:'1M4$L!
M A0#%     @ %(ED4P8Y<R&<!0  '1<  !H              ( !8A\  &=H
M+3 Y,S!X,C R,7@Q,'%X97@S,C(N:'1M4$L! A0#%     @ %(ED4UOG79FG
M!0  11<  !H              ( !-B4  &=H+3 Y,S!X,C R,7@Q,'%X97@S
M,C,N:'1M4$L! A0#%     @ %(ED4SJ2?2Q8V0( -6DA  \
M ( !%2L  &=H+3(P,C$P.3,P+FAT;5!+ 0(4 Q0    ( !2)9%.2J+X<J!4
M 'OT   /              "  9H$ P!G:"TR,#(Q,#DS,"YX<V102P$"% ,4
M    "  4B613HW"^$7DE   &>0$ $P              @ %O&@, 9V@M,C R
M,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( !2)9%.QIN')U'T  %O*!0 3
M          "  1E  P!G:"TR,#(Q,#DS,%]D968N>&UL4$L! A0#%     @
M%(ED4U!P!TQ8) $ <T$, !,              ( !'KX# &=H+3(P,C$P.3,P
M7VQA8BYX;6Q02P$"% ,4    "  4B613$X2L.7"Z  #KS0@ $P
M    @ &GX@0 9V@M,C R,3 Y,S!?<')E+GAM;%!+!08     #  , "X#  !(
%G04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
